PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	DICKSON, D				DICKSON, D			PEER-REVIEW - A CALL FOR HELP	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					597	597						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990944				2022-12-28	WOS:A1994PX30700032
J	DICKSON, D				DICKSON, D			EXPLOITING A MEDICAL TRADITION	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					597	597						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990944				2022-12-28	WOS:A1994PX30700031
J	FISCHL, MA; STANLEY, K; COLLIER, AC; ARDUINO, JM; STEIN, DS; FEINBERG, JE; ALLAN, JD; GOLDSMITH, JC; POWDERLY, WG; RAINES, CP; MAYJO, KJ; KERULY, JC; CRAVEN, D; HIRSHORN, L; HIRSCH, MS; JAYAWEERA, DT; YOUNG, SW; PATRONEREESE, J; BRETTLER, D; SPERBER, K; GERITS, P; SEREMETIS, S; GILL, JC; GELB, LD; MCGUIRE, ML; STIFFLER, T; LEDERMAN, MM; CAREY, JT; WALLACE, M; MACARTHUR, RD; BERGE, P; MILDVAN, D; COREY, L; COOMBS, RW; CUMMINGS, DK; SCHOOLEY, RT; RAY, MG; WAITE, V; KURITZKES, DR; FUHRER, J; TENZLER, RJ; DONLON, W; VANDERHORST, CM; TROIANI, L; HORTON, J; LANE, TW; MURPHY, RR; PHAIR, JP; KESSLER, HA; BENSON, CA; ROSENWALD, V; YONREN, S; VALENTINE, F; HASLETT, P; MITSUYASU, RT; GUERRO, M; GOETZ, MB; MATHISEN, GE; FRAME, PT; BRINKDOPKE, J; POWELL, T; HOELLE, M; MERIGAN, TC; SHAFER, R; CAIN, P; FESSELL, J; HENRY, K; RHAME, F; CHRISTENSON, J; STRYKE, D; ZINGMAN, B; KAHL, P; SOEIRO, R; CHOI, YS; REICHMAN, RL; REID, J; BLAIR, DC; STEIGBIGEL, RT; HEWITT, RG; CAMERON, ML; DONNELLY, MA; PACKARD, MV; BARTLETT, JA; FIFE, KH; ZWICKL, BW; BORUM, J; BURACK, JH; DYBECK, KA; COLEMAN, RL; JOHNSON, WR; MCKINLEY, GF; GRIECO, MH; KOLATCH, BR; SEPKOWITZ, K; PONTICELLO, L; GIORDANO, MF; MURRAY, HW; GOCKE, DJ; FASS, RJ; PARA, MF; STERN, JS; DREW, LJ; SPECTOR, SA; HAVLIR, DV; NUFFER, KL; RICHMAN, DD; CONNOR, EM; KLOSER, PC; PICARDI, JM; VANMATERMINER, C; LEEDOM, JM; HOLTOM, PD; RICHARDSON, W; EHMANN, WC; ZURLO, JJ; KREHER, M; EYSTER, ME; HYSLOP, NE; MUSHATT, DM; HOADLEY, DJ; ZACHARY, JA; SIMON, GL; PARENTI, DM; LELACHEUR, S; SCHUCK, S; HO, MT; MCMAHON, DK; PAZIN, GJ; ROSENER, R; CHEESEMAN, SH; MANGINI, LA; SANDS, MG; KAZIAL, K; JONES, G; PETTINELLI, CB; LANDRY, B; MARTINEZ, AI				FISCHL, MA; STANLEY, K; COLLIER, AC; ARDUINO, JM; STEIN, DS; FEINBERG, JE; ALLAN, JD; GOLDSMITH, JC; POWDERLY, WG; RAINES, CP; MAYJO, KJ; KERULY, JC; CRAVEN, D; HIRSHORN, L; HIRSCH, MS; JAYAWEERA, DT; YOUNG, SW; PATRONEREESE, J; BRETTLER, D; SPERBER, K; GERITS, P; SEREMETIS, S; GILL, JC; GELB, LD; MCGUIRE, ML; STIFFLER, T; LEDERMAN, MM; CAREY, JT; WALLACE, M; MACARTHUR, RD; BERGE, P; MILDVAN, D; COREY, L; COOMBS, RW; CUMMINGS, DK; SCHOOLEY, RT; RAY, MG; WAITE, V; KURITZKES, DR; FUHRER, J; TENZLER, RJ; DONLON, W; VANDERHORST, CM; TROIANI, L; HORTON, J; LANE, TW; MURPHY, RR; PHAIR, JP; KESSLER, HA; BENSON, CA; ROSENWALD, V; YONREN, S; VALENTINE, F; HASLETT, P; MITSUYASU, RT; GUERRO, M; GOETZ, MB; MATHISEN, GE; FRAME, PT; BRINKDOPKE, J; POWELL, T; HOELLE, M; MERIGAN, TC; SHAFER, R; CAIN, P; FESSELL, J; HENRY, K; RHAME, F; CHRISTENSON, J; STRYKE, D; ZINGMAN, B; KAHL, P; SOEIRO, R; CHOI, YS; REICHMAN, RL; REID, J; BLAIR, DC; STEIGBIGEL, RT; HEWITT, RG; CAMERON, ML; DONNELLY, MA; PACKARD, MV; BARTLETT, JA; FIFE, KH; ZWICKL, BW; BORUM, J; BURACK, JH; DYBECK, KA; COLEMAN, RL; JOHNSON, WR; MCKINLEY, GF; GRIECO, MH; KOLATCH, BR; SEPKOWITZ, K; PONTICELLO, L; GIORDANO, MF; MURRAY, HW; GOCKE, DJ; FASS, RJ; PARA, MF; STERN, JS; DREW, LJ; SPECTOR, SA; HAVLIR, DV; NUFFER, KL; RICHMAN, DD; CONNOR, EM; KLOSER, PC; PICARDI, JM; VANMATERMINER, C; LEEDOM, JM; HOLTOM, PD; RICHARDSON, W; EHMANN, WC; ZURLO, JJ; KREHER, M; EYSTER, ME; HYSLOP, NE; MUSHATT, DM; HOADLEY, DJ; ZACHARY, JA; SIMON, GL; PARENTI, DM; LELACHEUR, S; SCHUCK, S; HO, MT; MCMAHON, DK; PAZIN, GJ; ROSENER, R; CHEESEMAN, SH; MANGINI, LA; SANDS, MG; KAZIAL, K; JONES, G; PETTINELLI, CB; LANDRY, B; MARTINEZ, AI			COMBINATION AND MONOTHERAPY WITH ZIDOVUDINE AND ZALCITABINE IN PATIENTS WITH ADVANCED HIV DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						HIV INFECTIONS; ZIDOVUDINE; ZALCITABINE; DRUG THERAPY, COMBINATION; ANTIGENS, CD4	IMMUNODEFICIENCY-VIRUS-INFECTION; AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; PHASE-I TRIAL; 2',3'-DIDEOXYINOSINE DDI; DOUBLE-BLIND; 2',3'-DIDEOXYCYTIDINE; AZT; DIDEOXYCYTIDINE; EFFICACY	Objective: To compare the safety and efficacy of continuing zidovudine therapy with that of zalcitabine alone or zalcitabine and zidovudine used together. Design: A randomized, double-blind, controlled trial. Setting: AIDS Clinical Trials units and National Hemophilia Foundation sites. Patients: 1001 patients with symptomatic human immunodeficiency (HIV) disease and 300 or fewer CD4 cells/mm(3) or asymptomatic HIV disease and 200 or fewer CD4 cells/mm(3) who had tolerated zidovudine therapy for 6 months or more. Intervention: Patients were randomly assigned to receive zidovudine, 600 mg/d; zalcitabine, 2.25 mg/d; or zidovudine, 600 mg/d, and zalcitabine, 2.25 mg/d. Measurements: The primary end point was time to disease progression or death. Results: The median follow-up time was 17.7 months. The estimated 72-month event-free rates were 70%, 67%, and 73%, respectively, for the zidovudine, zalcitabine, and combination groups (P = 0.26). A trend analysis showed significantly lower progression rates for combination therapy compared with zidovudine therapy as the pretreatment CD4 cell count increased (P = 0.027). For patients with 150 or more CD4 cells/ mm(3), those receiving combination therapy were less likely to have disease progression or to die than were those receiving zidovudine (relative risk, 0.51; 95% Cl, 0.28 to 0.93; P = 0.029). We observed no difference between the zalcitabine and zidovudine groups (relative risk, 0.74; Cl, 0.40 to 1.36; P = 0.33). For patients with 50 to 150 CD4 cells/mm(3) or fewer than 50 CD4 cells/mm(3), we found no differences among the treatment groups (P = 0.69 and P = 0.57, respectively). Severe toxic effects occurred less frequently among patients with 150 or more CD4 cells/mm(3). Conclusions: We found no overall benefits of zalcitabine used alone or with zidovudine. However, a trend analysis suggested a better outcome for combination therapy compared with zidovudine as the pretreatment CD4 cell count increased.	HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, SEATTLE, WA 98104 USA; ALBANY MED COLL, ALBANY, NY 12208 USA; JOHNS HOPKINS UNIV HOSP, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, NIAID, CLIN TRIALS GRP, BALTIMORE, MD USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA; MEM HOSP, NEW ENGLAND AREA COMPREHENS HEMOPHILIA CTR, WORCESTER, MA USA; CUNY MT SINAI SCH MED, NEW YORK, NY 10029 USA; MT SINAI HEMOPHILIA CTR, NEW YORK, NY USA; GREAT LAKES HEMOPHILIA CTR, MILWAUKEE, WI USA; WASHINGTON UNIV, ST LOUIS, MO USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; MED COLL OHIO, TOLEDO, OH 43699 USA; BETH ISRAEL HOSP, NEW YORK, NY USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA; UNIV COLORADO, HLTH SCI CTR, DENVER, CO USA; SUNY STONY BROOK, STONY BROOK, NY USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; CAROLINAS MED CTR, CHARLOTTE, NC 28203 USA; MOSES CONE MEM HOSP, GREENSBORO, NC USA; NORTHWESTERN UNIV, CHICAGO, IL 60611 USA; RUSH PRESBYTERIAN HOSP, CHICAGO, IL USA; NYU, MED CTR, NEW YORK, NY USA; UNIV CALIF LOS ANGELES, CTR CARE, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, HARBOR MED CTR, LOS ANGELES, CA 90024 USA; SEPULVEDA VET ADM HOSP, LOS ANGELES, CA USA; OLIVE VIEW MED CTR, LOS ANGELES, CA USA; UNIV CINCINNATI, CINCINNATI, OH USA; STANFORD UNIV, STANFORD, CA 94305 USA; KAISER PERMANENTE MED CTR, SAN FRANCISCO, CA USA; ST PAUL RAMSEY MED CTR, MINNEAPOLIS, MN USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA; RIVERSIDE MED CTR, MINNEAPOLIS, MN USA; MONTEFIORE HOSP & MED CTR, BRONX, NY USA; ALBERT EINSTEIN COLL MED, BRONX, NY 10467 USA; BRONX MUNICIPAL HOSP CTR, BRONX, NY USA; UNIV ROCHESTER, ROCHESTER, NY USA; SUNY SYRACUSE, SYRACUSE, NY USA; SUNY BUFFALO, BUFFALO, NY USA; DUKE UNIV, MED CTR, DURHAM, NC USA; INDIANA UNIV, INDIANAPOLIS, IN 46204 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP, SAN FRANCISCO, CA USA; COLUMBIA UNIV, ST LUKES ROOSEVELT HOSP CTR, NEW YORK, NY USA; CORNELL UNIV, COLL MED, NEW YORK, NY USA; UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, NEW BRUNSWICK, NJ USA; OHIO STATE UNIV, COLUMBUS, OH 43210 USA; UNIV CALIF SAN DIEGO, SAN DIEGO, CA 92103 USA; UNIV MED & DENT NEW JERSEY, NEW JERSEY MED SCH, NEWARK, NJ 07103 USA; UNIV SO CALIF, LOS ANGELES, CA USA; PENN STATE UNIV, COLL MED, HERSHEY, PA USA; TULANE UNIV, SCH MED, NEW ORLEANS, LA 70112 USA; LOUISIANA STATE UNIV, MED CTR, SCH MED, NEW ORLEANS, LA 70112 USA; GEORGE WASHINGTON UNIV, WASHINGTON, DC USA; UNIV PITTSBURGH, PITTSBURGH, PA USA; UNIV MASSACHUSETTS, MED CTR, WORCESTER, MA USA; BAYSTATE MED CTR, SPRINGFIELD, MA 01107 USA; FRONTIER SCI & TECHNOL RES FDN INC, AMHERST, NY USA; NIAID, BETHESDA, MD 20892 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harborview Medical Center; University of Washington; University of Washington Seattle; Albany Medical College; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Washington University (WUSTL); Case Western Reserve University; University of Washington; University of Washington Seattle; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of North Carolina; University of North Carolina Chapel Hill; Carolinas Medical Center; Moses Cone Memorial Hospital; Northwestern University; Rush University; New York University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University System of Ohio; University of Cincinnati; Stanford University; Kaiser Permanente; Saint Paul Ramsey Medical Center; University of Minnesota System; University of Minnesota Twin Cities; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Rochester; State University of New York (SUNY) System; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Duke University; Indiana University System; Indiana University-Purdue University Indianapolis; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Cornell University; Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Ohio; Ohio State University; University of California System; University of California San Diego; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Southern California; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Tulane University; Louisiana State University System; George Washington University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Massachusetts System; University of Massachusetts Worcester; Baystate Medical Center; Frontier Science Foundation; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	FISCHL, MA (corresponding author), UNIV MIAMI, SCH MED, DEPT MED, R-60A, POB 016960, MIAMI, FL 33101 USA.		LeLacheur, Susan Frances/AAN-3064-2021; Goetz, Matthew Bidwell/GPX-4090-2022; Merigan, Thomas/AGQ-7464-2022; Murray, Heather/GQY-8016-2022; Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436; Powderly, William/0000-0001-7808-3086				APONTECIPRIANI SL, 1993, ANN INTERN MED, V119, P539, DOI 10.7326/0003-4819-119-6-199309150-00034; COOLEY TP, 1990, NEW ENGL J MED, V322, P1340, DOI 10.1056/NEJM199005103221902; COX DR, 1972, J R STAT SOC B, V34, P187; DAQUILA R, 1993, 9 INT C AIDS BERL; DOLIN R, 1994, IN PRESS ARCH INTERN; ERON JJ, 1992, ANTIMICROB AGENTS CH, V36, P1559, DOI 10.1128/AAC.36.7.1559; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1993, ANN INTERN MED, V118, P762, DOI 10.7326/0003-4819-118-10-199305150-00002; HOLLANDER M, 1973, NONPARAMETRIC STATIS; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LARDER BA, 1990, ANTIMICROB AGENTS CH, V34, P436, DOI 10.1128/AAC.34.3.436; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; MERIGAN TC, 1989, ANN INTERN MED, V110, P189, DOI 10.7326/0003-4819-110-3-189; Pocock SJ., 2013, CLIN TRIALS PRACTICA; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; SCOTT R, 1993, 9 INT C AIDS BERL; TORNEVIK Y, 1990, MOL PHARMACOL, V38, P237; VELLA S, 1992, JAMA-J AM MED ASSOC, V267, P1232, DOI 10.1001/jama.267.9.1232; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; YARCHOAN R, 1988, LANCET, V1, P76	25	113	114	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1995	122	1					24	32		10.7326/0003-4819-122-1-199501010-00004	http://dx.doi.org/10.7326/0003-4819-122-1-199501010-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY502	7985892				2022-12-28	WOS:A1995PY50200004
J	WATANABE, S; TAKAHASHI, H				WATANABE, S; TAKAHASHI, H			TREATMENT OF NEVUS OF OTA WITH THE Q-SWITCHED RUBY-LASER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GUINEA-PIG SKIN; SELECTIVE PHOTOTHERMOLYSIS; IRRADIATION; PULSES; INJURY	Background. Nevus of Ota is a benign bluish gray-brown lesion of the eye and the surrounding skin that has been reported to occur in about 1 in 200 people in Japan. Prior treatments have either been ineffective or caused scarring. The Q-switched ruby laser can produce very short high-energy pulses and can selectively target cells that contain pigment, such as dermal melanocytes. Methods. We treated the skin lesions of 114 patients (25 male and 89 female) with nevi of Ota with a Q-switched ruby laser set to deliver pulses of 6 J per square centimeter of body-surface area at a wavelength of 694.3 nm, with a pulse duration of 30 nanoseconds. The interval between treatments ranged from three to four months. Five dermatologists who were not familiar with the patients independently compared a full set of pretreatment and post-treatment photographs of each patient and determined the percentage of pigment lightening of the affected areas using standard criteria. Results. Of the 35 patients who received four or five treatments, 33 had an excellent response (lightening of 70 percent or more), and 2 had a good response (lightening of 40 to 69 percent). Of the 31 patients who received three treatments, 4 had an excellent response, 26 a good response, and 1 a fair response (lightening of 10 to 39 percent). Of the 25 patients who received two treatments, 2 had an excellent response, 16 a good response, and 7 a fair response. Of the 23 patients who received one treatment, 3 had a good response, 13 a fair response, and 7 no response (lightening of 9 percent or less). No patient had hypertrophic or atrophic scarring; eight patients had postinflammatory hyperpigmentation for up to two months after the first treatment. Conclusions. Selective photothermolysis with the Q-switched ruby laser is a safe and effective method for lightening nevi of Ota. Multiple treatments increase the response rate.			WATANABE, S (corresponding author), TEIKYO UNIV,SCH MED,DEPT DERMATOL,ITABASHI KU,11-1 KAGA,2 CHOME,TOKYO 173,JAPAN.							Anderson R R, 1981, Lasers Surg Med, V1, P263; ANDERSON RR, 1989, J INVEST DERMATOL, V93, P28, DOI 10.1111/1523-1747.ep12277339; ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297; ANDERSON RR, 1981, J INVEST DERMATOL, V77, P13, DOI 10.1111/1523-1747.ep12479191; APFELBERG DB, 1981, JAMA-J AM MED ASSOC, V245, P2073, DOI 10.1001/jama.245.20.2073; DOVER JS, 1989, ARCH DERMATOL, V125, P43, DOI 10.1001/archderm.125.1.43; GERONEMUS RG, 1992, ARCH DERMATOL, V128, P1618, DOI 10.1001/archderm.128.12.1618; GOLDBERG DJ, 1992, J DERMATOL SURG ONC, V18, P817, DOI 10.1111/j.1524-4725.1992.tb03040.x; HIDANO A, 1967, ARCH DERMATOL, V95, P187, DOI 10.1001/archderm.95.2.187; HRUZA GJ, 1991, ARCH DERMATOL, V127, P1799, DOI 10.1001/archderm.127.12.1799; LOWE NJ, 1993, J AM ACAD DERMATOL, V29, P997, DOI 10.1016/0190-9622(93)70280-7; MARGOLIS RJ, 1989, LASER SURG MED, V9, P389, DOI 10.1002/lsm.1900090412; MOSHER DB, 1987, DERMATOLOGY GENERAL, V1, P854; MURPHY GF, 1983, LAB INVEST, V49, P680; POLLA LL, 1987, J INVEST DERMATOL, V89, P281, DOI 10.1111/1523-1747.ep12471397; TAYLOR CR, 1990, ARCH DERMATOL, V126, P893, DOI 10.1001/archderm.126.7.893; TAYLOR CR, 1994, J AM ACAD DERMATOL, V30, P743, DOI 10.1016/S0190-9622(08)81505-8; WATANABE S, 1991, PHOTOCHEM PHOTOBIOL, V53, P757, DOI 10.1111/j.1751-1097.1991.tb09889.x	18	108	112	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	1994	331	26					1745	1750		10.1056/NEJM199412293312604	http://dx.doi.org/10.1056/NEJM199412293312604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ266	7984195				2022-12-28	WOS:A1994PZ26600004
J	KASTELER, JS; CALLEN, JP				KASTELER, JS; CALLEN, JP			SCALP INVOLVEMENT IN DERMATOMYOSITIS - OFTEN OVERLOOKED OR MISDIAGNOSED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							IDIOPATHIC INFLAMMATORY MYOPATHIES; SINE MYOSITIS; POLYMYOSITIS	Objective.-To characterize scalp involvement in patients with dermatomyositis. Design.-Case series. Patients.-All patients with dermatomyositis seen in our office between 1988 and mid 1993. Patient inclusion in this study required fulfillment of three or more of Bohan and Peter's criteria for dermatomyositis. Results.-Of 17 patients with the diagnosis of dermatomyositis, scalp involvement was present in 14. Five of the 14 patients with scalp involvement were diagnosed as having scalp psoriasis or seborrheic dermatitis before progression of their disease or tissue examination revealed the diagnosis of dermatomyositis. In all patients, the scalp involvement was manifested as atrophic, erythematous, scaly plaques. In addition, alopecia was noted in six of the 14 patients. Treatment of cutaneous involvement included sun avoidance, topical corticosteroids and/or antimalarials, and/or methotrexate. Conclusions.-Recognition of this process is important because scalp involvement is often overlooked, may be misdiagnosed initially, and can be the presenting complaint in some patients with dermatomyositis.	UNIV LOUISVILLE,SCH MED,DIV DERMATOL,LOUISVILLE,KY 40292	University of Louisville								BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BOHAN A, 1977, MEDICINE, V56, P255, DOI 10.1097/00005792-197707000-00001; CALLEN JP, 1993, J AM ACAD DERMATOL, V28, P477, DOI 10.1016/S0190-9622(08)81757-4; CALLEN JP, 1987, DM-DIS MON, V33, P242; EUWER RL, 1991, J AM ACAD DERMATOL, V24, P959, DOI 10.1016/0190-9622(91)70153-S; FAFALAK RG, 1994, J RHEUMATOL, V21, P643; JANIS JF, 1968, ARCH DERMATOL, V97, P640, DOI 10.1001/archderm.97.6.640; JOFFE MM, 1993, AM J MED, V94, P379, DOI 10.1016/0002-9343(93)90148-I; PLOTZ PH, 1989, ANN INTERN MED, V111, P143, DOI 10.7326/0003-4819-111-2-143; SCHWIETERMAN WD, 1993, ARTHRITIS RHEUM, V36, pS118; SINOWAY PA, 1994, J RHEUMATOL, V21, P353; STONECIPHER MR, 1993, J AM ACAD DERMATOL, V28, P951, DOI 10.1016/0190-9622(93)70136-H; URBANOMARQUEZ A, 1991, ANN RHEUM DIS, V50, P191, DOI 10.1136/ard.50.3.191	13	50	50	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	1994	272	24					1939	1941		10.1001/jama.272.24.1939	http://dx.doi.org/10.1001/jama.272.24.1939			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX927	7990247				2022-12-28	WOS:A1994PX92700040
J	ROSS, DA; SASAKI, CT				ROSS, DA; SASAKI, CT			ACUTE LARYNGEAL OBSTRUCTION	LANCET			English	Article							TRANS-TRACHEAL VENTILATION; AIRWAY MANAGEMENT; DIFFICULT AIRWAY; MASK VENTILATION; CRICOTHYROIDOTOMY; TRACHEOTOMY; EXPERIENCE; CPR; TRAUMA				ROSS, DA (corresponding author), YALE UNIV,SCH MED,OTOLARYNGOL SECT,333 CEDAR ST,POB 208041,NEW HAVEN,CT 06520, USA.							Albertario F, 1993, Monaldi Arch Chest Dis, V48, P272; BENUMOF JL, 1989, ANESTHESIOLOGY, V71, P769, DOI 10.1097/00000542-198911000-00023; BRANTIGAN CO, 1976, J THORAC CARDIOV SUR, V71, P72; BURKEY B, 1991, CLIN CHEST MED, V12, P561; CLANCY MJ, 1989, ARCH EMERG MED, V6, P143; COLEMAN DL, 1987, J INTENSIVE CARE MED, V2, P354; DELAURIER GA, 1990, AM SURGEON, V53, P13; DUNLAP LB, 1978, JACEP-J AM COLL EMER, V7, P42, DOI 10.1016/S0361-1124(78)80034-3; ELLING R, 1983, ANN EMERG MED, V12, P765, DOI 10.1016/S0196-0644(83)80254-6; FINCUANE BT, 1988, PRINCIPLES AIRWAY MA; HEFFNER JE, 1991, CLIN CHEST MED, V12, P611; HEIMLICH HJ, 1975, JAMA-J AM MED ASSOC, V234, P398, DOI 10.1001/jama.234.4.398; JACKSON C, 1921, SURG GYNECOL OBSTET, V32, P398; JACKSON C, 1909, LARYNGOSCOPE, V18, P285; JACOBS HB, 1974, CHEST, V65, P36, DOI 10.1378/chest.65.1.36; JACOBY JJ, 1956, JAMA-J AM MED ASSOC, V162, P625, DOI 10.1001/jama.1956.02970240007003; JACOBY JJ, 1951, AM J PHYSIOL, V167, P789; JESUDIAN MCS, 1985, CRIT CARE MED, V13, P122, DOI 10.1097/00003246-198502000-00015; Koopmann C F Jr, 1981, Am J Otolaryngol, V2, P123, DOI 10.1016/S0196-0709(81)80029-4; MELKER RJ, 1985, ANN EMERG MED, V14, P397, DOI 10.1016/S0196-0644(85)80280-8; MICHAEL TAD, 1985, CHEST, V87, P814, DOI 10.1378/chest.87.6.814; MONNIER P, 1988, CLIN OTOLARYNGOL, V13, P209, DOI 10.1111/j.1365-2273.1988.tb01120.x; NELSON T G, 1957, Am Surg, V23, P660; NELSON T G, 1957, Am Surg, V23, P750; NELSON T G, 1957, Am Surg, V23, P841; PEPE PE, 1993, ANN EMERG MED, V22, P3393; REED JP, 1954, ANESTHESIOLOGY, V153, P28; RONE CA, 1982, LARYNGOSCOPE, V92, P1259; RUBEN H, 1961, ACTA ANAESTH SCAND, V5, P107, DOI 10.1111/j.1399-6576.1961.tb00089.x; RUBEN HM, 1961, ANESTHESIOLOGY, V22, P271, DOI 10.1097/00000542-196103000-00017; SAFAR P, 1959, J APPL PHYSIOL, V14, P760, DOI 10.1152/jappl.1959.14.5.760; SALVINO CK, 1993, J TRAUMA, V34, P503, DOI 10.1097/00005373-199304000-00006; SCHLOSS MD, 1983, LARYNGOSCOPE, V93, P489; SCHWARTZ DE, 1991, CLIN CHEST MED, V12, P483; SCUDERI PE, 1982, ANESTH ANALG, V61, P867; SHEARER VE, 1993, ANESTH ANALG, V77, P1135; Smith R B, 1976, JACEP, V5, P765, DOI 10.1016/S0361-1124(76)80306-1; SPOEREL WE, 1971, BRIT J ANAESTH, V43, P932, DOI 10.1093/bja/43.10.932; STEWART RD, 1985, ANN EMERG MED, V14, P403, DOI 10.1016/S0196-0644(85)80281-X; WANG MB, 1992, LARYNGOSCOPE, V102, P157; WEYMULLER EA, 1987, ANN OTO RHINOL LARYN, V96, P34, DOI 10.1177/000348948709600108; XEROPOTAMOS NS, 1993, INJURY, V24, P222, DOI 10.1016/0020-1383(93)90172-3; ZARITSKY A, 1987, ANN EMERG MED, V16, P1107, DOI 10.1016/S0196-0644(87)80465-1; ZWILLICH CW, 1974, AM J MED, V57, P161, DOI 10.1016/0002-9343(74)90440-9; 1992, JAMA-J AM MED ASSOC, V268, P2184	45	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1743	1748		10.1016/S0140-6736(94)92889-4	http://dx.doi.org/10.1016/S0140-6736(94)92889-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7997004				2022-12-28	WOS:A1994PY28100012
J	SLOANLANCASTER, J; SHAW, AS; ROTHBARD, JB; ALLEN, PM				SLOANLANCASTER, J; SHAW, AS; ROTHBARD, JB; ALLEN, PM			PARTIAL T-CELL SIGNALING - ALTERED PHOSPHO-ZETA AND LACK OF ZAP70 RECRUITMENT IN APL-INDUCED T-CELL ANERGY	CELL			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTOR-ZETA; LYMPHOKINE PRODUCTION; CYTOPLASMIC TAIL; CROSS-LINKING; ACTIVATION; KINASE; CHAIN; TRANSDUCTION; ASSOCIATION	Studies of T cell responses to altered peptide ligands (APLs) have provided functional evidence that a T cell receptor (TCR) can interpret subtle changes in its ligand, resulting in different phenotypic outcomes. One dramatic effect of APL stimulation with live antigen-presenting cells (APCs) is the induction of energy as opposed to proliferation. We investigated the intracellular signaling events involved in generating this unresponsiveness by comparing protein-tyrosine phosphorylation patterns after stimulation with anergy-inducing APL or the immunogenic peptide. In resting T cell clones, presentation with APL/live APC stimulated a unique pattern of TCR phospho-zeta species and a subsequent lack of association with zap70. This demonstrates that the TCR-CD3 complex can engage selective intracellular biochemical signaling pathways as a direct consequence of the nature of the ligand recognized and the initial phosphotyrosine pattern of the TCR-CD3 proteins, leading to different phenotypes.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; IMMULOG, PALO ALTO, CA 94304 USA	Washington University (WUSTL)								ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BHANDOOLA A, 1993, J IMMUNOL, V151, P2355; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHO EA, 1993, J IMMUNOL, V151, P20; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVIS LS, 1989, J IMMUNOL, V142, P1084; DIANZANI U, 1992, J IMMUNOL, V148, P678; EVAVOLD BD, 1992, J IMMUNOL, V148, P347; EVAVOLD BD, 1993, J IMMUNOL, V150, P3131; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; FRANK SJ, 1992, J BIOL CHEM, V267, P13656; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; HERMANS MHA, 1993, EUR J IMMUNOL, V23, P2257, DOI 10.1002/eji.1830230931; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JANEWAY CA, 1989, COLD SH Q B, V54, P657; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JUNE CH, 1990, J IMMUNOL, V144, P1591; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LORENZ RG, 1989, NATURE, V340, P557, DOI 10.1038/340557a0; LOVE PE, 1994, J EXP MED, V179, P1485, DOI 10.1084/jem.179.5.1485; NORTON SD, 1991, J IMMUNOL, V146, P1125; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; QUILL H, 1987, J IMMUNOL, V138, P3704; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RONCHESE F, 1987, NATURE, V329, P254, DOI 10.1038/329254a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SLOANLANCASTER J, 1994, J EXP MED, V180, P1195, DOI 10.1084/jem.180.4.1195; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	47	587	593	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					913	922		10.1016/0092-8674(94)90080-9	http://dx.doi.org/10.1016/0092-8674(94)90080-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001128				2022-12-28	WOS:A1994PW05400018
J	KELLER, LF; ARCESE, P; SMITH, JNM; HOCHACHKA, WM; STEARNS, SC				KELLER, LF; ARCESE, P; SMITH, JNM; HOCHACHKA, WM; STEARNS, SC			SELECTION AGAINST INBRED SONG SPARROWS DURING A NATURAL-POPULATION BOTTLENECK	NATURE			English	Article							INBREEDING DEPRESSION; GREAT TIT; CONSEQUENCES; MORTALITY	THE genetic and demographic consequences of population subdivision have received considerable attention from conservation biologists. In particular, losses of genetic variability and reduced viability and fecundity due to inbreeding (inbreeding depression) are of concern(1-3). Studies of domestic, laboratory(4,5) and zoo populations(2,6,7) have shown inbreeding depression in a variety of traits related to fitness. Consequently, inbreeding depression is widely accepted as a fact. Recently, however, the relative impact of inbreeding on the viability of natural populations has been questioned(8-10). Work on the cheetah (Acinonyx jubatus), for example, has emphasized the overwhelming importance of environmental factors on mortality in the wild(9,10). Here we report that song sparrows (Melospiza melodia) that survived a severe population bottleneck were a non-random subset of the pre-crash population with respect to inbreeding, and that natural selection favoured outbred individuals. Thus, inbreeding depression was expressed in the face of an environmental challenge. Such challenges are also likely to be faced by inbred populations of endangered species. We suggest that environmental and genetic effects on survival may interact and, as a consequence, that their effects on individuals and populations should not be considered independently.	UNIV BRITISH COLUMBIA,DEPT ZOOL,VANCOUVER V6T 1Z4,BC,CANADA; UNIV BASEL,INST ZOOL,CH-4051 BASEL,SWITZERLAND	University of British Columbia; University of Basel	KELLER, LF (corresponding author), UNIV WISCONSIN,DEPT WILDLIFE ECOL,1630 LINDEN DR,MADISON,WI 53706, USA.		Hochachka, Wesley M./J-9768-2012	Hochachka, Wesley M./0000-0002-0595-7827; Lukas, Keller/0000-0002-0149-0174; Stearns, Stephen/0000-0002-6621-4373				ARCESE P, 1992, ECOLOGY, V73, P805, DOI 10.2307/1940159; BARRETT SCH, 1991, NATURE, V352, P522, DOI 10.1038/352522a0; BOYCE AJ, 1983, J HERED, V74, P400, DOI 10.1093/oxfordjournals.jhered.a109825; BULGER J, 1986, ANIM BEHAV, V36, P574; CARO TM, 1994, SCIENCE, V263, P485, DOI 10.1126/science.8290956; CAUGHLEY G, 1994, J ANIM ECOL, V63, P215, DOI 10.2307/5542; CHARLESWORTH D, 1987, ANNU REV ECOL SYST, V18, P237, DOI 10.1146/annurev.es.18.110187.001321; Falconer D. S., 1989, Introduction to quantitative genetics.; GIBBS HL, 1989, EVOLUTION, V43, P1273, DOI 10.1111/j.1558-5646.1989.tb02574.x; GREENWOOD PJ, 1978, NATURE, V271, P52, DOI 10.1038/271052a0; HARCOURT S, 1991, NATURE, V354, P10, DOI 10.1038/354010a0; Hoffmann A.A., 1991, EVOLUTIONARY GENETIC; HOOGLAND JL, 1992, AM NAT, V139, P591, DOI 10.1086/285345; Lacy Robert C., 1993, P352; LANDE R, 1988, SCIENCE, V241, P1455, DOI 10.1126/science.3420403; LANDE R, 1985, EVOLUTION, V39, P24, DOI [10.2307/2408514, 10.1111/j.1558-5646.1985.tb04077.x]; MACCLUER JW, 1983, J HERED, V74, P394, DOI 10.1093/oxfordjournals.jhered.a109824; OBRIEN SJ, 1985, SCIENCE, V227, P1428, DOI 10.1126/science.2983425; Ralls K., 1986, P35; RALLS K, 1979, SCIENCE, V206, P1101, DOI 10.1126/science.493997; ROGERS CM, 1991, ORNIS SCAND, V22, P387, DOI 10.2307/3676513; SMITH JNM, 1989, AM NAT, V133, P830, DOI 10.1086/284955; SMITH JNM, 1991, 20 ACT C INT ORN, P1514; Templeton A.R., 1987, P257; Thornhill N.W., 1993, NATURAL HIST INBREED; TOMPA FS, 1971, AUK, V88, P753, DOI 10.2307/4083835; VANNOORDWIJK AJ, 1981, EVOLUTION, V35, P674, DOI 10.1111/j.1558-5646.1981.tb04929.x; Wright S., 1977, EVOLUTION GENETICS P, V3; 1986, P WKSHOP GENETIC MAN, V5, P81	29	305	310	2	109	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					356	357		10.1038/372356a0	http://dx.doi.org/10.1038/372356a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969492				2022-12-28	WOS:A1994PU28700053
J	HECK, SD; SIOK, CJ; KRAPCHO, KJ; KELBAUGH, PR; THADEIO, PF; WELCH, MJ; WILLIAMS, RD; GANONG, AH; KELLY, ME; LANZETTI, AJ; GRAY, WR; PHILLIPS, D; PARKS, TN; JACKSON, H; AHLIJANIAN, MK; SACCOMANO, NA; VOLKMANN, RA				HECK, SD; SIOK, CJ; KRAPCHO, KJ; KELBAUGH, PR; THADEIO, PF; WELCH, MJ; WILLIAMS, RD; GANONG, AH; KELLY, ME; LANZETTI, AJ; GRAY, WR; PHILLIPS, D; PARKS, TN; JACKSON, H; AHLIJANIAN, MK; SACCOMANO, NA; VOLKMANN, RA			FUNCTIONAL CONSEQUENCES OF POSTTRANSLATIONAL ISOMERIZATION OF SER(46) IN A CALCIUM-CHANNEL TOXIN	SCIENCE			English	Article							GLUTAMATE RACEMASE; OMEGA-CONOTOXIN; CA2+ CHANNELS; PERIPHERAL NEURONS; EXPRESSION; PEPTIDE; NEUROPEPTIDES; DIVERSITY; MECHANISM; CLONING	The venom of the funnel-web spider Agelenopsis aperta contains several peptides that paralyze prey by blocking voltage-sensitive calcium channels. Two peptides, omega-Aga-IVB (IVB) and omega-Aga-IVC (IVC), have identical amino acid sequences, yet have opposite absolute configurations at serine 46. These toxins had similar selectivities for blocking voltage-sensitive calcium channel subtypes but different potencies for blocking P-type voltage-sensitive calcium channels in rat cerebellar Purkinje cells as well as calcium-45 influx into rat brain synaptosomes. An enzyme purified from venom converts IVC to IVB by isomerizing serine 46, which is present in the carboxyl-terminal tail, from the L to the D configuration. Unlike the carboxyl terminus of IVC, that of IVB was resistant to the major venom protease. These results show enzymatic activities in A. aperta venom being used in an unprecedented strategy for coproduction of necessary neurotoxins that possess enhanced stability and potency.	NPS PHARMACEUT INC,SALT LAKE CITY,UT 84108; UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT ANAT,SALT LAKE CITY,UT 84112; PFIZER RES INC,GROTON,CT 06340	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Pfizer								ADAMS ME, 1993, MOL PHARMACOL, V44, P681; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BRANTON WD, 1993, NATURE, V365, P496, DOI 10.1038/365496a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; FORD R, 1986, COMP BIOCHEM PHYS C, V85, P61, DOI 10.1016/0742-8413(86)90052-6; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GALLO KA, 1993, BIOCHEMISTRY-US, V32, P3991, DOI 10.1021/bi00066a020; GALLO KA, 1993, BIOCHEMISTRY-US, V32, P3981, DOI 10.1021/bi00066a019; GANONG AH, 1993, SOC NEUR ABSTR, V19, P7212; GRABNER M, 1994, FEBS LETT, V339, P189, DOI 10.1016/0014-5793(94)80413-3; HECK SD, IN PRESS J AM CHEM S; HORNBERG U, 1991, J COMP NEUROL, V303, P35; KREIL G, 1994, J BIOL CHEM, V269, P10967; LAMANGO NS, 1993, INSECT BIOCHEM MOLEC, V23, P801, DOI 10.1016/0965-1748(93)90068-4; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PHILLIPS D, 1992, Patent No. 5122596; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; RUDNICK G, 1975, BIOCHEMISTRY-US, V14, P4515, DOI 10.1021/bi00691a028; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SCHOOFS L, 1988, GEN COMP ENDOCR, V69, P1, DOI 10.1016/0016-6480(88)90046-9; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; SPEDDING M, 1992, PHARMACOL REV, V44, P363; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; TANNER ME, 1993, BIOCHEMISTRY-US, V32, P3998, DOI 10.1021/bi00066a021; TERAMOTO T, 1993, BIOCHEM BIOPH RES CO, V196, P134, DOI 10.1006/bbrc.1993.2225; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; WALSH C, 1979, ENZYMATIC REACTION M, P828; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; YAMAUCHI T, 1992, J BIOL CHEM, V267, P18361; YU HT, 1993, BIOCHEMISTRY-US, V32, P13123, DOI 10.1021/bi00211a022; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	39	131	134	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1065	1068		10.1126/science.7973665	http://dx.doi.org/10.1126/science.7973665			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973665				2022-12-28	WOS:A1994PQ92400052
J	VANOS, J; NEELEMAN, J				VANOS, J; NEELEMAN, J			MEDICINE IN EUROPE - CARING FOR MENTALLY-ILL PEOPLE	BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY; SUICIDE; RATES; CARE	Despite legislation to harmonise mental health practice throughout Europe and convergence in systems of training there remains an extraordinary diversity in psychiatric practice in Europe. Approaches to tackling substance misuse vary among nations; statistics on psychiatric morbidity are affected by different approaches to diagnosis and treatment of psychiatric disorders; attitudes towards mental illness show definite international differences. Everywhere, though, mental health care for patients with psychotic illnesses is a ''cinderella service,'' and there is a general move towards care falling increasingly on the family and the community.	MAUDSLEY & BETHLEM ROYAL HOSP,LONDON SE5 8AF,ENGLAND	South London & Maudsley NHS Trust	VANOS, J (corresponding author), INST PSYCHIAT,DEPT PSYCHOL MED,LONDON SE5 8AF,ENGLAND.		Vasconcelos, Ana Carolina Souza de/GXW-3453-2022; van Os, Jim/V-8884-2019; van Os, Jim/I-9496-2012	van Os, Jim/0000-0002-7245-1586; van Os, Jim/0000-0002-7245-1586				BERGER M, 1993, SPEKTRUM, V37, P4; BREARLEY S, 1992, BRIT MED J, V305, P661, DOI 10.1136/bmj.305.6855.661; CALMAN KC, 1992, SPECIALIST MED TRAIN; DIEKSTRA RFW, 1985, SUICIDE LIFE-THREAT, V15, P27; DONNELLY M, 1992, POLICIES MENTAL HLTH; Durkheim E, 1897, SUICIDE ETUDE SOCIOL; ENGELSMAN P, 1991, PSYCHIOTRIC B, V15, P689; FARRELL M, 1992, BRIT MED J, V304, P489, DOI 10.1136/bmj.304.6825.489; GROVES T, 1990, BRIT MED J, V300, P923, DOI 10.1136/bmj.300.6729.923; HALL P, 1991, BRIT MED J, V302, P1150, DOI 10.1136/bmj.302.6785.1150; HARRISON G, 1988, PSYCHOL MED, V18, P643, DOI 10.1017/S0033291700008321; JENSEN SB, 1989, ACTA PSYCHIAT SCAND, V80, P125, DOI 10.1111/j.1600-0447.1989.tb01313.x; Johns A, 1991, Lancet, V337, P38, DOI 10.1016/0140-6736(91)93348-D; KIROV K, IN PRESS HIST PSYCHI; LAZARIDIS K, 1987, NERVENARZT, V58, P250; LEFF J, 1991, EVALUATION COMPREHEN; LEROY B, 1992, DRUG ALCOHOL DEPEN, V29, P269, DOI 10.1016/0376-8716(92)90102-I; LESSE S, 1990, AM J PSYCHOTHER, V64, P157; LEYTEN J, 1933, TIJDSCHRIFTE PSYCHIA, V35, P5; MANGEN S, 1985, MENTAL HLTH CARE EUR; Mangen S P, 1987, Int J Soc Psychiatry, V33, P76, DOI 10.1177/002076408703300202; MANGEN SP, 1988, COMMUNITY CARE PRACT; MCGUINESS AJ, 1991, ALCOHOL TAXATION EUR; NEELEMAN J, 1990, TIJDSCHR PSYCHIAT, V32, P13; NEUMANN J, 1991, AM J PSYCHIAT, V148, P1386; NIJMAN H, 1993, TIJDSCHR PSYCHIAT, V35, P58; PRITCHARD C, 1988, SOC PSYCH PSYCH EPID, V23, P85, DOI 10.1007/BF01788426; RIHMER Z, 1990, J AFFECT DISORDERS, V20, P87, DOI 10.1016/0165-0327(90)90121-N; Sayil I, 1984, Int J Soc Psychiatry, V30, P267, DOI 10.1177/002076408403000403; SCHORNAGEL WHL, 1992, TIJDSCHR PSYCHIAT, V34, P131; SELTEN JP, IN PRESS SOCIAL PSYC; STALLKNECHT K, 1992, BRIT MED J, V304, P561, DOI 10.1136/bmj.304.6826.561; STEPTOE A, 1992, BRIT J CLIN PSYCHOL, V31, P485, DOI 10.1111/j.2044-8260.1992.tb01021.x; TYRIE CM, 1992, PSYCHIAT B, V16, P40; Van Hoorn E, 1992, Int J Soc Psychiatry, V38, P30, DOI 10.1177/002076409203800105; VANOS J, 1993, BRIT MED J, V307, P489, DOI 10.1136/bmj.307.6902.489; VARNIK A, 1992, ACTA PSYCHIAT SCAND, V86, P76, DOI 10.1111/j.1600-0447.1992.tb03230.x; 1993, MELDINGSPROCEDURE BI; 1987, MENTAL HLTH SERVICES; 1990, LANCET, V336, P911; 1992, MULTICITY STUDY DRUG; 1985, MENTAL HLTH SERVICES	42	7	7	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 5	1994	309	6963					1218	1221						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PQ662	7987157				2022-12-28	WOS:A1994PQ66200028
J	LOWE, SW; BODIS, S; MCCLATCHEY, A; REMINGTON, L; RULEY, HE; FISHER, DE; HOUSMAN, DE; JACKS, T				LOWE, SW; BODIS, S; MCCLATCHEY, A; REMINGTON, L; RULEY, HE; FISHER, DE; HOUSMAN, DE; JACKS, T			P53 STATUS AND THE EFFICACY OF CANCER-THERAPY IN-VIVO	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; C-MYC; GENE; MUTATIONS; INDUCTION; APOPTOSIS; MOUSE; TUMOR	The therapeutic responsiveness of genetically defined tumors expressing or devoid of the p53 tumor suppressor gene was compared in immunocompromised mice. Tumors expressing the p53 gene contained a high proportion of apoptotic cells and typically regressed after treatment with gamma radiation or adriamycin. In contrast, p53-deficient tumors treated with the same regimens continued to enlarge and contained few apoptotic cells. Acquired mutations in p53 were associated with both treatment resistance and relapse in p53-expressing tumors. These results establish that defects in apoptosis, here caused by the inactivation of p53, can produce treatment-resistant tumors and suggest that p53 status may be an important determinant of tumor response to therapy.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; VANDERBILT UNIV,SCH MED,DEPT IMMUNOL & MICROBIOL,NASHVILLE,TN 37232; HARVARD UNIV,CHILDRENS HOSP,SCH MED,BOSTON,MA 02115; MIT,CTR CANC RES,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Vanderbilt University; Harvard University; Boston Children's Hospital; Harvard Medical School; Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [P30CA014051, R01CA017575, R01CA040602, R37CA017575] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA40602, 5R27CA17575, CA14051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; ELROUBY S, 1993, BLOOD, V82, P3452; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FUJIWARA T, 1994, CANCER RES, V54, P2287; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIO Y, 1993, CANCER RES, V53, P11; HSIAO MH, 1994, BLOOD, V83, P2922, DOI 10.1182/blood.V83.10.2922.2922; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P954; LOWE SW, UNPUB; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; PELLETIER J, COMMUNICATION; SCHEULEN ME, 1989, STRAHLENTHER ONKOL, V165, P529; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THORLACIUS S, 1993, CANCER RES, V53, P1637; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	25	1489	1540	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					807	810		10.1126/science.7973635	http://dx.doi.org/10.1126/science.7973635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973635				2022-12-28	WOS:A1994PP75300041
J	STONE, JM; COLLINGE, MA; SMITH, RD; HORN, MA; WALKER, JC				STONE, JM; COLLINGE, MA; SMITH, RD; HORN, MA; WALKER, JC			INTERACTION OF A PROTEIN PHOSPHATASE WITH AN ARABIDOPSIS SERINE-THREONINE RECEPTOR KINASE	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE-PHOSPHATASE; NUCLEOTIDE EXCHANGE; EXPRESSION CLONING; BRASSICA-OLERACEA; ADAPTER PROTEIN; THALIANA; DOMAINS; LOCUS; GENE	A protein phosphatase was cloned that interacts with a serine-threonine receptor-like kinase, RLK5, from Arabidopsis thaliana. The phosphatase, designated KAPP (kinase-associated protein phosphatase), is composed of three domains: an amino-terminal signal anchor, a kinase interaction (KI) domain, and a type 2C protein phosphatase catalytic region. Association of RLK5 with the KI domain is dependent on phosphorylation of RLK5 and can be abolished by dephosphorylation. KAPP may function as a signaling component in a pathway involving RLK5.	UNIV MISSOURI, DIV BIOL SCI, COLUMBIA, MO 65211 USA; UNIV MISSOURI, DEPT BIOCHEM, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia				Walker, John/0000-0002-2050-1641				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BRAUN D, UNPUB; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; DECHERT U, 1994, J BIOL CHEM, V269, P5602; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; HARLOW E, 1988, ANTIBODIES LABORATOR; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; HORN MA, 1994, BIOCHIM BIOPHYS ACTA, V208, P65; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; MACKINTOSH C, 1991, BIOCHEM J, V273, P733, DOI 10.1042/bj2730733; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MANN DJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P100, DOI 10.1016/0167-4781(92)90471-B; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH RD, 1993, PLANT MOL BIOL, V21, P307, DOI 10.1007/BF00019946; SMITH RD, 1991, PLANT PHYSIOL, V97, P677, DOI 10.1104/pp.97.2.677; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; STONE JD, UNPUB; TOBIAS CM, 1992, PLANT PHYSIOL, V99, P284, DOI 10.1104/pp.99.1.284; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; WALKER JC, 1993, PLANT J, V3, P451, DOI 10.1046/j.1365-313X.1993.t01-23-00999.x; WALKER JC, 1990, NATURE, V345, P743, DOI 10.1038/345743a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	227	240	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	1994	266	5186					793	795		10.1126/science.7973632	http://dx.doi.org/10.1126/science.7973632			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973632				2022-12-28	WOS:A1994PP75300036
J	CRIQUI, MH; RINGEL, BL				CRIQUI, MH; RINGEL, BL			DOES DIET OR ALCOHOL EXPLAIN THE FRENCH PARADOX	LANCET			English	Article							CORONARY HEART-DISEASE; HIGH-DENSITY-LIPOPROTEIN; RED WINE; CONSUMPTION; RISK; MORTALITY	The low rate of coronary heart disease (CHD) in France compared with other developed countries with comparable dietary intake has been called the French paradox. We explored this paradox by looking at alcohol, diet, and mortality data from 21 developed, relatively affluent countries in the years 1965, 1970, 1980, and 1988. We assessed wine, beer, and spirits intake separately. France had the highest wine intake and the highest total alcohol intake, and the second lowest CHD mortality rate. In univariate analyses, ethanol in wine was slightly more inversely correlated with CHD than total wine volume. In multivariate analyses, animal fat tended to be positively correlated, and fruit consumption inversely correlated, with CHD. Beer and spirits were only weakly inversely correlated with CHD. The strongest and most consistent correlation was the inverse association of wine ethanol with CHD. However, wine ethanol was unrelated to total mortality. We conclude that ethanol, particularly wine ethanol, is inversely related to CHD but not to longevity in populations. Although light to moderate alcohol consumption may improve longevity, alcohol abuse-which sharply reduces longevity-is correlated with average alcohol consumption in populations. Thus, while the risk/benefit ratio varies for individuals, the use of alcohol for cardioprotective purposes should not be encouraged as a public health measure.	UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego	CRIQUI, MH (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT FAMILY & PREVENT MED,LA JOLLA,CA 92093, USA.							ARTAUDWILD SM, 1993, CIRCULATION, V88, P2771, DOI 10.1161/01.CIR.88.6.2771; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; CRIQUI MH, 1990, BRIT J ADDICT, V85, P854; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; CRIQUI MH, IN PRESS CONT DRUG P; DEMROW HS, 1994, J AM COLL CARDIOL, V23, pA49; FOLTS JD, 1994, J AM COLL CARDIOL, V23, pA66; FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; GOODWIN DW, 1978, HOSP PRACT, V13, P121, DOI 10.1080/21548331.1978.11707340; JACKSON R, 1991, BRIT MED J, V303, P211, DOI 10.1136/bmj.303.6796.211; KLATSKY AL, 1993, AM J CARDIOL, V71, P467, DOI 10.1016/0002-9149(93)90460-T; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; RENAUD SC, 1992, AM J CLIN NUTR, V55, P1012, DOI 10.1093/ajcn/55.5.1012; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROSE G, 1991, CIRCULATION, V84, P1405, DOI 10.1161/01.CIR.84.3.1405; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; ULBRICHT TLV, 1991, LANCET, V338, P985, DOI 10.1016/0140-6736(91)91846-M; VEENSTRA J, 1990, ALCOHOL ALCOHOLISM, V25, P371; 1993, WORLD TABLES 1993; 1977, INT STATISTICS ALCOH, V27; 1990, UNPUB WORLD DRINK TR	27	415	425	0	39	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1719	1723		10.1016/S0140-6736(94)92883-5	http://dx.doi.org/10.1016/S0140-6736(94)92883-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7996999				2022-12-28	WOS:A1994PY28100006
J	JENNEY, MEM				JENNEY, MEM			LANGERHANS CELL HISTIOCYTOSIS - WHERE DO WE GO FROM HERE	LANCET			English	Editorial Material							EPIPODOPHYLLOTOXINS; LEUKEMIA; CHILDREN				JENNEY, MEM (corresponding author), ROYAL MANCHESTER CHILDRENS HOSP,MANCHESTER,LANCS,ENGLAND.							BROADBENT V, 1989, MED PEDIATR ONCOL, V17, P97, DOI 10.1002/mpo.2950170205; CARSTENSEN H, 1923, MED PEDIATR ONCOL, V21, P387; CHU T, 1987, LANCET, V1, P208; EGELER RM, 1994, MED PEDIATR ONCOL, V23, P81, DOI 10.1002/mpo.2950230204; EGELER RM, 1993, CANCER, V71, P565; GADNER H, 1994, MED PEDIATR ONCOL, V23, P72, DOI 10.1002/mpo.2950230203; HAWKINS MM, 1992, BRIT MED J, V304, P951, DOI 10.1136/bmj.304.6832.951; KANNOURAKIS G, 1994, BRIT J CANCER, V70, pS37; KOMP DM, 1987, NEW ENGL J MED, V316, P747, DOI 10.1056/NEJM198703193161211; KOMP DM, 1980, MED PEDIATR ONCOL, V8, P35, DOI 10.1002/mpo.2950080106; Langerhans P, 1868, VIRCHOWS ARCH PATHOL, V44, P325, DOI [DOI 10.1007/BF01959006, 10.1007/BF01959006]; MATUSRIDLEY M, 1983, MED PEDIATR ONCOL, V11, P99, DOI 10.1002/mpo.2950110206; PRITCHARD J, 1994, BR J CANCER S23, V70; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RANEY RB, 1989, MED PEDIATR ONCOL, V17, P20, DOI 10.1002/mpo.2950170106; SIMS DG, 1977, ARCH DIS CHILD, V52, P433, DOI 10.1136/adc.52.6.433; WILLMAN CL, 1994, BRIT J CANCER, V70, pS29	17	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1717	1718		10.1016/S0140-6736(94)92882-7	http://dx.doi.org/10.1016/S0140-6736(94)92882-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7996998				2022-12-28	WOS:A1994PY28100005
J	FOSTER, JW; DOMINGUEZSTEGLICH, MA; GUIOLI, S; KWOK, C; WELLER, PA; STEVANOVIC, M; WEISSENBACH, J; MANSOUR, S; YOUNG, ID; GOODFELLOW, PN; BROOK, JD; SCHAFER, AJ				FOSTER, JW; DOMINGUEZSTEGLICH, MA; GUIOLI, S; KWOK, C; WELLER, PA; STEVANOVIC, M; WEISSENBACH, J; MANSOUR, S; YOUNG, ID; GOODFELLOW, PN; BROOK, JD; SCHAFER, AJ			CAMPOMELIC DYSPLASIA AND AUTOSOMAL SEX REVERSAL CAUSED BY MUTATIONS IN AN SRY-RELATED GENE	NATURE			English	Article							CAMPTOMELIC DWARFISM; DETERMINING REGION; Y-CHROMOSOME; DELETION; PROTEIN; INHERITANCE; SEQUENCES; ENCODES; SOX-4; MOUSE	Induction of testis development in mammals requires the presence of the Y-chromosome gene SRY. This gene must exert its effect by interacting with other genes in the sex-determination pathway. Cloning of a translocation chromosome breakpoint from a sex-reversed patient with campomelic dysplasia, followed by mutation analysis of an adjacent gene, indicates that SOX9, an SRY-related gene, is involved in both bone formation and control of testis development.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 3EH,ENGLAND; CITY HOSP,CTR MED GENET,NOTTINGHAM,ENGLAND; UNIV NOTTINGHAM,QUEENS MED CTR,DEPT GENET,NOTTINGHAM NG7 2UH,ENGLAND; LAB GENETHON,F-91002 EVRY,FRANCE; INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND	University of Cambridge; University of Nottingham; University of Nottingham; University of London; University College London				Brook, John David/0000-0002-5946-6740; Stevanovic, Milena/0000-0003-4286-7334; Guioli, Silvana/0000-0002-4920-7745	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; BENNETT CP, 1993, J MED GENET, V30, P518, DOI 10.1136/jmg.30.6.518; BERNSTEIN R, 1980, J MED GENET, V17, P291, DOI 10.1136/jmg.17.4.291; BIANCHINE JW, 1971, LANCET, V1, P1017; BLACK DM, 1993, AM J HUM GENET, V52, P702; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; BRIDGE J, 1985, AM J MED GENET, V21, P225, DOI 10.1002/ajmg.1320210204; BUEHR M, 1993, DEVELOPMENT, V117, P273; CAPEL B, 1993, NAT GENET, V5, P301, DOI 10.1038/ng1193-301; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; CREMIN BJ, 1973, LANCET, V1, P488; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; DILLON N, 1994, CURR OPIN GENET DEV, V5, P260; FARR CJ, 1993, MAMM GENOME, V4, P577, DOI 10.1007/BF00361388; FOSTER JW, 1994, P NATL ACAD SCI USA, V91, P1927, DOI 10.1073/pnas.91.5.1927; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HOEFNAGEL D, 1978, CLIN GENET, V13, P489; HOUSTON CS, 1983, AM J MED GENET, V15, P3, DOI 10.1002/ajmg.1320150103; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; LEHRACH H., 1990, GENOME ANAL, P39; LENZINI E, 1988, ANN GENET-PARIS, V31, P175; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LYNCH SA, 1993, J MED GENET, V30, P683, DOI 10.1136/jmg.30.8.683; MANSOUR S, 1994, THESIS U LONDON; MARAIA R, 1991, CLIN GENET, V39, P401; McKusick V.A., 1992, MENDELIAN INHERITANC; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PARKHURST SM, 1994, SCIENCE, V264, P924, DOI 10.1126/science.8178152; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SCHILHAM MW, 1993, NUCLEIC ACIDS RES, V21, P2009, DOI 10.1093/nar/21.8.2009; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STEVANOVIC M, 1993, HUM MOL GENET, V2, P2013, DOI 10.1093/hmg/2.12.2013; THURMON TF, 1973, J PEDIATR-US, V83, P841, DOI 10.1016/S0022-3476(73)80384-1; TOMMERUP N, 1993, NAT GENET, V4, P170, DOI 10.1038/ng0693-170; TOMMERUP N, 1993, J MED GENET, V30, P713, DOI 10.1136/jmg.30.9.713; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; WALTER MA, 1993, TRENDS GENET, V9, P352, DOI 10.1016/0168-9525(93)90040-O; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; Wheater P. R., 1979, FUNCTIONAL HISTOLOGY; WILKIE AOM, 1993, AM J MED GENET, V46, P597, DOI 10.1002/ajmg.1320460527; WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744; YOUNG ID, 1992, J MED GENET, V29, P251, DOI 10.1136/jmg.29.4.251	44	1251	1313	2	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					525	530		10.1038/372525a0	http://dx.doi.org/10.1038/372525a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990924				2022-12-28	WOS:A1994PW08200044
J	FORGACS, I				FORGACS, I			ESCAPING GAS - IMMORTALITY, DEFLATION, AND TOXIC DILATION	LANCET			English	Editorial Material							MEGACOLON				FORGACS, I (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT GASTROENTEROL,LONDON,ENGLAND.							GARRETT JM, 1967, GASTROENTEROLOGY, V53, P93; GREENSTEIN AJ, 1985, J CLIN GASTROENTEROL, V7, P137, DOI 10.1097/00004836-198504000-00007; JALAN KN, 1969, GASTROENTEROLOGY, V57, P68, DOI 10.1016/s0016-5085(19)33962-9; KRAMER P, 1981, GASTROENTEROLOGY, V80, P433; MCINERNEY GT, 1962, GASTROENTEROLOGY, V42, P244; PANOS MZ, 1993, GUT, V34, P1726, DOI 10.1136/gut.34.12.1726; PRESENT DH, 1988, J CLIN GASTROENTEROL, V10, P485, DOI 10.1097/00004836-198810000-00004	7	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1521	1521		10.1016/S0140-6736(94)90344-1	http://dx.doi.org/10.1016/S0140-6736(94)90344-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983949				2022-12-28	WOS:A1994PV01700004
J	CROSS, JC; WERB, Z; FISHER, SJ				CROSS, JC; WERB, Z; FISHER, SJ			IMPLANTATION AND THE PLACENTA - KEY PIECES OF THE DEVELOPMENT PUZZLE	SCIENCE			English	Review							EMBRYONIC STEM-CELLS; HUMAN CHORIONIC-GONADOTROPIN; LEUKEMIA INHIBITORY FACTOR; HEPARIN HEPARAN-SULFATE; CARBOHYDRATE ANTIGEN EXPRESSION; INTERFERON RESPONSE SEQUENCE; COLONY-STIMULATING FACTOR; MATERNAL-FETAL INTERFACE; TROPHOBLAST GIANT-CELLS; ALBINO-DELETION COMPLEX	The mammalian embryo cannot develop without the placenta. Its specialized cells (trophoblast, endoderm, and extraembryonic mesoderm) form early in development. They attach the embryo to the uterus (implantation) and form vascular connections necessary for nutrient transport. In addition, the placenta redirects maternal endocrine, immune, and metabolic functions to the embryo's advantage. These complex activities are sensitive to disruption, as shown by the high incidence of early embryonic mortality and pregnancy diseases in humans, as well as the numerous peri-implantation lethal mutations in mice. Integration of molecular and developmental approaches has recently produced insights into the molecules that control these processes.	UNIV CALIF SAN FRANCISCO, RADIOBIOL & ENVIRONM HLTH LAB, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT STOMATOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	CROSS, JC (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, 600 UNIV AVE, TORONTO M5G 1X5, ON, CANADA.		Cross, James/AAU-2973-2020; Cross, James/F-4814-2011	Cross, James/0000-0003-0956-9378; Cross, James/0000-0003-0956-9378	NICHD NIH HHS [HD 26732, HD 22210, HD 30367] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD030367] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022210, P01HD026732] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; ALEXANDER CM, UNPUB; [Anonymous], 1952, MARSHALLS PHYSL REPR; APTE SS, 1994, DEV DYNAM, V200, P177, DOI 10.1002/aja.1002000302; ARCECI RJ, 1992, DEV BIOL, V151, P1, DOI 10.1016/0012-1606(92)90207-W; ARMANT DR, 1986, DEV BIOL, V116, P519, DOI 10.1016/0012-1606(86)90152-1; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BARLOW DP, 1994, TRENDS GENET, V10, P194, DOI 10.1016/0168-9525(94)90255-0; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BARTON SC, 1984, NATURE, V311, P374, DOI 10.1038/311374a0; Bass K. E., 1994, Molecular Biology of the Cell, V5, p353A; BASS KE, 1994, DEV BIOL, V164, P550, DOI 10.1006/dbio.1994.1223; BASS KE, 1993, IN VITRO FERTILIZATI, P182; Bazer F W, 1989, J Reprod Fertil Suppl, V37, P85; BEHRENDTSEN O, 1992, DEVELOPMENT, V114, P447; BENNETT D, 1975, CELL, V6, P441, DOI 10.1016/0092-8674(75)90033-1; BERNSTEIN A, 1993, SEM DEV BIOL, V4, P351; BHATT H, 1991, P NATL ACAD SCI USA, V88, P11408, DOI 10.1073/pnas.88.24.11408; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BRAGA VMM, 1993, J CELL SCI, V105, P397; BROWN DG, 1993, HISTOCHEM J, V25, P452, DOI 10.1007/BF00157810; BROWN JJG, 1992, DIFFERENTIATION, V52, P61, DOI 10.1111/j.1432-0436.1992.tb00500.x; BRULET P, 1980, P NATL ACAD SCI-BIOL, V77, P4113, DOI 10.1073/pnas.77.7.4113; BURT D, 1991, INT J CANCER, P117; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARNEY EW, 1993, MOL REPROD DEV, V34, P357, DOI 10.1002/mrd.1080340403; CARSON DD, 1987, DEV BIOL, V120, P228, DOI 10.1016/0012-1606(87)90120-5; CARSON DD, 1993, DEV BIOL, V155, P97, DOI 10.1006/dbio.1993.1010; CERNEUS DP, 1993, J CELL BIOL, V122, P1223, DOI 10.1083/jcb.122.6.1223; CHAOUAT G, 1990, J REPROD FERTIL, V89, P447; CHARD T, 1991, J ENDOCRINOL, V131, P337, DOI 10.1677/joe.0.1310337; CHARD T, 1989, J DEV PHYSIOL, V11, P271; Cross J. C., 1994, Molecular Biology of the Cell, V5, p453A; CROSS JC, UNPUB; CROSS JC, UUNPUB; CROY BA, 1990, J REPROD FERTIL, V88, P231, DOI 10.1530/jrf.0.0880231; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; DAMSKY CH, IN PRESS DEVELOPMENT; DARDIK A, 1992, DEV BIOL, V154, P396, DOI 10.1016/0012-1606(92)90078-U; DARDIK A, 1991, DEVELOPMENT, V113, P919; DAS SK, 1994, DEVELOPMENT, V120, P1071; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DEGREGORI J, 1994, GENE DEV, V8, P265, DOI 10.1101/gad.8.3.265; DENIZ G, 1994, J IMMUNOL, V152, P4255; DING L, 1993, J IMMUNOL, V151, P1224; DONALDSON WL, 1990, DEVELOPMENT, V110, P63; DUNGY LJ, 1991, AM J OBSTET GYNECOL, V165, P853, DOI 10.1016/0002-9378(91)90428-T; ELLIS SA, 1990, J IMMUNOL, V144, P731; ENDERS AC, 1981, CELLULAR MOL ASPECTS, P365; EVAHOLD BD, 1993, IMMUNOL TODAY, V14, P602; EVANS SM, 1993, DEV BIOL, V159, P485, DOI 10.1006/dbio.1993.1258; FARACH MC, 1987, DEV BIOL, V123, P401, DOI 10.1016/0012-1606(87)90398-8; FARIA TN, 1991, BIOL REPROD, V44, P327, DOI 10.1095/biolreprod44.2.327; FARIA TN, 1991, ENDOCRINOLOGY, V129, P2895, DOI 10.1210/endo-129-6-2895; FELDMAN B, UNPUB; FENDERSON BA, 1993, DIFFERENTIATION, V54, P85; FINN CA, 1973, J REPROD FERTIL, V34, P247, DOI 10.1530/jrf.0.0340247; FORRESTER LM, 1991, P NATL ACAD SCI USA, V88, P7514, DOI 10.1073/pnas.88.17.7514; FOSTER GR, 1991, P NATL ACAD SCI USA, V88, P2888, DOI 10.1073/pnas.88.7.2888; FOX H, 1979, PLACENTA NEGLECTED E, P351; GARDNER RL, 1993, J EXP ZOOL, V265, P54, DOI 10.1002/jez.1402650108; GARDNER RL, 1972, J EMBRYOL EXP MORPH, V28, P279; GENBACEV O, UNPUB; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GLASSER SR, 1987, DIFFERENTIATION, V35, P132, DOI 10.1111/j.1432-0436.1987.tb00161.x; GODEFROY O, 1990, New Biologist, V2, P875; GOODGER AM, 1993, J REPROD FERTIL, V99, P451, DOI 10.1530/jrf.0.0990451; GRAHAM CH, 1992, BIOL REPROD, V46, P561, DOI 10.1095/biolreprod46.4.561; GRAHAM CH, 1991, J CELL PHYSIOL, V148, P228, DOI 10.1002/jcp.1041480207; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GU Y, 1992, ENDOCRINOLOGY, V131, P1321, DOI 10.1210/en.131.3.1321; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; GURTNER GC, IN PRESS GENES DEV; HAMLIN GP, 1994, ENDOCRINOLOGY, V134, P2390, DOI 10.1210/en.134.6.2390; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; HEARN JP, 1991, J REPROD FERTIL, V92, P497; HECKEL JL, 1990, CELL, V62, P447, DOI 10.1016/0092-8674(90)90010-C; HERZ J, 1993, CELL, V73, P428, DOI 10.1016/0092-8674(93)90130-I; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HOLDENERKENNY B, 1992, BIOESSAYS, V14, P831, DOI 10.1002/bies.950141208; HOWARD M, 1992, IMMUNOL TODAY, V13, P198, DOI 10.1016/0167-5699(92)90153-X; HU XL, 1992, J REPROD IMMUNOL, V22, P257, DOI 10.1016/0165-0378(92)90047-8; HUGHSON EJ, 1990, J CELL BIOL, V1110; ILGREN EB, 1983, PLACENTA, V4, P307, DOI 10.1016/S0143-4004(83)80010-1; ISRAEL A, 1986, NATURE, V322, P743, DOI 10.1038/322743a0; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; JACOBS AL, 1991, J BIOL CHEM, V266, P15464; JAN YN, 1993, P NATL ACAD SCI USA, V90, P8305, DOI 10.1073/pnas.90.18.8305; Janatpour M. J., 1994, Molecular Biology of the Cell, V5, p453A; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JULIAN JA, 1994, DEVELOPMENT, V120, P661; KAMEDA T, 1990, PLACENTA, V11, P205, DOI 10.1016/S0143-4004(05)80266-8; KANBOURSHAKIR A, 1993, BIOL REPROD, V48, P977, DOI 10.1095/biolreprod48.5.977; KAUMA S, 1990, AM J OBSTET GYNECOL, V163, P1430, DOI 10.1016/0002-9378(90)90601-3; KAUMA SW, 1992, J CLIN ENDOCR METAB, V75, P951, DOI 10.1210/jc.75.3.951; KIMBER SJ, 1993, HISTOCHEM J, V25, P628, DOI 10.1007/BF00157877; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KING WA, 1991, CAN VET J, V32, P99; KOVATS S, 1991, COLLOQ INSE, V212, P21; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEAMAN DW, 1992, J INTERFERON RES, V12, P1, DOI 10.1089/jir.1992.12.1; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LESSEY BA, 1992, J CLIN INVEST, V90, P188, DOI 10.1172/JCI115835; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIBRACH CL, 1994, J BIOL CHEM, V269, P17125; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; LIM KH, 1993, SOC GYNECOLOGICAL IN; LIN H, 1993, J IMMUNOL, V151, P4562; LIN TP, IN PRESS DEV BIOL; LINDENBERG S, 1988, J REPROD FERTIL, V83, P149; LINDENBERG S, 1990, J REPROD FERTIL, V89, P431, DOI 10.1530/jrf.0.0890431; LIU LM, 1994, BIOL REPROD, V50, P149; LOHLER J, 1984, CELL, V38, P597, DOI 10.1016/0092-8674(84)90514-2; LOKE YW, 1991, CURR OPIN IMMUNOL, V3, P762, DOI 10.1016/0952-7915(91)90110-M; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; MALEFYT RD, 1992, CURR OPIN IMMUNOL, V4, P314, DOI 10.1016/0952-7915(92)90082-P; MASUHIRO K, 1991, J CLIN ENDOCR METAB, V72, P594, DOI 10.1210/jcem-72-3-594; MATTSSON R, 1992, BIOL REPROD, V46, P1176, DOI 10.1095/biolreprod46.6.1176; MCLAREN A, 1968, J ENDOCRINOL, V42, P453, DOI 10.1677/joe.0.0420453; MCLAREN A, 1976, ANNU REV GENET, V10, P361, DOI 10.1146/annurev.ge.10.120176.002045; MCLAREN A, 1970, OVA IMPLANTATION HUM, P18; MCMASTER MT, UUNPUB; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; MINCHEVANILSSON L, 1992, J IMMUNOL, V149, P2203; MOENS CB, 1993, DEVELOPMENT, V119, P485; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; NAGY A, 1990, DEVELOPMENT, V110, P815; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NESTLER JE, 1993, ENDOCRINOLOGY, V132, P566, DOI 10.1210/en.132.2.566; NG YK, 1993, MOL BIOL CELL S, V4, P195; NISHINO E, 1990, J CLIN ENDOCR METAB, V71, P436, DOI 10.1210/jcem-71-2-436; NISWANDER L, 1989, DEVELOPMENT, V105, P175; NISWANDER L, 1988, DEVELOPMENT, V102, P45; Niswender G.D., 1988, P489; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OSHEA JD, 1983, AM J ANAT, V166, P271, DOI 10.1002/aja.1001660304; OSHIMA RG, 1983, DEV BIOL, V99, P447, DOI 10.1016/0012-1606(83)90294-4; PALMIERI SL, IN PRESS DEV BIOL; PAMPFER S, 1991, MOL ENDOCRINOL, V5, P1931, DOI 10.1210/mend-5-12-1931; PAPAIOANNOU VE, 1988, DEV GENET, V9, P155, DOI 10.1002/dvg.1020090302; PAPAIOANNOU VE, 1987, DEV GENET, V8, P27, DOI 10.1002/dvg.1020080105; PATERSON HF, 1979, J EMBRYOL EXP MORPH, V52, P115; PAULESU L, 1991, LYMPHOKINE CYTOK RES, V10, P443; PERRY JS, 1981, J REPROD FERTIL, V62, P321; PETRAGLIA F, 1990, J CLIN ENDOCR METAB, V71, P487, DOI 10.1210/jcem-71-2-487; PETRAGLIA F, 1992, J CLIN ENDOCR METAB, V74, P1184, DOI 10.1210/jc.74.5.1184; PLOEGH HL, 1981, CELL, V24, P287, DOI 10.1016/0092-8674(81)90318-4; POLLARD JW, 1991, CURR OPIN IMMUNOL, V3, P772, DOI 10.1016/0952-7915(91)90112-E; POLLARD JW, COMMUNICATION; PORTER DG, 1982, J REPROD FERTIL, P113; QUEENAN JT, 1987, J BIOL CHEM, V262, P10903; RABINOVICI J, 1992, J CLIN ENDOCR METAB, V75, P571, DOI 10.1210/jc.75.2.571; RABOUDI N, 1992, J BIOL CHEM, V267, P11930; REBSTOCK S, 1993, DEV DYNAM, V198, P171, DOI 10.1002/aja.1001980303; REDMAN CWG, 1990, NEW ENGL J MED, V323, P478, DOI 10.1056/NEJM199008163230710; REDMAN CWG, 1991, PLACENTA, V12, P301, DOI 10.1016/0143-4004(91)90339-H; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROBERTS JM, 1989, AM J OBSTET GYNECOL, V161, P1200, DOI 10.1016/0002-9378(89)90665-0; ROBERTS JM, 1993, FETAL MED REV; ROBERTS RM, 1990, OXFORD REV REPROD B, V12, P147; ROBERTS RM, 1992, ENDOCR REV, V13, P432, DOI 10.1210/er.13.3.432; ROBY KF, 1993, J BIOL CHEM, V268, P3136; ROCKLIN RE, 1979, ANNU REV MED, V30, P375, DOI 10.1146/annurev.me.30.020179.002111; ROGERS MB, 1991, DEVELOPMENT, V113, P815; ROTH I, UNPUB; RUGH R, 1968, MOUSE ITS REPRODUCTI; SAJI F, 1990, AM J REPROD IMMUNOL, V24, P99, DOI 10.1111/j.1600-0897.1990.tb01046.x; SANDERS SK, 1991, J EXP MED, V174, P737, DOI 10.1084/jem.174.3.737; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SHEN MM, 1992, P NATL ACAD SCI USA, V89, P8240, DOI 10.1073/pnas.89.17.8240; Sherman M. I., 1976, The cell surface in animal embryogenesis and development., P81; SHIMONOVITZ S, 1994, AM J OBSTET GYNECOL, V171, P832, DOI 10.1016/0002-9378(94)90107-4; SHORT R V, 1969, Ciba Foundation Symposium, P2, DOI 10.1002/9780470719688.ch2; SIMON C, 1994, ENDOCRINOLOGY, V134, P521, DOI 10.1210/en.134.2.521; Solomon S., 1988, P2085; SOLOWAY P, UNPUB; SPIEGELMAN M, 1976, J EMBRYOL EXP MORPH, V36, P373; SPYROPOULOS DD, 1994, GENE DEV, V8, P1949, DOI 10.1101/gad.8.16.1949; STARKEY PM, 1988, IMMUNOLOGY, V65, P129; STEPHENS L, COMMUNICATION; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; STOTT D, 1993, GENE DEV, V7, P197, DOI 10.1101/gad.7.2.197; STURM KS, 1994, DEV DYNAM, V201, P11, DOI 10.1002/aja.1002010103; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0; SUTHERLAND AE, 1988, J CELL BIOL, V106, P1331, DOI 10.1083/jcb.106.4.1331; SUTHERLAND AE, 1993, DEVELOPMENT, V119, P1175; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; THREADGILL DW, UNPUB; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; VANWINKLE LJ, 1991, DEV BIOL, V146, P158, DOI 10.1016/0012-1606(91)90456-D; WATERHOUSE P, 1993, MOL REPROD DEV, V35, P219, DOI 10.1002/mrd.1080350302; WEGMANN TG, 1988, IMMUNOL LETT, V17, P297, DOI 10.1016/0165-2478(88)90001-6; WEGMANN TG, 1992, DEV COMP IMMUNOL, V16, P425, DOI 10.1016/0145-305X(92)90026-9; Weitlauf H.M., 1988, P231; WELSH AO, 1993, BIOL REPROD, V49, P38, DOI 10.1095/biolreprod49.1.38; WELSH AO, 1985, AM J ANAT, V172, P1, DOI 10.1002/aja.1001720102; WELSH AO, 1991, AM J ANAT, V192, P215, DOI 10.1002/aja.1001920302; WELSH AO, 1991, AM J ANAT, V192, P347, DOI 10.1002/aja.1001920404; WEWER UM, 1985, LAB INVEST, V53, P624; WHITE R, 1994, ENDOCRINOLOGY, V135, P175, DOI 10.1210/en.135.1.175; WHITE S, 1994, BIOL REPROD, V50, P73, DOI 10.1095/biolreprod50.1.73; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; WILEY LM, 1990, BIOESSAYS, V12, P67, DOI 10.1002/bies.950120204; WILKINSON MF, 1990, DEV BIOL, V141, P451, DOI 10.1016/0012-1606(90)90400-D; WILSON O, 1990, J CELL PHYSIOL, V143, P60, DOI 10.1002/jcp.1041430108; YAGEL S, 1989, J CLIN ENDOCR METAB, V68, P992, DOI 10.1210/jcem-68-5-992; YANG JT, IN PRESS DEVELOPMENT; YANGJT, 1993, DEVELOPMENT, V119, P1093; ZHOU Y, 1993, J CLIN INVEST, V91, P950, DOI 10.1172/JCI116316; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZMUIDZINAS A, IN PRESS EMBO J	218	1113	1139	2	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 2	1994	266	5190					1508	1518		10.1126/science.7985020	http://dx.doi.org/10.1126/science.7985020			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985020				2022-12-28	WOS:A1994PV01500032
J	KORACH, KS				KORACH, KS			INSIGHTS FROM THE STUDY OF ANIMALS LACKING FUNCTIONAL ESTROGEN-RECEPTOR	SCIENCE			English	Article							HORMONE; GENE; ADENOCARCINOMA; ACTIVATION; RESISTANCE; BINDING; CELLS	Estrogen hormones produce physiological actions within a variety of target sites in the body and during development by activating a specific receptor protein. Hormone responsiveness for the estrogen receptor protein was investigated at different stages of development with the use of gene knockout techniques because no natural genetic mutants have been described. A mutant mouse line without a functional estrogen receptor was created and is being used to assess estrogen responsiveness. Both sexes of these mutant animals are infertile and show a variety of phenotypic changes, some of which are associated with the gonads, mammary glands, reproductive tracts, and skeletal tissues.			KORACH, KS (corresponding author), NIEHS,REPROD & DEV TOXICOL LAB,RECEPTOR BIOL SECT,RES TRIANGLE PK,NC 27709, USA.			Korach, Kenneth/0000-0002-7765-418X				CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHROUSOS GP, 1993, ANN INTERN MED, V119, P1113, DOI 10.7326/0003-4819-119-11-199312010-00009; CLARK JH, 1979, MONOGRAPHS ENDOCRINO, pCH5; CONTE FA, 1994, J CLIN ENDOCR METAB, V78, P1287, DOI 10.1210/jc.78.6.1287; DUUKES M, 1994, J ENDOCRINOL, V141, P335; FUQUA SAW, 1993, J CELL BIOCHEM, V51, P135, DOI 10.1002/jcb.240510204; George F. W., 1988, PHYSL REPROD, P2; GOLDZIEHER JW, 1962, J CLIN ENDOCR METAB, V22, P325, DOI 10.1210/jcem-22-3-325; GORSKI J, 1976, ANNU REV PHYSIOL, V38, P425, DOI 10.1146/annurev.ph.38.030176.002233; GREEN S, 1991, NUCLEAR HORMONE RECE, P15; HECKERT LL, 1992, MOL ENDOCRINOL, V6, P70, DOI 10.1210/me.6.1.70; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; HOU Q, 1993, P NATL ACAD SCI USA, V90, P946; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; JENSEN EV, 1991, NUCLEAR HORMONE RECE, P1; JORDAN VC, 1984, PHARMACOL REV, V36, P245; KOMM BS, 1988, SCIENCE, V241, P81, DOI 10.1126/science.3164526; KORACH KS, 1981, TARGET ORGAN TOXICIT, V38, P39; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LYDON JE, COMMUNICATION; MAEDA N, 1986, ANNU REV GENET, V20, P81; MCDERMOTT MT, 1993, AM J MED, V94, P424, DOI 10.1016/0002-9343(93)90155-I; MIGLIACCIO S, 1992, ENDOCRINOLOGY, V130, P2617, DOI 10.1210/en.130.5.2617; NEWBOLD RR, 1982, CANCER RES, V42, P2003; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; SUDO K, 1983, ENDOCRINOLOGY, V112, P425, DOI 10.1210/endo-112-2-425; Szego C., 1981, BIOCHEM ACTION HORM, V8, P307; TENG CT, 1989, ENDOCRINOLOGY, V124, P992, DOI 10.1210/endo-124-2-992; Wilson J.D., 1983, METABOLIC BASIS INHE, P1001; WINTER RM, 1993, GROWTH GENET HORM, V7, P6	32	495	521	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1524	1527		10.1126/science.7985022	http://dx.doi.org/10.1126/science.7985022			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985022				2022-12-28	WOS:A1994PV01500034
J	KELNER, GS; KENNEDY, J; BACON, KB; KLEYENSTEUBER, S; LARGAESPADA, DA; JENKINS, NA; COPELAND, NG; BAZAN, JF; MOORE, KW; SCHALL, TJ; ZLOTNIK, A				KELNER, GS; KENNEDY, J; BACON, KB; KLEYENSTEUBER, S; LARGAESPADA, DA; JENKINS, NA; COPELAND, NG; BAZAN, JF; MOORE, KW; SCHALL, TJ; ZLOTNIK, A			LYMPHOTACTIN - A CYTOKINE THAT REPRESENTS A NEW CLASS OF CHEMOKINE	SCIENCE			English	Article							EXPRESSION; FAMILY; RECEPTOR; CLONING; CELLS	In this study, the cytokine-producing profile of progenitor T cells (pro-T cells) was determined. During screening of a complementary DNA library generated from activated mouse pro-T cells, a cytokine designated lymphotactin was discovered. Lymphotactin is similar to members of both the Cys-Cys and Cys-X-Cys chemokine families but lacks two of the four cysteine residues that are characteristic of the chemokines. Lymphotactin is also expressed in activated CD8(+) T cells and CD4(-)CD8(-) T cell receptor alpha beta(+) thymocytes. It has chemotactic activity for lymphocytes but not for monocytes or neutrophils. The gene encoding lymphotactin maps to chromosome one. Taken together, these observations suggest that lymphotactin represents a novel addition to the chemokine superfamily.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304; NCI,FREDERICK CANC RES & DEV CTR,ADV BIOSCI LABS BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Largaespada, David/C-9832-2014; Zlotnik, Albert/C-3791-2011; Bazan, J. Fernando/B-4562-2010					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; BACON KB, 1988, BRIT J PHARMACOL, V95, P966, DOI 10.1111/j.1476-5381.1988.tb11727.x; BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3097, DOI 10.1093/nar/21.13.3097; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DAVATELIS G, 1988, J EXP MED, V167, P1939, DOI 10.1084/jem.167.6.1939; ELLIOTT JF, 1990, P NATL ACAD SCI USA, V87, P6363, DOI 10.1073/pnas.87.16.6363; GODFREY DI, 1994, J IMMUNOL, V152, P4783; GODFREY DI, 1993, J IMMUNOL, V150, P4244; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KENNEDY JD, UNPUB; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387; ZLOTNIK A, 1992, J IMMUNOL, V149, P1211	18	590	631	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1395	1399		10.1126/science.7973732	http://dx.doi.org/10.1126/science.7973732			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973732				2022-12-28	WOS:A1994PT63200047
J	ZORIO, DAR; CHENG, NSN; BLUMENTHAL, T; SPIETH, J				ZORIO, DAR; CHENG, NSN; BLUMENTHAL, T; SPIETH, J			OPERONS AS A COMMON FORM OF CHROMOSOMAL ORGANIZATION IN C-ELEGANS	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; LEADER SEQUENCE; MESSENGER-RNA; GENE; PROTEIN	ALTHOUGH eukaryotic genes are usually transcribed individually, at least a few Caenorhabditis elegans genes appear to be transcribed polycistronically in clusters resembling bacterial operons(1). The spliced leader SL2 (ref. 2) is specific for trans-splicing to downstream genes in these operons(1). In addition, many C. elegans pre-mRNAs are trans-spliced to SL1 (ref. 3) near the 5' ends of pre-mRNAs(4,5). Because operons have not previously been found in higher eukaryotes, we have investigated how widespread they are in the C. elegans genome. We identified gene clusters using the extensive data generated by the genome project(6,7) and tested seven for trans-splicing specificity. All were found to fit expectations for polycistronic transcription. In addition, we surveyed reported C. elegans genes for irans-splicing specificity. Both methods indicate that the pre-mRNAs of about 70% of C. elegans genes are trans-spliced and as many as a quarter are transcribed in operons.			ZORIO, DAR (corresponding author), INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA.							CAPOWSKI EE, 1991, GENETICS, V129, P1061; CLARK SG, 1994, GENETICS, V137, P987; CONRAD R, 1993, EMBO J, V12, P1249, DOI 10.1002/j.1460-2075.1993.tb05766.x; CONRAD R, 1991, MOL CELL BIOL, V11, P1921, DOI 10.1128/MCB.11.4.1921; HU E, 1991, J BIOL CHEM, V266, P19796; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; HUANG XY, 1989, J MOL BIOL, V206, P411, DOI 10.1016/0022-2836(89)90490-7; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KUWABARA PE, 1992, MOL BIOL CELL, V3, P461, DOI 10.1091/mbc.3.4.461; LAND M, 1994, J BIOL CHEM, V269, P14820; LEE YH, 1992, GENE, V121, P227, DOI 10.1016/0378-1119(92)90126-A; MORGAN WR, 1993, MOL CELL BIOL, V13, P7133, DOI 10.1128/MCB.13.11.7133; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	17	226	228	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	1994	372	6503					270	272		10.1038/372270a0	http://dx.doi.org/10.1038/372270a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969472				2022-12-28	WOS:A1994PR88900052
J	GESSLER, K; KRAUSS, N; STEINER, T; BETZEL, C; SANDMANN, C; SAENGER, W				GESSLER, K; KRAUSS, N; STEINER, T; BETZEL, C; SANDMANN, C; SAENGER, W			CRYSTAL-STRUCTURE OF BETA-D-CELLOTETRAOSE HEMIHYDRATE WITH IMPLICATIONS FOR THE STRUCTURE OF CELLULOSE-II	SCIENCE			English	Article							PACKING ANALYSIS; POLYSACCHARIDES	The crystal structure of beta-D-cellotetraose shows the same molecular packing as cellulose II, with two antiparallel molecules in the unit cell. For cellulose II, the orientation of the C6-O6 bonds has been described as gauche-trans and trans-gauche, respectively, for the two antiparallel molecules, which otherwise have identical conformations. In contrast, in beta-D-cellotetraose all C6-O6 bonds are gauche-trans, but the conformations of the two antiparallel molecules are different. Energy minimization and molecular dynamics studies suggest that the structure of cellulose II should be reinvestigated in light of these findings.	FREE UNIV BERLIN,INST KRISTALLOG,D-14195 BERLIN,GERMANY; DESY,EUROPEAN MOLEC BIOL LAB OUTSTN,D-22603 HAMBURG,GERMANY	Free University of Berlin; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)			Betzel, Christian/G-8105-2018	Betzel, Christian/0000-0002-3879-5019; Krauss, Norbert/0000-0002-7128-4632				ALTOMARE A, 1994, J APPL CRYSTALLOGR, V27, P435, DOI 10.1107/S002188989400021X; BLACKWELL J, 1980, FIBER DIFFRACTION ME, P315; CREMER D, 1975, J AM CHEM SOC, V97, P1354, DOI 10.1021/ja00839a011; DUDLEY RL, 1983, J AM CHEM SOC, V105, P2469, DOI 10.1021/ja00346a059; ISOGAI A, 1989, MACROMOLECULES, V22, P3168, DOI 10.1021/ma00197a045; KOLPAK FJ, 1976, MACROMOLECULES, V9, P273, DOI 10.1021/ma60050a019; PERTSIN AJ, 1987, ATOM ATOM POTENTIAL, P204; POLANYI M, 1921, NATURWISSENSCHAFTEN, V18, P337; SARKO A, 1974, MACROMOLECULES, V7, P486, DOI 10.1021/ma60040a016; SHELDRICK GM, 1976, SHELX PROGRAM CRYSTA; STEINER T, 1994, CARBOHYD RES, V259, P1, DOI 10.1016/0008-6215(94)84192-6; STEINER T, IN PRESS CARBOHYD RE; STIPANOVIC AJ, 1976, MACROMOLECULES, V9, P851, DOI 10.1021/ma60053a027; 1993, DISCOVER VERSION 310; [No title captured]	15	59	59	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1027	1029		10.1126/science.7973653	http://dx.doi.org/10.1126/science.7973653			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973653				2022-12-28	WOS:A1994PQ92400039
J	UMAR, A; BOYER, JC; KUNKEL, TA				UMAR, A; BOYER, JC; KUNKEL, TA			DNA LOOP REPAIR BY HUMAN CELL-EXTRACTS	SCIENCE			English	Article							COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; ADENOCARCINOMA CELLS; GENETIC INSTABILITY; ESCHERICHIA-COLI; CARCINOMA; LINES; ESTABLISHMENT; MUTATIONS; SEQUENCES	An activity in human cell extracts is described tt lat repairs DNA with loops of five or more unpaired bases. Repair is strand-specific and is directed by a nick located 5' or 3' to the loop. This repair is observed in a colorectal cancer cell line that is devoid of a wild-type hMLH1 gene and is deficient in repair of mismatches. However, a cell line with deletions in both hMSH2 alleles is deficient in repair of both loops and mismatches. Defects in loop repair may be relevant to the repetitive-sequence instability observed in cancers and other hereditary diseases.	NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Kunkel, Thomas A./D-5088-2019; Umar, Asad/AAI-4560-2020	Kunkel, Thomas A./0000-0002-9900-1788; Umar, Asad/0000-0002-6239-8494				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALLTONEN LA, 1994, CANCER RES, V54, P1645; BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CARRAWAY M, 1993, J BACTERIOL, V175, P3972, DOI 10.1128/JB.175.13.3972-3980.1993; DAWE CJ, 1964, JNCI-J NATL CANCER I, V33, P441; DEXTER DL, 1979, CANCER RES, V39, P1020; ENGEL LW, 1978, CANCER RES, V38, P3352; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1993, CELL, V75, P1075; FISHEL R, IN PRESS SCIENCE; FREAKE HC, 1981, BIOCHEM BIOPH RES CO, V101, P1131, DOI 10.1016/0006-291X(81)91565-5; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; HAN HJ, 1993, CANCER RES, V53, P5087; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOTHE RA, 1993, CANCER RES, V53, P5849; MERLO A, 1994, CANCER RES, V54, P2098; METZGAR RS, 1982, CANCER RES, V42, P601; MIRET JJ, 1994, ENV MOL MUTAGEN S23, V23, P45; MIRONOV NM, 1994, CANCER RES, V54, P41; Morisawa T, 1987, J JPN SOC CLIN CYTOL, V26, P433; PAPDOPOULOS N, 1994, SCIENCE, V263, P1625; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PELTOMAKI P, 1993, CANCER RES, V53, P5853; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; SHIBATA D, 1994, NAT GENET, V6, P278; SHRIDHAR V, 1994, CANCER RES, V54, P2084; STRAND M, 1993, NATURE, V365, P273; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; TOM BH, 1976, IN VITRO CELL DEV B, V12, P180; UMAR A, 1994, J BIOL CHEM, V269, P14367; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; WU C, 1994, ONCOGENE, V9, P991; YEE CJ, 1994, CANCER RES, V54, P1641; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104	44	131	133	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					814	816		10.1126/science.7973637	http://dx.doi.org/10.1126/science.7973637			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973637				2022-12-28	WOS:A1994PP75300043
J	MADDOX, J				MADDOX, J			FRONTIERS OF IGNORANCE - OUR ANCESTORS ANCESTORS	NATURE			English	Editorial Material																		ANDREWS P, 1992, NATURE, V360, P641, DOI 10.1038/360641a0	1	1	1	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					32	32						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969410				2022-12-28	WOS:A1994PQ34800043
J	MADDOX, J				MADDOX, J			FRONTIERS OF IGNORANCE - THE GREAT LEAP FORWARD	NATURE			English	Editorial Material																			0	0	0	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					34	35						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969412				2022-12-28	WOS:A1994PQ34800047
J	CALMAN, K				CALMAN, K			THE PROFESSION OF MEDICINE	BRITISH MEDICAL JOURNAL			English	Article								It seems timely to define the purpose of medicine and examine the concept of a profession. This paper does so in the wider context of health, values in society, and the need to involve patients and the public as a whole. The author looks closely at what doctors do and concludes that making the diagnosis is a key element. The consultation is the building block for resource allocation. In addition to the diagnosis it sets out the prognosis and possible treatment and emphasises the importance of communicating these to the patient. Looking at the kind of doctor we need raises such issues as ethical standards, continuing professional development, team working, clinical standards, quality, outcomes, and research and development. Throughout, the role of education is seen as crucial. Leadership and vision are required by senior members of the profession if the opportunities presented are to be developed further.			CALMAN, K (corresponding author), DEPT HLTH,LONDON SW1A 2NS,ENGLAND.		Calman, Kenneth C/C-9855-2010					Calman K, 1994, J INTERPROFESSIONAL, V8, P95, DOI 10.3109/1356182940901040625; Calman K C, 1991, Ann Acad Med Singap, V20, P287; CALMAN KC, 1992, LIVERPOOL MED T, P29; CALMAN KC, 1992, UPDATE          0415, P709; 1992, STATE PUBLIC HLTH; 1993, LEARNING SUCCEED	6	63	66	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1994	309	6962					1140	1143		10.1136/bmj.309.6962.1140	http://dx.doi.org/10.1136/bmj.309.6962.1140			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987111	Green Published			2022-12-28	WOS:A1994PP69100029
J	BYTZER, P; HANSEN, JM; DEMUCKADELL, OBS				BYTZER, P; HANSEN, JM; DEMUCKADELL, OBS			EMPIRICAL H-2-BLOCKER THERAPY OR PROMPT ENDOSCOPY IN MANAGEMENT OF DYSPEPSIA	LANCET			English	Article							NON-ULCER DYSPEPSIA; GENERAL-PRACTICE; CIMETIDINE; EFFICACY; CARE	The recommended strategy for management of dyspepsia is empirical treatment with an H-2-blocking drug, followed by endoscopy if the symptoms do not respond or recur. We compared two strategies for the management of dyspepsia-treatment based on the results of prompt endoscopy (group 1) and empirical H-2-blocker treatment with diagnostic endoscopy only in cases of therapeutic failure or symptomatic relapse within 1 year (group 2). Eligible patients had symptoms severe enough to justify empirical H-2-blocker therapy. Symptoms, drug consumption, and sick-leave days were assessed through monthly diaries. Patients with non-organic dyspepsia diagnosed by endoscopy did not receive ulcer drugs. Of 414 patients randomised, 373 completed 1-year follow-up. Organic disease was found at endoscopy in 68 (33%) of 208 group-1 patients (ulcer in 45). Endoscopy was done in 136 (66%) of 206 group-2 patients. Case selection for endoscopy was not improved by the empirical treatment strategy, since the diagnostic profile was the same as in group 1 and 40% of the expected ulcer cases remained undiagnosed. After 1 year there were no differences in symptoms or quality of life measures. The empirical treatment strategy in dyspepsia was associated with higher costs, due mainly to a higher number of sick-leave days and cost of ulcer drug use. Prompt endoscopy is a cost-effective strategy in dyspeptic patients with symptoms severe enough to justify the current practice of empirical H-2-blocker treatment.			BYTZER, P (corresponding author), ODENSE UNIV HOSP, DEPT MED GASTROENTEROL S, DK-5000 ODENSE, DENMARK.			Schaffalitzky de Muckadell, Ove B/0000-0003-1969-2329				BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BLEIJENBERG G, 1989, GUT, V30, P1076, DOI 10.1136/gut.30.8.1076; BROWN C, 1990, BRIT MED J, V300, P829, DOI 10.1136/bmj.300.6728.829; BYTZER P, 1993, SCAND J GASTROENTERO, V28, P119, DOI 10.3109/00365529309096057; COLINJONES DG, 1988, LANCET, V1, P576; COLINJONES DG, 1987, ADV MED, P112; EDENHOLM M, 1985, SCAND J GASTROENTERO, V20, P163, DOI 10.3109/00365528509103953; GOODSON JD, 1989, J GEN INTERN MED, V4, P367, DOI 10.1007/BF02599683; HANSEN JM, 1991, DAN MED BULL, V38, P288; JOHANNESSEN T, 1990, SCAND J GASTROENTERO, V25, P689, DOI 10.3109/00365529008997594; JONSSON BG, 1990, PRACTICAL GUIDELINES, P40; KAGEVI I, 1989, SCAND J GASTROENTERO, V24, P145, DOI 10.3109/00365528909093029; KERRIGAN DD, 1990, BRIT MED J, V300, P374, DOI 10.1136/bmj.300.6721.374; LENNARDJONES JE, 1991, GUT, V32, P95; LYDEARD S, 1989, J ROY COLL GEN PRACT, V39, P495; NYREN O, 1986, J CLIN GASTROENTEROL, V8, P339, DOI 10.1097/00004836-198606002-00004; NYREN O, 1986, NEW ENGL J MED, V314, P339, DOI 10.1056/NEJM198602063140603; NYREN O, 1985, SCAND J GASTROENTERO, V20, P41; NYREN O, 1985, THESIS U UPPSALA SWE; PENSTON J, 1989, SCAND J GASTROENTERO, V24, P1145, DOI 10.3109/00365528909089269; Read L, 1982, Med Decis Making, V2, P415, DOI 10.1177/0272989X8200200405; SONNENBERG A, 1993, GASTROENTEROLOGY, V104, P489; Talley N, 1991, GASTROENTEROL INT, V4, P145; TALLEY NJ, 1988, ANN INTERN MED, V108, P865, DOI 10.7326/0003-4819-108-6-865; TALLEY NJ, 1992, GASTROENTEROLOGY, V102, P1259; TALLEY NJ, 1991, SCAND J GASTROENTERO, V26, P47; WADE AG, 1988, BMJ-BRIT MED J, V296, P971, DOI 10.1136/bmj.296.6627.971; WHITE LJ, 1985, ANN INTERN MED, V102, P266, DOI 10.7326/0003-4819-102-2-266; WILLIAMS B, 1988, LANCET, V2, P1349	29	284	285	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 2	1994	343	8901					811	816		10.1016/S0140-6736(94)92023-0	http://dx.doi.org/10.1016/S0140-6736(94)92023-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7980747				2022-12-28	WOS:A1994ND79200006
J	ALMOHANNA, FA; CADDY, KWT; BOLSOVER, SR				ALMOHANNA, FA; CADDY, KWT; BOLSOVER, SR			THE NUCLEUS IS INSULATED FROM LARGE CYTOSOLIC CALCIUM-ION CHANGES	NATURE			English	Article							SMOOTH-MUSCLE CELLS; C-FOS EXPRESSION; INTRACELLULAR CALCIUM; CONFOCAL MICROSCOPY; PORE COMPLEX; NEURONS; TRANSCRIPTION; TRANSIENTS; GRADIENTS; DYNAMICS	EXTRACELLULAR events regulate functions in the cell nucleus by means of calcium ions acting through effector enzymes1-5. Recently, the traditional view of the nuclear pore as freely permeable to small ions6,7 has been questioned as a result of reports that nuclear calcium can be regulated independently of cytosolic calcium8-12. We have used confocal microscopy of fluorescent Ca2+ indicators to investigate the Ca2+ dynamics between cytosol and nucleus in neurons. We find that a previously reported amplification of Ca2+ changes in the nucleus13-16 is a measurement artefact. Small changes of cytosolic Ca2+ cause equally rapid changes in nuclear Ca2+, consistent with the free diffusion of Ca2+ through nuclear pores. In contrast, large cytosolic Ca2+ increases (above 300 nM) are attempted in the nucleus. Our results show the nuclear envelope shapes but does not block the passage of Ca2+ signals from cytosol to nucleus.	UNIV LONDON UNIV COLL,DEPT PHYSIOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALMOHANNA FA, 1992, DEV BRAIN RES, V70, P287, DOI 10.1016/0165-3806(92)90209-F; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; BIRCH BD, 1992, P NATL ACAD SCI USA, V89, P7978, DOI 10.1073/pnas.89.17.7978; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; CONNOR JA, 1993, CELL CALCIUM, V14, P185, DOI 10.1016/0143-4160(93)90066-F; DIVIRGILIO F, 1990, CELL CALCIUM, V11, P57, DOI 10.1016/0143-4160(90)90059-4; DRAGUNOW M, 1989, NEUROSCI LETT, V101, P274, DOI 10.1016/0304-3940(89)90545-4; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HIMPENS B, 1992, AM J PHYSIOL, V263, pC95, DOI 10.1152/ajpcell.1992.263.1.C95; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; HOLLIDAY J, 1991, NEURON, V7, P787, DOI 10.1016/0896-6273(91)90281-4; MEHMET H, 1991, BRIT MED BULL, V47, P76, DOI 10.1093/oxfordjournals.bmb.a072463; MINTA A, 1989, J BIOL CHEM, V264, P8171; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MURDOCH GH, 1985, J BIOL CHEM, V260, P1852; NEYLON CB, 1990, AM J PHYSIOL, V259, pC675, DOI 10.1152/ajpcell.1990.259.4.C675; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SILVER RA, 1990, NATURE, V343, P751, DOI 10.1038/343751a0; STRICKER SA, 1992, DEV BIOL, V149, P370, DOI 10.1016/0012-1606(92)90292-O; WAHL M, 1992, J CELL PHYSIOL, V150, P593, DOI 10.1002/jcp.1041500321; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0	25	228	232	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					745	750		10.1038/367745a0	http://dx.doi.org/10.1038/367745a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	7993399				2022-12-28	WOS:A1994MX63100061
J	LEDGER, GA; KHOSLA, S; LINDOR, NM; THIBODEAU, SN; GHARIB, H				LEDGER, GA; KHOSLA, S; LINDOR, NM; THIBODEAU, SN; GHARIB, H			GENETIC TESTING IN THE DIAGNOSIS AND MANAGEMENT OF MULTIPLE ENDOCRINE NEOPLASIA TYPE-II	ANNALS OF INTERNAL MEDICINE			English	Article							MEDULLARY-THYROID CARCINOMA; C-CELL HYPERPLASIA; RET PROTOONCOGENE; CALCITONIN; CHROMOSOME-10; EXPERIENCE; MUTATIONS; GLAND	Purpose: To review significant advances in the early diagnosis and treatment of medullary thyroid carcinoma in patients with the multiple endocrine neoplasia II (MEN II) syndromes, advances made possible by the application of recently discovered genetic information. Data Sources: Recently published English-language literature on linkage analysis and DNA analysis in the MEN II syndromes. Study Selection: Articles on familiar and sporadic forms of medullary thyroid carcinoma; pentagastrin-calcitonin determination; and genetic testing. Data Extraction: Information from recent studies on 1) the usefulness and limitations of genetic testing, especially DNA and linkage analysis, in the early diagnosis of the familial form of thyroid carcinoma and 2) the correlation between the results of genetic testing and the results of biochemical screening. Data Synthesis: Medullary thyroid carcinoma accounts for most of the morbidity and mortality among patients with the familiar medullary thyroid carcinoma syndromes. Multiple endocrine neoplasia IIa and IIb and familiar medullary thyroid carcinoma are inherited conditions with autosomal dominance and incomplete penetrance. Traditionally, diagnosis of and screening for these conditions have been done using pentagastrin stimulation tests and plasma calcitonin determinations. Recent genetic mapping, however, has assigned the genes responsible for these tumors to the pericentromeric region of chromosome 10. Available data suggest that mutations in exon 10, 11, or 16 of the RET protooncogene are responsible for MEN IIa and IIb and familial non-MEN medullary thyroid carcinoma. Thus, genetic testing can identify affected members of a kindred and will probably lead to early thyroidectomy and possible cure for gene carriers. Conclusions: Early studies confirm the usefulness of DNA analysis in the diagnosis and treatment of patients with familial forms of medullary thyroid carcinoma. We review changes in the diagnosis and treatment of these patients and offer a strategy for operative intervention based on results of genetic testing.	MAYO CLIN & MAYO FDN, DIV ENDOCRINOL METAB & INTERNAL MED, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT MED GENET, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DIV EXPTL PATHOL & LAB MED, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic			Khosla, Sundeep/AAE-6170-2020	Khosla, Sundeep/0000-0002-2936-4372				CHONG GC, 1975, CANCER, V35, P695, DOI 10.1002/1097-0142(197503)35:3<695::AID-CNCR2820350323>3.0.CO;2-W; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ELIAS S, 1994, NEW ENGL J MED, V330, P1611, DOI 10.1056/NEJM199406023302213; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; EVANS DB, 1994, ENDOCRIN METAB CLIN, V23, P167, DOI 10.1016/S0889-8529(18)30123-3; GAGEL RF, 1988, NEW ENGL J MED, V318, P478, DOI 10.1056/NEJM198802253180804; GAGEL RF, 1989, ANN INTERN MED, V111, P802, DOI 10.7326/0003-4819-111-10-802; GAGEL RF, 1982, J PEDIATR-US, V101, P941, DOI 10.1016/S0022-3476(82)80014-0; GHARIB H, 1987, MAYO CLIN PROC, V62, P373, DOI 10.1016/S0025-6196(12)65441-X; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; KANE L, 1993, 21ST ANN M EUR THYR; LANDSVATER RM, 1993, AM J HUM GENET, V52, P335; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; MCDERMOTT MT, 1992, ENDOCRINOLOGIST, V2, P366; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; RAUE F, 1994, ENDOCRIN METAB CLIN, V23, P137, DOI 10.1016/S0889-8529(18)30121-X; SCOPSI L, 1991, MODERN PATHOL, V4, P297; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; SIPPLE JH, 1961, AM J MED, V31, P163, DOI 10.1016/0002-9343(61)90234-0; SIZEMORE GW, 1977, SURG CLIN N AM, V57, P633; SNOW KJ, 1994, ENDOCRIN METAB CLIN, V23, P157, DOI 10.1016/S0889-8529(18)30122-1; TELANDER RL, 1986, J PEDIATR SURG, V21, P1190, DOI 10.1016/0022-3468(86)90037-0; THOMAS PM, 1994, ENDOCRINOLOGIST, V4, P140, DOI 10.1097/00019616-199403000-00010; TSAI MS, 1994, J CLIN ENDOCR METAB, V78, P1261, DOI 10.1210/jc.78.5.1261; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; WELLS SA, 1994, ENDOCRIN METAB CLIN, V23, P215, DOI 10.1016/S0889-8529(18)30126-9; WELLS SA, 1994, 5TH INT WORKSH MULT	28	65	65	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					118	124		10.7326/0003-4819-122-2-199501150-00008	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7992986				2022-12-28	WOS:A1995QC05900008
J	MALONEY, SA; PEARSON, ML; GORDON, MT; DELCASTILLO, R; BOYLE, JF; JARVIS, WR				MALONEY, SA; PEARSON, ML; GORDON, MT; DELCASTILLO, R; BOYLE, JF; JARVIS, WR			EFFICACY OF CONTROL MEASURES IN PREVENTING NOSOCOMIAL TRANSMISSION OF MULTIDRUG-RESISTANT TUBERCULOSIS TO PATIENTS AND HEALTH-CARE WORKERS	ANNALS OF INTERNAL MEDICINE			English	Article						RESISTANCE; MULTIPLE; CROSS INFECTION; DISEASE TRANSMISSION; TUBERCULOSIS; INFECTION CONTROL	MYCOBACTERIUM-TUBERCULOSIS; IMMUNODEFICIENCY-SYNDROME; INFECTION; OUTBREAK	Objective: To assess the efficacy of control measures in decreasing nosocomial transmission of multidrug-resistant tuberculosis. Design: Retrospective cohort study. Setting: A teaching hospital in New York City. Population: 40 patients hospitalized with multidrug-resistant tuberculosis (case-patients) and health care workers receiving tuberculin skin testing. Interventions: Centers for Disease Control and Prevention (CDC) 1990 guidelines for preventing transmission of tuberculosis, including 1) prompt isolation and treatment of patients with tuberculosis; 2) rapid diagnostic techniques for processing Mycobacterium tuberculosis specimens; 3) negative-pressure isolation rooms; and 4) molded surgical masks for health care workers. Measurements: Proportion of case-patients with nosocomially acquired tuberculosis and rate of tuberculin skin test conversion among health care workers before and after implementation of control measures. Results: The proportion of patients with multidrug-resistant strains of M. tuberculosis decreased after the interventions (10 of 70 [14%] compared with 30 of 95 [32%] patients before the intervention; relative risk [RR], 0.5; 95% CI, 0.2 to 0.9). Before onset of multidrug-resistant tuberculosis, case-patients in the intervention period were as likely to be hospitalized on high-risk wards containing patients with tuberculosis (4 of 10 compared with 17 of 30 patients; RR, 0.7; P = 0.5) but were less likely to be exposed to another case-patient with tuberculosis (1 of 10 compared with 20 of 30 patients; RR, 0.2; P = 0.003). Tuberculin skin test conversion rates for health care workers assigned to wards housing patients with tuberculosis were lower in the intervention period than in the preintervention period (4 of 78 [5%] compared with 15 of 90 [17%] conversions; P = 0.02), decreasing to levels observed for workers assigned to other wards (4 of 78 [5%] compared with 9 of 228 [4%] conversions; P = 0.7). Conclusions: Implementing control measures reduced nosocomial transmission of multidrug-resistant strains to patients and health care workers.	CTR DIS CONTROL, HOSP INFECT PROGRAM, ATLANTA, GA 30333 USA; CABRINI MED CTR, NEW YORK, NY 10003 USA	Centers for Disease Control & Prevention - USA								BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P718; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; CHEN SK, 1994, AM J INFECT CONTROL, V22, P65, DOI 10.1016/0196-6553(94)90116-3; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; DEAN AG, 1991, EPI INFO VERSION 5 0; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; HUTTON MD, 1992, AM J INFECT CONTROL, V20, P24, DOI 10.1016/S0196-6553(05)80121-X; ISEMAN MD, 1992, ANN INTERN MED, V117, P251, DOI 10.7326/0003-4819-117-3-251; NOLAN CM, 1992, AM J INFECT CONTROL, V20, P30, DOI 10.1016/S0196-6553(05)80123-3; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; PITCHENIK AE, 1990, LANCET, V336, P440, DOI 10.1016/0140-6736(90)91987-L; PUGLIESE G, 1992, AM J INFECT CONTROL, V20, P37, DOI 10.1016/S0196-6553(05)80125-7; RAMIREZ JA, 1992, INFECT CONT HOSP EP, V13, P579, DOI 10.2307/30148459; SNIDER DE, 1985, JAMA-J AM MED ASSOC, V253, P3438, DOI 10.1001/jama.253.23.3438; VALWAY S, 1993, 33 INT C ANT AG CHEM, P231	20	143	144	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					90	95		10.7326/0003-4819-122-2-199501150-00002	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7993001				2022-12-28	WOS:A1995QC05900002
J	RUTHERFORD, SL; ZUKER, CS				RUTHERFORD, SL; ZUKER, CS			PROTEIN-FOLDING AND THE REGULATION OF SIGNALING PATHWAYS	CELL			English	Review							HEAT-SHOCK PROTEIN; GLUCOCORTICOID RECEPTOR; TYROSINE KINASE; HSP90; DROSOPHILA; SEVENLESS; FK506; BINDS; CELL	A growing number of intracellular signaling molecules are found associated with components of the cellular protein folding machinery. In this minireview we suggest that the same ancient cellular process that promotes the folding and assembly of nascent proteins plays a pivotal role in signal transduction by promoting the regulated folding or assembly and disassembly of mature signaling molecules between active and inactive states. Members of the protein folding machinery mediate the activity of various kinases, receptors, and transcription factors. These may be poised in late stages of folding or assembly until upstream signaling events trigger their biogenesis into activated molecules.	UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	RUTHERFORD, SL (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.							Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; DOYLE HJ, 1993, GENE DEV, V7, P633, DOI 10.1101/gad.7.4.633; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; ROSE DW, 1989, J BIOL CHEM, V264, P6239; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WILLMANN T, 1986, NATURE, V324, P688, DOI 10.1038/324688a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	29	173	188	1	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1129	1132		10.1016/0092-8674(94)90003-5	http://dx.doi.org/10.1016/0092-8674(94)90003-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001149				2022-12-28	WOS:A1994PZ86000003
J	MOSS, G; COHEN, S				MOSS, G; COHEN, S			PATENTS IN THE PUBLIC-INTEREST	NATURE			English	Article								The UH High Court has granted an injunction allowing Chiron Corporation a monopoly in selling hepatitis C virus test kits. The decision will be welcomed by the pharmaceutical and biotechnology industries.			MOSS, G (corresponding author), TAYLOR JOYNSON GARRETT,50 VICTORIA EMBANKMENT,LONDON EC4Y 0DX,ENGLAND.								0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					814	814						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997274				2022-12-28	WOS:A1994PY21200063
J	CHOO, Y; SANCHEZGARCIA, I; KLUG, A				CHOO, Y; SANCHEZGARCIA, I; KLUG, A			IN-VIVO REPRESSION BY A SITE-SPECIFIC DNA-BINDING PROTEIN DESIGNED AGAINST AN ONCOGENIC SEQUENCE	NATURE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTION FACTOR-IIIA; C-ABL PROTEIN; MAMMALIAN-CELLS; PHILADELPHIA-CHROMOSOME; DOMAINS; EXPRESSION; GENES; BCR	A DNA-binding peptide comprising three zinc-fingers has been engineered to bind specifically to a unique nine-base-pair region of a BCR-ABL fusion oncogene in preference to the parent genomic sequences. Binding to the target oncogene in chromosomal DNA is possible In transformed cells in culture, and results in blockage of transcription. Consequently, murine cells rendered independent of growth factors by the action of the oncogene revert to factor dependence upon transient transfection with a vector expressing the peptide.			CHOO, Y (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		SANCHEZ-GARCIA, ISIDRO/A-5631-2019	SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905; Choo, Yen/0000-0002-3348-9602				BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; CHOO Y, 1993, NUCLEIC ACIDS RES, V21, P3341, DOI 10.1093/nar/21.15.3341; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COONEY M, 1988, SCIENCE, V245, P725; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAIRALL L, 1992, J MOL BIOL, V226, P349, DOI 10.1016/0022-2836(92)90952-G; Fields Stanley, 1993, Methods (Orlando), V5, P116, DOI 10.1006/meth.1993.1016; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HERSCHBACH BM, 1994, NATURE, V370, P309, DOI 10.1038/370309a0; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NOWELL PC, 1960, SCIENCE, V132, P1197; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515	37	235	300	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					642	645		10.1038/372642a0	http://dx.doi.org/10.1038/372642a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990954	Green Submitted			2022-12-28	WOS:A1994PX30700076
J	DIMARZO, V; FONTANA, A; CADAS, H; SCHINELLI, S; CIMINO, G; SCHWARTZ, JC; PIOMELLI, D				DIMARZO, V; FONTANA, A; CADAS, H; SCHINELLI, S; CIMINO, G; SCHWARTZ, JC; PIOMELLI, D			FORMATION AND INACTIVATION OF ENDOGENOUS CANNABINOID ANANDAMIDE IN CENTRAL NEURONS	NATURE			English	Article							N-ACYLETHANOLAMINE PHOSPHOLIPIDS; RECEPTOR; BRAIN; GLYCEROPHOSPHOLIPIDS; AGONIST; BINDS; CELLS	ANANDAMIDE (N-arachidonoyl-ethanolamine) was recently identified as a brain arachidonate derivative that binds to and activates cannabinoid receptors(1-4), yet the mechanisms underlying formation, release and inactivation of this putative messenger molecule are still unclear. Were we report that anandamide is produced in and released from cultured brain neurons in a calcium ion-dependent manner when the neurons are stimulated with membrane-depolarizing agents. Anandamide formation occurs through phosphodiesterase-mediated cleavage of a novel phospholipid precursor, N-arachidonoyl-phosphatidylethanolamine. A similar mechanism also governs the formation of a family of anandamide congeners, whose possible roles in neuronal signalling remain unknown. Our results and those of others(5,6) indicate therefore that multiple biochemical pathways may participate in anandamide formation in brain tissue. The life span of extracellular anandamide is limited by a rapid and selective process of cellular uptake, which is accompanied by hydrolytic degradation to ethanolamine and arachidonate. Our results thus strongly support the proposed role of anandamide as an endogenous neuronal messenger.	INSERM,CTR PAUL BROCA,UNITE NEUROBIOL & PHARMACOL,PARIS,FRANCE; CNR,IST CHIM MOLEC INTERESSE BIOL,NAPLES,ITALY	Institut National de la Sante et de la Recherche Medicale (Inserm); Consiglio Nazionale delle Ricerche (CNR)			Fontana, Angelo/C-3354-2012; Di Marzo, Vincenzo/AAD-7742-2019; Fontana, Angelo/AAO-2741-2021	Fontana, Angelo/0000-0002-5453-461X; Di Marzo, Vincenzo/0000-0002-1490-3070; Fontana, Angelo/0000-0002-5453-461X				BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; COLODZIN M, 1963, BIOCHEM BIOPH RES CO, V10, P165, DOI 10.1016/0006-291X(63)90044-5; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; EPPS DE, 1982, CELL CALCIUM, V3, P531, DOI 10.1016/0143-4160(82)90043-4; EPPS DE, 1980, BIOCHIM BIOPHYS ACTA, V618, P420, DOI 10.1016/0005-2760(80)90260-X; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656; GULAYA NM, 1993, BIOCHIM BIOPHYS ACTA, V1152, P280, DOI 10.1016/0005-2736(93)90259-3; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KRUSZKA KK, 1994, J BIOL CHEM, V269, P14345; LU B, 1991, J NEUROSCI, V11, P318; MACKIE K, 1993, MOL PHARMACOL, V44, P498; MATSUMOTO M, 1973, BIOCHIM BIOPHYS ACTA, V296, P350, DOI 10.1016/0005-2760(73)90093-3; NATARAJAN V, 1984, J NEUROCHEM, V42, P1613, DOI 10.1111/j.1471-4159.1984.tb12750.x; PERTWEE RG, 1993, BRIT J PHARMACOL, V110, P1483, DOI 10.1111/j.1476-5381.1993.tb13989.x; PIOMELLI D, 1994, CRIT REV NEUROBIOL, V8, P65; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; SCHMID PC, 1983, J BIOL CHEM, V258, P9302; SCHMID PC, 1985, J BIOL CHEM, V260, P4145; YUE TL, 1994, CRIT REV NEUROBIOL, V8, P11	22	1268	1297	0	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					686	691		10.1038/372686a0	http://dx.doi.org/10.1038/372686a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990962	Green Submitted			2022-12-28	WOS:A1994PX30700089
J	GRUNDEMANN, D; GORBOULEV, V; GAMBARYAN, S; VEYHL, M; KOEPSELL, H				GRUNDEMANN, D; GORBOULEV, V; GAMBARYAN, S; VEYHL, M; KOEPSELL, H			DRUG EXCRETION MEDIATED BY A NEW PROTOTYPE OF POLYSPECIFIC TRANSPORTER	NATURE			English	Article							BASOLATERAL MEMBRANE-VESICLES; RENAL BRUSH-BORDER; ORGANIC CATIONS; TETRAETHYLAMMONIUM; PROTEIN; CLONING; MECHANISM; UPTAKE2; RNA	CATIONIC drugs of different types and structures (antihistaminics, antiarrhythmics, sedatives, opiates, cytostatics and antibiotics, for example) are excreted in mammals by epithelial cells of the renal proximal tubules and by hepatocytes in the liver(1-4). In the proximal tubules, two functionally disparate transport systems are involved which are localized in the basolateral and luminal plasma membrane and are different from the previously identified neuronal monoamine transporters and ATP-dependent multidrug exporting proteins(1-3,5-12). Here we report the isolation of a complementary DNA from rat kidney that encodes a 556-amino-acid membrane protein, OCT1, which has the functional characteristics of organic cation uptake over the basolateral membrane of renal proximal tubules and of organic cation uptake into hepatocytes. OCT1 is not homologous to any other known protein and is found in kidney, liver and intestine. As OCT1 translocates hydrophobic and hydrophilic organic cations of different structures, it is considered to be a new prototype of polyspecific transporters that are important for drug elimination.	UNIV WURZBURG,INST ANAT,D-97070 WURZBURG,GERMANY	University of Wurzburg			Gambaryan, Stepan/I-3940-2016; Gründemann, Dirk/AAD-2217-2022	Gambaryan, Stepan/0000-0002-1470-0791; 				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVID D, 1994, K GESELLSCHAFT NEPHR, P472; GINGRICH JA, 1992, FEBS LETT, V312, P115, DOI 10.1016/0014-5793(92)80917-6; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HOHAGE H, 1994, J PHARMACOL EXP THER, V268, P897; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MAGAGNIN S, 1992, J BIOL CHEM, V267, P15384; MEIJER DKF, 1990, J PHARMACOKINET BIOP, V18, P35, DOI 10.1007/BF01063621; MONTROSERAFIZADEH C, 1989, AM J PHYSIOL, V257, pF243, DOI 10.1152/ajprenal.1989.257.2.F243; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Pritchard J.B., 1992, KIDNEY PHYSL PATHOPH, P2921; Roch-Ramel F., 1992, HDB PHYSL 8, P2189; RUSS H, 1992, N-S ARCH PHARMACOL, V346, P158, DOI 10.1007/BF00165297; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLOSS P, 1992, FEBS LETT, V307, P76, DOI 10.1016/0014-5793(92)80905-V; SCHOMIG E, 1993, N-S ARCH PHARMACOL, V347, P379, DOI 10.1007/BF00165387; SCHOMIG E, 1990, N-S ARCH PHARMACOL, V341, P404; SCHULDINER S, 1994, J NEUROCHEM, V62, P2067; SOKOL PP, 1990, AM J PHYSIOL, V258, pF1599; TAKANO M, 1984, BIOCHIM BIOPHYS ACTA, V773, P113, DOI 10.1016/0005-2736(84)90556-X; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; Trendelenburg U, 1988, HDB EXP PHARM, P279; ULLRICH KJ, 1991, PFLUG ARCH EUR J PHY, V419, P84, DOI 10.1007/BF00373751; ULLRICH KJ, 1994, BBA-REV BIOMEMBRANES, V1197, P45, DOI 10.1016/0304-4157(94)90018-3; VEYHL M, 1993, J BIOL CHEM, V268, P25041; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF1040, DOI 10.1152/ajprenal.1987.253.5.F1040	27	559	575	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					549	552		10.1038/372549a0	http://dx.doi.org/10.1038/372549a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990927	Green Submitted			2022-12-28	WOS:A1994PW08200052
J	HUMPHREYS, GW; ROMANI, C; OLSON, A; RIDDOCH, MJ; DUNCAN, J				HUMPHREYS, GW; ROMANI, C; OLSON, A; RIDDOCH, MJ; DUNCAN, J			NON SPATIAL EXTINCTION FOLLOWING LESIONS OF THE PARIETAL LOBE IN HUMANS	NATURE			English	Article							ATTENTION; PICTURES; OBJECT; WORDS	EFFICIENT behaviour in the visual environment requires selection between stimuli competing for control of action. Many current models of selection are spatial: relevant objects are chosen by attending to their locations(1-3). The unilateral stimulus extinction observed following lesions of the parietal lobe provides evidence for spatial selection(4). Such patients may identify a single stimulus presented in their contralesional field, but can fail to detect the same stimulus when a competing stimulus is shown simultaneously on the ipsilesional side(5). Here we demonstrate that extinction need not be spatial in nature, but may be determined by characteristics of the objects to be selected. In two patients with parietal lobe lesions and poor spatial localization, pictures extinguished words and closed shapes extinguished open shapes. This object-based extinction indicates the existence of biases within non-spatial selection mechanisms which are independent of biases produced by spatial selection mechanisms. We suggest that selection of objects for action requires that the 'winners' produced by the independent competitive biases for selection are bound together within distinct neural areas concerned with object properties and space.	MRC,APPL PSYCHOL UNIT,CAMBRIDGE CB2 2EF,ENGLAND	University of Cambridge	HUMPHREYS, GW (corresponding author), UNIV BIRMINGHAM,SCH PSYCHOL,COGNIT SCI RES CTR,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Riddoch, Jane/F-7968-2010	Romani, Cristina/0000-0002-5693-4131; Duncan, John S/0000-0002-1373-0681; Duncan, John/0000-0002-9695-2764				Balint R, 1909, MON PSYCHIATR NEUROL, V25, P51; BIEDERMAN I, 1987, PSYCHOL REV, V94, P115, DOI 10.1037/0033-295X.94.2.115; COSLETT HB, 1991, BRAIN, V114, P1523, DOI 10.1093/brain/114.4.1523; Critchley M., 1953, PARIETAL LOBES; DRIVER J, 1991, COGNITIVE NEUROPSYCH, V8, P475, DOI 10.1080/02643299108253384; DUNCAN J, 1993, PERCEPTION, V2, P1261; EGLY R, 1994, J EXP PSYCHOL GEN, V123, P161, DOI 10.1037/0096-3445.123.2.161; HUMPHREYS GW, 1981, Q J EXP PSYCHOL-A, V33, P17, DOI 10.1080/14640748108400765; HUMPHREYS GW, 1993, ATTENTION PERFORMANC, V14; KROLL JF, 1984, J VERB LEARN VERB BE, V23, P39, DOI 10.1016/S0022-5371(84)90499-7; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; Mozer M C, 1990, J Cogn Neurosci, V2, P96, DOI 10.1162/jocn.1990.2.2.96; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1984, J NEUROSCI, V4, P1863; POTTER MC, 1975, NATURE, V253, P437, DOI 10.1038/253437a0; UNGERLEIDER LG, 1982, ANAL VISUAL BEHAVIOR	16	99	99	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					357	359		10.1038/372357a0	http://dx.doi.org/10.1038/372357a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PU287	7969493				2022-12-28	WOS:A1994PU28700054
J	MCGILL, JI; WHITE, JE				MCGILL, JI; WHITE, JE			ACYCLOVIR AND POSTHERPETIC NEURALGIA AND OCULAR INVOLVEMENT	BRITISH MEDICAL JOURNAL			English	Article							ZOSTER				MCGILL, JI (corresponding author), UNIV SOUTHAMPTON,GEN HOSP,EYE UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.							MCGILL J, 1987, BRIT J OPHTHALMOL, V71, P118, DOI 10.1136/bjo.71.2.118; MCGILL J, 1983, J INFECTION, V6, P157, DOI 10.1016/S0163-4453(83)92787-1; MCKENDRICK MW, 1986, BRIT MED J, V293, P1529, DOI 10.1136/bmj.293.6561.1529; PETERSLUND NA, 1981, LANCET, V2, P827; RAGOZZINO MW, 1982, MEDICINE, V61, P310, DOI 10.1097/00005792-198209000-00003	5	15	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1994	309	6962					1124	1124		10.1136/bmj.309.6962.1124	http://dx.doi.org/10.1136/bmj.309.6962.1124			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987104	Green Published			2022-12-28	WOS:A1994PP69100021
J	NAISH, J; BROWN, J; DENTON, B				NAISH, J; BROWN, J; DENTON, B			INTERCULTURAL CONSULTATIONS - INVESTIGATION OF FACTORS THAT DETER NON-ENGLISH SPEAKING WOMEN FROM ATTENDING THEIR GENERAL-PRACTITIONERS FOR CERVICAL SCREENING	BRITISH MEDICAL JOURNAL			English	Article							CYTOLOGY; RECALL	Objectives-To determine the factors that deter ethnic minority women living in east London from attending their general practitioner for cervical cytology screening. Design-Qualitative study by means of focus group discussions between October 1993 and March 1994. Setting-East London. Subjects-Non-health specific established community groups and specially convened groups of Bengali, Kurdish, Turkish, Urdu and Punjabi, and Chinese speaking women. Main outcome measures-The spontaneous views of non-English speaking women resident in east London on cervical screening, focusing on attitudes to screening, their experiences of the cervical cytology screening services as currently provided, and their knowledge and beliefs about cervical screening. Results-Some reported attitudinal barriers to cervical cytology screening such as fear of cancer were not deterrents. Administrative and language barriers were more important, as were inadequate surgery premises and concerns about sterility. Conclusion-Contrary to popular belief. among general practitioners in east London, women from ethnic minorities are enthusiastic about cervical cytology screening once they understand the purpose of the test and the call and recall procedures. It is possible to consult with community groups in their own language through focus group discussions, working with bilingual health advocates who have had a short practical training in facilitating small group discussions. This form of user consultation could be carried out focusing on other aspects of health promotion.	ROYAL LONDON HOSP,QUEEN MARY WESTFIELD COLL,LONDON E1 4NS,ENGLAND	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	NAISH, J (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,JOINT ACAD DEPT GEN PRACTICE & PRIMARY CARE,LONDON E1 4NS,ENGLAND.							ALLMAN ST, 1974, HLTH TRENDS, V6, P39; BAILIE R, 1990, NZ MED J, V103, P292; BEARDOW R, 1989, BMJ-BRIT MED J, V299, P98, DOI 10.1136/bmj.299.6691.98; BOWLING A, 1989, BRIT MED J, V298, P545, DOI 10.1136/bmj.298.6673.545; CULLUM DE, 1983, BRIT MED J, V287, P329, DOI 10.1136/bmj.287.6388.329; DAVISON RL, 1971, MED OFFICER, V1, P329; ELKIND AK, 1988, SOC SCI MED, V27, P651, DOI 10.1016/0277-9536(88)90014-7; Gregory S, 1991, Nurs Stand, V5, P32; KITZINGER J, 1994, SOCIOL HEALTH ILL, V16, P103, DOI 10.1111/1467-9566.ep11347023; MCKIE L, 1990, PATTERNS TAKE UP ATT; NAISH J, 1992, GENERAL PRACTITIONER; NATHOO V, 1988, BRIT MED J, V296, P1041, DOI 10.1136/bmj.296.6628.1041; PIERCE M, 1989, BMJ-BRIT MED J, V299, P160, DOI 10.1136/bmj.299.6692.160; Posner T, 1988, PREVENTION CERVICAL; ROSS SK, 1989, BRIT MED J, V299, P101, DOI 10.1136/bmj.299.6691.101; SANSOM CD, 1975, BRIT J PREV SOC MED, V29, P40; SCHWARTZ M, 1989, COMMUNITY MED, V11, P279; SHROFF KJ, 1988, BRIT MED J, V297, P1317, DOI 10.1136/bmj.297.6659.1317	18	86	87	2	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1994	309	6962					1126	1128						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987106				2022-12-28	WOS:A1994PP69100024
J	WHITE, RH; MCKITTRICK, T; HUTCHINSON, R; TWITCHELL, J				WHITE, RH; MCKITTRICK, T; HUTCHINSON, R; TWITCHELL, J			TEMPORARY DISCONTINUATION OF WARFARIN THERAPY - CHANGES IN THE INTERNATIONAL NORMALIZED RATION	ANNALS OF INTERNAL MEDICINE			English	Note							ANTICOAGULANT-THERAPY; SURGERY; OPERATIONS	Objective: To measure the rate of decrease of the international normalized ratio (INR) after temporary discontinuation of warfarin therapy. Design: Prospective evaluation of an outpatient cohort. Setting: University medical center anticoagulation clinic. Patients: 22 patients receiving a fixed evening dose of warfarin for whom temporary discontinuation of therapy was deemed safe. Measurements: Serial plasma samples were drawn for INR measurements approximately 20, 65, 115, and 185 hours after patients received the last dose of warfarin. in five patients, INR was measured twice daily for 5 days. Results: For patients with a mean steady-state INR of 2.6, the mean INR 65 hours (2.7 days) after discontinuation of warfarin therapy was 1.6 (range, 1.11 to 2.16); 20 of 22 patients (98%) had an INR greater than 1.2. The mean INR 115 hours (4.7 days) after discontinuation of warfarin therapy was 1.1; 5 of 22 patients (23%) had an INR of 1.2 or greater. in 5 patients studied in detail, the INR decreased exponentially and had a half-life that ranged from 0.52 to 1.2 days; the onset of maximal decrease began 24 to 36 hours after discontinuation of warfarin therapy. In the total cohort, age was a significant (P < 0.005) independent predictor of smaller decreases in the INR between day 1 and day 3 (regression coefficient = -6.8% +/- 2%/2 days per decade of age; R(2) = 0.34). Conclusions: By simulating preoperative discontinuation of warfarin therapy, we found that the INR decreases exponentially, with wide interpatient variation in the rate of decrease. Age is associated with a slower rate of decrease. To be certain that the INR at the time of the surgery is less than 6.2, warfarin should be withheld for 96 to 115 hours (4 doses) in patients with a steady-state INR between 2.0 and 3.0. For patients with a higher steady-state INR, a longer wait is necessary.	UNIV CALIF DAVIS, DAVIS, CA 95616 USA	University of California System; University of California Davis								CADE JF, 1979, MED J AUSTRALIA, V2, P292, DOI 10.5694/j.1326-5377.1979.tb125717.x; GAINEY SP, 1989, AM J OPHTHALMOL, V108, P142, DOI 10.1016/0002-9394(89)90008-1; KATHOLI RE, 1978, AM HEART J, V96, P163, DOI 10.1016/0002-8703(78)90080-7; MCINTYRE H, 1966, LANCET, V2, P99; MOLL AC, 1989, DOC OPHTHALMOL, V72, P367, DOI 10.1007/BF00153505; MUNGALL DR, 1985, J PHARMACOKINET BIOP, V13, P213, DOI 10.1007/BF01065653; OREILLY RA, 1963, J CLIN INVEST, V42, P1542, DOI 10.1172/JCI104839; OREILLY RA, 1987, PRINCIPLES PHARM THE, P1344; RAMSTROM G, 1993, J ORAL MAXIL SURG, V51, P1211, DOI 10.1016/S0278-2391(10)80291-5; ROSE SD, 1987, MED EVALUATION SURGI, P253; SELVIN S, 1991, STATISTICAL ANAL EPI; TINKER JH, 1978, JAMA-J AM MED ASSOC, V239, P738, DOI 10.1001/jama.239.8.738; TRAVIS S, 1989, BRIT J SURG, V76, P1107, DOI 10.1002/bjs.1800761102	13	190	194	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1995	122	1					40	42		10.7326/0003-4819-122-1-199501010-00006	http://dx.doi.org/10.7326/0003-4819-122-1-199501010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY502	7985894				2022-12-28	WOS:A1995PY50200006
J	JIN, YS; HOSKINS, R; HORVITZ, HR				JIN, YS; HOSKINS, R; HORVITZ, HR			CONTROL OF TYPE-D GABAERGIC NEURON DIFFERENTIATION BY C-ELEGANS UNC-30 HOMEODOMAIN PROTEIN	NATURE			English	Article							CAENORHABDITIS-ELEGANS; NERVOUS-SYSTEM; GENE ENCODES	THE Caenorhabditis elegans gene unc-30 is required for the develop ment and functioning of the 19 inhibitory GABAergic (gamma-aminobutyric-acid-secreting) type D motor neurons, which control locomotion(1-4). In unc-30 mutants the D neurons lack GABA(2) and have defects in axonal pathfinding and synaptic connections (J. White, personal communication). We report here that unc-30 encodes a homeodomain protein that is present in the nuclei of the D neurons at high levels in young larvae, in which the motor circuitry is formed, and at low levels in older animals. The UNC-30 protein is also present in six non-GABAergic neurons and is absent from the seven non-D-type GABAergic neurons. Ectopic expression of unc-30 induced GABA expression in cells that are normally not GABAergic. We propose that unc-30 functions as a transcriptional regulator within the type D neurons to control their terminal differentiation and that unc-30 is sufficient in some but not all cell types to induce GABA expression.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); MRC Laboratory Molecular Biology				Jin, Yishi/0000-0002-9371-9860				BABU P, 1981, MUTAT RES, V82, P269, DOI 10.1016/0027-5107(81)90156-1; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BRENNER S, 1974, GENETICS, V77, P71; BURGLIN TR, 1993, GUIDEBOOK HOMEOBOX G, P25; EMMONS SW, 1983, CELL, V32, P55, DOI 10.1016/0092-8674(83)90496-8; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; HODGKIN J, 1983, GENETICS, V103, P43; HOSKINS R, 1990, THESIS U CAMBRIDGE; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; MCINTIRE SL, 1993, NATURE, V364, P334, DOI 10.1038/364334a0; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3957; MILLER DM, 1992, NATURE, V355, P841, DOI 10.1038/355841a0; RUVKUN G, 1989, GENETICS, V121, P501; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Sulston J., 1988, NEMATODE CAENORHABDI, P587; TREISMAN J, 1989, CELL, V59, P553; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; [No title captured]	30	180	184	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					780	783		10.1038/372780a0	http://dx.doi.org/10.1038/372780a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997265				2022-12-28	WOS:A1994PY21200053
J	LEE, JC; LAYDON, JT; MCDONNELL, PC; GALLAGHER, TF; KUMAR, S; GREEN, D; MCNULTY, D; BLUMENTHAL, MJ; HEYS, JR; LANDVATTER, SW; STRICKLER, JE; MCLAUGHLIN, MM; SIEMENS, IR; FISHER, SM; LIVI, GP; WHITE, JR; ADAMS, JL; YOUNG, PR				LEE, JC; LAYDON, JT; MCDONNELL, PC; GALLAGHER, TF; KUMAR, S; GREEN, D; MCNULTY, D; BLUMENTHAL, MJ; HEYS, JR; LANDVATTER, SW; STRICKLER, JE; MCLAUGHLIN, MM; SIEMENS, IR; FISHER, SM; LIVI, GP; WHITE, JR; ADAMS, JL; YOUNG, PR			A PROTEIN-KINASE INVOLVED IN THE REGULATION OF INFLAMMATORY CYTOKINE BIOSYNTHESIS	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; RNA-BINDING PROTEIN; TYROSINE PHOSPHORYLATION; MURINE MACROPHAGES; ENDOTOXIN; IL-1; LIPOPOLYSACCHARIDE; INTERLEUKIN-1; PURIFICATION; EXPRESSION	Production of interleukin-1 and tumour necrosis factor from stimulated human monocytes is inhibited by a new series of pyridinyl-imidazole compounds. Using radiolabelled and radio-photoaffinity-labelled chemical probes, the target of these compounds was identified as a pair of closely related mitogen-activated protein kinase homologues, termed CSBPs. Binding of the pyridinyl-imidazole compounds inhibited CSBP kinase activity and could be directly correlated with their ability to inhibit cytokine production, suggesting that the CSBPs are critical for cytokine production.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC IMMUNOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT RADIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT GENE EXPRESS SCI,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	LEE, JC (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,KING OF PRUSSIA,PA 19406, USA.			White, John R/0000-0003-2998-1626				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DINARELLO CA, 1991, CURR OPIN IMMUNOL, V3, P941, DOI 10.1016/S0952-7915(05)80018-4; DONG ZY, 1993, J EXP MED, V177, P1071, DOI 10.1084/jem.177.4.1071; ERICKSON RL, 1991, J BIOL CHEM, V266, P6007; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GRANTHAM R, 1981, NUCLEIC ACIDS RES, V9, pR43; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HAN JH, 1993, J BIOL CHEM, V268, P25009; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HUANG LY, 1993, J BIOL CHEM, V268, P25769; KASPAR RL, 1994, J IMMUNOL, V153, P277; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KRUYS V, 1992, P NATL ACAD SCI USA, V89, P673, DOI 10.1073/pnas.89.2.673; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDER HM, 1992, CELL IMMUNOL, V144, P155, DOI 10.1016/0008-8749(92)90233-F; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1990, INT J IMMUNOTHER, V6, P1; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LIVI GP, 1990, MOL CELL BIOL, V10, P2678, DOI 10.1128/MCB.10.6.2678; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAHKOV AN, 1990, J EXP MED, V171, P35; SCHINDLER R, 1990, BLOOD, V76, P1631; SETH A, 1991, J BIOL CHEM, V266, P23521; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUNG SSJ, 1992, J EXP MED, V176, P897, DOI 10.1084/jem.176.3.897; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; YOUNG P, 1993, AGENTS ACTIONS, V39, pC67, DOI 10.1007/BF01972723; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	44	3055	3188	2	122	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					739	746		10.1038/372739a0	http://dx.doi.org/10.1038/372739a0			8	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997261				2022-12-28	WOS:A1994PY21200042
J	ISNER, JM; FELDMAN, LJ				ISNER, JM; FELDMAN, LJ			GENE-THERAPY FOR ARTERIAL-DISEASE	LANCET			English	Editorial Material							INTIMAL HYPERPLASIA; EXPRESSION INVIVO; CELLS; WALL		TUFTS UNIV,ST ELIZABETHS MED CTR,SCH MED,DEPT BIOMED RES,BOSTON,MA 02111	St. Elizabeth's Medical Center; Tufts University	ISNER, JM (corresponding author), TUFTS UNIV,ST ELIZABETHS MED CTR,SCH MED,DEPT MED CARDIOL,BOSTON,MA 02111, USA.		Feldman, Laurent/AGM-4472-2022					FELDMAN LJ, 1994, CIRCULATION, V90, P1; GORSKI DH, 1993, MOL CELL BIOL, V13, P3722, DOI 10.1128/MCB.13.6.3722; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; LECLERC G, 1992, J CLIN INVEST, V90, P936, DOI 10.1172/JCI115970; LOSORDO DW, 1994, CIRCULATION, V89, P785, DOI 10.1161/01.CIR.89.2.785; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL EG, 1989, SCIENCE, V244, P1342, DOI 10.1126/science.2499928; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; RIESSEN R, 1993, HUM GENE THER, V4, P749, DOI 10.1089/hum.1993.4.6-749; STEG PG, 1994, CIRCULATION, V90, P1648, DOI 10.1161/01.CIR.90.4.1648; TAKESHITA S, 1994, J CLIN INVEST, V93, P652, DOI 10.1172/JCI117017; TAKESHITA S, IN PRESS P NATL ACAD; 1994, MINUTES RECOMBINANT	16	34	38	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1653	1654		10.1016/S0140-6736(94)90454-5	http://dx.doi.org/10.1016/S0140-6736(94)90454-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996957				2022-12-28	WOS:A1994PX30200005
J	CORDES, SP; BARSH, GS				CORDES, SP; BARSH, GS			THE MOUSE SEGMENTATION GENE KR ENCODES A NOVEL BASIC DOMAIN LEUCINE-ZIPPER TRANSCRIPTION FACTOR	CELL			English	Article							CHICK-EMBRYO HINDBRAIN; MAF ONCOGENE; V-MAF; EXPRESSION; PROTEIN; MUTAGENESIS; DNA; DISRUPTION; MUTATIONS; DEFECTS	The mouse kreisler(kr) mutation causes segmentation abnormalities in the caudal hindbrain and defective inner ear development. Based on an inversion discovered in the original kr allele, we selected a candidate cDNA highly expressed in the developing caudal hindbrain. This cDNA encodes a basic domain-leucine zipper (bZIP) transcription factor and was confirmed to represent the kr gene by analysis of a second kr allele, generated by chemical mutagenesis, in which a serine is substituted for an asparagine residue conserved in the DNA-binding domain of all known bZIP family members. The identity, expression, and mutant phenotype of kr indicate an early role in axial patterning and provide insights into the molecular and embryologic mechanisms that govern hindbrain and otic development.	STANFORD UNIV,DEPT GENET,STANFORD,CA 94305; STANFORD UNIV,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University	CORDES, SP (corresponding author), STANFORD UNIV,DEPT PEDIAT,STANFORD,CA 94305, USA.		Cordes, Sabine P/A-5423-2012					AKAM M, 1987, DEVELOPMENT, V101, P1; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; DAVISSON MT, 1989, GENETIC VARIANTS STR, P416; Deol M S, 1968, J Med Genet, V5, P137, DOI 10.1136/jmg.5.2.137; DEOL MS, 1964, J EMBRYOL EXP MORPH, V12, P475; DETWILER SR, 1950, J EXP ZOOL, V113, P179, DOI 10.1002/jez.1401130108; DOVE WF, 1987, GENETICS, V116, P5; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1993, DEVELOPMENT, V117, P925; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; GUTHRIE S, 1991, J NEUROBIOL, V22, P742, DOI 10.1002/neu.480220709; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HERTWIG P., 1944, Z. menschl Vererb. -u. KonstLehre, V28, P327; Hertwig P., 1942, ZEITSCHR INDUKT ABSTAMM U VERERBUNGSL, V80, P220, DOI 10.1007/BF01741984; JUSTICE MJ, 1986, GENET RES, V47, P187, DOI 10.1017/S0016672300023119; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KEYNES R, 1990, NEURON, V4, P1, DOI 10.1016/0896-6273(90)90438-L; KURATANI SC, 1993, DEVELOPMENT, V117, P105; LAWRENCE PA, 1990, NATURE, V344, P382, DOI 10.1038/344382a0; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MCKAY IJ, 1994, DEVELOPMENT, V120, P2199; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; OLLMANN MM, 1992, GENOMICS, V13, P731, DOI 10.1016/0888-7543(92)90149-M; Pankratz Michael J., 1993, P467; RINCHIK EM, 1990, P NATL ACAD SCI USA, V87, P896, DOI 10.1073/pnas.87.3.896; SCHNEIDERMAUNOU.S, 1993, CELL, V0075; SIRACUSA LD, 1992, GENOME, V3, pS20; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TZAMARIAS D, 1992, P NATL ACAD SCI USA, V89, P2007, DOI 10.1073/pnas.89.6.2007; Vaage S., 1969, ERG ANAT ENTWICKLU, V41, P1; WILKINSON DG, 1993, BIOESSAYS, V15, P499, DOI 10.1002/bies.950150802; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WINKES BM, 1994, MAMM GENOME, V5, P3, DOI 10.1007/BF00360560; YNTEMA CL, 1950, J EXP ZOOL, V113, P211, DOI 10.1002/jez.1401130110	39	328	333	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					1025	1034		10.1016/0092-8674(94)90033-7	http://dx.doi.org/10.1016/0092-8674(94)90033-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001130				2022-12-28	WOS:A1994PY08600012
J	LIAN, JP; STONE, S; JIANG, Y; LYONS, P; FERRONOVICK, S				LIAN, JP; STONE, S; JIANG, Y; LYONS, P; FERRONOVICK, S			YPT1P IMPLICATED IN V-SNARE ACTIVATION	NATURE			English	Article							INTEGRAL MEMBRANE-PROTEIN; ENDOPLASMIC-RETICULUM; GOLGI-COMPLEX; VESICULAR TRANSPORT; SECRETORY PATHWAY; YEAST; FUSION; ER; ENCODES; IDENTIFICATION	SYNAPTOBREVIN-LIKE membrane proteins that reside on transport vesicles, called the vesicle SNARE (v-SNARE), play a key role in ensuring that a vesicle targets and fuses with its correct acceptor compartment(1-3). Here we show that Bos1p, the v-SNARE of yeast endoplasmic reticulum-to-Golgi transport vesicles, pairs with another integral membrane protein of similar topology (Sec22p) on vesicles. This pairing, which appears to require functional Ypt1p (Rab in mammalian cells), may aid the activity of Bos1p on this compartment. These findings suggest that Rabs regulate the specificity of membrane fusion by selectively activating the v-SNARE on carrier vesicles. Because the v-SNARE resides on more than one membrane, such a regulated activation step may be necessary to prevent the premature fusion of donor and acceptor compartments(4).	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University								DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GROESCH ME, 1992, METHOD ENZYMOL, V219, P137; GROESCH ME, 1990, J CELL BIOL, V111, P45, DOI 10.1083/jcb.111.1.45; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; WARREN G, 1993, NATURE, V362, P297, DOI 10.1038/362297a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	21	175	177	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					698	701		10.1038/372698a0	http://dx.doi.org/10.1038/372698a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990964				2022-12-28	WOS:A1994PX30700092
J	LIUZZI, M; DEZIEL, R; MOSS, N; BEAULIEU, P; BONNEAU, AM; BOUSQUET, C; CHAFOULEAS, JG; GARNEAU, M; JARAMILLO, J; KROGSRUD, RL; LAGACE, L; MCCOLLUM, RS; NAWOOT, S; GUINDON, Y				LIUZZI, M; DEZIEL, R; MOSS, N; BEAULIEU, P; BONNEAU, AM; BOUSQUET, C; CHAFOULEAS, JG; GARNEAU, M; JARAMILLO, J; KROGSRUD, RL; LAGACE, L; MCCOLLUM, RS; NAWOOT, S; GUINDON, Y			A POTENT PEPTIDOMIMETIC INHIBITOR OF HSV RIBONUCLEOTIDE REDUCTASE WITH ANTIVIRAL ACTIVITY IN-VIVO	NATURE			English	Article							HERPES-SIMPLEX VIRUS; COLORIMETRIC ASSAY; CARBOXYL TERMINUS; DNA-POLYMERASE; MUTANTS; SUBUNIT; TYPE-1; ACYCLOVIR; ASSOCIATION; SENSITIVITY	HERPES simplex viruses (HSV) types 1 and 2 encode their own ribonucleotide reductases (RNRs) (EC 1.17.4.1) to convert ribonucleoside diphosphates into the corresponding deoxyribonucleotides(1). Like other iron-dependent RNRs, the viral enzyme is formed by the reversible association of two distinct homodimeric subunits(2). The carboxy terminus of the RNR small subunit (R2) is critical for subunit association(3,4) and synthetic peptides containing these amino-acid sequences selectively inhibit the viral enzyme by preventing subunit association(4-9). Increasing evidence indicates that the HSV RNR is important for virulence and reactivation from latency(10-14). Previously, we reported on the design of HSV RNR inhibitors with enhanced inhibitory potency in vitro(4,15,16). We now report on BILD 1263, which to our knowledge is the first HSV RNR subunit-association inhibitor with antiviral activity in vivo. This compound suppresses the replication of HSV-1, HSV-2 and acyclovir-resistant HSV strains in cell culture, and also strongly potentiates the antiviral activity of acyclovir. Most importantly, its anti-herpetic activity is shown in a murine ocular model of HSV-1-induced keratitis, providing an example of potent nonsubstrate-based antiviral agents that prevent protein-protein inter actions. The unique antiviral properties of BILD 1263 may lead to the design of new strategies to treat herpesvirus infections in humans.			LIUZZI, M (corresponding author), BIO MEGA BOEHRINGER INGELHEIM RES INC,2100 CUNARD ST,LAVAL H7S 2G5,PQ,CANADA.		Deziel, Robert/ABA-9629-2020					BRANDT CR, 1992, J VIROL METHODS, V36, P209, DOI 10.1016/0166-0934(92)90052-F; BRANDT CR, 1991, J GEN VIROL, V72, P2043, DOI 10.1099/0022-1317-72-9-2043; BRAZEAU P, 1982, P NATL ACAD SCI-BIOL, V79, P7909, DOI 10.1073/pnas.79.24.7909; CAMERON JM, 1988, J GEN VIROL, V69, P2607, DOI 10.1099/0022-1317-69-10-2607; CHATIS PA, 1992, ANTIMICROB AGENTS CH, V36, P1589, DOI 10.1128/AAC.36.8.1589; COEN DM, 1991, ANTIVIR RES, V15, P287, DOI 10.1016/0166-3542(91)90010-O; COEN DM, 1989, ANTIMICROB AGENTS CH, V33, P1395, DOI 10.1128/AAC.33.8.1395; COEN DM, 1989, P NATL ACAD SCI USA, V86, P4736, DOI 10.1073/pnas.86.12.4736; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; COSENTINO G, 1991, BIOCHEM CELL BIOL, V69, P79, DOI 10.1139/o91-011; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FILATOV D, 1992, J BIOL CHEM, V267, P15816; FURMAN PA, 1981, J VIROL, V40, P936, DOI 10.1128/JVI.40.3.936-941.1981; GARRETT C, 1979, ANAL BIOCHEM, V99, P268, DOI 10.1016/S0003-2697(79)80005-6; IDOWU AD, 1992, ANTIVIR RES, V17, P145, DOI 10.1016/0166-3542(92)90048-A; JACOBSON JG, 1989, VIROLOGY, V173, P276, DOI 10.1016/0042-6822(89)90244-4; KNIPE DM, 1982, J VIROL, V43, P314, DOI 10.1128/JVI.43.1.314-324.1982; KROGSRUD RL, 1993, ANAL BIOCHEM, V213, P386, DOI 10.1006/abio.1993.1436; LANGLOIS M, 1986, J BIOL STAND, V14, P201, DOI 10.1016/0092-1157(86)90004-1; Liuzzi Michel, 1993, P225; MCCLEMENTS W, 1988, VIROLOGY, V162, P270, DOI 10.1016/0042-6822(88)90421-7; MOSS N, 1993, J MED CHEM, V36, P3005, DOI 10.1021/jm00072a021; PARADIS H, 1988, J BIOL CHEM, V263, P16045; Reardon J E, 1991, Adv Pharmacol, V22, P1, DOI 10.1016/S1054-3589(08)60031-9; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SACKS SL, 1989, ANN INTERN MED, V111, P893, DOI 10.7326/0003-4819-111-11-893; SUHNEL J, 1990, ANTIVIR RES, V13, P23, DOI 10.1016/0166-3542(90)90042-6; YAMADA Y, 1991, J INFECT DIS, V164, P1091, DOI 10.1093/infdis/164.6.1091	30	122	134	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					695	698		10.1038/372695a0	http://dx.doi.org/10.1038/372695a0			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990963				2022-12-28	WOS:A1994PX30700091
J	TOTH, EL				TOTH, EL			NEVER AGAIN, LISA - CHILDHOOD DIABETES IN A DYSFUNCTIONAL FAMILY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											TOTH, EL (corresponding author), UNIV ALBERTA, WALTER C MACKENZIE HLTH SCI CTR 2F129, DEPT MED, EDMONTON T6G 2R7, AB, CANADA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1994	121	12					979	980		10.7326/0003-4819-121-12-199412150-00014	http://dx.doi.org/10.7326/0003-4819-121-12-199412150-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW083	7978726				2022-12-28	WOS:A1994PW08300014
J	DRENNAN, CL; HUANG, S; DRUMMOND, JT; MATTHEWS, RG; LUDWIG, ML				DRENNAN, CL; HUANG, S; DRUMMOND, JT; MATTHEWS, RG; LUDWIG, ML			HOW A PROTEIN BINDS B-12 - A 3.0-ANGSTROM X-RAY STRUCTURE OF B-12-BINDING DOMAINS OF METHIONINE SYNTHASE	SCIENCE			English	Article							METHYLMALONYL-COA MUTASE; CYTOCHROME-C PEROXIDASE; ESCHERICHIA-COLI; METH GENE; CLONING; ACTIVATION; FLAVODOXIN; SEQUENCE; MODELS; ENZYME	The crystal structure of a 27-kilodalton methylcobalamin-containing fragment of methi onine synthase from Escherichia coli was determined at 3.0 Angstrom resolution. This structure depicts cobalamin-protein interactions and reveals that the corrin macrocycle lies between a helical amino-terminal domain and an alpha/beta carboxyl-terminal domain that is a variant of the Rossmann fold. Methylcobalamin undergoes a conformational change on binding the protein; the dimethylbenzimidazole group, which is coordinated to the cobalt in the free cofactor, moves away from the corrin and is replaced by a histidine contributed by the protein. The sequence Asp-X-His-X-X-Gly, which contains this histidine ligand, is conserved in the adenosylcobalamin-dependent enzymes methylmalonyl-coenzyme A mutase and glutamate mutase, suggesting that displacement of the dimethylbenzimidazole will be a feature common to many cobalamin-binding proteins. Thus the cobalt ligand, His(759), and the neighboring residues Asp(757) and Ser(810), may form a catalytic quartet, Co-His-Asp-Ser, that modulates the reactivity of the B-12 prosthetic group in methionine synthase.	UNIV MICHIGAN, DIV BIOPHYS RES, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024908, R37GM024908, T32GM008570] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24908, GM16429, GM08570] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babior B. M., 1982, B12, V2, P263; Baker J. J., 1982, B12, V2, P203; BANERJEE RV, 1989, J BIOL CHEM, V264, P13888; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; Blakley R.L., 1982, B12, V2, P381; BRINKSHOEMAKER C, 1964, PROC R SOC LON SER-A, V278, P1, DOI 10.1098/rspa.1964.0042; BRUNGER A, 1993, X PLOR VERSION 3 1 M; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; COX JM, 1967, J MOL BIOL, V28, P151, DOI 10.1016/S0022-2836(67)80083-4; DRUMMOND JT, 1993, BIOCHEMISTRY-US, V32, P9290, DOI 10.1021/bi00087a005; DRUMMOND JT, 1994, BIOCHEMISTRY-US, V33, P3732, DOI 10.1021/bi00178a033; DRUMMOND JT, 1993, BIOCHEMISTRY-US, V32, P9282, DOI 10.1021/bi00087a004; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; FUJII K, 1977, ARCH BIOCHEM BIOPHYS, V178, P662, DOI 10.1016/0003-9861(77)90238-7; FUJII K, 1974, J BIOL CHEM, V249, P6745; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; HALPERN J, 1982, B12, V1, P501; HARRIS NL, 1994, J MOL BIOL, V236, P1356, DOI 10.1016/0022-2836(94)90063-9; HODGKIN DC, 1956, NATURE, V178, P64, DOI 10.1038/178064a0; HODGKIN DC, 1959, PROC R SOC LON SER-A, V251, P306, DOI 10.1098/rspa.1959.0111; HODGKIN DC, 1957, PROC R SOC LON SER-A, V242, P228, DOI 10.1098/rspa.1957.0174; HODGKIN DC, 1962, PROC R SOC LON SER-A, V266, P494, DOI 10.1098/rspa.1962.0074; JANSEN R, 1989, GENOMICS, V4, P198, DOI 10.1016/0888-7543(89)90300-5; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIMURA N, 1994, J AM CHEM SOC, V116, P4087, DOI 10.1021/ja00088a058; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUTLER B, 1987, HELV CHIM ACTA, V70, P1268, DOI 10.1002/hlca.19870700506; LENHERT PG, 1968, PROC R SOC LON SER-A, V303, P45, DOI 10.1098/rspa.1968.0039; LENHERT PG, 1961, NATURE, V192, P937, DOI 10.1038/192937a0; LEXA D, 1988, J AM CHEM SOC, V110, P7617, DOI 10.1021/ja00231a006; LEXA D, 1983, ACCOUNTS CHEM RES, V16, P235, DOI 10.1021/ar00091a001; LUDWIG ML, 1992, CHEM BIOCH FLAVOENZY, V3, P427; LUSCHINSKY CL, 1992, J MOL BIOL, V225, P557, DOI 10.1016/0022-2836(92)90940-L; MARSH ENG, 1992, FEBS LETT, V310, P167, DOI 10.1016/0014-5793(92)81321-C; MARSH N, 1988, J MOL BIOL, V200, P421, DOI 10.1016/0022-2836(88)90252-5; MATTHEWS RG, 1984, FOLATES PTERINS, V1, P497; MCKIE N, 1990, BIOCHEM J, V269, P293, DOI 10.1042/bj2690293; OLD IG, 1990, GENE, V87, P15, DOI 10.1016/0378-1119(90)90490-I; OSBORNE C, 1991, J BACTERIOL, V173, P1729, DOI 10.1128/jb.173.5.1729-1737.1991; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; POULOS TL, 1980, J BIOL CHEM, V255, P575; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Retey J., 1982, B12, VII, P357; ROSSI M, 1985, J AM CHEM SOC, V107, P1729, DOI 10.1021/ja00292a046; ROUSSEAU DG, 1992, J STRUCT BIOL, V109, P13; SCHRAUZER GN, 1969, J AM CHEM SOC, V91, P3341, DOI 10.1021/ja01040a041; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SMITH DR, 1994, U00017 GENBA; STEIGEMANN W, 1974, THESIS TU MUNICH; SUMMERS MF, 1983, J AM CHEM SOC, V105, P6259, DOI 10.1021/ja00358a012; SUMMERS MF, 1984, J AM CHEM SOC, V106, P4478, DOI 10.1021/ja00328a030; SWITZER RL, 1982, B12, V2, P289; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; TAYLOR RT, 1982, B12, V2, P307; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; Toraya T., 1982, B12, P233; WATT W, 1991, J MOL BIOL, V218, P195, DOI 10.1016/0022-2836(91)90884-9; WHITE JG, 1962, PROC R SOC LON SER-A, V266, P440, DOI 10.1098/rspa.1962.0072; WIRT MD, 1992, BIOPHYS J, V63, P412, DOI 10.1016/S0006-3495(92)81605-3	62	527	537	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	1994	266	5191					1669	1674		10.1126/science.7992050	http://dx.doi.org/10.1126/science.7992050			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992050				2022-12-28	WOS:A1994PW30800029
J	SPECHLER, SJ; ZEROOGIAN, JM; ANTONIOLI, DA; WANG, HH; GOYAL, RK				SPECHLER, SJ; ZEROOGIAN, JM; ANTONIOLI, DA; WANG, HH; GOYAL, RK			PREVALENCE OF METAPLASIA AT THE GASTROESOPHAGEAL JUNCTION	LANCET			English	Article							BARRETTS-ESOPHAGUS; INCREASING INCIDENCE; ADENOCARCINOMA; CARDIA	Specialised columnar epithelium (SCE), a form of intestinal metaplasia usually found in Barrett's oesophagus, cannot be distinguished endoscopically from normal gastric epithelium. Endoscopists seldom obtain biopsy specimens from a normal-appearing gastro-oesophageal junction, and therefore short segments of SCE in this region may go unrecognised. We studied patients who had short segments of SCE at the gastro-oesophageal junction. All patients scheduled for elective endoscopic examinations in our general endoscopy unit, irrespective of indication, were questioned for symptoms of gastro-oesophageal reflux disease. At endoscopy, severity of oesophagitis was graded, and biopsy specimens obtained from the squamocolumnar junction, irrespective of its appearance or location in the oesophagus. Among 142 patients without endoscopically apparent Barrett's oesophagus, 26 (18%) were found to have SCE. All patients with SCE were white, and the male/female ratio was 1.9. In contrast, non-whites accounted for 14% of the 114 patients without SCE and the male/female ratio was 0.8. The groups did not differ significantly in the frequency of symptoms and endoscopic signs of gastrooesophageal reflux. We conclude that adults frequently have unrecognised segments of SCE at the gastro-oesophageal junction; this may underlie the rising frequency of cancer of the gastrooesophageal junction in the USA and Europe.	BETH ISRAEL HOSP, DEPT PATHOL, CTR SWALLOWING DISORDERS, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	SPECHLER, SJ (corresponding author), BETH ISRAEL HOSP, DEPT MED, CTR SWALLOWING DISORDERS, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031092, R01DK031092] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31092] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRETT NR, 1950, BRIT J SURG, V38, P175, DOI 10.1002/bjs.18003815005; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BLOT WJ, 1993, JAMA-J AM MED ASSOC, V270, P1320, DOI 10.1001/jama.270.11.1320; BONELLI L, 1991, INT J CANCER, V48, P364; CAMERON AJ, 1992, GASTROENTEROLOGY, V103, P1241, DOI 10.1016/0016-5085(92)91510-B; DAS KM, 1994, ANN INTERN MED, V120, P753, DOI 10.7326/0003-4819-120-9-199405010-00006; DELAPAVA S, 1964, NEW YORK STATE J MED, V64, P1831; GOYAL RK, 1970, NEW ENGL J MED, V282, P1298, DOI 10.1056/NEJM197006042822305; Goyal RK, 1985, BARRETTS ESOPHAGUS P, P1; HAGGITT RC, 1992, HUM PATHOL, V23, P475, DOI 10.1016/0046-8177(92)90121-I; Haggitt RC, 1985, BARRETTS ESOPHAGUS P, P153; HAMILTON SR, 1988, HUM PATHOL, V19, P942, DOI 10.1016/S0046-8177(88)80010-8; HANSSON LE, 1993, INT J CANCER, V54, P402, DOI 10.1002/ijc.2910540309; HASSALL E, 1993, J PEDIATR GASTR NUTR, V16, P345, DOI 10.1097/00005176-199305000-00001; KIM SL, 1994, GASTROENTEROLOGY, V107, P945, DOI 10.1016/0016-5085(94)90217-8; MCCLAVE SA, 1987, GASTROINTEST ENDOSC, V33, P413, DOI 10.1016/S0016-5107(87)71676-9; Moller H, 1992, Eur J Cancer Prev, V1, P159; MORSON BC, 1955, BRIT J CANCER, V9, P365, DOI 10.1038/bjc.1955.35; OVASKA J, 1989, DIGEST DIS SCI, V34, P1336, DOI 10.1007/BF01538065; PAULL A, 1976, NEW ENGL J MED, V295, P476, DOI 10.1056/NEJM197608262950904; POWELL J, 1990, BRIT J CANCER, V62, P440, DOI 10.1038/bjc.1990.314; RAPHAEL HA, 1966, ANN SURG; REID BJ, 1987, ANNU REV MED, V38, P477, DOI 10.1146/annurev.med.38.1.477; ROTHERY GA, 1986, GUT, V27, P1062, DOI 10.1136/gut.27.9.1062; SCHMIDT HG, 1985, J CANCER RES CLIN, V110, P145, DOI 10.1007/BF00402729; SCHNELL TG, 1992, DIGEST DIS SCI, V37, P137, DOI 10.1007/BF01308357; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605; TRIER JS, 1985, BARRETTS ESOPHAGUS P, P19; Tuyns A J, 1992, Eur J Cancer Prev, V1, P275, DOI 10.1097/00008469-199204000-00010; Winters C, 1987, GASTROENTEROLOGY, V92, P118, DOI 10.1016/0016-5085(87)90847-X	30	492	500	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 3	1994	344	8936					1533	1536		10.1016/S0140-6736(94)90349-2	http://dx.doi.org/10.1016/S0140-6736(94)90349-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983953				2022-12-28	WOS:A1994PV01700009
J	JAFFE, HW; MCCURDY, JM; KALISH, ML; LIBERTI, T; METELLUS, G; BOWMAN, BH; RICHARDS, SB; NEASMAN, AR; WITTE, JJ				JAFFE, HW; MCCURDY, JM; KALISH, ML; LIBERTI, T; METELLUS, G; BOWMAN, BH; RICHARDS, SB; NEASMAN, AR; WITTE, JJ			LACK OF HIV TRANSMISSION IN THE PRACTICE OF A DENTIST WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; DENTISTS; DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT	HUMAN-IMMUNODEFICIENCY-VIRUS; TO-PATIENT TRANSMISSION; DENTAL PRACTICE; INFECTED DENTIST; SEQUENCES	Objectives: To determine whether dentist-to-patient or patient-to-patient transmission of human immunodeficiency virus (HIV) occurred in the practice of a dentist who had the acquired immunodeficiency syndrome (AIDS). Design: Retrospective epidemiologic investigation supported by molecular virology studies. Setting: The practice of a dentist with AIDS in an area with a high AIDS prevalence. Participants: A dentist with AIDS, his former employees, and his former patients, including 28 patients with HIV infection. Measurements: Identification of potential risks for acquisition of HIV infection-control practices. Results: A dentist with known behavioral risks for HIV infection, who was practicing in an area of Miami, Florida, that had a high rate of reported AIDS cases, disclosed that he frequently did invasive procedures and did not always follow recommended infection-control procedures. Of 6474 patients who had records of receiving care from the dentist during the last 5 years of practice, 1279 (19.8%) were known to have been tested for HIV infection and 24 of those (1.9%) were seropositive. Four other patients with HIV infection were identified through additional case-finding activities. Of these 28 patients with HIV infection, all but 4 had potential behavioral risk factors for infection. Phylogenetic tree analysis of HIV genetic sequences from the dentist and 24 of the patients with HIV infection showed an absence of strong bootstrap support for any grouping and therefore did not indicate that the virus strains were linked. Conclusions: Despite identifying numerous patients with HIV infection, we found no evidence of dentist-to-patient or patient-to-patient transmission of HIV during dental care. Our findings are consistent with those of all previous studies in this area, with the exception of one that did identify such transmission.	FLORIDA DEPT HLTH & REHABIL SERV, TALLAHASSEE, FL 32399 USA; ROCHE MOLEC SYST INC, ALAMEDA, CA 94501 USA	Florida Department of Health	JAFFE, HW (corresponding author), CTR DIS CONTROL & PREVENT, DIV HIV AIDS G29, ATLANTA, GA 30333 USA.							[Anonymous], 1993, MMWR Recomm Rep, V42, P1; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; ARNOW PM, 1993, PUBLIC HEALTH REP, V108, P273; BELL DM, 1993, J PUBLIC HEALTH DENT, V53, P170, DOI 10.1111/j.1752-7325.1993.tb02697.x; CABOT EL, 1989, COMPUT APPL BIOSCI, V5, P233; CHANT K, 1993, LANCET, V342, P1548, DOI 10.1016/S0140-6736(05)80112-6; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; Comer R W, 1991, J Dent Educ, V55, P187; Cottone J A, 1992, J Dent Educ, V56, P536; DICKINSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1802, DOI 10.1001/jama.269.14.1802; Favero M., 1991, DISINFECTION STERILI, P617; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; GOOCH B, 1993, J AM DENT ASSOC, V124, P38, DOI 10.14219/jada.archive.1993.0006; Heuer M A, 1992, J Dent Educ, V56, P528; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; LEWIS DL, 1992, J CLIN MICROBIOL, V30, P401, DOI 10.1128/JCM.30.2.401-406.1992; LONGFIELD JN, 1994, J INFECT DIS, V169, P1, DOI 10.1093/infdis/169.1.1; OU CY, 1993, LANCET, V341, P1171, DOI 10.1016/0140-6736(93)91001-3; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; Taylor M, 1992, J Dent Educ, V56, P540; YORK AK, 1993, J AM DENT ASSOC, V124, P74, DOI 10.14219/jada.archive.1993.0141; 1991, MMWR-MORBID MORTAL W, V40, P377; 1991, MMWR-MORBID MORTAL W, V40, P221; 1991, MMWR-MORBID MORTAL W, V40, P233; 1993, MMOWR MORB MORTAL WK, V42, P337; 1990, MMWR MROB MORTAL WKL, V39, P489; 1993, MMWR-MORBID MORTAL W, V42, P329	28	54	55	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					855	+		10.7326/0003-4819-121-11-199412010-00005	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7978698				2022-12-28	WOS:A1994PT62800005
J	FOX, PT; LANCASTER, JL				FOX, PT; LANCASTER, JL			NEUROSCIENCE ON THE NET	SCIENCE			English	Editorial Material							BRAIN				FOX, PT (corresponding author), UNIV TEXAS,HLTH SCI CTR,CTR RES IMAGING,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.		Fox, Peter/B-4725-2010; Lancaster, Jack L/F-2994-2010	Fox, Peter/0000-0002-0465-2028; 				BOWER JM, 1994, BOOK GENESIS WORKBOO; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Fox P.T., 1994, FUNCTIONAL NEUROIMAG, P95; FOX PT, 1990, J NUCL MED, V30, P141; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; GIBBONS A, 1992, SCIENCE, V258, P1872, DOI 10.1126/science.1470907; HUERTA MF, 1993, TRENDS NEUROSCI, V16, P436, DOI 10.1016/0166-2236(93)90069-X; LESLIE J, 1994, WIRED, V10, P68; MacWhinney B., 1991, CHILDES PROJECT TOOL; ROBBINS R, 1994, J COMPUT BIOL, V1, P173; SCHATZ BR, 1994, SCIENCE, V265, P895, DOI 10.1126/science.265.5174.895	11	79	79	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					994	996		10.1126/science.7973682	http://dx.doi.org/10.1126/science.7973682			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973682				2022-12-28	WOS:A1994PQ92400029
J	MCDONALD, DB; POTTS, WK				MCDONALD, DB; POTTS, WK			COOPERATIVE DISPLAY AND RELATEDNESS AMONG MALES IN A LEK-MATING BIRD	SCIENCE			English	Article							LONG-TAILED MANAKIN; SEXUAL SELECTION; LEKKING BIRD; RECIPROCITY; EVOLUTION; MAMMALS; KINSHIP	Long-tailed manakins mate in leks and cooperate in multiyear male-male partnerships. An alpha male is responsible for virtually all mating, whereas a beta male assists in the courtship displays. Such altruism by the beta male poses a problem for evolutionary theory because most theoretical treatments and empirical examples of cooperative behavior involve kin selection or reciprocity. Here it is shown that alpha and beta partners are not relatives and that reciprocity is not involved. Instead, direct, though long-delayed benefits to beta males are demonstrated, which include rare copulations, ascension to alpha status, and female lek fidelity. These benefits maintain this unusual form of male-male cooperation.	ARCHBOLD BIOL STN, LAKE PLACID, FL 33852 USA; SMITHSONIAN INST, MOLEC SYSTEMAT LAB, WASHINGTON, DC 20025 USA; UNIV FLORIDA, DEPT PATHOL, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, CTR MAMMALIAN GENET, GAINESVILLE, FL 32610 USA	Smithsonian Institution; State University System of Florida; University of Florida; State University System of Florida; University of Florida			McDonald, David Bartelle/C-3195-2008	McDonald, David Bartelle/0000-0001-8582-3775; Potts, Wayne/0000-0003-4137-0326				Boucher Douglas H., 1985, BIOL MUTUALISM ECOLO; Brown J.L., 1987, HELPING COMMUNAL BRE; ELGAR MA, 1989, BIOL REV, V64, P13, DOI 10.1111/j.1469-185X.1989.tb00636.x; EMLEN ST, 1988, BEHAV ECOL SOCIOBIOL, V23, P305, DOI 10.1007/BF00300577; FOSTER MS, 1985, NEOTROPICAL ORNITHOL, V36, P817; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Kruuk H., 1989, SOCIAL BADGER; LIGON JD, 1983, AM NAT, V121, P366, DOI 10.1086/284066; MCDONALD DB, 1993, BEHAV ECOL, V4, P297, DOI 10.1093/beheco/4.4.297; MCDONALD DB, 1989, ANIM BEHAV, V37, P1007, DOI 10.1016/0003-3472(89)90145-0; MCDONALD DB, 1993, ETHOLOGY, V94, P31; MCDONALD DB, 1989, AM NAT, V134, P709, DOI 10.1086/285007; MESTERTONGIBBONS M, 1992, Q REV BIOL, V67, P267, DOI 10.1086/417658; PACKER C, 1991, NATURE, V351, P562, DOI 10.1038/351562a0; QUELLER DC, 1989, EVOLUTION, V43, P258, DOI [10.2307/2409206, 10.1111/j.1558-5646.1989.tb04226.x]; QUELLER DC, 1989, P NATL ACAD SCI USA, V86, P3224, DOI 10.1073/pnas.86.9.3224; REYER HU, 1980, BEHAV ECOL SOCIOBIOL, V6, P219, DOI 10.1007/BF00569203; Sambrook J, 1989, MOL CLONING LABORATO; Sherman P. W., 1991, BIOL NAKED MOLE RAT; Sokal R. R., 1981, BIOMETRY; SULLIVAN KA, 1984, BEHAVIOUR, V91, P294, DOI 10.1163/156853984X00128; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; TRAINER JM, 1993, CONDOR, V95, P769, DOI 10.2307/1369416; WEBER JL, 1989, AM J HUM GENET, V44, P388; WILEY RH, 1984, EVOLUTION, V38, P609, DOI 10.1111/j.1558-5646.1984.tb00326.x; Wiley RH, 1991, ADV STUD BEHAV, V20, P201	26	175	178	0	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1030	1032		10.1126/science.7973654	http://dx.doi.org/10.1126/science.7973654			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973654				2022-12-28	WOS:A1994PQ92400040
J	DIAZBENJUMEA, FJ; COHEN, B; COHEN, SM				DIAZBENJUMEA, FJ; COHEN, B; COHEN, SM			CELL-INTERACTION BETWEEN COMPARTMENTS ESTABLISHES THE PROXIMAL-DISTAL AXIS OF DROSOPHILA LEGS	NATURE			English	Article							SEGMENT-POLARITY GENE; LIMB DEVELOPMENT; PATTERN-FORMATION; IMAGINAL DISKS; DECAPENTAPLEGIC GENE; ENGRAILED GENE; WINGLESS; MELANOGASTER; EXPRESSION; LESS	THE appendage primordia of Drosophila are subdivided into compartments(1-4) by the localized expression of transcription factors(5-7). Interaction between cells in adjacent compartments establishes organizing centres responsible for generating spatial pattern and promoting cell proliferation in the developing appendages(7-9). Localized expression of hedgehog (hh) in the posterior compartment of the leg: imaginal disc directs expression of wingless (wg) in ventral-anterior cells and decapentaplegic (dpp) in dorsal-anterior cells near the anterior-posterior compartment boundary(8); wg then acts to specify ventral cell fate(10-12) and to organize the dorsal-ventral axis of the leg(13,14). Interaction between wg-expressing ventral cells and dorsal cells near the anterior-posterior compartment boundary promotes axis formation in the leg(14,15). Here we show that the combined action of log-expressing cells in the ventral-anterior compartment and dpp-expressing cells in the dorsal-anterior compartment activates expression of Distal-less, a gene required for proximal-distal axis formation in the limbs. These results demonstrate that sequential interaction between anterior-posterior and dorsal-ventral compartments establishes the proximal-distal axis of the limbs.			DIAZBENJUMEA, FJ (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,POSTFACH 102209,D-69012 HEIDELBERG,GERMANY.		Diaz-Benjumea, Fernando/K-7667-2014; Cohen, Stephen M/G-9930-2011	Diaz-Benjumea, Fernando/0000-0003-3007-2489; Cohen, Stephen M/0000-0003-2858-9163				BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; COHEN SM, 1989, ROUX ARCH DEV BIOL, V198, P157, DOI 10.1007/BF02438941; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; PEIFER M, 1991, DEVELOPMENT, V111, P1029; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; Schubiger G., 1968, Wilhelm Roux Archiv fur Entwicklungsmechanik der Organismen, V160, P9, DOI 10.1007/BF00573645; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; SUNKEL CE, 1987, ROUX ARCH DEV BIOL, V196, P124, DOI 10.1007/BF00402034; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0	29	299	299	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					175	179		10.1038/372175a0	http://dx.doi.org/10.1038/372175a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969450				2022-12-28	WOS:A1994PQ68800055
J	TIITINEN, H; MAY, P; REINIKAINEN, K; NAATANEN, R				TIITINEN, H; MAY, P; REINIKAINEN, K; NAATANEN, R			ATTENTIVE NOVELTY DETECTION IN HUMANS IS GOVERNED BY PRE-ATTENTIVE SENSORY MEMORY	NATURE			English	Article							EVENT-RELATED POTENTIALS; MISMATCH NEGATIVITY; FREQUENCY DISCRIMINATION; SELECTIVE-ATTENTION; AUDITORY-CORTEX	BEING able to detect unusual, possibly dangerous events in the environment is a fundamental ability that helps ensure the survival of biological organisms(1-3). Novelty detection requires a memory system that models (builds neural representations of) events in the environment, so that changes are detected because they violate the predictions of the model. The earliest physiologically measurable brain response to novel auditory stimuli is the mismatch negativity(4), MMN, a component of the event-related potential. It is elicited when a predictable series of unvarying stimuli is unexpectedly followed by a deviating stimulus(5). As the occurrence of MMN is not usually affected by the direction of attention(5-7), MMN reflects the operation of automatic sensory (echoic) memorys(8) the earliest memory system that builds traces of the acoustic environment against which new stimuli can be compared(5). The dependence of attentive novelty detection on earlier, pre-attentive processes, however, has remained elusive. Previous, related studies(9-12) seem to suggest a relationship between MMN and attentive processes, although no conclusive evidence has so far been shown. Here we address novelty detection in humans both on a physiological and behavioural level, and show how attentive novelty detection is governed by a pre-attentive sensory memory mechanism.			TIITINEN, H (corresponding author), UNIV HELSINKI,DEPT PSYCHOL,COGNIT PSYCHOPHYSIOL RES UNIT,SF-00014 HELSINKI,FINLAND.		May, Patrick JC/E-1786-2015	May, Patrick JC/0000-0002-3954-0421				AHONEN AI, 1992, 14TH P SAT S NEUR TE, P16; HARI R, 1984, NEUROSCI LETT, V50, P127, DOI 10.1016/0304-3940(84)90474-9; James William, 1950, PRINCIPLES PHYSL, V1, P402; KOHONEN T, 1989, SELF ORG ASS MEMORY, P241; NAATANEN R, 1978, ACTA PSYCHOL, V42, P313, DOI 10.1016/0001-6918(78)90006-9; NAATANEN R, 1991, PSYCHOPHYSIOLOGY, V28, P478, DOI 10.1111/j.1469-8986.1991.tb00735.x; Naatanen R., 1992, ATTENTION BRAIN FUNC, P136, DOI DOI 10.1037/E516062012-002; NEISSER U, 1967, COGNITIVE PSYCHOL, P199; NOVAK G, 1992, PSYCHOPHYSIOLOGY, V29, P398, DOI 10.1111/j.1469-8986.1992.tb01713.x; NOVAK GP, 1990, ELECTROEN CLIN NEURO, V75, P255, DOI 10.1016/0013-4694(90)90105-S; RITTER W, 1992, ELECTROEN CLIN NEURO, V83, P306, DOI 10.1016/0013-4694(92)90090-5; SAMS M, 1985, ELECTROEN CLIN NEURO, V62, P437, DOI 10.1016/0168-5597(85)90054-1; Scherg M, 1989, J Cogn Neurosci, V1, P336, DOI 10.1162/jocn.1989.1.4.336; Sokolov EN., 1975, NEURONAL MECH ORIENT, P217; STEVENS SS, 1966, HEARING, P69; Thomas, 1986, HDB PERCEPTION HUMAN, VII; TIITINEN H, 1993, PSYCHOPHYSIOLOGY, V30, P537, DOI 10.1111/j.1469-8986.1993.tb02078.x; WIER CC, 1977, J ACOUST SOC AM, V61, P178, DOI 10.1121/1.381251; WINKLER I, 1993, PERCEPT PSYCHOPHYS, V53, P443, DOI 10.3758/BF03206788; WOLDORFF MG, 1991, PSYCHOPHYSIOLOGY, V28, P30, DOI 10.1111/j.1469-8986.1991.tb03384.x	20	523	536	1	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					90	92		10.1038/372090a0	http://dx.doi.org/10.1038/372090a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PQ348	7969425				2022-12-28	WOS:A1994PQ34800078
J	ZHANG, JF; ELLINOR, PT; ALDRICH, RW; TSIEN, RW				ZHANG, JF; ELLINOR, PT; ALDRICH, RW; TSIEN, RW			MOLECULAR DETERMINANTS OF VOLTAGE-DEPENDENT INACTIVATION IN CALCIUM CHANNELS	NATURE			English	Article							FUNCTIONAL EXPRESSION; SODIUM-CHANNEL; K+ CHANNELS; PERIODIC PARALYSIS; ION CHANNELS; CELLS; MECHANISMS; KINETICS; BLOCKADE; ANTIBODY	VOLTAGE-DEPENDENT Ca2+ channels respond to membrane depolarization by conformational changes that control channel opening and eventual closing by inactivation(1-3). The kinetics of inactivation differ considerably between types of Ca2+ channels(1-8) and are important in determining the amount of Ca2+ entry during electrical activity and its resulting impact on diverse cellular events(3). The most intensively characterized forms of inactivation in potassium(9,10) and sodium channels(11-13) involve pore block by a tethered plug(14). In contrast, little is known about the molecular basis of Ca2+-channel inactivation. We studied the molecular mechanism of inactivation of voltage-gated calcium channels by making chimaeras from channels with different inactivation rates. We report here that the amino acids responsible for the kinetic differences are localized to membrane-spanning segment S6 of the first repeat of the alpha(1) subunit (IS6), and to putative extracellular and cytoplasmic domains flanking IS6. Involvement of this region in Ca2+-channel inactivation was unexpected and raises interesting comparisons with Na+ channels, where the III-IV loop is a critical structural determinant. Ca2+-channel inactivation has some features that resemble C-type inactivation of potassium channels.	STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University				Ellinor, Patrick/0000-0002-2067-0533				ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; ARMSTRONG CM, 1985, SCIENCE, V227, P65, DOI 10.1126/science.2578071; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; CANNON SC, 1993, NEURON, V10, P317, DOI 10.1016/0896-6273(93)90321-H; CARBONE E, 1989, PROG BIOPHYS MOL BIO, V54, P31, DOI 10.1016/0079-6107(89)90008-4; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; Hille B., 1992, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; KIRSCH GE, 1992, BIOPHYS J, V62, P136, DOI 10.1016/S0006-3495(92)81800-3; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; REUTER H, 1984, ANNU REV PHYSIOL, V46, P473; ROJAS CV, 1991, NATURE, V354, P387, DOI 10.1038/354387a0; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; WILLIAMS ME, 1992, SCIENCE, V257, P390; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4	31	178	181	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					97	100		10.1038/372097a0	http://dx.doi.org/10.1038/372097a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969428				2022-12-28	WOS:A1994PQ34800081
J	HABETS, GGM; SCHOLTES, EHM; ZUYDGEEST, D; VANDERKAMMEN, RA; STAM, JC; BERNS, A; COLLARD, JG				HABETS, GGM; SCHOLTES, EHM; ZUYDGEEST, D; VANDERKAMMEN, RA; STAM, JC; BERNS, A; COLLARD, JG			IDENTIFICATION OF AN INVASION-INDUCING GENE, TIAM-1, THAT ENCODES A PROTEIN WITH HOMOLOGY TO GDP-GTP EXCHANGERS FOR RHO-LIKE PROTEINS	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; MURINE LEUKEMIA-VIRUS; T-LYMPHOMA CELLS; BINDING-PROTEIN; HEMATOPOIETIC-CELLS; ACTIVATING PROTEIN; SIGNALING PROTEINS; CDC42HS PROTEIN; HUMAN ONCOGENE; BCR	Using proviral tagging in combination with in vitro selection for invasiveness, we have identified a gene, designated Tiam-1, that affects invasion. In the selected invasive T lymphoma variants, proviral insertions were found within coding exons of the Tiam-1 gene, resulting in both truncated 5'-end and 3'-end transcripts that give rise to N- and C-terminal Tiam-1 protein fragments. In one invasive variant, amplification of the Tiam-1 locus was observed with concomitant increase in the amount of normal Tiam-1 protein. Cell clones that were invasive in vitro produced experimental metastases in nude mice, and transfection of truncated Tiam-1 cDNAs into noninvasive cells made these cells invasive. The predicted Tiam-1 protein harbors a Dbl- and Pleckstrin-homologous domain, which it shares with GDP-GTP exchangers for Rho-like proteins that have been implicated in cytoskeletal organization.	ANTONI VAN LEEUWENHOEK HUIS,NETHERLANDS CANC INST,DIV MOLEC GENET,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute	HABETS, GGM (corresponding author), ANTONI VAN LEEUWENHOEK HUIS,NETHERLANDS CANC INST,DIV CELL BIOL,121 PLESMANLAAN,1066 CX AMSTERDAM,NETHERLANDS.							ADAMS JM, 1992, ONCOGENE, V7, P611; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; COLLARD JG, 1987, CANCER RES, V47, P754; COLLARD JG, 1987, CANCER RES, V47, P6666; COLLARD JG, 1988, CANCER SURV, V7, P692; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CUYPERS HT, 1984, CELL, V37, P141; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DORSSERS LCJ, 1993, MOL ENDOCRINOL, V7, P870, DOI 10.1210/me.7.7.870; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HABETS GGM, 1990, CLIN EXP METASTAS, V8, P567, DOI 10.1007/BF00135878; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HART MJ, 1991, J BIOL CHEM, V266, P20840; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KATZAV S, 1993, MOL CELL BIOL, V11, P9106; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROGERS S, 1984, SCIENCE, V37, P1043; RON D, 1991, NEW BIOL, V3, P372; RON D, 1989, ONCOGENE, V4, P1076; ROOS E, 1985, CANCER RES, V45, P6238; ROOSSIEN FF, 1989, J CELL BIOL, V108, P1979, DOI 10.1083/jcb.108.5.1979; SCHWARTZBERG P, 1984, CELL, V37, P1043, DOI 10.1016/0092-8674(84)90439-2; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WIELENGA VJM, 1993, CANCER RES, V53, P4754	48	467	502	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					537	549		10.1016/0092-8674(94)90216-X	http://dx.doi.org/10.1016/0092-8674(94)90216-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	7999144				2022-12-28	WOS:A1994NM83200009
J	KELLEY, WN; RANDOLPH, MA				KELLEY, WN; RANDOLPH, MA			CAREERS IN CLINICAL RESEARCH - OBSTACLES AND OPPORTUNITIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											KELLEY, WN (corresponding author), INST MED,COMM ADDRESSING CAREER PATHS CLIN RES,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418, USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 4	1995	273	1					12	12						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ042	7996636				2022-12-28	WOS:A1995PZ04200004
J	LAROSA, GL; LUPO, L; GIUFFRIDA, D; GULLO, D; VIGNERI, R; BELFIORE, A				LAROSA, GL; LUPO, L; GIUFFRIDA, D; GULLO, D; VIGNERI, R; BELFIORE, A			LEVOTHYROXINE AND POTASSIUM-IODIDE ARE BOTH EFFECTIVE IN TREATING BENIGN SOLITARY SOLID COLD NODULES OF THE THYROID	ANNALS OF INTERNAL MEDICINE			English	Article						LEVOTHYROXINE; IODINE; THYROID NODULE; POTASSIUM IODIDE; GOITER, NODULAR	NEEDLE ASPIRATION BIOPSY; SUPPRESSIVE THERAPY; L-THYROXINE; ENDEMIC GOITER; BONE-DENSITY; CELLS; THYROTROPIN; MANAGEMENT; DEFICIENCY; ULTRASOUND	Objective: To determine the effectiveness of levothyroxine and potassium iodide in treating patients with benign solitary cold thyroid nodules. Design: Randomized controlled study. Setting: Outpatient clinic at a university hospital. Patients: 80 patients with solitary solid cold thyroid nodules found to be benign at cytologic examination were randomly assigned to no treatment, suppressive levothyroxine (thyroid-stimulating hormone level, < 0.3 mU/L), or low-dose potassium iodide (2 mg every 2 weeks). Seventy patients completed the 1-year study. After 1 year, patients receiving treatment discontinued drug therapy and were re-evaluated 4 months later; patients receiving no treatment were given levothyroxine and were followed for a second year. Measurements: Nodule volume was measured by ultrasonography at 4-month intervals by an observer masked to treatment assignment. Results: Mean nodule volume decreased by 40% of the basal volume in the 23 patients receiving levothyroxine (P < 0.001) and by 23% of the basat volume in the 25 patients receiving potassium iodide (P = 0.053). Volume slightly increased in the 22 untreated patients (P = 0.085). A clinically relevant reduction in nodule volume (greater than or equal to 50%) was observed in 9 of 23 patients treated with levothyroxine, in 5 of 25 patients treated with potassium iodide, and in none of 22 untreated patients (P = 0.004). Only nodules with a volume of 10 mt or less were reduced; nodules with Volumes of 5 mL or less shrank most frequently. Nodule Volume did not relevantly increase in treated patients but did increase in 3 of the 22 untreated patients. Drug withdrawal resulted in an increased mean nodule volume (P = 0.004) after 4 months. Conclusions: Levothyroxine and, to a lesser extent, potassium iodide are effective in arresting the growth or in reducing the volume of benign solitary solid cold thyroid nodules, especially small ones; discontinuation of therapy may result in resumed nodule growth.	UNIV CATANIA, IST IGIENE & MED PREVENT, I-95100 CATANIA, ITALY	University of Catania			Gullo, Damiano/GNP-5649-2022; Belfiore, Antonino/B-4652-2011; Vigneri, Riccardo/M-3968-2017	Belfiore, Antonino/0000-0002-6181-4193; Gullo, Damiano/0000-0002-4034-6378; LUPO, Lorenzo/0000-0001-6810-1244; Vigneri, Riccardo/0000-0002-4401-3140				ASTWOOD EB, 1960, JAMA-J AM MED ASSOC, V174, P459, DOI 10.1001/jama.1960.03030050001001; BELFIORE A, 1983, J CLIN ENDOCR METAB, V56, P283, DOI 10.1210/jcem-56-2-283; BELFIORE A, 1987, CANCER, V60, P3096, DOI 10.1002/1097-0142(19871215)60:12<3096::AID-CNCR2820601240>3.0.CO;2-V; BELFIORE A, 1992, AM J MED, V93, P363, DOI 10.1016/0002-9343(92)90164-7; BRUNN J, 1981, DEUT MED WOCHENSCHR, V106, P1338, DOI 10.1055/s-2008-1070506; CELANI MF, 1990, ACTA ENDOCRINOL-COP, V123, P603, DOI 10.1530/acta.0.1230603; Crowder MJ, 1990, ANAL REPEATED MEASUR, P25; ERMANS AM, 1985, 9TH P INT THYR C SAO, P1067; FILETTI S, 1986, ENDOCRINOLOGY, V118, P1395, DOI 10.1210/endo-118-4-1395; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; GARTNER R, 1990, THYROIDOLOGY, V3, P93; GHARIB H, 1987, NEW ENGL J MED, V317, P70, DOI 10.1056/NEJM198707093170202; HAMMING JF, 1990, ARCH INTERN MED, V150, P113, DOI 10.1001/archinte.150.1.113; HINTZE G, 1985, HORM METAB RES, V17, P362, DOI 10.1055/s-2007-1013543; HINTZE G, 1989, EUR J CLIN INVEST, V19, P527, DOI 10.1111/j.1365-2362.1989.tb00270.x; LAROSA GL, 1990, J ENDOCRINOL INVEST, V13, P701, DOI 10.1007/BF03349603; LAROSA GL, 1991, CANCER, V67, P2137, DOI 10.1002/1097-0142(19910415)67:8<2137::AID-CNCR2820670822>3.0.CO;2-Y; MAENHAUT C, 1990, HORM METAB RES, V23, P51; MARTINO E, 1984, ANN INTERN MED, V101, P28, DOI 10.7326/0003-4819-101-1-28; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; McCullagh P, 1983, GENERALIZED LINEAR M, P127; MILAZZO G, 1992, J CELL BIOCHEM, V49, P231, DOI 10.1002/jcb.240490305; MORITA T, 1989, J CLIN ENDOCR METAB, V69, P227, DOI 10.1210/jcem-69-2-227; NAGATAKI S, 1986, WERNERS THYROID, P319; NICOLOFF JT, 1990, J CLIN ENDOCR METAB, V71, P553, DOI 10.1210/jcem-71-3-553; PAPINI E, 1993, CLIN ENDOCRINOL, V38, P507, DOI 10.1111/j.1365-2265.1993.tb00347.x; PAUL T, 1988, METABOLISM, V37, P121, DOI 10.1016/S0026-0495(98)90004-X; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; REGALBUTO C, 1991, J ENDOCRINOL INVEST, V14, P675, DOI 10.1007/BF03347892; REVERTER JL, 1992, CLIN ENDOCRINOL, V36, P25, DOI 10.1111/j.1365-2265.1992.tb02898.x; ROJESKI MT, 1985, NEW ENGL J MED, V313, P428, DOI 10.1056/NEJM198508153130707; ROSS DS, 1992, THYROID, V2, P263, DOI 10.1089/thy.1992.2.263; ROSS DS, 1987, AM J MED, V82, P1167, DOI 10.1016/0002-9343(87)90219-1; SALLER B, 1991, ACTA ENDOCRINOL-COP, V125, P662, DOI 10.1530/acta.0.1250662; STALL GM, 1990, ANN INTERN MED, V113, P265, DOI 10.7326/0003-4819-113-4-265; STUDER H, 1989, ENDOCR REV, V10, P125, DOI 10.1210/edrv-10-2-125; 1987, NEW ENGL J MED, V317, P1663	37	91	92	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1995	122	1					1	8		10.7326/0003-4819-122-1-199501010-00001	http://dx.doi.org/10.7326/0003-4819-122-1-199501010-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY502	7985890				2022-12-28	WOS:A1995PY50200001
J	PELHAM, HRB				PELHAM, HRB			ABOUT TURN FOR THE COPS	CELL			English	Review							TRANSPORT VESICLES; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; MEMBRANE-PROTEIN; BREFELDIN-A; GOLGI				PELHAM, HRB (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DUDEN R, 1994, J BIOL CHEM, V269, P24486; DUNPHY WG, 1981, P NATL ACAD SCI-BIOL, V78, P7453, DOI 10.1073/pnas.78.12.7453; FRANZUSOFF A, 1992, NATURE, V355, P173, DOI 10.1038/355173a0; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; LADINSKY MS, 1994, J CELL BIOL, V127, P29, DOI 10.1083/jcb.127.1.29; LETOURNEUR F, 1994, CELL, V79; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LIPPINCOTTSCHWA.J, 1990, CELL, V60, P821; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PEPPERKOK R, 1993, CELL, V74, P1; PETER F, 1993, J CELL BIOL, V122, P865; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; ROTHMAN JE, 1984, J CELL BIOL, V99, P260, DOI 10.1083/jcb.99.1.260; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211	28	110	112	1	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1125	1127		10.1016/0092-8674(94)90002-7	http://dx.doi.org/10.1016/0092-8674(94)90002-7			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001148				2022-12-28	WOS:A1994PZ86000002
J	KHANUM, S; ASHWORTH, A; HUTTLY, SRA				KHANUM, S; ASHWORTH, A; HUTTLY, SRA			CONTROLLED TRIAL OF 3 APPROACHES TO THE TREATMENT OF SEVERE MALNUTRITION	LANCET			English	Article								Domiciliary treatment of severely malnourished children could have economic and practical advantages over other methods. We compared three approaches in a controlled trial. 437 children in Dhaka (<60% weight-for-height, and/or oedema) aged 12-60 months were sequentially allocated to treatment as inpatients, to day-care, or to care at home after one week of day-care. Institutional and parental costs incurred to reach 80% weight-for-height were compared. Costs for inpatient, day-care, and at-home groups averaged 6363, 2517, and 1552 taka (60 taka=UK pound 1). Mortality was low (<5%) in all three groups. Day-care treatment approached inpatient care for speed of recovery at less than half the cost, but it was unpopular with parents. The at-home group took significantly longer to attain 80% weight-for-height than the other groups, but did so at the lowest average cost. Parental costs were highest for the at-home group as no food supplements were provided; nevertheless this was the most popular option. We conclude that at-home management of severely malnourished children after 1 week of inpatient care is a cost-effective strategy.	UNIV LONDON LONDON SCH HYG & TROP MED, CTR HUMAN NUTR, LONDON WC1E 7HT, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, MATERNAL & CHILD EPIDEMIOL UNIT, LONDON, ENGLAND; SAVE CHILDREN FUND, CHILDRENS NUTR UNIT, DHAKA, BANGLADESH	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; Save the Children								Beaudry-Darisme M, 1973, J Trop Pediatr Environ Child Health, V19, P299; BEGHIN ID, 1973, ENV CHILD HLTH, V19, P404; BENGOA JOSE M., 1967, J TROP PEDIAT, V13, P169; Cook R, 1971, J Trop Pediatr Environ Child Health, V17, P15; COOPER E, 1980, J TROP PEDIATRICS, V26, P232, DOI 10.1093/tropej/26.6.232; Cutting W A, 1975, Indian Pediatr, V12, P99; FERNANDEZCONCHA D, 1991, T ROY SOC TROP MED H, V85, P809, DOI 10.1016/0035-9203(91)90465-B; KIRKWOOD BR, 1988, ESSENTIALS MED STATI; Rao M N, 1984, Indian Pediatr, V21, P389; Shah P M, 1971, Indian Pediatr, V8, P805; Webb R E, 1975, J Trop Pediatr Environ Child Health, V21, P7	11	85	86	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 24	1994	344	8939-4					1728	1732						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7997001				2022-12-28	WOS:A1994PY28100008
J	LAFONT, F; BURKHARDT, JK; SIMONS, K				LAFONT, F; BURKHARDT, JK; SIMONS, K			INVOLVEMENT OF MICROTUBULE MOTORS IN BASOLATERAL AND APICAL TRANSPORT IN KIDNEY-CELLS	NATURE			English	Article							DARBY CANINE KIDNEY; INTESTINAL EPITHELIAL-CELLS; PLASMA-MEMBRANE PROTEINS; MDCK CELLS; CYTOPLASMIC DYNEIN; SURFACE POLARITY; ACTIN-FILAMENTS; CACO-2; IDENTIFICATION; GLYCOPROTEIN	THE maintenance of a polarized cell surface requires vectorial transport of vesicles to the apical and the basolateral membrane domains(1). Transport of newly synthesized apical proteins and trans-cytosis from the basolateral to the apical surface have Motors been demonstrated to depend on microtubules(2-9). In contrast, movement of membrane proteins to the basolateral surface has been claimed to occur by diffusion and to be microtubule- and actin-independent(2,4,5,7,10-12). We have re-examined the role of microtubules using a recently developed polarized transport assay in permeabilized Madin-Darby canine kidney cells(13,14). Here we report that both apical and basolateral transport is inhibited by nocodazole treatment. Transport to the basolateral surface was inhibited by immunodepletion of cytosolic kinesin. In contrast, apical transport involved both dynein and kinesin. Our data demonstrate that in epithelial cells, microtubule motors are involved in the movement of apical and basolateral vesicles. Moreover, we propose that the differential requirement for microtubule-based motors is related to the microtubule organization.	EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAMME, D-69112 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)				Burkhardt, Janis/0000-0002-8176-1375; Simons, Kai/0000-0002-9231-9996; Lafont, frank/0000-0001-8668-2580				ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; BACALLAO R, 1989, METHOD CELL BIOL, V31, P437; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; EILERS U, 1989, J CELL BIOL, V108, P13, DOI 10.1083/jcb.108.1.13; FATH KR, 1993, J CELL BIOL, V120, P117, DOI 10.1083/jcb.120.1.117; GIBBONS IR, 1978, J BIOL CHEM, V25, P2780; GILBERT T, 1991, J CELL BIOL, V113, P275, DOI 10.1083/jcb.113.2.275; HIROKAWA N, 1990, J CELL BIOL, V111, P1027, DOI 10.1083/jcb.111.3.1027; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; MASSON D, 1993, J CELL BIOL, V123, P357, DOI 10.1083/jcb.123.2.357; MATTER K, 1990, EMBO J, V9, P3163, DOI 10.1002/j.1460-2075.1990.tb07514.x; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; OJAKIAN GK, 1992, J CELL SCI, V103, P677; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; REINSCH S, 1994, J CELL BIOL, V126, P1509, DOI 10.1083/jcb.126.6.1509; RINDLER MJ, 1987, J CELL BIOL, V104, P231, DOI 10.1083/jcb.104.2.231; SALAS PJI, 1986, J CELL BIOL, V102, P1853, DOI 10.1083/jcb.102.5.1853; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VANDERSLUIJS P, 1990, J CELL SCI, V95, P545; VANZEIJL MJAH, 1990, CELL REGUL, V1, P921, DOI 10.1091/mbc.1.12.921	30	168	169	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	1994	372	6508					801	803						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997271				2022-12-28	WOS:A1994PY21200059
J	ZIEGLER, A; JONASON, AS; LEFFELL, DJ; SIMON, JA; SHARMA, HW; KIMMELMAN, J; REMINGTON, L; JACKS, T; BRASH, DE				ZIEGLER, A; JONASON, AS; LEFFELL, DJ; SIMON, JA; SHARMA, HW; KIMMELMAN, J; REMINGTON, L; JACKS, T; BRASH, DE			SUNBURN AND P53 IN THE ONSET OF SKIN-CANCER	NATURE			English	Article							ULTRAVIOLET RADIATION; SOLAR KERATOSES; CELL; SUNLIGHT; MUTATION; APOPTOSIS; PROMOTION; EXPOSURE; GENE; DNA	SQUAMOUS cell carcinoma of the skin (SCC) can progress by stages: sun-damaged epidermis, with individual disordered keratinocytes; actinic keratosis (AK), spontaneously regressing keratinized patches having aberrant cell differentiation and proliferation; carcinoma in situ; SCC and metastasis(1-3). To understand how sunlight acts as a carcinogen, we determined the stage at which sunlight mutates the p53 tumour-suppressor gene and identified a function for p53 in skin. The p53 mutations induced by ultraviolet radiation and found in >90% of human SCCs4,5 were present in AKs. Inactivating p53 in mouse skin reduced the appearance of sunburn cells(6), apoptotic keratinocytes generated by overexposure to ultraviolet. Skin thus appears to possess a p53-dependent 'guardian-of-the-tissue' response to DNA damage which aborts precancerous cells. If this response is reduced in a single cell by a prior p53 mutation, sunburn can select for clonal expansion of the p53-mutated cell into the AK. Sunlight can act twice: as tumour initiator and tumour promoter.	YALE UNIV,SCH MED,DEPT DERMATOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; MIT,HOWARD HUGHES MED INST,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139	Yale University; Yale University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	ZIEGLER, A (corresponding author), YALE UNIV,SCH MED,DEPT THERAPEUT RADIOL,NEW HAVEN,CT 06510, USA.			Ziegler, Annemarie/0000-0003-0018-7031				BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BURNS FJ, 1976, CANCER RES, V36, P1422; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; CAMPBELL C, 1993, CANCER RES, V53, P2697; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DANNO K, 1987, PHOTOCHEM PHOTOBIOL, V45, P683, DOI 10.1111/j.1751-1097.1987.tb07401.x; EPSTEIN JH, 1970, PHOTOCHEM PHOTOBIOL, V12, P57, DOI 10.1111/j.1751-1097.1970.tb06038.x; EPSTEIN JH, 1962, J INVEST DERMATOL, V39, P455, DOI 10.1038/jid.1962.142; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gilchrest BA., 1984, SKIN AGING PROCESSES; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HUTCHINSON F, 1994, MUTAT RES-FUND MOL M, V309, P11, DOI 10.1016/0027-5107(94)90037-X; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KRICKER A, 1991, INT J CANCER, V48, P650, DOI 10.1002/ijc.2910480504; LEY RD, 1985, J INVEST DERMATOL, V85, P365, DOI 10.1111/1523-1747.ep12276992; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARKS R, 1990, MED J AUSTRALIA, V152, P62, DOI 10.5694/j.1326-5377.1990.tb124456.x; MARKS R, 1986, BRIT J DERMATOL, V115, P649, DOI 10.1111/j.1365-2133.1986.tb06644.x; MOOLGAVKAR SH, 1981, J NATL CANCER I, V66, P1037, DOI 10.1093/jnci/66.6.1037; POTTER VR, 1984, CANCER RES, V44, P2733; ROSARIO R, 1979, BRIT J DERMATOL, V101, P299; SCHWARTZ RA, 1993, DERMATOLOGY GEN MED, P804; Singer-Sam J, 1992, PCR Methods Appl, V1, P160; URBACH F, 1972, ENV CANCER, P355; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	30	1238	1270	3	98	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					773	776		10.1038/372773a0	http://dx.doi.org/10.1038/372773a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997263				2022-12-28	WOS:A1994PY21200051
J	LURIE, P; AVINS, AL; PHILLIPS, KA; KAHN, JG; LOWE, RA; CICCARONE, D				LURIE, P; AVINS, AL; PHILLIPS, KA; KAHN, JG; LOWE, RA; CICCARONE, D			THE COST-EFFECTIVENESS OF VOLUNTARY COUNSELING AND TESTING OF HOSPITAL INPATIENTS FOR HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE WORKERS; NEEDLESTICK INJURIES; UNITED-STATES; UNIVERSAL PRECAUTIONS; SURGICAL-PROCEDURES; RISK; POPULATION; ANTIBODY; BLOOD	Objective.-To evaluate the cost-effectiveness of voluntary counseling and testing of US hospital inpatients for the human immunodeficiency virus (HIV). Data Sources.-Data for entry into the model were derived from a review of the literature, consultation with experts, and consensus of the authors. Data Extraction.-We rated our confidence in these probabilities and costs by grading the data inputs using methods adapted from those of the US Preventive Services Task Force. Data Synthesis.-Decision analysis models were developed to evaluate two outcomes: (1) cost per health care worker (HCW) HIV infection averted if measures are taken by the HCW to reduce his or her risk of acquiring HIV; and (2) cost per inpatient HIV infection detected, Sensitivity analyses were also conducted, Using baseline input values, testing to avert HCW infection may prevent 3.6 HIV infections per year at a total program cost of $2.7 billion, or a cost of $753 million per infection averted. At baseline assumptions (seroprevalence=1%), testing to detect inpatient HIV infection would cost $16104 per year per infection detected. Cost-effectiveness at baseline drops to $8353 per HIV infection detected if the seroprevalence is 10%. If testing is limited to hospitals with inpatient seroprevalences of at least 1%, approximately 5400 persons per year will be falsely labeled HIV-positive. Conclusions.-This analysis provides no justification for testing inpatients to prevent HIV infection of HCWs. Screening inpatients to detect HIV infection may be justified at seroprevalences exceeding 1%, but issues of medical or social discrimination, false-positive results, informed consent, and logistics must be resolved first.	UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94110; UNIV CALIF BERKELEY,CTR STUDENT HLTH,BERKELEY,CA 94720	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California Berkeley	LURIE, P (corresponding author), UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA, USA.		Lowe, Robert A/A-4926-2008; Ciccarone, Daniel/I-5404-2013	Lowe, Robert A/0000-0002-4732-9634; Ciccarone, Daniel/0000-0002-2355-5477	AHRQ HHS [HS07373-01] Funding Source: Medline; NIMH NIH HHS [P50 MH42459, MH19105-02] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U01HS007373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019105, P50MH042459] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDRUS JK, 1989, AM J PUBLIC HEALTH, V79, P840, DOI 10.2105/AJPH.79.7.840; [Anonymous], 1989, GUIDE CLIN PREVENTIV; ARNO PS, 1991, SEP IMP REG GUID LEG; ARNOW PM, 1989, PUBLIC HEALTH REP, V104, P121; BARTON JJ, 1989, AM J OBSTET GYNECOL, V160, P1316, DOI 10.1016/0002-9378(89)90850-8; BLOOM DE, 1991, SCIENCE, V252, P1798, DOI 10.1126/science.1829547; BLOWER SM, 1994, SCIENCE, V265, P1451, DOI 10.1126/science.8073289; CLEARY PD, 1987, JAMA-J AM MED ASSOC, V258, P1757, DOI 10.1001/jama.258.13.1757; COLOMBOTOS J, 1991, PHYSICIANS NURSES AI; FREEMAN HE, 1991, MED CARE, V29, P87, DOI 10.1097/00005650-199102000-00001; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GERBERDING JL, 1991, INFECT CONT HOSP EP, V12, P443, DOI 10.1086/646376; GERBERT B, 1993, ARCH INTERN MED, V153, P313, DOI 10.1001/archinte.153.3.313; HAGEN MD, 1988, JAMA-J AM MED ASSOC, V259, P1357, DOI 10.1001/jama.259.9.1357; Hamory B H, 1984, Am J Infect Control, V12, P68, DOI 10.1016/0196-6553(84)90080-4; HAMORY BH, 1983, AM J INFECT CONTROL, V11, P174, DOI 10.1016/0196-6553(83)90077-9; HARDY LM, 1991, HIV SCREENING PREGNA, P91; HARRIS RL, 1990, INFECT CONT HOSP EP, V11, P628; HEDLUND K, 1990, 6TH INT C AIDS SAN F; HELLINGER FJ, 1992, INQUIRY-J HEALTH CAR, V29, P356; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HENDERSON DK, 1986, ANN INTERN MED, V104, P644, DOI 10.7326/0003-4819-104-5-644; HENDERSON DK, 1990, PRINCIPLES PRACTICE, P2221; HENRY K, 1992, PUBLIC HEALTH REP, V107, P138; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; HOLTGRAVE DR, 1993, ARCH INTERN MED, V153, P1225, DOI 10.1001/archinte.153.10.1225; HORVITZ DG, 1990, P SECTION SURV S218, V150; HOXIE NJ, 1990, AM J PUBLIC HEALTH, V80, P1129, DOI 10.2105/AJPH.80.9.1129; HULL HF, 1988, JAMA-J AM MED ASSOC, V260, P935, DOI 10.1001/jama.260.7.935; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; JANSSEN RS, 1992, NEW ENGL J MED, V327, P445, DOI 10.1056/NEJM199208133270701; KRAHN M, 1993, MED CARE, V31, P403, DOI 10.1097/00005650-199305000-00003; KRASINSKI K, 1988, NEW ENGL J MED, V318, P185; LAWRENCE VA, 1993, J CLIN EPIDEMIOL, V46, P1219, DOI 10.1016/0895-4356(93)90084-E; LINDAN CP, 1994, AIDS, V8, P1149, DOI 10.1097/00002030-199408000-00018; LINDSAY MK, 1989, OBSTET GYNECOL, V74, P289; LINNEMANN CC, 1991, INFECT CONT HOSP EP, V12, P214, DOI 10.2307/30146994; LURIE P, 1992, NEW ENGL J MED, V327, P1815, DOI 10.1056/NEJM199212173272512; MANGIONE CM, 1991, AM J MED, V90, P85, DOI 10.1016/0002-9343(91)90510-5; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MCCRAY E, 1986, NEW ENGL J MED, V314, P1127, DOI 10.1056/NEJM198604243141729; MCGEER A, 1990, J INFECT DIS, V162, P961, DOI 10.1093/infdis/162.4.961; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; PETERSEN LR, 1990, AM J PUBLIC HEALTH, V80, P1087, DOI 10.2105/AJPH.80.9.1087; PHILLIPS KA, 1994, JAMA-J AM MED ASSOC, V271, P851, DOI 10.1001/jama.271.11.851; PHILLIPS KA, IN PRESS PUBLIC HLTH; RIBNER BS, 1987, INFECT CONT HOSP EP, V8, P63, DOI 10.1017/S0195941700067096; SCHOCHETMAN G, 1989, ANNU REV MICROBIOL, V43, P629; SCHOCHETMAN G, 1992, AIDS TESTING METHODS; SCHWARCZ SK, 1993, AM J EPIDEMIOL, V137, P600, DOI 10.1093/oxfordjournals.aje.a116717; SCHWARTZ JS, 1988, JAMA-J AM MED ASSOC, V259, P2574, DOI 10.1001/jama.259.17.2574; SCHWARTZ JS, 1990, JAMA-J AM MED ASSOC, V264, P1704, DOI 10.1001/jama.264.13.1704; SLOAND EM, 1991, JAMA-J AM MED ASSOC, V266, P2861, DOI 10.1001/jama.266.20.2861; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; TANDBERG D, 1991, ANN EMERG MED, V20, P66, DOI 10.1016/S0196-0644(05)81122-9; TOKARS J, 1990, 6TH INT C AIDS SAN F; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; TURNOCK BJ, 1989, JAMA-J AM MED ASSOC, V261, P3415, DOI 10.1001/jama.261.23.3415; WEISS R, 1988, NEW ENGL J MED, V319, P1010, DOI 10.1056/NEJM198810133191509; Yawn B P, 1992, Fam Med, V24, P355; 1993, AIDS ALERT, V8, P49; 1991, ESTIMATES RISK ENDEM; 1994, ANN INTERN MED, V120, P310; 1990, NATIONAL HIV SEROPRE; 1989, GUIDELINES PREVENTIO; 1990, MMWR-MORBID MORTAL W, V39, P380; 1991, NATIONAL HOSPITAL DI; 1991, HIV SCREENING PREGNA; 1993, MMWR-MORBID MORTAL W, V42, P5; 1992, STATISTICAL ABSTRACT; 1991, MMWR-MORBID MORTAL W, V40, P1	73	26	26	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1832	1838		10.1001/jama.272.23.1832	http://dx.doi.org/10.1001/jama.272.23.1832			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PW980	7990217				2022-12-28	WOS:A1994PW98000031
J	GRIMES, DA				GRIMES, DA			SHIFTING INDICATIONS FOR HYSTERECTOMY - NATURE, NURTURE, OR NEITHER	LANCET			English	Editorial Material											GRIMES, DA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143, USA.							BACHMANN GA, 1990, J REPROD MED, V35, P839; BICKELL NA, 1994, AM J PUBLIC HEALTH, V84, P1649, DOI 10.2105/AJPH.84.10.1649; CARLSON KJ, 1993, NEW ENGL J MED, V328, P856; CARLSON KJ, 1994, OBSTET GYNECOL, V83, P556, DOI 10.1097/00006250-199404000-00012; CENTERWALL BS, 1981, AM J OBSTET GYNECOL, V139, P58, DOI 10.1016/0002-9378(81)90412-9; DWYER N, 1993, BRIT J OBSTET GYNAEC, V100, P237, DOI 10.1111/j.1471-0528.1993.tb15237.x; HAAS S, 1993, AM J OBSTET GYNECOL, V169, P150, DOI 10.1016/0002-9378(93)90152-9; KILKKU P, 1983, ACTA OBSTET GYN SCAN, V62, P147, DOI 10.3109/00016348309155779; NATHORSTBOOS J, 1992, ACTA OBSTET GYN SCAN, V71, P230, DOI 10.3109/00016349209009925; PALMER JR, 1992, AM J EPIDEMIOL, V136, P408, DOI 10.1093/oxfordjournals.aje.a116513; SUMMITT RL, 1992, OBSTET GYNECOL, V80, P895; 1994, ACOG1 AM COLL OBST G	12	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1652	1653		10.1016/S0140-6736(94)90453-7	http://dx.doi.org/10.1016/S0140-6736(94)90453-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996956				2022-12-28	WOS:A1994PX30200004
J	CROTHERS, DM				CROTHERS, DM			UPSETTING THE BALANCE OF FORCES IN DNA	SCIENCE			English	Editorial Material							CRYSTAL-STRUCTURE; PHOSPHATE GROUPS; NUCLEOSOMAL DNA				CROTHERS, DM (corresponding author), YALE UNIV,STERLING CHEM LAB,225 PROSPECT ST,NEW HAVEN,CT 06511, USA.							CROTHERS DM, 1992, METHOD ENZYMOL, V212, P46; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DICKERSON RE, 1994, P NATL ACAD SCI USA, V91, P3579, DOI 10.1073/pnas.91.9.3579; GOODSELL DS, 1994, J MOL BIOL, V239, P79, DOI 10.1006/jmbi.1994.1352; HARAN TE, 1994, J MOL BIOL, V244, P135, DOI 10.1006/jmbi.1994.1713; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; MANNING GS, 1989, J BIOMOL STRUCT DYN, V6, P877, DOI 10.1080/07391102.1989.10506519; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MARINI JC, 1982, P NATL ACAD SCI-BIOL, V79, P7664, DOI 10.1073/pnas.79.24.7664; MIRZABEKOV AD, 1979, P NATL ACAD SCI USA, V76, P1118, DOI 10.1073/pnas.76.3.1118; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0	13	31	31	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1819	1820		10.1126/science.7997876	http://dx.doi.org/10.1126/science.7997876			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997876				2022-12-28	WOS:A1994PX38300025
J	FEAVER, WJ; SVEJSTRUP, JQ; HENRY, NL; KORNBERG, RD				FEAVER, WJ; SVEJSTRUP, JQ; HENRY, NL; KORNBERG, RD			RELATIONSHIP OF CDK-ACTIVATING KINASE AND RNA-POLYMERASE-II CTD KINASE TFIIH/TFIIK	CELL			English	Article							CARBOXYL-TERMINAL-DOMAIN; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; INITIATION-FACTORS; CATALYTIC SUBUNIT; SEQUENCE; DNA; PHOSPHORYLATION; YEAST	KIN28, a member of the p34(cdc2/CDC28) family of protein kinases, is identified as a subunit of yeast RNA polymerase transcription factor IIH (TFIIH) on the basis of sequence determination, immunological reactivity, and copurification. KIN28 is, moreover, one of three subunits of TFIIK, a subassembly of TFIIH with protein kinase activity directed toward the C-terminal repeat domain (CTD) of the largest subunit of RNA polymerase II. Itself a phosphoprotein, KIN28 interacts specifically with the two largest subunits of RNA polymerase II. Previous work of others points to two further associations: KIN28 interacts in vivo with the cyclin CCL1, and KIN28 and CCL1 are homologous to human MO15 and cyclin H, which form the cyclin-dependent kinase-activating kinase (CAK). We show that human CAK possesses the CTD kinase activity characteristic of TFIIH.			FEAVER, WJ (corresponding author), STANFORD UNIV,SCH MED,DEPT BIOL STRUCT,STANFORD,CA 94305, USA.			Svejstrup, Jesper/0000-0003-4964-6147	NIGMS NIH HHS [GM36659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HENRY NL, 1994, IN PRESS GENES DEV; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; NAUMOVSKI L, 1985, MOL CELL BIOL, V5, P17, DOI 10.1128/MCB.5.1.17; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROY R, 1994, CELL, V79; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TSUJI JN, 1991, P NATL ACAD SCI USA, V88, P9006; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WU LT, 1994, ONCOGENE, V9, P2089; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	48	376	381	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					1103	1109		10.1016/0092-8674(94)90040-X	http://dx.doi.org/10.1016/0092-8674(94)90040-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001136				2022-12-28	WOS:A1994PY08600019
J	BOURANTAS, K; MALAMOUMITSI, VD; CHRISTOU, L; FILIPPIDOU, S; DROSOS, AA				BOURANTAS, K; MALAMOUMITSI, VD; CHRISTOU, L; FILIPPIDOU, S; DROSOS, AA			CUTANEOUS VASCULITIS AS THE INITIAL MANIFESTATION IN ACUTE MYELOMONOCYTIC LEUKEMIA	ANNALS OF INTERNAL MEDICINE			English	Note							HAIRY-CELL LEUKEMIA; CYCLOPHOSPHAMIDE THERAPY; CLASSIFICATION; MALIGNANCY; DISORDERS; DISEASE		UNIV IOANNINA, SCH MED, DEPT INTERNAL MED, GR-45110 IOANNINA, GREECE	University of Ioannina			Drosos, Alexandros A./AAK-1115-2020					ALARCONSEGOVIA D, 1980, CLIN RHEUM DIS, V6, P223; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BEYLOT J, 1989, REV MED INTERNE, V10, P509; BUTLER RC, 1987, J ROY SOC MED, V80, P168, DOI 10.1177/014107688708000314; COX NH, 1990, ARCH DERMATOL, V126, P61, DOI 10.1001/archderm.126.1.61; DROSOS AA, 1992, J INTERN MED, V232, P279, DOI 10.1111/j.1365-2796.1992.tb00584.x; FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660; FAUCI AS, 1979, NEW ENGL J MED, V301, P235, DOI 10.1056/NEJM197908023010503; GABRIEL SE, 1986, J RHEUMATOL, V13, P1167; GARCIAS VA, 1982, UROLOGY, V19, P155, DOI 10.1016/0090-4295(82)90571-4; GREER JM, 1988, MEDICINE, V67, P220, DOI 10.1097/00005792-198807000-00003; HUGHES GRV, 1979, LANCET, V1, P678; HUHN D, 1983, ACTA HAEMATOL-BASEL, V69, P36, DOI 10.1159/000206836; KESSELER ME, 1986, J ROY SOC MED, V79, P485, DOI 10.1177/014107688607900819; KLIMA M, 1984, HUM PATHOL, V15, P657, DOI 10.1016/S0046-8177(84)80291-9; LONGLEY S, 1986, AM J MED, V80, P1027, DOI 10.1016/0002-9343(86)90660-1; O'Shea J J, 1987, Am J Med, V82, P539; POSNETT DN, 1984, J IMMUNOL, V132, P2700; SANCHEZGUERRERO J, 1990, J RHEUMATOL, V17, P1458; VESOLE DH, 1987, ARCH INTERN MED, V147, P2026, DOI 10.1001/archinte.147.11.2026	20	27	27	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1994	121	12					942	944		10.7326/0003-4819-121-12-199412150-00006	http://dx.doi.org/10.7326/0003-4819-121-12-199412150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW083	7978719				2022-12-28	WOS:A1994PW08300006
J	VIJAYARAGHAVAN, S				VIJAYARAGHAVAN, S			SCIENCE FOR ARTS SAKE	NATURE			English	Editorial Material											VIJAYARAGHAVAN, S (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.								0	3	3	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					590	590		10.1038/372590a0	http://dx.doi.org/10.1038/372590a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990942	Bronze			2022-12-28	WOS:A1994PX30700026
J	LIU, HP; KOHLER, J; FINK, GR				LIU, HP; KOHLER, J; FINK, GR			SUPPRESSION OF HYPHAL FORMATION IN CANDIDA-ALBICANS BY MUTATION OF A STE12 HOMOLOG	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; FILAMENTOUS GROWTH; YEAST; PROTEIN	A Candida albicans gene (CPH1) was cloned that encodes a protein homologous to Saccharomyces cerevisiae Ste12p, a transcription factor that is the target of the pheromone response mitogen-activated protein kinase cascade. CPH1 complements both the mating defect of ste12 haploids and the filamentous growth defect of ste12/ste12 diploids. Candida albicans strains without a functional CPH1 gene (cph1/cph1) show suppressed hyphal formation on solid medium. However, cph1/cph1 strains can still form hyphae in liquid culture and in response to serum. Thus, filamentous growth may be activated in C. albicans by the same signaling kinase cascade that activates Ste12p in S. cerevisiae; however, alternative pathways may exist in C. albicans.	CHILDRENS HOSP, BOSTON, MA 02115 USA; MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA	Harvard University; Boston Children's Hospital; Massachusetts Institute of Technology (MIT); Whitehead Institute					NIGMS NIH HHS [GM402661] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANUETT F, 1994, GENE DEV, V8, P1367, DOI 10.1101/gad.8.12.1367; BARLOW AJE, 1974, J GEN MICROBIOL, V82, P261, DOI 10.1099/00221287-82-2-261; BUFFO J, 1984, MYCOPATHOLOGIA, V85, P21, DOI 10.1007/BF00436698; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FONZI WA, 1993, DIMORPHIC FUNGI IN BIOLOGY AND MEDICINE, P37; FONZI WA, 1993, GENETICS, V134, P717; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIMENO CJ, 1992, SCIENCE, V257, P626, DOI 10.1126/science.1496375; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GOSHORN AK, 1989, GENETICS, V123, P667; GOW NAR, 1994, P NATL ACAD SCI USA, V91, P6216, DOI 10.1073/pnas.91.13.6216; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KIRKMANCORREIA C, 1993, MOL CELL BIOL, V13, P3765, DOI 10.1128/MCB.13.6.3765; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MALATHI K, 1994, J BIOL CHEM, V269, P22945; SCHERER S, 1990, MICROBIOL REV, V54, P226, DOI 10.1128/MMBR.54.3.226-241.1990; SONG OK, 1991, GENE DEV, V5, P741, DOI 10.1101/gad.5.5.741; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; YUAN YLO, 1993, GENE DEV, V7, P1584, DOI 10.1101/gad.7.8.1584; YUAN YLO, 1991, MOL CELL BIOL, V11, P5910, DOI 10.1128/MCB.11.12.5910	24	674	707	2	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	1994	266	5191					1723	1726		10.1126/science.7992058	http://dx.doi.org/10.1126/science.7992058			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992058				2022-12-28	WOS:A1994PW30800045
J	MINVIELLESEBASTIA, L; PREKER, PJ; KELLER, W				MINVIELLESEBASTIA, L; PREKER, PJ; KELLER, W			RNA14 AND RNA15 PROTEINS AS COMPONENTS OF A YEAST PRE-MESSENGER-RNA 3'-END PROCESSING FACTOR	SCIENCE			English	Article							CYC1 MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; POLY(A) POLYMERASE; 3' END; GENE; SEQUENCE; POLYADENYLATION; MUTATIONS; INVITRO; BINDING	Most eukaryotic pre-messenger RNAs are processed at their 3' ends by endonucleolytic cleavage and polyadenylation. In yeast, this processing requires polyadenylate [poly(A)] polymerase (PAP) and other proteins that have not yet been characterized. Here, mutations in the PAP1 gene were shown to be synergistically lethal with previously identified mutations in the RNA14 and RNA15 genes, which suggests that their encoded proteins participate in 3'-end processing. Indeed, extracts from ma14 and ma15 mutants were shown to be deficient in both steps of processing. Biochemical complementation experiments and reconstitution of both activities with partially purified cleavage factor I (CF I) validated the genetic prediction.			MINVIELLESEBASTIA, L (corresponding author), UNIV BASEL,BIOCTR,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND.		Minvielle-Sebastia, Lionel/M-7154-2014					BLOCH JC, 1978, MOL GEN GENET, V165, P123, DOI 10.1007/BF00269900; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BONNEAUD N, 1994, J CELL SCI, V107, P913; BUTLER JS, 1988, SCIENCE, V242, P1270, DOI 10.1126/science.2848317; BUTLER JS, 1990, MOL CELL BIOL, V10, P2599, DOI 10.1128/MCB.10.6.2599; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; FRANK D, 1992, MOL CELL BIOL, V12, P5197, DOI 10.1128/MCB.12.11.5197; GUARENTE L, 1993, TRENDS GENET, V9, P362, DOI 10.1016/0168-9525(93)90042-G; HOU W, 1994, EMBO J, V13, P446, DOI 10.1002/j.1460-2075.1994.tb06279.x; HUFFAKER TC, 1987, ANNU REV GENET, V21, P259; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; LIAO XLC, 1993, GENE DEV, V7, P419, DOI 10.1101/gad.7.3.419; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LINGNER J, 1991, J BIOL CHEM, V266, P8741; LINGNER J, UNPUB; MINVIELLESEBAST.L, 1992, THESIS PARIS U; MINVIELLESEBAST.L, UNPUB; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MOORE CL, 1984, CELL, V36, P581, DOI 10.1016/0092-8674(84)90337-4; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; RUBY SW, 1993, GENE DEV, V7, P1909, DOI 10.1101/gad.7.10.1909; RUSSO P, 1991, EMBO J, V10, P563, DOI 10.1002/j.1460-2075.1991.tb07983.x; Sambrook J, 1989, MOL CLONING LABORATO; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	26	137	139	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1702	1705		10.1126/science.7992054	http://dx.doi.org/10.1126/science.7992054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992054				2022-12-28	WOS:A1994PW30800039
J	KASAHARA, N; DOZY, AM; KAN, YW				KASAHARA, N; DOZY, AM; KAN, YW			TISSUE-SPECIFIC TARGETING OF RETROVIRAL VECTORS THROUGH LIGAND-RECEPTOR INTERACTIONS	SCIENCE			English	Article							MURINE LEUKEMIA-VIRUS; HUMAN ERYTHROPOIETIN; EXPRESSION; CLONING; CELLS; GENE; INFECTION; MUTANT; MOUSE	The development of retroviral vectors that target specific cell types could have important implications for the design of gene therapy strategies. A chimeric protein containing the polypeptide hormone erythropoietin and part of the env protein of ecotropic Moloney murine leukemia virus was engineered into the virus. This murine virus became several times more infectious for murine cells bearing the erythropoietin receptor, and it also became infectious for human cells bearing the erythropoietin receptor. This type of tissue-specific targeting by means of ligand-receptor interactions may have broad applications to a variety of gene delivery systems.	UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GRAD PROGRAM ENDOCRINOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Kasahara, Noriyuki/0000-0002-6069-9082	NHLBI NIH HHS [HL 20985] Funding Source: Medline; NIADDK NIH HHS [AM16666] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM016666] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL020985] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; ETIENNEJULAN M, 1992, J GEN VIROL, V73, P3251, DOI 10.1099/0022-1317-73-12-3251; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; KASAHARA N, 1994, THESIS U CALIFORNIA; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILLER DG, 1994, P NATL ACAD SCI USA, V91, P78, DOI 10.1073/pnas.91.1.78; NEDA H, 1991, J BIOL CHEM, V266, P14143; ROUX P, 1989, P NATL ACAD SCI USA, V86, P9079, DOI 10.1073/pnas.86.23.9079; RUSSELL SJ, 1993, NUCLEIC ACIDS RES, V21, P1081, DOI 10.1093/nar/21.5.1081; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SIMONSEN CC, 1988, NUCLEIC ACIDS RES, V16, P2235, DOI 10.1093/nar/16.5.2235; VALSESIAWITTMANN S, 1994, J VIROL, V68, P4609, DOI 10.1128/JVI.68.7.4609-4619.1994; VANZEIJL M, 1994, P NATL ACAD SCI USA, V91, P1168, DOI 10.1073/pnas.91.3.1168; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617; WEISS R, 1984, RNA TUMOR VIRUSES MO; WILSON C, 1989, J VIROL, V63, P2374, DOI 10.1128/JVI.63.5.2374-2378.1989; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	23	385	424	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1373	1376		10.1126/science.7973726	http://dx.doi.org/10.1126/science.7973726			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973726				2022-12-28	WOS:A1994PT63200041
J	MOSS, G; COHEN, S				MOSS, G; COHEN, S			TIME TO ABANDON BRUSSELS BID ON PATENTS .2.	NATURE			English	Article								After six years of debate, the European Commission's attempts to harmonize biotechnology legislation still face opposition over the patenting of genes. Recent legal experience suggests that its efforts are unnecessary.			MOSS, G (corresponding author), TAYLOR JOYNSON GARRETT,LONDON EC4Y 0DX,ENGLAND.								0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					384	384		10.1038/372384a0	http://dx.doi.org/10.1038/372384a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969499				2022-12-28	WOS:A1994PU28700061
J	DISCHER, DE; MOHANDAS, N; EVANS, EA				DISCHER, DE; MOHANDAS, N; EVANS, EA			MOLECULAR MAPS OF RED-CELL DEFORMATION - HIDDEN ELASTICITY AND IN-SITU CONNECTIVITY	SCIENCE			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; BLOOD-CELLS; PROTEIN 4.1; SPECTRIN; SKELETON; BAND-3	Fluorescence-imaged micropipette aspiration was used to map redistribution of the proteins and lipids in highly extended human red blood cell membranes. Whereas the fluid bilayer distributed uniformly (+/-10 percent), the underlying, solidlike cytoskeleton of spectrin, actin, and protein 4.1 exhibited a steep gradient in density along the aspirated projection, which was reversible on release from deformation. Quantitation of the cytoskeletal protein density gradients showed that skeletal elasticity is well represented by a grafted polymer network with a ratio of surface dilation modulus to shear modulus of approximately 2:1. Fractionally mobile integral proteins, such as band 3, and highly mobile receptors, such as CD59 as well as glycophorin C in protein 4.1-deficient cells, appeared to be squeezed out of areas dense in the underlying network and enriched in areas of network dilation. This complementary segregation demonstrates patterning of cell surface components by cytoskeletal dilation.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV LIFE SCI, BERKELEY, CA 94720 USA; UNIV BRITISH COLUMBIA, DEPT PATHOL, VANCOUVER V6T 1W5, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT PHYS, VANCOUVER V6T 1W5, BC, CANADA	University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of British Columbia; University of British Columbia	DISCHER, DE (corresponding author), UNIV CALIF BERKELEY, JOINT GRAD GRP BIOENGN, BERKELEY, CA 94720 USA.			discher, dennis/0000-0001-6163-2229	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094, R01DK026263] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL31579-13] Funding Source: Medline; NIDDK NIH HHS [R01 DK26263-15, P01 DK32094-09] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOOM JA, 1983, BIOPHYS J, V42, P295, DOI 10.1016/S0006-3495(83)84397-5; BOAL DH, 1994, BIOPHYS J, V67, P521, DOI 10.1016/S0006-3495(94)80511-9; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; de Gennes P.G., 1988, SCALING CONCEPTS POL; DISCHER D, 1993, J BIOL CHEM, V268, P7186; DISCHER DE, 1993, THESIS U CALIFORNIA; DUBREUIL R, 1987, J CELL BIOL, V105, P2095, DOI 10.1083/jcb.105.5.2095; EVANS E, 1987, J PHYS CHEM-US, V91, P4219, DOI 10.1021/j100300a003; EVANS EA, 1989, METHOD ENZYMOL, V173, P3; EVANS EA, 1980, MECHANICS THERMODYNA; GILLIGAN DM, 1993, SEMIN HEMATOL, V30, P74; GOLAN DE, 1986, J CELL BIOL, V103, P819, DOI 10.1083/jcb.103.3.819; GOLAN DE, 1980, P NATL ACAD SCI-BIOL, V77, P2537, DOI 10.1073/pnas.77.5.2537; GOODMAN SR, 1988, CRIT REV BIOCHEM MOL, V23, P171, DOI 10.3109/10409238809088319; HAGELBERG C, 1990, BIOCHEM J, V271, P831, DOI 10.1042/bj2710831; HAMASAKI N, 1980, ANION TRANSPORT PROT; HIRAOKA Y, 1987, SCIENCE, V238, P36, DOI 10.1126/science.3116667; HOFFMAN JF, 1992, USE RESEALED ERYTHRO, P1; MOHANDAS N, 1994, ANNU REV BIOPH BIOM, V23, P787, DOI 10.1146/annurev.bb.23.060194.004035; NAKASHIMA K, 1978, P NATL ACAD SCI USA, V75, P3823, DOI 10.1073/pnas.75.8.3823; PINDER JC, 1993, BLOOD, V82, P3482; PODGORSKI A, 1985, BIOCHEMISTRY-US, V24, P7871, DOI 10.1021/bi00348a004; REID ME, 1990, BLOOD, V75, P2229; SCOTT MD, 1990, J LAB CLIN MED, V115, P470; SPENCER M, 1990, DEV BIOL, V139, P279, DOI 10.1016/0012-1606(90)90297-V; STOKKE BT, 1986, J THEOR BIOL, V123, P205, DOI 10.1016/S0022-5193(86)80154-0; TAKAKUWA Y, 1986, J CLIN INVEST, V78, P80, DOI 10.1172/JCI112577; TSUJI A, 1986, BIOCHEMISTRY-US, V25, P6133, DOI 10.1021/bi00368a045; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; VIITALA J, 1985, TRENDS BIOCHEM SCI, V10, P392, DOI 10.1016/0968-0004(85)90067-2; WANG DN, 1994, EMBO J, V13, P3230, DOI 10.1002/j.1460-2075.1994.tb06624.x; WAYS P, 1964, J LIPID RES, V5, P318; WELCH MD, 1994, CURR OPIN CELL BIOL, V6, P110, DOI 10.1016/0955-0674(94)90124-4	33	279	287	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1032	1035		10.1126/science.7973655	http://dx.doi.org/10.1126/science.7973655			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973655				2022-12-28	WOS:A1994PQ92400041
J	YAMAZAKI, S				YAMAZAKI, S			RANKING JAPAN LIFE-SCIENCE RESEARCH	NATURE			English	Editorial Material											YAMAZAKI, S (corresponding author), JIKEI UNIV,SCH MED,MED INFORMAT CTR EDUC & RES,TOKYO 105,JAPAN.							[Anonymous], 1991, ASAHI SHINBUN; MADDOX J, 1992, NATURE, V359, P573; SQUIRES BP, 1992, CAN MED ASSOC J, V146, P341; DIRECTORY MED ED ORG; 1993, NATURE, V365, P97; NATIONWIDE LIST RES; 1992, NATURE, V360, P403; 1993, NATURE, V362, P387; DIRECTORY MED SCI RE; 1992, SCIENCE, V258, P565; 1993, NATURE, V363, P570; 1993, NATURE, V361, P196	12	11	11	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					125	126		10.1038/372125a0	http://dx.doi.org/10.1038/372125a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969440				2022-12-28	WOS:A1994PQ68800025
J	MA, JY; YEE, A; BREWER, HB; DAS, S; POTTER, H				MA, JY; YEE, A; BREWER, HB; DAS, S; POTTER, H			AMYLOID-ASSOCIATED PROTEINS ALPHA(1)-ANTICHYMOTRYPSIN AND APOLIPOPROTEIN-E PROMOTE ASSEMBLY OF ALZHEIMER BETA-PROTEIN INTO FILAMENTS	NATURE			English	Article							INHIBITOR ALPHA-1-ANTICHYMOTRYPSIN; TYPE-4 ALLELE; DISEASE; PEPTIDE; DEPOSITS; BINDING; INVITRO; METABOLISM; FIBRILS; PLAQUE	THE protease inhibitor alpha(1)-antichymotrypsin and the lipid transport protein apolipoprotein E (apoE) are intimately associated with the 42-amino-acid beta-peptide (A beta) in the filamentous amyloid deposits of Alzheimer's disease(1-3). We report here that these two amyloid-associated proteins serve a strong stimulatory role in the polymerization of A beta into amyloid filaments. Addition of either alpha(1)-antichymotrypsin or apoE to the A beta peptide promoted a 10- to 20-fold increase in filament formation, with apoE-4, the isoform recently linked to the development of late-onset Alzheimer's disease, showing the highest catalytic activity. These and other experiments suggest that Alzheimer amyloid deposits arise when A beta is induced to form filaments by amyloid-promoting factors (pathological chaperones) expressed in certain brain regions.	NHLBI,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Harvard Medical School			Das, Saumya/R-7644-2019	Das, Saumya/0000-0002-4521-4606; Potter, Huntington/0000-0002-4051-2516				ABRAHAM CR, 1990, NEUROBIOL AGING, V11, P123, DOI 10.1016/0197-4580(90)90045-2; ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; CASTANO EM, 1986, BIOCHEM BIOPH RES CO, V141, P782, DOI 10.1016/S0006-291X(86)80241-8; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAS S, IN PRESS NEURON; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; FRASER PE, 1993, J NEUROCHEM, V61, P298, DOI 10.1111/j.1471-4159.1993.tb03568.x; GREGG RE, 1986, J CLIN INVEST, V78, P815, DOI 10.1172/JCI112645; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KOO EH, 1991, NEUROBIOL AGING, V12, P495, DOI 10.1016/0197-4580(91)90079-Y; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; PASTERNACK JM, 1989, AM J PATHOL, V135, P827; PICKEN MM, 1990, J NEUROPATH EXP NEUR, V49, P41, DOI 10.1097/00005072-199001000-00005; POTTER H, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P275; POTTER H, 1992, ANN NY ACAD SCI, V674, P161, DOI 10.1111/j.1749-6632.1992.tb27485.x; PROBST A, 1987, ACTA NEUROPATHOL, V74, P133, DOI 10.1007/BF00692843; REBECK GW, 1993, NEURON, V11, P575; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROZEMULLER JM, 1991, ACTA NEUROPATHOL, V82, P200, DOI 10.1007/BF00294446; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423; WISNIEWSKI T, IN PRESS AM J PATH	31	846	864	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					92	94		10.1038/372092a0	http://dx.doi.org/10.1038/372092a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969426				2022-12-28	WOS:A1994PQ34800079
J	CZEISLER, CA; SHANAHAN, TL; KLERMAN, EB; MARTENS, H; BROTMAN, DJ; EMENS, JS; KLEIN, T; RIZZO, JF				CZEISLER, CA; SHANAHAN, TL; KLERMAN, EB; MARTENS, H; BROTMAN, DJ; EMENS, JS; KLEIN, T; RIZZO, JF			SUPPRESSION OF MELATONIN SECRETION IN SOME BLIND PATIENTS BY EXPOSURE TO BRIGHT LIGHT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MAMMALIAN CIRCADIAN-RHYTHMS; ENTRAINMENT; TEMPERATURE; SYSTEM; SHIFTS; PHASE	Background. Complete blindness generally results in the loss of synchronization of circadian rhythms to the 24-hour day and in recurrent insomnia. However, some blind patients maintain circadian entrainment. We undertook this study to determine whether some blind patients' eyes convey sufficient photic information to entrain the hypothalamic circadian pacemaker acid suppress melatonin secretion, despite an apparently complete loss of visual function. Methods. We evaluated the input of light to the circadian pacemaker by testing the ability of bright light to decrease plasma melatonin concentrations in 11 blind patients with no conscious perception of light and in 6 normal subjects. We also evaluated circadian entrainment over time in the blind patients. Results. Plasma melatonin concentrations decreased during exposure to bright light in three sightless patients by an average (+/-SD) of 69+/-21 percent and in the normal subjects by an average of 66+/-15 percent. When two of these blind patients were tested with their eyes covered during exposure to light, plasma melatonin did not decrease. The three blind patients reported no difficulty sleeping and maintained apparent circadian entrainment to the 24-hour day. Plasma melatonin concentrations did not decrease during exposure to bright light in seven of the remaining blind patients; in the eighth, plasma melatonin was undetectable. These eight patients reported a history of insomnia, and in four the circadian temperature rhythm was not entrained to the 24-hour day. Conclusions. The visual subsystem that mediates the light-induced suppression of melatonin secretion remains functionally intact in some sightless patients. The absence of photic input to the circadian system thus constitutes a distinct form of blindness, associated with periodic insomnia, that afflicts most but not ail patients with no conscious perception of light.	BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT OPHTHALMOL,BOSTON,MA; MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary	CZEISLER, CA (corresponding author), HARVARD UNIV,SCH MED,DEPT MED,DIV ENDOCRINOL,SLEEP DISORDERS & CIRCADIAN MED SECT,BOSTON,MA 02115, USA.			Czeisler, Charles Andrew/0000-0002-7408-1849	NATIONAL INSTITUTE ON AGING [P01AG009975, R01AG006072] Funding Source: NIH RePORTER; NIA NIH HHS [1-P01-AG09975, 1-R01-AG06072] Funding Source: Medline; NIMH NIH HHS [1-R01-MH451] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARENDT J, 1975, J CLIN ENDOCR METAB, V40, P347, DOI 10.1210/jcem-40-2-347; ARGAMASO SM, IN PRESS BIOPHYS CHE; ASCHOFF J, 1971, SCIENCE, V171, P213, DOI 10.1126/science.171.3967.213; BERSON EL, 1985, AM J OPHTHALMOL, V99, P240, DOI 10.1016/0002-9394(85)90351-4; BROWN EN, 1992, J BIOL RHYTHM, V7, P177, DOI 10.1177/074873049200700301; CHIANG YP, 1992, MILBANK Q, V70, P319, DOI 10.2307/3350062; COOPER HM, 1993, NATURE, V361, P156, DOI 10.1038/361156a0; CZEISLER CA, 1989, SCIENCE, V244, P1328, DOI 10.1126/science.2734611; FARADJI H, 1980, BRAIN RES, V202, P41, DOI 10.1016/0006-8993(80)90642-3; FOSTER RG, 1991, J COMP PHYSIOL A, V169, P39, DOI 10.1007/BF00198171; GORTELMEYER R, 1984, METHODS SLEEP RES, P93; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KLEIN T, 1993, SLEEP, V16, P333, DOI 10.1093/sleep/16.4.333; LEWY AJ, 1980, SCIENCE, V210, P1267, DOI 10.1126/science.7434030; LI Y, 1989, CLIN ENDOCRINOL, V30, P47, DOI 10.1111/j.1365-2265.1989.tb03726.x; MARTENS H, 1992, 3RD M SOC RES BIOL R, P58; Martens H., 1990, SLEEP RES, V19, P398; MCINTYRE IM, 1989, J PINEAL RES, V6, P149; MILES LEM, 1977, SCIENCE, V198, P421, DOI 10.1126/science.910139; MILLS JN, 1978, J PHYSIOL-LONDON, V285, P455, DOI 10.1113/jphysiol.1978.sp012582; MOORE RY, IN PRESS J COMP NEUR; MORIN LP, 1994, BRAIN RES REV, V19, P102, DOI 10.1016/0165-0173(94)90005-1; NAKAGAWA H, 1992, SLEEP, V15, P330, DOI 10.1093/sleep/15.4.330; ORTH DN, 1979, CLIN ENDOCRINOL, V10, P603, DOI 10.1111/j.1365-2265.1979.tb02120.x; PROVENCIO I, 1994, VISION RES, V34, P1799, DOI 10.1016/0042-6989(94)90304-2; REME CE, 1991, J BIOL RHYTHM, V6, P5, DOI 10.1177/074873049100600104; REPPERT SM, 1987, CURRENT CONCEPTS PED, P91; RUSAK B, 1979, FED PROC, V38, P2589; SACK RL, 1992, J CLIN ENDOCR METAB, V75, P127, DOI 10.1210/jcem.75.1.1619000; SHANAHAN TL, 1991, J CLIN ENDOCR METAB, V73, P227, DOI 10.1210/jcem-73-2-227; TAKAHASHI JS, 1984, NATURE, V308, P186, DOI 10.1038/308186a0; Wever R.A., 1979, CIRCADIAN SYSTEM MAN; WURTMAN RJ, 1963, SCIENCE, V142, P1071, DOI 10.1126/science.142.3595.1071	33	446	474	0	45	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					6	11		10.1056/NEJM199501053320102	http://dx.doi.org/10.1056/NEJM199501053320102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990870				2022-12-28	WOS:A1995PZ49700002
J	CHUI, DW; GOODING, GAW; MCQUAID, KR; GRISWOLD, V; GRENDELL, JH				CHUI, DW; GOODING, GAW; MCQUAID, KR; GRISWOLD, V; GRENDELL, JH			HYDROCOLONIC ULTRASONOGRAPHY IN THE DETECTION OF COLONIC POLYPS AND TUMORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SONOGRAPHY; DIAGNOSIS	Background. Hydrocolonic ultrasonography - abdominal ultrasonography in conjunction with the retrograde instillation of water into the colon - has been advocated as an alternative to colonoscopy for detecting colorectal polyps and cancer. We conducted a prospective, blinded trial to evaluate the procedure further. Methods. Fifty-two consecutive patients (50 men and 2 women; average age, 62 years) who were referred for colonoscopy underwent hydrocolonic ultrasonography followed by colonoscopy. The physicians performing colonoscopy were blinded to the ultrasound results. Patients who had a history of colonic polyps or tumors or who had previously undergone flexible sigmoidoscopy or colonoscopy were excluded. Results. Twenty-two patients had normal results on colonoscopy, 26 had polyps, 3 had cancer and polyps, and 1 had cancer alone. Twenty patients had polyps less than 7 mm in diameter, eight had polyps 7 mm or more in diameter, and one had a polyp of unknown size. Hydrocolonic ultrasonography did not detect any cancers and detected only one polyp greater than or equal to 7 mm and one polyp <7 mm in diameter. The overall sensitivity of ultrasonography for identifying any polyp was 6.9 percent, and for identifying a polyp greater than or equal to 7 mm, it was 12.5 percent. Ultrasonography suggested the presence of five masses and five polyps that were not confirmed by colonoscopy. Six patients had incomplete ultrasound studies because of discomfort or the inability to retain water. There were two complications: one patient had two vasovagal episodes, and another had diaphoresis. Conclusions. Hydrocolonic ultrasonography was less useful than colonoscopy for detecting colorectal polyps and cancers. The usefulness of the technique in screening for colonic polyps and tumors appears to be limited.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT RADIOL,SAN FRANCISCO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	CHUI, DW (corresponding author), VET ADM MED CTR,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NIDDK NIH HHS [DK07007] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007007] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		LIMBERG B, 1990, LANCET, V335, P144, DOI 10.1016/0140-6736(90)90012-T; LIMBERG B, 1992, NEW ENGL J MED, V327, P65, DOI 10.1056/NEJM199207093270201	2	35	35	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 22	1994	331	25					1685	1688		10.1056/NEJM199412223312504	http://dx.doi.org/10.1056/NEJM199412223312504			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX382	7969359				2022-12-28	WOS:A1994PX38200004
J	WOODS, RP; IACOBONI, M; MAZZIOTTA, JC				WOODS, RP; IACOBONI, M; MAZZIOTTA, JC			BRIEF REPORT - BILATERAL SPREADING CEREBRAL HYPOPERFUSION DURING SPONTANEOUS MIGRAINE HEADACHE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							POSITRON EMISSION TOMOGRAPHY; BLOOD-FLOW CHANGES; CLASSIC MIGRAINE; AUTOMATED ALGORITHM; FOCAL HYPEREMIA; ATTACKS; DEPRESSION; OLIGEMIA; CORTEX; ISCHEMIA		UNIV CALIF LOS ANGELES, SCH MED, INST NEUROPSYCHIAT, DIV BRAIN MAPPING, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PSYCHOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PHARMACOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT RADIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	WOODS, RP (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT NEUROL, 710 WESTWOOD PLAZA, LOS ANGELES, CA 90024 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001646] Funding Source: NIH RePORTER; NINDS NIH HHS [1 K08 NS01646-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHERRY SR, 1992, PHYS MED BIOL, V37, P779, DOI 10.1088/0031-9155/37/3/020; CHERRY SR, 1993, INT CONGR SER, V1030, P79; CHERRY SR, 1993, J CEREBR BLOOD F MET, V13, P630, DOI 10.1038/jcbfm.1993.81; CLARKE S, 1990, J COMP NEUROL, V298, P188, DOI 10.1002/cne.902980205; DALGAARD P, 1991, HEADACHE, V31, P49, DOI 10.1111/j.1526-4610.1991.hed3101049.x; EDVINSSON L, 1983, NATURE, V306, P55, DOI 10.1038/306055a0; FABRICIUS M, 1993, BRAIN RES, V602, P350, DOI 10.1016/0006-8993(93)90701-N; FOX PT, 1984, J NEUROPHYSIOL, V51, P1109, DOI 10.1152/jn.1984.51.5.1109; FRIBERG L, 1987, BRAIN, V110, P917, DOI 10.1093/brain/110.4.917; GELMERS HJ, 1982, CEPHALALGIA, V2, P29, DOI 10.1046/j.1468-2982.1982.0201029.x; Gowers W. R., 1904, Q REV, V200; GRAFTON ST, 1991, J NEUROPHYSIOL, V66, P735, DOI 10.1152/jn.1991.66.3.735; Lashley KS, 1941, ARCH NEURO PSYCHIATR, V46, P331, DOI 10.1001/archneurpsyc.1941.02280200137007; LAURITZEN M, 1983, ANN NEUROL, V13, P633, DOI 10.1002/ana.410130609; LAURITZEN M, 1984, BRAIN, V107, P447, DOI 10.1093/brain/107.2.447; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; LAURITZEN M, 1982, ANN NEUROL, V12, P469, DOI 10.1002/ana.410120510; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; LEAO AAP, 1945, J NEUROPHYSIOL, V8, P33; MARSHALL WH, 1959, PHYSIOL REV, V39, P239, DOI 10.1152/physrev.1959.39.2.239; MAZZIOTTA JC, 1985, J CEREBR BLOOD F MET, V5, P70, DOI 10.1038/jcbfm.1985.10; MOSKOWITZ MA, 1993, J NEUROSCI, V13, P1167, DOI 10.1523/jneurosci.13-03-01167.1993; OLESEN J, 1990, ANN NEUROL, V28, P791, DOI 10.1002/ana.410280610; OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406; OLESEN J, 1993, BRAIN, V116, P187, DOI 10.1093/brain/116.1.187; Olesen Jes, 1993, P209; OLSEN TS, 1993, CEPHALALGIA, V13, P86, DOI 10.1046/j.1468-2982.1993.1302086.x; OLSEN TS, 1987, ARCH NEUROL-CHICAGO, V44, P156, DOI 10.1001/archneur.1987.00520140028013; PIPER RD, 1991, AM J PHYSIOL, V261, pH96, DOI 10.1152/ajpheart.1991.261.1.H96; PRESS WH, 1992, NUMERICAL RECIPES; RAICHLE ME, 1983, J NUCL MED, V24, P790; Raskin N, 1988, HEADACHE; REINHARD JF, 1979, SCIENCE, V206, P85, DOI 10.1126/science.482930; SACKS OW, 1985, MIGRAINE COMMON DISO; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; VOLKOW ND, 1991, J NUCL MED, V32, P58; WILSON MA, 1991, NEUROSCIENCE, V44, P555, DOI 10.1016/0306-4522(91)90077-2; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024; Zeki S., 1993, VISION BRAIN	40	459	466	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 22	1994	331	25					1689	1692		10.1056/NEJM199412223312505	http://dx.doi.org/10.1056/NEJM199412223312505			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX382	7969360				2022-12-28	WOS:A1994PX38200005
J	TAIRA, M; OTANI, H; SAINTJEANNET, JP; DAWID, IB				TAIRA, M; OTANI, H; SAINTJEANNET, JP; DAWID, IB			ROLE OF THE LIM CLASS HOMEODOMAIN PROTEIN XLIM-1 IN NEURAL AND MUSCLE INDUCTION BY THE SPEMANN ORGANIZER IN XENOPUS	NATURE			English	Article							MESSENGER-RNAS; DNA-BINDING; GENE; EXPRESSION; MESODERM; DOMAIN; LAEVIS; EMBRYOS; NOGGIN; PLATE	LIKE all known LIM class homeobox genes, Xlim-1 encodes a protein with two tandemly repeated cysteine-rich LIM domains upstream of the homeodomain(1). In Xenopus laevis, Xlim-1 is specifically expressed in the Spemann organizer, whose major functions include neural induction and dorsalization of ventral mesoderm(2-4). From RNA injection experiments we conclude here that: (1) the LIM domains behave as negative regulatory domains; (2) LIM domain mutants of Xlim-1 elicited neural differentiation in animal explants; (3) mutant, and to a lesser extent wild-type, Xlim-1 enhanced muscle formation after coinjection with Xbra; (4) both of these activities are mediated by extracellular signals as seen in combined explant experiments;. (5) Xlim-1 mutants activated goosecoid (gsc) expression in animal explants, but not expression of noggin or follistatin; (6) mutant Xlim-1 elicited formation of partial secondary axes, and cooperated with gsc in notochord formation. Thus Xlim-1 has latent activities, implicating it in organizer functions.	UNIV TOULOUSE 3,CNRS,UNITE MIXTE RECH 9925,CTR DEV BIOL,F-31062 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	TAIRA, M (corresponding author), NICHHD,MOLEC GENET LAB,BETHESDA,MD 20892, USA.							BOICE ME, 1992, DEVELOPMENT, V115, P681; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; DAWID IB, 1994, J BIOL CHEM, V269, P6259; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GILBERT SF, 1993, MECH DEVELOP, V41, P73, DOI 10.1016/0925-4773(93)90039-Z; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; JAMRICH M, 1989, DEVELOPMENT, V105, P779; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; SAINTJEANNET JP, 1994, P NATL ACAD SCI USA, V91, P3049, DOI 10.1073/pnas.91.8.3049; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; STEINBEISSER H, 1993, DEVELOPMENT, V118, P499; STEINBEISSER H, 1993, CR ACAD SCI III-VIE, V316, P966; TAIRA M, 1994, DEVELOPMENT, V120, P1525; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; WATANABE M, 1986, J CELL BIOL, V103, P1721, DOI 10.1083/jcb.103.5.1721; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	28	181	183	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					677	679		10.1038/372677a0	http://dx.doi.org/10.1038/372677a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990959				2022-12-28	WOS:A1994PX30700086
J	BONITA, R; BEAGLEHOLE, R				BONITA, R; BEAGLEHOLE, R			CARDIOVASCULAR-DISEASE EPIDEMIOLOGY IN DEVELOPING-COUNTRIES - ETHICS AND ETIQUETTE	LANCET			English	Editorial Material									UNIV AUCKLAND,SCH MED,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND	University of Auckland	BONITA, R (corresponding author), UNIV AUCKLAND,DEPT MED,GERIATR UNIT,AUCKLAND,NEW ZEALAND.							[Anonymous], 1994, MED GLOBAL SURVIVAL; [Anonymous], 1993, WORLD DEV REPORT INV; LI N, 1994, J CLIN EPIDEMIOL, V47, P599, DOI 10.1016/0895-4356(94)90208-9; LINDEBERG S, 1993, J INTERN MED, V233, P269, DOI 10.1111/j.1365-2796.1993.tb00986.x; LINDEBERG S, 1994, J INTERN MED, V236, P331, DOI 10.1111/j.1365-2796.1994.tb00804.x; PETO R, 1994, MORTALITY SMOKING; Snow J., 1855, MODE COMMUNICATION C; Wessen A., 1992, MIGRATION HLTH SMALL; 1994, CIRCULATION, V90, P583; 1992, J CLIN EPIDEMIOL, V45, P841	10	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1586	1587		10.1016/S0140-6736(94)90401-4	http://dx.doi.org/10.1016/S0140-6736(94)90401-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983989				2022-12-28	WOS:A1994PW05100004
J	DIERMAYER, M; HEDBERG, K; FLEMING, D				DIERMAYER, M; HEDBERG, K; FLEMING, D			BACKING OFF UNIVERSAL CHILDHOOD LEAD SCREENING IN THE USA - OPPORTUNITY OR PITFALL	LANCET			English	Editorial Material											DIERMAYER, M (corresponding author), OREGON HLTH DIV,PORTLAND,OR 97207, USA.							[Anonymous], 1991, PREVENTING LEAD POIS; BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; DIERMAYER M, 1994, 43RD ANN EP INT SERV, P72; PIRKLE JL, 1994, JAMA-J AM MED ASSOC, V272, P284, DOI 10.1001/jama.272.4.284	4	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1587	1588		10.1016/S0140-6736(94)90402-2	http://dx.doi.org/10.1016/S0140-6736(94)90402-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PW051	7983990				2022-12-28	WOS:A1994PW05100005
J	HASHIZUME, M; OHTA, M; KAWANAKA, H; KISHIHARA, F; SUGIMACHI, K				HASHIZUME, M; OHTA, M; KAWANAKA, H; KISHIHARA, F; SUGIMACHI, K			RECURRENCE RATE OF ESOPHAGEAL-VARICES WITH ENDOSCOPIC BANDING LIGATION FOLLOWED BY INJECTION SCLEROTHERAPY	LANCET			English	Letter							BLEEDING ESOPHAGEAL-VARICES; RANDOMIZED TRIAL				HASHIZUME, M (corresponding author), KYUSHU UNIV,FAC MED,DEPT SURG 2,FUKUOKA 812,JAPAN.							GIMSON AES, 1993, LANCET, V342, P391, DOI 10.1016/0140-6736(93)92812-8; HASHIZUME M, 1992, HEPATOLOGY, V15, P69, DOI 10.1002/hep.1840150114; HASHIZUME M, 1993, GASTROINTEST ENDOSC, V39, P123, DOI 10.1016/S0016-5107(93)70050-4; STIEGMANN GV, 1988, AM SURGEON, V54, P105; STIEGMANN GV, 1992, NEW ENGL J MED, V326, P1527, DOI 10.1056/NEJM199206043262304	5	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1643	1643		10.1016/S0140-6736(94)90440-5	http://dx.doi.org/10.1016/S0140-6736(94)90440-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7984023				2022-12-28	WOS:A1994PW05100051
J	WENZL, R; LEHNER, R; VRY, U; PATEISKY, N; SEVELDA, P; HUSSLEIN, P				WENZL, R; LEHNER, R; VRY, U; PATEISKY, N; SEVELDA, P; HUSSLEIN, P			3-DIMENSIONAL VIDEOENDOSCOPY - CLINICAL USE IN GYNECOLOGICAL LAPAROSCOPY	LANCET			English	Article								We describe a system that displays the abdominal organs in three dimensions during laparoscopy. The system consists of a single-rod-lens endoscope and two integrated microchip cameras. The surgeon has to wear active-liquid-crystal shutter-glasses to obtain a three-dimensional impression during the operation. Improved orientation in the abdominal cavity allows exact handling of surgical instruments. The three-dimensional system perm its surgery with more accuracy, speed, dexterity, and safety than conventional two-dimensional systems.	UNIV VIENNA,DEPT OBSTET & GYNAECOL,VIENNA,AUSTRIA; CARL ZEISS AG,ENDOSCOP DEV LAB,OBERKOCHEN,GERMANY	University of Vienna; Carl Zeiss AG								BECKER H, 1992, ENDOSCOPY, V25, P40; JACOBY S, 1905, ZENTRALBLATT HARN SE, V16, P535; KURJAK A, 1993, GYNECOL ONCOL, V50, P3, DOI 10.1006/gyno.1993.1154; LIU CY, 1993, J REPROD MED, V38, P526; NEZHAT CR, 1992, AM J OBSTET GYNECOL, V166, P864, DOI 10.1016/0002-9378(92)91351-A; SATAVA RM, 1993, SURG ENDOSC-ULTRAS, V7, P429, DOI 10.1007/BF00311737; SHIM KS, 1993, AM J GASTRONETEROL, V88, P1175; STRUTZ J, 1993, HNO, V41, P128; WENZL R, 1993, GEBURTSH FRAUENHEILK, V53, P776, DOI 10.1055/s-2007-1023725	9	59	60	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1621	1622		10.1016/S0140-6736(94)90412-X	http://dx.doi.org/10.1016/S0140-6736(94)90412-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983998				2022-12-28	WOS:A1994PW05100015
J	NOURSE, J; FIRPO, E; FLANAGAN, WM; COATS, S; POLYAK, K; LEE, MH; MASSAGUE, J; CRABTREE, GR; ROBERTS, JM				NOURSE, J; FIRPO, E; FLANAGAN, WM; COATS, S; POLYAK, K; LEE, MH; MASSAGUE, J; CRABTREE, GR; ROBERTS, JM			INTERLEUKIN-2-MEDIATED ELIMINATION OF THE P27(KIP1) CYCLIN-DEPENDENT KINASE INHIBITOR PREVENTED BY RAPAMYCIN	NATURE			English	Article							CATALYTIC SUBUNIT; PROTEIN-KINASE; CDK2 ACTIVITY; PHOSPHORYLATION; FIBROBLASTS; LYMPHOCYTES; ACTIVATION; P40(MO15); P34(CDC2); FK506	THE cyclin-dependent kinase (Cdk) enzymes, when associated with the G1 cycIins D and E, are rate-limiting for entry into the S phase of the cell cycle(1,2). During T-cell mitogenesis, antigen-receptor signalling promotes synthesis of cyclin E and its catalytic partner, Cdk2, and interleukin-2 (IL-2) signalling activates cyclin E/Cdk2 complexes(3). Rapamycin is a potent immunosuppressant which specifically inhibits G1-to-S-phase progression, leading to cell-cycle arrest in yeast and mammals(4-7) Here we report that IL-2 allows Cdk activation by causing the elimination of the Cdk inhibitor protein p27(Kip1), and that this is prevented by rapamycin. By contrast, the Cdk inhibitor p21 is induced by IL-2 and this induction is blocked by rapamycin. Our results show that p27(Kip1) governs Cdk activity during the transition from quiescence to S phase in T lymphocytes and that p21 function may be restricted to cycling cells.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104; MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021	Howard Hughes Medical Institute; Stanford University; Fred Hutchinson Cancer Center; Memorial Sloan Kettering Cancer Center	NOURSE, J (corresponding author), STANFORD UNIV,SCH MED,PROGRAM CANC BIOL,STANFORD,CA 94305, USA.			Lee, Mong-Hong/0000-0001-8675-8215; Massague, Joan/0000-0001-9324-8408				BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; KATO JY, IN PRESS CELL; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; MORICE WG, 1993, J BIOL CHEM, V268, P22737; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	24	903	933	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					570	573		10.1038/372570a0	http://dx.doi.org/10.1038/372570a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990932				2022-12-28	WOS:A1994PW08200058
J	STAESSEN, JA; THIJS, L; MANCIA, G; PARATI, G; OBRIEN, ET				STAESSEN, JA; THIJS, L; MANCIA, G; PARATI, G; OBRIEN, ET			CLINICAL-TRIALS WITH AMBULATORY BLOOD-PRESSURE MONITORING - FEWER PATIENTS NEEDED	LANCET			English	Article							REPRODUCIBILITY; HYPERTENSION	We have tested the concept that fewer patients are needed in trials of antihypertensive treatment if blood pressure is measured by ambulatory monitoring rather than by conventional sphygmomanometry. 233 patients (greater than or equal to 60 years old) with isolated systolic hypertension were randomly allocated placebo (n=119) or active treatment (n=114). Blood pressure measurements were compared by Wilcoxon's test and blood pressure profiles by ANOVA. With either method of measurement, the same number of patients (40 in each treatment group) was required to show a reduction after 1 year in clinic (13/8 mm tig) or average blood pressure over 24 h (9/5 mm Hg). To detect that the decrease in systolic pressure was not steadily maintained through the day, 40 patients in each treatment group were needed for blood pressure profiles made up of 4-hourly or 2-hourly means and 60 for profiles of 1-hourly means. For diastolic pressure, the corresponding numbers were 80, 100, and more than the number of available patients, respectively. We conclude that parallel-group trials focusing on the average blood pressure over 24 h, rather than on conventionally measured blood pressure, cannot economise on sample size. Moreover, trials studying the full course of blood pressure throughout the day, require more-not fewer-patients than studies of only the conventional or average 24 h blood pressure.	SYST EUR COORDINATING OFF,LOUVAIN,BELGIUM; CTR FISIOL CLIN & IPERTENS,MILAN,ITALY; OSPED SAN LUCA,IST SCI,MILAN,ITALY; BEAUMONT HOSP,BLOOD PRESSURE UNIT,DUBLIN 9,IRELAND		STAESSEN, JA (corresponding author), UNIV ZIEKENHUIS GASTHUISBERG,INWENDIGE GENEESKUNDE CARDIOL,KLIN LAB HYPERTENSIE,HEREST 49,B-3000 LOUVAIN,BELGIUM.		Staessen, Jan A/A-1065-2011; Parati, Gianfranco/K-7151-2016	Staessen, Jan A/0000-0002-3026-1637; Thijs, Lutgarde/0000-0002-8108-2356; Parati, Gianfranco/0000-0001-9402-7439				Amery A, 1991, Aging (Milano), V3, P287; CANTER DA, 1994, J HYPERTENS, V12, P491, DOI 10.1097/00004872-199404000-00021; COATS AJS, 1992, J HYPERTENS, V10, P385, DOI 10.1097/00004872-199204000-00011; COLE JWL, 1966, BIOMETRICS, V22, P810, DOI 10.2307/2528076; CONWAY J, 1988, J HYPERTENS, V6, P111; CONWAY J, 1989, J HYPERTENS, V7, pS29; EISEN SA, 1990, ARCH INTERN MED, V150, P1881, DOI 10.1001/archinte.150.9.1881; FAGARD R, 1993, AM J HYPERTENS, V6, P648, DOI 10.1093/ajh/6.8.648; GREENBERG RN, 1984, CLIN THER, V6, P592; MANCIA G, 1992, J HYPERTENS, V10, P1531, DOI 10.1097/00004872-199210120-00014; MANCIA G, 1983, LANCET, V2, P695; Mansoor G A, 1994, J Cardiovasc Risk, V1, P136; OBRIEN E, 1991, J AMBUL MONIT, V4, P207; OVERALL JE, 1994, CONTROL CLIN TRIALS, V15, P100, DOI 10.1016/0197-2456(94)90015-9; PARATI G, 1985, HYPERTENSION, V7, P597, DOI 10.1161/01.HYP.7.4.597; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; PICKERING TG, 1991, J HYPERTENS, V9, pS2; Pickering TG., 1991, AMBULATORY MONITORIN; ROSE M, 1990, AM J HYPERTENS, V3, P151, DOI 10.1093/ajh/3.2.151; STAESSEN J, 1992, AM J HYPERTENS, V5, P386, DOI 10.1093/ajh/5.6.386; Staessen J, 1992, Aging (Milano), V4, P85; STAESSEN JA, 1994, J HYPERTENS, V12, pS1; STAESSEN JA, 1994, J HYPERTENS S8, V12, pS105; Thijs L, 1992, HIGH BLOOD PRESSURE, V1, P17; TRAZZI S, 1991, J HYPERTENS, V9, P115, DOI 10.1097/00004872-199102000-00003; WAEBER B, 1987, LANCET, V2, P732; WHELTON A, 1992, J CLIN PHARMACOL, V32, P808, DOI 10.1002/j.1552-4604.1992.tb03887.x; WHITE WB, 1993, HYPERTENSION, V21, P504, DOI 10.1161/01.HYP.21.4.504	28	37	38	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1552	1556		10.1016/S0140-6736(94)90355-7	http://dx.doi.org/10.1016/S0140-6736(94)90355-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983959				2022-12-28	WOS:A1994PV01700015
J	WYATT, JC				WYATT, JC			CLINICAL-DATA SYSTEMS .1. DATA AND MEDICAL RECORDS	LANCET			English	Article							ACCURACY; HISTORY; RELIABILITY; INFORMATION; KNOWLEDGE; NEEDS; SCALE; TIME; COMA; CARE				WYATT, JC (corresponding author), IMPERIAL CANC RES FUND, BIOMED INFORMAT UNIT, POB 123, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.		Wyatt, Jeremy/F-8160-2010	Wyatt, Jeremy/0000-0001-7008-1473				ADAMS ID, 1986, BRIT MED J, V293, P800, DOI 10.1136/bmj.293.6550.800; BARR LC, 1992, LANCET, V339, P915, DOI 10.1016/0140-6736(92)90941-U; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BRAHAMS D, 1989, LANCET, V2, P632; BUCKLAND R, 1993, BRIT MED J, V306, P287, DOI 10.1136/bmj.306.6873.287; BURNUM JF, 1989, ANN INTERN MED, V110, P482, DOI 10.7326/0003-4819-110-6-482; BYAR DP, 1980, BIOMETRICS, V36, P337, DOI 10.2307/2529989; CLARK DA, 1990, CURR PSYCHOL RES REV, V9, P203, DOI 10.1007/BF02686861; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; COOK RI, 1989, ANESTHESIOLOGY, V71, P385, DOI 10.1097/00000542-198909000-00013; DALY KA, 1994, AM J EPIDEMIOL, V139, P1116, DOI 10.1093/oxfordjournals.aje.a116955; Dick R.S., 1991, COMPUTER BASED PATIE; DONNELLY WJ, 1992, ARCH INTERN MED, V152, P480; FERNOW LC, 1978, MED CARE, V16, P476, DOI 10.1097/00005650-197806000-00004; FLETCHER RH, 1974, NEW ENGL J MED, V290, P829, DOI 10.1056/NEJM197404112901505; FRIES JF, 1974, MED CARE, V12, P871, DOI 10.1097/00005650-197410000-00006; HODNETT ED, 1993, PREGNANCY CHILDBIRTH; HYLAND ME, 1993, BRIT MED J, V306, P487, DOI 10.1136/bmj.306.6876.487; KEE F, 1993, BRIT MED J, V307, P1528, DOI 10.1136/bmj.307.6918.1528; KORAN LM, 1975, NEW ENGL J MED, V293, P695, DOI 10.1056/NEJM197510022931405; KORAN LM, 1975, NEW ENGL J MED, V293, P642, DOI 10.1056/NEJM197509252931307; LILFORD RJ, 1992, BMJ-BRIT MED J, V305, P1181, DOI 10.1136/bmj.305.6863.1181; MILLER RA, 1982, NEW ENGL J MED, V307, P468, DOI 10.1056/NEJM198208193070803; OSHEROFF JA, 1991, ANN INTERN MED, V114, P576, DOI 10.7326/0003-4819-114-7-576; PICKERING TG, 1994, LANCET, V344, P31; RECTOR AL, 1991, METHOD INFORM MED, V30, P179; REULER JB, 1991, BRIT MED J, V303, P446, DOI 10.1136/bmj.303.6800.446; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2650, DOI 10.1001/jama.267.19.2650; SENSKY T, 1992, BRIT MED J, V305, P1109, DOI 10.1136/bmj.305.6862.1109; SHARP GB, 1990, CANCER, V66, P2215, DOI 10.1002/1097-0142(19901115)66:10<2215::AID-CNCR2820661029>3.0.CO;2-Q; SHEAGREN JN, 1990, ARCH INTERN MED, V150, P2014; SHORTLIFFE EH, 1990, MED INFORMATICS; SIDELI RV, 1991, 15TH P S COMP APPL M, P588; SPIEGELHALTER DJ, 1985, CLIN GASTROENTEROL, V14, P489; TEASDALE G, 1974, LANCET, V2, P81; Tufo H M, 1971, Med Care, V9, P509, DOI 10.1097/00005650-197111000-00007; VANDERLEI J, 1991, LANCET, V338, P1504, DOI 10.1016/0140-6736(91)92311-O; WEED LL, 1968, NEW ENGL J MED, V278, P652, DOI 10.1056/NEJM196803212781204; WEED LL, 1968, NEW ENGL J MED, V278, P593, DOI 10.1056/NEJM196803142781105; WHITINGOKEEFE QE, 1985, JAMA-J AM MED ASSOC, V254, P1185, DOI 10.1001/jama.254.9.1185; WURMAN RS, 1991, LANCET, V337, P37; WYATT J, 1991, LANCET, V338, P1368, DOI 10.1016/0140-6736(91)92245-W; WYATT J, 1991, LANCET, V338, P1431, DOI 10.1016/0140-6736(91)92731-G	45	41	42	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 3	1994	344	8936					1543	1547		10.1016/S0140-6736(94)90353-0	http://dx.doi.org/10.1016/S0140-6736(94)90353-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983957				2022-12-28	WOS:A1994PV01700013
J	GUCKENBERGER, R; HEIM, M; CEVC, G; KNAPP, HF; WIEGRABE, W; HILLEBRAND, A				GUCKENBERGER, R; HEIM, M; CEVC, G; KNAPP, HF; WIEGRABE, W; HILLEBRAND, A			SCANNING-TUNNELING-MICROSCOPY OF INSULATORS AND BIOLOGICAL SPECIMENS BASED ON LATERAL CONDUCTIVITY OF ULTRATHIN WATER FILMS	SCIENCE			English	Article							MEMBRANE; PROTEIN	Scanning tunneling microscopy is based on the flow of an electrical current and thus cannot be used to directly image insulating material. It has been found, however, that a very thin film of water (about one monolayer) adsorbed to a surface exhibits a surprisingly high conductivity that is sufficient to allow scanning tunneling microscope imaging at currents below 1 picoampere. Hydrophilic insulators, such as glass and mica, can thus be imaged in humid air. The same is true for biological specimens deposited on such surfaces, as demonstrated by the scanning tunneling microscope imaging of plasmid DNA on mica.	TECH UNIV MUNICH,KLINIKUM RECHTS ISAR,D-81675 MUNICH,GERMANY	Technical University of Munich	GUCKENBERGER, R (corresponding author), MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY.							BEAGLEHOLE D, 1991, PHYS REV LETT, V66, P2084, DOI 10.1103/PhysRevLett.66.2084; CEVC G, 1990, BIOCHIM BIOPHYS ACTA, V1031, P311, DOI 10.1016/0304-4157(90)90015-5; CEVC G, 1992, J ELECTROANAL CHEM, V330, P407, DOI 10.1016/0022-0728(92)80321-T; CEVC G, 1993, HYDRATION BIOL MACRO, P338; GATHERCOLE LJ, 1993, J CHEM SOC FARADAY T, V89, P2589, DOI 10.1039/ft9938902589; GUCKENBERGER R, 1988, ULTRAMICROSCOPY, V25, P111, DOI 10.1016/0304-3991(88)90218-5; GUCKENBERGER R, 1989, ULTRAMICROSCOPY, V31, P327, DOI 10.1016/0304-3991(89)90055-7; GUCKENBERGER R, 1991, J VAC SCI TECHNOL B, V9, P1227, DOI 10.1116/1.585210; GUCKENBERGER R, 1994, J VAC SCI TECHNOL B, V12, P1508, DOI 10.1116/1.587274; GUCKENBERGER R, UNPUB; GUCKENBERGER R, 1992, SCANNING TUNNELING M, V2, P52; HACKER B, 1992, ULTRAMICROSCOPY, V42, P1514, DOI 10.1016/0304-3991(92)90475-Y; HELM ML, UNPUB; KELL DB, 1992, BIOELECTROCH BIOENER, V27, P235, DOI 10.1016/0302-4598(92)87047-X; LEGGETT GJ, 1993, J PHYS CHEM-US, V97, P8852, DOI 10.1021/j100137a006; SCHAPER A, 1993, NUCLEIC ACIDS RES, V21, P6004, DOI 10.1093/nar/21.25.6004; WANG ZH, 1990, P NATL ACAD SCI USA, V87, P9343, DOI 10.1073/pnas.87.23.9343; YUAN JY, 1991, PHYS REV LETT, V67, P863, DOI 10.1103/PhysRevLett.67.863; [No title captured]	19	214	217	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1538	1540		10.1126/science.7985024	http://dx.doi.org/10.1126/science.7985024			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985024				2022-12-28	WOS:A1994PV01500036
J	KAUSHAL, S; SCHNEIDER, JW; NADALGINARD, B; MAHDAVI, V				KAUSHAL, S; SCHNEIDER, JW; NADALGINARD, B; MAHDAVI, V			ACTIVATION OF THE MYOGENIC LINEAGE BY MEF2A, A FACTOR THAT INDUCES AND COOPERATES WITH MYOD	SCIENCE			English	Article							ENHANCER-BINDING-FACTOR; MUSCLE-SPECIFIC EXPRESSION; CREATINE-KINASE GENE; TRANSCRIPTION FACTORS; CYCLIC AMPLIFICATION; MYOCARDIAL-CELLS; FACTOR MEF-2; FACTOR-II; PROTEINS; SKELETAL	Muscle enhancer factor-2A (MEF2A), a member of the MADS family, induced myogenic development when ectopically expressed in clones of nonmuscle cells of human clones, a function previously limited to the muscle basic helix-loop-helix (bHLH) proteins. During myogenesis, MEF2A and bHLH proteins cooperatively activate skeletal muscle genes and physically interact through the MADS domain of MEF2A and the three myogenic amino acids of the muscle bHLH proteins. Thus, skeletal myogenesis is mediated by two distinct families of mutually inducible and interactive muscle transcription factors, either of which can initiate the developmental cascade.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT CARDIOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School								ANDRES V, UNPUB; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BRAUN T, 1989, MOL CELL BIOL, V9, P2513, DOI 10.1128/MCB.9.6.2513; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; BUCHBERGER A, 1994, J BIOL CHEM, V269, P17289; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GARFINKEL LI, 1982, J BIOL CHEM, V257, P1078; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE KJ, 1992, J BIOL CHEM, V267, P15875; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Martin J., UNPUB; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NAKATSUJI Y, 1992, MOL CELL BIOL, V12, P4384, DOI 10.1128/MCB.12.10.4384; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; TRASK RV, 1992, NUCLEIC ACIDS RES, V20, P2313, DOI 10.1093/nar/20.9.2313; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WOLD JH, 1990, P NATL ACAD SCI USA, V87, P1089; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	52	206	211	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1236	1240		10.1126/science.7973707	http://dx.doi.org/10.1126/science.7973707			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973707				2022-12-28	WOS:A1994PT13200053
J	KONDO, T; TSINOREMAS, NF; GOLDEN, SS; JOHNSON, CH; KUTSUNA, S; ISHIURA, M				KONDO, T; TSINOREMAS, NF; GOLDEN, SS; JOHNSON, CH; KUTSUNA, S; ISHIURA, M			CIRCADIAN CLOCK MUTANTS OF CYANOBACTERIA	SCIENCE			English	Article							CHLAMYDOMONAS; EXPRESSION; RHYTHMS; STRAIN; GENE	A diverse set of circadian clock mutants was isolated in a cyanobacterial strain that carries a bacterial luciferase reporter gene attached to a clock-controlled promoter. Among 150,000 clones of chemically mutagenized bioluminescent cells, 12 mutants were isolated that exhibit a broad spectrum of periods (between 16 and 60 hours), and 5 mutants were found that show a variety of unusual patterns, including arrhythmia. These mutations appear to be clock-specific. Moreover, it was demonstrated that in this cyanobacterium it is possible to clone mutant genes by complementation, which provides a means to genetically dissect the circadian mechanism.	TEXAS A&M UNIV,DEPT BIOL,COLLEGE STN,TX 77843; VANDERBILT UNIV,DEPT BIOL,NASHVILLE,TN 37235; NAGOYA UNIV,GRAD SCH HUMAN INFORMAT,NAGOYA,AICHI 465,JAPAN	Texas A&M University System; Texas A&M University College Station; Vanderbilt University; Nagoya University	KONDO, T (corresponding author), NATL INST BASIC BIOL,OKAZAKI,AICHI 444,JAPAN.		Johnson, Carl H/I-4655-2014		NIGMS NIH HHS [GM37040] Funding Source: Medline; NIMH NIH HHS [MH43836] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH043836, R01MH043836] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BINDER BJ, 1990, J BACTERIOL, V172, P2313, DOI 10.1128/jb.172.5.2313-2319.1990; BRUCE VG, 1972, GENETICS, V70, P537; Bunning E, 1973, PHYSL CLOCK; BUSTOS SA, 1991, J BACTERIOL, V173, P7525, DOI 10.1128/jb.173.23.7525-7533.1991; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; FELDMAN JF, 1982, ANNU REV PLANT PHYS, V33, P583, DOI 10.1146/annurev.pp.33.060182.003055; HALL JC, 1990, ANNU REV GENET, V24, P659; HUANG TC, 1993, CURR MICROBIOL, V27, P249, DOI 10.1007/BF01575987; KONDO T, 1994, J BACTERIOL, V176, P1881, DOI 10.1128/jb.176.7.1881-1885.1994; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; KONDO T, 1991, PLANT PHYSIOL, V95, P197, DOI 10.1104/pp.95.1.197; KONDO T, UNPUB; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; MERGENHAGEN D, 1986, EUR J CELL BIOL, V33, P13; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; SUGIURA M, COMMUNICATION; TSINOREMAS NF, 1994, J BACTERIOL, V176, P6764, DOI 10.1128/JB.176.21.6764-6768.1994; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325	18	240	252	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1233	1236		10.1126/science.7973706	http://dx.doi.org/10.1126/science.7973706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973706				2022-12-28	WOS:A1994PT13200052
J	RABBITTS, TH				RABBITTS, TH			CHROMOSOMAL TRANSLOCATIONS IN HUMAN CANCER	NATURE			English	Review							T-CELL LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; DNA-BINDING DOMAIN; TUMOR ALVEOLAR RHABDOMYOSARCOMA; CANDIDATE PROTOONCOGENE BCL-3; CHIMERIC TRANSCRIPTION FACTOR; ACUTE LYMPHOCYTIC-LEUKEMIA; FINGER ENCODING GENE; C-ABL ONCOGENE	Chromosomal abnormalities in tumours were recognized at the end of the last century but their significance has only recently become clear. Distinct translocations in leukaemias and in solid tumours lead to the activation of proto-oncogene products or, more commonly, creation of tumour-specific fusion proteins. The proteins in both categories are often transcription factors and thus disruption of transcriptional control plays a major role in the aetiology of cancer. Fusion proteins formed after chromosomal translocations are common in a range of tumour types; these are unique tumour antigens and are therefore potential targets for therapy design.			RABBITTS, TH (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.		Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BAER R, 1985, CELL, V43, P705, DOI 10.1016/0092-8674(85)90243-0; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BERNARD OA, 1994, ONCOGENE, V9, P1039; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOEHM T, 1990, ONCOGENE, V5, P1103; Boveri T., 1914, FRAGE ENTSTEHUNG MAL; BURNETT RC, 1991, GENE CHROMOSOME CANC, V3, P461, DOI 10.1002/gcc.2870030608; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DEKLEIN A, 1986, BLOOD, V68, P1369; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DENNY CT, 1986, NATURE, V320, P549, DOI 10.1038/320549a0; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DUBE ID, 1991, BLOOD, V78, P2996; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FISCH P, 1993, ONCOGENE, V8, P3271; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GAUWERKY CE, 1993, SEMIN CANCER BIOL, V4, P333; GILLARD EF, 1993, SEMIN CANCER BIOL, V4, P359; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GRIMALDI JC, 1989, BLOOD, V73, P2081; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; ICHIKAWA H, 1994, CANCER RES, V54, P2865; IIDA S, 1993, ONCOGENE, V8, P3085; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; LAABI Y, 1992, EMBO J, V11, P3897, DOI 10.1002/j.1460-2075.1992.tb05482.x; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU D, 1991, ONCOGENE, V6, P1235; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MALCOLM S, 1982, P NATL ACAD SCI-BIOL, V79, P4957, DOI 10.1073/pnas.79.16.4957; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MEEKER TC, 1990, BLOOD, V76, P285; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MENGLEGAW L, 1987, EMBO J, V6, P2273, DOI 10.1002/j.1460-2075.1987.tb02501.x; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIZUNO K, 1994, ONCOGENE, V9, P1605; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NOWELL PC, 1960, SCIENCE, V132, P1497; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OHKI M, 1993, SEMIN CANCER BIOL, V4, P369; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PANAGOPOULOS I, IN PRESS GENES CHROM; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; PRASAD R, 1993, CANCER RES, V53, P5624; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; RIMOKH R, 1991, GENE CHROMOSOME CANC, V3, P24, DOI 10.1002/gcc.2870030106; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; SANCHEZGARCIA I, 1993, SEMIN CANCER BIOL, V4, P349; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHIMA EA, 1986, P NATL ACAD SCI USA, V83, P3439, DOI 10.1073/pnas.83.10.3439; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STERN MH, 1993, ONCOGENE, V8, P2475; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TYCKO B, 1991, J EXP MED, V174, P867, DOI 10.1084/jem.174.4.867; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VONLINDERN M, 1992, GENE CHROMOSOME CANC, V5, P227, DOI 10.1002/gcc.2870050309; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; YAMAMOTO K, 1993, ONCOGENE, V8, P2617; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	100	1349	1389	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	1994	372	6502					143	149		10.1038/372143a0	http://dx.doi.org/10.1038/372143a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969446				2022-12-28	WOS:A1994PQ68800046
J	DAWSON, PE; MUIR, TW; CLARKLEWIS, I; KENT, SBH				DAWSON, PE; MUIR, TW; CLARKLEWIS, I; KENT, SBH			SYNTHESIS OF PROTEINS BY NATIVE CHEMICAL LIGATION	SCIENCE			English	Article							SITE-SPECIFIC INCORPORATION; HIV-1 PROTEASE; CRYSTAL-STRUCTURE; INTERLEUKIN-8; PEPTIDES; BONDS	A simple technique has been devised that allows the direct synthesis of native backbone proteins of moderate size. Chemoselective reaction of two unprotected peptide segments gives an initial thioester-linked species. Spontaneous rearrangement of this transient intermediate yields a full-length product with a native peptide bond at the ligation site. The utility of native chemical ligation was demonstrated by the one-step preparation of a cytokine containing multiple disulfides. The polypeptide ligation product was folded and oxidized to form the native disulfide-containing protein molecule. Native chemical ligation is an important step toward the general application of chemistry to proteins.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, DEPT BIOCHEM, VANCOUVER V6T 1Z3, BC, CANADA	Scripps Research Institute; University of British Columbia			Ueno, Hiroshi/C-3301-2009; Wood, David W/B-2992-2012; Muir, Tom/AHD-0860-2022	Muir, Tom/0000-0001-9635-0344	NIGMS NIH HHS [GM48870-03, GM48897-01, GM 50969-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050969, R01GM048897, P01GM048870] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHMSEN L, 1991, BIOCHEMISTRY-US, V30, P4151, DOI 10.1021/bi00231a007; AKAJI K, 1985, CHEM PHARM BULL, V33, P184; BACA M, 1993, P NATL ACAD SCI USA, V90, P11638, DOI 10.1073/pnas.90.24.11638; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BERMAN AL, 1994, P NATL ACAD SCI USA, V91, P4044, DOI 10.1073/pnas.91.9.4044; BLAKE J, 1981, INT J PEPT PROT RES, V17, P273; BRENNER M., 1967, P1; CANNE LE, UNPUB; CANNE LE, 1994, JUL ANN M PROT SOC S; CHANG TK, IN PRESS P NATL ACAD; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CORNISH VW, 1994, P NATL ACAD SCI USA, V91, P2910, DOI 10.1073/pnas.91.8.2910; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; DAWSON PE, 1993, J AM CHEM SOC, V115, P7263, DOI 10.1021/ja00069a027; EIGENBROT C, 1992, Current Opinion in Biotechnology, V3, P333, DOI 10.1016/0958-1669(92)90160-K; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; HUANG LH, 1991, BIOCHEMISTRY-US, V30, P7402, DOI 10.1021/bi00244a006; KEMP DS, 1993, J ORG CHEM, V58, P2216, DOI 10.1021/jo00060a043; LIU CF, 1994, J AM CHEM SOC, V116, P4149, DOI 10.1021/ja00089a001; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MILTON RCD, 1992, TECHNIQUES PROTEIN C, V4, P257; Muir Tom W., 1993, Current Opinion in Biotechnology, V4, P420, DOI 10.1016/0958-1669(93)90007-J; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; OFFORD RE, 1990, N HORIZ TH, P253; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; RAJARATHNAM K, 1994, BIOCHEMISTRY-US, V29, P1689; RAO C, 1994, J AM CHEM SOC, V116, P6975, DOI 10.1021/ja00094a078; ROSE K, 1994, J AM CHEM SOC, V116, P30, DOI 10.1021/ja00080a004; SCHNOLZER M, 1992, SCIENCE, V256, P221, DOI 10.1126/science.1566069; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SMITH M, 1994, ANGEW CHEM INT EDIT, V33, P1214, DOI 10.1002/anie.199412141; WALLACE CJA, 1992, J BIOL CHEM, V267, P3852; WILLIAMS M, IN PRESS J AM CHEM S; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; YAMASHIRO D, 1988, INT J PEPT PROT RES, V31, P322	38	3156	3600	23	789	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					776	779		10.1126/science.7973629	http://dx.doi.org/10.1126/science.7973629			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973629				2022-12-28	WOS:A1994PP75300031
J	ROILA, F; BALLATORI, E; DEANGELIS, V; TONATO, M; RIVA, E; PANZA, MT; DELFAVERO, A; BASURTO, C; CICCARESE, G; PALLADINO, MA; MOSCONI, AM; ANASTASI, P; PICCIAFUOCO, M; CAMPORA, E; CHIARA, S; ROSSO, R; COGNETTI, F; FERRARESI, V; FABI, A; TONACHELLA, R; CIRULLI, S; SABBATINI, R; FEDERICO, M; DEPENNI, R; SILINGARDI, V; DONATI, D; MAESTRI, A; MALACARNE, P; RICCI, S; MUTTINI, MP; CONTE, PF; SALVATI, F; NUNZIATI, F; SIGNORA, M; CATALANO, G; CASCINU, S; DICOSTANZO, F; TAGLIAVENTI, M; ZANIBONI, A; MERIGGI, F; CORTESI, E; TRINCA, C; LUPORINI, G; LOCATELLI, MC; SANTORO, A; ZUCCHINELLI, P; MANTELLINI, E; FERRETTI, G; BONI, C; MORETTI, G; SCAGLIOTTI, G; DANIELE, O; LISSONI, A; TATEO, S				ROILA, F; BALLATORI, E; DEANGELIS, V; TONATO, M; RIVA, E; PANZA, MT; DELFAVERO, A; BASURTO, C; CICCARESE, G; PALLADINO, MA; MOSCONI, AM; ANASTASI, P; PICCIAFUOCO, M; CAMPORA, E; CHIARA, S; ROSSO, R; COGNETTI, F; FERRARESI, V; FABI, A; TONACHELLA, R; CIRULLI, S; SABBATINI, R; FEDERICO, M; DEPENNI, R; SILINGARDI, V; DONATI, D; MAESTRI, A; MALACARNE, P; RICCI, S; MUTTINI, MP; CONTE, PF; SALVATI, F; NUNZIATI, F; SIGNORA, M; CATALANO, G; CASCINU, S; DICOSTANZO, F; TAGLIAVENTI, M; ZANIBONI, A; MERIGGI, F; CORTESI, E; TRINCA, C; LUPORINI, G; LOCATELLI, MC; SANTORO, A; ZUCCHINELLI, P; MANTELLINI, E; FERRETTI, G; BONI, C; MORETTI, G; SCAGLIOTTI, G; DANIELE, O; LISSONI, A; TATEO, S			DEXAMETHASONE, GRANISETRON, OR BOTH FOR THE PREVENTION OF NAUSEA AND VOMITING DURING CHEMOTHERAPY FOR CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; ANTIEMETIC EFFICACY; INDUCED EMESIS; METOCLOPRAMIDE; METHYLPREDNISOLONE; ONDANSETRON; TRIAL; CYCLOPHOSPHAMIDE; PROPHYLAXIS; CMF	Background. Serotonin-receptor antagonists seem to be as effective as corticosteroids in preventing emesis induced by moderately emetogenic antineoplastic agents. We compared the antiemetic effect of a combination of granisetron and dexamethasone with that of granisetron or dexamethasone administered alone. Methods. From December 1992 to January 1994, 428 consecutive patients who were to receive moderately emetogenic chemotherapy for the first time (600 to 1000 mg of cyclophosphamide per square meter of body-surface area, greater than or equal to 50 mg of doxorubicin per square meter, greater than or equal to 75 mg of epirubicin per square meter, or greater than or equal to 300 mg of carboplatin per square meter, alone or in some combination) were enrolled in a double-blind, randomized, multicenter study evaluating the efficacy and toxicity of three antiemetic regimens. The following antiemetic regimens were used: 8 mg of dexamethasone given intravenously before chemotherapy plus 4 mg given orally immediately before chemotherapy and then every six hours for a total of four doses, 3 mg of granisetron given intravenously be fore chemotherapy, or a combination of granisetron and dexamethasone given in the doses used for the single-drug regimens. Results. We evaluated 408 patients (136 receiving dexamethasone, 137 receiving granisetron, and 135 receiving both drugs), In the first 24 hours after chemotherapy, complete protection from vomiting and complete protection from nausea were achieved in 70.6 and 55.1 percent, respectively, of the patients receiving dexamethasone, in 72.3 and 48.2 percent of those receiving granisetron, and in 92.6 and 71.9 percent of those receiving granisetron combined with dexamethasone (P<0.001 for all comparisons). Patients who received granisetron alone had less protection from delayed vomiting and nausea than those who received dexamethasone alone or the two drugs combined. All the regimens were equally well tolerated. Conclusion. Granisetron combined with dexamethasone was the most effective regimen for the prevention of emesis induced by moderately emetogenic chemotherapy.	UNIV LAQUILA,DEPT INTERNAL MED & PUBL HLTH,I-67100 LAQUILA,ITALY; SMITHKLINE BEEHAM ITALY,DEPT MED,MILAN,ITALY; UNIV PERUGIA,DEPT INTERNAL MED & ONCOL SCI,I-06100 PERUGIA,ITALY; NATL INST CANC RES,GENOA,ITALY; REGINA ELENA INST CANC RES,DEPT MED ONCOL,ROME,ITALY; UNIV MODENA,DEPT MED ONCOL,I-41100 MODENA,ITALY; ARCISPEDALE ST ANNA,DIV MED ONCOL,FERRARA,ITALY; ST CHIARA HOSP,DEPT MED ONCOL,PISA,ITALY; FORLANINI HOSP,DEPT PNEUMOL 8,ROME,ITALY; MED ONCOL SERV,PESARO,ITALY; MED ONCOL SERV,TERNI,ITALY; MED ONCOL DIV,BRESCIA,ITALY; UNIV ROMA LA SAPIENZA,DIV MED ONCOL,ROME,ITALY; SAN CARLO BORROMEO HOSP,DIV MED ONCOL,MILAN,ITALY; NATL CANC INST,I-20133 MILAN,ITALY; CIV HOSP,DIV PNEUMOL 2,ALESSANDRIA,ITALY; REGGIO EMILIA HOSP,SERV ONCOL,REGGIO EMILIA,ITALY; UNIV TURIN,DEPT CLIN & BIOL SCI,TURIN,ITALY; MED ONCOL DIV,PADUA,ITALY; UNIV MILAN,ST GERARDO HOSP,DEPT OBSTET & GYNECOL 3,MONZA,ITALY; UNIV PAVIA,INST GYNECOL,I-27100 PAVIA,ITALY	University of L'Aquila; University of Perugia; University of Genoa; IRCCS AOU San Martino IST; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universita di Modena e Reggio Emilia; University of Ferrara; Arcispedale Sant'Anna; Azienda Ospedaliera San Camillo-Forlanini; Sapienza University Rome; San Carlo Borromeo Hospital; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Turin; University of Milan; University of Pavia	ROILA, F (corresponding author), POLICLIN HOSP,DIV MED ONCOL,I-06122 PERUGIA,ITALY.		Cortesi, Enrico/AAA-2983-2019; Ferraresi, Virginia/A-2075-2019; Fabi, Alessandra/AAC-1021-2019; Cascinu, Stefano/G-2399-2017; mosconi, anna maria/AAN-5224-2020; Cascinu, Stefano/AAN-1923-2020; Federico, Massimo/A-6801-2012; Cognetti, Francesco/AAC-2637-2019	Cascinu, Stefano/0000-0003-2215-0731; Federico, Massimo/0000-0002-9889-3796; 				BASURTO C, 1988, AM J CLIN ONCOL-CANC, V11, P594, DOI 10.1097/00000421-198810000-00017; BONNETERRE J, 1990, J CLIN ONCOL, V8, P1063, DOI 10.1200/JCO.1990.8.6.1063; CHIARA S, 1987, AM J CLIN ONCOL-CANC, V10, P264, DOI 10.1097/00000421-198706000-00021; DELFAVERO A, 1993, DRUG SAFETY, V9, P410, DOI 10.2165/00002018-199309060-00004; JONES AL, 1991, LANCET, V338, P483, DOI 10.1016/0140-6736(91)90554-3; KAASA S, 1990, EUR J CANCER, V26, P311, DOI 10.1016/0277-5379(90)90227-K; MARKMAN M, 1984, NEW ENGL J MED, V311, P549, DOI 10.1056/NEJM198408303110901; MARSCHNER NW, 1991, EUR J CANCER, V27, P1137, DOI 10.1016/0277-5379(91)90311-Z; MARSCHNER NW, 1991, EUR J CANCER, V27, P1717; MARTY M, 1990, EUR J CANCER, V26, pS28; POLLERA CF, 1989, AM J CLIN ONCOL-CANC, V12, P524, DOI 10.1097/00000421-198912000-00014; ROILA F, 1988, ONCOLOGY, V45, P346, DOI 10.1159/000226638; ROILA F, 1987, EUR J CANCER CLIN ON, V23, P615, DOI 10.1016/0277-5379(87)90255-0; WARR D, 1991, J NATL CANCER I, V83, P1169, DOI 10.1093/jnci/83.16.1169; 1994, SUPPORT CARE CANCER, V2, P171; 1991, LANCET, V338, P478	16	219	223	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					1	5						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990859				2022-12-28	WOS:A1995PZ49700001
J	WEETMAN, AP				WEETMAN, AP			ENZYMES AS CATALYSTS OF AUTOIMMUNITY	LANCET			English	Editorial Material							HYDRALAZINE; PROPYLTHIOURACIL; LUPUS				WEETMAN, AP (corresponding author), NO GEN HOSP,DEPT MED,SHEFFIELD,S YORKSHIRE,ENGLAND.							BATCHELOR JR, 1980, LANCET, V1, P1107; CORNACCHIA E, 1988, J IMMUNOL, V140, P2197; DOLMAN KM, 1993, LANCET, V342, P651, DOI 10.1016/0140-6736(93)91761-A; FIBBE WE, 1986, BRIT J HAEMATOL, V64, P363, DOI 10.1111/j.1365-2141.1986.tb04130.x; HOFSTRA AH, 1992, DRUG METAB DISPOS, V20, P205; JIANG XX, 1994, SCIENCE, V266, P810, DOI 10.1126/science.7973636; UCHIGATA Y, 1993, J CLIN ENDOCR METAB, V77, P249, DOI 10.1210/jc.77.1.249; WEETMAN AP, 1984, CLIN ENDOCRINOL, V21, P1636; YAMAMOTO K, 1991, BIOCHEM PHARMACOL, V41, P905; YUNG RL, 1994, RHEUM DIS CLIN N AM, V20, P61; 1992, LANCET, V339, P779	11	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1716	1717		10.1016/S0140-6736(94)92881-9	http://dx.doi.org/10.1016/S0140-6736(94)92881-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7996997				2022-12-28	WOS:A1994PY28100004
J	BASERGA, R				BASERGA, R			ONCOGENES AND THE STRATEGY OF GROWTH-FACTORS	CELL			English	Review							FACTOR-I RECEPTOR; SIMIAN SARCOMA-VIRUS; ERYTHROPOIETIN RECEPTOR; PROTEIN; TRANSFORMATION; ANTIGEN; GLYCOPROTEIN; FIBROBLASTS; ACTIVATION; CELLS				BASERGA, R (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON CANC CTR,PHILADELPHIA,PA 19107, USA.							BRESCIANI F, 1974, CANCER RES, V34, P2405; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V912, P6344; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KOHRMAN DC, 1992, J VIROL, V66, P1752, DOI 10.1128/JVI.66.3.1752-1760.1992; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; LIU DL, 1993, J VIROL, V67, P6835, DOI 10.1128/JVI.67.11.6835-6840.1993; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; PETERSON JE, 1994, IN PRESS J BIOL CHEM; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; PORCU P, 1994, ONCOGENE, V9, P2125; REISS K, 1992, ONCOGENE, V7, P2243; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; YOAKIM M, 1994, MOL CELL BIOL, V14, P5929, DOI 10.1128/MCB.14.9.5929; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; ZON LI, 1992, MOL CELL BIOL, V12, P2949, DOI 10.1128/MCB.12.7.2949	35	237	269	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					927	930		10.1016/0092-8674(94)90023-X	http://dx.doi.org/10.1016/0092-8674(94)90023-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001140				2022-12-28	WOS:A1994PY08600002
J	THIBODEAU, J; CLOUTIER, I; LAVOIE, PM; LABRECQUE, N; MOURAD, W; JARDETZKY, T; SEKALY, RP				THIBODEAU, J; CLOUTIER, I; LAVOIE, PM; LABRECQUE, N; MOURAD, W; JARDETZKY, T; SEKALY, RP			SUBSETS OF HLA-DR1 MOLECULES DEFINED BY SEB AND TSST-1 BINDING	SCIENCE			English	Article							STAPHYLOCOCCAL ENTEROTOXIN-B; SHOCK SYNDROME TOXIN-1; CLASS-II MOLECULES; HLA-DR; T-CELLS; ANTIGEN; COMPLEX; SUPERANTIGEN; CHAIN; EXPRESSION	Superantigens bind to major histocompatibility complex class II molecules on antigen-presenting cells and stimulate T cells. Staphylococcus aureus enterotoxin B (SEB) and toxic shock syndrome toxin-1 (TSST-1) bind to the same region of human lymphocyte antigen (HL4)-DR1 but do not compete with each other, which indicates that they bind to different subsets of DR1 molecules. Here, a mutation in the peptide-binding groove disrupted the SEB and TSST-1 binding sites, which suggests that peptides can influence the interaction with bacterial toxins. in support of this, the expression of the DR1 molecule in various cell types differentially affected the binding of these toxins.	CLIN RES INST MONTREAL,IMMUNOL LAB,MONTREAL H2W 1R7,PQ,CANADA; UNIV MONTREAL,FAC MED,DEPT IMMUNOL & MICROBIOL,MONTREAL,PQ,CANADA; MCGILL UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,MONTREAL H3A 2B4,PQ,CANADA; CHU LAVAL,DEPT IMMUNOL & RHUMATOL,ST FOY G1V 4G2,PQ,CANADA; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University; Laval University; Harvard University				Mourad, Walid/0000-0002-1859-9387; Lavoie, Pascal/0000-0002-2205-0362				ACHARYA KR, 1994, NATURE, V367, P94, DOI 10.1038/367094a0; BLUESTONE JA, 1992, J EXP MED, V176, P1757, DOI 10.1084/jem.176.6.1757; BRAUNSTEIN NS, 1992, J EXP MED, V175, P1301, DOI 10.1084/jem.175.5.1301; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CHINTAGUMPALA MM, 1991, J IMMUNOL, V147, P3876; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HERMAN A, 1991, P NATL ACAD SCI USA, V88, P9954, DOI 10.1073/pnas.88.22.9954; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; LABRECQUE N, 1993, RES IMMUNOL, V144, P175, DOI 10.1016/0923-2494(93)80113-D; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LONG EO, 1991, HUM IMMUNOL, V31, P229, DOI 10.1016/0198-8859(91)90092-N; MARRACK P, 1993, J EXP MED, V178, P2173, DOI 10.1084/jem.178.6.2173; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MOLLICK JA, 1991, J IMMUNOL, V146, P463; NORCROSS MA, 1984, J EXP MED, V160, P1316, DOI 10.1084/jem.160.5.1316; PANINABORDIGNON P, 1992, J EXP MED, V176, P1779, DOI 10.1084/jem.176.6.1779; SCHOLL PR, 1990, EUR J IMMUNOL, V20, P1911, DOI 10.1002/eji.1830200907; SCHOLL PR, 1990, J IMMUNOL, V144, P226; SCHOLL PR, 1989, J IMMUNOL, V143, P2583; SEKALY RP, 1986, J EXP MED, V164, P1490, DOI 10.1084/jem.164.5.1490; SHERMAN MA, 1994, J EXP MED, V179, P229, DOI 10.1084/jem.179.1.229; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; THIBODEAU J, 1994, J EXP MED, V179, P1029, DOI 10.1084/jem.179.3.1029; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; VIGNALI DAA, 1994, J EXP MED, V179, P1945, DOI 10.1084/jem.179.6.1945; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YAGI JJ, 1991, J IMMUNOL, V147, P1398	38	89	90	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1874	1878		10.1126/science.7997881	http://dx.doi.org/10.1126/science.7997881			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997881				2022-12-28	WOS:A1994PX38300038
J	MINDEN, A; LIN, A; MCMAHON, M; LANGECARTER, C; DERIJARD, B; DAVIS, RJ; JOHNSON, GL; KARIN, M				MINDEN, A; LIN, A; MCMAHON, M; LANGECARTER, C; DERIJARD, B; DAVIS, RJ; JOHNSON, GL; KARIN, M			DIFFERENTIAL ACTIVATION OF ERK AND JNK MITOGEN-ACTIVATED PROTEIN-KINASES BY RAF-1 AND MEKK	SCIENCE			English	Article							C-JUN ACTIVITY; MAP KINASE; PHOSPHORYLATION; CELLS; GROWTH; EXPRESSION; TYROSINE; CASCADE; DOMAIN; SERINE-63	Growth factors activate mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinases (ERKs) and Jun kinases (JNKs). Although the signaling cascade from growth factor receptors to ERKs is relatively well understood, the pathway leading to JNK activation is more obscure. Activation of JNK by epidermal growth factor (EGF) or nerve growth factor (NGF) was dependent on H-Ras activation, whereas JNK activation by tumor necrosis factor alpha (TNF-alpha) was Ras-independent. Ras activates two protein kinases, Raf-1 and MEK (MAPK, or ERK, kinase) kinase (MEKK). Raf-1 contributes directly to ERK activation but not to JNK activation, whereas MEKK participated in JNK activation but caused ERK activation only after overexpression. These results demonstrate the existence of two distinct Ras-dependent MAPK cascades-one initiated by Raf-1 leading to ERK activation, and the other initiated by MEKK leading to JNK activation.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206; UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605	University of California System; University of California San Diego; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; National Jewish Health; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester			McMahon, Martin/L-3303-2013	McMahon, Martin/0000-0003-2812-1042; Lange, Carol/0000-0003-2751-3976				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AMERER G, 1994, CURR OPIN GENES DEV, V4, P90; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOULTON TG, 1991, CELL, V65, P664; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENG T, COMMUNICATION; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1028; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gupta SK, UNPUB; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAND H, 1986, MOL CELL BIOL, V6, P1979; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AL, UNPUB; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MINDEN A, UNPUB; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEGER R, 1992, J BIOL CHEM, V267, P25628; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WESTWICK JK, IN PRESS J BIOL CHEM; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	48	1049	1075	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1719	1723		10.1126/science.7992057	http://dx.doi.org/10.1126/science.7992057			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992057				2022-12-28	WOS:A1994PW30800044
J	ROLDAN, ERS; MURASE, T; SHI, QX				ROLDAN, ERS; MURASE, T; SHI, QX			EXOCYTOSIS IN SPERMATOZOA IN RESPONSE TO PROGESTERONE AND ZONA-PELLUCIDA	SCIENCE			English	Article							RAM SPERM ACROSOME; PHOSPHOLIPASE-D; SUBSEQUENT EXOCYTOSIS; TYROSINE KINASE; BINDING-SITES; MOUSE SPERM; ACTIVATION; PROTEIN; CA-2+; DIACYLGLYCEROL	Exocytosis in mammalian spermatozoa (the acrosome reaction) is a process essential for fertilization. Both progesterone and zona pellucida induce exocytosis in spermatozoa, which may encounter both during penetration of the oocyte's vestments. When mouse spermatozoa were exposed first to progesterone and then to zona pellucida, exocytosis was enhanced to a greater degree than that seen when the agonists were presented together or in the inverse order, which suggests that the steroid exerts a priming effect. Progesterone similarly primed the generation of intracellular messengers evoked by zona pellucida. The effects triggered by progesterone were mimicked by gamma-aminobutyric acid (GABA) and were blocked by bicuculline, which indicates that the steroid acts on a GABA(A) receptor.			ROLDAN, ERS (corresponding author), BIOTECHNOL & BIOL SCI RES COUNCIL,BABRAHAM INST,DEPT DEV & SIGNALLING,CAMBRIDGE CB2 4AT,ENGLAND.		Roldan, Eduardo R.S./M-7947-2014	Roldan, Eduardo R.S./0000-0002-7545-4248				BAULIEU EE, 1988, ANTIPROGESTIN STEROI; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLACKMORE PF, 1990, J BIOL CHEM, V265, P1376; Bleil J.D., 1991, ELEMENTS MAMMALIAN F, V1, P133; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; DOMINO SE, 1989, J BIOL CHEM, V264, P9412; ERDO SL, 1990, LIFE SCI, V47, P1147, DOI 10.1016/0024-3205(90)90175-Q; EXTON JH, 1990, J BIOL CHEM, V265, P1; FLORMAN HM, 1989, DEV BIOL, V135, P133, DOI 10.1016/0012-1606(89)90164-4; FRASER LR, 1989, J REPROD FERTIL, V86, P223, DOI 10.1530/jrf.0.0860223; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LEYTON L, 1992, P NATL ACAD SCI USA, V89, P11692, DOI 10.1073/pnas.89.24.11692; MEIZEL S, 1991, MOL CELL ENDOCRINOL, V11, pR1; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; NILSSON M, 1993, NEUROSCIENCE, V54, P605, DOI 10.1016/0306-4522(93)90232-5; OSMAN RA, 1989, BIOCHEM BIOPH RES CO, V160, P828, DOI 10.1016/0006-291X(89)92508-4; PAI JK, 1988, J BIOL CHEM, V263, P12472; PARINAUD J, 1992, FERTIL STERIL, V58, P599; ROBEL P, 1994, TRENDS ENDOCRIN MET, V5, P1, DOI 10.1016/1043-2760(94)90114-7; ROLDAN E, UNPUB; ROLDAN ERS, 1993, BIOCHIM BIOPHYS ACTA, V1168, P108, DOI 10.1016/0005-2760(93)90273-C; ROLDAN ERS, 1989, BIOCHEM J, V259, P397, DOI 10.1042/bj2590397; ROLDAN ERS, 1992, BIOCHEM J, V281, P767, DOI 10.1042/bj2810767; ROLDAN ERS, 1993, BIOCHEM SOC T, V21, P284, DOI 10.1042/bst0210284; ROLDAN ERS, 1993, BIOCHIM BIOPHYS ACTA, V1210, P48, DOI 10.1016/0005-2760(93)90048-E; ROLDAN ERS, 1993, J BIOL CHEM, V268, P13962; ROLDAN ERS, 1990, SERONO S, P179; SIEGHART W, 1992, TRENDS PHARMACOL SCI, V13, P446, DOI 10.1016/0165-6147(92)90142-S; TESARIK J, 1993, ENDOCRINOLOGY, V133, P328, DOI 10.1210/en.133.1.328; TESARIK J, 1993, MOL REPROD DEV, V34, P183, DOI 10.1002/mrd.1080340210; THOMAS P, 1989, BIOCHEM J, V264, P539, DOI 10.1042/bj2640539; TURNER KO, 1994, MOL CELL ENDOCRINOL, V101, P221, DOI 10.1016/0303-7207(94)90238-0; WARD CR, 1992, J BIOL CHEM, V267, P14061; WARD CR, 1993, DEV BIOL, V158, P9, DOI 10.1006/dbio.1993.1165; WISTROM CA, 1993, DEV BIOL, V159, P679; Yanagimachi R., 1994, P189; ZEISEL SH, 1993, FASEB J, V7, P551, DOI 10.1096/fasebj.7.6.8472893	37	284	299	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1578	1581		10.1126/science.7985030	http://dx.doi.org/10.1126/science.7985030			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985030				2022-12-28	WOS:A1994PV01500049
J	SASAI, Y; LU, B; STEINBEISSER, H; GEISSERT, D; GONT, LK; DEROBERTIS, EM				SASAI, Y; LU, B; STEINBEISSER, H; GEISSERT, D; GONT, LK; DEROBERTIS, EM			XENOPUS CHORDIN - A NOVEL DORSALIZING FACTOR-ACTIVATED BY ORGANIZER-SPECIFIC HOMEOBOX GENES	CELL			English	Article							SPEMANN ORGANIZER; LAEVIS EMBRYOS; MESODERM INDUCTION; INJECTED XWNT-8; BOX GENE; EXPRESSION; AXIS; DOMAIN; HYBRIDIZATION; ECTODERM	A Xenopus gene whose expression can be activated by the organizer-specific homeobox genes goosecoid and Xnot2 was isolated by differential screening. The chordin gene encodes a novel protein of 941 amino acids that has a signal sequence and four Cys-rich domains. The expression of chordin starts in Spemann's organizer subsequent to that of goosecoid, and its induction by activin requires de novo protein synthesis. Microinjection of chordin mRNA induces twinned axes and can completely rescue axial development in ventralized embryos. This molecule is a potent dorsalizing factor that is expressed at the right time and in the right place to regulate cell-cell interactions in the organizing centers of head, trunk, and tail development.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				De Robertis, Edward/0000-0002-7843-1869	NICHD NIH HHS [R37 HD021502-13, R37 HD021502, R01 HD021502, HD21502-09] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021502, R37HD021502] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTABA ARI, 1992, DEVELOPMENT, V116, P81; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; CUNLIFFE V, 1994, EMBO J, V13, P349, DOI 10.1002/j.1460-2075.1994.tb06268.x; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; GERHART J, 1991, BOD MAR LAB, P57; GILBERT SF, 1994, DEV BIOL, P597; GONT LK, 1993, DEVELOPMENT, V119, P991; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HUNT LT, 1987, BIOCHEM BIOPH RES CO, V144, P876, DOI 10.1016/S0006-291X(87)80046-3; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KELLER RE, 1991, METHOD CELL BIOL, V36, P62; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MOON RT, 1992, CELL, V71, P709, DOI 10.1016/0092-8674(92)90545-N; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SLACK JMW, 1988, DEVELOPMENT, V103, P581; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; SMITH JC, 1985, DIFFERENTIATION, V29, P109, DOI 10.1111/j.1432-0436.1985.tb00302.x; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SPEMANN H, 1931, ROUX ARCH ENTW MECH, V123, P389; STEINBEISSER H, 1993, DEVELOPMENT, V118, P499; STEWART RM, 1990, DEVELOPMENT, V109, P363; TADANO T, 1993, DEV GENET, V14, P204, DOI 10.1002/dvg.1020140307; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4	47	933	977	0	37	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	DEC 2	1994	79	5					779	790		10.1016/0092-8674(94)90068-X	http://dx.doi.org/10.1016/0092-8674(94)90068-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001117	Green Accepted			2022-12-28	WOS:A1994PW05400006
J	MORGAN, SL; BAGGOTT, JE; VAUGHN, WH; AUSTIN, JS; VEITCH, TA; LEE, JY; KOOPMAN, WJ; KRUMDIECK, CL; ALARCON, GS				MORGAN, SL; BAGGOTT, JE; VAUGHN, WH; AUSTIN, JS; VEITCH, TA; LEE, JY; KOOPMAN, WJ; KRUMDIECK, CL; ALARCON, GS			SUPPLEMENTATION WITH FOLIC-ACID DARING METHOTREXATE THERAPY FOR RHEUMATOID-ARTHRITIS - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						ARTHRITIS, RHEUMATOID; METHOTREXATE; FOLIC ACID; DRUG TOXICITY	LOW-DOSE METHOTREXATE; CONTROLLED CLINICAL-TRIAL; PULSE METHOTREXATE; LONG-TERM; FOLATE SUPPLEMENTATION; TOXICITY; LEUCOVORIN; EFFICACY; DISEASE	Objective: To determine the effect of two different weekly doses of folic acid on the toxicity and efficacy of low-dose methotrexate therapy for rheumatoid arthritis. Design: Randomized, double-blind, placebo-controlled study. Patients: 79 persons between 19 and 78 years of age who fulfilled the American Rheumatism Association's criteria for rheumatoid arthritis. Intervention: Participants were randomly assigned to visually identical placebo or to 5 mg or 27.5 mg of folic acid each week. Measurements: Duration, intensity, and clinical severity of toxic events; efficacy (indices of joint tenderness and swelling and grip strength); plasma and erythrocyte folate levels; and other laboratory variables. Results: Polio acid supplementation at either dose did not affect the efficacy of methotrexate therapy as judged by joint indices and patient and physician assessments of disease. Patients given folic acid supplements had lower toxicity scores than did participants given placebo (P less than or equal to 0.001). Low blood folate levels and increased mean corpuscular volumes were associated with substantial methotrexate toxicity, whereas daily dietary intakes of more than 900 nmol (400 mu g) of folic acid were associated with little methotrexate toxicity. Conclusions: Folic acid, an inexpensive vitamin, is safe in a broad range of doses and protects patients with rheumatoid arthritis who are taking methotrexate from toxicity while preserving the efficacy of methotrexate.	VET ADM MED CTR, BIRMINGHAM, AL USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	MORGAN, SL (corresponding author), UNIV ALABAMA, DEPT NUTR SCI, 212 WEBB, UBA STN, BIRMINGHAM, AL 35294 USA.				NCI NIH HHS [5P01-CA-28103-10] Funding Source: Medline; NCRR NIH HHS [RR-32-31S1] Funding Source: Medline; NIAMS NIH HHS [5P60-AR-20614] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020614] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALARCON GS, 1989, ARTHRITIS RHEUM, V32, P671, DOI 10.1002/anr.1780320603; ANDERSEN PA, 1985, ANN INTERN MED, V103, P489, DOI 10.7326/0003-4819-103-4-489; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; ANTONELLI MAS, 1991, AM J MED, V90, P295, DOI 10.1016/0002-9343(91)80008-A; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BAGGOTT JE, 1993, CLIN EXP RHEUMATOL, V11, pS101; Baker H., 1968, CLIN VITAMINOLOGY; BAYOUMI RA, 1976, CLIN CHEM, V22, P327; BORENSTEIN M, 1988, STATISTICAL POWER AN; BUCKLEY LM, 1990, J RHEUMATOL, V17, P1158; BUTTERWORTH CE, 1989, AM J CLIN NUTR, V50, P353, DOI 10.1093/ajcn/50.2.353; CANNON GW, 1983, ARTHRITIS RHEUM, V26, P1269, DOI 10.1002/art.1780261015; Cohen J, 1977, STATISTICAL POWER AN; DUHRA P, 1993, J AM ACAD DERMATOL, V28, P466, DOI 10.1016/0190-9622(93)70069-6; EDELMAN J, 1984, CLIN PHARMACOL THER, V35, P382, DOI 10.1038/clpt.1984.47; FURST DE, 1985, J RHEUMATOL, V12, P11; FURST DE, 1990, J RHEUMATOL, V17, P1628; FURST DE, 1989, J RHEUMATOL, V16, P313; GISPEN JG, 1987, J RHEUMATOL, V14, P74; HANNO R, 1980, J AM ACAD DERMATOL, V2, P171, DOI 10.1016/S0190-9622(80)80398-7; HANRAHAN PS, 1988, J RHEUMATOL, V15, P1078; HARGREAVES MR, 1992, THORAX, V47, P628, DOI 10.1136/thx.47.8.628; HINE R J, 1990, Arthritis and Rheumatism, V33, pS60; HOFFMAN GS, 1992, ARTHRITIS RHEUM, V35, P1322, DOI 10.1002/art.1780351113; HORNE DW, 1988, CLIN CHEM, V34, P2357; JACKSON RC, 1984, PHARMACOL THERAPEUT, V25, P61, DOI 10.1016/0163-7258(84)90024-X; JOYCE DA, 1991, ANN RHEUM DIS, V50, P913, DOI 10.1136/ard.50.12.913; KOZAREK RA, 1989, ANN INTERN MED, V110, P353, DOI 10.7326/0003-4819-110-5-353; KREMER JM, 1992, ARTHRITIS RHEUM, V35, P138, DOI 10.1002/art.1780350203; KREMER JM, 1994, ARTHRITIS RHEUM-US, V37, P316, DOI 10.1002/art.1780370304; LAFFORGUE P, 1993, J RHEUMATOL, V20, P263; LAU KS, 1965, BLOOD-J HEMATOL, V26, P202, DOI 10.1182/blood.V26.2.202.202; MACKENZIE AH, 1985, CLEVELAND CLIN Q, V52, P129, DOI 10.3949/ccjm.52.2.129; MACKINNON SK, 1985, SEMIN ARTHRITIS RHEU, V15, P119, DOI 10.1016/0049-0172(85)90029-0; METZGER AL, 1974, ANN INTERN MED, V81, P182, DOI 10.7326/0003-4819-81-2-182; Morgan S L, 1993, Arthritis Care Res, V6, P4, DOI 10.1002/art.1790060103; MORGAN SI, 1993, ANN RHEUM DIS, V52, P315, DOI 10.1136/ard.52.4.315-b; MORGAN SL, 1987, ARTHRITIS RHEUM, V30, P1348, DOI 10.1002/art.1780301205; MORGAN SL, 1990, ARTHRITIS RHEUM-US, V33, P9, DOI 10.1002/art.1780330102; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; NIGHTINGALE SL, 1993, JAMA-J AM MED ASSOC, V270, P2283, DOI 10.1001/jama.270.19.2283; OMAYE ST, 1987, ANN NY ACAD SCI, V498, P389, DOI 10.1111/j.1749-6632.1987.tb23776.x; OMER A, 1968, ANN RHEUM DIS, V27, P414, DOI 10.1136/ard.27.5.414; OWEN ET, 1979, ANN RHEUM DIS, V38, P48, DOI 10.1136/ard.38.1.48; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; SCHAKEL SF, 1988, J AM DIET ASSOC, V88, P1268; SHARP JT, 1985, ARTHRITIS RHEUM, V28, P1326, DOI 10.1002/art.1780281203; SHIROKY JB, 1993, ARTHRITIS RHEUM, V36, P795, DOI 10.1002/art.1780360609; SINNETT MJ, 1989, J RHEUMATOL, V16, P745; SKALA JH, 1987, NUTR RES, V7, P731, DOI 10.1016/S0271-5317(87)80103-3; STACEWICZSAPUNTZAKIS M, 1987, J MICRONUTR ANAL, V3, P27; STENGER AAME, 1992, ANN RHEUM DIS, V51, P1019, DOI 10.1136/ard.51.8.1019; STEWART KA, 1991, SEMIN ARTHRITIS RHEU, V20, P332, DOI 10.1016/0049-0172(91)90033-V; SUBAR AF, 1989, AM J CLIN NUTR, V50, P508, DOI 10.1093/ajcn/50.3.508; Tamura T., 1990, CONT ISSUES CLIN NU, V13, P121; THOMPSON RN, 1984, J RHEUMATOL, V11, P760; TISHLER M, 1988, ARTHRITIS RHEUM, V31, P906, DOI 10.1002/art.1780310712; WALKER AM, 1993, ARTHRITIS RHEUM, V36, P329, DOI 10.1002/art.1780360307; WARING PP, 1982, CLIN CHEM, V28, P2206; WEINBLATT ME, 1992, ARTHRITIS RHEUM, V35, P129, DOI 10.1002/art.1780350202; WEINBLATT ME, 1990, ARTHRITIS RHEUM, V33, P330, DOI 10.1002/art.1780330305; WEINBLATT ME, 1989, ARTHRITIS RHEUM, V32, P1592, DOI 10.1002/anr.1780321214; WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303; WEINBLATT ME, 1993, J RHEUMATOL, V20, P950; WILKE WS, 1984, POSTGRAD MED, V75, P69, DOI 10.1080/00325481.1984.11716308; WILLIAMS HJ, 1985, ARTHRITIS RHEUM-US, V28, P721, DOI 10.1002/art.1780280702; WOLFE F, 1991, J RHEUMATOL, V18, P973	68	308	314	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					833	841		10.7326/0003-4819-121-11-199412010-00002	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7978695				2022-12-28	WOS:A1994PT62800002
J	FRANKE, EK; YUAN, HEH; LUBAN, J				FRANKE, EK; YUAN, HEH; LUBAN, J			SPECIFIC INCORPORATION OF CYCLOPHILIN-A INTO HIV-1 VIRIONS	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYCLOSPORINE-A; GAG; CALCINEURIN; INHIBITION; EXPRESSION; SEQUENCE; BINDING; CELLS; RNA	LITTLE is known about host factors necessary for retroviral virion assembly or uncoating. We have previously shown that the principal structural protein of the human immunodeficiency virus HIV-1, the Gag polyprotein, binds the cyclophilin peptidyl-prolyl isomerases(1); cyclophilins catalyse a rate-limiting step in protein folding(2) and protect cells from heat shock(3). Here we demonstrate that cyclophilin A is specifically incorporated into HIV-1 virions but not into virions of other primate immunodeficiency viruses. A proline-rich region conserved in all HIV-1 Gag polyproteins is required for cyclophilin A binding and incorporation. Disruption of a single proline blocks the Gag-cyclophilin interaction in vitro, prevents cyclophilin A incorporation into virions, and inhibits HIV-1 replication. Our results indicate that the interaction of Gag with cyclophilin A is necessary for the formation of infectious HIV-1 virions.			FRANKE, EK (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,701 W 168TH ST,NEW YORK,NY 10032, USA.			Luban, Jeremy/0000-0001-5650-4054				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEWHURST S, 1990, NATURE, V345, P636, DOI 10.1038/345636a0; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FRANKE EK, 1994, J VIROL, V68, P5300, DOI 10.1128/JVI.68.8.5300-5305.1994; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; JIN MJ, 1994, EMBO J, V13, P2935, DOI 10.1002/j.1460-2075.1994.tb06588.x; KARPAS A, 1992, P NATL ACAD SCI USA, V89, P8351, DOI 10.1073/pnas.89.17.8351; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; KORNFELD H, 1987, NATURE, V326, P610, DOI 10.1038/326610a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LUBAN J, 1994, J VIROL, V68, P3784, DOI 10.1128/JVI.68.6.3784-3793.1994; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; LUBAN J, 1991, J VIROL, V65, P3203, DOI 10.1128/JVI.65.6.3203-3212.1991; MAMMANO F, 1994, J VIROL, V68, P4927, DOI 10.1128/JVI.68.8.4927-4936.1994; MYERS G, 1993, HUMAN RETROVIRUSES A; PANET A, 1975, J VIROL, V16, P146, DOI 10.1128/JVI.16.1.146-152.1975; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; SCHWARTZ S, 1992, J VIROL, V66, P7176, DOI 10.1128/JVI.66.12.7176-7182.1992; SYKES K, 1993, P NATL ACAD SCI USA, V90, P5853, DOI 10.1073/pnas.90.12.5853	26	614	635	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					359	362		10.1038/372359a0	http://dx.doi.org/10.1038/372359a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969494				2022-12-28	WOS:A1994PU28700055
J	MESELSON, M; GUILLEMIN, J; HUGHJONES, M; LANGMUIR, A; POPOVA, I; SHELOKOV, A; YAMPOLSKAYA, O				MESELSON, M; GUILLEMIN, J; HUGHJONES, M; LANGMUIR, A; POPOVA, I; SHELOKOV, A; YAMPOLSKAYA, O			THE SVERDLOVSK ANTHRAX OUTBREAK OF 1979	SCIENCE			English	Article								In April and May 1979, an unusual anthrax epidemic occurred in Sverdlovsk, Union of Soviet Socialist Republics. Soviet officials attributed it to consumption of contaminated meat. U.S. agencies attributed it to inhalation of spores accidentally released at a military microbiology facility in the city. Epidemiological data show that most victims worked or lived in a narrow zone extending from the military facility to the southern city limit. Farther south, livestock died of anthrax along the zone's extended axis. The zone paralleled the northerly wind that prevailed shortly before the outbreak. It is concluded that the escape of an aerosol of anthrax pathogen at the military facility caused the outbreak.	BOSTON COLL,DEPT SOCIOL,CHESTNUT HILL,MA 02167; LOUISIANA STATE UNIV,SCH VET MED,BATON ROUGE,LA 70803; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD 21205; URAL STATE UNIV,DIV SOCIAL & POLIT SERV,SVERDLOVSK 620083,RUSSIA; SALK INST,DIV GOVT SERV,SAN ANTONIO,TX 78228; BOTKIN HOSP,MOSCOW 125101,RUSSIA	Boston College; Louisiana State University School of Veterinary Medicine; Louisiana State University System; Louisiana State University; Johns Hopkins University; Ural Federal University; Salk Institute	MESELSON, M (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.							Abramova A. A., 1993, Arkhiv Patologii, V55, P12; Abramova A. A., 1993, Arkhiv Patologii, V55, P18; ABRAMOVA FA, 1993, P NATL ACAD SCI USA, V90, P2291, DOI 10.1073/pnas.90.6.2291; BEZDENEZHNYKH IS, 1980, ZH MIKROB EPID IMMUN, P111; BEZDENEZHNYKH IS, 1988, UNPUB EPIDEMIOLOGICA; Birenzvige Amnon, 1992, TR413 US ARM CHEM RE; Bliss CI, 1935, ANN APPL BIOL, V22, P134, DOI 10.1111/j.1744-7348.1935.tb07713.x; BOVALLIUS A, 1980, 1ST P INT C AER INT, P227; Brachman P. S, 1991, BACTERIAL INFECT HUM, P75; BRACHMAN PS, 1960, AM J HYG, V72, P6, DOI 10.1093/oxfordjournals.aje.a120135; CHAMBERLAIN AC, 1967, PROC R SOC LON SER-A, V296, P45, DOI 10.1098/rspa.1967.0005; CHELIKOV V, 1991, KOMSOMOLSKAYA P 1120, P4; CHEMENKO L, 1992, ROSSIYSKIYE VES 0922, P2; CRISTY GA, 1981, ORNL5519 REP; DAVIDS DE, 1981, 321 DEF RES EST SUFF; DITMER DS, 1958, HDB RESPIRATION; DRUETT HA, 1953, J HYG-CAMBRIDGE, V51, P359, DOI 10.1017/S0022172400015795; DRUETT HA, 1952, NATURE, V170, P288, DOI 10.1038/170288a0; ELKINA AV, 1971, ZH MIKROBIOL EPIDEMI, P112; GELB LH, 1981, NY TIMES MAGAZI 1129, P31; GLASSMAN HN, 1966, BACTERIOL REV, V30, P657, DOI 10.1128/MMBR.30.3.657-659.1966; GLEISER CA, 1963, BRIT J EXP PATHOL, V44, P416; GRINBERG L, COMMUNICATION; Grinberg L. M., 1993, Arkhiv Patologii, V55, P23; Gwertzman B., 1980, NY TIMES        0319, P1; Hanna S.R., 1982, HDB ATMOSPHERIC DIFF; HENDERSON D. W., 1956, JOUR HYG, V54, P28; HORST TW, 1980, ATMOSPHERIC SULFUR D, P275; JEMSKI JV, COMMUNICATION; JEMSKI JV, 1965, METHODS ANIMAL EXPT, P273; MESELSON MS, 1988, J FEDERATION AM SCI, V41, P1; PARFENOV S, 1990, RODINA MOSCOW    MAY, P21; PASHKOV, 1991, ISVESTIYA MOSCO 1111, P8; POPUGAYLO VM, 1974, CURRENT PROBLEMS ANT, P50; Robinson Julian Perry, 1982, ARMS CONTROL, V3, P41; SCHERRER R, 1987, CAN J MICROBIOL, V33, P304, DOI 10.1139/m87-052; SMITH RJ, 1988, WASHINGTON POST 0413, P1; YOUNG GA, 1946, J INFECT DIS, V79, P233, DOI 10.1093/infdis/79.3.233; ZHENOVA N, 1990, LIT GAZETA      0822, P12; ZHENOVA N, 1991, LIT GAZETA MOSC 1113, P2; ZHENOVA N, 1991, LIT GAZETA MOSC 1002, P6; 1992, RUSSIAN FEDERATION; 1970, HLTH ASPECTS CHEM BI; 1986, DST1610F05786 US DEP; 1980, VETERINARIYA, P3; 1980, POSEV FRANKFURT, V1, P7; 1980, CHELOVEK ZAKON, V117, P70	47	599	632	1	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1202	1208		10.1126/science.7973702	http://dx.doi.org/10.1126/science.7973702			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973702				2022-12-28	WOS:A1994PT13200044
J	DAVIS, AA; TEMPLE, S				DAVIS, AA; TEMPLE, S			A SELF-RENEWING MULTIPOTENTIAL STEM-CELL IN EMBRYONIC RAT CEREBRAL-CORTEX	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; NEURAL CREST; NEURONS; LINEAGE; DIFFERENTIATION; GENERATION; ASTROCYTES; PROGENITOR; RETINA; OLIGODENDROCYTES	NEUROECTODERM cells in the cortical ventricular zone generate many diverse cell types, maintain the ventricular zone during embryonic life and create another germinal layer, the subventricular zone, which persists into adulthood(1,2). In other vertebrate tissues, including skin, intestine, blood and neural crest, stem cells are important in maintaining a germinal population and generating differentiated progeny(3-6). By following the fates of single ventricular zone cells in culture, we show here that self-renewing, multipotential stem cells are present in the embryonic rat cerebral cortex. Forty per cent of these stem cells produced all three principal cell types of the central nervous system: neurons, astrocytes and oligodendrocytes. Stem cells constituted about 7% of cortical clones; in contrast, over 80% consisted of small numbers of neurons or glia. We suggest that multipotential stem cells may be the ancestors of other cortical progenitor cells that exhibit more limited proliferation and more restricted repertoires of progeny fates.	ALBANY MED COLL,DIV NEUROSURG,ALBANY,NY 12208	Albany Medical College	DAVIS, AA (corresponding author), ALBANY MED COLL,DEPT PHARMACOL,ALBANY,NY 12208, USA.							ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; AUSTIN CP, 1990, DEVELOPMENT, V110, P713; Bayer S.A., 1991, NEOCORTICAL DEV; CEPKO CL, 1990, COLD SH Q B, V55, P265; DAVIS AA, 1993, SOC NEUR ABSTR, V19; DEXTER TM, 1987, ANNU REV CELL BIOL, V3, P423; HALL PA, 1989, DEVELOPMENT, V106, P619; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; Jacobson M., 1991, DEV NEUROBIOLOGY; KAWAMOTO JC, 1986, BRAIN RES, V384, P84, DOI 10.1016/0006-8993(86)91222-9; LAJTHA LG, 1979, DIFFERENTIATION, V14, P23, DOI 10.1111/j.1432-0436.1979.tb01007.x; LEBER SM, 1990, J NEUROSCI, V10, P2451; LUMSDEN A, 1994, DEVELOPMENT, V120, P1581; LUSKIN MB, 1993, J NEUROSCI, V13, P1730; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; OGAWA M, 1983, BLOOD, V61, P823; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; PRICE J, 1988, DEVELOPMENT, V104, P473; PRICE J, 1991, DEVELOPMENT S, V2, P23; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; TEMPLE S, 1994, DEVELOPMENT, V120, P999; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; WILLIAMS BP, 1991, NEURON, V7, P685, DOI 10.1016/0896-6273(91)90381-9	29	483	548	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					263	266		10.1038/372263a0	http://dx.doi.org/10.1038/372263a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969470				2022-12-28	WOS:A1994PR88900050
J	ELLINOR, PT; ZHANG, JF; HORNE, WA; TSIEN, RW				ELLINOR, PT; ZHANG, JF; HORNE, WA; TSIEN, RW			STRUCTURAL DETERMINANTS OF THE BLOCKADE OF N-TYPE CALCIUM CHANNELS BY A PEPTIDE NEUROTOXIN	NATURE			English	Article							OMEGA-CONOTOXIN GVIA; CA2+ CHANNELS; FUNCTIONAL EXPRESSION; PERIPHERAL NEURONS; BRAIN; SUBUNIT; SENSITIVITY; SELECTIVITY; SYNAPSES	NEUROTOXINS that selectively block Na+, K+ or Ca2+ channels have provided valuable information about the functional diversity of the voltage-gated channel superfamily(1). For Ca2+ channels, a variety of toxins have been found to block individual channel types(2,3). The best-known example is omega-conotoxin-GVIA, a member of a large family of peptide toxins derived from venomous cone snails(2,3), which potently and selectively blocks N-type Ca2+ channels(4-9), allowing their purification(10,11), cellular localization(12,13), and the elucidation of their roles in Ca2+ entry(14), neurotransmitter release(15,16) and neuronal migration(17). In contrast to Na+ and K+ channels, little is known about the molecular features that underlie Ca2+-channel susceptibility to toxin block; it is also unknown whether block occurs by direct physical occlusion(3) or an action on channel gating(18). Here we describe structural determinants of the N-type Ca2+ channel's interaction with omega-conotoxin-GVIA. When chimaeras combining individual motifs from the N-type channel and from a channel insensitive to omega-conotoxin-GVIA were expressed in Xenopus oocytes, each of the four motifs appeared to contribute to interaction with the toxin. The most dramatic effects on toxin interactions were seen at a single cluster of residues in the large putative extracellular loop between IIIS5 and IIIH5, consistent with a direct pore-blocking mechanism. These results provide a starting point for delineating the architecture of the outer vestibule of the Ca2+ channel.	STANFORD UNIV,MED CTR,DEPT CELLULAR & MOLEC PHYSIOL,STANFORD,CA 94305; NEUREX CORP,MENLO PK,CA 94025	Stanford University				Ellinor, Patrick/0000-0002-2067-0533				AOSAKI T, 1989, PFLUG ARCH EUR J PHY, V414, P150, DOI 10.1007/BF00580957; BOLAND LM, IN PRESS J NEUROSCI; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; FUJITA Y, 1993, NEURON, V10, P585, DOI 10.1016/0896-6273(93)90162-K; Hille B., 1992, IONIC CHANNELS EXCIT; HIMING LD, 1988, SCIENCE, V239, P57; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; KOMORU H, 1992, SCIENCE, V257, P806; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MILLER C, 1994, BIOPHYS J, V66, pA23; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; OLIVERA BM, 1984, BIOCHEMISTRY-US, V23, P5087, DOI 10.1021/bi00317a001; OLIVERA BM, IN PRESS A REV BIOCH; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; STANLEY EF, 1991, J NEUROSCI, V11, P985; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; WITCHER DR, 1993, NEUROPHARMACOLOGY, V32, P1127, DOI 10.1016/0028-3908(93)90007-P; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; YOSHIKAMI D, 1989, ANN NY ACAD SCI, V560, P230, DOI 10.1111/j.1749-6632.1989.tb24100.x; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	29	165	169	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					272	275		10.1038/372272a0	http://dx.doi.org/10.1038/372272a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969473				2022-12-28	WOS:A1994PR88900053
J	TANIFUJI, M; SUGIYAMA, T; MURASE, K				TANIFUJI, M; SUGIYAMA, T; MURASE, K			HORIZONTAL PROPAGATION OF EXCITATION IN RAT VISUAL CORTICAL SLICES REVEALED BY OPTICAL IMAGING	SCIENCE			English	Article							INTRINSIC CONNECTIONS; ELECTRICAL-ACTIVITY; CORTEX; CAT; PROJECTIONS	Optical imaging with high spatial and temporal resolution of neural activity in rat cortical slices was used to investigate the dynamics of signal transmission through neural connections in the visual cortex. When inhibition due to gamma-aminobutyric acid was slightly suppressed, horizontal propagation of excitation in both the supra- and infragranular layers became prominent. This propagation was not affected by vertical cuts in either the supra- or infragranular layer, which suggests that excitation is at least partially conveyed horizontally by reciprocal vertical connections between neurons in these layers.			TANIFUJI, M (corresponding author), FUKUI UNIV,DEPT INFORMAT SCI,BUNKYO KU,FUKUI 910,JAPAN.		Tanifuji, Manabu/H-1744-2019; Murase, Kazuyuki/O-4881-2014	Tanifuji, Manabu/0000-0001-7754-7774; Murase, Kazuyuki/0000-0002-2358-995X				ALBOWITZ B, 1993, EXP BRAIN RES, V93, P213; BURKHALTER A, 1989, J COMP NEUROL, V279, P171, DOI 10.1002/cne.902790202; FERSTER D, 1983, J PHYSIOL-LONDON, V342, P181, DOI 10.1113/jphysiol.1983.sp014846; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1992, NEURON, V9, P1, DOI 10.1016/0896-6273(92)90215-Y; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRINVALD A, 1982, J PHYSIOL-LONDON, V333, P269, DOI 10.1113/jphysiol.1982.sp014453; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; ICHIKAWA M, 1993, BRAIN MECHANISMS OF PERCEPTION AND MEMORY: FROM NEURON TO BEHAVIOR, P638; KOMATSU Y, 1988, BRAIN RES, V442, P359, DOI 10.1016/0006-8993(88)91526-0; KONNERTH A, 1987, J PHYSIOL-LONDON, V393, P681, DOI 10.1113/jphysiol.1987.sp016848; KUROTANI T, 1993, DEV BRAIN RES, V71, P151, DOI 10.1016/0165-3806(93)90168-A; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MITZDORF U, 1978, EXP BRAIN RES, V33, P371; ROCKLAND KS, 1983, J COMP NEUROL, V216, P303, DOI 10.1002/cne.902160307; SUGITANI M, 1994, NEUROSCI LETT, V171, P175, DOI 10.1016/0304-3940(94)90633-5; SUGITANI M, 1994, NEUROSCI LETT, V165, P215, DOI 10.1016/0304-3940(94)90748-X; TANIFUJI M, 1991, Society for Neuroscience Abstracts, V17, P114; TANIFUJI M, UNPUB; TOYAMA K, 1991, BIOMED RES-TOKYO, V12, P145; NK3630 NIPP KANK SHI	21	135	135	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1057	1059		10.1126/science.7973662	http://dx.doi.org/10.1126/science.7973662			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973662				2022-12-28	WOS:A1994PQ92400049
J	FANJUL, A; DAWSON, MI; HOBBS, PD; JONG, L; CAMERON, JF; HARLEV, E; GRAUPNER, G; LU, XP; PFAHL, M				FANJUL, A; DAWSON, MI; HOBBS, PD; JONG, L; CAMERON, JF; HARLEV, E; GRAUPNER, G; LU, XP; PFAHL, M			A NEW CLASS OF RETINOIDS WITH SELECTIVE-INHIBITION OF AP-1 INHIBITS PROLIFERATION	NATURE			English	Article							ACID RECEPTOR-ALPHA; ISOTRETINOIN; PREVENTION; PATHWAYS; ANALOGS; LIGANDS; CANCER	RETINOIDS regulate many biological processes, including differentiation, morphogenesis and cell proliferation(1-3). They are also important therapeutic agents, but their clinical usefulness is limited because of side effects(4-8). Retinoid activities are mediated by specific nuclear receptors, the RARs and RXRs, which can induce transcriptional activation through specific DNA sites(3,9-11) or by inhibiting the transcription factor AP-1 (refs 12-15), which usually mediates cell proliferation signals(16). Because the two types of receptor actions are mechanistically distinct(12,15) we investigated whether conformationally restricted retinoids, selective for each type of receptor action, could be identified, Here we describe a new class of retinoids that selectively inhibits AP-1 activity but does not activate transcription. These retinoids do not induce differentiation in F9 cells but inhibit effectively the proliferation of several tumour cell lines, and could thus serve as candidates for new retinoid therapeutic agents with reduced side effects.	SRI INT,DIV LIFE SCI,MENLO PK,CA 94025; LA JOLLA CANC RES FDN,CTR CANC,LA JOLLA,CA 92037	SRI International; Sanford Burnham Prebys Medical Discovery Institute								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BOLLAG W, 1992, ANN ONCOL, V3, P513, DOI 10.1093/oxfordjournals.annonc.a058252; Dawson M. I., 1990, CHEM BIOL SYNTHETIC; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUSSMAN M, 1991, MOL CELL BIOL, V11, P4097; KRAEMER KH, 1988, NEW ENGL J MED, V318, P1633, DOI 10.1056/NEJM198806233182501; LEE MO, 1994, P NATL ACAD SCI USA, V91, P5632, DOI 10.1073/pnas.91.12.5632; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; Morris-Kay G., 1992, RETINOIDS NORMAL DEV; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Pfahl Magnus, 1994, Seminars in Cell Biology, V5, P95, DOI 10.1006/scel.1994.1013; ROBERTS AB, 1984, RETINOIDS, V2, P209; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; TITCOMB MW, 1994, MOL ENDOCRINOL, V8, P870, DOI 10.1210/me.8.7.870; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; YANGYEN HF, 1991, NEW BIOL, V3, P1206; [No title captured]	28	315	327	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					107	111		10.1038/372107a0	http://dx.doi.org/10.1038/372107a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969403				2022-12-28	WOS:A1994PQ34800084
J	TILLEY, BC; ALARCON, GS; HEYSE, SP; TRENTHAM, DE; NEUNER, R; KAPLAN, DA; CLEGG, DO; LEISEN, JCC; BUCKLEY, L; COOPER, SM; DUNCAN, H; PILLEMER, SR; TUTTLEMAN, M; FOWLER, SE				TILLEY, BC; ALARCON, GS; HEYSE, SP; TRENTHAM, DE; NEUNER, R; KAPLAN, DA; CLEGG, DO; LEISEN, JCC; BUCKLEY, L; COOPER, SM; DUNCAN, H; PILLEMER, SR; TUTTLEMAN, M; FOWLER, SE			MINOCYCLINE IN RHEUMATOID-ARTHRITIS - A 48-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						ARTHRITIS, RHEUMATOID; MINOCYCLINE; TETRACYCLINES; MYCOPLASMA INFECTIONS; COLLAGENASES	CONTROLLED CLINICAL-TRIAL; GOLD SODIUM THIOMALATE; TETRACYCLINE; DISEASE; METHOTREXATE; AURANOFIN; SULFASALAZINE; ANTIBIOTICS; MECHANISM; CRITERIA	Objective: To assess the safety and efficacy of minocycline in the treatment of rheumatoid arthritis. Design: A double-blind, randomized, multicenter, 48-week trial of oral minocycline (200 mg/d) or placebo. Setting: 6 clinical centers in the United States. Patients: 219 adults with active rheumatoid arthritis who had previous limited treatment with disease-modifying drugs. Measurements: As the primary outcomes, 60 diarthrodial joints were examined for tenderness, and 58 joints were examined for swelling (hips excluded). Grip strength, evaluator's global assessment, morning stiffness, Modified Health Assessment Questionnaire, patient's global assessment, hematocrit, erythrocyte sedimentation rate, platelet count, and IgM rheumatoid factor levels were also assessed; radiographs of both hands and wrists were taken. Results: 109 and 110 patients were randomly assigned to receive minocycline and placebo, respectively. At entry, demographic, clinical, and laboratory measurements were similar in both groups. Most patients had mild to moderate disease activity and some evidence of destructive disease. At the week 48 visit, 79% of the minocycline group and 78% of the placebo group continued to receive the study medication. At 48 weeks, more patients in the minocycline group than in the placebo group showed improvement in joint swelling (54% and 39%) and joint tenderness (56% and 41%) (P < 0.023 for both comparisons). The minocycline group also showed greater improvement in hematocrit, erythrocyte sedimentation rate, platelet count, and IgM rheumatoid factor levels (all P values < 0.001), and more patients receiving minocycline had laboratory values within normal ranges at 48 weeks. For the remaining outcomes, P values ranged from 0.04 to 0.76, all greater than the critical value of 0.005 (Bonferroni adjustment for multiple comparisons). The frequency of reported side effects was similar in both groups, and no serious toxicity occurred. Conclusions: Minocycline was safe and effective for patients with mild to moderate rheumatoid arthritis. Its mechanisms of action remain to be determined.	NIAMSD, OFF DIS PREVENT EPIDEMIOL & CLIN APPLICAT, MIRA TRIAL GRP, BETHESDA, MD 20892 USA; HENRY FORD HLTH SCI CTR, DETROIT, MI USA; UNIV ALABAMA, BIRMINGHAM, AL 35294 USA; BETH ISRAEL HOSP, DEPT RHEUMATOL, BOSTON, MA 02215 USA; UNIV UTAH, MED CTR, DIV RHEUMATOL, SALT LAKE CITY, UT 84132 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, MCV STN, RICHMOND, VA 23298 USA; UNIV VERMONT, CTR HLTH, BURLINGTON, VT 05401 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Henry Ford Health System; Henry Ford Hospital; University of Alabama System; University of Alabama Birmingham; Harvard University; Beth Israel Deaconess Medical Center; Utah System of Higher Education; University of Utah; Virginia Commonwealth University; University of Vermont					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [N01AR012203, N01AR012205, N01AR012202] Funding Source: NIH RePORTER; NIAMS NIH HHS [N01-AR-1-2202, N01-AR-1-2203, N01-AR-1-2205] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altman R., 1975, MMWR-MORBID MORTAL W, V24, P9; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BREEDVELD FC, 1990, J RHEUMATOL, V17, P43; BROWN TM, 1959, LONG TERM ILLNESS MA, P93; CLARK P, 1993, ANN INTERN MED, V119, P1067, DOI 10.7326/0003-4819-119-11-199312010-00002; CUNHA BA, 1982, MED CLIN N AM, V66, P293, DOI 10.1016/S0025-7125(16)31461-4; DAVIS MJ, 1991, BRIT J RHEUMATOL, V30, P451; FELSON DT, 1993, ARTHRITIS RHEUM-US, V36, P729, DOI 10.1002/art.1780360601; FORSGREN A, 1974, J INFECT DIS, V130, P412, DOI 10.1093/infdis/130.4.412; Friedman LM, 1985, FUNDAMENTALS CLIN TR; GOLUB LM, 1983, J PERIODONTAL RES, V18, P516, DOI 10.1111/j.1600-0765.1983.tb00388.x; GOLUB LM, 1984, J PERIODONTAL RES, V19, P651, DOI 10.1111/j.1600-0765.1984.tb01334.x; GREENWALD RA, 1987, J RHEUMATOL, V14, P28; HANNONEN P, 1993, ARTHRITIS RHEUM-US, V36, P1501, DOI 10.1002/art.1780361104; HANSEN K, 1988, J CLIN MICROBIOL, V26, P338, DOI 10.1128/JCM.26.2.338-346.1988; HAYES RD, 1989, MULTITRAIT SCALING A; HICKS MJ, 1982, AM J CLIN PATHOL, V78, P342; INGHAM E, 1991, J ANTIMICROB CHEMOTH, V27, P607, DOI 10.1093/jac/27.5.607; KLOPPENBURG M, 1994, ARTHRITIS RHEUM, V37, P629, DOI 10.1002/art.1780370505; KLOPPENBURG M, 1993, CLIN EXP RHEUMATOL, V11, pS113; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LANGEVITZ P, 1992, J RHEUMATOL, V19, P1502; LAWRENCE RC, 1989, J RHEUMATOL, V16, P427; LEE P, 1974, SCAND J RHEUMATOL, V3, P17, DOI 10.3109/03009747409165124; LEHMANN EL, 1975, NONPARAMETRICS STATI, P123; LOPEZMENDEZ A, 1993, ARTHRITIS RHEUM, V36, P1364; MACDONALD TT, 1979, J IMMUNOL, V122, P2624; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MARTIN RR, 1974, J INFECT DIS, V129, P110, DOI 10.1093/infdis/129.2.110; Miller Jr R. G, 1981, SIMULTANEOUS STAT IN, P67; PINALS R, 1989, TXB INTERNAL MED, P1094; PINALS RS, 1981, ARTHRITIS RHEUM, V24, P1308, DOI 10.1002/art.1780241012; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; PLEWIG G, 1975, J INVEST DERMATOL, V65, P532, DOI 10.1111/1523-1747.ep12610281; QUAN TJ, 1992, 5 INT C LYM BORR ARL; RIESBECK K, 1990, ANTIMICROB AGENTS CH, V34, P167, DOI 10.1128/AAC.34.1.167; SANCHEZ I, 1968, BRAS MED, V82, P22; SEWELL K L, 1990, Arthritis and Rheumatism, V33, pS106; SIEGEL S, 1988, NONPARAMETRIC STAT B, P137; SINGER JM, 1956, AM J MED, V21, P888, DOI 10.1016/0002-9343(56)90103-6; SKINNER M, 1971, ARTHRITIS RHEUM, V14, P727, DOI 10.1002/art.1780140607; SOSSONG JL, 1992, METHOD LC631 HPLC AN; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; THONG YH, 1979, CLIN EXP IMMUNOL, V35, P443; VANBAAR HMJ, 1987, BRIT J DERMATOL, V117, P131; WARD JR, 1983, ARTHRITIS RHEUM, V26, P1303, DOI 10.1002/art.1780261102; WASIL M, 1988, BIOCHEM PHARMACOL, V37, P775, DOI 10.1016/0006-2952(88)90159-1; WEINBLATT ME, 1990, ARTHRITIS RHEUM, V33, P330, DOI 10.1002/art.1780330305; WILLIAMS HJ, 1985, ARTHRITIS RHEUM-US, V28, P721, DOI 10.1002/art.1780280702; WILLIAMS HJ, 1988, ARTHRITIS RHEUM, V31, P702, DOI 10.1002/art.1780310602; WILLIAMS HJ, 1992, ARTHRITIS RHEUM, V35, P259, DOI 10.1002/art.1780350304; 1965, ARTHRITIS RHEUM, V8, P302	52	285	291	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					81	89		10.7326/0003-4819-122-2-199501150-00001	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7993000				2022-12-28	WOS:A1995QC05900001
J	STRAUSS, JK; MAHER, LJ				STRAUSS, JK; MAHER, LJ			DNA BENDING BY ASYMMETRIC PHOSPHATE NEUTRALIZATION	SCIENCE			English	Article							INTRINSICALLY BENT DNA; CRYSTAL-STRUCTURE; OLIGODEOXYRIBONUCLEOSIDE METHYLPHOSPHONATES; GENE-EXPRESSION; PROTEIN; OLIGONUCLEOTIDES; CURVATURE; COMPLEX; FLEXIBILITY; ADENINE	DNA is often bent when complexed with proteins. Understanding the forces responsible for DNA bending would be of fundamental Value in exploring the interplay of these macromolecules. A series of experiments was devised to test the hypothesis that proteins with cationic surfaces can induce substantial DNA bending by neutralizing phosphates on one DNA face. Repulsions between phosphates in the remaining anionic helix are predicted to result in an unbalanced compression force acting to deform the DNA toward the protein. This hypothesis is supported by the results of electrophoretic experiments in which DNA spontaneously bends when one helical face is partially modified by incorporation of neutral phosphate analogs. Phasing with respect to a site of intrinsic DNA curvature (hexadeoxyadenylate tract) permits estimation of the electrostatic bend angle, and demonstrates that such modified DNAs are deformed toward the neutralized surface, as predicted. Similar model systems may be useful in exploring the extent to which phosphate neutralization can account for DNA bending by particular proteins.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOLEC BIOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NCI NIH HHS [P30 CA36727-08] Funding Source: Medline; NIGMS NIH HHS [GM47814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.genet.23.1.227; BOTFIELD MC, 1994, BIOCHEMISTRY-US, V33, P2349, DOI 10.1021/bi00175a001; BOWER M, 1987, NUCLEIC ACIDS RES, V15, P4915, DOI 10.1093/nar/15.12.4915; CALLAHAN L, 1986, P NATL ACAD SCI USA, V83, P1617, DOI 10.1073/pnas.83.6.1617; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P46; CROTHERS DM, 1993, CURR BIOL, V3, P675, DOI 10.1016/0960-9822(93)90065-V; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DRIPPS D, 1987, J BIOMOL STRUCT DYN, V5, P1; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HAGERMAN PJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P125, DOI 10.1016/0167-4781(92)90066-9; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; HAMY F, 1993, J MOL BIOL, V230, P111, DOI 10.1006/jmbi.1993.1129; HAN F, 1990, NUCLEIC ACIDS RES, V18, P2759, DOI 10.1093/nar/18.9.2759; HODGESGARCIA Y, 1992, BIOCHEMISTRY-US, V31, P7595, DOI 10.1021/bi00148a022; HOGREFE RI, 1993, NUCLEIC ACIDS RES, V21, P2031, DOI 10.1093/nar/21.9.2031; IKEDA K, 1993, GENE, V136, P341; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KAN LS, 1980, BIOCHEMISTRY-US, V19, P2122, DOI 10.1021/bi00551a020; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; MAHER LJ, 1988, NUCLEIC ACIDS RES, V16, P3341, DOI 10.1093/nar/16.8.3341; MANNING GS, 1989, J BIOMOL STRUCT DYN, V6, P877, DOI 10.1080/07391102.1989.10506519; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; MCGHEE JD, 1980, NUCLEIC ACIDS RES, V8, P2751, DOI 10.1093/nar/8.12.2751; MILLER PS, 1988, ANNU REP MED CHEM, V23, P295; MILLER PS, 1987, ANTI-CANCER DRUG DES, V2, P117; MILLER PS, 1990, HERPESVIRUSES IMMUNE, P343; NOBLE SA, 1984, NUCLEIC ACIDS RES, V12, P3387, DOI 10.1093/nar/12.7.3387; OLSON WK, 1993, J MOL BIOL, V232, P530, DOI 10.1006/jmbi.1993.1409; PIELES U, 1993, NUCLEIC ACIDS RES, V21, P3191, DOI 10.1093/nar/21.14.3191; RICE JA, 1989, BIOCHEMISTRY-US, V28, P4512, DOI 10.1021/bi00436a058; ROJO F, 1991, EMBO J, V10, P3429, DOI 10.1002/j.1460-2075.1991.tb04907.x; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SNYDER UK, 1989, NATURE, V341, P255, DOI 10.1038/341255a0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; UHLMANN E, 1990, CHEM REV, V90, P544; WARWICKER J, 1987, PROTEINS, V2, P283, DOI 10.1002/prot.340020404; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	50	268	274	2	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1829	1834		10.1126/science.7997878	http://dx.doi.org/10.1126/science.7997878			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997878				2022-12-28	WOS:A1994PX38300027
J	ABBOTT, A				ABBOTT, A			CLINICAL-EFFICIENCY	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					604	604						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990946				2022-12-28	WOS:A1994PX30700040
J	PETERSON, ED; JOLLIS, JG; BEBCHUK, JD; DELONG, ER; MUHLBAIER, LH; MARK, DB; PRYOR, DB				PETERSON, ED; JOLLIS, JG; BEBCHUK, JD; DELONG, ER; MUHLBAIER, LH; MARK, DB; PRYOR, DB			CHANGES IN MORTALITY AFTER MYOCARDIAL REVASCULARIZATION IN THE ELDERLY - THE NATIONAL MEDICARE EXPERIENCE	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL REVASCULARIZATION; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOPULMONARY BYPASS; AGE FACTORS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE)	INTERNAL-MAMMARY-ARTERY; TRANSLUMINAL CORONARY ANGIOPLASTY; ICD-9-CM ADMINISTRATIVE DATA; CLINICAL COMORBIDITY INDEX; BYPASS GRAFT-SURGERY; RISK-FACTORS; PUBLICATION BIAS; SURGICAL VOLUME; PATIENTS OLDER; HEART-DISEASE	Objective: To examine secular changes in the use and outcome of percutaneous transluminal coronary angioplasty and cardiac bypass graft surgery in the elderly. Design: A retrospective cohort study based on a longitudinal database created from the administrative files of Medicare. Setting: U.S. hospitals that perform myocardial revascularization procedures covered by Medicare. Patients: 225 915 consecutive patients who had angioplasty and 357 885 consecutive patients who had bypass surgery from 1987 to 1990. Measurements: The rates of angioplasty and bypass surgery use; unadjusted 30-day and I-year mortality rates after revascularization; and adjusted odds ratios for mortality by year of procedure for 1987 to 1990. Results: From 1987 to 1990, the rates of angioplasty and bypass surgery done in the elderly increased by 55% and 18%, respectively. During this period, 30-day unadjusted mortality rates after angioplasty and bypass surgery decreased by 25% (95% CI, 22% to 28%) and 12% (CI, 10% to 14%), and I-year mortality rates decreased by 10% (CI, 8% to 11%) and 8% (CI, 7% to 10%), respectively. After adjustment for changes in patient characteristics, 30-day mortality rates after these procedures decreased by 37% (CI, 32% to 41%) and 18% (CI, 14% to 21%), and I-year mortality rates decreased by 22% (CI, 18% to 25%) and 19% (CI, 16% to 21%), respectively. Conclusions: The use of cardiac revascularization procedures in the elderly has steadily increased. Patients who had revascularization are progressively older, have more coded comorbid conditions, and present with more acute diseases. Although elderly patients have apparently higher risk profiles, mortality rates after angioplasty and bypass surgery in the elderly have decreased, suggesting a national improvement in the outcomes of these interventions. Health policy decisions concerning revascularization procedures in the elderly must consider these trends in improved outcome.			PETERSON, ED (corresponding author), DUKE UNIV, MED CTR, DEPT MED, DIV CARDIOL, DUMC 3236, DURHAM, NC 27710 USA.		Peterson, Eric David/ABF-5033-2021	Mark, Daniel/0000-0001-6340-8087	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS005635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017670] Funding Source: NIH RePORTER; AHRQ HHS [HS-06503, HS-05635] Funding Source: Medline; NHLBI NIH HHS [HL-17670] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZARIADES M, 1990, ANN THORAC SURG, V50, P940, DOI 10.1016/0003-4975(90)91126-V; BAIM DS, 1994, CIRCULATION, V89, P471, DOI 10.1161/01.CIR.89.1.471; BAIM DS, 1992, HEART DIS TXB CARDIO, P1365; BEDOTTO JB, 1991, AM J CARDIOL, V67, P1051, DOI 10.1016/0002-9149(91)90864-H; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHASSIN MR, 1993, JAMA-J AM MED ASSOC, V270, P377, DOI 10.1001/jama.270.3.377; CHRISTAKIS GT, 1989, CIRCULATION, V80, P151; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; DONABEDIAN A, 1990, ARCH PATHOL LAB MED, V114, P1115; FEINLEIB M, 1989, CIRCULATION, V79, P13; GARDNER TJ, 1990, ANN THORAC SURG, V49, P188, DOI 10.1016/0003-4975(90)90137-U; GERSH BJ, 1983, CIRCULATION, V68, P190; GOLD S, 1991, ARCH INTERN MED, V151, P1085, DOI 10.1001/archinte.151.6.1085; GRONDIN CM, 1984, CIRCULATION, V70, P208; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HANNAN EL, 1991, MED CARE, V29, P1094, DOI 10.1097/00005650-199111000-00003; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; HARTZ AJ, 1992, AM J CARDIOL, V70, P179, DOI 10.1016/0002-9149(92)91272-6; HSIA DC, 1992, JAMA-J AM MED ASSOC, V268, P896, DOI 10.1001/jama.268.7.896; Jollis James G., 1994, P343; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; JOLLIS JG, 1993, CIRCULATION, V88, P480; JONES RH, 1989, CIRCULATION, V79, P132; KARP RB, 1989, CIRCULATION, V79, P182; KELSEY SF, 1990, AM J CARDIOL, V66, P1033, DOI 10.1016/0002-9149(90)90500-Z; KING SB, 1989, CIRCULATION, V79, P19; KIRKLIN JK, 1989, CIRCULATION, V79, P185; KIRKLIN JW, 1989, CIRCULATION, V79, P81; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; LOOP FD, 1988, CLEV CLIN J MED, V55, P23, DOI 10.3949/ccjm.55.1.23; LUFT HS, 1993, JAMA-J AM MED ASSOC, V270, P331, DOI 10.1001/jama.270.3.331; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; MOHAN R, 1992, CARDIOLOGY, V80, P215, DOI 10.1159/000175005; MOSTELLER F, 1985, ASSESSING MED TECHNO, P70; NAUNHEIM KS, 1988, J AM COLL CARDIOL, V11, P494, DOI 10.1016/0735-1097(88)91522-7; PRYOR DB, 1993, CIRCULATION, V87, P291, DOI 10.1161/01.CIR.87.1.291; PRYOR DB, 1988, TRENDS CORONARY HEAR, P76; RITCHIE JL, 1993, CIRCULATION, V88, P2735, DOI 10.1161/01.CIR.88.6.2735; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1085, DOI 10.1016/0895-4356(93)90106-B; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; SIMMONS BE, 1987, AM J CARDIOL, V59, P547, DOI 10.1016/0002-9149(87)91167-2; SIMPFENDORFER C, 1988, AM J CARDIOL, V62, P959, DOI 10.1016/0002-9149(88)90901-0; STEINWALD B, 1989, HEALTH AFFAIR, V8, P35, DOI 10.1377/hlthaff.8.2.35; STERLING RP, 1984, AM HEART J, V108, P695, DOI 10.1016/0002-8703(84)90657-4; TAEUBER C, 1992, CURRENT POPULATI P23, V178; THOMPSON RC, 1991, J AM COLL CARDIOL, V17, P1245, DOI 10.1016/S0735-1097(10)80130-5; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; WAREING TH, 1990, CIRCULATION, V82, P224; WATKINS L, 1983, J NATL MED ASSOC, V75, P381; WEINTRAUB WS, 1991, CIRCULATION, V84, P226; WENNBERG JE, 1991, JAMA-J AM MED ASSOC, V265, P1306, DOI 10.1001/jama.265.10.1306; 1989, CURRENT POPULATI P25, V1018; 1991, INT CLASSIFICATION D; 1993, ANN REPORT CALIFORNI; 1991, AGING AM TRENDS PROJ; 1990, VITAL HLTH STATIS 10, V176	63	135	137	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1994	121	12					919	927		10.7326/0003-4819-121-12-199412150-00003	http://dx.doi.org/10.7326/0003-4819-121-12-199412150-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW083	7978717				2022-12-28	WOS:A1994PW08300003
J	BLAU, JN				BLAU, JN			MIGRAINE IN DOCTORS - WORK LOSS AND CONSUMPTION OF MEDICATION	LANCET			English	Editorial Material							HEADACHE				BLAU, JN (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							BOSANQUET N, 1992, BR J MED EC, V2, P82; HONKASALO ML, 1993, HEADACHE, V33, P403, DOI 10.1111/j.1526-4610.1993.hed3308403.x; Jarcho S, 1967, B N Y ACAD MED, V43, P1224; JONES A, 1980, J INT MED RES, V8, P321, DOI 10.1177/030006058000800503; LIPTON RB, 1993, NEUROLOGY, V43, P6; RASMUSSEN BK, 1991, HEADACHE, V31, P290, DOI 10.1111/j.1526-4610.1991.hed3105290.x	6	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1623	1624		10.1016/S0140-6736(94)90413-8	http://dx.doi.org/10.1016/S0140-6736(94)90413-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983999				2022-12-28	WOS:A1994PW05100016
J	GAUTHIER, VJ; BARBOSA, LM				GAUTHIER, VJ; BARBOSA, LM			BONE PAIN IN TRANSPLANT RECIPIENTS RESPONSIVE TO CALCIUM-CHANNEL BLOCKERS	ANNALS OF INTERNAL MEDICINE			English	Note							RENAL-TRANSPLANTATION; CYCLOSPORINE; OSTEONECROSIS; NECROSIS				GAUTHIER, VJ (corresponding author), UNIV WASHINGTON, DEPT MED, RG-28, SEATTLE, WA 98195 USA.		Luiz Mauro Barbosa, Luiz Mauro/E-3485-2017		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043050] Funding Source: NIH RePORTER; NIAMS NIH HHS [T32-AR07108] Funding Source: Medline; NIDDK NIH HHS [R29-DK43050] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARLET J, 1992, CLIN ORTHOP RELAT R, P12; Arlet J, 1990, BONE CIRCULATION BON, P48; BOUTEILLER G, 1989, REV RHUM, V56, P753; GOFFIN E, 1993, KIDNEY INT, V44, P98, DOI 10.1038/ki.1993.218; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; LAROCHE M, 1990, REV RHUM, V57, P669; LUCAS V, 1990, REV RHUM, V57, P79; LUCAS VP, 1991, NEW ENGL J MED, V325, P1449; MANKIN HJ, 1992, NEW ENGL J MED, V326, P1473; ZIZIC TM, 1986, ARTHRITIS RHEUM-US, V29, P1177, DOI 10.1002/art.1780291001	10	43	46	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					863	865		10.7326/0003-4819-121-11-199412010-00007	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7978699				2022-12-28	WOS:A1994PT62800007
J	CHANFREAU, G; JACQUIER, A				CHANFREAU, G; JACQUIER, A			CATALYTIC SITE COMPONENTS COMMON TO BOTH SPLICING STEPS OF A GROUP-II INTRON	SCIENCE			English	Article							RNA; SPLICEOSOME; MECHANISM; LARIAT	The splicing of group II introns occurs in two steps involving substrates with different chemical configurations. The question of whether these two steps are catalyzed by a single or two separate active sites is a matter of debate. Here, certain bases and phosphate oxygen atoms at conserved positions in domain V of a group II self-splicing intron are shown to be required for catalysis of both splicing steps. These results show that the active sites catalyzing the two steps must, at least, share common components, ruling out the existence of two completely distinct active sites in group II introns.	INST PASTEUR, DEPT BIOL MOLEC,UNITE GENET MOLEC LEVURES,CNRS, URA 1149, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				JACQUIER, ALAIN/0000-0001-5707-9184				BACHL J, 1990, J MOL BIOL, V212, P113, DOI 10.1016/0022-2836(90)90308-9; CHANFREAU G, UNPUB; CHRISTIAN EL, 1993, BIOCHEMISTRY-US, V32, P4475, DOI 10.1021/bi00068a001; CONWAY L, 1989, METHOD ENZYMOL, V180, P369; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KOCH JL, 1992, MOL CELL BIOL, V12, P1950, DOI 10.1128/MCB.12.5.1950; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; NILSEN T, COMMUNICATION; PEEBLES C, COMMUNICATION; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P2716, DOI 10.1021/bi00175a047; PYLE AM, COMMUNICATION; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SUH E, 1992, NUCLEIC ACIDS RES, V20, P6303, DOI 10.1093/nar/20.23.6303	18	114	118	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 25	1994	266	5189					1383	1387		10.1126/science.7973729	http://dx.doi.org/10.1126/science.7973729			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973729				2022-12-28	WOS:A1994PT63200044
J	GUTTMAN, DS; DYKHUIZEN, DE				GUTTMAN, DS; DYKHUIZEN, DE			CLONAL DIVERGENCE IN ESCHERICHIA-COLI AS A RESULT OF RECOMBINATION, NOT MUTATION	SCIENCE			English	Article							MOLECULAR EVOLUTION; NATURAL-POPULATIONS; BACTERIA; CHROMOSOME; SEQUENCES; BOOTSTRAP; DNA	Nucleotide sequence analysis was performed on 12 natural isolates of Escherichia coli in four loci located in close proximity on the chromosome. A comparison of gene genealogies indicated that three recombination events have occurred in a subset of the strains (ECOR group A) in the time since their divergence from a common ancestor, while during the same time, no mutational divergence has occurred. The common ancestor of this subset existed no more than 2400 years ago, and recombination was shown to occur at a rate of 5.0 x 10(-9) changes per nucleotide per generation-50-fold higher than the mutation rate. Thus, recombination has been the dominant force driving the clonal divergence of the ECOR group A strains and must be considered a significant factor in structuring E. coli populations.			GUTTMAN, DS (corresponding author), SUNY STONY BROOK,DEPT ECOL & EVOLUT,DIV BIOL SCI,STONY BROOK,NY 11794, USA.		Guttman, David S/A-7839-2011	Guttman, David S/0000-0001-8479-3869	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032454] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32454] Funding Source: Medline; NIGMS NIH HHS [GM3020] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Drake J. W, 1970, MOL BASIS MUTATION; DYKHUIZEN DE, 1991, J BACTERIOL, V173, P7257, DOI 10.1128/jb.173.22.7257-7268.1991; DYKHUIZEN DE, UNPUB; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; GUTTMAN DS, IN PRESS GENETICS; HERZER PJ, 1990, J BACTERIOL, V172, P6175, DOI 10.1128/jb.172.11.6175-6181.1990; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; HUDSON RR, 1987, GENET RES, V50, P245, DOI 10.1017/S0016672300023776; HUDSON RR, 1985, GENETICS, V111, P147; LAWRENCE JG, 1992, GENETICS, V131, P753; LAWRENCE JG, 1992, GENETICS, V131, P9; MARGOLIN P, 1987, ESCHERICHIA COLI SAL, V2, P1154; MILKMAN R, 1988, GENETICS, V120, P359; MILKMAN R, 1990, GENETICS, V126, P505; MILKMAN R, 1993, GENETICS, V133, P455; OCHMAN H, 1984, J BACTERIOL, V157, P690, DOI 10.1128/JB.157.2.690-693.1984; RUDD KE, 1992, SHORT COURSE BACTERI; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SELANDER RK, 1987, ESCHERICHIA COLI SAL, V2, P1625; SMITH JM, 1993, P NATL ACAD SCI USA, V90, P4384, DOI 10.1073/pnas.90.10.4384; Swofford D. L., 1993, ILLINOIS NATURAL HIS; VALDES AM, 1992, EVOLUTION, V46, P641, DOI 10.1111/j.1558-5646.1992.tb02072.x; WHITTAM TS, 1983, P NATL ACAD SCI-BIOL, V80, P1751, DOI 10.1073/pnas.80.6.1751; WHITTAM TS, 1993, MECHANISMS OF MOLECULAR EVOLUTION, P223; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; WOESE CR, 1980, NATURE, V283, P212, DOI 10.1038/283212a0	26	322	329	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1380	1383		10.1126/science.7973728	http://dx.doi.org/10.1126/science.7973728			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973728				2022-12-28	WOS:A1994PT63200043
J	SOMLYO, AP; SOMLYO, AV				SOMLYO, AP; SOMLYO, AV			SIGNAL-TRANSDUCTION AND REGULATION IN SMOOTH-MUSCLE	NATURE			English	Review							MYOSIN LIGHT-CHAIN; RABBIT MESENTERIC-ARTERY; PROTEIN-KINASE-C; PORCINE CORONARY-ARTERY; SARCOPLASMIC-RETICULUM; INOSITOL 1,4,5-TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; ARACHIDONIC-ACID; CA2+ RELEASE; CYTOPLASMIC CALCIUM	Smooth muscle cells in the walls of many organs are vital for most bodily functions, and their abnormalities contribute to a range of diseases. Although based on a sliding-filament mechanism similar to that of striated muscles, contraction of smooth muscle is regulated by pharmacomechanical as well as by electromechanical coupling mechanisms. Recent studies have revealed previously unrecognized contractile regulatory processes, such as G-protein-coupled inhibition of myosin light-chain phosphatase, regulation of myosin light-chain kinase by other kinases, and the functional effects of smooth muscle myosin isoforms. Abnormalities of these regulatory mechanisms and isoform variations may contribute to diseases of smooth muscle, and the G-protein-coupled inhibition of protein phosphatase is also likely to be important in regulating non-muscle cell functions mediated by cytoplasmic myosin II.			SOMLYO, AP (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT MOLEC PHYSIOL & BIOL PHYS,JORDAN HALL 449,CHARLOTTESVILLE,VA 22908, USA.							AARONSON P, 1981, J PHYSIOL-LONDON, V319, P443, DOI 10.1113/jphysiol.1981.sp013920; ADAM LP, 1992, FEBS LETT, V302, P223, DOI 10.1016/0014-5793(92)80446-N; ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; AMEDEE T, 1990, J PHYSIOL-LONDON, V423, P551, DOI 10.1113/jphysiol.1990.sp018039; AMER A, 1987, J MUSCLE RES CELL M, V8, P377; ANDREA JE, 1992, HYPERTENSION, V20, P585, DOI 10.1161/01.HYP.20.5.585; AXELROD J, 1990, BIOCHEM SOC T, V18, P503, DOI 10.1042/bst0180503; BOND M, 1984, J PHYSIOL-LONDON, V357, P185, DOI 10.1113/jphysiol.1984.sp015496; BRADLEY AB, 1987, J PHYSIOL-LONDON, V385, P437, DOI 10.1113/jphysiol.1987.sp016500; BULBRING E, 1987, PHARMACOL REV, V39, P49; CARAFOLI E, 1993, TRENDS CARDIOVAS MED, V3, P177, DOI 10.1016/1050-1738(93)90003-O; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; DISALVO J, 1993, BIOCHEM BIOPH RES CO, V190, P968, DOI 10.1006/bbrc.1993.1144; DRISKA SP, 1989, AM J PHYSIOL, V256, pC315, DOI 10.1152/ajpcell.1989.256.2.C315; EBASHI SA, 1991, REV PHYSL, V53, P1; EDELMAN AM, 1990, MOL CELL BIOCHEM, V97, P87; FILO RS, 1965, SCIENCE, V147, P1581, DOI 10.1126/science.147.3665.1581; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FUGLSANG A, 1993, J MUSCLE RES CELL M, V15, P666; FUJIWARA T, 1989, J PHYSIOL-LONDON, V408, P535, DOI 10.1113/jphysiol.1989.sp017474; GANITKEVICH VY, 1993, J PHYSIOL-LONDON, V470, P35, DOI 10.1113/jphysiol.1993.sp019845; GONG MC, 1992, J BIOL CHEM, V267, P21492; GONG MC, 1992, J BIOL CHEM, V267, P14662; GONG MC, 1994, BIOPHYS J, V66, pA409; HARRIS DE, 1994, J MUSCLE RES CELL M, V15, P11, DOI 10.1007/BF00123828; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HASHIMOTO T, 1986, J PHYSIOL-LONDON, V370, P605, DOI 10.1113/jphysiol.1986.sp015953; HERRMANNFRANK A, 1991, PFLUG ARCH EUR J PHY, V418, P353, DOI 10.1007/BF00550873; HIBBERD MG, 1986, ANNU REV BIOPHYS BIO, V15, P119; HIMPENS B, 1990, PFLUG ARCH EUR J PHY, V417, P21, DOI 10.1007/BF00370764; HIMPENS B, 1989, J PHYSIOL-LONDON, V413, P489, DOI 10.1113/jphysiol.1989.sp017665; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HORIUTI K, 1989, J GEN PHYSIOL, V94, P769, DOI 10.1085/jgp.94.4.769; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; IINO M, 1989, J GEN PHYSIOL, V94, P363; IMAIZUMI Y, 1991, AM J PHYSIOL, V260, pC17, DOI 10.1152/ajpcell.1991.260.1.C17; INAGAKI M, 1987, ARCH BIOCHEM BIOPHYS, V254, P136, DOI 10.1016/0003-9861(87)90089-0; ITO M, 1989, J BIOL CHEM, V264, P13971; ITOH H, 1993, AM J PHYSIOL, V265, pC1319; ITOH T, 1988, J PHYSIOL-LONDON, V397, P401, DOI 10.1113/jphysiol.1988.sp017008; ITOH T, 1989, NATURE, V338, P164, DOI 10.1038/338164a0; ITOH T, 1992, J PHYSIOL-LONDON, V451, P307, DOI 10.1113/jphysiol.1992.sp019166; Johansson B, 1980, HDB PHYSL          2, P301; JUHASOVA M, 1993, AM J PHYSIOL, V266, pC234; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAWASE T, 1992, EUR J PHARMACOL, V214, P39, DOI 10.1016/0014-2999(92)90093-J; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KOBAYASHI S, 1991, AM J PHYSIOL, V260, pC364, DOI 10.1152/ajpcell.1991.260.2.C364; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; KOWARSKI D, 1985, J PHYSIOL-LONDON, V366, P153, DOI 10.1113/jphysiol.1985.sp015790; KURIYAMA H, 1992, JPN J PHARM, V58; LEVITSKY DO, 1993, J BIOL CHEM, V268, P8325; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1980, J MOL BIOL, V139, P573, DOI 10.1016/0022-2836(80)90050-9; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MILLERHANCE WC, 1988, J BIOL CHEM, V263, P13979; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; MORELAND S, 1987, AM J PHYSIOL, V252, pH1049, DOI 10.1152/ajpheart.1987.252.6.H1049; MURPHY RA, 1980, HDB PHYSL 2, V2, P325; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; NISHIMURA J, 1990, AM J PHYSIOL, V259, pH2, DOI 10.1152/ajpheart.1990.259.1.H2; NIXON GF, 1994, J MUSCLE RES CELL M, V15, P682, DOI 10.1007/BF00121075; OKUBO S, 1994, BIOCHEM BIOPH RES CO, V200, P429, DOI 10.1006/bbrc.1994.1467; OKUBO S, 1993, ADV PROTEIN PHOSPHAT, V7, P295; PAPE PC, 1988, FEBS LETT, V235, P57, DOI 10.1016/0014-5793(88)81233-X; PAUL RJ, 1989, ANNU REV PHYSIOL, V51, P331, DOI 10.1146/annurev.physiol.51.1.331; PETROU S, 1994, J GEN PHYSIOL, V103, P471, DOI 10.1085/jgp.103.3.471; PFITZER G, 1984, PFLUG ARCH EUR J PHY, V401, P277, DOI 10.1007/BF00582596; PROSSER C L, 1992, News in Physiological Sciences, V7, P100; RAEYMAEKERS L, 1986, BIOCHIM BIOPHYS ACTA, V882, P258, DOI 10.1016/0304-4165(86)90163-7; REMBOLD CM, 1988, CIRC RES, V63, P593, DOI 10.1161/01.RES.63.3.593; REMBOLD CM, 1993, J MUSCLE RES CELL M, V14, P325, DOI 10.1007/BF00123097; SATOH S, 1993, FEBS LETT, V324, P211, DOI 10.1016/0014-5793(93)81395-G; SELLERS JR, 1984, J BIOL CHEM, V259, P7740; SHIMADA T, 1992, J GEN PHYSIOL, V100, P27, DOI 10.1085/jgp.100.1.27; SHIRAZI A, IN PRESS J BIOL CHEM; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; SIEGMAN MJ, 1980, J GEN PHYSIOL, V76, P609, DOI 10.1085/jgp.76.5.609; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOMLYO AP, 1989, FASEB J, V3, P2266, DOI 10.1096/fasebj.3.11.2506092; SOMLYO AP, 1988, PHILOS T ROY SOC B, V320, P399, DOI 10.1098/rstb.1988.0084; SOMLYO AP, 1990, REV PHYSL, V52, P857; SOMLYO AP, 1993, J MUSCLE RES CELL M, V15, P557; SOMLYO AP, 1991, HEART CARDIOVASCULAR, P845; SOMLYO AP, 1989, ADV PROTEIN PHOSPHAT, V5, P181; SOMLYO AV, 1992, J BIOL CHEM, V267, P22316; SOMLYO AV, 1968, J PHARMACOL EXP THER, V159, P129; SOMLYO AV, 1967, J GEN PHYSIOL, V50, P168; SOMLYO AV, 1988, J GEN PHYSIOL, V91, P1165; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; SUTTON TA, 1990, J BIOL CHEM, V265, P2749; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TANG DC, 1993, FEBS LETT, V331, P272, DOI 10.1016/0014-5793(93)80351-T; TANSEY MG, 1994, J BIOL CHEM, V269, P9912; TULLOCH AG, 1991, J BIOL CHEM, V266, P20168; TYRBUS KM, 1994, J CELL BIOL, V1243, P963; UMEMOTO S, 1989, J BIOL CHEM, V264, P1431; VAGI S, 1988, P NATL ACAD SCI USA, V85, P4109; VILLA A, 1993, J CELL BIOL, V121, P1041, DOI 10.1083/jcb.121.5.1041; VYAS TB, 1994, J BIOL CHEM, V269, P7316; WINDER SJ, 1993, CELL SIGNAL, V5, P677, DOI 10.1016/0898-6568(93)90029-L; WUYTACK F, 1987, BIOCHIM BIOPHYS ACTA, V899, P151, DOI 10.1016/0005-2736(87)90395-6; ZHOU CJ, 1993, BIOCHEM J, V289, P401, DOI 10.1042/bj2890401	107	1621	1676	3	82	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					231	236		10.1038/372231a0	http://dx.doi.org/10.1038/372231a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969467				2022-12-28	WOS:A1994PR88900040
J	MOSBACHER, J; SCHOEPFER, R; MONYER, H; BURNASHEV, N; SEEBURG, PH; RUPPERSBERG, JP				MOSBACHER, J; SCHOEPFER, R; MONYER, H; BURNASHEV, N; SEEBURG, PH; RUPPERSBERG, JP			A MOLECULAR DETERMINANT FOR SUBMILLISECOND DESENSITIZATION IN GLUTAMATE RECEPTORS	SCIENCE			English	Article							AMPA-KAINATE RECEPTORS; RAT HIPPOCAMPAL SLICES; SYNAPTIC TRANSMISSION; OPERATED CHANNELS; ION FLOW; PERMEABILITY; SUBUNITS; NEURONS; CELLS; CURRENTS	The decay of excitatory postsynaptic currents in central neurons mediated by alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptors is likely to be shaped either by receptor desensitization or by offset after removal of glutamate from the synaptic cleft. Native AMPA receptors show desensitization time constants of 1 to about 10 milliseconds, but the underlying molecular determinants of these large differences are unknown. Cloned AMPA receptors carrying the ''flop'' splice variants of glutamate receptor subtype C (GluR-C) and GluR-D are shown to have desensitization time constants of around 1 millisecond, whereas those with the ''flip'' variants are about four ti mes slower. Cerebellar granule cells switch their expression of GluR-D splice variants from mostly flip forms in early stages to predominantly flop forms in the adult rat brain. These findings suggest that rapid desensitization of AM PA receptors can be regulated by the expression and alternative splicing of GluR-D gene transcripts.	UNIV TUBINGEN,EAR NOSE & THROAT HOSP,DEPT SENSORY BIOPHYS,D-72076 TUBINGEN,GERMANY; MAX PLANCK INST MED RES,D-69028 HEIDELBERG,GERMANY; UNIV LONDON UNIV COLL,DEPT PHARMACOL,WELLCOME LAB MOLEC PHARMACOL,LONDON WC1E 6BT,ENGLAND; UNIV HEIDELBERG,CTR BIOL MOLEC,D-69120 HEIDELBERG,GERMANY	Eberhard Karls University of Tubingen; Max Planck Society; University of London; University College London; Ruprecht Karls University Heidelberg			Burnashev, Nail/G-4056-2013	Monyer, Hannah/0000-0002-9332-5749	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; BOCHET P, 1994, NEURON, V12, P383, DOI 10.1016/0896-6273(94)90279-8; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; BURNASHEV N, 1993, CELL PHYSIOL BIOCHEM, V3, P318, DOI 10.1159/000154696; BURNASHEV N, 1992, SCIENCE, V256, P1566, DOI 10.1126/science.1317970; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; DUDEL J, 1987, NEUROSCI LETT, V77, P199; Edmonds B., 1993, Society for Neuroscience Abstracts, V19, P1515; GALLO V, 1992, J NEUROSCI, V12, P1010; HACKETT JT, 1982, NEUROSCIENCE, V7, P1455, DOI 10.1016/0306-4522(82)90257-3; HERLITZE S, 1993, NEURON, V10, P1131, DOI 10.1016/0896-6273(93)90061-U; HESTRIN S, 1993, NEURON, V11, P1083, DOI 10.1016/0896-6273(93)90221-C; HESTRIN S, 1992, NEURON, V9, P991, DOI 10.1016/0896-6273(92)90250-H; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; JONAS P, 1992, J PHYSIOL-LONDON, V455, P143, DOI 10.1113/jphysiol.1992.sp019294; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; RAMAN IM, 1992, NEURON, V9, P173, DOI 10.1016/0896-6273(92)90232-3; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VYKLICKY L, 1991, NEURON, V7, P971, DOI 10.1016/0896-6273(91)90342-W	27	485	491	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1059	1062		10.1126/science.7973663	http://dx.doi.org/10.1126/science.7973663			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973663				2022-12-28	WOS:A1994PQ92400050
J	ENQUIST, M; ARAK, A				ENQUIST, M; ARAK, A			SYMMETRY, BEAUTY AND EVOLUTION	NATURE			English	Article								HUMANS and certain other species find symmetrical patterns more attractive than asymmetrical ones. These preferences may appear in response to biological signals(1-3), or in situations where there is no obvious signalling context, such as exploratory behaviour(4,5) and human aesthetic response to pattern(6-8). It has been proposed(9,10) that preferences for symmetry have evolved in animals because the degree of symmetry in signals indicates the signaller's quality. By contrast, we show here that symmetry preferences may arise as a by-product of the need to recognize objects irrespective of their position and orientation in the visual field. The existence of sensory biases for symmetry may have been exploited independently by natural selection acting on biological signals and by human artistic innovation. This may account for the observed convergence on symmetrical forms in nature and decorative art(11).	ARCHWAY ENGN UK LTD,ELLAND HX5 9JP,W YORKSHIRE,ENGLAND		ENQUIST, M (corresponding author), UNIV STOCKHOLM,DEPT ZOOL,S-10691 STOCKHOLM,SWEDEN.							ARAK A, 1993, PHILOS T R SOC B, V340, P207, DOI 10.1098/rstb.1993.0059; Berlyne D.E., 1971, AESTHETICS PSYCHOBIO; BROOKES M, 1994, TRENDS ECOL EVOL, V9, P201, DOI 10.1016/0169-5347(94)90241-0; Cronly-Dillon J., 1991, EVOLUTION EYE VISUAL; Darwin Charles, 1998, EXPRESS EMOT MAN, V3rd, DOI [10.1037/h0076058, DOI 10.1037/10001-000]; DEREFELDT G, 1991, PERCEPTION COLOUR, P218; DOLL TJ, 1967, J EXP PSYCHOL, V75, P508, DOI 10.1037/h0025116; ENQUIST M, 1993, NATURE, V361, P446, DOI 10.1038/361446a0; GOMBRICH EH, 1984, SENSE ORDER; HUBBELL MB, 1940, AM J PSYCHOL, V53, P46; LEIMAR O, 1986, AM NAT, V128, P469, DOI 10.1086/284581; Mackintosh N. J., 1974, PSYCHOL ANIMAL LEARN; MOLLER AP, 1992, NATURE, V357, P238, DOI 10.1038/357238a0; MUSINGER H, 1964, PSYCHOL MONOGR, V9, P1; RADESATER T, 1993, ANIM BEHAV, V45, P626, DOI 10.1006/anbe.1993.1075; Rensch B., 1957, Zeitschrift fuer Tierpsychologie, V14, P71; Rensch B., 1958, Zeitschrift fuer Tierpsychologie, V15, P447; RYAN MJ, 1991, OXFORD SURVEYS EVOLU, V7, P156; STADDON JER, 1975, AM NAT, V109, P541, DOI 10.1086/283025; Stewart I., 1993, FEARFUL SYMMETRY IS; SWADDLE JP, 1994, NATURE, V367, P165, DOI 10.1038/367165a0; Tinbergen N, 1951, STUDY INSTINCT; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; Wallace AR, 1889, DARWINISM; WATSON PJ, 1994, TRENDS ECOL EVOL, V9, P21, DOI 10.1016/0169-5347(94)90227-5	25	297	301	4	94	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					169	172		10.1038/372169a0	http://dx.doi.org/10.1038/372169a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969448				2022-12-28	WOS:A1994PQ68800053
J	ALLAND, D; KALKUT, GE; MOSS, AR; MCADAM, RA; HAHN, JA; BOSWORTH, W; DRUCKER, E; BLOOM, BR				ALLAND, D; KALKUT, GE; MOSS, AR; MCADAM, RA; HAHN, JA; BOSWORTH, W; DRUCKER, E; BLOOM, BR			TRANSMISSION OF TUBERCULOSIS IN NEW-YORK-CITY - AN ANALYSIS BY DNA-FINGERPRINTING AND CONVENTIONAL EPIDEMIOLOGIC METHODS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MYCOBACTERIUM-TUBERCULOSIS; COMPLEX STRAINS; INFECTION; OUTBREAK; HOMELESS; SHELTER; RISK; TOOL	Background. The incidence of tuberculosis and drug resistance is increasing in the United States, but it is not clear how much of the increase is due to reactivation of latent infection and how much to recent transmission. Methods. We performed DNA fingerprinting using restriction-fragment-length polymorphism (RFLP) analysis of at least one isolate from every patient with confirmed tuberculosis at a major hospital in the Bronx, New York, from December 1, 1989, through December 31, 1992. Medical records and census-tract data were reviewed for relevant clinical, social, and demographic data. Results. Of 130 patients with tuberculosis, 104 adults (80 percent) had complete medical records and isolates whose DNA fingerprints could be evaluated. Isolates from 65 patients (62.5 percent) had unique RFLP patterns, whereas isolates from 39 patients (37.5 percent) had RFLP patterns that were identical to those of an isolate from at least 1 other study patient; the isolates in the latter group were classified into 12 clusters. Patients whose isolates were included in one of the clusters were inferred to have recently transmitted disease. Independent risk factors for having a clustered isolate included seropositivity for the human immunodeficiency virus (HIV) (odds ratio for Hispanic patients, 4.31; P = 0.02; for non-Hispanic patients, 3.12; P = 0.07), Hispanic ethnicity combined with HIV seronegativity (odds ratio, 5.13; P = 0.05), infection with drug-resistant tuberculosis (odds ratio, 4.52; P = 0.005), and younger age (odds ratio, 1.59; P = 0.02). Residence in sections of the Bronx with a median household income below $20,000 was also associated with having a clustered isolate (odds ratio, 3.22; P = 0.04). Conclusions. In the inner-city community we studied, recently transmitted tuberculosis accounts for approximately 40 percent of the incident cases and almost two thirds of drug-resistant cases. Recent transmission of tuberculosis, and not only reactivation of latent disease, contributes substantially to the increase in tuberculosis.	MONTEFIORE MED CTR,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10467; ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10467; ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10467; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,DIV EPIDEMIOL & MED,SAN FRANCISCO,CA 94110; CUNY HERBERT H LEHMAN COLL,DEPT POLIT SCI,BRONX,NY 10468	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; City University of New York (CUNY) System; Lehman College (CUNY)	ALLAND, D (corresponding author), MONTEFIORE MED CTR,N CENT BRONX HOSP,DEPT MED,DIV INFECT DIS,111 E 210 ST,BRONX,NY 10467, USA.		Hahn, Judith/J-5813-2014	Hahn, Judith/0000-0002-2697-8264; Kalkut, Gary/0000-0002-6160-2262	NCI NIH HHS [2T32CA09173-16] Funding Source: Medline; NIAID NIH HHS [T32AI07183-13, T32AI07183-14] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007183] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DOBKIN J, 1993, 9 INT C AIDS JUN 6 1, P324; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1993, NEW ENGL J MED, V329, P148; HERMANS PWM, 1991, INFECT IMMUN, V59, P2695, DOI 10.1128/IAI.59.8.2695-2705.1991; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; Hewlett D. Jr., 1993, Morbidity and Mortality Weekly Report, V42, P427; Kent PT, 1985, GUIDE LEVEL 3 LAB; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NARDELL EA, 1993, AM REV RESPIR DIS, V148, P2, DOI 10.1164/ajrccm/148.1.2; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3; STYBLO K, 1984, EPIDEMIOLOGY TUBERCU; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; 1990, MMWR-MORBID MORTAL W, V39, P1; 1992, AM REV RESPIR DIS, V146, P1623; 1993, TUBERCULOSIS NEW YOR; 1990, MMWR-MORBID MORTAL W, V39, P9; 1991, MMWR-MORBID MORTAL W, V40, P585; 1992, TUBERCULOSIS NEW YOR; 1993, MMWR-MORBID MORTAL W, V42, P696; 1993, MMWR-MORBID MORTAL W, V42, P703	28	760	779	1	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 16	1994	330	24					1710	1716		10.1056/NEJM199406163302403	http://dx.doi.org/10.1056/NEJM199406163302403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR109	7993412	Bronze			2022-12-28	WOS:A1994NR10900003
J	HEMENWAY, D; SOLNICK, SJ; AZRAEL, DR				HEMENWAY, D; SOLNICK, SJ; AZRAEL, DR			FIREARM TRAINING AND STORAGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADOLESCENT SUICIDE; GUN OWNERSHIP; HOME; PROTECTION; VIOLENCE; HOMICIDE; CHILDREN; VICTIMS; DEATHS; SAFETY	Objective.-To determine the extent of firearm training among gun owners, how gun owners currently store their weapons, and the relationship between gun training and gun storage. Design and Setting.-A national random telephone survey of gun owners conducted from May through June 1994. Participants.-A total of 800 adult gun owners residing in the United States. Main Outcome Measures.-Number of gun owners who received firearm training and number who store a firearm loaded and unlocked. Logistic regression analyses were conducted to examine factors associated with firearm training and gun storage practices. Results.-A total of 451 (56%) of gun owners have received firearm training. A total of 170 (21%) of gun owners keep a firearm both loaded and unlocked in the home. Factors associated with an increased likelihood of storing guns loaded and unlocked included owning a gun for protection (odds ratio [OR], 2.40; 95% confidence interval [Cl], 1.62 to 3.54), owning a handgun (OR, 3.31; 95% Cl, 1.85 to 5.95), and having received firearm training (OR, 1.71; 95% Cl, 1.10 to 2.67). Length of firearm training and how recently training was received have little effect on storage practices. Conclusion.-lt has been suggested that many homicide, suicide, and accidental firearm injuries might be prevented if ready access to lethal weapons was reduced, in part through appropriate storage of guns. Although increased training has been advocated as the prime method to improve gun storage practices, our results cast doubt on whether firearm training, at least as currently provided, will substantially reduce the inappropriate storage of firearms.			HEMENWAY, D (corresponding author), HARVARD UNIV,SCH PUBL HLTH,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.							ADAY L, 1989, DESIGNING CONDUCTING; BRENT DA, 1988, ARCH GEN PSYCHIAT, V45, P581, DOI 10.1001/archpsyc.1988.01800300079011; BRENT DA, 1993, AM J DIS CHILD, V147, P1066, DOI 10.1001/archpedi.1993.02160340052013; BRENT DA, 1993, J AM ACAD CHILD PSY, V32, P494, DOI 10.1097/00004583-199305000-00002; Cook P.J., 1991, CRIME JUSTICE, V14, P1, DOI [10.1086/449183, DOI 10.1086/449183]; COOK PJ, 1985, J QUANTITATIVE CRIMI, V0001; Frey J. H, 1989, SURVEY RES TELEPHONE, V150; GOODMAN RA, 1986, AM J PUBLIC HEALTH, V76, P144, DOI 10.2105/AJPH.76.2.144; HEINS M, 1974, AM J PUBLIC HEALTH, V64, P326, DOI 10.2105/AJPH.64.4.326; HEMENWAY D, 1990, J POLICY ANAL MANAG, V9, P94, DOI 10.2307/3325116; Kalton G., 1983, INTRO SURVEY SAMPLIN, DOI DOI 10.4135/9781412984683; KECK NJ, 1988, AM J DIS CHILD, V142, P623, DOI 10.1001/archpedi.1988.02150060057029; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1986, NEW ENGL J MED, V314, P1557, DOI 10.1056/NEJM198606123142406; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; KELLERMANN AL, 1991, AM J EPIDEMIOL, V131, P1080; KOOP CE, 1992, JAMA-J AM MED ASSOC, V267, P3075, DOI 10.1001/jama.267.22.3075; KOOP CE, 1994, JAMA-J AM MED ASSOC, V271, P1404; KOOP CE, 1992, JAMA-J AM MED ASSOC, V268, P3074; LAVRAKAS PJ, 1987, APPLIED SOCIAL RES M, V7; LEE RK, 1993, AM J PREV MED, V9, P16, DOI 10.1016/S0749-3797(18)30673-1; MARTIN JR, 1991, ANN EMERG MED, V20, P58, DOI 10.1016/S0196-0644(05)81120-5; ORDOG GJ, 1988, AM J DIS CHILD, V142, P618, DOI 10.1001/archpedi.1988.02150060052028; PATTERSON PJ, 1987, AM J DIS CHILD, V141, P221, DOI 10.1001/archpedi.1987.04460020111042; RIVARA FP, 1982, J DEV BEHAV PEDIATR, V3, P35; SEIDEN RH, 1977, OMEGA-J DEATH DYING, V8, P267, DOI 10.2190/KXY8-J7QB-7BR7-J8YW; VOGEL RE, 1986, J POLICE SCI ADMIN, V14, P242; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WEIL DS, 1992, JAMA-J AM MED ASSOC, V267, P3033, DOI 10.1001/jama.267.22.3033; WHITE AM, 1993, HOUS L REV, V30, P1389; WINTEMUTE GJ, 1987, JAMA-J AM MED ASSOC, V257, P3107, DOI 10.1001/jama.257.22.3107; ZIMRING FE, 1983, CITIZENS GUIDE GUN C; ZWERLING C, 1993, AM J PREV MED S, V49, P52; 1993, GUN CONTROL ADULT SU; 1987, FIREARMS SAFETY DEPE; NRA BASIC FIREARM TR; 1993, GALLUP CNN US TODAY; 1990, NRA HOME FIREARM SAF; 1990, PHS9150212 US DEP HL; 1991, ACCIDENTAL SHOOTINGS; 1991, SOURCEBOOK CRIMINAL; 1994, STOP FIREARM INJURY; 1990, HANDGUN SAFETY GUIDE; 1993, CRIME VICTIMIZATION	44	87	87	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 4	1995	273	1					46	50		10.1001/jama.273.1.46	http://dx.doi.org/10.1001/jama.273.1.46			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PZ042	7996649				2022-12-28	WOS:A1995PZ04200027
J	CAO, XY; JIANG, XM; DOU, ZH; RAKEMAN, MA; ZHANG, ML; ODONNELL, K; MA, T; AMETTE, K; DELONG, N; DELONG, GR				CAO, XY; JIANG, XM; DOU, ZH; RAKEMAN, MA; ZHANG, ML; ODONNELL, K; MA, T; AMETTE, K; DELONG, N; DELONG, GR			TIMING OF VULNERABILITY OF THE BRAIN TO IODINE DEFICIENCY IN ENDEMIC CRETINISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IODIZED OIL; PREGNANCY; SUPPLEMENTATION; DISORDER	Background. Endemic cretinism, caused by severe iodine deficiency during pregnancy, is the world's most common preventable cause of mental retardation. It can be prevented by iodine treatment before conception, but whether it can be prevented or ameliorated by treatment during pregnancy or after delivery is not known. Methods. In a severely iodine-deficient area of the Xinjiang region of China, we systematically administered iodine to groups of children from birth to three years of age (n = 689) and women at each trimester of pregnancy (n = 295); we then followed the treated children and the babies born to the treated women for two years. We used three independent measures of neural development: the results of the neurologic examination, the head circumference (which correlates with brain weight in the first postnatal year), and indexes of cognitive and motor development. Untreated children one to three years of age, who were studied when first seen, served as control subjects. Results. The prevalence of moderate or severe neurologic abnormalities among the 120 infants whose mothers received iodine in the first or second trimester was 2 percent, as compared with 9 percent among the 752 infants who received iodine during the third trimester (through the treatment of their mothers) or after birth (P = 0.008). The prevalence of microcephaly (defined as a head circumference more than 3 SD below U.S. norms) decreased from 27 percent in the untreated children to 11 percent in the treated children (P = 0.006), and the mean (+/-SD) developmental quotient at two years of age increased (90 +/- 14, vs. 75 +/- 18 in the untreated children; P < 0.001). Treatment in the third trimester of pregnancy or after delivery did not improve neurologic status, but head growth and developmental quotients improved slightly. Treatment during the first trimester, which was technically problematic, improved the neurologic outcome. Conclusions. Up to the end of the second trimester, iodine treatment protects the fetal brain from the effects of iodine deficiency. Treatment later in pregnancy or after delivery may improve brain growth and developmental achievement slightly, but it does not improve neurologic status.	DUKE UNIV,MED CTR,DIV PEDIAT NEUROL,DURHAM,NC 27710; TIANJIN MED COLL,TIANJIN,PEOPLES R CHINA; XINJIANG ANTIEPIDEM & HLTH STN,URUMQI,PEOPLES R CHINA; INST ENDEM DIS RES,URUMQI,PEOPLES R CHINA	Duke University; Tianjin Medical University								Bayley N., 1969, BAYLEY SCALES INFANT; Bleichrodt N., 1989, IODINE BRAIN, P269; BOYAGES SC, 1989, MED J AUSTRALIA, V150, P676, DOI 10.5694/j.1326-5377.1989.tb136760.x; CAO XY, 1994, LANCET, V344, P107, DOI 10.1016/S0140-6736(94)91286-6; CHOUFOER JC, 1965, J CLIN ENDOCR METAB, V25, P385, DOI 10.1210/jcem-25-3-385; DEESCOBAR GM, 1993, AM J CLIN NUTR, V57, pS280; DELONG GR, 1985, DEV MED CHILD NEUROL, V27, P317; DOBBING J, 1974, SCI F PAEDIATRICS, P565; DUNN JT, 1993, ANN NY ACAD SCI, V678, P158; EAYRS JT, 1960, BRIT MED BULL, V16, P122, DOI 10.1093/oxfordjournals.bmb.a069810; GILLES FH, 1983, DEV HUMAN BRAIN GROW, P58; GLINOER D, 1990, J CLIN ENDOCR METAB, V71, P276, DOI 10.1210/jcem-71-2-276; HALPERN JP, 1991, BRAIN, V114, P825, DOI 10.1093/brain/114.2.825; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HETZEL BS, 1989, J NUTR, V119, P145, DOI 10.1093/jn/119.2.145; KOCHUPILLAI N, 1986, IODINE NUTR THYROXIN, P87; Legrand J, 1984, NEUROBEHAVIORAL TERA, P331; LIU JL, 1989, IODINE BRAIN, P249; MA T, 1993, ANN NEUROL, V34, P91, DOI 10.1002/ana.410340116; Ma T., 1989, IODINE BRAIN, P259, DOI 10.1007/978-1-4613-0765-5_24; MANO MT, 1989, ACTA ENDOCRINOL-COP, V121, P7, DOI 10.1530/acta.0.1210007; McCarrison R, 1908, LANCET, V2, P1275; Pharoah P O, 1972, Adv Exp Med Biol, V30, P201; PHAROAH POD, 1991, ARCH DIS CHILD, V66, P145, DOI 10.1136/adc.66.1.145; PHAROAH POD, 1971, LANCET, V1, P308; TONGLET R, 1992, NEW ENGL J MED, V326, P236, DOI 10.1056/NEJM199201233260405; WEINBERG WA, 1974, J PEDIATR-US, V85, P482, DOI 10.1016/S0022-3476(74)80449-X; 1981, LANCET, V2, P1095; [No title captured]	29	274	293	1	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	1994	331	26					1739	1744		10.1056/NEJM199412293312603	http://dx.doi.org/10.1056/NEJM199412293312603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ266	7984194	Bronze			2022-12-28	WOS:A1994PZ26600003
J	DANZL, DF; POZOS, RS				DANZL, DF; POZOS, RS			CURRENT CONCEPTS - ACCIDENTAL HYPOTHERMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CARDIOPULMONARY BYPASS; PERITONEAL-LAVAGE; BODY-TEMPERATURE; ARREST; RESUSCITATION; COAGULATION; FAILURE; CPR		USN,HLTH RES CTR,DIV THERMAL,SAN DIEGO,CA 92152	United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); Naval Health Research Center (NHRC)	DANZL, DF (corresponding author), UNIV LOUISVILLE,DEPT EMERGENCY MED,LOUISVILLE,KY 40292, USA.							ALTHAUS U, 1982, ANN SURG, V195, P492, DOI 10.1097/00000658-198204000-00018; Baraka A, 1984, Middle East J Anaesthesiol, V7, P235; Bjornstad H, 1991, Arctic Med Res, V50 Suppl 6, P71; BRUNETTE DD, 1992, AM J EMERG MED, V10, P32, DOI 10.1016/0735-6757(92)90121-D; CHANDRA NC, 1993, ANN EMERG MED, V22, P281; CHERNOW B, 1983, CRIT CARE MED, V11, P677, DOI 10.1097/00003246-198309000-00001; CLEMMER TP, 1992, CRIT CARE MED, V20, P1395, DOI 10.1097/00003246-199210000-00006; DANZL DF, 1989, CRIT CARE MED, V17, P227, DOI 10.1097/00003246-198903000-00005; DANZL DF, 1987, ANN EMERG MED, V16, P1042, DOI 10.1016/S0196-0644(87)80757-6; DELANEY KA, 1989, ANN EMERG MED, V18, P72, DOI 10.1016/S0196-0644(89)80319-1; DELROSSI AJ, 1990, J TRAUMA, V30, P79, DOI 10.1097/00005373-199001000-00012; FELICETTA JV, 1980, J CLIN ENDOCR METAB, V50, P93, DOI 10.1210/jcem-50-1-93; FISCHBECK KH, 1981, ANN NEUROL, V10, P384, DOI 10.1002/ana.410100411; GALLAHER MM, 1992, JAMA-J AM MED ASSOC, V267, P1345, DOI 10.1001/jama.267.10.1345; GAUTAM P, 1989, PUBLIC HEALTH, V103, P15, DOI 10.1016/S0033-3506(89)80097-6; GENTILELLO LM, 1992, J TRAUMA, V32, P316, DOI 10.1097/00005373-199203000-00009; GREGORY JS, 1991, J TRAUMA, V31, P1247, DOI 10.1097/00005373-199109000-00008; HALL KN, 1990, ANN EMERG MED, V19, P204, DOI 10.1016/S0196-0644(05)81810-4; HAMLET MP, 1987, MIL MED, V152, P393; HAUTY MG, 1987, J TRAUMA, V27, P1107, DOI 10.1097/00005373-198710000-00002; HAYWARD JS, 1984, RESUSCITATION, V11, P21, DOI 10.1016/0300-9572(84)90031-5; ISERSON KV, 1991, TRANSFUSION, V31, P558, DOI 10.1046/j.1537-2995.1991.31691306256.x; IVERSEN RJ, 1990, ANN EMERG MED, V19, P1335, DOI 10.1016/S0196-0644(05)82300-5; JOLLY B T, 1992, Emergency Medicine Clinics of North America, V10, P311; KRAMER MR, 1989, ARCH INTERN MED, V149, P1521, DOI 10.1001/archinte.149.7.1521; KRISTENSEN G, 1985, ACTA ANAESTH SCAND, V29, P846, DOI 10.1111/j.1399-6576.1985.tb02308.x; KRONCKE GM, 1986, ARCH SURG-CHICAGO, V121, P303; LETSOU GV, 1992, ARCH SURG-CHICAGO, V127, P525; LLOYD EL, 1991, J WILDERNESS MED, V2, P330, DOI 10.1580/0953-9859-2.4.330; LONG WB, 1992, FEB CRIT DEC HYP ANN; Mills W J Jr, 1980, Alaska Med, V22, P9; MOSS JF, 1986, J TRAUMA, V26, P68, DOI 10.1097/00005373-198601000-00013; ORTS A, 1992, AM J EMERG MED, V10, P311, DOI 10.1016/0735-6757(92)90008-L; OTTO RJ, 1988, CRIT CARE MED, V16, P869, DOI 10.1097/00003246-198809000-00010; PATON BC, 1983, PHARMACOL THERAPEUT, V22, P331, DOI 10.1016/0163-7258(83)90008-6; PATT A, 1988, SURG CLIN N AM, V68, P775; RAHN H, 1974, PNEUMONOLOGIE, V151, P87, DOI 10.1007/BF02097155; REED RL, 1990, CIRC SHOCK, V32, P141; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; ROSENKRANZ L, 1985, SOUTHERN MED J, V78, P358, DOI 10.1097/00007611-198503000-00033; SCHALLER MD, 1990, JAMA-J AM MED ASSOC, V264, P1842, DOI 10.1001/jama.264.14.1842; Sofer S, 1986, Pediatr Emerg Care, V2, P211, DOI 10.1097/00006565-198612000-00001; SPLITTGERBER FH, 1986, AM SURGEON, V52, P407; STEINMAN AM, 1986, CIRCULATION, V74, P29; SWAIN JA, 1988, ARCH INTERN MED, V148, P1643, DOI 10.1001/archinte.148.7.1643; VALERI CR, 1987, ANN SURG, V205, P175, DOI 10.1097/00000658-198702000-00012; WALPOTH BH, 1990, EUR J CARDIO-THORAC, V4, P390, DOI 10.1016/1010-7940(90)90048-5; WEBB P, 1986, J APPL PHYSIOL, V60, P385, DOI 10.1152/jappl.1986.60.2.385; WEINBERG AD, 1993, ANN EMERG MED, V22, P370, DOI 10.1016/S0196-0644(05)80467-6; WHITE FN, 1981, J THORAC CARDIOV SUR, V82, P821; WHITE JD, 1985, J TRAUMA, V25, P989, DOI 10.1097/00005373-198510000-00011; WONG KC, 1983, WESTERN J MED, V138, P227	52	259	270	1	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	1994	331	26					1756	1760		10.1056/NEJM199412293312607	http://dx.doi.org/10.1056/NEJM199412293312607			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ266	7984198				2022-12-28	WOS:A1994PZ26600007
J	MANSFIELD, PF; HOHN, DC; FORNAGE, BD; GREGURICH, MA; OTA, DM				MANSFIELD, PF; HOHN, DC; FORNAGE, BD; GREGURICH, MA; OTA, DM			COMPLICATIONS AND FAILURES OF SUBCLAVIAN-VEIN CATHETERIZATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CENTRAL VENOUS ACCESS; ULTRASONOGRAPHIC GUIDANCE; PARENTERAL-NUTRITION; CANNULATION; SAFE	Background. Although catheterization of the subclavian vein is a common procedure, the risk factors for complications and failures, with the exception of the physician's experience, are poorly understood. Ultrasonography has been recommended to help guide the placement of central venous catheters. Methods. We conducted a prospective randomized trial of ultrasound-guided location of the subclavian vein as compared with standard insertion procedures. In the group of patients undergoing catheterization with ultrasound guidance, the site of the insertion was marked before the catheterization attempt; real-time ultrasound guidance was not used. The 821 eligible patients (411 in the ultrasound group and 410 in the control group) underwent catheterization in a single procedure suite under controlled nonemergency conditions, in most cases for the administration of chemotherapy. Results. Ultrasound guidance had no effect on the rate of complications or failures of subclavian-vein catheterization (risk ratio for complications, 1.00; 95 percent confidence interval, 0.66 to 1.52; risk ratio for failures, 1.04; 95 percent confidence interval, 0.72 to 1.50). In multivariate analyses, prior major surgery in the region (P = 0.002), a body-mass index (the weight in kilograms divided by the square of the height in meters) higher than 30 or lower than 20 (P = 0.009), and previous catheterization (P = 0.043) were associated with failed attempts, Complications were also associated with failed attempts: 52 of the 721 patients (7.2 percent) in whom catheterization was successful had complications, as compared with 28 of the 100 patients (28 percent) in whom physicians were unable to place catheters. The number of needle passes was strongly associated with the rates of failure and complications. The complication rate rose from 4.3 percent with one pass to 24.0 percent with more than two passes. Conclusions. Ultrasound guidance of subclavian-vein catheterization, as used in this study, was not beneficial. In patients at highest risk for complications and failures, catheterization should be attempted by the most experienced physicians available.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT DIAGNOST RADIOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT ACAD & RES COMP, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	MANSFIELD, PF (corresponding author), UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT SURG ONCOL, BOX 106, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.							ANDERSON S, 1989, STATISTICAL METHODS, P162; CONCES DJ, 1984, ARCH SURG-CHICAGO, V119, P293; DEFALQUE RJ, 1988, JPEN-PARENTER ENTER, V12, P406, DOI 10.1177/0148607188012004406; DEJONG PCM, 1985, ACTA ANAESTH SCAND, V29, P48; DENYS BG, 1991, NEW ENGL J MED, V324, P566; FARES LG, 1986, AM SURGEON, V52, P108; HOSMER DW, 1989, APPLIED LOGISTIC REG, P83; KAWAMURA R, 1987, JPEN-PARENTER ENTER, V11, P505, DOI 10.1177/0148607187011005505; KRAMER MS, 1988, CLIN EPIDEMIOLOGY BI, P64; LADEFOGED K, 1981, SCAND J GASTROENTERO, V16, P913, DOI 10.3109/00365528109181822; LEE ET, 1992, STATISTICAL METHODS, P355; LEE W, 1989, AM J OBSTET GYNECOL, V161, P1012, DOI 10.1016/0002-9378(89)90774-6; MACHI J, 1987, AM J SURG, V153, P321, DOI 10.1016/0002-9610(87)90619-2; MUGHAL MM, 1989, BRIT J SURG, V76, P15, DOI 10.1002/bjs.1800760107; NOLSOE C, 1989, ACTA RADIOL, V30, P108; PADBERG FT, 1981, ANN SURG, V193, P264, DOI 10.1097/00000658-198103000-00002; PATEL C, 1986, CRIT CARE MED, V14, P195, DOI 10.1097/00003246-198603000-00005; 1989, CONTEMP SURG, V34, P93	18	576	598	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 29	1994	331	26					1735	1738		10.1056/NEJM199412293312602	http://dx.doi.org/10.1056/NEJM199412293312602			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ266	7984193				2022-12-28	WOS:A1994PZ26600002
J	PANKRATZ, L; JACKSON, J				PANKRATZ, L; JACKSON, J			HABITUALLY WANDERING PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POPULATION; SERVICES; CARE	Background. Physicians are sometimes confronted with patients who gain admission to one hospital after another, sometimes referred to as ''wandering patients.'' Little is known about the presenting symptoms of these patients, their use of hospital resources, or the costs of their medical care, We analyzed the demographic and clinical characteristics of wandering patients served by Department of Veterans Affairs medical centers (VAMCs), Methods. For each patient they admit, all 159 hospitals in the Veterans Affairs medical system submit demographic and diagnostic information to a central data base at the Data Processing Center in Austin, Texas, We searched these records to identify patients who were admitted to four or more VAMCs within each year from fiscal year 1988 through 1992. Patients so identified in any one year were called ''wanderers''; those identified in all five years were designated ''habitual wanderers, Results. We identified 1013 wanderers in 1988. The number gradually declined each year to 729 in 1992, In 1991 there were 810 wandering patients, who averaged about eight admissions per year and more than 100 days of inpatient care; they accounted for about $26.5 million in costs for inpatient and outpatient care in that year. Only 35 patients wandered in all five years from 1988 through 1992. The most common discharge diagnoses of these 35 men were related to substance abuse (mostly alcoholism) and mental disorders. Their 2268 admissions and 7832 outpatient visits cost an estimated $6.5 million over the five-year period. Conclusions. Patients who are repeatedly admitted to different hospitals - wandering patients - accumulate high numbers of admissions, cause diagnostic confusion, and receive uncoordinated care. Because of the complexity of their disorders, such patients require case management on a regional or national basis.	OREGON HLTH SCI UNIV,DEPT PSYCHIAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PSYCHOL MED,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University	PANKRATZ, L (corresponding author), VET AFFAIRS MED CTR,PSYCHOL SERV 116B,POB 1034,PORTLAND,OR 97207, USA.							ANDERSON GF, 1984, NEW ENGL J MED, V311, P1349, DOI 10.1056/NEJM198411223112105; BUCKLEY R, 1992, COMMUNITY MENT HLT J, V28, P43, DOI 10.1007/BF00756701; CATON CLM, 1981, HOSP COMMUNITY PSYCH, V32, P475; DRAKE RE, 1992, COMMUNITY MENT HLT J, V28, P5, DOI 10.1007/BF00756697; Durance P W, 1992, J Ment Health Adm, V19, P178, DOI 10.1007/BF02521318; FINK P, 1993, GEN HOSP PSYCHIAT, V15, P211, DOI 10.1016/0163-8343(93)90035-M; GELLER JL, 1992, AM J PSYCHIAT, V149, P1526; GELLER JL, 1992, HOSP COMMUNITY PSYCH, V43, P904; Gordon R E, 1975, J Fla Med Assoc, V62, P21; Gordon R E, 1973, JFMA, V60, P27; Hadley T R, 1990, Psychiatr Q, V61, P41, DOI 10.1007/BF01065163; McLean E K, 1990, Int J Soc Psychiatry, V36, P172, DOI 10.1177/002076409003600302; MECHANIC D, 1987, NEW ENGL J MED, V317, P1634, DOI 10.1056/NEJM198712243172605; PANKRATZ L, 1989, DRUG ALCOHOL DEPEN, V24, P115, DOI 10.1016/0376-8716(89)90073-2; PANKRATZ L, 1978, J OPER PSYCHIATR, V9, P42; PANKRATZ L, 1989, PERSPECT HEALTHCARE, V9, P5; PEPPER B, 1981, HOSP COMMUNITY PSYCH, V32, P463; ROSENHECK R, 1993, SCHIZOPHRENIA BULL, V19, P843, DOI 10.1093/schbul/19.4.843; SCHWARTZ SR, 1981, HOSP COMMUNITY PSYCH, V32, P470; SPARR L, 1983, AM J PSYCHIAT, V140, P1016; SURLES RC, 1987, HOSP COMMUNITY PSYCH, V38, P401; VICTOR CR, 1989, BRIT MED J, V299, P725, DOI 10.1136/bmj.299.6701.725	22	25	26	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	1994	331	26					1752	1755		10.1056/NEJM199412293312606	http://dx.doi.org/10.1056/NEJM199412293312606			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PZ266	7984197				2022-12-28	WOS:A1994PZ26600006
J	CHOSIDOW, O; CHASTANG, C; BRUE, C; BOUVET, E; IZRI, M; MONTENY, N; BASTUJIGARIN, S; ROUSSET, JJ; REVUZ, J				CHOSIDOW, O; CHASTANG, C; BRUE, C; BOUVET, E; IZRI, M; MONTENY, N; BASTUJIGARIN, S; ROUSSET, JJ; REVUZ, J			CONTROLLED-STUDY OF MALATHION AND D-PHENOTHRIN LOTIONS FOR PEDICULUS-HUMANUS VAR CAPITIS-INFESTED SCHOOLCHILDREN	LANCET			English	Article							HEAD LICE; INFESTATION; INFECTION	Anecdotal reports have suggested that reduced efficacy of pediculicides against Pediculus humanus capitis could be related to resistance to treatments. Ovicidal and pediculicidal activities of 0.5% malathion and 0.3% d-phenothrin lotions were tested in an experimental model of P humanus capitis grown on rabbits to ensure that the two treatments were pharmacologically equipotent. We then did a randomised controlled trial in which the lotions were administered to 193 P humanus capitis-infested schoolchildren (malathion, 95; d-phenothrin, 98). Success rate was defined as the absence of both live lice and viable nits. Before treatment, live lice were collected and subjected to a pediculicidal test. Pharmacological tests showed 100% killing of the rabbit-grown nits and lice after exposure to both pediculicides. On day 1 of the controlled trial, the success rate was 92% in the malathion group (95% CI, 0.86-0.97) and 40% in the d-phenothrin group (0.30-0.49) (p<0.0001); on day 7, it was 95% in the malathion group (0.90-0.99) and 39% in the d-phenothrin group (0.29-0.48, p<0.0001). Malathion was also significantly more active in the pediculicidal tests compared to d-phenothrin and control. These results suggest an acquired resistance to d-phenothrin in the schoolchildren tested, since all other conditions of the administration of insecticides were standardised.	HOP ST LOUIS,DEPT BIOSTAT & INFORMAT MED,PARIS,FRANCE; HOP BICHAT,SERV MALAD INFECT,PARIS,FRANCE; INSPECT GEN PROTECT SANITAIRE,PARIS,FRANCE; HOP AVICENNE,PARASITOL LAB,BOBIGNY,FRANCE; ORSTOM,LUTTE CONTRE INSECTRES NUISIBLES LAB,MONTPELLIER,FRANCE; HOP HENRI MONDOR,DEPT SANTE PUBL,CRETEIL,FRANCE; HOP HENRI MONDOR,SERV DERMATOL,CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Institut de Recherche pour le Developpement (IRD); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	CHOSIDOW, O (corresponding author), HOP LA PITIE SALPETRIERE,SERV MED INTERNE,47 BLVD HOP,F-75013 PARIS,FRANCE.		Bastuji-Garin, Sylvie/R-3479-2018	Bastuji-Garin, Sylvie/0000-0001-9855-5183				BURNS DA, 1991, BRIT J DERMATOL, V125, P89, DOI 10.1111/j.1365-2133.1991.tb06053.x; COLE MM, 1961, J ECON ENTOMOL, V54, P649, DOI 10.1093/jee/54.4.649; COLE MM, 1973, J ECON ENTOMOL, V66, P118, DOI 10.1093/jee/66.1.118; COMBESCOT C, 1990, B ACAD NAT MED PARIS, V174, P231; DOSS S, 1991, J ROY SOC HEALTH, V111, P47, DOI 10.1177/146642409111100202; FINE BC, 1983, NEW ENGL J MED, V309, P1461; GRATZ NG, 1983, CUTANEOUS INFESTATIO, P151; GULATI PV, 1981, CLINICIAN, V45, P177; King F., 1988, Pharmaceutical Journal, V241, P667; KUCIRKA SA, 1983, INT J DERMATOL, V22, P551, DOI 10.1111/j.1365-4362.1983.tb02123.x; KYLE DR, 1990, J ROY SOC HEALTH, V110, P62, DOI 10.1177/146642409011000210; Maunder J.W., 1983, Proceedings of the Royal Institution of Great Britain, V55, P1; Maunder JW, 1971, MED OFFICERS, V125, P27, DOI DOI 10.1542/peds.2008-3762; MEINKING TL, 1986, ARCH DERMATOL, V122, P267, DOI 10.1001/archderm.122.3.267; MILLER RN, 1972, T ROY SOC TROP MED H, V66, P372, DOI 10.1016/0035-9203(72)90262-3; MUMCUOGLU KY, 1990, INT J DERMATOL, V29, P502, DOI 10.1111/j.1365-4362.1990.tb04845.x; PASTEUR N, 1990, PESTICIDES AND ALTERNATIVES : INNOVATIVE CHEMICAL AND BIOLOGICAL APPROACHES TO PEST CONTROL, P439; Rasmussen J E, 1986, Adv Dermatol, V1, P109; TAPLIN D, 1982, JAMA-J AM MED ASSOC, V247, P3103, DOI 10.1001/jama.247.22.3103; TAPLIN D, 1990, ARCH DERMATOL, V126, P213, DOI 10.1001/archderm.126.2.213; UNAL G, 1993, INT J DERMATOL, V32, P30; VALADE M, 1985, THESIS PARIS; 1981, WHO655 RAPP TECHN; 1979, LANCET, V2, P19; 1990, PHARM J, V244, P263	25	106	109	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1724	1727		10.1016/S0140-6736(94)92884-3	http://dx.doi.org/10.1016/S0140-6736(94)92884-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7997000	Green Submitted			2022-12-28	WOS:A1994PY28100007
J	HUBBARD, SR; WEI, L; ELIS, L; HENDRICKSON, WA				HUBBARD, SR; WEI, L; ELIS, L; HENDRICKSON, WA			CRYSTAL-STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN-RECEPTOR	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; AUTOPHOSPHORYLATION; PHOSPHOTRANSFERASE; PHOSPHORYLATION; IDENTIFICATION; INHIBITOR; FEATURES; FAMILY; CELLS	The X-ray crystal structure of the tyrosine kinase domain of the human insulin receptor has been determined by multiwavelength anomalous diffraction phasing and refined to 2.1 Angstrom resolution. The structure reveals the determinants of substrate preference for tyrosine rather than serine or threonine and a novel autoinhibition mechanism whereby one of the tyrosines that is autophosphorylated in response to insulin, Tyr 1,162, is bound in the active site.	COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032; TEXAS A&M UNIV,INST BIOSCI & TECHNOL,WM KECK CTR GENOME INFORMAT,HOUSTON,TX 77030	Columbia University; Howard Hughes Medical Institute; Texas A&M University System	HUBBARD, SR (corresponding author), COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.							ACCILI D, 1992, J ENDOCRINOL INVEST, V15, P857, DOI 10.1007/BF03348820; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COBB MH, 1989, J BIOL CHEM, V264, P18701; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FRATTALI AL, 1992, J BIOL CHEM, V267, P19521; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5773, DOI 10.1021/bi00073a008; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHOELSON SE, 1991, BIOCHEMISTRY-US, V30, P7740, DOI 10.1021/bi00245a010; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VERNON M, 1993, P NATL ACAD SCI USA, V90, P10618; VILLALBA M, 1989, P NATL ACAD SCI USA, V86, P7848, DOI 10.1073/pnas.86.20.7848; WEI L, 1994, CURR OPIN STRUC BIOL, V4, P450, DOI 10.1016/S0959-440X(94)90115-5; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, J BIOL CHEM, V263, P2969; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; 1979, SERC4 DAR LAB COLL C	47	930	973	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					746	754		10.1038/372746a0	http://dx.doi.org/10.1038/372746a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997262				2022-12-28	WOS:A1994PY21200043
J	PERNEGER, TV; WHELTON, PK; KLAG, MJ				PERNEGER, TV; WHELTON, PK; KLAG, MJ			RISK OF KIDNEY FAILURE ASSOCIATED WITH THE USE OF ACETAMINOPHEN, ASPIRIN, AND NONSTEROIDAL ANTIINFLAMMATORY DRUGS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC RENAL-DISEASE; ANALGESIC USE; IBUPROFEN; SULINDAC	Background. People who take analgesic drugs frequently may be at increased risk of end-stage renal disease (ESRD), but the extent of this risk remains unclear. Methods. We studied 716 patients treated for ESRD and 361 control subjects of similar age from Maryland, Virginia, West Virginia, and Washington, D.C. The study participants were interviewed by telephone about their past use of medications containing acetaminophen, aspirin, and other nonsteroidal antiinflammatory drugs (NSAIDs). For each analgesic drug, the average use (in pills per year) and the cumulative intake (in pills) were examined for any association with ESRD. Results. Heavier acetaminophen use was associated with an increased risk of ESRD in a dose-dependent fashion. When persons who took an average of 0 to 104 pills per year were used for reference, the odds ratio of ESRD was 1.4 (95 percent confidence interval, 0.8 to 2.4) for those who took 105 to 365 pills per year and 2.1 (95 percent confidence interval, 1.1 to 3.7) for those who took 366 or more pills per year, after adjustment for race, sex, age, and intake of other analgesic drugs. When persons who had taken fewer than 1000 pills containing acetaminophen in their lifetime were used for reference, the odds ratio was 2.0 (95 percent confidence interval, 1.3 to 3.2) for those who had taken 1000 to 4999 pills and 2.4 (95 percent confidence interval, 1.2 to 4.8) for those who had taken 5000 or more pills. Approximately 8 to 10 percent of the overall incidence of ESRD was attributable to acetaminophen use. A cumulative dose of 5000 or more pills containing NSAIDs was also associated with an increased odds of ESRD (odds ratio, 8.8), but the use of aspirin was not. Conclusions. People who often take acetaminophen or NSAIDs have an increased risk of ESRD, but not those who often take aspirin.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MED,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,WELCH CTR PREVENT EPIDEMIOL & CLIN RES,BALTIMORE,MD	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	PERNEGER, TV (corresponding author), UNIV GENEVA,CTR MED,INST SOCIAL & PREVENT MED,UNIV CASE POSTALE,CH-1211 GENEVA 4,SWITZERLAND.				AHRQ HHS [R03 HS 06978-01] Funding Source: Medline; NCRR NIH HHS [RR00035, 5MOIRR00722] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R03HS006978] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CIABATTONI G, 1984, NEW ENGL J MED, V310, P279, DOI 10.1056/NEJM198402023100502; DUBACH UC, 1991, NEW ENGL J MED, V324, P155, DOI 10.1056/NEJM199101173240304; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; MORLANS M, 1990, BRIT J CLIN PHARMACO, V30, P717, DOI 10.1111/j.1365-2125.1990.tb03841.x; MURRAY TG, 1983, ARCH INTERN MED, V143, P1687, DOI 10.1001/archinte.143.9.1687; NATH KA, 1992, AM J KIDNEY DIS, V20, P1; PERNEGER TV, 1993, AM J EPIDEMIOL, V138, P574, DOI 10.1093/oxfordjournals.aje.a116898; POMMER W, 1989, AM J NEPHROL, V9, P403, DOI 10.1159/000168002; SANDLER DP, 1989, NEW ENGL J MED, V320, P1238, DOI 10.1056/NEJM198905113201903; SANDLER DP, 1991, ANN INTERN MED, V115, P165, DOI 10.7326/0003-4819-115-3-165; SCHWARZ A, 1984, LANCET, V2, P1163; SPUHLER O, 1953, Z KLIN MED, V151, P1; STEWART J, 1993, ANALGESIC NSAID INDU; WHELTON A, 1990, ANN INTERN MED, V112, P568, DOI 10.7326/0003-4819-112-8-568; WILKINSON L, 1990, SYSTAT SYSTEM STATIS; 1993, USRDS1993 NAT I DIAB	17	353	367	1	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 22	1994	331	25					1675	1679		10.1056/NEJM199412223312502	http://dx.doi.org/10.1056/NEJM199412223312502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX382	7969358				2022-12-28	WOS:A1994PX38200002
J	FONG, IW				FONG, IW			HAIR LOSS ASSOCIATED WITH LAMIVUDINE	LANCET			English	Letter											FONG, IW (corresponding author), UNIV TORONTO,ST MICHAELS HOSP,DEPT MED,TORONTO M5B 1W8,ON,CANADA.							DANNER S, 1993, 11TH INT C AIDS BERL, P477; LEWIS L, 1993, 9TH INT C AIDS, P478; PLUDA J, 1993, 9TH INT C AIDS, P69; SOUDEYNS H, 1991, ANTIMICROB AGENTS CH, V35, P1386, DOI 10.1128/AAC.35.7.1386	4	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1702	1702		10.1016/S0140-6736(94)90483-9	http://dx.doi.org/10.1016/S0140-6736(94)90483-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996976				2022-12-28	WOS:A1994PX30200036
J	BALICEGORDON, RJ; LICHTMAN, JW				BALICEGORDON, RJ; LICHTMAN, JW			LONG-TERM SYNAPSE LESS INDUCED BY FOCAL BLOCKADE OF POSTSYNAPTIC RECEPTORS	NATURE			English	Article							DEVELOPING NEUROMUSCULAR-JUNCTIONS; ACETYLCHOLINE-RECEPTOR; INVIVO VISUALIZATION; NERVE-TERMINALS; SKELETAL-MUSCLE; RAT MUSCLE; ELIMINATION; MOUSE; INNERVATION; PROTEIN	Focal application in vivo of alpha-bungarotoxin to block neurotransmission in a small region of a neuromuscular junction causes long-lasting synapse elimination at that site. In contrast, blockade of neurotransmission throughout a junction does not cause synapse elimination. These and related experiments indicate that active synaptic sites can destabilize inactive synapses in their vicinity.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)				Balice-Gordon, Rita/0000-0002-9950-7965				BALICEGORDON RJ, 1990, J NEUROSCI, V10, P894; BALICEGORDON RJ, 1990, J NEUROSCI, V10, P2660; BALICEGORDON RJ, 1993, NEURON, V11, P801, DOI 10.1016/0896-6273(93)90110-D; BALICEGORDON RJ, 1993, J NEUROSCI, V13, P834; BENOIT P, 1978, BRAIN RES, V149, P89, DOI 10.1016/0006-8993(78)90589-9; BROWN MC, 1976, J PHYSIOL-LONDON, V261, P387, DOI 10.1113/jphysiol.1976.sp011565; Burke RE, 1994, MYOLOGY, P464; CALLAWAY EM, 1987, NATURE, V328, P422, DOI 10.1038/328422a0; CHEN LL, 1991, J NEUROSCI, V11, P2920; COLMAN H, 1993, DEV BIOL, V156, P1, DOI 10.1006/dbio.1993.1054; CORFAS G, 1993, P NATL ACAD SCI USA, V90, P1624, DOI 10.1073/pnas.90.4.1624; Culican S. M., 1993, Society for Neuroscience Abstracts, V19, P1294; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FRASER SE, 1982, CURR TOP DEV BIOL, V17, P77; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; HATA Y, 1994, SCIENCE, V265, P1732, DOI 10.1126/science.8085163; HENNEMAN E, 1957, SCIENCE, V126, P1345, DOI 10.1126/science.126.3287.1345; HERRERA AA, 1990, J NEUROCYTOL, V19, P85, DOI 10.1007/BF01188441; HILL RR, 1991, J NEUROCYTOL, V20, P165, DOI 10.1007/BF01186990; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041, DOI 10.1152/jn.1965.28.6.1041; LANGENFELDOSTER B, 1993, J NEUROCYTOL, V22, P517, DOI 10.1007/BF01189040; LEVITT TA, 1980, SCIENCE, V210, P550, DOI 10.1126/science.7423205; LICHTMAN JW, 1985, NATURE, V314, P357, DOI 10.1038/314357a0; LICHTMAN JW, 1987, J NEUROSCI, V7, P1215; LINGLE CJ, 1988, INT ANESTHESIOL CLIN, V26, P288, DOI 10.1097/00004311-198802640-00007; LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LUTHER PW, 1985, J CELL BIOL, V100, P235, DOI 10.1083/jcb.100.1.235; MA J, 1993, J BIOL CHEM, V288, P25108; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; OBRIEN RAD, 1984, NEUROSCIENCE, V12, P637, DOI 10.1016/0306-4522(84)90079-4; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; POO MM, 1985, ANNU REV NEUROSCI, V8, P369; REDFERN PA, 1970, J PHYSIOL-LONDON, V209, P701, DOI 10.1113/jphysiol.1970.sp009187; RIBCHESTER RR, 1988, J PHYSL, V40, P53; RICH M, 1989, NEURON, V3, P677, DOI 10.1016/0896-6273(89)90236-5; RICH MM, 1994, NEUROLOGY, V44, P2138, DOI 10.1212/WNL.44.11.2138; RICH MM, 1989, J NEUROSCI, V9, P1781, DOI 10.1523/jneurosci.09-05-01781.1989; RIDGE RMAP, 1984, J NEUROSCI, V4, P2614; SCOTT LJC, 1990, J NEUROSCI, V10, P346; SRIHARI T, 1978, J NEUROCYTOL, V7, P529, DOI 10.1007/BF01260887; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; THOMPSON W, 1983, NATURE, V302, P614, DOI 10.1038/302614a0; VANMIER P, 1994, J NEUROSCI, V14, P5672; WERNIG A, 1980, J NEUROCYTOL, V9, P277, DOI 10.1007/BF01181538; WIESEL TN, 1965, J NEUROPHYSIOL, V28, P1029, DOI 10.1152/jn.1965.28.6.1029; WIGSTON DJ, 1990, J NEUROSCI, V10, P1753; WIGSTON DJ, 1989, J NEUROSCI, V9, P639	49	223	224	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					519	524		10.1038/372519a0	http://dx.doi.org/10.1038/372519a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990923				2022-12-28	WOS:A1994PW08200043
J	YUN, MS; HO, PTP; LO, KY				YUN, MS; HO, PTP; LO, KY			A HIGH-RESOLUTION IMAGE OF ATOMIC-HYDROGEN IN THE M81 GROUP OF GALAXIES	NATURE			English	Article							NEUTRAL-HYDROGEN; KINEMATICS; NGC-3077	It has long been recognized that interactions between galaxies are important in determining their evolution. The distribution of gas-out of which new stars are formed-is strongly affected; in particular, gas may be concentrated near the nucleus, leading to a burst of star formation(1-4). Here we present a map of atomic hydrogen (H I) in the nearest interacting group of galaxies (that dominated by M81), obtained by combining 12 separate fields observed with the Very Large Array. The Hr that surrounds M81, M82 and NGC3077 (the most prominent galaxies in the group) is dominated by filamentary structures, clearly demonstrating the violent disruption of this system by tidal interactions. These observations should have detected all H I complexes more massive than 10(6) solar masses, meaning that our map contains all structures that might evolve into new dwarf galaxies.	CALTECH,PASADENA,CA 91125; UNIV ILLINOIS,DEPT ASTRON,URBANA,IL 61801	California Institute of Technology; University of Illinois System; University of Illinois Urbana-Champaign	YUN, MS (corresponding author), HARVARD SMITHSONIAN CTR ASTROPHYS,60 GARDEN ST,CAMBRIDGE,MA 02138, USA.		Ho, Paul/AAZ-5108-2020	Ho, Paul/0000-0002-3412-4306				APPLETON PN, 1988, MON NOT R ASTRON SOC, V234, P957, DOI 10.1093/mnras/234.4.957; APPLETON PN, 1981, MON NOT R ASTRON SOC, V195, P327, DOI 10.1093/mnras/195.2.327; ARP H, 1965, SCIENCE, V148, P363, DOI 10.1126/science.148.3668.363; BARBIERI C, 1974, ASTRON ASTROPHYS, V35, P463; Barnes J. E, 1988, APJ, V331, P669; BARNES JE, 1991, ASTROPHYS J, V370, pL65, DOI 10.1086/185978; BROUILLET N, 1992, ASTRON ASTROPHYS, V262, pL5; COTTRELL GA, 1977, MON NOT R ASTRON SOC, V178, P577, DOI 10.1093/mnras/178.4.577; COTTRELL GA, 1976, MON NOT R ASTRON SOC, V174, P455, DOI 10.1093/mnras/174.2.455; DEMOULIN M, 1960, ASTROPHYS J, V157, P81; FREEDMAN WL, 1994, ASTROPHYS J, V427, P628, DOI 10.1086/174172; GOTTESMAN ST, 1977, ASTROPHYS J, V211, P47, DOI 10.1086/154902; GOTTESMAN ST, 1975, ASTROPHYS J, V195, P23, DOI 10.1086/153301; HIBBARD JE, 1994, ASTRON J, V107, P67, DOI 10.1086/116835; KENT SM, 1987, ASTRON J, V93, P816, DOI 10.1086/114366; LIN CC, 1969, ASTROPHYS J, V155, P721, DOI 10.1086/149907; PEIMBERT M, 1981, ASTROPHYS J, V245, P845, DOI 10.1086/158860; PRICE JS, 1989, ASTROPHYS J, V337, P658, DOI 10.1086/167137; RIEKE GH, 1980, ASTROPHYS J, V238, P24, DOI 10.1086/157954; ROBERTS MS, 1972, EXTERNAL GALAXIES QU, P12; Rots A. H., 1980, Astronomy & Astrophysics Supplement Series, V41, P189; ROTS AH, 1975, ASTRON ASTROPHYS, V45, P25; ROTS AH, 1975, ASTRON ASTROPHYS, V45, P43; SANDERS DB, 1988, ASTROPHYS J, V325, P74, DOI 10.1086/165983; SCOVILLE N, 1991, P C MASSIVE STARS ST, P233; TOOMRE A, 1972, ASTROPHYS J, V178, P623, DOI 10.1086/151823; VANDERHULST JM, 1979, ASTRON ASTROPHYS, V75, P97; VISSER HCD, 1978, STRUCTURE PROPERTIES, P105; WISNIEWSKI WZ, 1968, ASTRON J, V73, P866, DOI 10.1086/110721; YUN MS, 1993, ASTROPHYS J, V411, pL17, DOI 10.1086/186901	30	404	406	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					530	532		10.1038/372530a0	http://dx.doi.org/10.1038/372530a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990925				2022-12-28	WOS:A1994PW08200045
J	WINKLER, WB; KARNIK, R; SLANY, J				WINKLER, WB; KARNIK, R; SLANY, J			TREATMENT OF EXUDATIVE FIBRINOUS PERICARDITIS WITH INTRAPERICARDIAL UROKINASE	LANCET			English	Note							INTRAPLEURAL STREPTOKINASE; EFFUSION	Three male patients with purulent pericarditis, in whom complete drainage could not be obtained by pericardiocentesis, were treated with transcatheter intrapericardial urokinase to prevent the development of chronic constrictive pericarditis. As shown by echocardiography, the intrapericardial fibrin layers disappeared in two cases and were,educed by more than half in the third. Effects on systemic coagulation indices and complications related to intrapericardial lysis were not observed.			WINKLER, WB (corresponding author), KRANKENANSTALT RUDOLFSTIFTUNG WIEN,DEPT INTERNAL MED 2,A-1030 VIENNA,AUSTRIA.							BERGLIN E, 1981, THORAC CARDIOVASC SU, V21, P265; COSELLI JS, 1984, AM J SURG, V148, P786, DOI 10.1016/0002-9610(84)90438-0; COUSER JI, 1992, CHEST, V101, P1467, DOI 10.1378/chest.101.5.1467; CROSS JH, 1989, BRIT HEART J, V62, P217; GODLEY PJ, 1984, CHEST, V86, P486, DOI 10.1378/chest.86.3.486; Lorell B.H., 1992, HEART DISEASE TXB CA, P1465; MOULTON JS, 1989, AM J ROENTGENOL, V153, P941, DOI 10.2214/ajr.153.5.941; ROSEN H, 1993, CHEST, V103, P1190, DOI 10.1378/chest.103.4.1190; SPANN JF, 1990, HEART, P2177; TILLETT WS, 1949, J CLIN INVEST, V28, P173, DOI 10.1172/JCI102046	10	34	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1541	1542		10.1016/S0140-6736(94)90352-2	http://dx.doi.org/10.1016/S0140-6736(94)90352-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983956				2022-12-28	WOS:A1994PV01700012
J	PAROUSH, Z; FINLEY, RL; KIDD, T; WAINWRIGHT, SM; INGHAM, PW; BRENT, R; ISHHOROWICZ, D				PAROUSH, Z; FINLEY, RL; KIDD, T; WAINWRIGHT, SM; INGHAM, PW; BRENT, R; ISHHOROWICZ, D			GROUCHO IS REQUIRED FOR DROSOPHILA NEUROGENESIS, SEGMENTATION, AND SEX DETERMINATION AND INTERACTS DIRECTLY WITH HAIRY-RELATED BHLH PROTEINS	CELL			English	Article							HELIX-LOOP-HELIX; RULE GENE-EXPRESSION; OF-SPLIT COMPLEX; PAN-NEURAL GENE; FUSHI-TARAZU; DETERMINATION SIGNAL; ACHAETE-SCUTE; DNA-BINDING; ZYGOTIC CONTROL; SHOWS HOMOLOGY	We have used the interaction trap, a yeast two-hybrid system, to identify proteins interacting with hairy, a basic-helix-loop-helix (bHLH) protein that represses transcription during Drosophila embryonic segmentation. We find that the groucho (gro) protein binds specifically to hairy and also to hairy-related bHLH proteins encoded by deadpan and the Enhancer of split complex. The C-terminal WRPW motif present in all these bHLH proteins is essential for this interaction. We demonstrate that these associations reflect in vivo maternal requirements for gro during neurogenesis, segmentation, and sex determination, three processes regulated by the above bHLH proteins, and we propose that gro is a transcriptional corepressor recruited to specific target promoters by hairy-related bHLH proteins.	UNIV OXFORD,DEPT ZOOL,IMPERIAL CANC RES FUND,DEV BIOL UNIT,DEV GENET LAB,OXFORD OX1 3PS,ENGLAND; UNIV OXFORD,DEPT ZOOL,IMPERIAL CANC RES FUND,DEV BIOL UNIT,MOLEC EMBRYOL LAB,OXFORD OX1 3PS,ENGLAND; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114	University of Oxford; University of Oxford; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Ingham, Philip William/AAH-5884-2020; Kidd, Thomas/AAT-9993-2020; Ingham, Philip W/E-6710-2010; Ingham, Philip W/G-9903-2011	Ingham, Philip William/0000-0001-8224-9958; Ingham, Philip W/0000-0001-8224-9958; Finley, Russ/0000-0003-1144-6887; Ish-Horowicz, David/0000-0001-5684-7129; Kidd, Thomas/0000-0001-7190-4208				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIER E, 1992, GENE DEV, V6, P2137, DOI 10.1101/gad.6.11.2137; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; Campos-Ortega Jose A., 1993, P1091; CARROLL SB, 1986, CELL, V45, P113, DOI 10.1016/0092-8674(86)90543-X; CARROLL SB, 1989, DEVELOPMENT, V107, P673; CLINE TW, 1988, GENETICS, V119, P829; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DELIDAKIS C, 1992, P NATL ACAD SCI USA, V89, P8731, DOI 10.1073/pnas.89.18.8731; DELIDAKIS C, 1991, GENETICS, V129, P803; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY RL, 1994, IN PRESS GENE PROBES; FORBES Z, 1993, ESSENTIAL DEV BIOL P, P3; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; GARRELL J, 1991, BIOESSAYS, V13, P493, DOI 10.1002/bies.950131002; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; Howard K, 1990, Semin Cell Biol, V1, P161; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1986, EMBO J, V5, P1659, DOI 10.1002/j.1460-2075.1986.tb04409.x; INGHAM PW, 1985, GENETICS, V111, P643; ISHHOROWICZ D, 1987, CELL, V51, P405, DOI 10.1016/0092-8674(87)90636-2; ISHHOROWICZ D, 1989, CELL, V57, P223, DOI 10.1016/0092-8674(89)90960-4; JACKLE H, 1992, J CELL SCI S, V16, pS39; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KNUST E, 1992, GENETICS, V132, P505; KRAUSE HM, 1988, GENE DEV, V2, P1021, DOI 10.1101/gad.2.8.1021; LAWRENCE PA, 1989, DEVELOPMENT, V107, P847; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; MANOUKIAN AS, 1992, GENE DEV, V6, P1740, DOI 10.1101/gad.6.9.1740; MARTINEZ C, 1993, MOL CELL BIOL, V13, P3514, DOI 10.1128/MCB.13.6.3514; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PARKHURST SM, 1994, SCIENCE, V264, P924, DOI 10.1126/science.8178152; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PARKHURST SM, 1993, DEVELOPMENT, V117, P737; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; Sambrook J, 1989, MOL CLONING LABORATO; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SCHRONS H, 1992, GENETICS, V132, P481; SMITH DB, 1988, GENE AMST, V76, P31; SOMMER RJ, 1993, NATURE, V361, P448, DOI 10.1038/361448a0; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; TIETZE K, 1992, P NATL ACAD SCI USA, V89, P6152, DOI 10.1073/pnas.89.13.6152; TORRES M, 1989, EMBO J, V8, P3079, DOI 10.1002/j.1460-2075.1989.tb08459.x; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VAVRA SH, 1989, DEVELOPMENT, V107, P663; WAINWRIGHT SM, 1992, MOL CELL BIOL, V12, P2475, DOI 10.1128/MCB.12.6.2475; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Wieschaus E., 1986, P199; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YOUNGERSHEPHERD S, 1992, CELL, V70, P911, DOI 10.1016/0092-8674(92)90242-5	72	503	518	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 2	1994	79	5					805	815		10.1016/0092-8674(94)90070-1	http://dx.doi.org/10.1016/0092-8674(94)90070-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001118				2022-12-28	WOS:A1994PW05400008
J	RUETER, P; RABUS, R; WILKES, H; AECKERSBERG, F; RAINEY, FA; JANNASCH, HW; WIDDEL, F				RUETER, P; RABUS, R; WILKES, H; AECKERSBERG, F; RAINEY, FA; JANNASCH, HW; WIDDEL, F			ANAEROBIC OXIDATION OF HYDROCARBONS IN CRUDE-OIL BY NEW TYPES OF SULFATE-REDUCING BACTERIA	NATURE			English	Article							HYDROTHERMAL VENT SITE; 16S RDNA ANALYSIS; MICROBIAL-DEGRADATION; GUAYMAS BASIN; NORTH-SEA; SULFATE; PETROLEUM; TOLUENE; SEDIMENTS	MANY crude oil constituents are biodegradable in the presence of oxygen; however, a substantial anaerobic degradation has never been demonstrated(1,2). An unusually low content of n-alkanes in oils of certain deposits is commonly attributed to selective utilization of these hydrocarbons by aerobic microorganisms(3,4). On the other hand, oil wells and production fluids were shown to harbour anaerobic sulphate-reducing bacteria(5-8), but their actual electron donors and carbon sources were unknown. On the basis of nutritional properties of various bacterial isolates it was assumed that fatty acids and H-2 are potential electron donors for sulphate reduction in situ(5-8). Here we demonstrate that hydrocarbons in crude oil are used directly by sulphate-reducing bacteria growing under strictly anoxic conditions. A moderately thermophilic pure culture selectively utilizes n-alkanes in oil for sulphate reduction to sulphide. In addition, a mesophilic sulphate-reducing enrichment culture is shown to oxidize alkylbenzenes in oil. Thus, sulphate-reducing bacteria utilizing aliphatic and aromatic hydrocarbons as electron donors may present a significant source of sulphide in oil deposits and oil production plants.	MAX PLANCK INST MARINE MIKROBIOL, D-28359 BREMEN, GERMANY; FORSCHUNGSZENTRUM JULICH, FORSCHUNGSZENTRUM, INST ERDOL & ORGAN GEOCHEM ICG4, D-52428 JULICH, GERMANY; DEUTSCH SAMMLUNG MIKROORGANISMEN & ZELLKULTUREN, D-38124 BRAUNSCHWEIG, GERMANY; WOODS HOLE OCEANOG INST, WOODS HOLE, MA 02543 USA	Max Planck Society; Helmholtz Association; Research Center Julich; Leibniz Institut fur Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); Woods Hole Oceanographic Institution			Abu Laban, Nidal/E-5809-2011; Rainey, Fred A/C-8767-2013; Rainey, Fred/AAG-7996-2019	Rainey, Fred A/0000-0001-9129-6844; 				AECKERSBERG F, 1991, ARCH MICROBIOL, V156, P5, DOI 10.1007/BF00418180; ATLAS RM, 1981, MICROBIOL REV, V45, P180, DOI 10.1128/MMBR.45.1.180-209.1981; Balows A., 1992, PROKARYOTES, P3352, DOI [10.1007/978-1-4757-2191-1_21, DOI 10.1007/978-1-4757-2191-1_]; BAZYLINSKI DA, 1989, APPL ENVIRON MICROB, V55, P2832, DOI 10.1128/AEM.55.11.2832-2836.1989; BAZYLINSKI DA, 1988, ORG GEOCHEM, V12, P547, DOI 10.1016/0146-6380(88)90146-5; BELLER HR, 1992, APPL ENVIRON MICROB, V58, P786, DOI 10.1128/AEM.58.3.786-793.1992; Blanc Ph., 1993, APPL PETROLEUM GEOCH, P151; CORDRUWISCH R, 1987, J PETROL TECHNOL, V39, P97, DOI 10.2118/13554-PA; DESOETE G, 1983, PSYCHOMETRIKA, V48, P621, DOI 10.1007/BF02293884; EDWARDS EA, 1992, APPL ENVIRON MICROB, V58, P794, DOI 10.1128/AEM.58.3.794-800.1992; JORGENSEN BB, 1992, SCIENCE, V258, P1756, DOI 10.1126/science.258.5089.1756; Jukes T.H., 1969, MAMMALIAN PROTEIN ME; LEAHY JG, 1990, MICROBIOL REV, V54, P305, DOI 10.1128/MMBR.54.3.305-315.1990; NAZINA TN, 1985, GEOMICROBIOL J, V4, P103, DOI 10.1080/01490458509385927; NIELSEN H, 1991, SCOPE, V43, P65; ORR WL, 1974, AAPG BULL, V58, P2295; Postgate JR, 1984, SULPHATE REDUCING BA, V2nd; RABUS R, 1993, APPL ENVIRON MICROB, V59, P1444, DOI 10.1128/AEM.59.5.1444-1451.1993; RADKE M, 1980, ANAL CHEM, V52, P406, DOI 10.1021/ac50053a009; RAINEY FA, 1993, FEMS MICROBIOL LETT, V113, P125, DOI 10.1111/j.1574-6968.1993.tb06501.x; RAINEY FA, 1992, SYST APPL MICROBIOL, V15, P197, DOI 10.1016/S0723-2020(11)80092-5; ROSNES JT, 1991, APPL ENVIRON MICROB, V57, P2302, DOI 10.1128/AEM.57.8.2302-2307.1991; Schidlowski M., 1983, P149; SIMONEIT BRT, 1982, NATURE, V295, P198, DOI 10.1038/295198a0; STETTER KO, 1993, NATURE, V365, P743, DOI 10.1038/365743a0; Tissot B.P., 1984, PETROLEUM FORMATION, DOI 10.1007/978-3-642-96446-6	26	342	368	1	113	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					455	458		10.1038/372455a0	http://dx.doi.org/10.1038/372455a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984238				2022-12-28	WOS:A1994PV01200054
J	SMITH, ML; CHEN, IT; ZHAN, QM; BAE, IS; CHEN, CY; GILMER, TM; KASTAN, MB; OCONNOR, PM; FORNACE, AJ				SMITH, ML; CHEN, IT; ZHAN, QM; BAE, IS; CHEN, CY; GILMER, TM; KASTAN, MB; OCONNOR, PM; FORNACE, AJ			INTERACTION OF THE P53-REGULATED PROTEIN GADD45 WITH PROLIFERATING CELL NUCLEAR ANTIGEN	SCIENCE			English	Article							CYCLIN-DEPENDENT KINASES; DNA-REPLICATION; EXCISION REPAIR; P53; PCNA	GADD45 is a ubiquitously expressed mammalian gene that is induced by DNA damage and certain other stresses. Like another p53-regulated gene, p21(WAF1/CIP1), whose product binds to cyclin-dependent kinases (Cdk's) and proliferating cell nuclear antigen (PCNA), GADD45 has been associated with growth suppression. Gadd45 was found to bind to PCNA, a normal component of Cdk complexes and a protein involved in DNA replication and repair. Gadd45 stimulated DNA excision repair in vitro and inhibited entry of cells into S phase. These results establish GADD45 as a link between the p53-dependent cell cycle checkpoint and DNA repair.	NCI, DEV THERAPEUT PROGRAM, MOLEC PHARMACOL LAB, BETHESDA, MD 20892 USA; JOHNS HOPKINS UNIV, CTR ONCOL, BALTIMORE, MD 21287 USA; GLAXO INC, RES INST, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; Johns Hopkins Medicine; GlaxoSmithKline			Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005777, R37ES005777] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05777] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KILPATRICK KE, IN PRESS J BIOL CHEM; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; MICHIELI P, 1994, CANCER RES, V54, P3391; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PROTIC M, 1988, SOMAT CELL MOLEC GEN, V14, P351, DOI 10.1007/BF01534643; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WASEEM NH, 1990, J CELL SCI, V96, P121; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YOON K, 1988, GENE, V66, P11, DOI 10.1016/0378-1119(88)90220-X; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	26	911	942	2	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 25	1994	266	5189					1376	1380		10.1126/science.7973727	http://dx.doi.org/10.1126/science.7973727			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973727	Green Submitted			2022-12-28	WOS:A1994PT63200042
J	FICKER, E; TAGLIALATELA, M; WIBLE, BA; HENLEY, CM; BROWN, AM				FICKER, E; TAGLIALATELA, M; WIBLE, BA; HENLEY, CM; BROWN, AM			SPERMINE AND SPERMIDINE AS GATING MOLECULES FOR INWARD RECTIFIER K+ CHANNELS	SCIENCE			English	Article							RECTIFYING POTASSIUM CURRENT; INTERNAL MG-2+; CELLS; RECTIFICATION; EXPRESSION; POLYAMINES; MYOCYTES; HEART; BLOCK	Inward rectifier K+ channels pass prominent inward currents, while outward currents are largely blocked. The inward rectification is due to block by intracellular Mg2+ and a Mg2+-independent process described as intrinsic gating. The rapid loss of gating upon patch excision suggests that cytoplasmic factors participate in gating. ''intrinsic'' gating can be restored in excised patches by nanomolar concentrations of two naturally occurring polyamines, spermine and spermidine. Spermine and spermidine may function as physiological blockers of inward rectifier K+ channels and ''intrinsic'' gating may largely reflect voltage-dependent block by these cations.	CASE WESTERN RESERVE UNIV,METRO HLTH SYST,RAMMELKAMP CTR,CLEVELAND,OH 44109; CASE WESTERN RESERVE UNIV,DEPT PHYSIOL,CLEVELAND,OH 44109; BAYLOR COLL MED,DEPT PHYSIOL & MOLEC BIOPHYS,HOUSTON,TX 77030; UNIV NAPLES FEDERICO II,SCH MED 2,DEPT NEUROSCI,PHARMACOL SECT,I-80121 NAPLES,ITALY; BAYLOR COLL MED,DEPT OTORHINOLARYNGOL,HOUSTON,TX 77030	Case Western Reserve University; MetroHealth System; Case Western Reserve University; Baylor College of Medicine; University of Naples Federico II; Baylor College of Medicine			Taglialatela, Maurizio/A-2062-2019; Taglialatela, Maurizio/ABH-4262-2020; Taglialatela, Maurizio/K-1840-2013; Taglialatela, Maurizio/AAB-8621-2022	Taglialatela, Maurizio/0000-0002-8202-0560; Taglialatela, Maurizio/0000-0002-8202-0560	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037044, R01HL036930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37044, HL36930] Funding Source: Medline; NINDS NIH HHS [NS23877] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDRICH R, 1993, NATURE, V362, P107, DOI 10.1038/362107a0; ANUMONWO JMB, 1991, CARDIOVASC DRUG REV, V9, P299, DOI 10.1111/j.1527-3466.1991.tb00418.x; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BROCK M, 1994, HEARING RES, V72, P37, DOI 10.1016/0378-5955(94)90203-8; BROWN ND, 1982, J CHROMATOGR, V245, P101, DOI 10.1016/S0021-9673(00)82479-6; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HARVEY RD, 1988, J GEN PHYSIOL, V91, P593, DOI 10.1085/jgp.91.4.593; HILGEMANN DW, 1989, PFLUG ARCH EUR J PHY, V415, P247, DOI 10.1007/BF00370601; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LOPATIN AN, 1994, J PHYSIOL-LONDON, V477P, pP86; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; PEGG AE, 1988, CANCER RES, V48, P759; SCOTT RH, 1993, TRENDS NEUROSCI, V16, P153, DOI 10.1016/0166-2236(93)90124-5; SHIMONI Y, 1992, J PHYSIOL-LONDON, V448, P709, DOI 10.1113/jphysiol.1992.sp019066; SILVER MR, 1990, J GEN PHYSIOL, V96, P109, DOI 10.1085/jgp.96.1.109; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; USHERWOOD PNR, 1991, PHARMACOL THERAPEUT, V52, P245, DOI 10.1016/0163-7258(91)90012-B; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WEIGER T, 1994, J MEMBRANE BIOL, V140, P133; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; WILLIAMS K, 1991, LIFE SCI, V48, P469, DOI 10.1016/0024-3205(91)90463-L	30	463	467	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1068	1072		10.1126/science.7973666	http://dx.doi.org/10.1126/science.7973666			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973666				2022-12-28	WOS:A1994PQ92400053
J	GIFFORD, DK				GIFFORD, DK			ON THE PATH TO COMPUTATION WITH DNA	SCIENCE			English	Editorial Material											GIFFORD, DK (corresponding author), MIT,DEPT ELECT ENGN & COMP SCI,CAMBRIDGE,MA 02139, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; Garey M.R., 1979, COMPUTERS INTRACTABI; Minsky M., 1967, COMPUTATION FINITE I	3	23	30	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					993	994		10.1126/science.7973681	http://dx.doi.org/10.1126/science.7973681			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973681				2022-12-28	WOS:A1994PQ92400028
J	POCOCK, SJ; SMITH, M; BAGHURST, P				POCOCK, SJ; SMITH, M; BAGHURST, P			ENVIRONMENTAL LEAD AND CHILDRENS INTELLIGENCE - A SYSTEMATIC REVIEW OF THE EPIDEMIOLOGIC EVIDENCE	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-LEAD; SCHOOL POPULATION; DENTIN LEAD; EXPOSURE; PERFORMANCE; ATTAINMENT; BEHAVIOR; IQ; ABILITY; COHORT	Objective-To quantify the magnitude of the relation between full scale IQ in children aged 5 or more and their body burden of lead. Design-A systematic review of 26 epidemiological studies since 1979: prospective studies of birth cohorts, cross sectional studies of blood lead, and cross sectional studies of tooth lead. Setting-General populations of children greater than or equal to 5 years. Main outcome measures-For each study, the regression coefficient of IQ on lead, after adjustment for confounders when possible, was used to derive the estimated change in IQ for a specific doubling of either blood or tooth lead. Results-The five prospective studies with over 1100 children showed no association of cord blood lead or antenatal maternal blood lead with subsequent IQ. Blood lead at around age 2 had a small and significant inverse association with IQ, somewhat greater than that for mean blood lead over the preschool years. The 14 cross sectional studies of blood lead with 3499 children showed a significant inverse association overall, but showed more variation in their results and their ability to allow for confounders. The seven cross sectional studies of tooth lead with 2095 children were more consistent in finding an inverse association, although the estimated:magnitude was somewhat smaller. Overall synthesis of this evidence, including a meta-analysis, indicates that a typical doubling of body lead burden (from 10 to 20 mu g/dl (0.48 to 0.97 mu mol/l) blood lead or from 5 to 10 mu g/g tooth lead) is associated with a mean deficit in full scale IQ of around 1-2 IQ points. Conclusion-While low level lead exposure may cause a small IQ deficit, other explanations need considering: are the published studies representative; is there inadequate allowance for confounders; are there selection biases in recruiting and following children; and do children of lower IQ adopt behaviour which makes them more prone to lead uptake (reverse causality)? Even if moderate increases in body lead burden adversely affect IQ, a threshold below which there is negligible influence cannot currently be determined. Because of these uncertainties, the degree of public health priority that should be devoted to detecting and reducing moderate increases in children's blood lead, compared with other important social detriments that impede children's development, needs careful consideration.	W LONDON INST HIGHER EDUC,THOMAS CORAM RES UNIT,LONDON WC1H 0AA,ENGLAND; CSIRO,DIV HUMAN NUTR,ADELAIDE,SA 5000,AUSTRALIA	Brunel University; University of London; University College London; UCL Institute of Education; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	POCOCK, SJ (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,MED STAT UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.							BAGHURST PA, 1992, NEW ENGL J MED, V327, P1279, DOI 10.1056/NEJM199210293271805; BELLINGER D, 1989, INT J EPIDEMIOL, V18, P180, DOI 10.1093/ije/18.1.180; BELLINGER DC, 1992, PEDIATRICS, V90, P855; BERGOMI M, 1989, DEV MED CHILD NEUROL, V31, P181; BRADLEY RH, 1979, AM J MENT DEF, V84, P235; COONEY G, 1991, HEAVY METALS ENV, P16; DIETRICH KN, 1993, NEUROTOXICOL TERATOL, V15, P37, DOI 10.1016/0892-0362(93)90043-N; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; ERNHART CB, 1989, NEUROTOXICOL TERATOL, V11, P161, DOI 10.1016/0892-0362(89)90055-X; FERGUSSON DM, 1988, J CHILD PSYCHOL PSYC, V29, P793, DOI 10.1111/j.1469-7610.1988.tb00754.x; FULTON M, 1987, LANCET, V1, P1221; Fulton M., 1989, HEAVY METALS ENV, V2, P68; GRANDJEAN P, 1986, J TOXICOL ENV HEALTH, V19, P437, DOI 10.1080/15287398609530941; GRANT LD, 1989, LEAD EXPOSURE AND CHILD DEVELOPMENT, P49; HARVEY PG, 1988, BRIT J DEV PSYCHOL, V6, P145, DOI 10.1111/j.2044-835X.1988.tb01089.x; HATZAKIS A, 1989, LEAD EXPOSURE AND CHILD DEVELOPMENT, P211; LANSDOWN R, 1986, INT ARCH OCC ENV HEA, V57, P225, DOI 10.1007/BF00405790; MCMICHAEL A, 1994, IN PRESS AM J EPIDEM; NEEDLEMAN HL, 1985, SCIENCE, V227, P701, DOI 10.1126/science.227.4688.701-a; NEEDLEMAN HL, 1990, JAMA-J AM MED ASSOC, V263, P673, DOI 10.1001/jama.263.5.673; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; NEEDLEMAN HL, 1991, ANNU REV PUBL HEALTH, V12, P111, DOI 10.1146/annurev.pu.12.050191.000551; POCOCK SJ, 1987, INT J EPIDEMIOL, V16, P57, DOI 10.1093/ije/16.1.57; POCOCK SJ, 1985, STATISTICIAN, V35, P31; RUBIN RA, 1979, DEV PSYCHOL, V15, P225, DOI 10.1037/0012-1649.15.2.225; SCHWARTZ J, 1994, ENVIRON RES, V65, P42, DOI 10.1006/enrs.1994.1020; SILVA PA, 1988, J CHILD PSYCHOL PSYC, V29, P43, DOI 10.1111/j.1469-7610.1988.tb00687.x; SMITH M, 1989, LEAD EXPOSURE AND CHILD DEVELOPMENT, P3; SMITH RE, 1983, SOIL SCI SOC AM J, V47, P1; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; THOMPSON SG, 1991, LANCET, V338, P1127, DOI 10.1016/0140-6736(91)91975-Z; WANG T, 1989, BIOMED ENVIRON SCI, V2, P325; WINNEKE G, 1983, INT ARCH OCC ENV HEA, V51, P231, DOI 10.1007/BF00377755; WINNEKE G, 1985, ENVIRON RES, V38, P155, DOI 10.1016/0013-9351(85)90081-7; WINNEKE G, 1990, NEUROTOXICOL TERATOL, V12, P553, DOI 10.1016/0892-0362(90)90022-5; YULE W, 1981, DEV MED CHILD NEUROL, V23, P567; 1988, NEUROPSYCHOLOGICAL E; [No title captured]	38	290	307	1	21	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 5	1994	309	6963					1189	1197		10.1136/bmj.309.6963.1189	http://dx.doi.org/10.1136/bmj.309.6963.1189			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PQ662	7987149	Green Published			2022-12-28	WOS:A1994PQ66200018
J	PUVACIC, Z; WEINBERG, J				PUVACIC, Z; WEINBERG, J			IMPACT OF WAR ON INFECTIOUS-DISEASE IN BOSNIA-HERZEGOVINA	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH		REPUBL INST PUBL HLTH, DEPT EPIDEMIOL, SARAJEVO, BOSNIA & HERCEG; WHO, HLTH MONITORING UNIT, ZAGREB AREA OFF, ZAGREB, CROATIA	World Health Organization								ARMENIAN HK, 1986, AM J EPIDEMIOL, V124, P28, DOI 10.1093/oxfordjournals.aje.a114367; SHEARS P, 1987, BMJ-BRIT MED J, V295, P314, DOI 10.1136/bmj.295.6593.314; TOOLE MJ, 1993, LANCET, V341, P1193, DOI 10.1016/0140-6736(93)91013-C; 1990, LANCET, V336, P845; 1993, MMWR-MORBID MORTAL W, V42, P973	5	4	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	1994	309	6963					1207	1208		10.1136/bmj.309.6963.1207	http://dx.doi.org/10.1136/bmj.309.6963.1207			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ662	7987152	Green Published			2022-12-28	WOS:A1994PQ66200022
J	LEUFKENS, H; HAAIJER-RUSKAMP, FM; BAKKER, A; DUKES, G				LEUFKENS, H; HAAIJER-RUSKAMP, FM; BAKKER, A; DUKES, G			SCENARIO ANALYSIS OF THE FUTURE OF MEDICINES	BRITISH MEDICAL JOURNAL			English	Article							DRUGS	Planning future policy for medicines poses difficult problems. The main players in the drug business have their own views as to how the world around them functions and how the future of medicines should be shaped. In this paper we show how a scenario analysis can provide a powerful teaching device to readjust peoples' preconceptions. Scenarios are plausible, not probable or preferable, portraits of alternative futures. A series of four of alternative scenarios were constructed: ''sobriety in sufficiency,'' ''risk avoidance,'' ''technology on demand,'' and ''free market unfettered.'' Each scenario was drawn as a narrative, documented quantitatively wherever possible, that described the world as it might be if particular trends were to dominate development. The medical community and health policy makers may use scenarios to take a long term view in order to be prepared adequately for the future.	UNIV GRONINGEN, INST DRUG STUDIES, 9713 AV GRONINGEN, NETHERLANDS; WORLD BANK, DEPT PHN PHARMACEUT, WASHINGTON, DC 20433 USA	University of Groningen; The World Bank	LEUFKENS, H (corresponding author), UNIV UTRECHT, DEPT PHARMACOEPIDEMIOL & PHARMACOTHERAPY, POB 80082, 3508 TB UTRECHT, NETHERLANDS.		Bakker, Arnold B./F-8494-2010	Bakker, Arnold B./0000-0003-1489-1847				Dukes M N G., 1993, WHO REGIONAL PUBLICA, V45; DUKES MNG, 1991, POSTMARKETING SURVEI, V5, P231; FOLB PI, 1993, LANCET, V342, P294, DOI 10.1016/0140-6736(93)91829-B; GILLEY J, 1994, BRIT MED J, V308, P731, DOI 10.1136/bmj.308.6931.731; GRABOWSKI H, 1991, 1991 CMR ANN LECT CA; GRIFFIN MT, 1991, AM J LAW MED, V17, P363; LEUFKENS HGM, 1993, LANCET, V342, P1178; RAY WA, 1993, NEW ENGL J MED, V329, P2029, DOI 10.1056/NEJM199312303292710; Schwartz P., 1991, ART LONG VIEW; TAYLOR D, 1992, BRIT MED J, V304, P239, DOI 10.1136/bmj.304.6821.239; WACK P, 1985, HARVARD BUS REV, V63, P139; YOUNG FE, 1993, CANCER, V72, P2854, DOI 10.1002/1097-0142(19931101)72:9+<2854::AID-CNCR2820721517>3.0.CO;2-2; [No title captured]	13	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1994	309	6962					1137	1140		10.1136/bmj.309.6962.1137	http://dx.doi.org/10.1136/bmj.309.6962.1137			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987110	Green Published			2022-12-28	WOS:A1994PP69100028
J	MIKKILINENI, RS; FLORES, D				MIKKILINENI, RS; FLORES, D			FUNGUS BALL	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											MIKKILINENI, RS (corresponding author), JERSEY CITY MED CTR,JERSEY CITY,NJ 07304, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 12	1995	332	2					91	91		10.1056/NEJM199501123320205	http://dx.doi.org/10.1056/NEJM199501123320205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA241	7990906				2022-12-28	WOS:A1995QA24100005
J	CLARK, JG; MILBERG, JA; STEINBERG, KP; HUDSON, LD				CLARK, JG; MILBERG, JA; STEINBERG, KP; HUDSON, LD			TYPE-III PROCOLLAGEN PEPTIDE IN THE ADULT-RESPIRATORY-DISTRESS-SYNDROME - ASSOCIATION OF INCREASED PEPTIDE LEVELS IN BRONCHOALVEOLAR LAVAGE FLUID WITH INCREASED RISK FOR DEATH	ANNALS OF INTERNAL MEDICINE			English	Article						RESPIRATORY DISTRESS SYNDROME, ADULT; PROCOLLAGEN; PEPTIDES; RISK; OUTCOME ASSESSMENT (HEALTH CARE)	PULMONARY FIBROSIS; SERUM CONCENTRATIONS; COLLAGEN; SARCOIDOSIS; FAILURE; MARKERS; INJURY	Objective: To determine whether bronchoalveolar lavage fluid levels of the N-terminal peptide of type III procollagen (procollagen III) are increased in patients with the adult respiratory distress syndrome and, if so, whether increased procollagen III levels in lavage fluid are associated with increased fatality rates. Design: Prospective cohort study. Setting: Intensive care units of a tertiary care hospital affiliated with a medical school. Patients: 117 consecutive patients with the adult respiratory distress syndrome prospectively identified on admission; 6 healthy volunteers served as controls. Measurements: Bronchoalveolar lavage fluid procollagen III levels in 117 patients at 3, 7, and 14 days after onset of the adult respiratory distress syndrome (total of 196 ravage samples). Results: The median procollagen III level was 1.75 U/mL (range, 0 to 13.4 U/mL) in lavage fluid obtained from patients with the adult respiratory distress syndrome. We detected procollagen III levels in lavage fluid from 80% of patients (94 of 117) but not in 6 normal volunteers. The overall fatality rate was 41% (48 of 117 patients). In a univariate analysis, the relative risk (RR) for death was increased in patients with procollagen Ill levels of 1.75 U/mL or more obtained on day 3 (RR, 2.4; 95% Cl, 1.3 to 4.3), day 7 (RR, 2.7; Cl, 1.4 to 5.4), and day 14 (RR, 2.7; Cl, 1.1 to 6.3). Inclusion of other variables in a multivariate model only minimally decreased the risk associated with increased procollagen ill levels. Conclusion: Increased levels of type III procollagen in bronchoalveolar lavage fluid are frequently detected in patients with the adult respiratory distress syndrome and are strongly associated with increased risk for fatal outcome independent of other variables related to fatality in patients with the syndrome.	UNIV WASHINGTON, HARBORVIEW MED CTR, SCH MED, DIV PULM & CRIT CARE MED, SEATTLE, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle	CLARK, JG (corresponding author), FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, M677, SEATTLE, WA 98104 USA.				NHLBI NIH HHS [HL-30542] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL030542] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMITAGE P, 1987, STATISTICAL METHOD M, P412; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BITTERMAN PB, 1992, AM J MED, V92, pS39, DOI 10.1016/0002-9343(92)90606-C; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P142; CLARK JG, 1983, INT REV CONNECT TISS, V10, P249; COLLINS JF, 1984, CHEST, V85, P641, DOI 10.1378/chest.85.5.641; CROUCH E, 1990, AM J PHYSIOL, V259, pL159, DOI 10.1152/ajplung.1990.259.4.L159; ENTZIAN P, 1990, AM REV RESPIR DIS, V142, P1079, DOI 10.1164/ajrccm/142.5.1079; FARJANEL J, 1993, AM REV RESPIR DIS, V147, P1091, DOI 10.1164/ajrccm/147.5.1091; HASSELBALCH H, 1986, AM J HEMATOL, V23, P101, DOI 10.1002/ajh.2830230204; HAUKIPURO K, 1990, SURGERY, V107, P381; KIRK JME, 1984, THORAX, V39, P726, DOI 10.1136/thx.39.10.726; LAMY M, 1976, AM REV RESPIR DIS, V114, P267; LOW RB, 1983, LAB INVEST, V48, P755; LOW RB, 1992, AM REV RESPIR DIS, V146, P701, DOI 10.1164/ajrccm/146.3.701; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MEDURI GU, 1991, CHEST, V100, P943, DOI 10.1378/chest.100.4.943; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; NOWACK H, 1976, EUR J BIOCHEM, V70, P205, DOI 10.1111/j.1432-1033.1976.tb10971.x; PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2; POHL WR, 1992, AM REV RESPIR DIS, V145, P412, DOI 10.1164/ajrccm/145.2_Pt_1.412; RAEDSCH R, 1983, GASTROENTEROLOGY, V85, P1265; RAGHU G, 1985, AM REV RESPIR DIS, V131, P281, DOI 10.1164/ajrccm/138.3.703; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P172; SELVIN P, 1991, STATISTICAL ANAL EPI, P214; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUTHERLAND KR, 1994, IN PRESS AM J RESPIR; WAYDHAS C, 1993, CRIT CARE MED, V21, P240, DOI 10.1097/00003246-199302000-00016; ZAPOL WM, 1979, AM REV RESPIR DIS, V119, P547	30	168	172	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1995	122	1					17	23		10.7326/0003-4819-122-1-199501010-00003	http://dx.doi.org/10.7326/0003-4819-122-1-199501010-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY502	7985891				2022-12-28	WOS:A1995PY50200003
J	MULROW, CD; CORNELL, JA; HERRERA, CR; KADRI, A; FARNETT, L; AGUILAR, C				MULROW, CD; CORNELL, JA; HERRERA, CR; KADRI, A; FARNETT, L; AGUILAR, C			HYPERTENSION IN THE ELDERLY - IMPLICATIONS AND GENERALIZABILITY OF RANDOMIZED TRIALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY-HEART-DISEASE; BLOOD-PRESSURE; SYSTOLIC HYPERTENSION; MILD HYPERTENSION; RISK-FACTORS; MANAGEMENT; MORBIDITY; MORTALITY; PREVALENCE; THERAPY	Objective.-To estimate morbidity and mortality benefits of drug therapy for hypertensive elderly subjects, compare these benefits with effects in younger subjects, and provide a framework for generalizing results derived from trials to actual patients. Data Sources.-A literature search using MEDLINE from 1966 to 1993, references from reviews and trial articles, and experts. Study Selection.-Randomized trials lasting at least 1 year that evaluated effects of drug treatment on morbidity and mortality outcomes in hypertensive persons. Data Extraction.-Four independent reviewers appraised protocol characteristics and quality of selected trials. Data Synthesis.-There were 13 trials involving 16 564 elderly persons (age 60 years and older). The prevalence of cardiovascular risk factors, cardiovascular disease, and competing comorbid diseases was lower among trial participants than the general population of hypertensive elderly persons. When the six large high-quality trials were combined, trial results showed 43 subjects (95% confidence interval [CI], 31 to 69) and 61 subjects (95% CI, 39 to 141) needed to be treated for 5 years to prevent one cerebrovascular event and one coronary heart disease event, respectively. Including the other seven trials did not change the results significantly. Only 18 subjects (95% CI, 14 to 25) needed to be treated to prevent one cardiovascular event (cerebrovascular or cardiac). Twelve trials in primarily younger and middle-aged adults involved approximately 33 000 persons. For all outcomes except cardiac mortality, two to four times as many of the younger subjects as the older subjects needed to be treated for 5 years to prevent morbid and mortal events. No significant effect on cardiac mortality was seen among younger subjects, while 78 older subjects (95% CI, 50 to 180) needed to be treated to prevent a fatal cardiac event. Conclusions.-Randomized trials demonstrate that treating healthy older persons with hypertension is highly efficacious. Five-year morbidity and mortality benefits derived from trials are greater for older than younger subjects. Extrapolating benefits from trials to individual patients is difficult, but should take into account multiple issues including the patient's risk factors, preexisting cardiovascular disease, and competing comorbid illnesses.	UNIV TEXAS, HLTH SCI CTR, HOUSTON, TX USA; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health San Antonio	MULROW, CD (corresponding author), AUDIE L MURPHY MEM VET ADM MED CTR, CTR GERIATR RES EDUC & CLIN, 7400 MERTON MINTER BLVD, SAN ANTONIO, TX 78284 USA.							ALDERMAN MH, 1993, ANN INTERN MED, V119, P329, DOI 10.7326/0003-4819-119-4-199308150-00013; ALDERMAN MH, 1981, HYPERTENSION, V3, P192, DOI 10.1161/01.HYP.3.2.192; AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1991, Arch Intern Med, V151, P1413; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1973, BMJ-BRIT MED J, V3, P434; [Anonymous], 1974, JAMA-J AM MED ASSOC, V229, P409; [Anonymous], 1967, J AMER MED ASSOC, V202, P1028, DOI 10.1001/jama.1967.03130240070013; [Anonymous], 1972, CIRCULATION, V45, P991; [Anonymous], 1980, LANCET, V1, P1261; [Anonymous], 1979, JAMA, V242, P2562; APPLEGATE WB, 1992, ARCH INTERN MED, V152, P1969, DOI 10.1001/archinte.152.10.1969; BILD DE, 1993, J AM GERIATR SOC, V41, P1047, DOI 10.1111/j.1532-5415.1993.tb06451.x; BROWN MA, 1989, ENERG BUILDINGS, V13, P51, DOI 10.1016/0378-7788(89)90017-0; CARTER AB, 1970, LANCET, V1, P485; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DENKE MA, 1994, ARCH INTERN MED, V154, P401, DOI 10.1001/archinte.154.4.401; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FROHLICH ED, 1992, NEW ENGL J MED, V327, P998, DOI 10.1056/NEJM199210013271406; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HULLEY SB, 1985, AM J CARDIOL, V56, P913, DOI 10.1016/0002-9149(85)90404-7; KAPLAN NM, 1993, AM HEART J, V125, P1485, DOI 10.1016/0002-8703(93)90444-E; KURAMOTO K, 1981, JPN HEART J, V22, P75; LANGFORD HG, 1986, PROG CARDIOVASC DIS, V29, P29, DOI 10.1016/0033-0620(86)90033-2; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEREN P, 1986, DRUGS, V31, P41, DOI 10.2165/00003495-198600311-00008; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; MANN SJ, 1992, ARCH INTERN MED, V152, P1977, DOI 10.1001/archinte.152.10.1977; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MITTELMARK MB, 1993, AM J EPIDEMIOL, V137, P311, DOI 10.1093/oxfordjournals.aje.a116678; PERRY HM, 1978, ANN NY ACAD SCI, V304, P267; POULTER N, 1991, AM HEART J, V121, P246, DOI 10.1016/0002-8703(91)90851-8; PSATY BM, 1993, JAMA-J AM MED ASSOC, V270, P1837, DOI 10.1001/jama.270.15.1837; PSATY BM, 1992, JAMA-J AM MED ASSOC, V268, P1287, DOI 10.1001/jama.268.10.1287; ROCCELLA EJ, 1991, ANN INTERN MED, V114, P224, DOI 10.7326/0003-4819-114-3-224; SILBERBERG JS, 1991, MED J AUSTRALIA, V155, P670, DOI 10.5694/j.1326-5377.1991.tb93957.x; SMITH WM, 1977, CIRC RES, V40, P98; SPRACKLING ME, 1981, BRIT MED J, V283, P1151, DOI 10.1136/bmj.283.6300.1151; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; Veterans Administration Cooperative Study Group, 1970, JAMA-J AM MED ASSOC, V213, P1143, DOI DOI 10.1001/JAMA.1970.03170330025003; WOLFF FW, 1966, J CHRON DIS, V19, P227, DOI 10.1016/0021-9681(66)90128-7; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; ZANCHETTI A, 1993, HYPERTENSION, V22, P392; 1990, DHHS PHS9150212 US D, P114; 1979, JAMA-J AM MED ASSOC, V242, P2572; 1981, MED J AUSTRALIA, V2, P398; 1989, MMWR-MORBID MORTAL W, V38, P788; 1990, JAMA-J AM MED ASSOC, V263, P209	51	198	199	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	1994	272	24					1932	1938		10.1001/jama.272.24.1932	http://dx.doi.org/10.1001/jama.272.24.1932			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX927	7990246				2022-12-28	WOS:A1994PX92700039
J	BEMBI, B; ZANATTA, M; CARROZZI, M; BARALLE, F; GORNATI, R; BERRA, B; AGOSTI, E				BEMBI, B; ZANATTA, M; CARROZZI, M; BARALLE, F; GORNATI, R; BERRA, B; AGOSTI, E			ENZYME REPLACEMENT TREATMENT IN TYPE-1 AND TYPE-3 GAUCHERS-DISEASE	LANCET			English	Article							MACROPHAGE-TARGETED GLUCOCEREBROSIDASE; THERAPY; GENE; DEFICIENCY; MUTATION	The development of intravenous enzyme-replacement treatment for Gaucher's disease has changed life expectancy in cases without neurological involvement (type 1). The effects in patients with neurological involvement are unknown. We treated 12 Italian patients, types 1 (9) and 3 (3), with intravenous alglucerase: 70-120 IU/kg per month for type 3 and 30-60 IU/kg per month for type 1. Maintenance infusions were biweekly in patients without neurological symptoms, whereas in one symptomatic type 3 patient, influsion was weekly. All patients improved; a resumption of growth in children with growth retardation was observed and spleen and liver reduced in size. In one type 3 patient, a bone callus formed during treatment and enabled the patient to walk. Laboratory tests showed rapid increase of haemoglobin in anaemic patients, and a slower response in patients with thrombocytopaenia. In 4 patients there was temporary hypocalcaemia immediately after the beginning of treatment. Neurological symptoms were present in 1 of the type 3 patients, and electroencephalogram was abnormal in another. After 2 years of treatment, the patient with symptoms showed an improvement of psychomotor skills and of IQ from 50 to 60. Genotype analysis showed a high frequency of the 1448C mutation (54.5%). The 9 patients carrying this allele came from Italian regions which in the past had been invaded from north Europe and Scandinavia. Enzyme replacement in Gaucher's type 1 can also be effective at low doses and even with a 2-week interval between infusions. This makes treatment cheaper, and reduces hospital stay for patients.	IST RICOVERO & CURA CARATTERE SCI BURLO GAROFOLO,DIV NEUROPSICHIAT INFANTILE,TRIESTE,ITALY; UNIV MILAN,FAC FARMACOL,MILAN,ITALY; INT CTR GENET ENGN & BIOTECHNOL,AREA RIC TRIESTE,I-34012 TRIESTE,ITALY	IRCCS Burlo Garofolo; University of Milan; International Center for Genetic Engineering & Biotechnology (ICGEB)	BEMBI, B (corresponding author), UNIV TRIESTE,IST RICOVERO & CURA CARATTERE SCI BURLO GAROFOLO,IST CLIN PEDIAT,VIA ISTRIA 65-1,I-34137 TRIESTE,ITALY.			Carrozzi, Marco/0000-0001-6282-4417				Barranger J. A., 1989, METABOLIC BASIS INHE, P1677; BARTON NW, 1992, J PEDIATR-US, V120, P277, DOI 10.1016/S0022-3476(05)80444-5; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BARTON NW, 1990, P NATL ACAD SCI USA, V87, P1913, DOI 10.1073/pnas.87.5.1913; BEMBI B, 1994, ACTA PAEDIATR, V83, P122, DOI 10.1111/j.1651-2227.1994.tb12968.x; BERRA B, 1986, REPORTS ISTISAN, V5, P121; BEUTLER E, 1992, SCIENCE, V256, P794, DOI 10.1126/science.1589760; BEUTLER E, 1991, BLOOD, V78, P1183; BRADY RO, 1993, ARCH NEUROL-CHICAGO, V50, P1212, DOI 10.1001/archneur.1993.00540110088009; BRADY RO, 1974, NEW ENGL J MED, V291, P989, DOI 10.1056/NEJM197411072911901; ERIKSON A, 1986, ACTA PAEDIATR SCAN S, V326; FALLET S, 1992, PEDIATR RES, V31, P496, DOI 10.1203/00006450-199205000-00018; FIGEROA ML, 1992, NEW ENGL J MED, V327, P1632; FIGUEROA ML, 1992, CLIN RES, V40, P167; FIRON N, 1990, AM J HUM GENET, V46, P527; FURBISH FS, 1981, BIOCHIM BIOPHYS ACTA, V673, P425, DOI 10.1016/0304-4165(81)90474-8; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; HOROWITZ M, 1989, GENOMICS, V4, P87, DOI 10.1016/0888-7543(89)90319-4; KAYE EM, 1986, ANN NEUROL, V20, P223, DOI 10.1002/ana.410200208; LAKS Y, 1987, ACTA PAEDIATR SCAND, V76, P378, DOI 10.1111/j.1651-2227.1987.tb10485.x; MOSCICKI RA, 1993, NEW ENGL J MED, V328, P1564; REINER O, 1988, DNA-J MOLEC CELL BIO, V7, P107, DOI 10.1089/dna.1988.7.107; Svennerholm L, 1982, Prog Clin Biol Res, V95, P67; THEOPHILUS B, 1989, AM J HUM GENET, V45, P212; TSUJI S, 1987, NEW ENGL J MED, V316, P570, DOI 10.1056/NEJM198703053161002; TUTEJA R, 1993, HUM MOL GENET, V2, P781, DOI 10.1093/hmg/2.6.781; ULMANN MD, 1977, J LIPID RES, V18, P371; WHITTINGTON R, 1992, DRUGS, V44, P72, DOI 10.2165/00003495-199244010-00007; ZIMRAN A, 1989, LANCET, V2, P349; ZIMRAN A, 1991, AM J HUM GENET, V49, P855	30	53	56	1	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1679	1682		10.1016/S0140-6736(94)90462-6	http://dx.doi.org/10.1016/S0140-6736(94)90462-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996964				2022-12-28	WOS:A1994PX30200013
J	SENGUPTA, P; COLBERT, HA; BARGMANN, CI				SENGUPTA, P; COLBERT, HA; BARGMANN, CI			THE C-ELEGANS GENE ODR-7 ENCODES AN OLFACTORY-SPECIFIC MEMBER OF THE NUCLEAR RECEPTOR SUPERFAMILY	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DNA-BINDING DOMAIN; STEROID-HORMONE RECEPTORS; RETINOID-X RECEPTOR; GLUCOCORTICOID RECEPTOR; CHEMOSENSORY NEURONS; ESTROGEN-RECEPTOR; SEQUENCE-ANALYSIS; LEADER SEQUENCE; EXPRESSION	Olfactory discrimination is achieved through the action of olfactory neurons with diverse chemical specificities. In C. elegans, at least ten different types of chemosensory neurons respond to different chemicals. The odr-7 gene is required for the function of one pair of chemosensory neurons called AWA neurons. odr-7 null mutants fail to respond to all odorants detected by the AWA neurons, while a missense mutation in odr-7 causes a specific defect in one odorant response. odr-7 encodes a protein with similarity to the DNA-binding domain of the nuclear receptor genes; it is expressed predominantly in the AWA neurons. odr-7 may regulate the expression of olfactory signaling molecules that define a single type of olfactory neuron.	UNIV CALIF SAN FRANCISCO, DEPT ANAT, PROGRAM NEUROSCI, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, GENET PROGRAM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	SENGUPTA, P (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT ANAT, PROGRAM DEV BIOL, SAN FRANCISCO, CA 94143 USA.			Bargmann, Cornelia/0000-0002-8484-0618	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001393] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC01393] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AATSINKI JT, 1994, BIOTECHNIQUES, V16, P282; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANIAHMAD A, 1993, J CELL BIOCHEM, V51, P151, DOI 10.1002/jcb.240510206; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BARGMANN CI, 1990, COLD SPRING HARB SYM, V55, P529; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BRENNER S, 1974, GENETICS, V77, P71; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CULOTTI JG, 1978, GENETICS, V90, P243; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIBB NJ, 1985, J MOL BIOL, V183, P543, DOI 10.1016/0022-2836(85)90170-6; FINK G, 1991, J STEROID BIOCHEM, V40, P123, DOI 10.1016/0960-0760(91)90175-5; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; GIGUERE V, 1989, NATURE, V337, P566, DOI 10.1038/337566a0; GOUTTE C, 1993, J MOL BIOL, V233, P359, DOI 10.1006/jmbi.1993.1517; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; KLEIN RD, 1993, CELL, V72, P349, DOI 10.1016/0092-8674(93)90113-5; KOLODZIEJ PA, 1991, MOL CELL BIOL, V11, P4669, DOI 10.1128/MCB.11.9.4669; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MAUE RA, 1987, J GEN PHYSIOL, V90, P95, DOI 10.1085/jgp.90.1.95; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NELSON CC, 1993, MOL ENDOCRINOL, V7, P1185, DOI 10.1210/me.7.9.1185; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; NIES DH, 1989, P NATL ACAD SCI USA, V86, P7351, DOI 10.1073/pnas.86.19.7351; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Riddle DL., 1988, NEMATODE CAENORHABDI, P393; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SICARD G, 1984, BRAIN RES, V292, P283, DOI 10.1016/0006-8993(84)90764-9; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WARE RW, 1975, J COMP NEUROL, V162, P71, DOI 10.1002/cne.901620106; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056	61	148	151	3	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 16	1994	79	6					971	980		10.1016/0092-8674(94)90028-0	http://dx.doi.org/10.1016/0092-8674(94)90028-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001144				2022-12-28	WOS:A1994PY08600007
J	AMOR, JC; HARRISON, DH; KAHN, RA; RINGE, D				AMOR, JC; HARRISON, DH; KAHN, RA; RINGE, D			STRUCTURE OF THE HUMAN ADP-RIBOSYLATION FACTOR-1 COMPLEXED WITH GDP	NATURE			English	Article							PHOSPHOLIPASE-D; PROTEIN; BINDING; RESOLUTION; COFACTOR; ARF	ADP-ribosylation factors (ARFs) are essential and ubiquitous in eukaryotes, being involved in vesicular transport and functioning as an activator of phospholipase D (refs 1, 2) and cholera toxin(3,4). The functions of ARF proteins in membrane traffic and organelle integrity(5,6) are intimately tied to its reversible association with membranes and specific interactions with membrane phospholipids. One common feature of these functions is their regulation by the binding and hydrolysis of GTP. Here we report the three-dimensional structure of full-length human ARF1 (M(r) 21,000) in its GDP-bound non-myristoylated form. The presence of a unique amino-terminal alpha-helix and loop, together with differences in Mg2+ ligation and the existence of a non-crystallographic dimer, set this structure apart from other GTP-binding proteins. These features provide a structural basis for the GTP-dependent modulation of membrane affinity, the lack of intrinsic GTPase activity, and the nature of effector binding surfaces.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOCHEM,PROGRAM BIOORGAN CHEM,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT CHEM & BIOCHEM,WALTHAM,MA 02254; NCI,DEV THERAPEUT PROGRAM,BIOL CHEM LAB,BETHESDA,MD 20892	Brandeis University; Brandeis University; Brandeis University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				Barbacid M., 1987, REV BIOCH, V56, P779; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DICKERSO.RE, 1968, ACTA CRYSTALL B-STRU, VB 24, P997, DOI 10.1107/S0567740868003626; FRECH M, 1994, BIOCHEMISTRY-US, V33, P3237, DOI 10.1021/bi00177a014; HALKIDES CJ, 1994, BIOCHEMISTRY-US, V33, P4019, DOI 10.1021/bi00179a031; JOHN J, 1989, J BIOL CHEM, V264, P13086; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, IN PRESS J BIOL CHEM; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; ROSENWALD AG, 1994, GTPASE CONTROLLED MO; SEUELL JL, 1988, P NATL ACAD SCI USA, V85, P4620; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISS O, 1989, J BIOL CHEM, V264, P21066; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; PROGRAM MANUAL GCG P	29	242	247	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					704	708						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990966				2022-12-28	WOS:A1994PX30700094
J	DUH, E; FEINGLOS, M				DUH, E; FEINGLOS, M			HYPOGLYCEMIA-INDUCED ANGINA-PECTORIS IN A PATIENT WITH DIABETES-MELLITUS	ANNALS OF INTERNAL MEDICINE			English	Note									DUKE UNIV, MED CTR, DURHAM, NC 27710 USA	Duke University								BOWMAN CE, 1985, LANCET, V1, P639; PLADZIEWICZ DS, 1989, AM J CARDIOL, V63, P1531, DOI 10.1016/0002-9149(89)90025-8	2	29	29	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1994	121	12					945	946		10.7326/0003-4819-121-12-199412150-00007	http://dx.doi.org/10.7326/0003-4819-121-12-199412150-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW083	7978720				2022-12-28	WOS:A1994PW08300007
J	GEERTS, WH; CODE, KI; JAY, RM; CHEN, EL; SZALAI, JP				GEERTS, WH; CODE, KI; JAY, RM; CHEN, EL; SZALAI, JP			A PROSPECTIVE-STUDY OF VENOUS THROMBOEMBOLISM AFTER MAJOR TRAUMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; SPINAL-CORD INJURY; IMPEDANCE PLETHYSMOGRAPHY; PULMONARY-EMBOLISM; HIP-SURGERY; MULTIPLE TRAUMA; LEG; DIAGNOSIS; ULTRASONOGRAPHY; PHLEBOGRAPHY	Background, Although deep-vein thrombosis and pulmonary embolism are considered common complications after major trauma, their frequency and the associated risk factors have not been carefully quantified. Methods. We performed serial impedance plethysmography and lower-extremity contrast venography to detect deep-vein thrombosis in a cohort of 716 patients admitted to a regional trauma unit. Prophylaxis against thromboembolism was not used. Results. Deep-vein thrombosis in the lower extremities was found in 201 of the 349 patients (58 percent) with adequate venographic studies, and proximal-vein thrombosis was found in 63 (18 percent). Three patients died of massive pulmonary embolism before venography could be performed. Before venography, only three of the patients with deep-vein thrombosis had clinical features suggestive of the condition. Deep-vein thrombosis was found in 65 of the 129 patients with major injuries involving the face, chest, or abdomen (50 percent); in 49 of the 91 patients with major head injuries (54 percent); in 41 of the 66 with spinal injuries (62 percent); and in 126 of the 182 with lower-extremity orthopedic injuries (69 percent). Thrombi were detected in 61 of the 100 patients with pelvic fractures (61 percent), in 59 of the 74 with femoral fractures (80 percent), and in 66 of the 86 with tibial fractures (77 percent). A multivariate analysis identified five independent risk factors for deep-vein thrombosis: older age (odds ratio, 1.05 per year of age; 95 percent confidence interval, 1.03 to 1.06), blood transfusion (odds ratio, 1.74; 95 percent confidence interval, 1.03 to 2.93), surgery (odds ratio, 2.30; 95 percent confidence interval, 1.08 to 4.89), fracture of the femur or tibia (odds ratio, 4.82; 95 percent confidence interval, 2.79 to 8.33), and spinal cord injury (odds ratio, 8.59; 95 percent confidence interval, 2.92 to 25.28). Conclusions. Venous thromboembolism is a common complication in patients with major trauma, and effective, safe prophylactic regimens are needed.	UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT RES DESIGN & BIOSTAT, TORONTO M4N 3M5, ON, CANADA; UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, CLIN EPIDEMIOL UNIT, TORONTO M4N 3M5, ON, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	GEERTS, WH (corresponding author), UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT MED, RM D674, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ON, CANADA.							AGNELLI G, 1991, ARCH INTERN MED, V151, P2167, DOI 10.1001/archinte.151.11.2167; ANDERSON FA, 1992, ARCH INTERN MED, V152, P1660, DOI 10.1001/archinte.152.8.1660; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bauer G, 1944, ACTA CHIR SCAND, V90, P229; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; BORRIS LC, 1989, THROMB HAEMOSTASIS, V61, P363; BOULANGER BR, 1993, J TRAUMA, V35, P261, DOI 10.1097/00005373-199308000-00015; BURNS GA, 1993, J TRAUMA, V35, P405, DOI 10.1097/00005373-199309000-00012; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; CLAGETT GP, 1992, CHEST, V102, pS391, DOI 10.1378/chest.102.4_Supplement.391S; COLDITZ GA, 1986, LANCET, V2, P143; CRUICKSHANK MK, 1989, THROMB HAEMOSTASIS, V62, P830; DAVIDSON BL, 1992, ANN INTERN MED, V117, P735, DOI 10.7326/0003-4819-117-9-735; ELLIOTT CG, 1993, ANGIOLOGY, V44, P26, DOI 10.1177/000331979304400105; FREEARK RJ, 1967, ARCH SURG-CHICAGO, V95, P567; GILLUM RF, 1987, AM HEART J, V114, P1262, DOI 10.1016/0002-8703(87)90212-2; GINSBERG JS, 1991, RADIOLOGY, V181, P651, DOI 10.1148/radiology.181.3.1947076; HAAKE DA, 1989, CLIN ORTHOP RELAT R, P212; HARLAN LC, 1990, AM J PUBLIC HEALTH, V80, P453, DOI 10.2105/AJPH.80.4.453; HJELMSTEDT A, 1968, ACTA CHIR SCAND, V134, P209; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1992, CHEST, V102, pS658; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; HULL RD, 1984, CLIN CHEST MED, V5, P439; KAKKAR VV, 1970, AM J SURG, V120, P527, DOI 10.1016/S0002-9610(70)80023-X; KNUDSON MM, 1992, J TRAUMA, V32, P2, DOI 10.1097/00005373-199201000-00002; KUDSK KA, 1989, AM J SURG, V158, P515, DOI 10.1016/0002-9610(89)90182-7; McCartney JS, 1927, ARCH PATHOL LAB MED, V3, P921; MCMURTRY RY, 1989, CAN MED ASSOC J, V141, P555; MONTREY JS, 1985, J TRAUMA, V25, P534, DOI 10.1097/00005373-198506000-00011; Moser, 1988, J INTENSIVE CARE MED, V3, P87, DOI DOI 10.1177/088506668800300205; MYLLYNEN P, 1985, J TRAUMA, V25, P541, DOI 10.1097/00005373-198506000-00013; PAIEMENT G, 1988, AM J SURG, V155, P400, DOI 10.1016/S0002-9610(88)80099-0; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; SEVITT S, 1961, BRIT J SURG, V48, P475, DOI 10.1002/bjs.18004821103; SEVITT S, 1968, BRIT J SURG, V55, P481, DOI 10.1002/bjs.1800550702; SHACKFORD SR, 1990, AM J SURG, V159, P365, DOI 10.1016/S0002-9610(05)81272-3; VANCE BM, 1934, AM J SURG, V26, P19; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WEBB P, 1981, BRIT J SURG, V68, P807; WOOLSON ST, 1991, CLIN ORTHOP RELAT R, V273, P131; YELNIK A, 1991, PARAPLEGIA, V29, P253, DOI 10.1038/sc.1991.36; 1988, J TRAUMA, V28, P87; 1985, INJURY AM CONTINUING; 1992, J TRAUMA, V32, P130	46	994	1053	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	1994	331	24					1601	1606		10.1056/NEJM199412153312401	http://dx.doi.org/10.1056/NEJM199412153312401			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW446	7969340				2022-12-28	WOS:A1994PW44600001
J	ZHENG, B; XUE, W; KELSOE, G				ZHENG, B; XUE, W; KELSOE, G			LOCUS-SPECIFIC SOMATIC HYPERMUTATION IN GERMINAL CENTER T-CELLS	NATURE			English	Article							IMMUNOGLOBULIN GENES; ANTIGEN RECEPTOR; IMMUNE-RESPONSE; CHAIN GENES; MUTATION; GENERATION; SEQUENCES; CENTERS; MEMORY; DNA	SOMATIC hypermutation and affinity-driven selection of active immunoglobulin genes occur in germinal centres (GCs), resulting in the generation of high-affinity memory B cells(1-3). In contrast, T lymphocytes do not require the germinal centre microenvironment to establish memory and the T-cell antigen receptor (TCR) genes, though homologous to immunoglobulin genes, are believed to be incapable of hypermutation(5-7). Here we present direct evidence that the small population of antigen-specific T cells that are recruited into splenic GCs acquire mutations in the variable region of genes encoding TCR alpha-chains (V alpha) but not those of beta-chains. These locus-specific mutations reach frequencies comparable to mutated inmunoglobulin V-H exons recovered from the same site and exhibit similar substitution biases and DNA strand polarity. T cells bearing identical mutations appear in multiple GCs, raising the possibility that some cells bearing mutant TCRs may re-enter the peripheral lymphocyte pool.			ZHENG, B (corresponding author), UNIV MARYLAND,SCH MED,DEPT MICROBIOL & IMMUNOL,655 W BALTIMORE ST,BALTIMORE,MD 21201, USA.			Kelsoe, Garnett/0000-0002-8770-040X				ALLEN D, 1988, EMBO J, V7, P1995, DOI 10.1002/j.1460-2075.1988.tb03038.x; BECKER DM, 1985, NATURE, V317, P430, DOI 10.1038/317430a0; BERNARD O, 1978, CELL, V15, P1133, DOI 10.1016/0092-8674(78)90041-7; BETZ AG, 1993, IMMUNOL TODAY, V14, P405, DOI 10.1016/0167-5699(93)90144-A; BLOMBERG B, 1982, P NATL ACAD SCI-BIOL, V79, P530, DOI 10.1073/pnas.79.2.530; CHIEN YH, 1984, NATURE, V309, P322, DOI 10.1038/309322a0; CUMANO A, 1986, EMBO J, V5, P2459, DOI 10.1002/j.1460-2075.1986.tb04522.x; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; FULLER K, 1993, J IMMUNOL, V9, P4505; HACKETT J, 1992, J EXP MED, V176, P225, DOI 10.1084/jem.176.1.225; HAYDAY AC, 1985, NATURE, V316, P828, DOI 10.1038/316828a0; JACOB J, 1993, J EXP MED, V178, P1293, DOI 10.1084/jem.178.4.1293; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JACOB J, 1992, J EXP MED, V176, P678; KELSOE G, 1993, CURR OPIN IMMUNOL, V5, P418, DOI 10.1016/0952-7915(93)90062-W; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LANE P, 1994, J EXP MED, V179, P819, DOI 10.1084/jem.179.3.819; LEBECQUE SG, 1990, J EXP MED, V172, P1717, DOI 10.1084/jem.172.6.1717; LUNDBERG KS, 1991, GENE, V106, P1; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MALISSEN M, 1988, CELL, V55, P49, DOI 10.1016/0092-8674(88)90008-6; OKADA A, 1994, J EXP MED, V180, P261, DOI 10.1084/jem.180.1.261; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; TAO W, 1990, J IMMUNOL, V145, P3216; VITETTA ES, 1991, ANNU REV IMMUNOL, V9, P193, DOI 10.1146/annurev.iy.09.040191.001205; WEISS U, 1990, J EXP MED, V172, P1680; WINOTO A, 1986, NATURE, V324, P679, DOI 10.1038/324679a0; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	30	115	117	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					556	559		10.1038/372556a0	http://dx.doi.org/10.1038/372556a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990929				2022-12-28	WOS:A1994PW08200054
J	SANDERSON, F; KLEIJMEER, MJ; KELLY, A; VERWOERD, D; TULP, A; NEEFJES, JJ; GEUZE, HJ; TROWSDALE, J				SANDERSON, F; KLEIJMEER, MJ; KELLY, A; VERWOERD, D; TULP, A; NEEFJES, JJ; GEUZE, HJ; TROWSDALE, J			ACCUMULATION OF HLA-DM, A REGULATOR OF ANTIGEN PRESENTATION, IN MHC CLASS-II COMPARTMENTS	SCIENCE			English	Article							INVARIANT CHAIN PEPTIDES; PROCESSING MUTANT; RNA-POLYMERASE; DR MOLECULES; CLONED GENES; EXPRESSION; LOCUS	The HLA-DM genes encode an unconventional HLA (human leukocyte antigen) class II molecule that is required for appropriate binding of peptide to classical HLA class II products. In the absence of DM, other class II molecules are unstable upon electrophoresis in sodium dodecyl sulfate and are largely associated with a nested set of peptides derived from the invariant chain called CLIP, for class Ii-associated invariant chain peptides. DMA and DMB associated and accumulated in multilaminar, intracellular compartments with classical class II molecules, but were found infrequently, if at all, at the cell surface. Thus, DM may facilitate peptide binding to class II molecules within these intracellular compartments.	IMPERIAL CANC RES FUND,HUMAN IMMUNOGENET LAB,LONDON WC2A 3PX,ENGLAND; UNIV UTRECHT,SCH MED,DEPT CELL BIOL,3584 CX UTRECHT,NETHERLANDS; NETHERLANDS CANC INST,DEPT CELLULAR BIOCHEM,1066 CX AMSTERDAM,NETHERLANDS	Cancer Research UK; Utrecht University; Netherlands Cancer Institute			Neefjes, Jacques J.C./H-8780-2017	Neefjes, Jacques J.C./0000-0001-6763-2211				AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GEUZE HJ, 1981, J CELL BIOL, V89, P653, DOI 10.1083/jcb.89.3.653; HARDING CV, 1993, J IMMUNOL, V151, P3988; HARLOW E, 1988, ANTIBODIES LABORATOR; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; LIOU W, 1994, P INT C ELECTRON MIC, V13; LUZIO JP, 1993, TRENDS BIOCHEM SCI, V18, P395, DOI 10.1016/0968-0004(93)90097-7; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; RIBERDY JM, 1994, J CELL BIOL, V125, P1225, DOI 10.1083/jcb.125.6.1225; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; STAM NJ, 1986, J IMMUNOL, V137, P2299; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THORPE C, COMMUNICATION; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TULP A, 1993, ELECTROPHORESIS, V14, P1295, DOI 10.1002/elps.11501401198; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	29	232	235	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1566	1569		10.1126/science.7985027	http://dx.doi.org/10.1126/science.7985027			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985027				2022-12-28	WOS:A1994PV01500045
J	SOMERS, W; ULTSCH, M; DEVOS, AM; KOSSIAKOFF, AA				SOMERS, W; ULTSCH, M; DEVOS, AM; KOSSIAKOFF, AA			THE X-RAY STRUCTURE OF A GROWTH-HORMONE PROLACTIN RECEPTOR COMPLEX	NATURE			English	Article							EXTRACELLULAR DOMAIN; BINDING DETERMINANTS; RATIONAL DESIGN; DIMERIZATION; SUPERFAMILY; ANTAGONISTS; REFINEMENT; VARIANTS; CRYSTALS; DETECTOR	THE human pituitary hormones, growth hormone (hGH) and prolactin (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation(1). These activities are initiated by hormone-receptor binding. The hGH and hPRL receptors (hGH(R) and hPRL(R), respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily(2,3). This classification is based on sequence similarity in their extracellular domains, notably a highly conserved pentapeptide, the so-called 'WSXWS box', the function of which is controversial. All ligands in class 1 activate their respective receptors by clustering mechanisms(4). In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex(5-8). hPRL does not bind to the hGH receptor, but hGH binds to both the hGH(R) and hPRL(R), and mutagenesis studies have shown that the receptor-binding sites on hGH overlap(9). We present here the crystal structure of the 1:1 complex of hGH bound to the extracellular domain of the hPRL(R). Comparisons with the hGH-hGH(R) complex(10) reveal how hGH can bind to the two distinctly different receptor binding surfaces.	GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRUNER AT, 1992, X PLOR REFERENCE MAN; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CHAWLA RK, 1983, ANNU REV MED, V34, P519, DOI 10.1146/annurev.me.34.020183.002511; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; ROZAKISADCOCK M, 1992, J BIOL CHEM, V267, P7428; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; ULTSCH M, 1991, J MOL BIOL, V222, P865, DOI 10.1016/0022-2836(91)90578-T; ULTSCH M, 1993, J MOL BIOL, V231, P1133, DOI 10.1006/jmbi.1993.1359; ULTSCH MH, 1994, J MOL BIOL, V236, P286, DOI 10.1006/jmbi.1994.1135	24	339	350	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					478	481		10.1038/372478a0	http://dx.doi.org/10.1038/372478a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984244				2022-12-28	WOS:A1994PV01200061
J	BURTON, DR; PYATI, J; KODURI, R; SHARP, SJ; THORNTON, GB; PARREN, PWHI; SAWYER, LSW; HENDRY, RM; DUNLOP, N; NARA, PL; LAMACCHIA, M; GARRATTY, E; STIEHM, ER; BRYSON, YJ; CAO, YZ; MOORE, JP; HO, DD; BARBAS, CF				BURTON, DR; PYATI, J; KODURI, R; SHARP, SJ; THORNTON, GB; PARREN, PWHI; SAWYER, LSW; HENDRY, RM; DUNLOP, N; NARA, PL; LAMACCHIA, M; GARRATTY, E; STIEHM, ER; BRYSON, YJ; CAO, YZ; MOORE, JP; HO, DD; BARBAS, CF			EFFICIENT NEUTRALIZATION OF PRIMARY ISOLATES OF HIV-1 BY A RECOMBINANT HUMAN MONOCLONAL-ANTIBODY	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SOLUBLE CD4; COMBINATORIAL LIBRARIES; TYPE-1; GP120; ASSAY; VACCINE; BINDING; GP160; GENES	The ability of antibodies to neutralize diverse primary isolates of human immunodeficiency virus-type 1 in vitro has been questioned, with implications for the likely efficacy of vaccines. A recombinant human antibody to envelope glycoprotein gp120 was generated and used to show that primary isolates are not refractory to antibody neutralization. The recombinant antibody neutralized more than 75 percent of the primary isolates tested at concentrations that could be achieved by passive immunization, for example, to interrupt maternal-fetal transmission of virus. The broad specificity and efficacy of the antibody implies the conservation of a structural feature on gp120, which could be important in vaccine design.	SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA; RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA; CALIF DEPT HLTH SERV, VIRAL & RICKETTSIAL DIS LAB, BERKELEY, CA 94704 USA; NCI, FREDERICK CANC RES & DEV CTR, TUMOR CELL BIOL LAB, VIRUS BIOL SECT, FREDERICK, MD 21702 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, LOS ANGELES, CA 90024 USA; NYU, SCH MED, AARON DIAMOND AIDS RES CTR, NEW YORK, NY 10016 USA	Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA; California Department of Health Care Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; New York University	BURTON, DR (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Dr. Peter L. Nara, M.Sc./I-7432-2019	Thornton, George/0000-0002-8744-4987; Parren, Paul/0000-0002-4365-3859	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI033292, R01AI033292, P30AI027742] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27742, AI33292, AI35168] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBAS CF, 1994, P NATL ACAD SCI USA, V91, P3809, DOI 10.1073/pnas.91.9.3809; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARBAS CF, 1993, J MOL BIOL, V230, P812, DOI 10.1006/jmbi.1993.1203; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P9939; Bender Eckhard, 1993, Human Antibodies and Hybridomas, V4, P74; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BRYSON Y, 1993, J CELL BIOCH SE, V17, P95; BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; COHEN J, 1994, SCIENCE, V264, P1072, DOI 10.1126/science.8178162; COHEN J, 1993, SCIENCE, V262, P980, DOI 10.1126/science.8235635; CONLEY AJ, 1994, P NATL ACAD SCI USA, V91, P3348, DOI 10.1073/pnas.91.8.3348; CUMMINS LM, 1991, BLOOD, V77, P1111; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; DSOUZA MP, 1994, AIDS, V8, P169; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HANSON CV, 1990, J CLIN MICROBIOL, V28, P2030, DOI 10.1128/JCM.28.9.2030-2034.1990; HANSON CV, 1994, AIDS RES HUM RETROV, V10, P633; HO DD, 1991, J VIROL, V65, P489, DOI 10.1128/JVI.65.1.489-493.1991; LETVIN NL, 1993, NEW ENGL J MED, V329, P1400, DOI 10.1056/NEJM199311043291908; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MOORE JP, 1990, AIDS, V4, P307, DOI 10.1097/00002030-199004000-00004; MOORE JP, 1994, J VIROL, V68, P469, DOI 10.1128/JVI.68.1.469-484.1994; MOORE JP, 1989, AIDS, V3, P155, DOI 10.1097/00002030-198903000-00006; MOORE JS, UNPUB; NARA PL, 1987, AIDS RES HUM RETROV, V3, P283, DOI 10.1089/aid.1987.3.283; OBRIEN WA, 1992, J VIROL, V66, P3125, DOI 10.1128/JVI.66.5.3125-3130.1992; OBRIEN WA, 1994, J VIROL, V68, P5264, DOI 10.1128/JVI.68.8.5264-5269.1994; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; ROBERTGUROFF M, 1985, NATURE, V316, P72, DOI 10.1038/316072a0; SAWYER LSW, 1994, J VIROL, V68, P1342, DOI 10.1128/JVI.68.3.1342-1349.1994; SCARLATTI G, 1993, J INFECT DIS, V168, P207, DOI 10.1093/infdis/168.1.207; SCHWARTZ DH, 1993, LANCET, V342, P69, DOI 10.1016/0140-6736(93)91283-R; WRIN T, 1994, J ACQ IMMUN DEF SYND, V7, P211; 1993, AIDS CLIN TRIALS GRO	38	956	1041	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1024	1027		10.1126/science.7973652	http://dx.doi.org/10.1126/science.7973652			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973652				2022-12-28	WOS:A1994PQ92400038
J	WERNER, S; SMOLA, H; LIAO, X; LONGAKER, MT; KRIEG, T; HOFSCHNEIDER, PH; WILLIAMS, LT				WERNER, S; SMOLA, H; LIAO, X; LONGAKER, MT; KRIEG, T; HOFSCHNEIDER, PH; WILLIAMS, LT			THE FUNCTION OF KGF IN MORPHOGENESIS OF EPITHELIUM AND REEPITHELIALIZATION OF WOUNDS	SCIENCE			English	Article							KERATINOCYTE GROWTH-FACTOR; TRANSGENIC MICE; EXPRESSION; DIFFERENTIATION; RECEPTOR; INHIBITION; INSIGHTS; ALPHA; GENE; SKIN	The function of keratinocyte growth factor (KGF) in normal and wounded skin was assessed by expression of a dominant-negative KGF receptor transgene in basal keratinocytes. The skin of transgenic mice was characterized by epidermal atrophy, abnormalities in the hair follicles, and dermal hyperthickening. Upon skin injury, inhibition of KGF receptor signaling reduced the proliferation rate of epidermal keratinocytes at the wound edge, resulting in substantially delayed reepithelialization of the wound.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV COLOGNE,DERMATOL & VENEROL KLIN,D-50931 COLOGNE,GERMANY; NYU,MED CTR,INST RECONSTRUCT PLAST SURG,NEW YORK,NY 10016	University of California System; University of California San Francisco; University of Cologne; New York University	WERNER, S (corresponding author), MAX PLANCK INST BIOCHEM,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.			Werner, Sabine/0000-0001-7397-8710	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821, R01HL032898] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL32898, HL-43821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Clark RAF, 1991, PHYSL BIOCH MOL BIOL, P576; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; MARTIN P, 1992, Progress in Growth Factor Research, V4, P25, DOI 10.1016/0955-2235(92)90003-Z; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; PETERS KG, 1992, DEVELOPMENT, V114, P233; PIERCE GF, 1994, J EXP MED, V179, P831, DOI 10.1084/jem.179.3.831; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; TSUBOI R, 1993, J INVEST DERMATOL, V101, P49, DOI 10.1111/1523-1747.ep12358892; TURKSEN K, 1992, P NATL ACAD SCI USA, V89, P5068, DOI 10.1073/pnas.89.11.5068; UENO H, 1993, J BIOL CHEM, V268, P22814; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1397; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WERNER S, UNPUB	19	512	529	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					819	822		10.1126/science.7973639	http://dx.doi.org/10.1126/science.7973639			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973639				2022-12-28	WOS:A1994PP75300045
J	CALDER, SJ; ANDERSON, GH; HARPER, WM; GREGG, PJ				CALDER, SJ; ANDERSON, GH; HARPER, WM; GREGG, PJ			ETHNIC VARIATION IN EPIDEMIOLOGY AND REHABILITATION OF HIP FRACTURE	BRITISH MEDICAL JOURNAL			English	Article							OSTEOMALACIA				CALDER, SJ (corresponding author), UNIV LEICESTER,GLENFIELD GEN HOSP,DEPT ORTHOPAED SURG,LEICESTER LE3 9QP,LEICS,ENGLAND.							ANDERSON GH, 1993, J BONE JOINT SURG BR, V75, P441, DOI 10.1302/0301-620X.75B3.8496217; ROBINSON CM, 1992, INJURY, V23, P300, DOI 10.1016/0020-1383(92)90172-O; STAMP TCB, 1980, CLIN ENDOCRINOL META, V9, P81, DOI 10.1016/S0300-595X(80)80022-3; STEPHENS WP, 1982, Q J MED, V202, P171; WILTON TJ, 1987, J BONE JOINT SURG BR, V69, P388, DOI 10.1302/0301-620X.69B3.3584190	5	11	12	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1994	309	6962					1124	1125		10.1136/bmj.309.6962.1124a	http://dx.doi.org/10.1136/bmj.309.6962.1124a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987105	Green Published			2022-12-28	WOS:A1994PP69100022
J	PATEL, P; MENDALL, MA; KHULUSI, S; NORTHFIELD, TC; STRACHAN, DP				PATEL, P; MENDALL, MA; KHULUSI, S; NORTHFIELD, TC; STRACHAN, DP			HELICOBACTER-PYLORI INFECTION IN CHILDHOOD - RISK-FACTORS AND EFFECT ON GROWTH	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UNIDENTIFIED CURVED BACILLI; CAMPYLOBACTER-PYLORI; GASTRITIS; SEROEPIDEMIOLOGY; SYMPTOMS; HEIGHT	Objective-To investigate the current prevalence of Helicobacter pylori infection in childhood, the risk factors for infection, and the effect of infection on growth in preadolescent schoolchildren. Design-Population based sample of 7 year old schoolchildren followed up at age 11; data on risk factors for infection collected at age 7; presence of infection at age 11 determined by measurement of salivary IgG against H pylori by a newly developed: enzyme linked immunosorbent assay (ELISA). Height was measured at 7 and 11 years of age. Subjects-554 schoolchildren from Edinburgh. Results-62 (11%) children had H pylori infection. Independent risk factors for infection were single parent families (adjusted odds ratio=2.5; 95% confidence interval 1.1 to 5.7), the 10% most crowded homes (3.1; 1.3 to 7.2), and schools serving predominantly rented housing estates (2.5; 1.0 to 6.5). School catchment area was more important than parental social class or housing tenure. Growth in height between 7 and 11 was diminished in infected children by a mean of 1.1 cm (0.3 to 2.0 cm) over four years. This growth reduction was largely confined to girls (1.6 cm over four years), among whom it correlated with salivary IgG (P=0.015). Conclusion-Data from salivary assay to investigate the epidemiology of H pylori suggest that factors relating to the type of community in which the child lives may now be as important for acquisition of this infection as features of the family home. The greater reduction of growth among infected girls raises the possibility that H pylori infection may delay or diminish the pubertal growth spurt.	ST GEORGE HOSP, SCH MED, DEPT PUBL HLTH SCI, LONDON SW17 0RE, ENGLAND	St Georges University London	PATEL, P (corresponding author), ST GEORGE HOSP, SCH MED, DIV BIOCHEM MED, LONDON SW17 0RE, ENGLAND.							BAKER RJ, 1978, GLIM SYSTEM; BIRKHOLZ S, 1993, FEMS IMMUNOL MED MIC, V6, P317, DOI 10.1111/j.1574-695X.1993.tb00344.x; CAMPBELL AGM, 1992, FORFAR ARNEILS TXB P, P423; CRABTREE JE, 1993, SCAND J IMMUNOL, V37, P65, DOI 10.1111/j.1365-3083.1993.tb01666.x; CROWNE EC, 1991, EUR J PEDIATR, V150, P708, DOI 10.1007/BF01958760; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; FORMAN D, 1993, LANCET, V341, P1359; GRAHAM DY, 1991, DIGEST DIS SCI, V36, P1084, DOI 10.1007/BF01297451; HILL ID, 1987, ARCH DIS CHILD, V62, P1215, DOI 10.1136/adc.62.12.1215; JIVANI SKM, 1973, ARCH DIS CHILD, V48, P109, DOI 10.1136/adc.48.2.109; JONES DM, 1987, BRIT MED J, V294, P615, DOI 10.1136/bmj.294.6572.615-a; KLEIN PD, 1991, LANCET, V337, P1503, DOI 10.1016/0140-6736(91)93196-G; KUH DL, 1991, INT J EPIDEMIOL, V20, P1001, DOI 10.1093/ije/20.4.1001; MARSHALL BJ, 1984, LANCET, V1, P1311; MEGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870; MENDALL M, 1994, GUT               S1, V35, pS4; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MENDALL MA, 1993, GUT, V34, pS3; MURCH SH, 1991, GUT, V32, P913, DOI 10.1136/gut.32.8.913; PARSONNET J, 1992, GASTROENTEROLOGY, V102, P41, DOI 10.1016/0016-5085(92)91782-Y; PATEL D, 1994, GUT, V35, pS64; PATEL P, IN PRESS LANCET; RAYMOND J, 1994, J CLIN MICROBIOL, V32, P461, DOI 10.1128/JCM.32.2.461-463.1994; ROTHWELL NJ, 1991, J ENDOCRINOL, V128, P171, DOI 10.1677/joe.0.1280171; STRACHAN DP, 1988, BMJ-BRIT MED J, V297, P1223, DOI 10.1136/bmj.297.6658.1223; TANNER JM, 1973, NATURE, V243, P95, DOI 10.1038/243095a0; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; THOMAS J, 1988, GUT, V29, pA707; WARREN JR, 1983, LANCET, V1, P1273; WEBB PM, 1994, BRIT MED J, V308, P750, DOI 10.1136/bmj.308.6931.750; 1991, ITALIAN J GASTROE S2, V23, P19	31	210	215	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 29	1994	309	6962					1119	1123		10.1136/bmj.309.6962.1119	http://dx.doi.org/10.1136/bmj.309.6962.1119			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987103	Green Published			2022-12-28	WOS:A1994PP69100020
J	STURM, R; WELLS, KB				STURM, R; WELLS, KB			HOW CAN CARE FOR DEPRESSION BECOME MORE COST-EFFECTIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL OUTCOMES; TREATING DEPRESSION; ADULT OUTPATIENTS; RECOGNITION; MANAGEMENT; MORBIDITY; ANXIETY; WORK	Objective.-To determine the cost and health effects of changes in the content and quality of care for depressed patients treated in prepaid general medical practices (internal and family medicine) and mental health specialty practices and shifts in the proportion of patients treated in general medicine, Methods.-Cost-effectiveness analysis and simulations, which are empirically based on data from the Medical Outcomes Study, Outcome Measures.-Change in serious functional limitations, annual treatment costs' per patient, and costs per reduction in one functional limitation. Results.-More appropriate care for depression (increased counseling, use of appropriate antidepressant medications, or avoidance of regular minor tranquilizer use) improves functioning outcomes. Although this approach increases total costs of care, it also improves the value of care because each dollar spent on care now provides more benefits in terms of health improvements. In contrast with the effects of more appropriate care for depression, the trend away from mental health specialty care and toward general medical provider care under current treatment patterns reduces costs, worsens outcomes, and does not increase the value of health care spending in terms of health improvement per dollar. Conclusion.-Quality improvement measures that roughly follow practice guidelines for depression can improve outcomes and the value or cost-effectiveness of care, but at increased treatment costs; shifting patients away from mental health specialists decreases costs but worsens functioning outcomes, The best strategy for making care for depression more cost-effective is through quality improvement, not through changing specialty mix. Yet combining these strategies may achieve better outcomes, lower treatment costs, and better value of care compared with current practice patterns, To realize this potential, however, substantial quality improvement of care for depression is necessary in general medical practice.	UNIV CALIF LOS ANGELES,NEUROPSYCHIAT INST & HOSP,DEPT PSYCHIAT & BEHAV SCI,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	STURM, R (corresponding author), RAND CORP,1700 MAIN ST,SANTA MONICA,CA 90407, USA.				AHRQ HHS [1RO1HS06802-0252] Funding Source: Medline; NIMH NIH HHS [5RO1MH481] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006802] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BADGER LW, 1988, INT J PSYCHIAT MED, V18, P123; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; BRODY DS, 1990, ARCH INTERN MED, V150, P993, DOI 10.1001/archinte.150.5.993; BURNAM MA, 1988, MED CARE, V26, P775, DOI 10.1097/00005650-198808000-00004; EISENBERG L, 1992, NEW ENGL J MED, V326, P1080, DOI 10.1056/NEJM199204163261610; ELLIS RP, 1993, J ECON PERSPECT, V257, P135; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P405; HOEPER EW, 1984, LANCET, V1, P33; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; KAMLET MS, 1992, EC MENTAL HLTH; KATON W, 1992, GEN HOSP PSYCHIAT, V14, P237, DOI 10.1016/0163-8343(92)90094-Q; KATON W, 1992, MED CARE, V30, P67, DOI 10.1097/00005650-199201000-00007; KUPFER DJ, 1991, J CLIN PSYCHIAT, V52, P28; LINN LS, 1982, MED CARE, V20, P1233, DOI 10.1097/00005650-198212000-00009; MAGRUDERHABIB K, 1990, MED CARE, V28, P239, DOI 10.1097/00005650-199003000-00004; MINTZ J, 1992, ARCH GEN PSYCHIAT, V49, P761; MUMFORD E, 1984, AM J PSYCHIAT, V141, P1145; ORMEL J, 1991, ARCH GEN PSYCHIAT, V48, P700; RICE DP, 1990, EC COSTS ALCOHOL DRU; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; ROGERS WH, 1993, ARCH GEN PSYCHIAT, V50, P517; ROGERS WM, 1992, MEASURING FUNCTIONIN; SCHULBERG HC, 1989, GEN HOSP PSYCHIAT, V11, P208, DOI 10.1016/0163-8343(89)90043-1; SHAPIRO S, 1987, MED CARE, V25, P327, DOI 10.1097/00005650-198704000-00006; STURM R, 1994, MED CARE, V32, P917, DOI 10.1097/00005650-199409000-00003; STURM R, 1994, DRU692AHCPR RAND PUB; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; WELLS KB, 1994, AM J PSYCHIAT, V151, P694; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WELLS KB, 1992, ARCH GEN PSYCHIAT, V49, P788; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P925; 1993, AM J PSYCHIATRY S, V150, P1; 1994, PHYSICIAN MARKETPLAC; 1993, PHS AHCPR930550 US D; 1993, PHS AHCPR930551 US D	35	231	233	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 4	1995	273	1					51	58						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PZ042	7996651				2022-12-28	WOS:A1995PZ04200028
J	FAN, CM; TESSIERLAVIGNE, M				FAN, CM; TESSIERLAVIGNE, M			PATTERNING OF MAMMALIAN SOMITES BY SURFACE ECTODERM AND NOTOCHORD - EVIDENCE FOR SCLEROTOME INDUCTION BY A HEDGEHOG HOMOLOG	CELL			English	Article							FLOOR PLATE; CELL-DIFFERENTIATION; NEURAL-TUBE; GENE; MOUSE; SEGMENTATION; MORPHOGENESIS; SPECIFICATION; NEUROGENESIS; EXPRESSION	An early step in the development of vertebrae, ribs, muscle, and dermis is the differentiation of the semitic mesoderm into dermomyotome dorsally and sclerotome ventrally. To analyze this process, we have developed an in vitro assay for semitic mesoderm differentiation. We show that sclerotomal markers can be induced by a diffusible factor secreted by notochord and floor plate and that heterologous cells expressing Sonic hedgehog (shh/vhh-1) mimic this effect. In contrast, expression of dermomyotomal markers can be caused by a contact-dependent signal from surface ectoderm and a diffusible signal from dorsal neural tube. Our results extend previous studies by suggesting that dorsoventral patterning of somites involves the coordinate action of multiple dorsalizing and ventralizing signals and that a diffusible form of Shh/Vhh-1 mediates sclerotome induction.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	FAN, CM (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143, USA.							AOYAMA H, 1988, DEVELOPMENT, V104, P15; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BRANDSABERI B, 1993, ANAT EMBRYOL, V188, P239; BUFFINGER N, 1994, DEVELOPMENT, V120, P1443; CHANG DT, 1994, DEVELOPMENT, V120, P3339; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRIST B, 1974, Verhandlungen der Anatomischen Gesellschaft, V68, P573; CHRIST B, 1992, ANAT EMBRYOL, V186, P505; CREWS S, 1992, J EXP ZOOL, V261, P234, DOI 10.1002/jez.1402610303; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; Dickinson ME, 1992, CURR OPIN GENET DEV, V2, P562, DOI 10.1016/S0959-437X(05)80172-8; DIETRICH S, 1993, MECH DEVELOP, V44, P189, DOI 10.1016/0925-4773(93)90067-8; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; Gallera J., 1966, Revue Suisse de Zoologie, V73, P492; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; JESSELL TM, 1992, HARVEY LECT, V86, P87; JOHNSON RL, 1994, CELL, V79; JONES CM, 1991, DEVELOPMENT, V111, P531; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; KENNYMOBBS T, 1987, DEVELOPMENT, V100, P449; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOSEKI H, 1993, DEVELOPMENT, V119, P649; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; KURATANI S, 1994, DEV BIOL, V161, P357, DOI 10.1006/dbio.1994.1037; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MOURY JD, 1989, DEV BIOL, V141, P243; OFARRELL F, 1994, NATURE, V368, P188; ORDAHL CP, 1993, MOL BASIS MORPHOGENE, P165; PARR BA, 1993, DEVELOPMENT, V119, P247; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RIDDLE RD, 1993, CELL, V75, P1501; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; RONG PM, 1992, DEVELOPMENT, V115, P657; Sambrook J, 1989, MOL CLONING LABORATO; SMITH JC, 1994, CELL, V76, P193, DOI 10.1016/0092-8674(94)90325-5; STERN CD, 1988, DEVELOPMENT, V104, P231; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAM PPL, 1986, J EMBRYOL EXP MORPH, V92, P269; TESSIERLAVIGNE M, 1987, NATURE, V336, P775; THEILER K, 1988, ADV ANAT EMBRYOL CEL, V112, P1; WATTERSON RL, 1954, AM J ANAT, V95, P337, DOI 10.1002/aja.1000950302; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I	49	507	542	1	20	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1175	1186		10.1016/0092-8674(94)90009-4	http://dx.doi.org/10.1016/0092-8674(94)90009-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001153				2022-12-28	WOS:A1994PZ86000009
J	RUSTGI, AK				RUSTGI, AK			MEDICAL PROGRESS - HEREDITARY GASTROINTESTINAL POLYPOSIS AND NONPOLYPOSIS SYNDROMES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FAMILIAL ADENOMATOUS POLYPOSIS; PEUTZ-JEGHERS SYNDROME; COLI GARDNERS-SYNDROME; OCULAR FUNDUS LESIONS; MUIR-TORRE SYNDROME; (LYNCH SYNDROME-I; APC GENE-PRODUCT; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; JUVENILE POLYPOSIS		HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	RUSTGI, AK (corresponding author), MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,JACKSON 7,50 BLOSSOM ST,BOSTON,MA 02114, USA.				PHS HHS [R01 43351] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAUGHMAN FA, 1969, NEW ENGL J MED, V281, P1345, DOI 10.1056/NEJM196912112812407; BECKER JM, 1991, SURGERY, V110, P718; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOMAN BM, 1988, CANCER GENET CYTOGEN, V34, P153, DOI 10.1016/0165-4608(88)90182-3; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUFILL JA, 1990, ANN INTERN MED, V113, P779, DOI 10.7326/0003-4819-113-10-779; BULOW S, 1984, DIS COLON RECTUM, V27, P105, DOI 10.1007/BF02553986; BURDICK D, 1982, CANCER, V50, P2139, DOI 10.1002/1097-0142(19821115)50:10<2139::AID-CNCR2820501028>3.0.CO;2-K; BURT RW, 1984, GASTROENTEROLOGY, V86, P295; BURT RW, 1988, GASTROENTEROL CLIN N, V17, P657; Bussey H.J.R., 1975, FAMILIAL POLYPOSIS C; BUSSEY HJR, 1978, GASTROENTEROLOGY, V74, P1325; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CARLSON HE, 1986, AM J HUM GENET, V38, P908; COHEN PR, 1991, AM J MED, V90, P606; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FISHEL R, 1994, CELL, V77, P167; FOLEY TR, 1988, GASTROENTEROLOGY, V95, P1535, DOI 10.1016/S0016-5085(88)80074-X; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; GOODMAN ZD, 1979, CANCER, V43, P1906, DOI 10.1002/1097-0142(197905)43:5<1906::AID-CNCR2820430548>3.0.CO;2-O; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GURBUZ AK, 1994, GUT, V35, P377, DOI 10.1136/gut.35.3.377; HAGGITT RC, 1986, AM J SURG PATHOL, V10, P871, DOI 10.1097/00000478-198612000-00006; HAKALA T, 1991, CANCER, V68, P1656, DOI 10.1002/1097-0142(19911001)68:7<1656::AID-CNCR2820680732>3.0.CO;2-7; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; HIXSON LJ, 1993, AM J GASTROENTEROL, V88, P1652; HOWELL J, 1981, J PEDIATR SURG, V16, P82, DOI 10.1016/S0022-3468(81)80124-8; IIDA M, 1985, GASTROENTEROLOGY, V89, P1021, DOI 10.1016/0016-5085(85)90203-3; IIDA M, 1989, GASTROENTEROLOGY, V96, P1301, DOI 10.1016/S0016-5085(89)80017-4; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JARVINEN H, 1983, GUT, V24, P333, DOI 10.1136/gut.24.4.333; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KLEIN WA, 1987, CANCER, V60, P2863, DOI 10.1002/1097-0142(19871215)60:12<2863::AID-CNCR2820601202>3.0.CO;2-I; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KONISHI F, 1987, DIS COLON RECTUM, V30, P790, DOI 10.1007/BF02554629; KURTZ RC, 1987, DIGEST DIS SCI, V32, P459, DOI 10.1007/BF01296027; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LAW IP, 1977, CANCER-AM CANCER SOC, V39, P1229, DOI 10.1002/1097-0142(197703)39:3<1229::AID-CNCR2820390331>3.0.CO;2-J; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LIU B, 1994, CANCER RES, V54, P4590; LUK GD, 1984, NEW ENGL J MED, V311, P80, DOI 10.1056/NEJM198407123110202; LYNCH HT, 1990, J UROLOGY, V143, P24, DOI 10.1016/S0022-5347(17)39853-1; LYNCH HT, 1992, DIS COLON RECTUM, V35, P411, DOI 10.1007/BF02049396; LYNCH HT, 1985, CANCER, V56, P934, DOI 10.1002/1097-0142(19850815)56:4<934::AID-CNCR2820560439>3.0.CO;2-I; LYNCH HT, 1985, BRIT J CANCER, V52, P271, DOI 10.1038/bjc.1985.187; LYNCH HT, 1985, BRIT J DERMATOL, V113, P295, DOI 10.1111/j.1365-2133.1985.tb02081.x; LYNCH HT, 1993, CANCER, V71, P2709, DOI 10.1002/1097-0142(19930501)71:9<2709::AID-CNCR2820710904>3.0.CO;2-T; LYNCH HT, 1985, CANCER, V56, P939, DOI 10.1002/1097-0142(19850815)56:4<939::AID-CNCR2820560440>3.0.CO;2-T; LYNCH HT, 1991, SEMIN ONCOL, V18, P337; MARRA G, 1994, J CLIN GASTROENTEROL, V18, P42, DOI 10.1097/00004836-199401000-00011; MECKLIN JP, 1992, CANCER, V69, P1112; MECKLIN JP, 1987, GASTROENTEROLOGY, V93, P101; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; NICHOLLS RJ, 1988, BRIT MED J, V296, P1707, DOI 10.1136/bmj.296.6638.1707-a; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1980, DOI 10.1016/0016-5085(92)90322-P; OLSCHWANG S, 1993, CELL, V75, P959, DOI 10.1016/0092-8674(93)90539-3; ORIORDAIN DS, 1991, CANCER, V68, P889, DOI 10.1002/1097-0142(19910815)68:4<889::AID-CNCR2820680435>3.0.CO;2-0; PAINTER TA, 1985, CANCER, V55, P2001, DOI 10.1002/1097-0142(19850501)55:9<2001::AID-CNCR2820550929>3.0.CO;2-7; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1991, CANCER RES, V51, P4135; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PERZIN KH, 1982, CANCER-AM CANCER SOC, V49, P971, DOI 10.1002/1097-0142(19820301)49:5<971::AID-CNCR2820490522>3.0.CO;2-1; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RICHARDS RC, 1981, CANCER, V47, P597, DOI 10.1002/1097-0142(19810201)47:3<597::AID-CNCR2820470329>3.0.CO;2-Z; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUTGEERTS P, 1981, GASTROINTEST ENDOSC, V27, P22, DOI 10.1016/S0016-5107(81)73137-7; SALEM OS, 1983, J AM ACAD DERMATOL, V8, P686, DOI 10.1016/S0190-9622(83)70081-2; SARRE RG, 1987, SURGERY, V101, P50; SCULLY RE, 1970, CANCER, V25, P1107, DOI 10.1002/1097-0142(197005)25:5<1107::AID-CNCR2820250516>3.0.CO;2-7; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SOGOL PB, 1983, WESTERN J MED, V139, P324; SPIRIO L, 1992, AM J HUM GENET, V51, P92; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; STARINK TM, 1986, CLIN GENET, V29, P222; STERN HS, 1990, SURGERY, V108, P528; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TONELLI F, 1985, DIS COLON RECTUM, V28, P664, DOI 10.1007/BF02553447; TOPS CMJ, 1993, AM J MED GENET, V47, P563, DOI 10.1002/ajmg.1320470425; TRABOULSI EI, 1990, ARCH OPHTHALMOL-CHIC, V108, P525, DOI 10.1001/archopht.1990.01070060073052; TRABOULSI EI, 1987, NEW ENGL J MED, V316, P661, DOI 10.1056/NEJM198703123161104; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; VOGEL VG, 1989, HEMATOL ONCOL CLIN N, V3, P35, DOI 10.1016/S0889-8588(18)30566-5; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WATANABE H, 1978, HUM PATHOL, V9, P269, DOI 10.1016/S0046-8177(78)80085-9; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WINAWER SJ, 1991, JNCI-J NATL CANCER I, V83, P243, DOI 10.1093/jnci/83.4.243	105	179	188	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 22	1994	331	25					1694	1702		10.1056/NEJM199412223312507	http://dx.doi.org/10.1056/NEJM199412223312507			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX382	7969362				2022-12-28	WOS:A1994PX38200007
J	WYATT, JC				WYATT, JC			CLINICAL-DATA SYSTEMS .3. DEVELOPMENT AND EVALUATION	LANCET			English	Article							MEDICAL RECORD SYSTEM; INFORMATION-SYSTEM; GENERAL-PRACTICE; QUALITY ASSURANCE; COMPUTER; CARE; SURVEILLANCE; MANAGEMENT; EXPERIENCE; ACCURACY				WYATT, JC (corresponding author), IMPERIAL CANC RES FUND, BIOMED INFORMAT UNIT, POB 123, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.		Greiver, Michelle/N-8764-2015; Wyatt, Jeremy/F-8160-2010	Greiver, Michelle/0000-0001-8957-0285; Wyatt, Jeremy/0000-0001-7008-1473				AMBROSINI MT, 1992, LANCET, V339, P935, DOI 10.1016/0140-6736(92)90978-C; BARNETT GO, 1978, MED CARE, V16, P962, DOI 10.1097/00005650-197811000-00007; BARRIE JL, 1992, BRIT MED J, V304, P159, DOI 10.1136/bmj.304.6820.159; BIGNALL J, 1994, LANCET, V343, P1631, DOI 10.1016/S0140-6736(94)93080-5; BLEICH HL, 1985, NEW ENGL J MED, V312, P756, DOI 10.1056/NEJM198503213121205; BRADSHAW KE, 1989, COMPUT BIOMED RES, V22, P575, DOI 10.1016/0010-4809(89)90077-3; Brooks Fred, 1982, MYTHICAL MAN MONTH; BULPITT CJ, 1976, BMJ-BRIT MED J, V1, P677, DOI 10.1136/bmj.1.6011.677; CAREY TS, 1992, ARCH INTERN MED, V152, P1845, DOI 10.1001/archinte.152.9.1845; CHAN LS, 1993, COMPUT BIOMED RES, V26, P582, DOI 10.1006/cbmr.1993.1041; CHRISTIE P, 1990, LECTURE NOTES MED IN, V40, P567; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; DEGOULET P, 1990, AM J HYPERTENS, V3, P156, DOI 10.1093/ajh/3.2.156; Dewey J. B., 1994, Seventeenth Annual Symposium on Computer Applications in Medical Care. Patient-Centered Computing, P79; EDSALL DW, 1993, J CLIN ANESTH, V5, P275, DOI 10.1016/0952-8180(93)90118-X; FRIEDMAN C, IN PRESS EVALUATION; GODLEE F, 1994, BMJ-BRIT MED J, V309, P969, DOI 10.1136/bmj.309.6960.969; HAMMOND KW, 1990, COMPUT BIOL MED, V20, P267, DOI 10.1016/0010-4825(90)90052-Q; Happ B. A., 1994, Seventeenth Annual Symposium on Computer Applications in Medical Care. Patient-Centered Computing, P183; HARRISON GSM, 1991, BRIT J UROL, V67, P532, DOI 10.1111/j.1464-410X.1991.tb15201.x; HAYNES RB, 1987, ARCH INTERN MED, V147, P1297, DOI 10.1001/archinte.147.7.1297; Heathfield H. A., 1994, Seventeenth Annual Symposium on Computer Applications in Medical Care. Patient-Centered Computing, P129; HEATHFIELD HA, 1993, METHOD INFORM MED, V32, P1; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; JOHNSON N, 1991, BRIT MED J, V302, P763, DOI 10.1136/bmj.302.6779.763; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; JONES RB, 1986, CURRENT PERSPECTIVES, P80; KENT DL, 1985, J CLIN ONCOL, V3, P1409, DOI 10.1200/JCO.1985.3.10.1409; KUHN K, 1992, METHOD INFORM MED, V31, P268; LEANING MS, 1993, BRIT MED J, V307, P217, DOI 10.1136/bmj.307.6898.217; LEVY RP, 1964, JAMA-J AM MED ASSOC, V190, P77; Marr P B, 1993, Comput Nurs, V11, P176; MASSARO TA, 1993, ACAD MED, V16, P99; MCDONALD CJ, 1976, ANN INTERN MED, V84, P162, DOI 10.7326/0003-4819-84-2-162; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCDONALD CJ, 1989, ANN INTERN MED, V110, P333, DOI 10.7326/0003-4819-110-5-333; MUMFORD E, 1991, BRIT MED J, V302, P1587, DOI 10.1136/bmj.302.6792.1587; NAZARETH I, 1993, BRIT MED J, V307, P32, DOI 10.1136/bmj.307.6895.32; Norman D. A., 1990, DESIGN EVERYDAY THIN; Nowlan W A, 1993, Yearb Med Inform, P173; PRINGLE M, 1991, BMJ-BRIT MED J, V302, P741, DOI 10.1136/bmj.302.6779.741; Rind D. M., 1994, Seventeenth Annual Symposium on Computer Applications in Medical Care. Patient-Centered Computing, P74; RUBIN PC, 1984, BRIT MED J, V289, P537, DOI 10.1136/bmj.289.6444.537; Safran C., 1994, Seventeenth Annual Symposium on Computer Applications in Medical Care. Patient-Centered Computing, P224; SITTIG DF, 1994, J AM MED INFORM ASSN, V1, P108, DOI 10.1136/jamia.1994.95236142; SITTIG DF, 1993, METHOD INFORM MED, V32, P167; SMITH AP, 1992, BRIT MED J, V305, P415, DOI 10.1136/bmj.305.6850.415; SMITH M, 1993, BR J HLTH CARE COMP, V10, P25; Smith M. F., 1991, SOFTWARE PROTOTYPING; Suermondt H. J., 1994, Seventeenth Annual Symposium on Computer Applications in Medical Care. Patient-Centered Computing, P229; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; VANMULLIGEN EM, 1993, METHOD INFORM MED, V32, P292; WEISER M, 1991, SCI AM, V265, P94, DOI 10.1038/scientificamerican0991-94; WHITINGOKEEFE QE, 1985, JAMA-J AM MED ASSOC, V254, P1185, DOI 10.1001/jama.254.9.1185; WYATT J, 1990, LANCET, V335, P1223; WYATT J, 1991, LANCET, V338, P1431, DOI 10.1016/0140-6736(91)92731-G; WYATT J, 1991, 15TH P ANN S COMP AP, P3; WYATT JC, 1994, COMPUT METH PROG BIO, V43, P283, DOI 10.1016/0169-2607(94)90081-7; YEOH C, 1993, BRIT MED J, V306, P972, DOI 10.1136/bmj.306.6883.972; YOUNG DW, 1984, J ROY SOC MED, V77, P663, DOI 10.1177/014107688407700810; 1993, 1993 RECOMMENDATIONS; [No title captured]; [No title captured]	63	46	46	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 17	1994	344	8938					1682	1688		10.1016/S0140-6736(94)90463-4	http://dx.doi.org/10.1016/S0140-6736(94)90463-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996965				2022-12-28	WOS:A1994PX30200014
J	MUSCATELLI, F; STROM, TM; WALKER, AP; ZANARIA, E; RECAN, D; MEINDL, A; BARDONI, B; GUIOLI, S; ZEHETNER, G; RABL, W; SCHWARZ, HP; KAPLAN, JC; CAMERINO, G; MEITINGER, T; MONACO, AP				MUSCATELLI, F; STROM, TM; WALKER, AP; ZANARIA, E; RECAN, D; MEINDL, A; BARDONI, B; GUIOLI, S; ZEHETNER, G; RABL, W; SCHWARZ, HP; KAPLAN, JC; CAMERINO, G; MEITINGER, T; MONACO, AP			MUTATIONS IN THE DAX-1 GENE GIVE RISE TO BOTH X-LINKED ADRENAL HYPOPLASIA CONGENITA AND HYPOGONADOTROPIC HYPOGONADISM	NATURE			English	Article							GLYCEROL KINASE-DEFICIENCY; RESTRICTION MAP; INDUCE PUBERTY; HEMOPHILIA-A; XP21; DELETION; FAILURE; CLONING; DISTAL; CONTIG	ADRENAL hypoplasia congenita (AHC) is an X-linked disorder characterized by primary adrenal insufficiency(1,2). Hypogonadotropic hypogonadism (HHG) is frequently associated with this disorder but is thought not to be caused by the low adrenal androgen levels due to adrenal hypoplasia(3,4). It is uncertain whether there are two distinct yet physically linked genes responsible for AHC and HHG or a single gene responsible for both diseases. AHC can occur as a part of a contiguous deletion syndrome together with Duchenne muscular dystrophy (DMD) and/or glycerol kinase deficiency (GKD). From the analysis of deletions, the following gene order has been deduced: Xpter-AHC-GKD-DMD-cen(5,6). An AHC critical region of 200-500 kilobases has been defined by physical mapping(7,8) and partially overlaps with a 160-kilobase dosage-sensitive sex (DSS) reversal critical region(9). The DAX-1 (DSS-AHC critical region on the X, gene 1) gene was isolated and found to encode a new member of the nuclear hormone receptor family(10). Here we report that DAX-1 is deleted in 14 patients and point mutations were found in the coding region in DNA from 12 unrelated individuals. All AHC patients over 14 years old and with only point mutations in DAX-1 mere also diagnosed with HHG, confirming that the DAX-1 gene is responsible for both X-linked AHC and HHG. But in four sporadic cases and a single familial case, no point mutations were found, suggesting genetic heterogeneity or differential expression of DAX-1.	UNIV MUNICH,KINDERPOLIKLIN,PADIAT GENET ABT,D-80336 MUNICH,GERMANY; UNIV PAVIA,I-27100 PAVIA,ITALY; HOP COCHIN,F-75014 PARIS,FRANCE; ICRF LABS,LONDON WC2A 3PX,ENGLAND; TECH UNIV MUNICH,KINDERKLIN,D-80804 MUNICH,GERMANY; UNIV MUNICH,DR VON HAUNERSCHES KINDERSPITAL,D-80337 MUNICH,GERMANY	University of Munich; University of Pavia; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Technical University of Munich; University of Munich	MUSCATELLI, F (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND.		Bardoni, Barbara/F-9918-2013; Monaco, Anthony P/A-4495-2010; Muscatelli, Françoise/P-4650-2016; Walker, Ann P/C-1628-2008	Monaco, Anthony P/0000-0001-7480-3197; Muscatelli, Françoise/0000-0003-4001-6528; Guioli, Silvana/0000-0002-4920-7745; Meitinger, Thomas/0000-0002-8838-8403; Bardoni, Barbara/0000-0001-6411-1517	Telethon [B.05] Funding Source: Medline	Telethon(Fondazione Telethon)		BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; BASERGA SJ, 1988, P NATL ACAD SCI USA, V85, P2056, DOI 10.1073/pnas.85.7.2056; BAXENDALE S, 1993, NAT GENET, V4, P181, DOI 10.1038/ng0693-181; CHELLY J, 1988, HUM GENET, V78, P222, DOI 10.1007/BF00291665; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; COHEN HN, 1982, LANCET, V2, P1471; FAIRWEATHER N, 1994, HUM MOL GENET, V3, P29, DOI 10.1093/hmg/3.1.29; FRANCKE U, 1987, AM J HUM GENET, V40, P212; GOONEWARDENA P, 1989, CLIN GENET, V35, P5; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; Kelch RP, 1984, PEDIATR ADOLESC ENDO, V13, P156; KIKUCHI K, 1987, ACTA ENDOCRINOL-COP, V114, P153, DOI 10.1530/acta.0.1140153; KLECZKOWSKA A, 1991, GENET COUNSELING, V1, P241; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MARHLENS F, 1987, HUM GENET, V77, P379; MATFIN G, 1994, CLIN ENDOCRINOL, V40, P807, DOI 10.1111/j.1365-2265.1994.tb02517.x; NAYLOR JA, 1993, HUM MOL GENET, V2, P11, DOI 10.1093/hmg/2.1.11; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; RACKWITZ HR, 1985, GENE, V40, P259, DOI 10.1016/0378-1119(85)90048-4; RECAN D, 1992, J CLIN INVEST, V89, P712, DOI 10.1172/JCI115640; Sambrook J, 1989, MOL CLONING LABORATO; SIZONENKO PC, 1978, AM J DIS CHILD, V132, P704, DOI 10.1001/archpedi.1978.02120320064015; WALKER AP, 1992, HUM MOL GENET, V1, P579, DOI 10.1093/hmg/1.8.579; WALKER AP, 1993, HUM MOL GENET, V2, P107, DOI 10.1093/hmg/2.2.107; WORLEY KC, 1993, GENOMICS, V16, P407, DOI 10.1006/geno.1993.1204; YATES JRW, 1987, CYTOGENET CELL GENET, V46, P723; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; ZEHETNER G, 1986, NUCLEIC ACIDS RES, V14, P335, DOI 10.1093/nar/14.1.335	29	586	609	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					672	676		10.1038/372672a0	http://dx.doi.org/10.1038/372672a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990958				2022-12-28	WOS:A1994PX30700085
J	STARK, K; VAINIO, S; VASSILEVA, G; MCMAHON, AP				STARK, K; VAINIO, S; VASSILEVA, G; MCMAHON, AP			EPITHELIAL TRANSFORMATION OF METANEPHRIC MESENCHYME IN THE DEVELOPING KIDNEY REGULATED BY WNT-4	NATURE			English	Article							DEVELOPING EXCRETORY SYSTEM; WILMS-TUMOR GENE; MOUSE DEVELOPMENT; EXPRESSION; PROTOONCOGENE; EMBRYO; DISRUPTION; HOMOLOG	THE kidney has been widely exploited as a model system for the study of tissue inductions regulating vertebrate organogenesis(1,2). Kidney development is initiated by the ingrowth of the Wolfian duct-derived ureteric bud into the presumptive kidney mesenchyme. In response to a signal from the ureter, mesenchymal cells condense, aggregate into pretubular clusters and undergo an epithelial conversion generating a simple tubule. This then undergoes morphogenesis and is transformed into the excretory system of the kidney, the nephron. We report here that the expression of Wnt-4, which encodes a secreted glycoprotein, correlates with, and is required for, kidney tubulogenesis. Mice lacking Wnt-1 activity fail to form pretubular cell aggregates; however, other aspects of mesenchymal and ureteric development are unaffected. Thus, Wnt-4 appears to act as an autoinducer of the mesenchyme to epithelial transition that underlies nephron development.	HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, BIOLABS, CAMBRIDGE, MA 02138 USA	Harvard University			Vassileva, Galya/A-6807-2009; McMahon, Andrew P/ABE-7520-2020	Vainio, Seppo/0000-0001-9319-3566				ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GROBSTEIN C, 1955, J EXP ZOOL, V130, P319, DOI 10.1002/jez.1401300207; GUMBINER BM, 1993, J CELL SCI, P155; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOON RT, 1993, DEVELOPMENT, V119, P97; MUGRAUER G, 1991, J CELL BIOL, V112, P13, DOI 10.1083/jcb.112.1.13; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PARR BA, 1993, DEVELOPMENT, V119, P247; PLACHOV D, 1990, DEVELOPMENT, V110, P643; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; SAXEN L, 1971, EXP CELL RES, V66, P369, DOI 10.1016/0014-4827(71)90690-2; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SHIMAMURA K, 1994, DEVELOPMENT, V120, P2225; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SONNENBERG E, 1991, EMBO J, V10, P3693, DOI 10.1002/j.1460-2075.1991.tb04937.x; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; VESTWEBER D, 1985, DEV BIOL, V112, P213, DOI 10.1016/0012-1606(85)90135-6; WILKINSON DG, 1987, DEVELOPMENT, V99, P493	30	845	872	0	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 15	1994	372	6507					679	683		10.1038/372679a0	http://dx.doi.org/10.1038/372679a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990960				2022-12-28	WOS:A1994PX30700087
J	LAI, CG; LYMAN, RF; LONG, AD; LANGLEY, CH; MACKAY, TFC				LAI, CG; LYMAN, RF; LONG, AD; LANGLEY, CH; MACKAY, TFC			NATURALLY-OCCURRING VARIATION IN BRISTLE NUMBER AND DNA POLYMORPHISMS AT THE SCABROUS LOCUS OF DROSOPHILA-MELANOGASTER	SCIENCE			English	Article							PERIPHERAL NERVOUS-SYSTEM; STABILIZING SELECTION; MUTATION; GENETICS; BALANCE	The association between quantitative genetic variation in bristle number and molecular Variation at a candidate neurogenic locus, scabrous, was examined in Drosophila melanogaster. Approximately 32 percent of the genetic Variation in abdominal bristle number (21 percent for sternopleural bristle number) among 47 second chromosomes from a natural population was correlated with DNA sequence polymorphisms at this locus. Several polymorphic sites associated with large phenotypic effects occurred at intermediate frequency. Quantitative genetic variation in natural populations caused by alleles that have large effects at a few loci and that segregate at intermediate frequencies conflicts with the classical infinitesimal model of the genetic basis of quantitative variation.	N CAROLINA STATE UNIV, DEPT GENET, RALEIGH, NC 27695 USA; MCMASTER UNIV, DEPT BIOL, HAMILTON L8S 4K1, ON, CANADA	University of North Carolina; North Carolina State University; McMaster University	LAI, CG (corresponding author), UNIV CALIF DAVIS, CTR POPULAT BIOL, DAVIS, CA 95616 USA.			Lai, Chao-Qiang/0000-0003-1107-8375; Long, Tony/0000-0002-5007-8514	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM045344, R01GM045146] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45146, GM45344] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUADE M, 1994, P NATL ACAD SCI USA, V91, P4658, DOI 10.1073/pnas.91.11.4658; AGUADE M, 1989, GENETICS, V122, P607; AQUADRO CF, 1992, TRENDS GENET, V8, P355, DOI 10.1016/0168-9525(92)90281-8; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BARTON NH, 1989, ANNU REV GENET, V23, P337, DOI 10.1146/annurev.ge.23.120189.002005; CLAYTON G. A., 1957, JOUR GENETICS, V55, P131, DOI 10.1007/BF02981620; Falconer D. S., 1989, Introduction to quantitative genetics.; Frankham R., 1980, Selection experiments in laboratory and domestic animals., P56; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GRABA Y, 1992, EMBO J, V11, P3375, DOI 10.1002/j.1460-2075.1992.tb05416.x; HELD LI, 1991, BIOESSAYS, V13, P633, DOI 10.1002/bies.950131203; HILL WG, 1990, 4TH WORLD C GEN APPL, P219; HOLM S, 1979, SCAND J STAT, V6, P65; KEARSEY MJ, 1970, HEREDITY, V25, P11, DOI 10.1038/hdy.1970.2; KEIGHTLEY PD, 1990, P ROY SOC B-BIOL SCI, V242, P95, DOI 10.1098/rspb.1990.0110; KEIGHTLEY PD, 1988, GENET RES, V52, P33, DOI 10.1017/S0016672300027282; KONDRASHOV AS, 1992, GENETICS, V132, P603; LANDE R, 1975, GENET RES, V26, P221, DOI 10.1017/S0016672300016037; LANGLEY CH, 1990, POPULATION BIOL GENE, P75; Long A., UNPUB; LYNCH M, 1986, EVOLUTION, V40, P915, DOI 10.1111/j.1558-5646.1986.tb00561.x; MACKAY TFC, 1990, NATURE, V348, P64, DOI 10.1038/348064a0; MACKAY TFC, 1990, 4TH P WORLD C GEN AP; MARTIN R, 1990, BIOTECHNIQUES, V9, P762; MCBRIDE G, 1963, GENET RES, V4, P356, DOI 10.1017/S001667230000375X; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269; NUZHDIN SV, INPRESS GENETICS; ORR HA, 1992, AM NAT, V140, P725, DOI 10.1086/285437; POSAKONY JW, 1994, CELL, V76, P415, DOI 10.1016/0092-8674(94)90105-8; SHERIDAN A K, 1968, Theoretical and Applied Genetics, V38, P179, DOI 10.1007/BF00935264; SIMPSON P, 1990, DEVELOPMENT, V109, P509; TURELLI M, 1984, THEOR POPUL BIOL, V25, P138, DOI 10.1016/0040-5809(84)90017-0	33	135	136	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	1994	266	5191					1697	1702		10.1126/science.7992053	http://dx.doi.org/10.1126/science.7992053			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992053				2022-12-28	WOS:A1994PW30800038
J	STUBBE, J				STUBBE, J			BINDING-SITE REVEALED OF NATURES MOST BEAUTIFUL COFACTOR	SCIENCE			English	Editorial Material							DEPENDENT METHIONINE SYNTHASE; ESCHERICHIA-COLI; CLONING		MIT,DEPT BIOCHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	STUBBE, J (corresponding author), MIT,DEPT CHEM,CAMBRIDGE,MA 02139, USA.							BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P11101, DOI 10.1021/bi00502a013; BANERJEE RV, 1989, J BIOL CHEM, V264, P13888; BANERJEE RV, 1990, FASEB J, V4, P1450, DOI 10.1096/fasebj.4.5.2407589; BATTERSBY AR, 1994, SCIENCE, V264, P1551, DOI 10.1126/science.8202709; BIANCHI V, 1993, BIOCHEM BIOPH RES CO, V197, P792, DOI 10.1006/bbrc.1993.2548; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; DRENNAN CL, IN PRESS CURR OPIN S; FREY M, 1994, J BIOL CHEM, V269, P12432; FUGII K, 1974, J BIOL CHEM, V249, P6745; HODGKIN DC, 1956, NATURE, V178, P64, DOI 10.1038/178064a0; LENHERT PG, 1961, NATURE, V192, P937, DOI 10.1038/192937a0; MARSH ENG, 1992, FEBS LETT, V310, P167, DOI 10.1016/0014-5793(92)81321-C; Roessner C A, 1994, Chem Biol, V1, P119; ZAGALAK B, 1979, VITAMIN B12	14	47	50	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1663	1664		10.1126/science.7992049	http://dx.doi.org/10.1126/science.7992049			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992049				2022-12-28	WOS:A1994PW30800027
J	STEVENSON, JC; GODSLAND, IF; WYNN, V				STEVENSON, JC; GODSLAND, IF; WYNN, V			CARDIOLOGISTS REBUKED	LANCET			English	Editorial Material											STEVENSON, JC (corresponding author), WYNN INST METAB RES, LONDON NW8 9SQ, ENGLAND.							BERG G, 1994, MODERN MANAGEMENT ME; CLARKE KW, 1994, BMJ-BRIT MED J, V309, P563, DOI 10.1136/bmj.309.6954.563; COLLINS P, 1993, LANCET, V341, P1264, DOI 10.1016/0140-6736(93)91158-I; JACKSON G, 1994, BRIT MED J, V309, P555, DOI 10.1136/bmj.309.6954.555; LACROIX AZ, 1989, AM J EPIDEMIOL, V129, P669, DOI 10.1093/oxfordjournals.aje.a115183; LEY CJ, 1994, J AM COLL CARDIOL, V23, P377, DOI 10.1016/0735-1097(94)90423-5; OLIVER MF, 1994, LANCET, V344, P633; PEDERSEN TR, 1994, LANCET, V344, P1383; PYORALA K, 1994, EUR HEART J, V15, P1300; ROBERTS WC, 1993, AM J CARDIOL, V72, P745, DOI 10.1016/0002-9149(93)90898-M; STEVENSON JC, 1994, HORIZONS MED, V5, P92; WILKINSON P, 1994, BRIT MED J, V309, P566, DOI 10.1136/bmj.309.6954.566; 1994, EUR HEART J S, V15	13	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 3	1994	344	8936					1557	1557		10.1016/S0140-6736(94)90356-5	http://dx.doi.org/10.1016/S0140-6736(94)90356-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983960				2022-12-28	WOS:A1994PV01700016
J	THALI, M; BUKOVSKY, A; KONDO, E; ROSENWIRTH, B; WALSH, CT; SODROSKI, J; GOTTLINGER, HG				THALI, M; BUKOVSKY, A; KONDO, E; ROSENWIRTH, B; WALSH, CT; SODROSKI, J; GOTTLINGER, HG			FUNCTIONAL ASSOCIATION OF CYCLOPHILIN-A WITH HIV-1 VIRIONS	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CIS-TRANS ISOMERASE; BINDING-PROTEIN; CYCLOSPORINE-A; HISTOCOMPATIBILITY; REPLICATION; CELLS; GENE	CYCLOPHILINS are a family of proteins that bind the immunosuppressant cyclosporin A, possess peptidyl-prolyl cis-trans isomerase activity, and assist in the folding of proteins(1-6). Human cyclophilins A and B are host cell proteins that bind specifically to the HIV-1 Gag polyprotein p55(gag) in vitro(7). Here we report that viral particles formed by p55(gag), in contrast to particles formed by the Gag polyproteins of other retroviruses, contain significant amounts of cyclophilin A. Sequences in the capsid domain of p55(gag) are both required and sufficient for the virion-association of cyclophilin A. The association of cyclophilin A with HIV-1 virions was inhibited in a dose-dependent manner by cyclosporin A as well as by SDZ NIM811 ([Melle-4] cyclosporin), a non-immunosuppressive analogue of cyclosporin A(8). Drug-induced reductions in virion-associated cyclophilin A levels were accompanied by reductions in virion infectivity, indicating that the association is functionally relevant. Moreover, SDZ NIM811 inhibited the replication of HIV-1 but was inactive against SIVIMAC, a primate immunodeficiency virus closely related to HIV-1, which does not incorporate cyclophilin A.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HUMAN RETROVIROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; SANDOZ GMBH,FORSCHUNGSINST,A-1235 VIENNA,AUSTRIA; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Novartis; Sandoz; Harvard University; Harvard Medical School				Gottlinger, Heinrich/0000-0003-4124-5824; Thali, Markus/0000-0001-8621-2095				ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DORFMAN T, 1994, J VIROL, V68, P1689, DOI 10.1128/JVI.68.3.1689-1696.1994; DORFMAN T, 1994, J VIROL, V68, P8180, DOI 10.1128/JVI.68.12.8180-8187.1994; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; GELDERBLOM H, 1987, Z NATURFORSCH C, V42, P1328; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; GOTTLINGER HG, 1993, P NATL ACAD SCI USA, V90, P7381, DOI 10.1073/pnas.90.15.7381; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; KANNAGI M, 1987, J VIROL, V61, P1421, DOI 10.1128/JVI.61.5.1421-1426.1987; KAYE RE, 1992, P NATL ACAD SCI USA, V89, P8542, DOI 10.1073/pnas.89.18.8542; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MAMMANO F, 1994, J VIROL, V68, P4927, DOI 10.1128/JVI.68.8.4927-4936.1994; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; SCHOLS D, 1992, VIROLOGY, V189, P374, DOI 10.1016/0042-6822(92)90719-6; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; STAMNES M A, 1992, Trends in Cell Biology, V2, P272, DOI 10.1016/0962-8924(92)90200-7; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TERWILLIGER EF, 1989, P NATL ACAD SCI USA, V86, P3857, DOI 10.1073/pnas.86.10.3857; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002	23	551	570	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					363	365		10.1038/372363a0	http://dx.doi.org/10.1038/372363a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969495				2022-12-28	WOS:A1994PU28700056
J	SCHNELL, DJ; KESSLER, F; BLOBEL, G				SCHNELL, DJ; KESSLER, F; BLOBEL, G			ISOLATION OF COMPONENTS OF THE CHLOROPLAST PROTEIN IMPORT MACHINERY	SCIENCE			English	Article							SIGNAL RECOGNITION PARTICLE; ENVELOPE CONTACT SITES; TRANSIT PEPTIDE; PHOSPHATE TRANSLOCATOR; PRECURSOR PROTEINS; MEMBRANES; RECEPTOR; BINDING; IDENTIFICATION; SEQUENCE	Components of the protein import machinery of the chloroplast were isolated by a procedure in which the import machinery was engaged in vitro with a tagged import substrate under conditions that yielded largely chloroplast envelope-bound import intermediates. Subsequent detergent solubilization of envelope membranes showed that six envelope polypeptides copurified specifically and, apparently, stoichiometrically with the import intermediates. Four of these polypeptides are components of the outer membrane import machinery and are associated with early import intermediates. Two of these polypeptides have been characterized. One is a homolog of the heat shock protein hsp70; the other one is a channel-protein candidate.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University	SCHNELL, DJ (corresponding author), RUTGERS STATE UNIV,DEPT BIOL SCI,NEWARK,NJ 07102, USA.		Kessler, Felix Henrique/AAO-1722-2020	Kessler, Felix/0000-0001-6409-5043				ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BUVINGER WE, 1989, J BIOL CHEM, V264, P1195; CHUA NH, 1979, J CELL BIOL, V81, P461, DOI 10.1083/jcb.81.3.461; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; CLINE K, 1985, PROTOPLASMA, V125, P111, DOI 10.1007/BF01297356; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CORNWELL KL, 1987, PLANT PHYSIOL, V85, P780, DOI 10.1104/pp.85.3.780; COWAN SW, 1994, SCIENCE, V264, P914, DOI 10.1126/science.8178151; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; FRIEDMAN AL, 1989, PLANT PHYSIOL, V89, P993, DOI 10.1104/pp.89.3.993; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GROSSMAN A, 1980, NATURE, V285, P625, DOI 10.1038/285625a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; KADERBHAI MA, 1988, FEBS LETT, V232, P313, DOI 10.1016/0014-5793(88)80760-9; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LODDENKOTTER B, 1993, P NATL ACAD SCI USA, V90, P2155, DOI 10.1073/pnas.90.6.2155; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PAUL C, 1985, EMBO J, V4, P1593, DOI 10.1002/j.1460-2075.1985.tb03822.x; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PERRY SE, 1991, J BIOL CHEM, V266, P11882; Sambrook J, 1989, MOL CLONING LABORATO; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SCHNELL DJ, 1991, J BIOL CHEM, V266, P3335; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1985, NUCLEIC ACIDS RES, V13, P3179, DOI 10.1093/nar/13.9.3179; THEG SM, 1989, J BIOL CHEM, V264, P6730; TIANF, UNPUB; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x	38	339	355	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1007	1012		10.1126/science.7973649	http://dx.doi.org/10.1126/science.7973649			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973649				2022-12-28	WOS:A1994PQ92400033
J	GERSHON, D				GERSHON, D			CHANGING TIMES FOR NEUROSCIENTISTS	NATURE			English	Article								At a time of considerable uncertainty for the biotechnology industry, Nature reviews the prospects for neuroscientists considering a move out of the academic sector.											0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					203	204		10.1038/372203a0	http://dx.doi.org/10.1038/372203a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969454				2022-12-28	WOS:A1994PQ68800064
J	JONES, DA; THOMAS, CM; HAMMONDKOSACK, KE; BALINTKURTI, PJ; JONES, JDG				JONES, DA; THOMAS, CM; HAMMONDKOSACK, KE; BALINTKURTI, PJ; JONES, JDG			ISOLATION OF THE TOMATO CF-9 GENE FOR RESISTANCE TO CLADOSPORIUM-FULVUM BY TRANSPOSON TAGGING	SCIENCE			English	Article							PLATELET GLYCOPROTEIN-IB; LEUCINE-RICH REPEATS; PROTEIN-KINASE; TRANSMEMBRANE PROTEIN; DISEASE-RESISTANCE; ARABIDOPSIS-THALIANA; RECEPTOR; CLONING; DOMAIN; SEQUENCE	The tomato Cf-9 gene confers resistance to infection by races of the fungus Cladosporium fulvum that carry the avirulence gene Avr9. The Cf-9 gene was isolated by transposon tagging with the maize transposable element Dissociation, The DNA sequence of Cf-9 encodes a putative membrane-anchored extracytoplasmic glycoprotein. The predicted protein shows homology to the receptor domain of several receptor-like protein kinases in Arabidopsis, to antifungal polygalacturonase-inhibiting proteins in plants, and to other members of the leucine-rich repeat family of proteins. This structure is consistent with that of a receptor that could bind Avr9 peptide and activate plant defense.	JOHN INNES INST,JOHN INNES CTR PLANT SCI RES,SAINSBURY LAB,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Balint-kurti, Peter/AES-0111-2022; Jones, Jonathan DG/J-5129-2012; Jones, David A/C-9507-2009	Jones, Jonathan DG/0000-0002-4953-261X; Jones, David A/0000-0001-8809-5822; Balint-Kurti, Peter/0000-0002-3916-194X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; HAMMONDKOSACK KE, 1994, PLANT CELL, V6, P361, DOI 10.2307/3869756; HAMMONDKOSACK KE, 1994, P NATL ACAD SCI USA, V91, P10445, DOI 10.1073/pnas.91.22.10445; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; Jones D. B., UNPUB; JONES DA, 1993, MOL PLANT MICROBE IN, V6, P348, DOI 10.1094/MPMI-6-348; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; PRYOR T, 1987, TRENDS GENET, V3, P157, DOI 10.1016/0168-9525(87)90217-4; PRYOR T, 1993, ADV PLANT PATHOL, V10, P281; ROMMENS CMT, 1992, PLANT MOL BIOL, V20, P61, DOI 10.1007/BF00029149; ROTH S, 1994, CURR BIOL, V4, P755, DOI 10.1016/S0960-9822(00)00170-6; SCOFIELD SR, 1992, PLANT CELL, V4, P573, DOI 10.1105/tpc.4.5.573; STEINMAYR M, 1994, PLANT J, V5, P459, DOI 10.1046/j.1365-313X.1994.5040459.x; STOTZ HU, 1993, PLANT PHYSIOL, V102, P133, DOI 10.1104/pp.102.1.133; STOTZ HU, 1994, PLANT MOL BIOL, V25, P607, DOI 10.1007/BF00029600; SUDUPAK MA, 1993, GENETICS, V133, P119; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TOUBART P, 1992, PLANT J, V2, P367; TOURVIEILLE B, 1986, SCIENCE, V234, P610, DOI 10.1126/science.3094146; TOWNSLEY FM, 1994, EUROPEAN J CELL BIOL, V64, P221; VALON C, 1993, PLANT MOL BIOL, V23, P415, DOI 10.1007/BF00029017; VANDENACKERVEKEN GFJM, 1992, PLANT J, V2, P359, DOI 10.1111/j.1365-313X.1992.00359.x; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALKER JC, 1993, PLANT J, V3, P451, DOI 10.1046/j.1365-313X.1993.t01-23-00999.x; WARE J, 1993, J CLIN INVEST, V92, P1213, DOI 10.1172/JCI116692; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6	38	716	897	6	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					789	793		10.1126/science.7973631	http://dx.doi.org/10.1126/science.7973631			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973631				2022-12-28	WOS:A1994PP75300035
J	LEE, GU; CHRISEY, LA; COLTON, RJ				LEE, GU; CHRISEY, LA; COLTON, RJ			DIRECT MEASUREMENT OF THE FORCES BETWEEN COMPLEMENTARY STRANDS OF DNA	SCIENCE			English	Article							MICROSCOPY; OLIGONUCLEOTIDES; MOLECULES	Interaction forces between single strands of DNA were measured with the atomic force microscope by a procedure in which DNA oligonucleotides were covalently attached to a spherical probe and surface. Adhesive forces measured between complementary 20-base strands fell into three distinct distributions centered at 1.52, 1.11, and 0.83 nano-newtons, which are associated with the rupture of the interchain interaction between a single pair of molecules involving 20, 16, and 12 base pairs, respectively. When a third long DNA molecule was coupled between complementary surfaces, both intra- and interchain forces were observed. The intrachain interaction resulting from the molecule's elasticity manifested itself as a long-range cohesive force.z	USN, RES LAB, CTR BIOMOLEC SCI & ENGN, WASHINGTON, DC 20375 USA	United States Department of Defense; United States Navy; Naval Research Laboratory	LEE, GU (corresponding author), USN, RES LAB, DIV CHEM, CODE 6177, WASHINGTON, DC 20375 USA.		Lee, Gil U/P-8696-2016	Lee, Gil U/0000-0002-7949-5848				ALBRECHT TR, 1988, J VAC SCI TECHNOL A, V6, P271, DOI 10.1116/1.575441; ASHKIN A, 1987, NATURE, V330, P769, DOI 10.1038/330769a0; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BHATIA SK, 1989, ANAL BIOCHEM, V178, P408, DOI 10.1016/0003-2697(89)90662-3; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; CHRISEY LA, 1994, MATER RES SOC SYMP P, V330, P179; CONNOLLY BA, 1985, NUCLEIC ACIDS RES, V13, P4485, DOI 10.1093/nar/13.12.4485; DENG GR, 1983, METHOD ENZYMOL, V100, P96; DURIG U, 1992, J APPL PHYS, V72, P1778, DOI 10.1063/1.352348; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; Flory PJ., 1953, PRINCIPLES POLYM CHE, V672; FLORY PJ, 1989, STATISTICAL MECHANIC; INMAN RB, 1964, J MOL BIOL, V8, P452, DOI 10.1016/S0022-2836(64)80003-6; INMAN RB, 1964, J MOL BIOL, V9, P624, DOI 10.1016/S0022-2836(64)80171-6; ISRAELACHVILI JN, 1992, INTERMOLECULAR SURFA, pCH10; James HM, 1943, J CHEM PHYS, V11, P455, DOI 10.1063/1.1723785; KLUMP HH, 1988, BIOCH THERMODYNAMICS, P105; KUMAR A, 1991, NUCLEIC ACIDS RES, V19, P4561, DOI 10.1093/nar/19.16.4561; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; MEYER G, 1988, APPL PHYS LETT, V53, P1045, DOI 10.1063/1.100061; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; PUTMAN CAJ, 1992, J APPL PHYS, V72, P6, DOI 10.1063/1.352149; RAU DC, 1984, P NATL ACAD SCI-BIOL, V81, P2621, DOI 10.1073/pnas.81.9.2621; SAENGER W, 1983, PRINCIPLES NUCLEIC A, pCH6; Sambrook J, 1989, MOL CLONING LABORATO; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0	28	745	793	4	148	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					771	773		10.1126/science.7973628	http://dx.doi.org/10.1126/science.7973628			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973628				2022-12-28	WOS:A1994PP75300029
J	SURH, CD; SPRENT, J				SURH, CD; SPRENT, J			T-CELL APOPTOSIS DETECTED IN-SITU DURING POSITIVE AND NEGATIVE SELECTION IN THE THYMUS	NATURE			English	Article							MONOCLONAL-ANTIBODIES; COMPLEX; DEATH; IDENTIFICATION; THYMOCYTES; MEDULLA; INVIVO	BECAUSE of positive and negative selection to molecules of the major histocompatibility complex (MHC)(1), only a small proportion of the massive numbers of T cells generated is the thymus are selected for expert(2,3). Immature thymocytes have a rapid turnover(2), and it has long been assumed that most thymocytes die in situ(4,5), presumably from apoptosis(6). This has yet to be proved, however, and conventional staining techniques have shown only minimal evidence of cell death in the normal thymus(7,8). Using a method for detecting cells with DNA strand breaks, we now present direct evidence for apoptosis in the normal thymus. In sections of thymus from adult mice, apoptotic cells are scattered throughout the cortex and are engulfed locally by F4/80(+) macrophages. Apoptosis in the thymic cortex is not reduced in MHC-deficient mice, which suggests that T-cell death is primarily a reflection of lack of positive selection rather than negative selection. Direct evidence for apoptosis due to negative selection was obtained by crossing a V beta 5 transgenic line(9) to I-E(+) and I-E(-) mice: I-E(+) mice are known to eliminate V beta 5(+) T cells in the thymus whereas I-E(-) mice do not(10). In marked contrast to I-E(-) mice, the medulla of I-E(+) V beta 5 transgenic mice contains dense aggregates of apoptotic cells; these cells are engulfed by a distinct population of F4/80(-) MAC-3(+) macrophages. Negative selection of V beta 5(+) cells is thus restricted to the medulla.			SURH, CD (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL IMM4, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							Anderson R E, 1976, Adv Immunol, V24, P215, DOI 10.1016/S0065-2776(08)60331-4; CARDELL S, 1994, ADV IMMUNOL, V55, P423; DUIJVESTIJN AM, 1981, CELL TISSUE RES, V218, P279; FINK PJ, 1992, J EXP MED, V176, P1733, DOI 10.1084/jem.176.6.1733; FLOTTE TJ, 1983, AM J PATHOL, V111, P112; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HENGARTNER H, 1988, NATURE, V336, P388, DOI 10.1038/336388a0; KENDALL MD, 1984, IMMUNOL TODAY, V5, P286, DOI 10.1016/0167-5699(84)90148-8; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MALEK TR, 1983, P NATL ACAD SCI-BIOL, V80, P5694, DOI 10.1073/pnas.80.18.5694; METCALF DONALD, 1966, P242; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; PULLEN AM, 1989, IMMUNOL REV, V107, P125, DOI 10.1111/j.1600-065X.1989.tb00006.x; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; Saint-Marie G., 1970, REV CAN BIOL, V30, P51; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SCOLLAY R, 1985, RECOGNITION REGULATI, P3; SHI YF, 1991, J IMMUNOL, V146, P3340; Shortman K, 1990, Semin Immunol, V2, P3; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SURH CD, 1992, J EXP MED, V176, P495, DOI 10.1084/jem.176.2.495; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	29	884	902	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					100	103		10.1038/372100a0	http://dx.doi.org/10.1038/372100a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969401				2022-12-28	WOS:A1994PQ34800082
J	MCCLAIN, KL; LEACH, CT; JENSON, HB; JOSHI, VV; POLLOCK, BH; PARMLEY, RT; DICARLO, FJ; CHADWICK, EG; MURPHY, SB				MCCLAIN, KL; LEACH, CT; JENSON, HB; JOSHI, VV; POLLOCK, BH; PARMLEY, RT; DICARLO, FJ; CHADWICK, EG; MURPHY, SB			ASSOCIATION OF EPSTEIN-BARR-VIRUS WITH LEIOMYOSARCOMAS IN YOUNG-PEOPLE WITH AIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; POLYMERASE CHAIN-REACTION; MONOCLONAL-ANTIBODIES; CELL-LINES; DNA; AMPLIFICATION; NEOPLASIA; INFECTION; CHILDREN; LYMPHOMA	Background. Children with the acquired immunodeficiency syndrome (AIDS) have an unusually high incidence of smooth-muscle tumors (leiomyomas and leiomyosarcomas) in addition to malignant lymphomas. We tested the hypothesis that the smooth-muscle tumors in these children are associated with the Epstein-Barr virus (EBV). Methods. Tissue specimens of five leiomyosarcomas and two leiomyomas from five children and one young man with AIDS were studied for evidence of the human immunodeficiency virus (HIV) and EBV by in situ hybridization and quantitative polymerase chain reaction (PCR). Comparison specimens included samples of leiomyosarcoma and leiomyoma from HIV-negative children, EBV clonality of leiomyosarcomas was determined by Southern blot analysis with oligonucleotide probes for EBV terminal-repeat fragments, Tumor specimens were tested by immunoperoxidase staining for infiltration by B lymphocytes and expression of the EBV receptor, Serologic testing for EBV was performed. Results. In situ hybridization showed EBV genomes in all muscle cells of the five leiomyosarcomas and the two leiomyomas from the six HIV-infected patients, Quantitative PCR demonstrated strikingly high levels of EBV in tumor tissue, with as many as 4.3 genome copies per cell, Two colonic leiomyosarcomas obtained from different sites at different times from one patient contained different episomal EBV clones, signifying the presence of distinct monoclonal EBV-related tumors, We found biclonal EBV infection in the leiomyosarcoma of another patient, No EBV was detected in normal muscle or tumor specimens from HIV-negative patients, Immunostaining for the EBV receptor was strongly positive in six of the seven leiomyomas and leiomyosarcomas from the patients with AIDS. Conclusions. EBV can infect smooth-muscle cells, at least in patients with AIDS, and it may contribute to the pathogenesis of leiomyomas and leiomyosarcomas in patients with AIDS, EBV seems to play no part in smooth-muscle tumors in HIV-negative patients.	BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; UNIV TEXAS, HLTH SCI CTR, DEPT PEDIAT, SAN ANTONIO, TX 78284 USA; E CAROLINA UNIV, DEPT PATHOL & LAB MED, GREENVILLE, NC 27834 USA; UNIV FLORIDA, COLL MED, DEPT PEDIAT, GAINESVILLE, FL USA; CAROLINAS MED CTR, CHARLOTTE, NC 28203 USA; CHILDRENS HOSP NEW JERSEY, DEPT PATHOL, NEWARK, NJ USA; NORTHWESTERN UNIV, SCH MED, DEPT PEDIAT, CHICAGO, IL 60611 USA; CHILDRENS MEM HOSP, CHICAGO, IL 60614 USA	Baylor College of Medicine; University of Texas System; University of Texas Health San Antonio; University of North Carolina; East Carolina University; State University System of Florida; University of Florida; Carolinas Medical Center; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago				Jenson, Hal/0000-0002-6549-860X; McClain, Kenneth/0000-0003-0725-6263	NATIONAL CANCER INSTITUTE [R01CA056296, U10CA030969, R01CA055507] Funding Source: NIH RePORTER; NCI NIH HHS [CA55507, CA30969, CA56296] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAN GJ, 1989, VIROLOGY, V173, P489, DOI 10.1016/0042-6822(89)90561-8; CATTORETTI G, 1992, J PATHOL, V168, P357, DOI 10.1002/path.1711680404; CHADWICK EG, 1990, JAMA-J AM MED ASSOC, V263, P3182, DOI 10.1001/jama.263.23.3182; CHANG KL, 1993, BLOOD, V81, P496; CHEUNG A, 1982, J VIROL, V44, P286, DOI 10.1128/JVI.44.1.286-294.1982; CUNNINGHAM L, 1991, BRIT MED BULL, V47, P852, DOI 10.1093/oxfordjournals.bmb.a072516; DELECLUSE HJ, 1993, J VIROL, V67, P1292, DOI 10.1128/JVI.67.3.1292-1299.1993; ERICKSONVIITANEN S, 1989, AIDS RES HUM RETROV, V5, P577, DOI 10.1089/aid.1989.5.577; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; FRICKHOFEN N, 1991, J VIROL METHODS, V35, P65, DOI 10.1016/0166-0934(91)90086-F; GAFFEY MJ, 1992, PATHOL ANNU, V27, P55; KARP JE, 1991, CANCER RES, V51, P4743; KNOWLES DM, 1988, ANN INTERN MED, V108, P744, DOI 10.7326/0003-4819-108-5-744; LACK E E, 1986, Pediatric Pathology, V6, P181; LEE E, 1993, MODERN PATHOL, V6, pA127; LEVINE PH, 1992, LEUKEMIA, V6, pS54; MCLOUGHLIN LC, 1991, CANCER, V67, P2618, DOI 10.1002/1097-0142(19910515)67:10<2618::AID-CNCR2820671036>3.0.CO;2-5; MUELLER BU, 1994, PEDIATRIC AIDS CHALL, P603; NAKAMURA S, 1994, CANCER, V73, P2239, DOI 10.1002/1097-0142(19940501)73:9<2239::AID-CNCR2820730902>3.0.CO;2-#; ORLOW SJ, 1992, AM J PEDIAT HEMATOL, V14, P265; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; OU CY, 1988, SCIENCE, V240, P130; PEIPER SC, 1990, ARCH PATHOL LAB MED, V114, P711; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; ROSS JS, 1992, HUM PATHOL, V23, P69, DOI 10.1016/0046-8177(92)90014-T; ROWLANDS DC, 1993, BRIT J CANCER, V68, P1014, DOI 10.1038/bjc.1993.472; SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STARASOLER L, 1991, AM J CLIN PATHOL, V95, P858, DOI 10.1093/ajcp/95.6.858; SUMAYA CV, 1992, MANUAL CLIN LABORATO, P568; TIMENS W, 1991, HISTOCHEMISTRY, V95, P605, DOI 10.1007/BF00266748; VANHOEVEN KH, 1993, AM J SURG PATHOL, V17, P1176, DOI 10.1097/00000478-199311000-00011	32	417	431	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					12	18		10.1056/NEJM199501053320103	http://dx.doi.org/10.1056/NEJM199501053320103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990860				2022-12-28	WOS:A1995PZ49700003
J	NELSON, ME; FIATARONE, MA; MORGANTI, CM; TRICE, I; GREENBERG, RA; EVANS, WJ				NELSON, ME; FIATARONE, MA; MORGANTI, CM; TRICE, I; GREENBERG, RA; EVANS, WJ			EFFECTS OF HIGH-INTENSITY STRENGTH TRAINING ON MULTIPLE RISK-FACTORS FOR OSTEOPOROTIC FRACTURES - A RANDOMIZED CONTROLLED TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MINERAL DENSITY; WEIGHT-BEARING EXERCISE; POSTMENOPAUSAL WOMEN; SKELETAL-MUSCLE; OLDER MEN; CALCIUM SUPPLEMENTATION; PREMENOPAUSAL WOMEN; PHYSICAL-ACTIVITY; BODY-COMPOSITION; ELDERLY PERSONS	Objective.-To determine how multiple risk factors for osteoporotic fractures could be modified by high-intensity strength training exercises in postmenopausal women. Design.-Randomized controlled trial of 1-year duration. Setting.-Exercise laboratory at Tufts University, Boston, Mass. Population.-Forty postmenopausal white women, 50 to 70 years of age, participated in the study; 39 women completed the study. The subjects were sedentary and estrogen-deplete. Interventions.-High-intensity strength training exercises 2 days per week using five different exercises (n=20) vs untreated controls (n=19). Main Outcome Measures.-Dual-energy x-ray absorptiometry for bone status, one repetition maximum for muscle strength, 24-hour urinary creatinine for muscle mass, and backward tandem walk for dynamic balance. Results.-Femoral neck bone mineral density and lumbar spine bone mineral density increased by 0.005+/-0.039 g/cm(2) (0.9%+/-4.5%) (mean+/-SD) and 0.009+/-0.033 g/cm(2) (1.0%+/-3.6%), respectively, in the strength-trained women and decreased by -0.022+/-0.035 g/cm(2) (-2.5%+/-3.8%) and -0.019+/-0.035 g/cm(2) (-1.8%+/-3.5%), respectively, in the controls (P=.02 and .04). Total body bone mineral content was preserved in the strength-trained women (+2.0+/-68 g; 0.0%+/-3.0%) and tended to decrease in the controls (-33+77 g; -1.2%+/-3.4%, P=.12). Muscle mass, muscle strength, and dynamic balance increased in the strength-trained women and decreased in the controls (P=.03 to <.001). Conclusions.-High-intensity strength training exercises are an effective and feasible means to preserve bone density while improving muscle mass, strength, and balance in postmenopausal women.	HARVARD UNIV,SCH MED,DIV AGING,BOSTON,MA 02115; PENN STATE UNIV,NOLL PHYSIOL RES CTR,UNIVERSITY PK,PA	Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	NELSON, ME (corresponding author), TUFTS UNIV,JEAN MAYER USDA HUMAN NUTR RES CTR AGING,711 WASHINGTON ST,BOSTON,MA 02111, USA.				NIDDK NIH HHS [P01-DK42618] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042618] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AINSWORTH BE, 1993, J CLIN EPIDEMIOL, V46, P1403, DOI 10.1016/0895-4356(93)90140-V; AVIOLI LV, 1991, CALCIFIED TISSUE INT, V49, pS5, DOI 10.1007/BF02555078; BEVIER WC, 1989, J BONE MINER RES, V4, P421; BORG G, 1970, ACTA MED SCAND, V187, P17; BREWER V, 1983, MED SCI SPORT EXER, V15, P445; BUTLER RN, 1993, GERIATRICS, V48, P11; CAVANAUGH DJ, 1988, BONE, V9, P201, DOI 10.1016/8756-3282(88)90031-2; CHAMAY A, 1972, J BIOMECH, V5, P173, DOI 10.1016/0021-9290(72)90053-X; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CHOW R, 1987, BMJ-BRIT MED J, V295, P1441, DOI 10.1136/bmj.295.6611.1441; CUMMINGS SR, 1994, NEW ENGL J MED, V331, P872, DOI 10.1056/NEJM199409293311310; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DALSKY GP, 1988, ANN INTERN MED, V108, P824, DOI 10.7326/0003-4819-108-6-824; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; DAWSONHUGHES B, 1987, CALCIFIED TISSUE INT, V40, P310, DOI 10.1007/BF02556691; DOYLE F, 1970, LANCET, V1, P391, DOI 10.1016/S0140-6736(70)91520-5; EVANS WJ, 1993, J NUTR, V123, P465, DOI 10.1093/jn/123.suppl_2.465; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FRONTERA WR, 1991, J APPL PHYSIOL, V71, P644, DOI 10.1152/jappl.1991.71.2.644; FRONTERA WR, 1990, J APPL PHYSIOL, V68, P329, DOI 10.1152/jappl.1990.68.1.329; FRONTERA WR, 1988, J APPL PHYSIOL, V64, P1038, DOI 10.1152/jappl.1988.64.3.1038; GLEESON PB, 1990, J BONE MINER RES, V5, P153, DOI 10.1002/jbmr.5650050208; HEYMSFIELD SB, 1983, AM J CLIN NUTR, V37, P478, DOI 10.1093/ajcn/37.3.478; JOHNSON J, 1991, CALCIFIED TISSUE INT, V49, P174, DOI 10.1007/BF02556113; JOHNSTON C, 1993, BONE DENSITY MEASURE, P137; KRALL EA, 1994, AM J MED, V96, P20, DOI 10.1016/0002-9343(94)90111-2; LARSEN K, 1972, CLIN CHIM ACTA, V41, P209, DOI 10.1016/0009-8981(72)90513-X; MCDONAGH MJN, 1984, EUR J APPL PHYSIOL, V52, P139, DOI 10.1007/BF00433384; MICHEL BA, 1989, ARCH INTERN MED, V149, P2325, DOI 10.1001/archinte.149.10.2325; NELSON ME, 1988, J CLIN ENDOCR METAB, V66, P927, DOI 10.1210/jcem-66-5-927; NELSON ME, 1991, AM J CLIN NUTR, V53, P1304, DOI 10.1093/ajcn/53.5.1304; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; NOTELOVITZ M, 1991, J BONE MINER RES, V6, P583, DOI 10.1002/jbmr.5650060609; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; POCOCK N, 1989, J BONE MINER RES, V4, P441; PREECE MA, 1974, CLIN CHIM ACTA, V54, P235, DOI 10.1016/0009-8981(74)90241-1; PRINCE RL, 1991, NEW ENGL J MED, V325, P1189, DOI 10.1056/NEJM199110243251701; PRUITT LA, 1992, J BONE MINER RES, V7, P179; ROCKWELL JC, 1990, J CLIN ENDOCR METAB, V71, P988, DOI 10.1210/jcem-71-4-988; SOROCK GS, 1988, J GERONTOL, V43, pM134, DOI 10.1093/geronj/43.5.M134; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; WHIPPLE RH, 1987, J AM GERIATR SOC, V35, P13, DOI 10.1111/j.1532-5415.1987.tb01313.x; ZYLSTRA S, 1989, INT J SPORTS MED, V10, P181, DOI 10.1055/s-2007-1024897; 1990, SAS USERS GUIDE STAT; 1989, RECOMMENDED DIETARY	48	719	733	2	67	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	1994	272	24					1909	1914		10.1001/jama.272.24.1909	http://dx.doi.org/10.1001/jama.272.24.1909			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX927	7990242				2022-12-28	WOS:A1994PX92700035
J	TUCKER, J				TUCKER, J			PRIMARY-CARE	LANCET			English	Letter											TUCKER, J (corresponding author), UNIV DUNDEE,DEPT EPIDEMIOL & PUBL HLTH,SCOTTISH ANTENATAL CARE TRIAL,DUNDEE DD1 9SY,SCOTLAND.							FAWDRY R, 1990, PRACTITIONER, V234, P352; ORTON, 1994, LANCET, V344, P1413; TUCKER J, 1994, J PUBLIC HEALTH MED, V16, P60, DOI 10.1093/oxfordjournals.pubmed.a042937; 1984, J R SOC MED, V77, P340; 1982, 1 DEP HLTH SOC SERV	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1707	1707						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996986				2022-12-28	WOS:A1994PX30200047
J	RORTH, P				RORTH, P			SPECIFICATION OF C/EBP FUNCTION DURING DROSOPHILA DEVELOPMENT BY THE BZIP BASIC REGION	SCIENCE			English	Article							NF-KAPPA-B; LEUCINE ZIPPER; DNA-BINDING; SEQUENCE RECOGNITION; TRANSCRIPTION FACTOR; NUCLEAR-PROTEIN; FAMILY MEMBERS; GENE; EXPRESSION; CELLS	The biologically relevant interactions of a transcription factor are those that are important for function in the organism. Here, a transgenic rescue assay was used to determine which molecular functions of Drosophila CCAAT/enhancer binding protein (C/EBP), a basic region-leucine zipper transcription factor, are required for it to fulfill its essential role during development. Chimeric proteins that contain the Drosophila C/EBP (DmC/EBP) basic region, a heterologous zipper, and a heterologous activation domain could functionally substitute for DmC/EBP. Mammalian C/EBPs were also functional in Drosophila. In contrast, 9 of 25 single amino acid substitutions in the basic region disrupted biological function. Thus, the conserved basic region specifies DmC/EBP activity in the organism.			RORTH, P (corresponding author), CARNEGIE INST WASHINGTON,DEPT EMBRYOL,115 W UNIV PKWY,BALTIMORE,MD 21210, USA.		Rørth, Pernille/H-3020-2011					AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DRIEVER W, 1989, NATURE, V342, P149, DOI 10.1038/342149a0; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; KIM J, 1993, P NATL ACAD SCI USA, V90, P4513, DOI 10.1073/pnas.90.10.4513; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RORTH P, 1992, GENE DEV, V6, P2299, DOI 10.1101/gad.6.12a.2299; RORTH P, UNPUB; SCOTT LM, 1992, BLOOD, V80, P1725; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SUCKOW M, 1993, EMBO J, V12, P1193, DOI 10.1002/j.1460-2075.1993.tb05760.x; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; ZHAO JJ, 1993, GENE DEV, V7, P343, DOI 10.1101/gad.7.3.343	30	28	30	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1878	1881		10.1126/science.7997882	http://dx.doi.org/10.1126/science.7997882			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997882				2022-12-28	WOS:A1994PX38300039
J	BECKER, L; BADA, JL; WINANS, RE; BUNCH, TE				BECKER, L; BADA, JL; WINANS, RE; BUNCH, TE			FULLERENES IN ALLENDE METEORITE	NATURE			English	Letter							CHEMISTRY		ARGONNE NATL LAB,DIV CHEM,ARGONNE,IL 60439; NASA,AMES RES CTR,DIV SPACE SCI,MOFFETT FIELD,CA 94035	United States Department of Energy (DOE); Argonne National Laboratory; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	BECKER, L (corresponding author), UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093, USA.			Winans, Randall/0000-0002-7080-7673				BECKER L, 1994, SCIENCE, V265, P642, DOI 10.1126/science.11536660; BECKER L, 1993, NATURE, V361, P595, DOI 10.1038/361595a0; BOHME DK, 1992, CHEM REV, V92, P1487, DOI 10.1021/cr00015a002; DEVRIES MS, 1993, GEOCHIM COSMOCHIM AC, V57, P933, DOI 10.1016/0016-7037(93)90179-Z; DIBROZOLO FR, 1994, NATURE, V369, P37, DOI 10.1038/369037a0; HAHN JH, 1988, SCIENCE, V239, P1523, DOI 10.1126/science.239.4847.1523; HEYMANN D, 1994, SCIENCE, V265, P645, DOI 10.1126/science.265.5172.645; PETRIE S, 1993, ASTRON ASTROPHYS, V271, P275; POPE CJ, 1993, J PHYS CHEM-US, V97, P11001, DOI 10.1021/j100144a018; TIELENS AGGM, 1990, NASA CONF P, V3061, P59	10	60	61	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					507	507		10.1038/372507a0	http://dx.doi.org/10.1038/372507a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990921				2022-12-28	WOS:A1994PW08200033
J	TAMEMOTO, H; KADOWAKI, T; TOBE, K; YAGI, T; SAKURA, H; HAYAKAWA, T; TERAUCHI, Y; UEKI, K; KABURAGI, Y; SATOH, S; SEKIHARA, H; YOSHIOKA, S; HORIKOSHI, H; FURUTA, Y; IKAWA, Y; KASUGA, M; YAZAKI, Y; AIZAWA, S				TAMEMOTO, H; KADOWAKI, T; TOBE, K; YAGI, T; SAKURA, H; HAYAKAWA, T; TERAUCHI, Y; UEKI, K; KABURAGI, Y; SATOH, S; SEKIHARA, H; YOSHIOKA, S; HORIKOSHI, H; FURUTA, Y; IKAWA, Y; KASUGA, M; YAZAKI, Y; AIZAWA, S			INSULIN-RESISTANCE AND GROWTH-RETARDATION IN MICE LACKING INSULIN-RECEPTOR SUBSTRATE-1	NATURE			English	Article							TYROSINE-PHOSPHORYLATION; RAT ADIPOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; SIGNALING PATHWAYS; FACTOR-I; PROTEIN; IRS-1; KINASE; ASSOCIATION	INSULIN receptor substrate-1 (IRS-1) is the major substrate of insulin receptor and IGF-1 receptor tyrosine kinases; it has an apparent relative molecular mass of 160-190,000 (M(r), 160-190K) on SDS polyacrylamide gel(1-3). Tyrosine-phosphorylated IRS-1 binds the 85K subunit of phosphatidylinositol 3-kinase(4,5) which may be involved in the translocation of glucose transporters(6,7) and the abundant src homology protein (ASH)/Grb2(8,9) which may be involved in activation of p21(ras) and MAP kinase cascade(10). IRS-1 also has binding sites for Syp(11) and Nck(12) and other src homology 2 (SH2) signalling molecules. To clarify the physiological roles of IRS-1 in vivo, we made mice with a targeted disruption of the IRS-1 gene locus. Mice homozygous for targeted disruption of the IRS-1 gene were born alive but were retarded in embryonal and postnatal growth. They also had resistance to the glucose-lowering effects of insulin, IGF-1 and IGF-2. These data suggest the existence of both IRS-1-dependent and IRS-1-independent pathways for signal transduction of insulin and IGFs.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,ONCOL MOLEC LAB,TSUKUBA,IBARAKI 305,JAPAN; SANKYO CO LTD,PHARMACOL & MOLEC BIOL RES LABS,SHINAGAWA KU,TOKYO 140,JAPAN; YOKOHAMA CITY UNIV,FAC MED,SCH MED,DEPT INTERNAL MED 3,YOKOHAMA,KANAGAWA 236,JAPAN; UNIV KOBE,FAC MED,DEPT INTERNAL MED 2,KOBE,HYOGO 650,JAPAN	University of Tokyo; RIKEN; Daiichi Sankyo Company Limited; Yokohama City University; Kobe University			Terauchi, Yasuo/AAO-4347-2020; Sancheti, Harsh/H-3538-2012					BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; HARA K, IN PRESS P NATN ACAD; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MOONEY RA, 1992, ENDOCRINOLOGY, V130, P1533, DOI 10.1210/en.130.3.1533; OKADA T, 1994, J BIOL CHEM, V269, P3568; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STAGSTED J, 1990, CELL, V62, P297, DOI 10.1016/0092-8674(90)90367-N; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TOBE K, 1991, J BIOL CHEM, V266, P24793; TOBE K, 1993, J BIOL CHEM, V268, P11167; URLAUB G, 1989, MOL CELL BIOL, V9, P2868; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1994, J BIOL CHEM, V268, P1; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YAMAMOTOHONDA R, 1993, J BIOL CHEM, V268, P16859; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	30	844	873	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					182	186		10.1038/372182a0	http://dx.doi.org/10.1038/372182a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969452				2022-12-28	WOS:A1994PQ68800057
J	YUAN, JG; HENRY, R; MCCAFFERY, M; CLINE, K				YUAN, JG; HENRY, R; MCCAFFERY, M; CLINE, K			SECA HOMOLOG IN PROTEIN-TRANSPORT WITHIN CHLOROPLASTS - EVIDENCE FOR ENDOSYMBIONT-DERIVED SORTING	SCIENCE			English	Article							THYLAKOID PRECURSOR PROTEIN; ESCHERICHIA-COLI; CHROMOPHYTIC ALGA; RED ALGA; MEMBRANE; IMPORT; TRANSLOCATION; GENOME; INTEGRATION; MACHINERY	The SecA protein is an essential, azide-sensitive component of the bacterial protein translocation machinery. A SecA protein homolog (CPSecA) now identified in pea chloroplasts was purified to homogeneity. CPSecA supported protein transport into thylakoids, the chloroplast internal membrane network, in an azide-sensitive fashion. Only one of three pathways for protein transport into thylakoids uses the CPSecA mechanism. The use of a bacteria-homologous mechanism in intrachloroplast protein transport provides evidence for conservative sorting of proteins within chloroplasts.	UNIV FLORIDA,PLANT MOLEC & CELLULAR BIOL PROGRAM,GAINESVILLE,FL 32611; UNIV FLORIDA,DEPT HORT SCI,GAINESVILLE,FL 32611	State University System of Florida; University of Florida; State University System of Florida; University of Florida			Cline, Kenneth/J-6238-2013		NIGMS NIH HHS [1 R01 GM46951] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046951] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1986, J BIOL CHEM, V261, P4804; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; FLACHMANN R, 1993, J BIOL CHEM, V268, P7514; FULSON DR, 1988, PLANT PHYSIOL, V88, P1146, DOI 10.1104/pp.88.4.1146; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HENRY R, 1994, J BIOL CHEM, V269, P10189; HULFORD A, 1994, J BIOL CHEM, V269, P3251; KLOSE M, 1993, J BIOL CHEM, V268, P4504; KNOTT TG, 1994, J BIOL CHEM, V269, P7843; MATSUYAMA S, 1992, BIOCHIM BIOPHYS ACTA, V1122, P77, DOI 10.1016/0167-4838(92)90130-6; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; REED JE, 1990, EUR J BIOCHEM, V194, P33, DOI 10.1111/j.1432-1033.1990.tb19423.x; REITH M, 1993, PLANT CELL, V5, P465, DOI 10.1105/tpc.5.4.465; SCARAMUZZI CD, 1992, FEBS LETT, V304, P119, DOI 10.1016/0014-5793(92)80601-C; SCARAMUZZI CD, 1992, CURR GENET, V22, P421, DOI 10.1007/BF00352444; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; SEIDLER A, 1990, EMBO J, V9, P1743, DOI 10.1002/j.1460-2075.1990.tb08298.x; SIMPSON DJ, 1989, CARLSBERG RES COMMUN, V54, P55, DOI 10.1007/BF02907585; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; Theg Steven M., 1993, Trends in Cell Biology, V3, P186, DOI 10.1016/0962-8924(93)90212-J; VALENTIN K, 1993, MOL GEN GENET, V236, P245, DOI 10.1007/BF00277119; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; YUAN J, UNPUB; YUAN JG, 1993, P NATL ACAD SCI USA, V90, P8552, DOI 10.1073/pnas.90.18.8552; YUAN JG, 1994, J BIOL CHEM, V269, P18463	35	150	152	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					796	798		10.1126/science.7973633	http://dx.doi.org/10.1126/science.7973633			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973633				2022-12-28	WOS:A1994PP75300037
J	HAYES, MA; TIMMINS, AC; YAU, EHS; PALAZZO, M; HINDS, CJ; WATSON, D				HAYES, MA; TIMMINS, AC; YAU, EHS; PALAZZO, M; HINDS, CJ; WATSON, D			ELEVATION OF SYSTEMIC OXYGEN DELIVERY IN THE TREATMENT OF CRITICALLY ILL PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK SURGICAL PATIENTS; SEPTIC SHOCK; THERAPEUTIC GOALS; CLINICAL-TRIAL; ORGAN FAILURE; SUPRANORMAL VALUES; MORTALITY; SURVIVORS; MORBIDITY; PATTERNS	Background. Elevation of systemic oxygen delivery and consumption has been associated with an improved outcome in critically ill patients. We conducted a randomized trial to determine whether boosting oxygen delivery by infusing the inotropic agent dobutamine would improve the outcome in a diverse group of such patients. Methods. On the basis of previously published recommendations, we established the following goals: a cardiac index above 4.5 liters per minute per square meter of body-surface area, oxygen delivery above 600 ml per minute per square meter, and oxygen consumption above 170 ml per minute per square meter. If these goals were not achieved with volume expansion alone, patients were randomly assigned to a treatment or control group. The treatment group received intravenous dobutamine (5 to 200 mu g per kilogram of body weight per minute) until all three goals had been achieved. Dobutamine was administered to the control group only if the cardiac index was below 2.8 liters per minute per square meter. Results. A total of 109 patients were studied. In nine patients the therapeutic goals were achieved with volume expansion alone; all nine patients survived to leave the hospital. Fifty patients were randomly assigned to the treatment group, and 50 to the control group. During treatment, there were no differences between the two groups in mean arterial pressure or oxygen consumption, despite a significantly higher cardiac index and level of oxygen delivery in the treatment group (P < 0.05). Although the predicted risk of death during hospitalization was 34 percent for both groups, the in-hospital mortality was lower in the control group (34 percent) than in the treatment group (54 percent) (P = 0.04; 95 percent confidence interval, 0.9 to 39.1 percent). Conclusions. The use of dobutamine to boost the cardiac index and systemic oxygen delivery failed to improve the outcome in this heterogeneous group of critically ill patients. Contrary to what might have been expected, our results suggest that in some cases aggressive efforts to increase oxygen consumption may have been detrimental.	ST BARTHOLOMEWS HOSP SMITHFIELD,DEPT ANESTHESIA,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP SMITHFIELD,DEPT INTENS CARE,LONDON,ENGLAND; ST BARTHOLOMEWS HOSP HOMERTON,DEPT ANESTHESIA,LONDON,ENGLAND; ST BARTHOLOMEWS HOSP HOMERTON,DEPT INTENS CARE,LONDON,ENGLAND; CHARING CROSS HOSP,DEPT ANESTHESIA,LONDON,ENGLAND; CHARING CROSS HOSP,DEPT INTENS CARE,LONDON,ENGLAND	Imperial College London; Imperial College London								BARTON R, 1989, CHEST, V96, P1153, DOI 10.1378/chest.96.5.1153; BLAND RD, 1985, CRIT CARE MED, V13, P85, DOI 10.1097/00003246-198502000-00006; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; EDWARDS JD, 1989, CRIT CARE MED, V17, P1098, DOI 10.1097/00003246-198911000-00002; FLEMING A, 1992, ARCH SURG-CHICAGO, V127, P1175; HAYES MA, 1993, CHEST, V103, P886, DOI 10.1378/chest.103.3.886; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1989, CRIT CARE CLIN, V5, P221; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; MARTIN C, 1990, ACTA ANAESTH SCAND, V34, P413, DOI 10.1111/j.1399-6576.1990.tb03114.x; PINSKY MR, 1993, YB INTENSIVE EMERGEN, P373; POCOCK SJ, 1992, BMJ-BRIT MED J, V305, P235, DOI 10.1136/bmj.305.6847.235; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P231; SHOEMAKER WC, 1988, CRIT CARE MED, V16, P1117, DOI 10.1097/00003246-198811000-00007; SHOEMAKER WC, 1973, ARCH SURG-CHICAGO, V106, P630; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SHOEMAKER WC, 1990, ARCH SURG-CHICAGO, V125, P1332; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; YU MH, 1993, CRIT CARE MED, V21, P830, DOI 10.1097/00003246-199306000-00009	20	1005	1041	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 16	1994	330	24					1717	1722		10.1056/NEJM199406163302404	http://dx.doi.org/10.1056/NEJM199406163302404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR109	7993413				2022-12-28	WOS:A1994NR10900004
J	AMBROSIONI, E; BORGHI, C; MAGNANI, B				AMBROSIONI, E; BORGHI, C; MAGNANI, B			THE EFFECT OF THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR ZOFENOPRIL ON MORTALITY AND MORBIDITY AFTER ANTERIOR MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR DYSFUNCTION; SURVIVAL; CAPTOPRIL; DILATATION	Background. Left ventricular dilatation and neuroendocririe activation are common after acute anterior myocardial infarction. Long-term treatment with an angiotensin-converting-enzyme (ACE) inhibitor may improve outcome by attenuating these processes. We investigated whether the ACE inhibitor zofenopril, administered for six weeks after anterior myocardial infarction, could improve both short-term and long-term outcome. Methods. A total of 1556 patients were enrolled within 24 hours after the onset of symptoms of acute anterior myocardial infarction, and they were randomly assigned in a double-blind fashion to receive either placebo (784 patients) or zofenopril (772 patients) for six weeks. At this time we assessed the incidence of death or severe congestive heart failure. The patients were reexamined after one year to assess survival. Results. The incidence of death or severe congestive heart failure at six weeks was significantly reduced in the zofenopril group (55 patients, 7.1 percent), as compared with the placebo group (83 patients, 10.6 percent); the cumulative reduction in the risk of death or severe congestive heart failure was 34 percent (95 percent confidence interval, 8 to 54 percent; P = 0.018). The reduction in risk was 46 percent (95 percent confidence interval, 11 to 71 percent; P = 0.018) for severe congestive heart failure and 25 percent (95 percent confidence interval, -11 to 60 percent; P = 0.19) for death. After one year of observation, the mortality rate was significantly lower in the zofenopril group (10.0 percent) than in the placebo group (14.1 percent); the reduction in risk was 29 percent (95 percent confidence interval, 6 to 51 percent; P = 0.017). Conclusions. Treatment with zofenopril significantly improved both short-term and long-term outcome when this drug was started within 24 hours after the onset of acute anterior myocardial infarction and continued for six weeks.	UNIV BOLOGNA, DEPT INTERNAL MED, BOLOGNA, ITALY; UNIV BOLOGNA, DEPT CARDIOL, BOLOGNA, ITALY	University of Bologna; University of Bologna			Mattioli, Annavittoria/G-6001-2012	Mattioli, Annavittoria/0000-0003-1487-9530				AMBROSIONI E, 1991, AM J CARDIOL, V68, pD101; Ambrosioni Ettore, 1994, Controlled Clinical Trials, V15, P201, DOI 10.1016/0197-2456(94)90057-4; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1986, LANCET, V2, P57; BALL SG, 1993, LANCET, V342, P821; BORGHI C, 1993, AM J CARDIOL, V72, pG169, DOI 10.1016/0002-9149(93)90124-U; CAIRNS JA, 1989, CHEST, V95, pS73, DOI 10.1378/chest.95.2.73S; CUSHMAN DW, 1989, AM J HYPERTENS, V2, P294, DOI 10.1093/ajh/2.4.294; DEFORREST JM, 1989, J CARDIOVASC PHARM, V13, P887, DOI 10.1097/00005344-198906000-00011; DEGRAEFF PA, 1987, J CARDIOVASC PHARM, V9, pS37, DOI 10.1097/00005344-198700002-00009; DEVITA C, 1994, LANCET, V343, P1115; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P421, DOI 10.1161/01.CIR.59.3.421; MADSEN EB, 1984, AM HEART J, V108, P1431, DOI 10.1016/0002-8703(84)90688-4; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; PRZYKLENK K, 1991, AM HEART J, V121, P1319, DOI 10.1016/0002-8703(91)90134-4; PYE M, 1990, CIRCULATION, V82, P674; Rouleau JL, 1993, J AM COLL CARDIOL, V22, P390, DOI 10.1016/0735-1097(93)90042-Y; SHARPE N, 1988, LANCET, V1, P255; SHARPE N, 1991, LANCET, V337, P872, DOI 10.1016/0140-6736(91)90202-Z; SHARPE N, 1991, LANCET, V337, P1174; SIMOONS ML, 1994, LANCET, V344, P279, DOI 10.1016/S0140-6736(94)91333-1; SOGAARD P, 1994, AM HEART J, V127, P1, DOI 10.1016/0002-8703(94)90502-9; STONE PH, 1988, J AM COLL CARDIOL, V11, P453, DOI 10.1016/0735-1097(88)91517-3; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; TAN LB, 1991, CIRC RES, V69, P1185, DOI 10.1161/01.RES.69.5.1185; VANGILST WH, 1988, CIRCULATION, V77, P24; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; YUSUF S, 1990, CIRCULATION, V82, P117; 1992, NEW ENGL J MED, V327, P1768; 1993, CIRCULATION S1, V88, P394	34	634	658	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 12	1995	332	2					80	85		10.1056/NEJM199501123320203	http://dx.doi.org/10.1056/NEJM199501123320203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA241	7990904				2022-12-28	WOS:A1995QA24100003
J	SORUM, PC				SORUM, PC			COMPENSATING PHYSICIANS FOR TELEPHONE CALLS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARE		ALBANY MED COLL,DEPT PEDIAT,ALBANY,NY 12208	Albany Medical College	SORUM, PC (corresponding author), ALBANY MED COLL,DEPT MED,A-130,ALBANY,NY 12208, USA.							BERTERA EM, 1981, AM J PUBLIC HEALTH, V71, P626, DOI 10.2105/AJPH.71.6.626; BRAITHWAITE SS, 1993, J CLIN ETHIC, V4, P219; EDEN J, 1994, JAMA-J AM MED ASSOC, V272, P12, DOI 10.1001/jama.272.1.12; EMMONS DW, 1994, SOCIOECONOMIC CHARAC, P25; EVENS S, 1985, FAM PRACT, V2, P10, DOI 10.1093/fampra/2.1.10; INGLEHART JK, 1994, NEW ENGL J MED, V331, P63; KRASNIK A, 1990, BRIT MED J, V300, P1698, DOI 10.1136/bmj.300.6741.1698; MENDENHALL R, 1981, MED PRACTICE US SPEC; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; YANOVSKI SZ, 1992, PEDIATRICS, V89, P701	10	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	1994	272	24					1949	1950		10.1001/jama.272.24.1949	http://dx.doi.org/10.1001/jama.272.24.1949			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PX927	7990249				2022-12-28	WOS:A1994PX92700042
J	CHAPMAN, AH; CHAPMANSANTANA, M				CHAPMAN, AH; CHAPMANSANTANA, M			IS IT POSSIBLE TO HAVE AN UNCONSCIOUS THOUGHT	LANCET			English	Editorial Material																			0	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1752	1753		10.1016/S0140-6736(94)92892-4	http://dx.doi.org/10.1016/S0140-6736(94)92892-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7997007				2022-12-28	WOS:A1994PY28100015
J	MACKEWICZ, CE; YANG, LC; LIFSON, JD; LEVY, JA				MACKEWICZ, CE; YANG, LC; LIFSON, JD; LEVY, JA			NONCYTOLYTIC CD8 T-CELL ANTI-HIV RESPONSES IN PRIMARY HIV-1 INFECTION	LANCET			English	Note							PLASMA; VIRUS	Acute HIV infection is accompanied by a sharp rise in virus titres that soon fall, but the role of humoral and cellular immunity is not clear in the control of initial virus replication. We have found seven HIV-1 infected subjects who had CD8 T-cell non-cytolytic anti-HIV activity in plasma many months before neutralising antibodies can be detected. We observed an inverse relation between the extent of this CD8 cell response and the level of plasma viraemia in some subjects. These results suggest that a cellular immune response controls viral replication soon after HIV infection.	UNIV CALIF SAN FRANCISCO,SCH MED,CANC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143; GENELABS TECHNOL INC,REDWOOD CITY,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIAID NIH HHS [AI35467, R01-AI30350] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030350, R01AI035467, R37AI035467] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CHENGMAYER C, 1988, P NATL ACAD SCI USA, V85, P2815, DOI 10.1073/pnas.85.8.2815; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LANDAY AL, 1993, CLIN IMMUNOL IMMUNOP, V69, P106, DOI 10.1006/clin.1993.1157; MACKEWICZ C, 1992, AIDS RES HUM RETROV, V8, P629; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; SHEPPARD HW, 1993, J ACQ IMMUN DEF SYND, V6, P1339; TINDALL B, 1991, AIDS, V5, P1, DOI 10.1097/00002030-199101000-00001; WALKER BD, 1990, AIDS, V4, P177, DOI 10.1097/00002030-199003000-00001	10	102	107	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1671	1673						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996961				2022-12-28	WOS:A1994PX30200010
J	ORENGO, CA; JONES, DT; THORNTON, JM				ORENGO, CA; JONES, DT; THORNTON, JM			PROTEIN SUPERFAMILIES AND DOMAIN SUPERFOLDS	NATURE			English	Article							STRUCTURE ALIGNMENT; GLOBULAR-PROTEINS; SEQUENCES; FOLD; SIMILARITIES; FAMILIES	As the protein sequence and structure databases expand rapidly a better understanding of the relationships between proteins is required. A classification is considered that extends the sequence-based superfamilies to include proteins with similar function and three-dimensional structures but no sequence similarity. So far there are only nine protein folds known to recur in proteins having neither sequence nor functional similarity. These folds dominate the structure database, representing more than 30 per cent of all determined structures. This observation has implications for protein-fold recognition.	NATL INST MED RES,MATH BIOL LAB,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	ORENGO, CA (corresponding author), UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,BIOMOLEC STRUCT & MODELLING UNIT,GOWER ST,LONDON WC1E 6BT,ENGLAND.			Thornton, Janet/0000-0003-0824-4096	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALEXANDROV NN, 1994, PROTEIN SCI, V3, P866; BORK P, 1994, CURR OPIN STRUC BIOL, V4, P393, DOI 10.1016/S0959-440X(94)90109-0; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CHOTHIA C, 1992, NATURE, V357, P543, DOI 10.1038/357543a0; Dayhoff MO, 1978, ATLAS PROTEIN SEQUEN, V5; FINKELSTEIN AV, 1987, PROG BIOPHYS MOL BIO, V50, P171, DOI 10.1016/0079-6107(87)90013-7; FINKELSTEIN AV, 1994, CURR OPIN STRUC BIOL, V4, P422, DOI 10.1016/S0959-440X(94)90112-0; FLORES TP, 1993, PROTEIN SCI, V2, P1811, DOI 10.1002/pro.5560021104; GOTOH O, 1982, J MOL BIOL, V162, P705, DOI 10.1016/0022-2836(82)90398-9; HILBERT M, 1993, PROTEINS, V17, P138, DOI 10.1002/prot.340170204; HOLM L, 1992, PROTEIN SCI, V1, P1691, DOI 10.1002/pro.5560011217; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; ORENGO CA, 1992, PROTEINS, V14, P139, DOI 10.1002/prot.340140203; ORENGO CA, 1993, PROTEIN ENG, V6, P485, DOI 10.1093/protein/6.5.485; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; PASCARELLA S, 1992, PROTEIN ENG, V5, P121, DOI 10.1093/protein/5.2.121; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PTITSYN OB, 1980, Q REV BIOPHYS, V13, P339, DOI 10.1017/S0033583500001724; RACKOVSKY S, 1990, PROTEINS, V7, P378, DOI 10.1002/prot.340070409; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; TAYLOR WR, 1989, J MOL BIOL, V208, P1, DOI 10.1016/0022-2836(89)90084-3; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K; YEE DP, 1993, PROTEIN SCI, V2, P884, DOI 10.1002/pro.5560020603	27	652	677	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					631	634		10.1038/372631a0	http://dx.doi.org/10.1038/372631a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990952				2022-12-28	WOS:A1994PX30700074
J	ROMANEK, CS; GRADY, MM; WRIGHT, IP; MITTLEFEHLDT, DW; SOCKI, RA; PILLINGER, CT; GIBSON, EK				ROMANEK, CS; GRADY, MM; WRIGHT, IP; MITTLEFEHLDT, DW; SOCKI, RA; PILLINGER, CT; GIBSON, EK			RECORD OF FLUID-ROCK INTERACTIONS ON MARS FROM THE METEORITE ALH84001	NATURE			English	Article							ISOTOPE FRACTIONATIONS; STABLE ISOTOPES; SNC METEORITES; CARBON-DIOXIDE; OXYGEN; CALCITE; EVOLUTION	ALLAN HILLS (ALH) 84001 is the most recently recognized(1) member of a suite of meteorites-the SNCs-that almost certainly originated on Mars(2). Several factors distinguish ALH84001 from the other SNC meteorites. Preliminary studies(3,4) suggest that it may be older than other martian meteorites. Moreover, it contains abundant, zoned domains of calcium-iron-magnesium carbonate that are indigenous to the sample(1) and thus may hold important clues regarding near-surface processes on Mars and the evolution of the martian atmosphere. We report here analyses of the carbon and oxygen stable-isotope Compositions of the carbonates that place constraints on their formation conditions. Our results imply the presence of at least two chemically distinct carbonates-one Ca,Fe-rich, the other Mg-rich-that are enriched in C-13 relative to terrestrial carbonates (delta(13)C approximate to + 41%parts per thousand), consistent with martian atmospheric CO2 as the carbon source. The oxygen isotope compositions of the carbonates indicate that they precipitated from a low-temperature fluid in the martian crust. Combined with textural and bulk geochemical considerations, the isotope data suggest that carbonate deposition took place in an open-system environment in which the ambient temperature fluctuated.	BRITISH MUSEUM NAT HIST,DEPT MINERAL,LONDON SW7 5BD,ENGLAND; OPEN UNIV,DEPT EARTH SCI,PLANETARY SCI UNIT,MILTON KEYNES MK7 6AA,BUCKS,ENGLAND; LOCKHEED ENGN & SCI CO,HOUSTON,TX 77058	British Museum of Natural History; Open University - UK; Lockheed Martin	ROMANEK, CS (corresponding author), NASA,LYNDON B JOHNSON SPACE CTR,PLANETARY SCI BRANCH SN4,HOUSTON,TX 77058, USA.			Grady, Monica/0000-0002-4055-533X				ALASAM IS, 1990, CHEM GEOL, V80, P119; BOGARD DD, 1983, SCIENCE, V221, P651, DOI 10.1126/science.221.4611.651; CARR RH, 1985, NATURE, V314, P248, DOI 10.1038/314248a0; CHACKO T, 1991, GEOCHIM COSMOCHIM AC, V55, P2867, DOI 10.1016/0016-7037(91)90452-B; CHIBA H, 1989, GEOCHIM COSMOCHIM AC, V53, P2985, DOI 10.1016/0016-7037(89)90174-9; Clayton R., 1993, ANTARCT METEORITE NE, V16, P4; CLAYTON RN, 1988, GEOCHIM COSMOCHIM AC, V52, P925, DOI 10.1016/0016-7037(88)90363-8; CLIFFORD SM, 1993, J GEOPHYS RES-PLANET, V98, P10973, DOI 10.1029/93JE00225; GRADY MM, 1994, METEORITICS, V29, P469; JAGOUTZ E, 1994, METEORITICS, V29, P478; JAKOSKY BM, 1991, ICARUS, V94, P14, DOI 10.1016/0019-1035(91)90138-J; JULL AJT, 1994, METEORITICS, V29, P479; MCCREA JM, 1950, J CHEM PHYS, V18, P849, DOI 10.1063/1.1747785; MCSWEEN HY, 1985, REV GEOPHYS, V23, P391, DOI 10.1029/RG023i004p00391; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; MOZLEY PS, 1993, J SEDIMENT PETROL, V63, P73; Owen T., 1977, J GEOPHYS RES, V82, P4635, DOI DOI 10.1029/JS082I028P04635; ROSENBAUM J, 1986, GEOCHIM COSMOCHIM AC, V50, P1147, DOI 10.1016/0016-7037(86)90396-0; SQUYRES SW, 1994, SCIENCE, V265, P744, DOI 10.1126/science.265.5173.744; SWART PK, 1991, CHEM GEOL, V86, P89, DOI 10.1016/0168-9622(91)90055-2; TREIMAN AH, 1994, METEORITICS, V29, P542; Veizer J., 1983, REV MINERAL GEOCHEM, V11, P265; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; WRIGHT IP, 1992, GEOCHIM COSMOCHIM AC, V56, P817, DOI 10.1016/0016-7037(92)90100-W; [No title captured]	25	198	201	0	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					655	657		10.1038/372655a0	http://dx.doi.org/10.1038/372655a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990956				2022-12-28	WOS:A1994PX30700079
J	DANON, A; MAYFIELD, SP				DANON, A; MAYFIELD, SP			LIGHT-REGULATED TRANSLATION OF CHLOROPLAST MESSENGER-RNAS THROUGH REDOX POTENTIAL	SCIENCE			English	Article							CHLAMYDOMONAS-REINHARDTII; GENE-EXPRESSION; PHOTOSYSTEM-II; CO2 ASSIMILATION; HIGHER-PLANTS; MUTATIONS; NUCLEAR; PSBA; BIOGENESIS; PROTEINS	Translation of key proteins in the chloroplast is regulated by light. Genetic and biochemical studies in the unicellular alga Chlamydomonas reinhardtii suggest that light may regulate translation by modulating the binding of activator proteins to the 5' untranslated region of chloroplast messenger RNAs. in vitro binding of the activator proteins to psbA messenger RNA and in vivo translation of psbA messenger RNA is regulated by the redox state of these proteins, suggesting that the light stimulus is transduced by the photosynthesis-generated redox potential.	Scripps Res Inst, DEPT CELL BIOL, DIV PLANT BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute								BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; DANON AD, UNPUB; DENG XW, 1988, EMBO J, V7, P3301, DOI 10.1002/j.1460-2075.1988.tb03200.x; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FROMM H, 1985, EMBO J, V4, P291, DOI 10.1002/j.1460-2075.1985.tb03628.x; GIRARDBASCOU J, 1987, CURR GENET, V12, P483, DOI 10.1007/BF00419556; GIRARDBASCOU J, 1992, CURR GENET, V22, P47, DOI 10.1007/BF00351741; GRANT DM, 1980, P NATL ACAD SCI-BIOL, V77, P6067, DOI 10.1073/pnas.77.10.6067; JENSEN KH, 1986, J CELL BIOL, V103, P1315, DOI 10.1083/jcb.103.4.1315; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KLEIN RR, 1988, J CELL BIOL, V106, P289, DOI 10.1083/jcb.106.2.289; KRUPINSKA K, 1989, MOL GEN GENET, V219, P467, DOI 10.1007/BF00259621; KUCHKA MR, 1988, EMBO J, V7, P319, DOI 10.1002/j.1460-2075.1988.tb02815.x; MALNOE P, 1988, J CELL BIOL, V106, P609, DOI 10.1083/jcb.106.3.609; MATTOO AK, 1981, P NATL ACAD SCI-BIOL, V78, P1572, DOI 10.1073/pnas.78.3.1572; MAYFIELD SP, 1994, J CELL BIOL, V127, P6; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; ROCHAIX JD, 1989, EMBO J, V8, P1013, DOI 10.1002/j.1460-2075.1989.tb03468.x; TOBIN EM, 1985, ANNU REV PLANT PHYS, V36, P569, DOI 10.1146/annurev.pp.36.060185.003033; WETTERN M, 1984, ISRAEL J BOT, V33, P253; WOLOSIUK RA, 1993, FASEB J, V7, P622, DOI 10.1096/fasebj.7.8.8500687	23	279	284	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1717	1719		10.1126/science.7992056	http://dx.doi.org/10.1126/science.7992056			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992056				2022-12-28	WOS:A1994PW30800043
J	PEIFER, M				PEIFER, M			THE 2 FACES OF HEDGEHOG	SCIENCE			English	Editorial Material							CELL-CELL COMMUNICATION; POLARITY GENE HEDGEHOG; DROSOPHILA; EXPRESSION				PEIFER, M (corresponding author), UNIV N CAROLINA, DEPT BIOL, CB3280, COKER HALL, CHAPEL HILL, NC 27599 USA.		Peifer, Mark/A-1152-2010	Peifer, Mark/0000-0003-1412-3987				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; CAPDEVILA J, 1994, DEVELOPMENT, V120, P987; DUBOISSTRINGFEL.N, COMMUNICATION; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FORBES AJ, 1993, DEVELOPMENT S, V115; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SMITH JC, 1994, CELL, V76, P193, DOI 10.1016/0092-8674(94)90325-5; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183	25	2	5	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 2	1994	266	5190					1492	1493		10.1126/science.7985017	http://dx.doi.org/10.1126/science.7985017			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985017				2022-12-28	WOS:A1994PV01500028
J	ZHUANG, Y; SORIANO, P; WEINTRAUB, H				ZHUANG, Y; SORIANO, P; WEINTRAUB, H			THE HELIX-LOOP-HELIX GENE E2A IS REQUIRED FOR B-CELL FORMATION	CELL			English	Article							DNA-BINDING PROTEINS; TRANSCRIPTION FACTORS; IMMUNOGLOBULIN HEAVY; TARGETED DISRUPTION; SEX DETERMINATION; HLH PROTEINS; STEM-CELLS; MICE; DIFFERENTIATION; REARRANGEMENT	Heterodimers between tissue-specific basic-helix-loop-helix proteins and the gene products of E2A play major roles in determining tissue-specific cell fate. To understand the broad role of E2A in development, we have generated E2A mutant mice following homologous recombination in embryonic stem cells. Homozygous mutant mice develop to full term without apparent abnormalities, but then display a high rate of postnatal death. The surviving mice show retarded postnatal growth. Detailed examination of hematopoiesis reveals that the homozygous mutant mice contain no B cells while other lineages including T cell, granulocyte, macrophage, and erythroid are intact. The block to B cell differentiation occurs prior to immunoglobulin gene D-H-J(H) rearrangement and the expression of the B lineage-specific marker B220. Surprisingly, heterozygous embryos contain, on average, about half as many B cells as wild-type embryos, suggesting the existence of a counting mechanism that translates levels of E2A into numbers of B cells.			ZHUANG, Y (corresponding author), FRED HUTCHINSON CANC RES CTR, HOWARD HUGHES MED INST, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X; zhuang, yuan/0000-0002-2964-3654	NCI NIH HHS [R35 CA42506-09] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CLINE TW, 1993, TRENDS GENET, V9, P385, DOI 10.1016/0168-9525(93)90138-8; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; FELDHAUS AL, 1993, EMBO J, V12, P2763, DOI 10.1002/j.1460-2075.1993.tb05937.x; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KAWAGUCHI N, 1992, P NATL ACAD SCI USA, V89, P4569, DOI 10.1073/pnas.89.10.4569; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEWIS J, 1977, J THEOR BIOL, V65, P579, DOI 10.1016/0022-5193(77)90216-8; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCKEARN JP, 1984, J IMMUNOL, V132, P332; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; PARK CW, 1992, J BIOL CHEM, V267, P15642; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PFEFFER K, 1994, ANNU REV IMMUNOL, V12, P367, DOI 10.1146/annurev.immunol.12.1.367; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; ROLINK A, 1993, ADV IMMUNOL, V53, P123, DOI 10.1016/S0065-2776(08)60499-X; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132	54	575	585	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					875	884		10.1016/0092-8674(94)90076-0	http://dx.doi.org/10.1016/0092-8674(94)90076-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001124				2022-12-28	WOS:A1994PW05400014
J	SAINTRUF, C; UNGEWISS, K; GROETTRUP, M; BRUNO, L; FEHLING, HJ; VONBOEHMER, H				SAINTRUF, C; UNGEWISS, K; GROETTRUP, M; BRUNO, L; FEHLING, HJ; VONBOEHMER, H			ANALYSIS AND EXPRESSION OF A CLONED PRE-T CELL-RECEPTOR GENE	SCIENCE			English	Article							BETA-CHAIN GENE; THYMOCYTE DEVELOPMENT; TRANSGENIC MICE; IMMATURE THYMOCYTES; REARRANGEMENT; TCR; RESTORATION; CD3-EPSILON; PROTEINS; SURFACE	The T cell antigen receptor (TCR) beta chain regulates early T cell development in the absence of the TCR alpha chain. The developmentally controlled gene described here encodes the pre-TCR alpha (pT alpha) chain, which covalently associates with TCR beta and with the CD3 proteins forms a pre-TCR complex that transduces signals in immature thymocytes. Unlike the lambda 5 pre-B cell receptor protein, the pT alpha chain is a type I transmembrane protein whose cytoplasmic tail contains two potential phosphorylation sites and a Src homology 3 (SH3)-domain binding sequence. Pre-TCR alpha transfection experiments indicated that surface expression of the pre-TCR is controlled by additional developmentally regulated proteins. Identification of the pT alpha gene represents an essential step in the structure-function analysis of the pre-TCR complex.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND		SAINTRUF, C (corresponding author), INST NECKER,INSERM,U373,F-75730 PARIS 15,FRANCE.							ANDERSON SJ, 1992, EMBO J, V11, P4877, DOI 10.1002/j.1460-2075.1992.tb05594.x; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CHANG HC, 1990, J EXP MED, V172, P351, DOI 10.1084/jem.172.1.351; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DUDLEY EC, 1994, IMMUNITY, V1, P83, DOI 10.1016/1074-7613(94)90102-3; FENG DF, 1987, J MOL EVOL, V35, P359; FENTON RG, 1988, SCIENCE, V241, P1089, DOI 10.1126/science.2970670; GROETTRUP M, 1993, EUR J IMMUNOL, V23, P1393, DOI 10.1002/eji.1830230633; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; GROETTRUP M, 1993, THESIS U BASEL; GROETTRUP M, 1993, IMMUNOL TODAY, V14, P6101; JACOBS H, 1994, EUR J IMMUNOL, V24, P934, DOI 10.1002/eji.1830240423; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; LEVELT CN, 1993, J EXP MED, V177, P707, DOI 10.1084/jem.177.3.707; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LYNCH F, 1993, INT IMMUNOL, V5, P991, DOI 10.1093/intimm/5.8.991; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAULET DH, 1985, NATURE, V314, P101, DOI 10.1038/314101a0; RODEWALD HR, UNPUB; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHORES EW, 1991, EUR J IMMUNOL, V21, P973, DOI 10.1002/eji.1830210417; SNODGRASS HR, 1985, NATURE, V315, P232, DOI 10.1038/315232a0; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VONBOEHMER H, 1988, P NATL ACAD SCI USA, V85, P9729, DOI 10.1073/pnas.85.24.9729; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; YU H, 1994, STRUCTURAL BIOL, V1, P417	38	362	365	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1208	1212		10.1126/science.7973703	http://dx.doi.org/10.1126/science.7973703			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973703	Green Submitted			2022-12-28	WOS:A1994PT13200045
J	NOBRE, AC; ALLISON, T; MCCARTHY, G				NOBRE, AC; ALLISON, T; MCCARTHY, G			WORD RECOGNITION IN THE HUMAN INFERIOR TEMPORAL-LOBE	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; CORTEX; CELLS; FACE	STUDIES of primates(1) and of patients with brain lesions(2) have shown that the visual system represents the external world in regions and pathways specialized to compute visual features and attributes. For example, object recognition is performed by a ventral pathway located in the inferior portion of the temporal lobe(3). We studied visual processing of words and word-like stimuli (letter-strings) by recording held potentials directly from the human inferior temporal lobe. Our results showed that two discrete portions of the fusiform gyrus responded preferentially to letter-strings. A region of the posterior fusiform gyrus responded equally to words and nonwords, and was unaffected by the semantic context in which words were presented. In contrast, a region of the anterior fusiform gyrus was sensitive to these stimulus dimensions. These regions were distinct from areas that responded to other types of complex visual stimuli, including faces and coloured patterns, and thus form a functionally specialized stream within the ventral visual pathway.	VET ADM MED CTR,NEUROPSYCHOL LAB,W HAVEN,CT 06516; YALE UNIV,SCH MED,DEPT NEUROL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,NEUROSURG SECT,NEW HAVEN,CT 06510	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Yale University				Nobre, Anna Christina/0000-0001-5762-2802				ALLISON T, 1994, J NEUROPHYSIOL, V71, P5; Allison T., 1994, CEREB CORTEX, V5, P544; ALLISON T, 1986, PSYCHOPHYSIOLOGY, P385; Black S., 1994, LOCALIZATION NEUROIM, P331; CORBETTA M, 1991, J NEUROSCI, V11, P2382; DAMASIO AR, 1983, NEUROLOGY, V33, P1573, DOI 10.1212/WNL.33.12.1573; DERENZI E, 1987, BRAIN, V110, P1099, DOI 10.1093/brain/110.5.1099; DESIMONE R, 1991, J COGNITIVE NEUROSCI, V3, P1, DOI 10.1162/jocn.1991.3.1.1; FARA MJ, 1990, VISUAL AGNOSIA; GROSS CG, 1993, 3RD P ANN NEC RES S, P44; HAXBY JV, 1993, FUNCTIONAL ORG HUMAN, P329; HOWARD D, 1992, BRAIN, V115, P1769, DOI 10.1093/brain/115.6.1769; KUTAS M, 1980, SCIENCE, V207, P203, DOI 10.1126/science.7350657; LUDERS H, 1991, BRAIN, V114, P743, DOI 10.1093/brain/114.2.743; MCCARTHY G, IN PRESS J NEUROSCI; MESULAM MM, 1994, PRINCIPLES PRACTICE, P2640; NOBRE AC, IN PRESS J NEUROSCI; PERRETT DI, 1992, PHILOS T ROY SOC B, V335, P23, DOI 10.1098/rstb.1992.0003; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; ROLLS ET, 1985, VISION RES, V25, P1021, DOI 10.1016/0042-6989(85)90091-4; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; SPENCER SS, 1982, ANN NEUROL, V12, P248, DOI 10.1002/ana.410120306; Talairach J., 1988, COPLANAR STEREOTAXIC; UNGERLEIDER LG, 1982, ANAL VISUAL BEHAVIOR; VANESSEN DC, 1992, SCIENCE, V255, P419, DOI 10.1126/science.1734518; WARRINGTON EK, 1980, BRAIN, V103, P99, DOI 10.1093/brain/103.1.99; ZEKL SM, 1990, BRAIN, V113, P1721	29	617	623	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					260	263		10.1038/372260a0	http://dx.doi.org/10.1038/372260a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969469				2022-12-28	WOS:A1994PR88900049
J	GRAZIANO, MSA; YAP, GS; GROSS, CG				GRAZIANO, MSA; YAP, GS; GROSS, CG			CODING OF VISUAL SPACE BY PREMOTOR NEURONS	SCIENCE			English	Article							PARIETAL NEURONS; CORTEX; MOVEMENTS; REPRESENTATION; ORGANIZATION; MONKEY	In primates, the premotor cortex is involved in the sensory guidance of movement. Many neurons in ventral premotor cortex respond to visual stimuli in the space adjacent to the hand or arm. These visual receptive fields were found to move when the arm moved but not when the eye moved; that is, they are in arm-centered, not retinocentric, coordinates. Thus, they provide a representation of space near the body that may be useful for the visual control of reaching.			GRAZIANO, MSA (corresponding author), PRINCETON UNIV, DEPT PSYCHOL, PRINCETON, NJ 08544 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH019420] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 19420] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Andersen R A, 1993, Curr Opin Neurobiol, V3, P171, DOI 10.1016/0959-4388(93)90206-E; ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; BRUCE CJ, 1990, NEUROSCI IN, P261; CAMINITI R, 1990, J NEUROSCI, V10, P2039; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; FOGASSI L, 1992, EXP BRAIN RES, V89, P686, DOI 10.1007/BF00229894; GALLETTI C, 1989, J NEUROSCI, V9, P1112; GALLETTI C, 1993, EXP BRAIN RES, V96, P221; GENTILUCCI M, 1988, EXP BRAIN RES, V71, P475, DOI 10.1007/BF00248741; GOLDMANRAKIC PS, 1990, COLD SPRING HARB SYM, V55, P1025; GRAZIANO MS, 1992, BEHAV BRAIN SCI, V15, P750; GRAZIANO MS, ATTENTION PERFORMANC, V16; GRAZIANO MSA, 1993, EXP BRAIN RES, V97, P96; GRAZIANO MSA, 1994, CURR DIR PSYCHOL SCI, V3, P164, DOI 10.1111/1467-8721.ep10770670; GRAZIANO MSA, 1994, COGNITIVE NEUROSCIEN, P1021; GROSS CG, IN PRESS NEUROSCIENT; HE SQ, 1993, J NEUROSCI, V13, P952; MILLER EK, 1993, BRAIN RES, V616, P25, DOI 10.1016/0006-8993(93)90187-R; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; RIZZOLATTI G, 1981, BEHAV BRAIN RES, V2, P147, DOI 10.1016/0166-4328(81)90053-X; Rosenthal Robert., 1985, CONTRAST ANAL FOCUSE; SPARKS DL, 1991, BRAIN SPACE, P3; WISE SP, 1985, ANNU REV NEUROSCI, V8, P1, DOI 10.1146/annurev.ne.08.030185.000245	23	553	560	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1054	1057		10.1126/science.7973661	http://dx.doi.org/10.1126/science.7973661			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973661	Green Published			2022-12-28	WOS:A1994PQ92400048
J	CEPEK, KL; SHAW, SK; PARKER, CM; RUSSELL, GJ; MORROW, JS; RIMM, DL; BRENNER, MB				CEPEK, KL; SHAW, SK; PARKER, CM; RUSSELL, GJ; MORROW, JS; RIMM, DL; BRENNER, MB			ADHESION BETWEEN EPITHELIAL-CELLS AND T-LYMPHOCYTES MEDIATED BY E-CADHERIN AND THE ALPHA(E)BETA(7) INTEGRIN	NATURE			English	Article							MONOCLONAL-ANTIBODY; VLA-4; EXPRESSION; MOLECULES; RECEPTOR; PROTEINS; HOMOLOGY; ANTIGEN; SUBUNIT; FAMILY	IN contrast to sessile cell types, lymphocytes migrate through the vasculature to become diffusely distributed in tissues or organized in lymphoid structures. A complex array of adhesion molecules including selectins, integrins and their counter-receptors mediate lymphocyte homing and migration into tissues and may be constitutively expressed or induced(1,2). However, the molecules that mediate the tissue-specific retention of lymphocytes within the parenchyma have not been identified. Along the epithelium at the basolateral surface of enterocytes, intestinal intraepithelial lymphocytes are found. These T cells of the mucosal immune system serve as a model for the tissue-specific compartmentalization of lymphocytes. We investigated whether the localization of these intestinal intraepithelial lymphocytes could be mediated by specific interactions between adhesion molecules expressed selectively on this subpopulation of T cells and tissue-restricted adhesion molecules on epithelial cells. Here we show that heterotypic adhesive interactions between epithelial cells and intraepithelial lymphocytes in vitro are mediated by E-cadherin and the alpha(E) beta(7) integrin.	HARVARD UNIV,DIV MED SCI,BOSTON,MA 02115; YALE UNIV,DEPT PATHOL,NEW HAVEN,CT 06510	Harvard University; Yale University	CEPEK, KL (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT RHEUMATOL & IMMUNOL,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115, USA.			Rimm, David/0000-0001-5820-4397; Shaw, Sunil/0000-0001-9701-6065				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRENNER MB, 1987, J IMMUNOL, V138, P1502; CEPEK KL, 1993, J IMMUNOL, V150, P3459; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CERFBENSUSSAN N, 1983, J IMMUNOL, V130, P2615; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVID V, 1993, J BIOL CHEM, V268, P9585; DAVIES MDJ, 1981, GUT, V22, P481, DOI 10.1136/gut.22.6.481; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KRUSCHWITZ M, 1991, J CLIN PATHOL, V44, P636, DOI 10.1136/jcp.44.8.636; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mackay C R, 1992, Semin Immunol, V4, P51; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; RIMM DL, 1994, BIOCHEM BIOPH RES CO, V200, P1754, DOI 10.1006/bbrc.1994.1656; ROBERTS AI, 1993, CANCER RES, V53, P1608; RUSSELL GJ, IN PRESS EUR J IMMUN; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SHIMIZU Y, 1990, IMMUNOL REV, V114, P109, DOI 10.1111/j.1600-065X.1990.tb00563.x; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TANG AM, 1993, NATURE, V361, P82, DOI 10.1038/361082a0; YUAN Q, 1990, INT IMMUNOL, V2, P1097, DOI 10.1093/intimm/2.11.1097	27	943	961	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					190	193		10.1038/372190a0	http://dx.doi.org/10.1038/372190a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969453				2022-12-28	WOS:A1994PQ68800059
J	BEDOS, JP; CHASTANG, C; LUCET, JC; KALO, T; GACHOT, B; WOLFF, M				BEDOS, JP; CHASTANG, C; LUCET, JC; KALO, T; GACHOT, B; WOLFF, M			EARLY PREDICTORS OF OUTCOME FOR HIV PATIENTS WITH NEUROLOGICAL FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; INTENSIVE-CARE; RESPIRATORY-FAILURE; MECHANICAL VENTILATION; CONTROLLED TRIAL; VIRUS INFECTION; AIDS; SURVIVAL; CORTICOSTEROIDS	Objective.-To carry out a descriptive study of human immunodeficiency virus (HIV)-infected patients admitted to an intensive care unit (ICU) with neurological failure and to identify parameters that are predictive of death within 3 months. Design.-Case series study. Population and Setting.-A total of 84 consecutive HIV-infected patients admitted to an infectious disease ICU in a university hospital for neurological failure. A thorough clinical, laboratory, and brain computed tomography (CT) scan workup was done within 48 hours of admission. Main Results.-The mean (+/-SD) CD4(+) lymphocyte count was 0.067 (+/-0.086) x10(9)/L. Mechanical ventilation was necessary within 48 hours of admission in 67 cases (80%). The brain CT scan revealed abscesses in 51 patients (61%). The abscesses were attributed to probable toxoplasmosis in 47 patients. A total of 57 patients died, yielding a 3-month survival rate of 32%. By the log-rank test, the following factors were predictive of death within 3 months of admission to the ICU: Glasgow Coma Scale score less than 7 (P=.01), signs of brain stem involvement (P=.001), and need for mechanical ventilation in the 48 hours after admission (P=.02). In a Cox model, only Glasgow Coma Scale score less than 7 (P=.006) and clinical signs of brain stem involvement (P=.02) were predictive of death within 3 months of admission to the ICU. Conclusions.-Despite a thorough examination, no initial HIV-specific parameters were identified as predictive of death. The prognostic factors found simply reflected the severity of neurological involvement in the various etiologies.	HOP ST LOUIS,DEPT BIOSTAT & MED COMP,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	BEDOS, JP (corresponding author), UNIV LYON 1,HOP BICHAT,REANIMAT MALAD INFECT CLIN,INFECT INTENS CARE UNIT,48 RUE HENRI HUCHARD,F-75018 PARIS,FRANCE.							BEDOS JP, 1992, SCAND J INFECT DIS, V24, P309, DOI 10.3109/00365549209061336; BISHBURG E, 1989, ARCH INTERN MED, V149, P941, DOI 10.1001/archinte.149.4.941; BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; BREW BJ, 1992, MED CLIN N AM, V76, P63, DOI 10.1016/S0025-7125(16)30371-6; CASALINO E, 1993, 9TH INT C AIDS BERL; CHUN CH, 1986, MEDICINE, V65, P415, DOI 10.1097/00005792-198611000-00006; DEPALO VA, 1993, AM REV RESPIR DIS, V147, pA1004; EFFEREN LS, 1989, AM J MED, V87, P401, DOI 10.1016/S0002-9343(89)80821-6; FISCHER PA, 1987, J NEUROL, V234, P269, DOI 10.1007/BF00314279; FRIEDMAN Y, 1989, CHEST, V96, P862, DOI 10.1378/chest.96.4.862; FRIEDMAN Y, 1991, JAMA-J AM MED ASSOC, V266, P89, DOI 10.1001/jama.266.1.89; GACHOT B, 1992, INTENS CARE MED, V18, P155, DOI 10.1007/BF01709239; GAGNON S, 1990, NEW ENGL J MED, V323, P1444, DOI 10.1056/NEJM199011223232103; GARAY SM, 1989, CHEST, V95, P769, DOI 10.1378/chest.95.4.769; KALES CP, 1987, ARCH INTERN MED, V147, P1413; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; LEVY RM, 1988, ANN NEUROL, V23, pS7, DOI 10.1002/ana.410230706; LUCE JM, 1988, AM REV RESPIR DIS, V137, P1261, DOI 10.1164/ajrccm/137.6.1261; LUFT BJ, 1988, J INFECT DIS, V157, P1, DOI 10.1093/infdis/157.1.1; MASON GR, 1987, AM REV RESPIR DIS, V139, P1336; MCARTHUR JC, 1987, MEDICINE, V66, P407, DOI 10.1097/00005792-198711000-00001; MILLER RF, 1990, THORAX, V45, P140, DOI 10.1136/thx.45.2.140; MONTANER JSG, 1989, CHEST, V95, P881, DOI 10.1378/chest.95.4.881; NIELSEN TL, 1991, SCAND J INFECT DIS, V23, P37, DOI 10.3109/00365549109023372; NIGHTINGALE SD, 1993, ARCH INTERN MED, V153, P1313, DOI 10.1001/archinte.153.11.1313; ROGERS PL, 1989, CRIT CARE MED, V17, P113, DOI 10.1097/00003246-198902000-00001; ROSEN MJ, 1986, J INTENSIVE CARE MED, V1, P55; SCHEIN RMH, 1986, CRIT CARE MED, V14, P1026, DOI 10.1097/00003246-198612000-00006; SMITH RL, 1989, CHEST, V96, P857, DOI 10.1378/chest.96.4.857; STAIKOWSKY F, 1993, CHEST, V104, P756, DOI 10.1378/chest.104.3.756; STEINBROOK R, 1985, ANN INTERN MED, V103, P787, DOI 10.7326/0003-4819-103-5-787; WACHTER RM, 1991, AM REV RESPIR DIS, V143, P251, DOI 10.1164/ajrccm/143.2.251; WACHTER RM, 1986, AM REV RESPIR DIS, V134, P891, DOI 10.1164/arrd.1986.134.5.891; WACHTER RM, 1992, JAMA-J AM MED ASSOC, V267, P541, DOI 10.1001/jama.267.4.541; ZAMAN MK, 1985, AM REV RESPIR DIS, V137, P796; 1992, LANCET, V340, P1135; 1990, NEW ENGL J MED, V323, P1500	38	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 4	1995	273	1					35	40		10.1001/jama.273.1.35	http://dx.doi.org/10.1001/jama.273.1.35			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ042	7996648				2022-12-28	WOS:A1995PZ04200025
J	SUSSMAN, GL; BEEZHOLD, DH				SUSSMAN, GL; BEEZHOLD, DH			ALLERGY TO LATEX RUBBER	ANNALS OF INTERNAL MEDICINE			English	Article							IMMEDIATE ALLERGY; CONTACT URTICARIA; GLOVES; SENSITIZATION; SPECTRUM; BRANDS	Objective: To summarize the clinical symptoms of latex rubber allergy and provide guidelines for the management of this allergy. Data Sources: The English-language literature was searched from 1979 through 1994 manually and using MEDLINE. Conference proceedings and reference lists of relevant articles were reviewed. Data Extraction: Studies clinically relevant to latex allergy were selected. Results: The most common clinical presentation of latex allergy is a nonimmunologic, irritant dermatitis of the hand. Contact dermatitis (type IV delayed hypersensitivity reactions to rubber additives) is the most common immunologic manifestation of latex rubber allergy. Type I allergic responses are less common and include contact urticaria, rhinoconjunctivitis, asthma, and anaphylaxis. Seven percent to 10% of health care workers regularly exposed to latex and 28% to 67% of children with spina bifida have a positive skin test result to latex proteins indicating increased blood levels of IgE antibody. About one third of patients with positive skin test results, however, do not yet have symptoms of latex allergy. Systemic (life-threatening) anaphylactic shock can occur intraoperatively in highly sensitive patients because of mucosal absorption of latex protein allergens from the surgeon's gloves. The present treatment for latex allergy is careful avoidance of latex materials. In addition, the use of powder-free latex gloves can eliminate airborne latex exposure and can allow health care workers with inhalant allergic reactions to return to work. Conclusion: Latex allergy currently affects thousands of people. These persons have IgE-mediated cutaneous, respiratory, and systemic allergic reactions. A reduction of the total protein level on latex rubber devices may prevent further sensitization and eliminate latex allergic reactions.	GUTHRIE MED CTR, SAYRE, PA 18840 USA					Beezhold, Donald/0000-0001-5543-5747				ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; BEEZHOLD D, 1992, ARCH SURG-CHICAGO, V127, P1354; BEEZHOLD DH, 1993, P INT C EUROPEAN RUB; CHAROUS BL, 1994, J ALLERGY CLIN IMMUN, V94, P12, DOI 10.1016/0091-6749(94)90065-5; DECORRES LF, 1993, ANN ALLERGY, V70, P35; Hamann CP, 1993, AM J CONTACT DERMATI, V4, P4, DOI DOI 10.1097/01634989-199303000-00003; HEESE A, 1991, J AM ACAD DERMATOL, V25, P831, DOI 10.1016/S0190-9622(08)80977-2; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V93, P813, DOI 10.1016/0091-6749(94)90370-0; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; LAHTI A, 1992, CONTACT DERMATITIS, V26, P259, DOI 10.1111/j.1600-0536.1992.tb00239.x; SCARBECK K, 1993, ACAD GEN DENTISTRY, V21, P2; SLATER JE, 1992, ANN ALLERGY, V68, P203; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1993, P INT C RUBBER CONSU, pP17; YUNGINGER JW, 1994, J ALLERGY CLIN IMMUN, V93, P836, DOI 10.1016/0091-6749(94)90374-3; 1993, J ALLERGY CLIN IMMUN, V92, P16	22	145	151	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1995	122	1					43	46		10.7326/0003-4819-122-1-199501010-00007	http://dx.doi.org/10.7326/0003-4819-122-1-199501010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY502	7985895				2022-12-28	WOS:A1995PY50200007
J	WELLS, PS; LENSING, AWA; DAVIDSON, BL; PRINS, MH; HIRSH, J				WELLS, PS; LENSING, AWA; DAVIDSON, BL; PRINS, MH; HIRSH, J			ACCURACY OF ULTRASOUND FOR THE DIAGNOSIS OF DEEP VENOUS THROMBOSIS IN ASYMPTOMATIC PATIENTS AFTER ORTHOPEDIC-SURGERY - A METAANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Review							B-MODE ULTRASONOGRAPHY; MOLECULAR-WEIGHT HEPARIN; COLOR DOPPLER ULTRASOUND; VEIN-THROMBOSIS; IMPEDANCE PLETHYSMOGRAPHY; HIP-SURGERY; LOWER-EXTREMITY; DUPLEX ULTRASONOGRAPHY; KNEE ARTHROPLASTY; STANDARD HEPARIN	Objective: To evaluate, by meta-analysis, the accuracy of ultrasound screening for deep venous thrombosis in patients after orthopedic surgery. Data Sources: The MEDLINE database from January 1982 to October 1993. Bibliographies of retrieved articles and recent journal publications were searched independently and using Current Contents. Study Selection: All articles evaluating the use of venous ultrasound imaging (B-mode, duplex, and color Doppler) compared with standard contrast venography for detecting deep venous thrombosis. We excluded abstracts, early reports of studies later reported in full, and studies in which venography was not done in all patients. Seventeen of 30 identified studies were eligible. Data Extraction: Eligible articles were reviewed for the presence of three key criteria necessary for evaluating the accuracy of the diagnostic tests: 1) previously established objective criteria for venography and ultrasound, 2) independent blinded comparisons of venography and ultrasound, and 3) prospective evaluations of consecutive patients. Studies including all three key criteria were defined as level 1 (minimized bias) studies; otherwise, they were defined as level 2 studies. Data Synthesis: In level 1 studies, ultrasonography had a sensitivity of 62% (95 of 153; 95% Cl, 54% to 70%), a specificity of 97% (Cl, 96% to 98%), and a positive predictive value of 66% (95 of 144; Cl, 58% to 74%) for detecting proximal thrombi. For level 2 studies, the sensitivity was 95% (Cl, 87% to 99%), the specificity was 100% (Cl, 99% to 100%), and the positive predictive value was 100% (Cl, 94% to 100%). Differences between level 1 and revel 2 studies appeared to be related to bias in study design. Conclusions: Venous ultrasound imaging has only moderate sensitivity and a moderate positive predictive value when used to screen for deep venous thrombosis in patients after orthopedic surgery; thus, ultrasound imaging may have limitations as a screening test.	UNIV AMSTERDAM, ACAD MED CTR, CTR HEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLA, 1105 AZ AMSTERDAM, NETHERLANDS; HAHNEMANN UNIV, DIV PULM & CRIT CARE MED, DIV ALLERGY, PHILADELPHIA, PA 19102 USA; UNIV AMSTERDAM, ACAD MED CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, 1105 AZ AMSTERDAM, NETHERLANDS; HAMILTON CIV HOSP, RES CTR, HENDERSON GEN DIV, HAMILTON, ON L8V 1C3, CANADA	University of Amsterdam; Academic Medical Center Amsterdam; Drexel University; University of Amsterdam; Academic Medical Center Amsterdam; McMaster University	WELLS, PS (corresponding author), OTTAWA CIVIC HOSP, CIV PARKDALE CLIN, ROOM 455, 4TH FLOOR, 737 PARKDALE AVE, OTTAWA, ON K1Y 1J8, CANADA.							AGNELLI G, 1991, ARCH INTERN MED, V151, P2167, DOI 10.1001/archinte.151.11.2167; AGNELLI G, 1992, THROMB HAEMOSTASIS, V68, P257; AGNELLI G, 1991, THROMB HAEMOSTASIS, V65, P1175; ANDERSON DR, 1993, ANN INTERN MED, V119, P1105, DOI 10.7326/0003-4819-119-11-199312010-00008; ANSCOMBE FJ, 1956, BIOMETRIKA, V43, P461, DOI 10.1093/biomet/43.3-4.461; BARNES CL, 1991, CLIN ORTHOP RELAT R, P180; BARNES RW, 1989, J VASC SURG, V9, P251, DOI 10.1067/mva.1989.vs0090251; BAXTER GM, 1990, CLIN RADIOL, V42, P32, DOI 10.1016/S0009-9260(05)81618-6; BETTMANN MA, 1987, RADIOLOGY, V165, P113, DOI 10.1148/radiology.165.1.3306781; Borris L C, 1990, Eur J Vasc Surg, V4, P473, DOI 10.1016/S0950-821X(05)80786-8; BORRIS LC, 1989, THROMB HAEMOSTASIS, V61, P363; CLAGETT GP, 1992, CHEST, V102, pS391, DOI 10.1378/chest.102.4_Supplement.391S; COGO A, 1993, ARCH INTERN MED, V153, P2777, DOI 10.1001/archinte.153.24.2777; COMEROTA AJ, 1990, J VASC SURG, V11, P53, DOI 10.1067/mva.1990.16342; COMEROTA AJ, 1993, THROMB HAEMOST S, V69, P1813; CRONAN JJ, 1991, J CLIN ULTRASOUND, V19, P133, DOI 10.1002/jcu.1870190302; CRONAN JJ, 1987, RADIOLOGY, V162, P191, DOI 10.1148/radiology.162.1.3538148; CRUICKSHANK MK, 1989, THROMB HAEMOSTASIS, V62, P830; DAUZAT MM, 1986, J ULTRAS MED, V5, P625; DAVIDSON BL, 1992, ANN INTERN MED, V117, P735, DOI 10.7326/0003-4819-117-9-735; DONNER A, 1988, J CLIN EPIDEMIOL, V41, P899, DOI 10.1016/0895-4356(88)90107-2; DORFMAN GS, 1990, AM J ROENTGENOL, V154, P851, DOI 10.2214/ajr.154.4.2107688; ELIAS A, 1987, INT ANGIOL, V6, P175; ELLIOTT CG, 1993, ANGIOLOGY, V44, P26, DOI 10.1177/000331979304400105; FLINN WR, 1989, ARCH SURG-CHICAGO, V124, P901; FROEHLICH JA, 1989, J BONE JOINT SURG AM, V71A, P249, DOI 10.2106/00004623-198971020-00012; GINSBERG JS, 1991, RADIOLOGY, V181, P651, DOI 10.1148/radiology.181.3.1947076; HABSCHEID W, 1990, ANGIOLOGY, V41, P599, DOI 10.1177/000331979004100803; HECKERLING PS, 1988, J GEN INTERN MED, V3, P604, DOI 10.1007/BF02596109; HULL R, 1993, NEW ENGL J MED, V329, P1370, DOI 10.1056/NEJM199311043291902; HULL R, 1976, CIRCULATION, V53, P696, DOI 10.1161/01.CIR.53.4.696; JONGBLOETS LMM, 1994, LANCET, V343, P1142, DOI 10.1016/S0140-6736(94)90240-2; KERR TM, 1990, SURGERY, V108, P520; KRAAY MJ, 1993, CLIN ORTHOP RELAT R, V286, P18; LENSING AW, 1993, THROMB HAEMOST S, V69, P2941; LENSING AWA, 1993, THROMB HAEMOSTASIS, V69, P2; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; MATTOS MA, 1992, J VASC SURG, V15, P366, DOI 10.1016/0741-5214(92)90258-A; MITCHELL DC, 1991, BRIT J SURG, V78, P611, DOI 10.1002/bjs.1800780528; MONREAL M, 1989, ANGIOLOGY, V40, P527, DOI 10.1177/000331978904000603; MUSSURAKIS S, 1990, SURG GYNECOL OBSTET, V171, P233; NICOLAIDES A, 1993, HAEMOSTASIS, V23, P72; NIX ML, 1989, J VASC TECH, V8, P121; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; PETERS SHA, 1982, THROMB HAEMOSTASIS, V48, P297; PIOVELLA F, 1993, THROMB HAEMOST S, V69, P1829; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; Rose S C, 1993, J Vasc Interv Radiol, V4, P111, DOI 10.1016/S1051-0443(93)71832-1; ROSE SC, 1990, RADIOLOGY, V175, P639, DOI 10.1148/radiology.175.3.2188293; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; Tremaine M D, 1992, J Arthroplasty, V7, P187, DOI 10.1016/0883-5403(92)90015-I; VOGEL P, 1987, RADIOLOGY, V163, P747, DOI 10.1148/radiology.163.3.3554344; WELLS PS, 1992, BLOOD S, V80, P316; WHITE RH, 1989, ANN INTERN MED, V111, P297, DOI 10.7326/0003-4819-111-4-297; WHITE RH, 1990, J BONE JOINT SURG AM, V72A, P495, DOI 10.2106/00004623-199072040-00004; WHITE RH, 1988, CLIN RES, V36, pA751; WILLEJORGENSEN P, 1993, THROMB HAEMOST S, V69, P279; WOOLSON ST, 1990, J BONE JOINT SURG AM, V72A, P983, DOI 10.2106/00004623-199072070-00004; WOOLSON ST, 1991, CLIN ORTHOP RELAT R, V273, P131	60	291	301	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1995	122	1					47	53		10.7326/0003-4819-122-1-199501010-00008	http://dx.doi.org/10.7326/0003-4819-122-1-199501010-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY502	7985896				2022-12-28	WOS:A1995PY50200008
J	DAKE, MD; MILLER, DC; SEMBA, CP; MITCHELL, RS; WALKER, PJ; LIDDELL, RP				DAKE, MD; MILLER, DC; SEMBA, CP; MITCHELL, RS; WALKER, PJ; LIDDELL, RP			TRANSLUMINAL PLACEMENT OF ENDOVASCULAR STENT-GRAFTS FOR THE TREATMENT OF DESCENDING THORACIC AORTIC-ANEURYSMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-HISTORY; GRAFT PLACEMENT; FEASIBILITY	Background. The usual treatment for thoracic aortic aneurysms is surgical replacement with a prosthetic graft, but the associated morbidity and mortality are considerable. We studied the use of transluminally placed endovascular stent-graft devices as an alternative to surgical repair. Methods. We evaluated the feasibility, safety, and effectiveness of transluminally placed stent-grafts to treat descending thoracic aortic aneurysms in 13 patients over a 24-month period. Atherosclerotic, anastomotic, and post-traumatic true or false aneurysms and aortic dissections were treated. The mean diameter of the aneurysms was 6.1 cm (range, 5 to 8). The endovascular stent-grafts were custom-designed for each patient and were constructed of self-expanding stainless-steel stents covered with woven Dacron grafts. Results. Endovascular placement of the stent-graft prosthesis was successful in all patients. There was complete thrombosis of the thoracic aortic aneurysm surrounding the stent-graft in 12 patients, and partial thrombosis in 1. Two patients initially had small, residual patent proximal tracts into the aneurysm sac, but both tracts thrombosed within two months after the procedure. in four patients, two prostheses were required to bridge the aneurysm adequately. There have been no deaths or instances of paraplegia, stroke, distal embolization, or infection during an average follow-up of 11.6 months. One patient with an extensive chronic aortic dissection required open surgical graft replacement four months later because of progressive dilatation of the arch. Conclusions. These preliminary results demonstrate that endovascular stent-graft repair is safe in highly selected patients with descending thoracic aortic aneurysms. This new method of treatment will, however, require careful long-term evaluation.	STANFORD UNIV,SCH MED,DEPT RADIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT CARDIOVASC SURG,STANFORD,CA 94305	Stanford University; Stanford University			Walker, Philip J/F-3034-2010	Miller, D. Craig/0000-0001-7619-0080				BALKO A, 1986, J SURG RES, V40, P305, DOI 10.1016/0022-4804(86)90191-5; BICKERSTAFF LK, 1982, SURGERY, V92, P1103; CHUTER TAM, 1993, J VASC SURG, V18, P185, DOI 10.1016/0741-5214(93)90598-G; CRAGG AH, 1993, RADIOLOGY, V187, P643, DOI 10.1148/radiology.187.3.8497609; DOTTER CT, 1969, INVEST RADIOL, V4, P329, DOI 10.1097/00004424-196909000-00008; ESTES JE, 1950, CIRCULATION, V2, P258, DOI 10.1161/01.CIR.2.2.258; JOYCE JW, 1964, CIRCULATION, V29, P176, DOI 10.1161/01.CIR.29.2.176; LABORDE JC, 1992, RADIOLOGY, V184, P185, DOI 10.1148/radiology.184.1.1535160; LAWRENCE DD, 1987, RADIOLOGY, V163, P357, DOI 10.1148/radiology.163.2.2951767; MARIN ML, 1993, J VASC SURG, V18, P299, DOI 10.1016/0741-5214(93)90611-O; MAY J, 1993, J VASC SURG, V18, P1056, DOI 10.1016/0741-5214(93)90562-Z; MCNAMARA JJ, 1978, ANN THORAC SURG, V26, P468, DOI 10.1016/S0003-4975(10)62927-X; MIRICH D, 1989, RADIOLOGY, V170, P1033, DOI 10.1148/radiology.170.3.2916054; MITCHELL RS, 1983, J THORAC CARDIOV SUR, V86, P400; MORENOCABRAL CE, 1984, J THORAC CARDIOV SUR, V88, P1020; Najafi H, 1980, World J Surg, V4, P553; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; PRESSLER V, 1980, J THORAC CARDIOV SUR, V79, P489; YOSHIOKA T, 1988, AM J ROENTGENOL, V151, P673, DOI 10.2214/ajr.151.4.673	19	1163	1366	1	53	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	1994	331	26					1729	1734		10.1056/NEJM199412293312601	http://dx.doi.org/10.1056/NEJM199412293312601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ266	7984192				2022-12-28	WOS:A1994PZ26600001
J	TUNNICLIFFE, WS; BURGE, PS; AYRES, JG				TUNNICLIFFE, WS; BURGE, PS; AYRES, JG			EFFECT OF DOMESTIC CONCENTRATIONS OF NITROGEN-DIOXIDE ON AIRWAY RESPONSES TO INHALED ALLERGEN IN ASTHMATIC-PATIENTS	LANCET			English	Article							RESPIRATORY SYMPTOMS; LUNG-FUNCTION; SHORT-TERM; IN-VITRO; POLLUTION; EXPOSURE; METHACHOLINE; CHILDREN; ILLNESS	Nitrogen dioxide is a common indoor pollutant. In the light of suggestions that outdoor air pollution can harm people with asthma, we investigated the effect of 1 h exposures to domestic concentrations of nitrogen dioxide on the airway response to house-dust mite (HDM) allergen in ten patients with mild asthma. Each subject breathed air, 100 ppb nitrogen dioxide, or 400 ppb nitrogen dioxide for 1 h, in double-blind, random order, then immediately underwent a fixed-dose HDM challenge. Baseline forced expiratory volume in 1 s (FEV(1)) was not affected by any of the gas mixtures. The mean early asthmatic response (maximum percentage change in FEV(1) during first 2 h after challenge) was -14.62% (SD 8.03) after air, -14.41% (7.86) after 100 ppb nitrogen dioxide, and -18.64% (7.28) after 400 ppb nitrogen dioxide. The difference between air and 400 ppb (-4.01%) was significant (95% CI -1.34 to -6.69%, p<0.009), but those between air and 100 ppb and between 100 and 400 ppb were not (0.21 [-3.10 to 3.53]% and -4.23 [-8.75 to 0.29]%). The mean late asthmatic response (maximum percentage change in FEV(1)) to challenge after air was -2.85% (3.95), after 100 ppb nitrogen dioxide -7.76% (6.92), and after 400 ppb -8.13% (6.64). The difference in means between the air and 400 ppb exposures was significant (-5.28 [-0.73 to -9.83]%, p<0.02) but those between air and 100 ppb (-4.90 [-10.60 to 0.78]%) and 100 and 400 ppb (0.37 [-3.06 to 3.80]%) were not. These findings suggest that nitrogen dioxide, at concentrations encountered in the home environment, can potentiate the specific airway response of patients with mild asthma to inhaled HDM allergen, although the effect is small.	BIRMINGHAM HEARTLANDS HOSP,CHEST RES INST,LUNG RES LAB,BIRMINGHAM B9 5SS,W MIDLANDS,ENGLAND	Heart of England NHS Foundation Trust; University of Birmingham								BERNSTEIN IL, 1988, J ALLERGY CLIN IMMUN, V82, P487, DOI 10.1016/0091-6749(88)90958-X; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42, DOI 10.1164/ajrccm/145.1.42; BYLIN G, 1985, EUR J RESPIR DIS, V66, P205; CAVIGIOLI G, 1993, ANN ALLERGY, V70, P411; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CLENCHAAS J, 1991, HLTH EFFECTS TRAFFIC; COCKCROFT DW, 1983, CHEST, V84, P505, DOI 10.1378/chest.84.4.505; COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb01763.x; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271, DOI 10.1165/ajrcmb/9.3.271; DEVALIA JL, 1993, EUR RESPIR J, V6, P1308; EDWARDS J, IN PRESS ARCH ENV HL; GAMBLE J, 1987, ENVIRON RES, V42, P201, DOI 10.1016/S0013-9351(87)80022-1; HASSELBLAD V, 1992, J AIR WASTE MANAGE, V42, P662, DOI 10.1080/10473289.1992.10467018; JORRES R, 1991, LUNG, V169, P77, DOI 10.1007/BF02714145; LOVE GJ, 1982, ARCH ENVIRON HEALTH, V37, P75, DOI 10.1080/00039896.1982.10667539; LOWRY T, 1956, JAMA-J AM MED ASSOC, V162, P153, DOI 10.1001/jama.1956.02970200001001; MELIA RJW, 1982, INT J EPIDEMIOL, V11, P155, DOI 10.1093/ije/11.2.155; MOHESIN V, 1988, ARCH ENVIRON HEALTH, V43, P242; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MORROW PE, 1989, RES REP HLTH EFF I, V23, P1; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; QUACKENBOSS JJ, 1982, ENVIRON INT, V8, P249; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; SAMET JM, 1991, INDOOR AIR POLLUTION, P170; SCHWARTZ J, 1990, AM REV RESPIR DIS, V141, P62, DOI 10.1164/ajrccm/141.1.62; SPEIZER FE, 1963, AM REV RESPIR DIS, V88, P205; SPENGLER JD, 1983, SCIENCE, V221, P9, DOI 10.1126/science.6857273; VEDAL S, 1987, AM J PUBLIC HEALTH, V77, P694, DOI 10.2105/AJPH.77.6.694; 1993, 3RD ADV GROUP MED AS	29	245	251	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1733	1736		10.1016/S0140-6736(94)92886-X	http://dx.doi.org/10.1016/S0140-6736(94)92886-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7997002				2022-12-28	WOS:A1994PY28100009
J	YAN, MH; DAI, TN; DEAK, JC; KYRIAKIS, JM; ZON, LI; WOODGETT, JR; TEMPLETON, DJ				YAN, MH; DAI, TN; DEAK, JC; KYRIAKIS, JM; ZON, LI; WOODGETT, JR; TEMPLETON, DJ			ACTIVATION OF STRESS-ACTIVATED PROTEIN-KINASE BY MEKK1 PHOSPHORYLATION OF ITS ACTIVATOR SEK1	NATURE			English	Article							RAF; TYROSINE	A KINASE distinct from the MEK activator Raf(1-3), termed MEK kinase-1 (MEKK), was originally identified by virtue of its homology to kinases involved in yeast mating signal cascades(4). Like Raf, MEKK is capable of activating MEK in vitro(4,5). High-level expression of MEKK in COS-7 cells(4) or using vaccinia virus vectors(5) also activates MEK and MAPK, indicating that MEKK and Raf provide alternative means of activating the MAPK signalling pathmay. We have derived NIH3T3 cell sublines that can be induced to express active MEKK. Here we show that induction of MEKK does not result in the activation of MAPK, but instead stimulates the stress-activated protein kinases (SAPKs)(6-8) which are identical to a Jun amino-terminal kinase(9,10). We find that MEKK regulates a new signalling cascade by phosphorylating an SAPK activator, SEK1 which in turn phosphorylates and activates SAPK.	CASE WESTERN RESERVE UNIV HOSP, SCH MED, CELL BIOL PROGRAM, CLEVELAND, OH 44106 USA; PRINCESS MARGARET HOSP, ONTARIO CANC INST, TORONTO M4X 1K9, ON, CANADA; MASSACHUSETTS GEN HOSP E, MED SERV, DIABET RES LAB, BOSTON, MA 02129 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP EAST, DEPT MED, BOSTON, MA 02129 USA; HARVARD UNIV, CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST, DIV HEMATOL, BOSTON, MA 02115 USA	Case Western Reserve University; Case Western Reserve University Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	YAN, MH (corresponding author), CASE WESTERN RESERVE UNIV HOSP, SCH MED, INST PATHOL, 10900 E EUCLID AVE, CLEVELAND, OH 44106 USA.		Woodgett, Jim/F-1087-2010; Templeton, Dennis J/F-7695-2011	Woodgett, Jim/0000-0003-3731-5797; 				DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FERNANDEZ A, 1994, ONCOGENE, V9, P2009; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; YAN MH, 1994, J BIOL CHEM, V269, P19067	20	706	723	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	1994	372	6508					798	800						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997270				2022-12-28	WOS:A1994PY21200058
J	MULLOOLY, JP; BENNETT, MD; HORNBROOK, MC; BARKER, WH; WILLIAMS, WW; PATRIARCA, PA; RHODES, PH				MULLOOLY, JP; BENNETT, MD; HORNBROOK, MC; BARKER, WH; WILLIAMS, WW; PATRIARCA, PA; RHODES, PH			INFLUENZA VACCINATION PROGRAMS FOR ELDERLY PERSONS - COST-EFFECTIVENESS IN A HEALTH MAINTENANCE ORGANIZATION	ANNALS OF INTERNAL MEDICINE			English	Article							NURSING-HOMES; RISK; REDUCTION; PNEUMONIA; EPIDEMIC; IMPACT	Objective: To estimate the cost-effectiveness and net medical care costs of programs for annual influenza vaccinations for the elderly in a health maintenance organization (HMO). Design: Population-based, case-control study. Setting: The Northwest Region of Kaiser Permanente, a prepaid group practice HMO in Portland, Oregon. Participants: Kaiser Permanente members 65 years of age and older who had at least 1 month of HMO eligibility during any of nine influenza seasons in the 1980s. Measurements: The HMO's costs for providing medical care and conducting Vaccination programs were estimated using accounting data. Results: 32% of high-risk elderly persons and 22% of non-high-risk elderly persons received influenza vaccinations. Aggregate vaccine effectiveness in preventing pneumonia and influenza hospitalizations was 30% (95% CI, 17% to 42%) for high-risk and 40% (CI, 1% to 64%) for non-high-risk elderly persons. The net savings to the HMO per vaccination was $6.11 for high-risk elderly persons and $1.10 for all elderly persons. The HMO incurred a net cost of $4.82 per vaccination for non-high-risk elderly persons. Conclusions: Influenza vaccination rates in this HMO were relatively low for high-risk elderly persons. The medical care costs saved by preventing pneumonia and influenza through Vaccination of high-risk elderly persons provide a compelling rationale to increase compliance with recommendations for annual influenza vaccination. Indirect benefits, such as prevention of suffering, incapacity, and lost wages, are likely to compensate for the small net cost of vaccinating non-highrisk elderly persons.	UNIV ROCHESTER, DEPT COMMUNITY & PREVENT SERV, ROCHESTER, NY 14642 USA; CTR DIS CONTROL & PREVENT, DIV IMMUNIZAT, ATLANTA, GA 30305 USA	University of Rochester; Centers for Disease Control & Prevention - USA	MULLOOLY, JP (corresponding author), KAISER PERMANENTE CTR HLTH RES, 3800 N KAISER CTR DR, PORTLAND, OR 97227 USA.				PHS HHS [200-89-0748] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARKER W, 1993, OPTIONS CONTROL INFL, V2, P143; BARKER WH, 1980, JAMA-J AM MED ASSOC, V244, P2547, DOI 10.1001/jama.244.22.2547; BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; BARKER WH, 1986, OPTIONS CONTROL INFL, P169; BARTON MB, 1990, AM J PUBLIC HEALTH, V80, P534, DOI 10.2105/AJPH.80.5.534; FEDSON DS, 1993, JAMA-J AM MED ASSOC, V270, P1956, DOI 10.1001/jama.270.16.1956; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; MONTO AS, 1993, OPTIONS CONTROL INFL, V2, P135; MULLOOLY JP, 1982, AM J PUBLIC HEALTH, V72, P1008, DOI 10.2105/AJPH.72.9.1008; MULLOOLY JP, 1987, AM J PUBLIC HEALTH, V77, P626, DOI 10.2105/AJPH.77.5.626; PATRIARCA PA, 1986, AM J EPIDEMIOL, V124, P114, DOI 10.1093/oxfordjournals.aje.a114355; PATRIARCA PA, 1985, JAMA-J AM MED ASSOC, V253, P1136, DOI 10.1001/jama.253.8.1136; RIDDIOUGH MA, 1983, JAMA-J AM MED ASSOC, V249, P3189; SCHOENBAUM S C, 1990, Journal of General Internal Medicine, V5, pS123, DOI 10.1007/BF02600857; SENCER DJ, 1973, P INT S INFLUENZA VA, V20, P244; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; 1989, MMWR-MORBID MORTAL W, V38, P297; 1989, MMWR-MORBID MORTAL W, V38, P124; 1985, MMWR-MORBID MORTAL W, V34, P639; 1991, HLTH PEOPLE 2000 NAT, P76; 1993, MMWR-MORBID MORTAL W, V42, P601; 1981, COST EFFECTIVENESS I	22	261	278	1	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1994	121	12					947	952		10.7326/0003-4819-121-12-199412150-00008	http://dx.doi.org/10.7326/0003-4819-121-12-199412150-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW083	7978721				2022-12-28	WOS:A1994PW08300008
J	HEINZE, HJ; MANGUN, GR; BURCHERT, W; HINRICHS, H; SCHOLZ, M; MUNTE, TF; GOS, A; SCHERG, M; JOHANNES, S; HUNDESHAGEN, H; GAZZANIGA, MS; HILLYARD, SA				HEINZE, HJ; MANGUN, GR; BURCHERT, W; HINRICHS, H; SCHOLZ, M; MUNTE, TF; GOS, A; SCHERG, M; JOHANNES, S; HUNDESHAGEN, H; GAZZANIGA, MS; HILLYARD, SA			COMBINED SPATIAL AND TEMPORAL IMAGING OF BRAIN ACTIVITY DURING VISUAL SELECTIVE ATTENTION IN HUMANS	NATURE			English	Article							PET IMAGES; CORTEX	VISUAL-SPATIAL attention is an essential brain function that enables os to select and preferentially process high priority information in the visual fields. Several brain areas have been shown to participate in the control of spatial attention in humans(3-5), but little is known about the underlying selection mechanisms. Non-invasive scalp recordings of event-related potentials (e.r.ps) in humans have shown that attended visual stimuli are preferentially selected as early as 80-90 ms after stimulus onset(6,7), but current e.r.p. methods do not permit a- precise localization of the participating cortical areas. In this study we combined neuroimaging (positron emission tomography) with e.r.p. recording in order to describe both the cortical anatomy and time course of attentional selection processes. Together these methods showed that visual inputs from attended locations receive enhanced processing in the extrastriate cortex (fusiform gyrus) at 80-130 ms after stimulus onset. These findings reinforce early selection models of attention(8-10).	UNIV CALIF DAVIS, DEPT PSYCHOL, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, CTR NEUROSCI, DAVIS, CA 95616 USA; HANNOVER MED SCH, DEPT NUCL MED, W-3000 HANNOVER, GERMANY; UNIV HEIDELBERG, DEPT NEUROL, HEIDELBERG, GERMANY; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA	University of California System; University of California Davis; University of California System; University of California Davis; Hannover Medical School; Ruprecht Karls University Heidelberg; University of California System; University of California San Diego	HEINZE, HJ (corresponding author), UNIV MAGDEBURG, DEPT CLIN NEUROPHYSIOL, D-39120 MAGDEBURG, GERMANY.		Münte, Thomas/C-2077-2014; Burchert, Wolfgang/ABF-4194-2020					Broadbent D.E., 1958, PERCEPTION COMMUNICA; CORBETTA M, 1991, J NEUROSCI, V11, P2383; CORBETTA M, 1993, J NEUROSCI, V13, P1202; DESIMONE R, 1992, COLD SPRING HARB SYM, P963; FISCHER B, 1985, BRAIN RES, V345, P111, DOI 10.1016/0006-8993(85)90841-8; FOX PT, 1989, J NUCL MED, V30, P141; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; GONZALEZ G, IN PRESS BRAIN TOPOG; HAWKINS HL, 1990, J EXP PSYCHOL HUMAN, V16, P802, DOI 10.1037/0096-1523.16.4.802; HEINZE HJ, 1994, PERCEPT PSYCHOPHYS, V56, P42, DOI 10.3758/BF03211689; HILLYARD SA, 1993, CURR OPIN NEUROBIOL, V3, P217, DOI 10.1016/0959-4388(93)90213-I; JEFFREYS DA, 1972, EXP BRAIN RES, V16, P1; Laberge D, 1990, J Cogn Neurosci, V2, P358, DOI 10.1162/jocn.1990.2.4.358; MANGUN GR, 1993, ATTENTION PERFORM, V14, P219; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; Petersen S E, 1992, Curr Opin Neurobiol, V2, P217, DOI 10.1016/0959-4388(92)90016-E; PETERSEN SE, 1993, BRAIN MECHANISMS OF PERCEPTION AND MEMORY: FROM NEURON TO BEHAVIOR, P413; Posner M I, 1992, Curr Opin Neurobiol, V2, P165, DOI 10.1016/0959-4388(92)90006-7; POSNER MI, 1980, J EXP PSYCHOL GEN, V109, P160, DOI 10.1037/0096-3445.109.2.160; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; SCHERG M, 1991, Brain Topography, V4, P143, DOI 10.1007/BF01132771; SPITZER H, 1988, SCIENCE, V240, P338, DOI 10.1126/science.3353728; Talairach I., 1988, COPLANAR STEREOTACTI; TANAKA K, 1993, J NEUROPHYSIOL, V69, P128, DOI 10.1152/jn.1993.69.1.128; TREISMAN A, 1988, Q J EXP PSYCHOL-A, V40, P201, DOI 10.1080/02724988843000104; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; van der Heijden AHC., 1992, SELECTIVE ATTENTION; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; ZEKI S, 1991, J NEUROSCI, V11, P641	30	758	770	1	47	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 8	1994	372	6506					543	546		10.1038/372543a0	http://dx.doi.org/10.1038/372543a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990926				2022-12-28	WOS:A1994PW08200050
J	FEENEY, G				FEENEY, G			FERTILITY DECLINE IN EAST-ASIA	SCIENCE			English	Article							CHINA	With the fall of fertility in China to near or below replacement levels in the early 1990s, the whole of East Asia may now be said to have completed a demographic transition. Its experience lies between that of the West and the many developing countries in which demographic transition is now under way. The main features and possible underlying causes of the fertility declines in Japan, Taiwan, South Korea, and China during this century are discussed. Fertility decline in East Asia is interesting both in its own right, as a chapter in the history of human reproduction, and for the light it may shed on fertility decline in the rest of the world.			FEENEY, G (corresponding author), EAST WEST CTR,PROGRAM POPULAT,HONOLULU,HI 96848, USA.			Feeney, Griffith/0000-0001-8348-2786				[Anonymous], 1985, 1982 POPULATION CENS; [Anonymous], 1977, CITY LATE IMPERIAL C; BAKER HDR, 1979, CHHINESE FAMILY KINS; BANISTER J, 1981, POPUL DEV REV, V7, P1; Banister J., 1987, CHINAS CHANGING POPU; Barclay, 1954, COLONIAL DEV POPULAT; BARCLAY GW, 1976, POPUL INDEX, V72, P42; BONGAARTS J, 1987, FAMILY DEMOGRAPHY; Bulatao RA., 1983, DETERMINANTS FERTILI; BUUCK JL, 1937, LAND UTILIZATION CHI, P367; Caldwell J. C., 1982, THEORY FERTILITY DEC; Caldwell John C., 1988, CAUSES DEMOGRAPHIC C; CHEN PC, 1992, POPULATION REPORTS 4, V25; CLELAND J, 1985, REPRODUCTIVE CHANGE, pCH10; Coale AJ., 1987, BASIC DATA FERTILITY; COALE AJ, 1980, 1 NAT AC SCI COMM PO, P2; COALE AJ, 1987, 1104 E W POP I PAP; COALE AJ, 1974, POPUL INDEX, V40, P195; Coale Ansley., 1986, DECLINE FERTILITY EU; DAVIS K, 1963, POPUL INDEX, V29, P345; DAVIS K, 1967, SCIENCE, V158, P730, DOI 10.1126/science.158.3802.730; DYSON T, 1985, POPUL DEV REV, V11, P399, DOI 10.2307/1973246; Easterlin R.A., 1978, HIST STUDIES CHANGIN; FEENEY G, 1993, POPUL DEV REV, V19, P61, DOI 10.2307/2938385; FEENEY G, 1994, FUTURE POPULATION WO; FEENEY G, IN PRESS POPUL STUD; FEENEY G, 1994, PERIOD PARITY PROGR; FEENEY G, 1991, ASIAN PACIFIC POPUL, V5, P80; FEENEY G, 1990, NUPRI55 NIH U POP RE; FEENEY G, 1992, OCT INT SEM CHIN 199; FEENEY G, 1991, FUTURE DEMOGRAPHIC T; FEENEY G, 1989, POPUL DEV REV, V15, P2; FEENEYG, 1987, POPULATION STUDIES, V41, P1; GREENHALGH S, 1994, POPUL DEV REV, V20, P365, DOI 10.2307/2137523; GREENHALGH S, 1990, CHINA QUART, V122, P191; GREENHALGH S, 1994, AM ETHNOL, V21, P1; GREENHALGH S, 1993, CHINSES FAMILIES POS; Hanley S., 1977, EC DEMOGRAPHIC CHANG; HARDING H, 1987, CHINAS 2ND REVOLUTIO; HAUSER PM, 1967, DEMOGRAPHY, V4, P1; HIRSCHMAN C, 1994, ANNU REV SOCIOL, V20, P203; Ho Ping-ti, 1959, STUDIES POPULATION C, DOI DOI 10.4159/HARVARD.9780674184510; Hodge Robert W., 1991, FERTILITY CHANGE CON; Kelliher Daniel Roy, 1992, PEASANT POWER CHINA; KURODA T, 1991, POPULATION DEV JAPAN, P23; Kwon Tai Hwan, 1977, DEMOGRAPHY KOREA POP; KWON TH, 1993, REVOLUTION ASIAN FER; LAVELY W, 1990, CHINA QUART, V121, P61, DOI DOI 10.1017/S0305741000013515; LAVELY W, 1990, DEMOGRAPHY, V27, P3; Little D., 2014, WHAT IS METHODOLOGY; LUTHER NY, 1990, POP STUD-J DEMOG, V44, P341, DOI 10.1080/0032472031000144626; LYONS TP, 1994, TRANSFORMATION S CHI; MASON A, 1987, 106 E W POP I E W CT; MOSK C, 1983, PATRIARCHY FERTILITY; OGAWA N, 1993, POPL DEV REV, V19, P4; Peng X., 1991, DEMOGRAPHIC TRANSITI; Potter S.H., 1990, CHINAS PEASANTS; PRITCHETT LH, 1994, POPUL DEV REV, V20, P1, DOI 10.2307/2137629; RYDER NB, 1980, DEMOGRAPHIC PATTERNS; RYDER NB, 1980, DEMOGRAPHIC PATTERNS, P25; Shue Vivienne, 1980, PEASANT CHINA TRANSI; Skinner G. William, 1985, J ASIAN STUDIES, V44, P2; SMIL V, 1986, POPUL DEV REV, V12, P25, DOI 10.2307/1973350; Smith Thomas C., 1977, NAKAHARA; SUN TH, 1975, MEASURING EFFECT FAM; SZRETER S, 1993, POPUL DEV REV, V19, P659, DOI 10.2307/2938410; Taeuber Irene, 1958, POPULATION JAPAN; Thornton A., 1994, SOCIAL CHANGE FAMILY; Tien H. Yuan, 1991, CHINAS STRATEGIC DEM; TSUYA NO, 1991, NUPRI RES PAPER SERI, V58, P17; Tsuya Noriko O., 1991, NUPRI RES PAPER SERI, V58; Unger, 1984, CHEN VILLAGE RECENT; WOLF AP, 1986, POPUL DEV REV, V12, P1; Wolf Arthur P., 1980, MARRIAGE ADOPTION CH; 1987, HIST STATISTICS JAPA, V1, P272; 1982, 1980 CENS OFF EX YUA; 1993, 1992 TAIWAN FUKIEN D	77	24	25	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1518	1523		10.1126/science.7985021	http://dx.doi.org/10.1126/science.7985021			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PV015	7985021				2022-12-28	WOS:A1994PV01500033
J	TAKAGAKI, Y; MANLEY, JL				TAKAGAKI, Y; MANLEY, JL			A POLYADENYLATION FACTOR SUBUNIT IS THE HUMAN HOMOLOG OF THE DROSOPHILA SUPPRESSOR OF FORKED PROTEIN	NATURE			English	Article							PRE-MESSENGER-RNAS; POLY(A) POLYMERASE; SACCHAROMYCES-CEREVISIAE; SPECIFICITY FACTOR; BINDING DOMAIN; MELANOGASTER; CLEAVAGE; EXPRESSION; SEQUENCE; GENES	POLYADENYLATION of messenger RNA precursors is a complex process that requires multiple protein factors (for reviews, see refs 1, 2). Cleavage stimulation factor (CstF) is one of these, functioning together with cleavage-polyadenylation specificity factor, two cleavage factors, and poly(A)(+) polymerase(3-7) CstF is composed of three subunits of M(r) 77, 64 and 50K(8,9). The 64K(10) and 50K(11) subunits contain, respectively, an RNP-type RNA-binding domain that contacts the pre-mRNA and transducin repeats characteristic of G-protein beta-subunits. Here we report the cloning and characterization of the 77K subunit of human CstF (referred to as 77K). We show that the 77K subunit is required for formation of active CstF and bridges the 64K and 50K subunits. Sequence analyses indicate that the 77K subunit is the homologue of the protein encoded by the Drosophila melanogaster suppressor of forked (su(f)) gene(12). Mutations in su(f) can enhance or suppress the effects of transposable element insertions(13), and our data indicate that this is due to changes in polyadenylation. Both the 77K subunit and the su(f) protein share homology with Saccharomyces cerevisiae RNA14 previously shown to be involved in mRNA metabolism(14). Our results thus also indicate that components of the complex polyadenylation machinery are conserved from yeast to man.			TAKAGAKI, Y (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Manley, James/0000-0002-8341-1459				AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; DORSETT D, 1989, GENE DEV, V3, P454, DOI 10.1101/gad.3.4.454; DRIVER A, 1989, MOL GEN GENET, V220, P49, DOI 10.1007/BF00260854; DUDICK ME, 1974, GENETICS, V76, P487; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HARLOW E, 1988, ANTIBODIES LABORATOR; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MANLEY JL, 1994, GENE DEV, V8, P259, DOI 10.1101/gad.8.3.259; MILLER DW, 1986, GENETIC ENG PRINCIPL, V8, P277; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MITCHELSON A, 1993, GENE DEV, V7, P241, DOI 10.1101/gad.7.2.241; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RUTLEDGE BJ, 1988, GENETICS, V119, P391; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WILSON TG, 1980, J EMBRYOL EXP MORPH, V55, P247; ZACHAR ZZ, 1987, EMBO J, V6, P4105, DOI 10.1002/j.1460-2075.1987.tb02756.x	30	118	119	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					471	474		10.1038/372471a0	http://dx.doi.org/10.1038/372471a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984242				2022-12-28	WOS:A1994PV01200059
J	SEMPOS, CT; LOOKER, AC; GILLUM, RF; MAKUC, DM				SEMPOS, CT; LOOKER, AC; GILLUM, RF; MAKUC, DM			BODY IRON STORES AND THE RISK OF CORONARY HEART-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BINDING PROTEINS; MORTALITY; DEFICIENCY; HEMATOCRIT; PROGRAM; CANCER; MEN; INFORMATION; FRAMINGHAM; SMOKING	Background. Recent studies have suggested an association between higher body iron stores and the risk of coronary heart disease. To assess these findings, we examined the association between transferrin saturation and the risk of coronary heart disease, myocardial infarction, overall mortality, and mortality from cardiovascular causes in a large population. Methods. We studied a total of 4518 men and women from the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study, using a multivariate Cox proportional-hazards model. Base-line data were collected from 1971 to 1974, with follow-up through 1987. Transferrin saturation (serum iron concentration divided by total iron-binding capacity) was used as a measure of the amount of circulating iron available to tissues. Results. The risk of coronary heart disease was not related to transferrin-saturation levels in white men or women. Estimates of the relative risk of coronary heart disease for the fifth quintile of transferrin saturation as compared with the first quintile were 0.72 (95 percent confidence interval, 0.51 to 1.00) for men and 0.85 (95 percent confidence interval, 0.60 to 1.21) for women. The results were similar for myocardial infarction. A significant inverse association with transferrin saturation was found for overall mortality and for mortality from cardiovascular causes in white men and women. Transferrin saturation was not associated with any of the clinical outcomes in blacks, possibly owing to the small sample. Conclusions. Higher transferrin-saturation levels were not associated with an increased risk of coronary heart disease or myocardial infarction. On the contrary, the results indicate that there may be an inverse association of iron stores with overall mortality and with mortality from cardiovascular causes.			SEMPOS, CT (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, 6525 BELCREST RD, RM 1070, HYATTSVILLE, MD 20782 USA.							ABELL LL, 1952, J BIOL CHEM, V195, P357; ABRAHAM S, 1978, VITAL HLTH STAT, V11, P1; ABUZEID HAH, 1976, J CHRON DIS, V29, P395, DOI 10.1016/0021-9681(76)90060-6; BAKER IA, 1982, BRIT HEART J, V47, P490, DOI 10.1136/hrt.47.5.490; BEATON GH, 1989, AM J CLIN NUTR, V50, P575, DOI 10.1093/ajcn/50.3.575; Bothwell T.H., 1979, IRON METABOLISM MAN; BOTTIGER LE, 1980, ATHEROSCLEROSIS, V36, P389, DOI 10.1016/0021-9150(80)90219-1; BRAND RJ, 1976, CIRCULATION, V53, P348, DOI 10.1161/01.CIR.53.2.348; BURCH GE, 1962, JAMA-J AM MED ASSOC, V180, P63, DOI 10.1001/jama.1962.03050140065017b; Campbell M J, 1983, Stat Med, V2, P223, DOI 10.1002/sim.4780020217; CAMPBELL MJ, 1985, J CHRON DIS, V38, P881, DOI 10.1016/0021-9681(85)90113-4; CARTER C, 1983, AM HEART J, V105, P674, DOI 10.1016/0002-8703(83)90493-3; Clayton D., 1993, STAT MODELS EPIDEMIO, P249; Cohen B B, 1987, Vital Health Stat 1, P1; COOPER RS, 1993, CIRCULATION, V87, P686; COX CS, 1992, VITAL HLTH STAT, V1, P1; COX DR, 1972, J R STAT SOC B, V34, P187; CULLEN KJ, 1981, LANCET, V2, P1288; DEPASQUALE NP, 1963, JAMA-J AM MED ASSOC, V183, P142; DOUMAS BT, 1971, CLIN CHIM ACTA, V31, P87, DOI 10.1016/0009-8981(71)90365-2; EAVENSON E, 1966, J AM OIL CHEM SOC, V43, P652, DOI 10.1007/BF02682563; ELWOOD PC, 1974, LANCET, V1, P891; FINCH CA, 1982, NEW ENGL J MED, V306, P1520, DOI 10.1056/NEJM198206243062504; FINCH CA, 1984, AM J CLIN NUTR, V39, P471, DOI 10.1093/ajcn/39.3.471; Finucane F F, 1990, Vital Health Stat 1, P1; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; GIOVANNIELLO TJ, 1968, J LAB CLIN MED, V71, P874; HUEBERS HA, 1987, PHYSIOL REV, V67, P520, DOI 10.1152/physrev.1987.67.2.520; INGRAM DD, IN PRESS VITAL HLTH, V2; KAHN HA, 1989, MONOGRAPHS EPIDEMIOL, V12; KNOTTNERUS JA, 1988, J CLIN EPIDEMIOL, V41, P67, DOI 10.1016/0895-4356(88)90010-8; KORN EL, 1991, AM J PUBLIC HEALTH, V81, P1166, DOI 10.2105/AJPH.81.9.1166; LAUFFER RB, 1991, MED HYPOTHESES, V35, P96, DOI 10.1016/0306-9877(91)90030-3; MACHLIN SR, 1989, STAT MED, V8, P997, DOI 10.1002/sim.4780080810; MADANS JH, 1986, PUBLIC HEALTH REP, V101, P474; MAYER GA, 1965, CAN MED ASSOC J, V93, P1151; MCLAUGHLIN JK, 1987, AM J EPIDEMIOL, V126, P144, DOI 10.1093/oxfordjournals.aje.a114647; MILLIMAN JD, 1973, BIOL GEOLOGY CORAL R, V1, P1; PAUL O, 1963, CIRCULATION, V28, P20, DOI 10.1161/01.CIR.28.1.20; RAMSAY WNM, 1957, CLIN CHIM ACTA, V2, P221, DOI 10.1016/0009-8981(57)90106-7; RIMM EB, 1993, CIRCULATION, V87, P692; ROBERTS J, 1977, VITAL HLTH STAT, V11, P1; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SCHATZKIN A, 1984, AM J EPIDEMIOL, V120, P888, DOI 10.1093/oxfordjournals.aje.a113960; SELBY JV, 1988, INT J CANCER, V41, P677, DOI 10.1002/ijc.2910410507; SHAH BV, 1991, SUDAAN USERS MANUAL; SORLIE PD, 1981, AM HEART J, V101, P456, DOI 10.1016/0002-8703(81)90136-8; STAMPFER MJ, 1993, CIRCULATION, V87, P688; STEVENS RG, 1986, J NATL CANCER I, V76, P605, DOI 10.1093/jnci/76.4.605; STEVENS RG, 1983, AM J EPIDEMIOL, V118, P550, DOI 10.1093/oxfordjournals.aje.a113660; STEVENS RG, 1988, NEW ENGL J MED, V319, P1047, DOI 10.1056/NEJM198810203191603; STUART J, 1988, J CLIN PATHOL, V41, P1203; SULLIVAN JL, 1989, AM HEART J, V117, P1177, DOI 10.1016/0002-8703(89)90887-9; SZATROWSKI TP, 1984, J CHRON DIS, V37, P569, DOI 10.1016/0021-9681(84)90007-9; TAKKUNEN H, 1974, LANCET, V2, P523; TRUETT J, 1967, J CHRON DIS, V20, P511, DOI 10.1016/0021-9681(67)90082-3; WILHELMSEN L, 1973, CIRCULATION, V48, P950, DOI 10.1161/01.CIR.48.5.950; Wintrobe MM, 1935, AM J MED SCI, V189, P102, DOI 10.1097/00000441-193501000-00012; YANO K, 1984, AM J EPIDEMIOL, V119, P653, DOI 10.1093/oxfordjournals.aje.a113787; YIP R, 1988, AM J CLIN NUTR, V48, P1295, DOI 10.1093/ajcn/48.5.1295; 1986, SGI SUPPLEMENTAL LIB; 1971, TECHNICON AUTO ANAL; 1979, HANES 1 HEMATOLOGY C	63	225	227	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 21	1994	330	16					1119	1124		10.1056/NEJM199404213301604	http://dx.doi.org/10.1056/NEJM199404213301604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF699	7993405				2022-12-28	WOS:A1994NF69900004
J	MEVORACH, D; HEYMAN, SN				MEVORACH, D; HEYMAN, SN			PAIN IN THE MARRIAGE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; CARBON-MONOXIDE; ARRHYTHMIAS; EXPOSURE; ANGINA				MEVORACH, D (corresponding author), HADASSAH UNIV HOSP,DEPT MED,MT SCOPUS,POB 24035,IL-91240 JERUSALEM,ISRAEL.							ALLRED EN, 1989, NEW ENGL J MED, V321, P1426, DOI 10.1056/NEJM198911233212102; ALLRED EN, 1990, NEW ENGL J MED, V322, P1019; ARONOW WS, 1973, ANN INTERN MED, V79, P392, DOI 10.7326/0003-4819-79-3-392; BIRNSTINGL MA, 1971, BRIT J SURG, V58, P837, DOI 10.1002/bjs.1800581110; GRACE TW, 1981, JAMA-J AM MED ASSOC, V246, P1698; HEYMAN SN, 1991, DICP ANN PHARMAC, V25, P1068, DOI 10.1177/106002809102501007; ILANO AL, 1990, CHEST, V97, P165, DOI 10.1378/chest.97.1.165; KARNEVALI R, 1987, MINERVA MED, V78, P175; KASSIRER JP, 1989, ANN INTERN MED, V110, P893, DOI 10.7326/0003-4819-110-11-893; LERMAN A, 1992, CIRCULATION, V86, P12; MARIUSNUNEZ AL, 1990, CHEST, V97, P491, DOI 10.1378/chest.97.2.491; OGAWA M, 1974, Industrial Health, V12, P121; Olson K R, 1984, J Emerg Med, V1, P233, DOI 10.1016/0736-4679(84)90078-7; SCHARF SM, 1974, NEW ENGL J MED, V291, P85, DOI 10.1056/NEJM197407112910208; SHEPS DS, 1990, ANN INTERN MED, V113, P343, DOI 10.7326/0003-4819-113-5-343; SPIERS ASD, 1983, LANCET, V1, P120; WALDEN SM, 1990, ANN INTERN MED, V113, P337, DOI 10.7326/0003-4819-113-5-337	17	6	6	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					48	50		10.1056/NEJM199501053320109	http://dx.doi.org/10.1056/NEJM199501053320109			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990865				2022-12-28	WOS:A1995PZ49700009
J	WILSON, IB; CLEARY, PD				WILSON, IB; CLEARY, PD			LINKING CLINICAL-VARIABLES WITH HEALTH-RELATED QUALITY-OF-LIFE - A CONCEPTUAL-MODEL OF PATIENT OUTCOMES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PRIMARY CARE PATIENTS; SELF-RATED HEALTH; MOS SHORT-FORM; OF-LIFE; RHEUMATOID-ARTHRITIS; PERCEIVED HEALTH; FOLLOW-UP; FUNCTIONAL DISABILITY; PHYSIOLOGIC HEALTH; MEDICAL OUTCOMES		HARVARD UNIV, SCH MED, DEPT HLTH CARE POLICY, BOSTON, MA 02115 USA; TUFTS UNIV, NEW ENGLAND MED CTR, PRIMARY CARE OUTCOMES RES INST, BOSTON, MA 02111 USA; TUFTS UNIV, DEPT MED, BOSTON, MA 02111 USA	Harvard University; Harvard Medical School; Tufts Medical Center; Tufts University; Tufts University			Wilson, Ira/F-9190-2016; Cleary, Paul/AAF-7048-2019	Wilson, Ira/0000-0002-0246-738X; 	AHRQ HHS [1-R01-HS06239] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALMY TP, 1988, ANN INTERN MED, V109, P70, DOI 10.7326/0003-4819-109-1-70; ALONSO J, 1992, MED CARE, V30, pMS125, DOI 10.1097/00005650-199205001-00011; Andrews F. M., 1976, SOCIAL INDICATORS WE; ANESHENSEL CS, 1984, J HEALTH SOC BEHAV, V25, P350, DOI 10.2307/2136376; ANGEL R, 1984, SOC SCI QUART, V65, P814; APPLEGATE WB, 1990, NEW ENGL J MED, V322, P1572, DOI 10.1056/NEJM199005313222205; BARSKY AJ, 1994, J NERV MENT DIS, V182, P63, DOI 10.1097/00005053-199402000-00001; BARSKY AJ, 1992, SOC SCI MED, V34, P1147, DOI 10.1016/0277-9536(92)90288-2; BARSKY AJ, 1993, AM J PSYCHIAT, V150, P484; BARSKY AJ, 1993, CARDIOLOGY, V83, P304, DOI 10.1159/000175986; BARSKY AJ, 1994, AM J MED, V97, P214, DOI 10.1016/0002-9343(94)90003-5; BERG RL, 1976, HEALTH SERV RES, V11, P391; BERGNER M, 1989, MED CARE, V27, pS148, DOI 10.1097/00005650-198903001-00012; BERGNER M, 1985, MED CARE, V23, P696, DOI 10.1097/00005650-198505000-00028; BERKI SE, 1979, MED CARE, V17, P1163, DOI 10.1097/00005650-197912000-00001; BLAZER DG, 1979, J AM GERIATR SOC, V27, P330, DOI 10.1111/j.1532-5415.1979.tb06051.x; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; BOMBARDIER C, 1986, AM J MED, V81, P565, DOI 10.1016/0002-9343(86)90539-5; BOMBARDIER C, 1991, CONTROL CLIN TRIALS, V12, pS243, DOI 10.1016/S0197-2456(05)80028-5; BURDON JGW, 1982, AM REV RESPIR DIS, V126, P825; BURT RS, 1978, SOCIOL METHOD RES, V6, P365, DOI 10.1177/004912417800600305; CALKINS DR, 1991, ANN INTERN MED, V114, P451, DOI 10.7326/0003-4819-114-6-451; Campbell A, 1981, SENSE WELL BEING AM; CLEARY PD, 1993, MED CARE, V31, P569, DOI 10.1097/00005650-199307000-00001; CLEARY PD, 1991, JAMA-J AM MED ASSOC, V266, P73, DOI 10.1001/jama.266.1.73; CLEARY PD, 1991, MED CARE, V29, P939, DOI 10.1097/00005650-199110000-00001; CLEARY PD, 1982, J HEALTH SOC BEHAV, V23, P106, DOI 10.2307/2136508; CLEARY PD, 1991, CONTROL CLIN TRIALS, V12, pS189, DOI 10.1016/S0197-2456(05)80023-6; CONNELLY JE, 1989, MED CARE, V27, pS99, DOI 10.1097/00005650-198903001-00009; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; DWOSH IL, 1983, NEW ENGL J MED, V308, P1124, DOI 10.1056/NEJM198305123081903; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; Feinstein AR, 1987, CLINIMETRICS; FILLENBAUM GG, 1979, J HEALTH SOC BEHAV, V20, P45, DOI 10.2307/2136478; FISCHHOFF B, 1991, AM PSYCHOL, V46, P835, DOI 10.1037/0003-066X.46.8.835; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; FOWLER FJ, 1988, JAMA-J AM MED ASSOC, V259, P3018, DOI 10.1001/jama.259.20.3018; FOWLER FJ, 1991, EUR UROL, V20, P44; FOWLER FJ, IN PRESS MED DECIS M; FRIES JF, 1991, CONTROL CLIN TRIALS, V12, pS106, DOI 10.1016/S0197-2456(05)80016-9; FRIMODTMOLLER PC, 1984, J UROLOGY, V132, P272, DOI 10.1016/S0022-5347(17)49587-5; FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P345, DOI 10.1016/0895-4356(89)90039-5; GARRITY TF, 1978, SOC SCI MED-MED SOC, V12, P77, DOI 10.1016/0271-7123(78)90032-9; GELBER RD, 1991, ANN INTERN MED, V114, P621, DOI 10.7326/0003-4819-114-8-621; GELBER RD, 1992, ANN INTERN MED, V116, P961, DOI 10.7326/0003-4819-116-12-961; GREENFIELD S, 1992, MED CARE, V30, pMS23, DOI 10.1097/00005650-199205001-00003; GUYATT G, 1991, CONTROL CLIN TRIALS, V12, pS81, DOI 10.1016/S0197-2456(05)80014-5; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; Guyatt GH, 1991, CONTROLLED CLIN TRIA, V12, p266S; HESSLER RM, 1971, J HEALTH SOC BEHAV, V12, P191, DOI 10.2307/2948554; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; HUSSAR AE, 1956, AM J MED SCI, V232, P518, DOI 10.1097/00000441-195611000-00005; IDLER EL, 1991, J GERONTOL, V46, pS55, DOI 10.1093/geronj/46.2.S55; IDLER EL, 1990, AM J PUBLIC HEALTH, V80, P446, DOI 10.2105/AJPH.80.4.446; IDLER EL, 1990, AM J EPIDEMIOL, V131, P91, DOI 10.1093/oxfordjournals.aje.a115489; JETTE AM, 1986, J GEN INTERN MED, V1, P143, DOI 10.1007/BF02602324; JOHNSON RJ, 1993, J HEALTH SOC BEHAV, V34, P105, DOI 10.2307/2137238; KAPLAN G, 1988, J GERONTOL, V43, pS114, DOI 10.1093/geronj/43.4.S114; KAPLAN GA, 1983, AM J EPIDEMIOL, V117, P292, DOI 10.1093/oxfordjournals.aje.a113541; KAPLAN RM, 1989, MED CARE, V27, pS27, DOI 10.1097/00005650-198903001-00003; KAPLAN SH, 1987, J CHRON DIS, V40, pS27, DOI 10.1016/S0021-9681(87)80029-2; KAZIS LE, 1990, J CLIN EPIDEMIOL, V43, P1243, DOI 10.1016/0895-4356(90)90025-K; KELLNER R, 1985, ARCH GEN PSYCHIAT, V42, P821; LANE DA, 1987, J CHRON DIS, V40, P585, DOI 10.1016/0021-9681(87)90018-X; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; LAUPACIS A, 1991, CONTROL CLIN TRIALS, V12, pS168, DOI 10.1016/S0197-2456(05)80021-2; LEFTON E, 1983, J AM GERIATR SOC, V31, P149, DOI 10.1111/j.1532-5415.1983.tb04854.x; LENDERKING WR, 1994, NEW ENGL J MED, V330, P738, DOI 10.1056/NEJM199403173301102; LEVKOFF SE, 1987, MED CARE, V25, P1148, DOI 10.1097/00005650-198712000-00004; LIEM PH, 1986, J GERONTOL, V41, P44, DOI 10.1093/geronj/41.1.44; LOHR KN, 1989, MED CARE, V27, pS1, DOI 10.1097/00005650-198903001-00001; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; MAHLER DA, 1984, CHEST, V85, P751, DOI 10.1378/chest.85.6.751; MAHLER DA, 1985, AM REV RESPIR DIS, V131, P22; MANNING WG, 1982, EC ASPECTS HLTH; MCCRAE RR, 1976, INT J AGING HUM DEV, V7, P49, DOI 10.2190/493K-DD4Q-59MF-GGVF; McDowell I, 1987, MEASURING HLTH GUIDE; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1992, MED CARE, V30, pMS253, DOI 10.1097/00005650-199205001-00025; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MECHANIC D, 1982, MED CARE, V20, P361, DOI 10.1097/00005650-198204000-00002; MECHANIC D, 1986, PSYCHOL MED, V16, P1, DOI 10.1017/S0033291700002476; MECHANIC D, 1972, NEW ENGL J MED, V286, P1132, DOI 10.1056/NEJM197205252862105; Mechanic D., 1982, SYMPTOMS ILLNESS BEH, P1; Mechanic D., 1978, MED SOCIOLOGY; MEENAN RF, 1984, ARTHRITIS RHEUM, V27, P1344, DOI 10.1002/art.1780271204; MOSSEY JM, 1982, AM J PUBLIC HEALTH, V72, P800, DOI 10.2105/AJPH.72.8.800; MULLEY AG, 1989, MED CARE, V27, pS269, DOI 10.1097/00005650-198903001-00021; Nagi SZ., 1965, SOCIOLOGY REHABILITA, P13; NELSON E, 1983, JAMA-J AM MED ASSOC, V249, P3331, DOI 10.1001/jama.249.24.3331; NELSON E, 1987, J CHRON DIS, V40, pS55, DOI 10.1016/S0021-9681(87)80033-4; NELSON E C, 1989, Medical Care (Philadelphia), V27, pS77, DOI 10.1097/00005650-198903001-00007; NERENZ DR, 1992, MED CARE, V30, pMS112, DOI 10.1097/00005650-199205001-00010; PARKERSON GR, 1993, MED CARE, V31, P629, DOI 10.1097/00005650-199307000-00005; PARKERSON GR, 1990, MED CARE, V28, P1056, DOI 10.1097/00005650-199011000-00007; Patrick D. L., 1993, HLTH STATUS HLTH POL; PATRICK DL, 1987, J CHRON DIS, V40, pS37, DOI 10.1016/S0021-9681(87)80030-9; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; PATRICK DL, 1990, ANNU REV PUBL HEALTH, V11, P165; PATRICK DL, 1988, QUALITY LIFE ASSESSM, P9; PENNEBAKER JW, 1982, PSYCHOL PHYSICAL SYM; PETERSON WL, 1977, NEW ENGL J MED, V297, P341, DOI 10.1056/NEJM197708182970701; READ JL, 1987, J CHRON DIS, V40, pS7, DOI 10.1016/S0021-9681(87)80027-9; REVICKI DA, 1992, MED CARE, V30, pMS274, DOI 10.1097/00005650-199205001-00027; ROBINSON JC, 1986, MILBANK Q, V64, P133, DOI 10.2307/3350008; RUBENSTEIN LV, 1989, ANN INTERN MED, V111, P836, DOI 10.7326/0003-4819-111-10-836; RUBENSTEIN LZ, 1984, NEW ENGL J MED, V311, P1664, DOI 10.1056/NEJM198412273112604; RYFF CD, 1989, J PERS SOC PSYCHOL, V57, P1069, DOI 10.1037/0022-3514.57.6.1069; Schwarz N, 1991, SUBJECTIVE WELL BEIN, P27; SHERBOURNE CD, 1992, MEASURING FUNCTIONIN, P260; Stewart A, 1992, MEASURING FUNCTIONIN, P12; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; Stewart AL, 1992, MEASURING FUNCTIONIN; THIER SO, 1992, MED CARE, V30, pMS15, DOI 10.1097/00005650-199205001-00002; TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1; TSEVAT J, 1991, MED CARE, V29, P1153, DOI 10.1097/00005650-199111000-00007; TSEVAT J, 1994, J GEN INTERN MED, V9, P576, DOI 10.1007/BF02599287; TUGWELL P, 1987, J RHEUMATOL, V14, P446; TUGWELL P, 1990, ARCH INTERN MED, V150, P59, DOI 10.1001/archinte.150.1.59; Veenhoven R., 1991, SUBJECTIVE WELL BEIN, P7; VERBRUGGE LM, 1991, PRIMARY CARE RES THE, P31; WACHTEL T, 1992, ANN INTERN MED, V116, P129, DOI 10.7326/0003-4819-116-2-129; WAN TTH, 1976, HEALTH SERV RES, V11, P464; WARE JE, 1981, AM J PUBLIC HEALTH, V71, P620, DOI 10.2105/AJPH.71.6.620; WARE JE, 1987, J CHRON DIS, V40, P473; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wassertheilsmoller S, 1991, ANN INTERN MED, V114, P613, DOI 10.7326/0003-4819-114-8-613; WASSON J, 1992, MED CARE, V30, pMS42, DOI 10.1097/00005650-199205001-00004; WELLS KB, 1986, MED CARE, V24, P75, DOI 10.1097/00005650-198601000-00008; WIESEL SW, 1984, SPINE, V9, P549, DOI 10.1097/00007632-198409000-00003	131	2422	2483	4	223	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 4	1995	273	1					59	65		10.1001/jama.273.1.59	http://dx.doi.org/10.1001/jama.273.1.59			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PZ042	7996652				2022-12-28	WOS:A1995PZ04200029
J	LUTHI, A; LAURENT, JP; FIGUROV, A; MULLER, D; SCHACHNER, M				LUTHI, A; LAURENT, JP; FIGUROV, A; MULLER, D; SCHACHNER, M			HIPPOCAMPAL LONG-TERM POTENTIATION AND PLEURAL CELL-ADHESION MOLECULES L1 AND NCAM	NATURE			English	Article							IMMUNOELECTRON-MICROSCOPIC LOCALIZATION; PASSIVE-AVOIDANCE RESPONSE; N-CAM; NEURITE OUTGROWTH; MOUSE CEREBELLUM; MEMORY; CONSOLIDATION; ASSOCIATION; COMPONENT; MEMBRANES	SYNAPTIC membranes express cell adhesion molecules(1). Here we investigate the role of the neural cell adhesion molecules L1 and NCAM in hippocampal long-term potentiation (LTP), a sustained-use-dependent increase in synaptic efficacy that has been implicated in learning and memory(2). L1 and NCAM mediate cell interactions during neural development(3) and are strongly expressed in the hippocampus(4,5). They cooperate to strengthen L1-dependent cell adhesion(6-9) and are coupled to second messenger pathways(10-12). We show that LTP in CA1 neurons of rat hippocampal slices was reduced by application of various L1 and NCAM antibodies, recombinant L1 fragments, and upon dissociation of the L1/NCAM complex through oligomannosidic carbohydrates and NCAM peptides. Neither the activation of NMDA (N-methyl-D-aspartate) receptors nor the maintenance of LTP was affected. These results suggest that L1 and NCAM modulate the development or the stabilization of LTP(13).	CTR MED UNIV GENEVA,DEPT PHARMACOL,CH-1211 GENEVA 4,SWITZERLAND; ETH ZURICH,DEPT NEUROBIOL,CH-8093 ZURICH,SWITZERLAND	University of Geneva; Swiss Federal Institutes of Technology Domain; ETH Zurich	LUTHI, A (corresponding author), F HOFFMANN LA ROCHE & CO LTD,PRECLIN RES,DIV PHARMA,CH-4002 BASEL,SWITZERLAND.							APPEL F, 1993, J NEUROSCI, V13, P4764; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; DOYLE E, 1992, J NEUROSCI RES, V31, P513, DOI 10.1002/jnr.490310315; DOYLE E, 1992, J NEUROCHEM, V59, P1570, DOI 10.1111/j.1471-4159.1992.tb08477.x; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; GREENOUGH WT, 1988, TRENDS NEUROSCI, V11, P142, DOI 10.1016/0166-2236(88)90139-7; HANSE E, 1994, NEUROSCI RES, V20, P15, DOI 10.1016/0168-0102(94)90018-3; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; MILLER PD, 1993, J COMP NEUROL, V327, P341, DOI 10.1002/cne.903270303; PERSOHN E, 1987, J CELL BIOL, V105, P569, DOI 10.1083/jcb.105.1.569; PERSOHN E, 1989, J COMP NEUROL, V288, P92, DOI 10.1002/cne.902880108; RATHJEN FG, 1984, EMBO J, V3, P1; SCHOLEY AB, 1993, NEUROSCIENCE, V55, P499, DOI 10.1016/0306-4522(93)90519-L; SIMON H, 1991, EUR J NEUROSCI, V3, P634, DOI 10.1111/j.1460-9568.1991.tb00849.x; VONBOHLEN F, 1992, EUR J NEUROSCI, V4, P896; ZHANG H, 1992, J NEUROSCI, V12, P3107, DOI 10.1523/JNEUROSCI.12-08-03107.1992	25	451	459	2	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					777	779		10.1038/372777a0	http://dx.doi.org/10.1038/372777a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997264				2022-12-28	WOS:A1994PY21200052
J	KARSDORP, VHM; VANVUGT, JMG; VANGEIJN, HP; KOSTENSE, PJ; ARDUINI, D; MONTENEGRO, N; TODROS, T				KARSDORP, VHM; VANVUGT, JMG; VANGEIJN, HP; KOSTENSE, PJ; ARDUINI, D; MONTENEGRO, N; TODROS, T			CLINICAL-SIGNIFICANCE OF ABSENT OR REVERSED END-DIASTOLIC VELOCITY WAVE-FORMS IN UMBILICAL ARTERY	LANCET			English	Article							LOW-BIRTH-WEIGHT; GESTATIONAL-AGE; BLOOD-FLOW; NECROTIZING ENTEROCOLITIS; GROWTH-RETARDATION; CEREBRAL DOPPLER; FETAL AORTA; WAVE-FORMS; INFANTS; BORN	Doppler ultrasound provides a non invasive method to assess fetal haemodynamics. We looked at the outcome of doppler velocimetry of the umbilical artery in three groups of pregnancies: those with positive end diastolic Velocities (FED; n=214), absent end diastolic velocities (AED; n=178) and reversed end diastolic velocities (RED; n=67). We collected our data from 9 European centres. Logistic regression showed that compared with pregnancies with hypertension only, pregnancies complicated by intra uterine growth retardation (IUGR) had a higher risk of developing absent or reversed end diastolic velocity waveforms (ARED) flow. ARED flow in the umbilical artery (odds ratio: OR=3.1). Pregnancies complicated by both IUGR and hypertension had an even higher risk (OR=7.4). Maternal age and smoking habits did not influence the risk of developing ARED flow. The overall perinatal mortality rate was 28%. Significantly more neonates in the ARED flow group needed admittance to the neonatal intensive care unit (FED group 60%, AED group 96%, RED group 98%). The OR for perinatal mortality in pregnancies complicated by AED flow was 4.0 and in RED flow was 10.6, compared with FED flow, even after adjustment for menstrual age. ARED flow in the umbilical artery did not influence the risk of respiratory distress syndrome or necrotising enterocolitis of the neonate, but ARED flow significantly influenced the risk of cerebral haemorrhage, anaemia, or hypoglycaemia. We advise that pregnancies complicated by IUGR and/or hypertension should be followed up with doppler velocimetry to trace utero-placental problems as early as possible. A caesarean section is recommended in all pregnancies complicated by ARED flow if the gestational age and predicted neonatal weight can be handled by the local neonatal intensive care unit.	FREE UNIV AMSTERDAM,DEPT BIOSTAT & EPIDEMIOL,AMSTERDAM,NETHERLANDS; UNIV CATTOLICA SACRO CUORE,OBSTET & GINECOL CLIN 1,ROME,ITALY; HOSP SAO JOAO,DEPT OBSTET & GYNAECOL,OPORTO,PORTUGAL; INST GINECOL & OBSTET,TURIN,ITALY	Vrije Universiteit Amsterdam; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Sao Joao Hospital	KARSDORP, VHM (corresponding author), FREE UNIV AMSTERDAM HOSP,DEPT OBSTET & GYNAECOL,DIV MATERNAL FETAL MED & PRENATAL DIAG,POB 7057,1007 MB AMSTERDAM,NETHERLANDS.		Vugt, J.M.G./L-4737-2015	Todros, Tullia/0000-0003-3016-1510; Montenegro, Nuno/0000-0002-3733-3613				AKALINSEL T, 1992, EUR J OB GYN, V46, P2; ARDUINI D, 1992, J PERINAT MED, V20, P29, DOI 10.1515/jpme.1992.20.1.29; BATTAGLIA C, 1993, ACTA OBSTET GYN SCAN, V72, P167, DOI 10.3109/00016349309013366; Breslow N, 1980, STATISTICAL METHODS, V32; BRUNER JB, 1993, SOUTHERN MED J, V86, P418, DOI 10.1097/00007611-199304000-00009; CHANDRAN R, 1993, BRIT J OBSTET GYNAEC, V100, P139, DOI 10.1111/j.1471-0528.1993.tb15209.x; CHAOUI R, 1991, GEBURTSH FRAUENHEILK, V51, P532, DOI 10.1055/s-2007-1026194; COOPER RL, 1993, AM J OBSTET GYNECOL, V168, P78; DEVOE LD, 1992, OBSTET GYNECOL, V80, P684; ECONOMIDES DL, 1991, J PERINAT MED, V91, P97; GOLDENBERG RL, 1984, AM J OBSTET GYNECOL, V149, P508, DOI 10.1016/0002-9378(84)90026-7; HACKETT GA, 1987, BRIT MED J, V294, P13, DOI 10.1136/bmj.294.6563.13; HERSCHEL M, 1982, OBSTET GYNECOL, V60, P154; JOHNSON A, 1993, BRIT MED J, V306, P1715, DOI 10.1136/bmj.306.6894.1715; KOOPS BL, 1982, J PEDIATR-US, V101, P969; MALCOLM G, 1991, ARCH DIS CHILD-FETAL, V66, P805, DOI 10.1136/adc.66.7_Spec_No.805; MCILWAINE G M, 1990, Lancet, V336, P782; OLIVARES M, 1992, ACTA PAEDIATR, V81, P824, DOI 10.1111/j.1651-2227.1992.tb12111.x; PATTINSON RC, 1993, EARLY HUM DEV, V33, P61, DOI 10.1016/0378-3782(93)90173-R; PEETERS LLH, 1979, AM J OBSTET GYNECOL, V135, P637, DOI 10.1016/S0002-9378(16)32989-1; PERKINS RP, 1981, AM J OBSTET GYNECOL, V139, P546, DOI 10.1016/0002-9378(81)90515-9; SCHERJON SA, 1993, AM J OBSTET GYNECOL, V169, P169, DOI 10.1016/0002-9378(93)90156-D; SOOTHILL PW, 1986, LANCET, V2, P1118; TODD AL, 1992, AM J OBSTET GYNECOL, V167, P66, DOI 10.1016/S0002-9378(11)91628-7; TRUDINGER BJ, 1991, BRIT J OBSTET GYNAEC, V98, P378, DOI 10.1111/j.1471-0528.1991.tb13428.x; VANVUGT JMG, 1994, CRITICAL APPRAISAL F, P483; WEISS E, 1992, EUR J OBSTET GYN R B, V45, P93, DOI 10.1016/0028-2243(92)90223-L; WLADIMIROFF JW, 1986, BRIT J OBSTET GYNAEC, V93, P471, DOI 10.1111/j.1471-0528.1986.tb08656.x; YU VYH, 1986, ARCH DIS CHILD, V61, P554, DOI 10.1136/adc.61.6.554	29	258	263	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1664	1668		10.1016/S0140-6736(94)90457-X	http://dx.doi.org/10.1016/S0140-6736(94)90457-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996959				2022-12-28	WOS:A1994PX30200008
J	SMITH, AC; DOWSETT, JF; RUSSELL, RCG; HATFIELD, ARW; COTTON, PB				SMITH, AC; DOWSETT, JF; RUSSELL, RCG; HATFIELD, ARW; COTTON, PB			RANDOMIZED TRIAL OF ENDOSCOPIC STENTING VERSUS SURGICAL BYPASS IN MALIGNANT LOW BILEDUCT OBSTRUCTION	LANCET			English	Article							PANCREATIC-CANCER; UNRESECTABLE CARCINOMA; BILIARY ENDOPROSTHESIS; PALLIATION; SURGERY; HEAD; DUCT; MORBIDITY; MORTALITY; INSERTION	The development of non-surgical techniques for the relief of malignant low bileduct obstruction has cast doubt on the best way of relieving jaundice, particularly in patients fit for surgery whose life expectancy is more than a few weeks. We did a randomised prospective controlled trial comparing endoscopic stent insertion and surgical biliary bypass in patients with malignant low bileduct obstruction. 204 patients were randomised (surgery 103, stent 101); 3 subsequently proved to have benign disease and were excluded, leaving 101 surgical and 100 stented patients for assessment. Technical success was achieved in 94 surgical and 95 stented patients, with functional biliary decompression obtained in 92 patients in both groups. In stented patients, there was a lower procedure-related mortality (3% vs 14%, p=0.01), major complication rate (11% vs 29%, p=0.02), and median total hospital stay (20 vs 26 days, p=0.001). Recurrent jaundice occurred in 36 stented patients and 2 surgical patients. Late gastric outlet obstruction occurred in 17% of stented patients and 7% of the surgical group. Despite the early benefits of stenting there was no significant difference in overall survival between the two groups (median survival: surgical 26 weeks; stented 21 weeks; p=0.065). Endoscopic stenting and surgery are effective palliative treatments with the former having fewer early treatment-related complications and the latter fewer late complications.	MIDDLESEX HOSP, DEPT GASTROENTEROL, LONDON W1N 8AA, ENGLAND	University of London; University College London								ALLENMERSH TG, 1986, ANN ROY COLL SURG, V68, P154; ANDERSEN JR, 1989, GUT, V30, P1132, DOI 10.1136/gut.30.8.1132; ANDERSSON T, 1987, ANN SURG, V206, P728, DOI 10.1097/00000658-198712000-00007; AOKI Y, 1984, AM J SURG, V147, P349, DOI 10.1016/0002-9610(84)90165-X; BAKKEVOLD KE, 1993, ANN SURG, V217, P356, DOI 10.1097/00000658-199304000-00007; BORNMAN PC, 1986, LANCET, V1, P69; CONNOLLY MM, 1987, ANN SURG, V206, P366, DOI 10.1097/00000658-198709000-00015; COTTON PB, 1993, SCAND J GASTROENTERO, V28, P44, DOI 10.3109/00365529309098357; COTTON PB, 1989, SURG CLIN N AM, V69, P613; CRIST DW, 1987, ANN SURG, V206, P358, DOI 10.1097/00000658-198709000-00014; DOWSETT JF, 1989, BRIT J SURG, V76, P454, DOI 10.1002/bjs.1800760510; DOWSETT JF, 1989, GASTROENTEROLOGY, V96, P1180, DOI 10.1016/0016-5085(89)91639-9; DOWSETT JF, 1988, GUT, V29, pA1458; GUDJONSSON B, 1987, CANCER, V60, P2284, DOI 10.1002/1097-0142(19871101)60:9<2284::AID-CNCR2820600930>3.0.CO;2-V; Huguier M, 1993, Eur J Surg Oncol, V19, P342; KERR RM, 1988, GASTROINTEST ENDOSC, V34, P432, DOI 10.1016/S0016-5107(88)71413-3; KEYMLING M, 1993, GASTROINTEST ENDOSC, V39, P439, DOI 10.1016/S0016-5107(93)70125-X; KNYRIM K, 1993, ENDOSCOPY, V25, P207, DOI 10.1055/s-2007-1010294; KOCJAN G, 1989, J CLIN PATHOL, V42, P341, DOI 10.1136/jcp.42.4.341; LILLEMOE KD, 1993, SURG GYNECOL OBSTET, V176, P1; LYGIDAKIS NJ, 1989, SURG GYNECOL OBSTET, V168, P157; MOSDELL DM, 1991, SOUTHERN MED J, V84, P571; NICHOLSON AA, 1993, CLIN RADIOL, V47, P245, DOI 10.1016/S0009-9260(05)81131-6; POTTS JR, 1990, AM J SURG, V159, P72, DOI 10.1016/S0002-9610(05)80609-9; RAMACHANDRA V, 1990, BRIT J ANAESTH, V65, P373; SARR MG, 1984, WORLD J SURG, V8, P906, DOI 10.1007/BF01656032; SHEPHERD HA, 1988, BRIT J SURG, V75, P1166, DOI 10.1002/bjs.1800751207; SIRINEK KR, 1986, SURG CLIN N AM, V66, P757; SPEER AG, 1987, LANCET, V2, P57, DOI 10.1016/S0140-6736(87)92733-4; WARSHAW AL, 1988, ANN SURG, V208, P541, DOI 10.1097/00000658-198811000-00001; WARSHAW AL, 1986, AM J SURG, V151, P76, DOI 10.1016/0002-9610(86)90015-2; WARSHAW AL, 1990, ARCH SURG-CHICAGO, V125, P230; WATANAPA P, 1992, BRIT J SURG, V79, P8, DOI 10.1002/bjs.1800790105; YUDUSUDA K, 1988, GASTROINTEST ENDOSC, V34, P1	34	643	666	2	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 17	1994	344	8938					1655	1660		10.1016/S0140-6736(94)90455-3	http://dx.doi.org/10.1016/S0140-6736(94)90455-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996958				2022-12-28	WOS:A1994PX30200006
J	PERNEGER, TV; BRANCATI, FL; WHELTON, PK; KLAG, MJ				PERNEGER, TV; BRANCATI, FL; WHELTON, PK; KLAG, MJ			END-STAGE RENAL-DISEASE ATTRIBUTABLE TO DIABETES-MELLITUS	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES MELLITUS, INSULIN-DEPENDENT; KIDNEY FAILURE, CHRONIC; DIABETIC NEPHROPATHIES; DIABETES MELLITUS, NON-INSULIN-DEPENDENT	NATURAL-HISTORY; NEPHROPATHY; HYPERTENSION; PROTEINURIA; PREVALENCE	Objective: To determine the proportion of end-stage renal disease associated with diabetes mellitus in a biracial population, using population-attributable risk estimates. Design: Case-control study. Setting: Population-based study in Maryland, Virginia, West Virginia, and Washington, D.C. Participants: 716 newly treated patients with kidney failure aged 20 to 64 years and 361 age-matched controls. Measurements: Self-reported history of diabetes mellitus, including type, duration, treatment, and complications. Results: Persons with insulin-dependent diabetes (odds ratio, 33.7) and non-insulin-dependent diabetes (odds ratio, 7.0) were at greater risk for end-stage renal disease than were persons without diabetes. The odds ratio was only slightly increased for diabetes lasting less than 15 years, but the ratio increased more than 20-fold for diabetes lasting 15 years or more. The population-attributable risk for kidney failure was 21% for insulin-dependent diabetes and 21% for noninsulin-dependent diabetes (42% overall). A similar proportion of end-stage renal disease was attributed to diabetes in whites (44%) and in blacks (41%). Insulin-dependent diabetes had a relatively greater effect on the incidence of kidney failure in whites; in contrast, non-insulin-dependent diabetes had a relatively greater effect on kidney failure in blacks. Conclusions: Diabetes mellitus has a major effect on the incidence of end-stage renal disease in nonelderly adults. In black persons, diabetes may be responsible for a larger proportion of end-stage renal disease than is suggested by the use of clinical diagnoses of underlying renal disease made by patients' nephrologists. Prevention of end-stage renal disease associated with diabetes mellitus (both insulin-dependent and noninsulin-dependent diabetes) requires increased attention from laboratory and clinical researchers.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD USA	Johns Hopkins University; Johns Hopkins University	PERNEGER, TV (corresponding author), UNIV GENEVA, INST SOCIAL & PREVENT MED, CMU CASE POSTALE, CH-1211 GENEVA 4, SWITZERLAND.				AHRQ HHS [R03 HS 06978-01] Funding Source: Medline; NCRR NIH HHS [5MOIRR00722, RR00035] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R03HS006978] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; BRANCATI FL, 1992, JAMA-J AM MED ASSOC, V268, P3079, DOI 10.1001/jama.268.21.3079; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FITZSIMMONS SC, 1989, AM J KIDNEY DIS, V13, P7, DOI 10.1016/S0272-6386(89)80105-2; Fleiss JL, 1981, STAT METHODS RATES P; Gahlinger PM, 1993, COMPUTER PROGRAMS EP; HAMILTON BPM, 1990, AM J KIDNEY DIS, V16, P20; HOSMER DW, 1989, APPL LOGISTIC REGRES, P216; HUMPHREY LL, 1989, ANN INTERN MED, V111, P788, DOI 10.7326/0003-4819-111-10-788; KLAG MJ, 1994, CIRCULATION, V18, P10; KLEIN R, 1991, ARCH INTERN MED, V151, P1344, DOI 10.1001/archinte.151.7.1344; KOFOEDENEVOLDSEN A, 1987, DIABETES, V36, P205, DOI 10.2337/diabetes.36.2.205; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531; MIDTHJELL K, 1992, J EPIDEMIOL COMMUN H, V46, P537, DOI 10.1136/jech.46.5.537; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; ORCHARD TJ, 1990, DIABETES, V39, P1116, DOI 10.2337/diabetes.39.9.1116; PERNEGER TV, 1993, AM J EPIDEMIOL, V138, P574, DOI 10.1093/oxfordjournals.aje.a116898; PERNEGER TV, 1995, IN PRESS ARCH INTERN; PERNEGER TV, 1995, IN PRESS AM J EPIDEM; PERNEGER TV, 1993, THESIS J HOPKINS U B; RICHARDS NT, 1992, NEPHROL DIAL TRANSPL, V7, P397; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; WILKINSON L, 1990, SYSTAT SYSTEM STATIS; 1991, USRDS1991 NIH NAT I	27	159	160	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1994	121	12					912	918		10.7326/0003-4819-121-12-199412150-00002	http://dx.doi.org/10.7326/0003-4819-121-12-199412150-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW083	7978716				2022-12-28	WOS:A1994PW08300002
J	LOMELI, H; MOSBACHER, J; MELCHER, T; HOGER, T; GEIGER, JRP; KUNER, T; MONYER, H; HIGUCHI, M; BACH, A; SEEBURG, PH				LOMELI, H; MOSBACHER, J; MELCHER, T; HOGER, T; GEIGER, JRP; KUNER, T; MONYER, H; HIGUCHI, M; BACH, A; SEEBURG, PH			CONTROL OF KINETIC-PROPERTIES OF AMPA RECEPTOR CHANNELS BY NUCLEAR-RNA EDITING	SCIENCE			English	Article							GLUTAMATE-OPERATED CHANNELS; RAT HIPPOCAMPAL SLICES; CA2+ PERMEABILITY; BRAIN-SLICES; DESENSITIZATION; NEURONS; PATCHES; SUBUNIT; SWITCH; CELLS	AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor channels mediate the fast component of excitatory postsynaptic currents in the central nervous system. Site-selective nuclear RNA editing controls the calcium permeability of these channels, and RNA editing at a second site is shown here to affect the kinetic aspects of these channels in rat brain. In three of the four AMPA receptor subunits (GluR-B, -C, and -D), intronic elements determine a codon switch (AGA, arginine, to GGA, glycine) in the primary transcripts in a position termed the R/G site, which immediately precedes the alternatively spliced modules ''flip'' and ''flop.'' The extent of editing at this site progresses with brain development in a manner specific for subunit and splice form, and edited channels possess faster recovery rates from desensitization.	UNIV HEIDELBERG,CTR BIOL MOLEC,MOLEC NEUROENDOCRINOL LAB,D-69120 HEIDELBERG,GERMANY; MAX PLANCK INST MED RES,D-69120 HEIDELBERG,GERMANY; BASF AG,D-67056 LUDWIGSHAFEN,GERMANY	Ruprecht Karls University Heidelberg; Max Planck Society; BASF				Lomeli, Hilda/0000-0001-9659-0102; Monyer, Hannah/0000-0002-9332-5749				BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; BOCHET P, 1994, NEURON, V12, P383, DOI 10.1016/0896-6273(94)90279-8; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; DODT HU, 1990, BRAIN RES, V537, P333, DOI 10.1016/0006-8993(90)90380-T; FRANKE C, 1987, NEUROSCI LETT, V77, P199, DOI 10.1016/0304-3940(87)90586-6; HESTRIN S, 1992, NEURON, V9, P991, DOI 10.1016/0896-6273(92)90250-H; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HIGUCHI M, UNPUB; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; JONAS P, 1992, J PHYSIOL-LONDON, V455, P143, DOI 10.1113/jphysiol.1992.sp019294; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; JONAS P, 1994, CURR OPIN NEUROBIOL, V4, P365; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; KOHLER M, 1994, J BIOL CHEM, V269, P17367; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; MOSBACHER J, IN PRESS SCIENCE; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; PARTIN KM, 1994, MOL PHARMACOL, V46, P129; ROCHE KW, 1994, J BIOL CHEM, V269, P11679; SCHELL TJ, 1990, CELL, V61, P361; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STEIN E, 1992, MOL PHARMACOL, V42, P864; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; TAVERNA FA, 1994, J BIOL CHEM, V269, P14159; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; TRUSSELL LO, 1994, SEMIN NEUROSCI, V6, P71; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	623	640	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1709	1713		10.1126/science.7992055	http://dx.doi.org/10.1126/science.7992055			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992055				2022-12-28	WOS:A1994PW30800041
J	LEE, JJ; EKKER, SC; VONKESSLER, DP; PORTER, JA; SUN, BI; BEACHY, PA				LEE, JJ; EKKER, SC; VONKESSLER, DP; PORTER, JA; SUN, BI; BEACHY, PA			AUTOPROTEOLYSIS IN HEDGEHOG PROTEIN BIOGENESIS	SCIENCE			English	Article							CELL-CELL COMMUNICATION; POLARITY GENE HEDGEHOG; DROSOPHILA-EMBRYO; EXPRESSION; TRANSCRIPTION; MEMBER	Extracellular signaling proteins encoded by the hedgehog (hh) multigene family are responsible for the patterning of a variety of embryonic structures in vertebrates and invertebrates. The Drosophila hh gene has now been shown to generate two predominant protein species that are derived by an internal autoproteolytic cleavage of a larger precursor. Mutations that reduced the efficiency of autoproteolysis in vitro diminished precursor cleavage in vivo and also impaired the signaling and patterning activities of the HH protein. The two HH protein species exhibited distinctive biochemical properties and tissue distribution, and these differences suggest a mechanism that could account for the long- and short-range signaling activities of HH in vivo.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University				Ekker, Stephen/0000-0003-0726-4212				ARIAS AM, 1988, DEVELOPMENT, V103, P157; ASHBURNER M, 1989, DROSOPHILA LABORATOR; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHANG DT, IN PRESS DEVELOPMENT; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EKKER SC, UNPUB; Eugene O., 1979, TCA (TISSUE CULTURE ASSOCIATION) MANUAL, V5, P1055, DOI 10.1007/BF00919788; FAN CM, IN PRESS CELL; HARLOW E, 1988, ANTIBODIES LABORATOR; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JONES DH, 1992, BIOTECHNIQUES, V12, P528; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE J, 1993, DROSOPHILA RES C; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PATEL H, METHODS CELL BIOL; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1993, CELL, V75, P761; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; VONKESSLER DP, UNPUB	37	441	478	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1528	1537		10.1126/science.7985023	http://dx.doi.org/10.1126/science.7985023			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985023				2022-12-28	WOS:A1994PV01500035
J	MEASDAY, V; MOORE, L; OGAS, J; TYERS, M; ANDREWS, B				MEASDAY, V; MOORE, L; OGAS, J; TYERS, M; ANDREWS, B			THE PCL2 (ORFD)-PHO85 CYCLIN-DEPENDENT KINASE COMPLEX - A CELL-CYCLE REGULATOR IN YEAST	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; MATING PHEROMONE; G1 CYCLINS; PHO SYSTEM; GENE; SWI4; PHOSPHATASE; CDC28; CLN1	Cyclin-dependent kinase (cdk) complexes are essential activators of cell cycle progression in all eukaryotes. In contrast to mammalian cells, in which multiple cdk's contribute to cell cycle regulation, the yeast cell cycle is largely controlled by the activity of a single cdk, CDC28. Analysis of the putative G(1) cyclin PCL2 (ORFD) identified a second cyclin-cdk complex that contributes to cell cycle progression in yeast. PCL2 interacted with the cdk PHO85 in vivo and in vitro and formed a kinase complex that had G(1)-periodic activity. Under genetic conditions in which the Start transition was compromised, PHO85 and its associated cyclin subunits were essential for cell cycle commitment. Because PHO85 and another cyclin-like molecule, PHO80, also take part in inorganic phosphate metabolism, this cdk enzyme may integrate responses to nutritional conditions with the cell cycle.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A8, ON, CANADA; UNIV TORONTO, BANTING & BEST DEPT MED RES, TORONTO M5G 1L6, ON, CANADA; STANFORD UNIV, CARNEGIE INST, STANFORD, CA 94305 USA	University of Toronto; University of Toronto; Carnegie Institution for Science; Stanford University			Tyers, Michael/ABE-3194-2021	Ogas, Joe/0000-0002-1332-7729				Andrews B., UNPUB; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1992, P NATL ACAD SCI USA, V89, P11852, DOI 10.1073/pnas.89.24.11852; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; CROSS FR, 1994, MOL CELL BIOL, V14, P4779, DOI 10.1128/MCB.14.7.4779; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ESPINOZA H, 1994, SCIENCE, V266, P1388; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARPER JW, 1993, CELL, V75, P805; Hunt T., COMMUNICATION; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, pCH5; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; MEASDAY V, UNPUB; MOORE L, UNPUB; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; OGAS J, 1992, THESIS U CALIFORNIA; PINES J, 1993, BIOCHEM SOC T, V21, P921, DOI 10.1042/bst0210921; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SIKORSKI RS, 1989, GENETICS, V122, P19; STUART D, 1994, MOL CELL BIOL, V14, P4788, DOI 10.1128/MCB.14.7.4788; TOHE A, 1988, MOL GEN GENET, V214, P162, DOI 10.1007/BF00340196; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; TYERS M, 1992, EMBO J, V11, P1173; TYERS M, UNPUB; UEDA Y, 1975, J BACTERIOL, V122, P911, DOI 10.1128/JB.122.3.911-922.1975; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	39	153	157	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 25	1994	266	5189					1391	1395		10.1126/science.7973731	http://dx.doi.org/10.1126/science.7973731			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973731				2022-12-28	WOS:A1994PT63200046
J	PIJNENBORG, L; VANDELDEN, JJM; KARDAUN, JWPF; GLERUM, JJ; van der Maas, PJ				PIJNENBORG, L; VANDELDEN, JJM; KARDAUN, JWPF; GLERUM, JJ; van der Maas, PJ			NATIONWIDE STUDY OF DECISIONS CONCERNING THE END OF LIFE IN GENERAL-PRACTICE IN THE NETHERLANDS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FAMILY DOCTORS; PATIENT; PHYSICIAN; EUTHANASIA	Objective-To gain insight into decisions made in general practice about the end of life. Design-Study I: interviews with 405 physicians. Study II: analysis of death certificates with data obtained on 5197 cases in which decisions about the end of life may have been made. Study III: prospective study with doctors from study I: questionnaires used to collect information about 2257 deaths. The information was representative for all deaths in the Netherlands. Results-Over two fifths of all patients in the Netherlands die at home. General practitioners took fewer decisions about the end of life than hospital doctors and doctors in nursing homes (34%, 40%, and 56% of all dying patients, respectively). Specifically, decisions to withhold or withdraw treatment to prolong life were taken less often. Euthanasia or assisted suicide, however, was performed in 3.2% of all deaths in general practice compared with 1.4% in hospital practice. In over half of the cases concerning pain relief or non-treatment general practitioners did not discuss the decision with the patient, mostly because of incapacity of the patient, but in 20% of cases for ''paternalistic'' reasons. Older general practitioners discussed such decisions less often with their patients. Colleagues were consulted more often if the general practitioner worked in group practice. Conclusion-Differences in work situation between general practitioners and hospital doctors and differences between the group of general practitioners contribute to differences in the number and type of decisions about the end of life as well as in the decision making process.	UNIV UTRECHT, CTR BIOETH & HLTH LAW, UTRECHT, NETHERLANDS; STAT NETHERLANDS, VOORBURG, NETHERLANDS	Utrecht University	PIJNENBORG, L (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.							BATTIN MP, 1994, LEAST WORST DEATH ES, P130; Beauchamp T, 1989, PRINCIPLES BIOMEDICA; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; HOFFMASTER CB, 1991, SOC SCI MED, V33, P647, DOI 10.1016/0277-9536(91)90018-8; ORR RD, 1991, J FAM PRACTICE, V33, P500; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; SIEGLER M, 1985, ARCH INTERN MED, V145, P713, DOI 10.1001/archinte.145.4.713; van der Maas P. J., 1992, EUTHANASIA OTHER MED; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDERWAL G, 1992, FAM PRACT, V9, P130, DOI 10.1093/fampra/9.2.130; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; 1987, BIOETHICS, V1, P163; 1992, END LIFE MED PRACTIC	13	15	15	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	1994	309	6963					1209	1212		10.1136/bmj.309.6963.1209	http://dx.doi.org/10.1136/bmj.309.6963.1209			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ662	7987154	Green Published			2022-12-28	WOS:A1994PQ66200024
J	MADDOX, J				MADDOX, J			FRONTIERS OF IGNORANCE - HOW TO MARK 125 YEARS OF DISCOVERY	NATURE			English	Editorial Material																			0	0	0	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					11	12						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969404				2022-12-28	WOS:A1994PQ34800021
J	CAULEY, JA; SEELEY, DG; ENSRUD, K; ETTINGER, B; BLACK, D; CUMMINGS, SR				CAULEY, JA; SEELEY, DG; ENSRUD, K; ETTINGER, B; BLACK, D; CUMMINGS, SR			ESTROGEN REPLACEMENT THERAPY AND FRACTURES IN OLDER WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						ESTROGEN REPLACEMENT THERAPY; FRACTURES; OSTEOPOROSIS, POSTMENOPAUSAL; AGE FACTORS; BONE DENSITY	POST-MENOPAUSAL WOMEN; HIP FRACTURE; ELDERLY WOMEN; POSTMENOPAUSAL OSTEOPOROSIS; BONE-DENSITY; CIGARETTE-SMOKING; PHYSICAL-ACTIVITY; TRABECULAR BONE; RISK; DISEASE	Objective: To determine the relation between estrogen replacement therapy and fractures. Design: Prospective cohort study. Setting: Four clinical centers in Baltimore County, Maryland; Minneapolis, Minnesota; Portland, Oregon; and the Monongahela Valley, Pennsylvania. Participants: 9704 ambulatory, nonblack women 65 years of age or older. Measurements: Estrogen use, medical history, and anthropometric data were obtained by questionnaire, interview, and examination. Appendicular bone mass was measured by single-photon absorptiometry. Incident fractures were validated by radiographic report. Results: After adjustment for potential confounders, current estrogen use was associated with a decrease int he risk for wrist fractures (relative risk [RR], 0.39; 95% Cl, 0.24 to 0.64) and for all nonspinal fractures (RR, 0.66; Cl, 0.54 to 0.80) when compared with no estrogen use. Results were similar for women using unopposed estrogen or estrogen plus progestin, for women younger or older than 75 years of age, and for current smokers or nonsmokers. The effect of estrogen remained after adjustment was made for appendicular bone mass. The relative risk for hip fracture tended to be lower among current users (RR, 0.60; Cl, 0.36 to 1.02) than among never-users. Estrogen was most effective in preventing hip fracture among those older than 75 years. Current users who started estrogen within 5 years of menopause had a decreased risk for hip fractures (RR, 0.29; Cl, 0.09 to 0.92), wrist fractures (RR, 0.29; Cl, 0.13 to 0.68), and all nonspinal fractures (RR, 0.50; Cl, 0.36 to 0.70) when compared with women who had never used estrogen. Previous use of estrogen for more than 10 years or use begun soon after menopause had no substantial effect on the risk for fractures. Conclusions: Current use of estrogen appears to decrease the risk for fracture in older women. These results suggest that for protection against fractures, estrogen should be initiated soon after menopause and continued indefinitely.	UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94143 USA; VET AFFAIRS MED CTR, DEPT MED, MINNEAPOLIS, MN 55417 USA; KAISER PERMANENTE MED CARE PROGRAM, DIV RES, OAKLAND, CA 94611 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Kaiser Permanente; University of Minnesota System; University of Minnesota Twin Cities	CAULEY, JA (corresponding author), UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT EPIDEMIOL, A524 CRABTREE HALL, 130 DESOTO ST, PITTSBURGH, PA 15261 USA.		Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408; Ensrud, Kristine/0000-0002-9069-3036	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005395] Funding Source: NIH RePORTER; NIADDK NIH HHS [1-R01-AM35584] Funding Source: Medline; NIAMS NIH HHS [1-R01-AR35582] Funding Source: Medline; NIA NIH HHS [1-R01-AG05395] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BUSH TL, 1991, 31ST ANN C CARD DIS; CAULEY JA, 1989, AM J EPIDEMIOL, V129, P1120, DOI 10.1093/oxfordjournals.aje.a115234; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; CAULEY JA, 1987, J CHRON DIS, V40, P115, DOI 10.1016/0021-9681(87)90062-2; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; CIVITELLI R, 1988, CALCIFIED TISSUE INT, V42, P77, DOI 10.1007/BF02556338; CUMMINGS SR, 1987, AM J EPIDEMIOL, V126, P796, DOI 10.1093/oxfordjournals.aje.a114716; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GALLAGHER JC, 1991, AM J MED, V90, P171; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; HUTCHINSON TA, 1979, LANCET, V2, P705; JOHNSON RE, 1981, AM J PUBLIC HEALTH, V71, P138, DOI 10.2105/AJPH.71.2.138; KANIS JA, 1992, BRIT MED J, V305, P1124, DOI 10.1136/bmj.305.6862.1124; KIEL DP, 1992, ANN INTERN MED, V116, P716, DOI 10.7326/0003-4819-116-9-716; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; LINDENSTROM E, 1993, STROKE, V24, P1468, DOI 10.1161/01.STR.24.10.1468; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MARX CW, 1992, J BONE MINER RES, V7, P1275; MAXIM P, 1994, IN PRESS OSTEOPOROSI; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PECK WA, 1993, AM J MED, V94, P646; PHILLIPS SK, 1993, CLIN SCI, V84, P95, DOI 10.1042/cs0840095; QUIGLEY MET, 1987, AM J OBSTET GYNECOL, V156, P1516; RIIS BJ, 1987, AM J OBSTET GYNECOL, V156, P61, DOI 10.1016/0002-9378(87)90203-1; SCHLENKER RA, 1976, CALC TISS RES, V20, P41, DOI 10.1007/BF02546396; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; SEELEY DG, 1994, IN PRESS ARCH INTERN; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; VOGEL JM, 1987, OSTEOPOROSIS UPDATE, P219; WASNICH RD, 1986, OBSTET GYNECOL, V67, P457; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WILLIAMS AR, 1982, OBSTET GYNECOL, V60, P695	43	680	689	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1995	122	1					9	16		10.7326/0003-4819-122-1-199501010-00002	http://dx.doi.org/10.7326/0003-4819-122-1-199501010-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY502	7985914				2022-12-28	WOS:A1995PY50200002
J	GRABOWSKI, GA; BARTON, NW; PASTORES, G; DAMBROSIA, JM; BANERJEE, TK; MCKEE, MA; PARKER, C; SCHIFFMANN, R; HILL, SC; BRADY, RO				GRABOWSKI, GA; BARTON, NW; PASTORES, G; DAMBROSIA, JM; BANERJEE, TK; MCKEE, MA; PARKER, C; SCHIFFMANN, R; HILL, SC; BRADY, RO			ENZYME THERAPY IN TYPE-1 GAUCHER DISEASE - COMPARATIVE EFFICACY OF MANNOSE-TERMINATED GLUCOCEREBROSIDASE FROM NATURAL AND RECOMBINANT SOURCES	ANNALS OF INTERNAL MEDICINE			English	Article						GAUCHERS DISEASE; GLUCOCERAMIDASE; LYSOSOMAL STORAGE DISEASES; ENZYMES; GLUCOSPHINGOLIPIDS	ACID BETA-GLUCOSIDASE; MACROPHAGE-TARGETED GLUCOCEREBROSIDASE; REPLACEMENT THERAPY; GENE; HETEROGENEITY; GLYCOSYLATION	Objective: To compare the efficacy of mannoseterminated glucocerebrosidase prepared from natural (alglucerase; Ceredase, Genzyme Corp., Cambridge, Massachusetts) and recombinant (imiglucerase; Cerezyme, Genzyme Corp.) sources in treating type 1 Gaucher disease. Design: Double-blind, randomized, parallel trial. Setting: University medical center and clinical research hospital. Patients: 15 patients (4 children and 11 adults) randomly assigned to receive Ceredase and 15 patients (3 children and 12 adults) assigned to receive Cerezyme. Intervention: Ceredase and Cerezyme were infused every 2 weeks for 9 months at a dose of 60 U/kg body weight. Outcome Measures: Hemoglobin levels, platelet counts, and serum acid phosphatase and angiotensin-converting enzyme activities were monitored every 2 weeks during the trial. Hepatic and splenic volumes were assessed at the time of randomization and after 6 and 9 months of enzyme infusion. Formation of IgG antibodies to Ceredase or Cerezyme was monitored every 3 months by radioimmunoprecipitation assay. Results: No significant differences were found in the rate or extent of improvement in hemoglobin levels, platelet counts, serum acid phosphatase or angiotensin-converting enzyme activities, or hepatic or splenic volumes between either treatment group. The incidence of IgG antibody formation was greater in the Ceredase group (40%) than in the Cerezyme group (20%). No major immunologic adverse events occurred in either group. Conclusions: Our study shows the therapeutic similarity of Ceredase and Cerezyme. Cerezyme has the advantage of being theoretically unlimited in supply and free of potential pathogenic contaminants.	NINCDS, DEV & METAB NEUROL BRANCH, BETHESDA, MD 20892 USA; MT SINAI MED CTR, DEPT MED GENET, NEW YORK, NY 10029 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Icahn School of Medicine at Mount Sinai	GRABOWSKI, GA (corresponding author), CHILDRENS HOSP, MED CTR, DIV HUMAN GENET, PAVIL 3-52, 3333 BURNET AVE, CINCINNATI, OH 45229 USA.		Pastores, Gregory M./AAE-8647-2020					ACHORD DT, 1978, CELL, V15, P269, DOI 10.1016/0092-8674(78)90102-2; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BARTON NW, 1990, P NATL ACAD SCI USA, V87, P1913, DOI 10.1073/pnas.87.5.1913; BERGFUSSMAN A, 1993, J BIOL CHEM, V268, P14861; BEUTLER E, 1993, AM J HUM GENET, V52, P85; BEUTLER E, 1991, BLOOD, V78, P1183; Beutler E., 1995, METABOLIC MOL BASES, P2641; Desnick R J, 1981, Adv Hum Genet, V11, P281; Devine E A, 1982, Prog Clin Biol Res, V95, P511; FABBRO D, 1987, AM J HUM GENET, V40, P15; FALLET S, 1992, PEDIATR RES, V31, P496, DOI 10.1203/00006450-199205000-00018; FIGUEROA ML, 1992, NEW ENGL J MED, V327, P1632, DOI 10.1056/NEJM199212033272304; GINNS EI, 1985, P NATL ACAD SCI USA, V82, P7101, DOI 10.1073/pnas.82.20.7101; GRACE ME, 1990, BIOCHEM BIOPH RES CO, V168, P771, DOI 10.1016/0006-291X(90)92388-G; GRACE ME, 1994, J BIOL CHEM, V269, P2283; HILL SC, 1992, RADIOLOGY, V184, P561, DOI 10.1148/radiology.184.2.1620865; HO MW, 1972, AM J HUM GENET, V24, P37; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; LATHAM TE, 1991, DNA CELL BIOL, V10, P15, DOI 10.1089/dna.1991.10.15; Ludwig J, 1979, CURRENT METHODS AUTO, P676; PASTORES GM, 1993, BLOOD, V82, P408; RICHARDS SM, 1993, BLOOD, V82, P1402; SCHNEIDER EL, 1972, J PEDIATR-US, V81, P1134; SIBILLE A, 1993, AM J HUM GENET, V52, P1094; STAHL PD, 1978, P NATL ACAD SCI USA, V75, P1399, DOI 10.1073/pnas.75.3.1399; ZIMRAN A, 1994, AM J MED, V97, P3, DOI 10.1016/0002-9343(94)90042-6; ZIMRAN A, 1991, AM J HUM GENET, V49, P855	27	351	394	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1995	122	1					33	39		10.7326/0003-4819-122-1-199501010-00005	http://dx.doi.org/10.7326/0003-4819-122-1-199501010-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY502	7985893				2022-12-28	WOS:A1995PY50200005
J	VLADECK, BC				VLADECK, BC			PHYSICIAN-PAYMENT REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											VLADECK, BC (corresponding author), HLTH CARE FINANCING ADM,6325 SECUR BLVD,RM 700,BALTIMORE,MD 21207, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	1994	272	24					1890	1890		10.1001/jama.272.24.1890	http://dx.doi.org/10.1001/jama.272.24.1890			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX927	7990228				2022-12-28	WOS:A1994PX92700011
J	BAINTON, DF				BAINTON, DF			CALIFORNIA BIGFOOT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											BAINTON, DF (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143, USA.								0	0	0	1	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 22	1994	331	25					1693	1693						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX382	7969361				2022-12-28	WOS:A1994PX38200006
J	KEHLENBACH, RH; MATTHEY, J; HUTTNER, WB				KEHLENBACH, RH; MATTHEY, J; HUTTNER, WB			XL-ALPHA-S IS A NEW-TYPE OF G-PROTEIN	NATURE			English	Article							CONSTITUTIVE SECRETORY VESICLES; SYNAPTIC-LIKE MICROVESICLES; TRANS-GOLGI NETWORK; GTP-BINDING; RECEPTOR; MEMBRANE; MUTATIONS; ENDOSOMES; SUBUNITS; P100	THE GTP-binding proteins are well-known regulators of cellular functions(1-4), including vesicular transport(5-7). Cholera toxin, which is known to catalyse ADP-ribosylation of the as subunit of heterotrimeric G proteins, stimulates secretory vesicle formation from the trans-Golgi network(8). Here we describe a new cholera toxin target, an 'extra large' G protein (XLas; M(r) 92K) which consists of a new 51K XL-portion linked to a Gas truncated at the amino terminus. XLas is specifically associated with the trans-Golgi network and occurs selectively in cells containing both the regulated and the constitutive pathway of protein secretion. Hence, XLas may mediate the effects of cholera toxin on secretory vesicle formation.	UNIV HEIDELBERG, INST NEUROBIOL, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg			Huttner, Wieland B./P-4080-2018	Kehlenbach, Ralph/0000-0003-4920-9916				Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DESHAZER D, 1994, BIOTECHNIQUES, V17, P288; GILL DM, 1991, METHOD ENZYMOL, V195, P267; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HINSCH KD, 1988, FEBS LETT, V238, P191, DOI 10.1016/0014-5793(88)80254-0; ISHIKAWA Y, 1990, J BIOL CHEM, V265, P8458; JONES DT, 1987, J BIOL CHEM, V262, P14241; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MONTMAYEUR JP, 1994, SCIENCE, V263, P95, DOI 10.1126/science.8272874; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; Sambrook J, 1989, MOL CLONING LABORATO; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SWAROOP A, 1991, NUCLEIC ACIDS RES, V19, P4725, DOI 10.1093/nar/19.17.4725; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TOOZE SA, 1992, METHOD ENZYMOL, V219, P81; TRAUB LM, 1991, J BIOL CHEM, V266, P24642; TRAUB LM, 1991, BIOCHEM J, V280, P171, DOI 10.1042/bj2800171; TRAUB LM, 1990, BIOCHEM J, V272, P453, DOI 10.1042/bj2720453; UDRISAR D, 1990, P NATL ACAD SCI USA, V87, P6321, DOI 10.1073/pnas.87.16.6321; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	35	186	189	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	1994	372	6508					804	809						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997272				2022-12-28	WOS:A1994PY21200060
J	ZHANG, GH; TANEJA, KL; SINGER, RH; GREEN, MR				ZHANG, GH; TANEJA, KL; SINGER, RH; GREEN, MR			LOCALIZATION OF PRE-MESSENGER-RNA SPLICING IN MAMMALIAN NUCLEI	NATURE			English	Article							INSITU HYBRIDIZATION; NASCENT TRANSCRIPTS; CELL-NUCLEUS; POLY(A) RNA; RIBONUCLEOPROTEINS; ORGANIZATION; IDENTIFICATION; DOMAINS; PROTEIN; INTERPHASE	IN mammalian nuclei, precursor messenger RNA splicing factors are distributed non-uniformly. Antibodies directed against structural polypeptides of small nuclear ribonucleoprotein particles (snRNPs)(1) and some non-snRNP splicing factors(2) have shown that these components are concentrated in about 20-50 nuclear 'speckles'. These and other non-homogeneous distributions have been proposed to indicate nuclear 'compartments' that are distinct from the sites of transcription and in which RNA processing (3-9). We have tested this idea using a new approach. Previous structural(10-13) and biochemical(14-16) data have shown that splicing can occur in association with transcription. Nascent RNA of specific genes can be detected by in situ hybridization as intense spots of nuclear stain which map to the sites of transcription(17-19). Here we identify active pre-mRNA splicing sites by localizing the nascent spliced mRNA of specific genes. We find that splicing occurs at the sites of transcription, which are not coincident with intranuclear speckles. We conclude that the nucleus is not compartmentalized with respect to transcription and pre-mRNA splicing.	UNIV MASSACHUSETTS,MED CTR,DEPT CELL BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	ZHANG, GH (corresponding author), UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605, USA.							AEBI M, 1987, TRENDS GENET, V3, P102, DOI 10.1016/0168-9525(87)90193-4; BAUREN G, 1994, CELL, V76, P183, DOI 10.1016/0092-8674(94)90182-1; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BRIDGE E, 1993, J VIROL, V67, P5792, DOI 10.1128/JVI.67.10.5792-5802.1993; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; FAKAN S, 1984, J CELL BIOL, V98, P358, DOI 10.1083/jcb.98.1.358; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LEMAIRE MF, 1990, MOL CELL BIOL, V10, P6059, DOI 10.1128/MCB.10.11.6059; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; ROSBASH M, 1993, CELL, V75, P399, DOI 10.1016/0092-8674(93)90373-X; SASS H, 1984, J MOL BIOL, V180, P911, DOI 10.1016/0022-2836(84)90263-8; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SPECTOR DL, 1990, P NATL ACAD SCI USA, V87, P147, DOI 10.1073/pnas.87.1.147; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; TURNER BM, 1987, J CELL SCI, V87, P269; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; VAZQUEZNIN GH, 1990, CHROMOSOMA, V99, P44, DOI 10.1007/BF01737288; VOELKERDING K, 1986, J VIROL, V60, P353, DOI 10.1128/JVI.60.2.353-362.1986; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; WU ZG, 1991, J CELL BIOL, V113, P465, DOI 10.1083/jcb.113.3.465; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; Xing Yigong, 1993, Trends in Cell Biology, V3, P346, DOI 10.1016/0962-8924(93)90105-A; ZACHAR Z, 1993, J CELL BIOL, V121, P729, DOI 10.1083/jcb.121.4.729	30	229	234	1	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					809	812						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997273				2022-12-28	WOS:A1994PY21200061
J	FINKELSTEIN, JS; KLIBANSKI, A; SCHAEFER, EH; HORNSTEIN, MD; SCHIFF, I; NEER, RM				FINKELSTEIN, JS; KLIBANSKI, A; SCHAEFER, EH; HORNSTEIN, MD; SCHIFF, I; NEER, RM			PARATHYROID-HORMONE FOR THE PREVENTION OF BONE LOSS INDUCED BY ESTROGEN DEFICIENCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							X-RAY ABSORPTIOMETRY; MINERAL DENSITY; OVARIECTOMIZED RATS; RANDOMIZED TRIAL; TRABECULAR BONE; SPINAL BONE; WOMEN; MASS; OSTEOPOROSIS; THERAPY	Background. Analogues of gonadotropin-releasing hormone (GnRH) are often given to induce hypogonadism in women who have estrogen-dependent disorders such as endometriosis and uterine leiomyomas. Because estrogen deficiency causes bone loss, concern about premature osteoporosis has prevented long-term therapy with GnRH analogues. We conducted a study to determine whether parathyroid hormone could prevent bone loss in women receiving therapy with GnRH analogues. Methods. We administered human parathyroid hormone (40 mu g subcutaneously daily) to 20 of 40 women with endometriosis who were being treated with nafarelin (200 mu g intranasally twice daily) for six months; the remaining 20 women received only nafarelin. Cortical and trabecular bone density and biochemical markers of bone turnover were measured every three months during the six-month study period. Results. Serum estradiol concentrations fell to postmenopausal values in 36 of the 40 women. In the women who received nafarelin alone, the mean (+/-SE) bone density in the lumbar spine decreased by 2.8+/-0.5 percent (P<0.001) when measured in the anteroposterior projection and by 3.5+/-0.8 percent (P<0.001) when measured in the lateral projection. In contrast, bone density in the lumbar spine did not change when measured in the anteroposterior projection and increased by 3.4+/-1.2 percent when measured in the lateral projection (P = 0.01) in the women who also received parathyroid hormone. Bone density at the femoral neck decreased slightly and similarly in both groups. Radial bone density did not change in either group. Serum alkaline phosphatase and osteocalcin concentrations and urinary hydroxyproline and pyridinoline excretion increased (P<0.001) in the women who received nafarelin plus parathyroid hormone. Conclusions. Parathyroid hormone can prevent bone loss in the lumbar spine in young women with estrogen deficiency caused by treatment with GnRH analogues.	MASSACHUSETTS GEN HOSP,DEPT MED,NEUROENDOCRINE UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT GYNECOL,BOSTON,MA 02114; BRIGHAM & WOMENS HOSP,DEPT OBSTET & GYNECOL,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital	FINKELSTEIN, JS (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MED,ENDOCRINE UNIT,BULFINCH 327,BOSTON,MA 02114, USA.		Finkelstein, Joel/M-6463-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD021204, R01HD021204] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043341] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-1066] Funding Source: Medline; NICHD NIH HHS [HD-21204] Funding Source: Medline; NIDDK NIH HHS [1 R29 DK/43341-01A2] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; CHRISTIANSEN C, 1981, LANCET, V1, P459; COMITE F, 1989, J CLIN ENDOCR METAB, V69, P837, DOI 10.1210/jcem-69-4-837; COMPSTON JE, IN PRESS BONE; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; FINKELSTEIN JS, 1994, J CLIN ENDOCR METAB, V78, P724, DOI 10.1210/jc.78.3.724; FINKELSTEIN JS, 1992, NEW ENGL J MED, V326, P600, DOI 10.1056/NEJM199202273260904; FRIEDMAN AJ, 1993, J CLIN ENDOCR METAB, V76, P1439, DOI 10.1210/jc.76.6.1439; GENANT HK, 1982, ANN INTERN MED, V97, P699, DOI 10.7326/0003-4819-97-5-699; GUNNESSHEY M, 1984, METAB BONE DIS RELAT, V5, P177, DOI 10.1016/0221-8747(84)90026-2; HADDAWAY MJ, 1992, BRIT J RADIOL, V65, P213, DOI 10.1259/0007-1285-65-771-213; HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110; HOCK JM, 1988, ENDOCRINOLOGY, V122, P2899, DOI 10.1210/endo-122-6-2899; HOCK JM, 1990, ENDOCRINOLOGY, V127, P1804, DOI 10.1210/endo-127-4-1804; HODSMAN AB, 1991, BONE MINER, V14, P67, DOI 10.1016/0169-6009(91)90103-7; HODSMAN AB, 1993, J CLIN INVEST, V91, P1138, DOI 10.1172/JCI116273; HOSCH RD, 1989, CALCIFIED TISSUE INT, V44, P176; JOHANSEN JS, 1988, J CLIN ENDOCR METAB, V67, P701, DOI 10.1210/jcem-67-4-701; KLIBANSKI A, 1980, NEW ENGL J MED, V303, P1511, DOI 10.1056/NEJM198012253032605; KLIBANSKI A, 1988, J CLIN ENDOCR METAB, V67, P124, DOI 10.1210/jcem-67-1-124; LANE N, 1991, J CLIN ENDOCR METAB, V72, P510, DOI 10.1210/jcem-72-2-510; LARCOS G, 1991, J NUCL MED, V32, P2101; LINDSAY R, 1993, J BONE MINER RES, V8, pS130; LIU CC, 1990, J BONE MINER RES, V5, P973; MITLAK BH, 1992, J BONE MINER RES, V7, P479; NEER R, 1990, OSTEOPOROSIS 1990, V3, P1314; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; Reeve J, 1991, Osteoporos Int, V1, P162, DOI 10.1007/BF01625448; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; RIGGS BL, 1993, NEW ENGL J MED, V328, P65; RIGOTTI NA, 1984, NEW ENGL J MED, V311, P1601, DOI 10.1056/NEJM198412203112503; RIIS BJ, 1990, J CLIN ENDOCR METAB, V70, P920, DOI 10.1210/jcem-70-4-920; ROUX C, 1993, J BONE MINER RES, V8, pS151; SCHARLA SH, 1990, J CLIN ENDOCR METAB, V70, P1055, DOI 10.1210/jcem-70-4-1055; SHEN V, 1993, J CLIN INVEST, V91, P2479, DOI 10.1172/JCI116483; SLOVIK DM, 1986, J BONE MINER RES, V1, P377; SURREY ES, 1992, J CLIN ENDOCR METAB, V75, P558, DOI 10.1210/jc.75.2.558; TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo-110-2-506	38	199	204	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 15	1994	331	24					1618	1623		10.1056/NEJM199412153312404	http://dx.doi.org/10.1056/NEJM199412153312404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW446	7969342				2022-12-28	WOS:A1994PW44600004
J	JOLLIS, JG; PETERSON, ED; DELONG, ER; MARK, DB; COLLINS, SR; MUHLBAIER, LH; PRYOR, DB				JOLLIS, JG; PETERSON, ED; DELONG, ER; MARK, DB; COLLINS, SR; MUHLBAIER, LH; PRYOR, DB			THE RELATION BETWEEN THE VOLUME OF CORONARY ANGIOPLASTY PROCEDURES AT HOSPITALS TREATING MEDICARE BENEFICIARIES AND SHORT-TERM MORTALITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURGICAL VOLUME; COMORBIDITIES; OPERATIONS; REGISTRY; SURGERY	Background. Previous studies have found that hospitals at which more procedures, such as coronary-artery bypass grafting (CABG) and other vascular surgery, are performed have lower rates of mortality related to these procedures than hospitals where fewer such procedures are performed. Methods. We examined the relation between the number of percutaneous transluminal coronary angioplasty (PTCA) procedures performed at hospitals (volume) and short-term mortality in a population of 217,836 Medicare beneficiaries 65 years of age or older who underwent angioplasty in the United States from 1987 through 1990. Results. The unadjusted in-hospital mortality among patients who underwent PTCA increased from 2.5 percent among the 10 percent of patients treated in hospitals with the highest volume of such procedures to 3.9 percent among the 10 percent of patients treated in hospitals with the lowest volume. The rate of bypass surgery after PTCA also increased, from 2.8 percent among patients in the highest-volume hospitals to 5.3 percent among those in the lowest-volume hospitals. Higher rates of mortality and CABG persisted in all the groups of patients treated in hospitals that performed fewer than 100 angioplasty procedures per year in Medicare beneficiaries; this volume in Medicare beneficiaries can be extrapolated to an overall annual volume of 200 to 400 angioplasty procedures. In a logistic-regression model, the volume of PTCA procedures at a hospital was found to be a highly significant predictor of in-hospital mortality (P<0.001). These results suggest that if the hospitals with the lowest volume had achieved the experience and technical results of the highest-volume hospitals, 381 fewer patients would have undergone CABG and there would have been 300 fewer in-hospital deaths in the population we studied. Conclusions. Hospitals that perform more PTCA procedures have lower short-term mortality rates after the procedure. These data provide evidence in support of the regionalization of angioplasty services.	DUKE UNIV,MED CTR,DEPT FAMILY & COMMUNITY MED,DIV BIOMETRY,DURHAM,NC 27708	Duke University	JOLLIS, JG (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOL,BOX 3254,DURHAM,NC 27708, USA.		Peterson, Eric David/ABF-5033-2021	Mark, Daniel/0000-0001-6340-8087	AHRQ HHS [HS-06503, HS-05635] Funding Source: Medline; NHLBI NIH HHS [HL-17670] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS005635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017670] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; HANNAN EL, 1991, MED CARE, V29, P1094, DOI 10.1097/00005650-199111000-00003; IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; Jollis James G., 1994, P343; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; KRONE RJ, 1993, CIRCULATION, V88, P300; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; RITCHIE JL, 1993, CIRCULATION, V88, P2735, DOI 10.1161/01.CIR.88.6.2735; RYAN TJ, 1993, CIRCULATION, V88, P2987, DOI 10.1161/01.CIR.88.6.2987; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P2438; THOMPSON RC, 1991, J AM COLL CARDIOL, V17, P1245, DOI 10.1016/S0735-1097(10)80130-5; 1993, LANCET, V341, P573; 1993, ANN REPORT CALIFORNI; 1991, ICD 9 CM INT CLASSIF; 1993, HEART STROKE FACTS 1	17	244	246	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 15	1994	331	24					1625	1629		10.1056/NEJM199412153312406	http://dx.doi.org/10.1056/NEJM199412153312406			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW446	7969344				2022-12-28	WOS:A1994PW44600006
J	ALBERTS, B; SHINE, K				ALBERTS, B; SHINE, K			SCIENTISTS AND THE INTEGRITY OF RESEARCH	SCIENCE			English	Editorial Material											ALBERTS, B (corresponding author), NATL ACAD SCI,INST MED,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418, USA.							ALBERTS B, 1994, P NATL ACAD SCI USA, V9179, P3479; 1992, RESPONSIBLE SCI ENSU; 1989, RESPONSIBLE CONDUCT; 1994, TEACHING RESPONSIBLE; 1989, BEING SCI	5	37	37	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1660	1661		10.1126/science.7992048	http://dx.doi.org/10.1126/science.7992048			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992048				2022-12-28	WOS:A1994PW30800025
J	BUSBY, S; EBRIGHT, RH				BUSBY, S; EBRIGHT, RH			PROMOTER STRUCTURE, PROMOTER RECOGNITION, AND TRANSCRIPTION ACTIVATION IN PROKARYOTES	CELL			English	Review							COLI RNA-POLYMERASE; CAMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; ALPHA-SUBUNIT; POSITIVE CONTROL; REGION; CRP; IDENTIFICATION; BINDING; DNA		RUTGERS STATE UNIV,DEPT CHEM,NEW BRUNSWICK,NJ 08855; RUTGERS STATE UNIV,WAKSMAN INST,NEW BRUNSWICK,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick	BUSBY, S (corresponding author), UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140				BANNER C, 1983, J MOL BIOL, V160, P351; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; BUSBY S, 1994, J MOL BIOL, V241, P341, DOI 10.1006/jmbi.1994.1511; CHEN Y, 1986, EMBO J, V5, P2987; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GOFF CG, 1984, METHOD ENZYMOL, V106, P418; Gross C. A., 1992, TRANSCRIPTIONAL REGU, V1, P129; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; HU JC, 1985, MOL GEN GENET, V199, P7, DOI 10.1007/BF00327502; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; JENNINGS MP, 1993, MOL MICROBIOL, V9, P155, DOI 10.1111/j.1365-2958.1993.tb01677.x; JOUNG JK, 1993, P NATL ACAD SCI USA, V90, P3083, DOI 10.1073/pnas.90.7.3083; JOUNG JK, 1994, SCIENCE, V265, P1863, DOI 10.1126/science.8091212; KEENER J, 1993, P NATL ACAD SCI USA, V90, P1751, DOI 10.1073/pnas.90.5.1751; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; NEWLANDS JT, 1992, NUCLEIC ACIDS RES, V20, P719, DOI 10.1093/nar/20.4.719; RAO L, 1994, J MOL BIOL, V235, P1421, DOI 10.1006/jmbi.1994.1098; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; RUSSO FD, 1992, J BIOL CHEM, V267, P14515; SHARIF KA, 1994, J BIOL CHEM, V269, P23655; TANG H, 1994, GENE DEV, V243, P603; ZHOU Y, 1994, IN PRESS EMBO J; ZHOU Y, 1994, J MOL BIOL, V13, P4549; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081; ZHOU YH, 1993, CELL, V73, P375, DOI 10.1016/0092-8674(93)90236-J; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x	28	367	377	0	30	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 2	1994	79	5					743	746		10.1016/0092-8674(94)90063-9	http://dx.doi.org/10.1016/0092-8674(94)90063-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001112				2022-12-28	WOS:A1994PW05400001
J	BURMEISTER, WP; GASTINEL, LN; SIMISTER, NE; BLUM, ML; BJORKMAN, PJ				BURMEISTER, WP; GASTINEL, LN; SIMISTER, NE; BLUM, ML; BJORKMAN, PJ			CRYSTAL-STRUCTURE AT 2.2-ANGSTROM RESOLUTION OF THE MHC-RELATED NEONATAL FC RECEPTOR	NATURE			English	Article							CLASS-I H-2K(B); HISTOCOMPATIBILITY ANTIGEN; 3-DIMENSIONAL STRUCTURE; PEPTIDE ANTIGENS; SMALL-INTESTINE; BINDING; COMPLEX; RECOGNITION; HLA-A2; RAT	The three-dimensional structure of the rat neonatal Fe receptor (FcRn) is similar to the structure of molecules of the major histocompatibility complex (MHC). The counterpart of the MHC peptide-binding site is closed in FcRn, making the FcRn groove incapable of binding peptides. A dimer of FcRn heterodimers seen in the crystals may represent a receptor dimer that forms when the Fc portion of a single immunoglobulin binds. An alternative use of the MHC fold for immune recognition is indicated by the FcRn and FcRn/Fc co-crystal structures.	CALTECH,DEPT BIOL,PASADENA,CA 91125; CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; Brandeis University; Brandeis University				Burmeister, Wim/0000-0003-0876-6118				AHOUSE JJ, 1993, J IMMUNOL, V151, P6076; BEAVIL AJ, 1993, BIOCHEM SOC T, V21, P968, DOI 10.1042/bst0210968; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1992, XPLOR VERSION 31 SYS; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; DAVIES DR, 1983, ANNU REV IMMUNOL, V1, P87, DOI 10.1146/annurev.iy.01.040183.000511; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FAHNESTOCK ML, 1992, SCIENCE, V258, P1658, DOI 10.1126/science.1360705; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOPE H, 1990, ANNU REV BIOPHYS BIO, V19, P107; HUBER AH, 1993, J MOL BIOL, V230, P1077, DOI 10.1006/jmbi.1993.1220; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, SET AVERAGING PROGRA; JONES TA, 1993, CRYSTALLOGRAPHIC COM; Kabat EA, 1991, SEQUENCES PROTEINS I; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANCET D, 1979, P NATL ACAD SCI USA, V76, P3844, DOI 10.1073/pnas.76.8.3844; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MARTIN LH, 1987, P NATL ACAD SCI USA, V84, P9189, DOI 10.1073/pnas.84.24.9189; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; RAGHAVAN M, 1994, IMMUNITY, V1, P303, DOI 10.1016/1074-7613(94)90082-5; RAGHAVAN M, 1993, BIOCHEMISTRY-US, V32, P8654, DOI 10.1021/bi00084a037; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; ROBERTS DM, 1990, J CELL BIOL, V111, P1867, DOI 10.1083/jcb.111.5.1867; RODEWALD R, 1976, J CELL BIOL, V71, P666, DOI 10.1083/jcb.71.2.666; RODEWALD R, 1970, J CELL BIOL, V45, P635, DOI 10.1083/jcb.45.3.635; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHALL S, 1969, J MOL BIOL, V41, P237; SIMISTER NE, 1985, EUR J IMMUNOL, V15, P733, DOI 10.1002/eji.1830150718; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403; 1979, CCP4 ERC DAR LAB COL	50	266	282	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					336	343		10.1038/372336a0	http://dx.doi.org/10.1038/372336a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969491				2022-12-28	WOS:A1994PU28700047
J	WOODWARD, SR; WEYAND, NJ; BUNNELL, M				WOODWARD, SR; WEYAND, NJ; BUNNELL, M			DNA-SEQUENCE FROM CRETACEOUS PERIOD BONE FRAGMENTS	SCIENCE			English	Article							AMPLIFICATION; EXTRACTION; EVOLUTION	DNA was extracted from 80-million-year-old bone fragments found in strata of the Upper Cretaceous Blackhawk Formation in the roof of an underground coal mine in eastern Utah. This DNA was used as the template in a polymerase chain reaction that amplified and sequenced a portion of the gene encoding mitochondrial cytochrome b. These sequences differ from all other cytochrome b sequences investigated, including those in the GenBank and European Molecular Biology Laboratory databases. DNA isolated from these bone fragments and the resulting gene sequences demonstrate that small fragments of DNA may survive in bone for millions of years.			WOODWARD, SR (corresponding author), BRIGHAM YOUNG UNIV,DEPT MICROBIOL,788 WIDTSOE BLDG,PROVO,UT 84602, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BALSLEY JK, 1982, AM ASS PET GEOL GUID, P263; CANO R J, 1992, Medical Science Research, V20, P619; CANO RJ, 1993, NATURE, V363, P536, DOI 10.1038/363536a0; CURRY GB, 1988, SHORT COURSES PALEON, V1, P20; DESALLE R, 1992, SCIENCE, V257, P1933, DOI 10.1126/science.1411508; Doelling H. H., 1972, UTAH GEOL SURV MONOG, V3, P571; GURLEY LR, 1991, J PROTEIN CHEM, V10, P75, DOI 10.1007/BF01024658; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAGELBERG E, 1989, NATURE, V342, P485, DOI 10.1038/342485a0; HINTZE LF, 1988, B YOUNG U GEOL STUD, V7, P53; IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; PAABO S, 1989, P NATL ACAD SCI USA, V86, P1939, DOI 10.1073/pnas.86.6.1939; Parker L.R., 1989, P353; POINAR HN, 1993, NATURE, V363, P677, DOI 10.1038/363677a0; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; WOODWARD SR, 1994, PCR METH APPL, V2, P244	20	153	166	2	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1229	1232						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973705				2022-12-28	WOS:A1994PT13200051
J	GOTZ, R; KOSTER, R; WINKLER, C; RAULF, F; LOTTSPEICH, F; SCHARTL, M; THOENEN, H				GOTZ, R; KOSTER, R; WINKLER, C; RAULF, F; LOTTSPEICH, F; SCHARTL, M; THOENEN, H			NEUROTROPHIN-6 IS A NEW MEMBER OF THE NERVE GROWTH-FACTOR FAMILY	NATURE			English	Article							EMBRYONIC-DEVELOPMENT; SENSORY NEURONS; CELL-SURFACE; IDENTIFICATION; SURVIVAL; CLEAVAGE; PROTEINS; RECEPTOR; BINDING; BIOLOGY	DURING vertebrate development, many neurons depend for survival and differentiation on their target cells(1-3). The best documented mediator of such a retrograde trophic action is the neurotrophin nerve growth factor (NGF)(1). NGF and the other known members of the neurotrophin family, brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5) are conserved as distinct genes over large evolutionary distances(4-6). Here we report the cloning of neurotrophin-6 (NT-6), a new member of this family from the teleost fish Xiphophorus. NT-6 distinguishes itself from the other known neurotrophins in that it is not found as a soluble protein in the medium of producing cells. The addition of heparin (but not chondroitin) effects the release of NT-6 from cell surface and extracellular matrix molecules. Recombinant purified NT-6 has a spectrum of actions similar to NGF on chick sympathetic and sensory neurons, albeit with a lower potency. NT-6 is expressed in the embryonic valvulla cerebelli; expression persists in some adult tissues. The interaction of NT-6 with heparin-binding molecules may modulate its action in the nervous system.	MAX PLANCK INST PSYCHIAT,DEPT NEUROCHEM,D-82152 MARTINSRIED,GERMANY; UNIV WURZBURG,BIOZENTRUM,DEPT PHYSIOL CHEM 1,D-97074 WURZBURG,GERMANY; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society; University of Wurzburg; Max Planck Society			Winkler, Christoph/G-4822-2012	Schartl, Manfred/0000-0001-9882-5948; Koster, Reinhard/0000-0001-6593-8196; Winkler, Christoph/0000-0003-4688-6241				BARDE YA, 1980, P NATL ACAD SCI-BIOL, V77, P1199, DOI 10.1073/pnas.77.2.1199; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; CRAWFORD JL, 1973, P NATL ACAD SCI USA, V70, P538, DOI 10.1073/pnas.70.2.538; GOTZ R, 1994, COMP BIOCHEM PHYS C, V108, P1, DOI 10.1016/1367-8280(94)90082-5; GOTZ R, 1992, J NEUROCHEM, V59, P432, DOI 10.1111/j.1471-4159.1992.tb09389.x; GOTZ R, 1992, EUR J BIOCHEM, V204, P745, DOI 10.1111/j.1432-1033.1992.tb16689.x; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; KRIMLAUF R, 1991, GENE TRANSFER EXPRES, P307; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; LEE BA, 1991, J CELL BIOL, V113, P361, DOI 10.1083/jcb.113.2.361; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; MARCEY D, 1986, NATURE, V321, P380, DOI 10.1038/321380a0; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MEEK J, 1992, EUR J MORPHOL, V1, P37; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; POWERS DA, 1989, SCIENCE, V246, P352, DOI 10.1126/science.2678474; PURVES D, 1988, BODY BRAIN TROPIC TH; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROSSANT J, 1992, GENE DEV, V6, P1, DOI 10.1101/gad.6.1.1; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; TAVOLGA WILLIAM N., 1949, BULL AMER MUS NAT HIST, V94, P161; VLODAVSKY L, 1991, TRENDS BIOCHEM SCI, V168, P268; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	30	338	373	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					266	269		10.1038/372266a0	http://dx.doi.org/10.1038/372266a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969471	Green Published			2022-12-28	WOS:A1994PR88900051
J	SCINTO, LFM; DAFFNER, KR; DRESSLER, D; RANSIL, BI; RENTZ, D; WEINTRAUB, S; MESULAM, M; POTTER, H				SCINTO, LFM; DAFFNER, KR; DRESSLER, D; RANSIL, BI; RENTZ, D; WEINTRAUB, S; MESULAM, M; POTTER, H			A POTENTIAL NONINVASIVE NEUROBIOLOGICAL TEST FOR ALZHEIMERS-DISEASE	SCIENCE			English	Article							APOLIPOPROTEIN-E; DEPOSITS	Currently Alzheimer's disease, which affects more than 20 million people worldwide, can only be definitively diagnosed by histological examination of brain tissue obtained at autopsy or biopsy. There is a great need for an early, noninvasive, sensitive, and easily administered diagnostic test of Alzheimer's disease. Here it is reported that patients diagnosed with probable Alzheimer's disease by standard clinical criteria exhibited a marked hypersensitivity in their pupil dilation response to a cholinergic antagonist, tropicamide, placed in their eyes. It was possible to distinguish 18 of 19 individuals (95%) either clinically diagnosed with Alzheimer's disease or classified as suspect Alzheimer's individuals by neuropsychological screening from 30 of 32 normal elderly controls (94%).	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; BETH ISRAEL HOSP,BOSTON,MA 02215; NORTHWESTERN UNIV,SCH MED,CTR COGNIT & BEHAV NEUROL,CHICAGO,IL 60611	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Northwestern University	SCINTO, LFM (corresponding author), BRIGHAM & WOMENS HOSP,EYE MOVEMENTS & HIGHER CORT FUNCT LAB,BRIGHAM BEHAV GRP,BOSTON,MA 02115, USA.							BERG JM, 1959, LANCET, V2, P441; BLASS JP, 1993, NEUROLOGY S4, V43, P825; BUGIANI O, 1990, NEUROSCI LETT, V119, P56, DOI 10.1016/0304-3940(90)90754-W; COYLE JT, 1986, BRAIN RES BULL, V16, P773, DOI 10.1016/0361-9230(86)90074-2; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HARDY J, 1989, LANCET, V2, P877; HARRIS WS, 1968, NEW ENGL J MED, V279, P407, DOI 10.1056/NEJM196808222790805; HESTON LL, 1981, ARCH GEN PSYCHIAT, V38, P1084; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MESULAM MM, IN PRESS ANN NEUROL; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; OLSON MI, 1969, BRAIN, V92, P147, DOI 10.1093/brain/92.1.147; PETERSEN RC, 1994, NEUROLOGY, V44, P867, DOI 10.1212/WNL.44.5.867; POTTER H, 1991, AM J HUM GENET, V48, P1192; POTTER H, IN PRESS GENES MED D; PRICE BH, 1993, ARCH NEUROL-CHICAGO, V50, P931, DOI 10.1001/archneur.1993.00540090038008; PRICE DL, 1986, ANNU REV NEUROSCI, V9, P489; ROCCA WA, 1986, ANN NEUROL, V19, P415, DOI 10.1002/ana.410190502; SACKS B, 1989, J NEUROL NEUROSUR PS, V52, P1294, DOI 10.1136/jnnp.52.11.1294; SCINTO LFM, 1994, ARCH NEUROL-CHICAGO, V51, P682, DOI 10.1001/archneur.1994.00540190062016; TERRY RD, 1983, NEUROLOGY AGING, P51; WISNIEWSKI HM, 1988, BANBURY REPORT, P399; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; YANKNER BA, 1991, NEW ENGL J MED, V325, P1849	26	179	189	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1051	1054		10.1126/science.7973660	http://dx.doi.org/10.1126/science.7973660			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PQ924	7973660				2022-12-28	WOS:A1994PQ92400047
J	DAVIS, S; GALE, NW; ALDRICH, TH; MAISONPIERRE, PC; LHOTAK, V; PAWSON, T; GOLDFARB, M; YANCOPOULOS, GD				DAVIS, S; GALE, NW; ALDRICH, TH; MAISONPIERRE, PC; LHOTAK, V; PAWSON, T; GOLDFARB, M; YANCOPOULOS, GD			LIGANDS FOR EPH-RELATED RECEPTOR TYROSINE KINASES THAT REQUIRE MEMBRANE ATTACHMENT OR CLUSTERING FOR ACTIVITY	SCIENCE			English	Article							NEUROTROPHIC FACTOR; NERVOUS-SYSTEM; PROTEIN; GENE; FAMILY; EXPRESSION; IDENTIFICATION; HINDBRAIN; CLONING; CHICKEN	The EPH-related transmembrane tyrosine kinases constitute the largest known family of receptor-like tyrosine kinases, with many members displaying specific patterns of expression in the developing and adult nervous system. A family of cell surface-bound ligands exhibiting distinct, but overlapping, specificities for these EPH-related kinases was identified. These ligands were unable to act as conventional soluble factors. However, they did function when presented in membrane-bound form, suggesting that they require direct cell-to-cell contact to activate their receptors. Membrane attachment may serve to facilitate ligand dimerization or aggregation, because antibody-mediated clustering activated previously inactive soluble forms of these ligands.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	DAVIS, S (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.		Pawson, Tony J/E-4578-2013					BAPTISTA CA, 1994, NEURON, V12, P243, DOI 10.1016/0896-6273(94)90268-2; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BOYD AW, 1992, J BIOL CHEM, V267, P3262; CHAN J, 1991, ONCOGENE, V6, P1057; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Davis S.M, UNPUB; GALE NW, UNPUB; GAO WQ, 1991, NEURON, V6, P705, DOI 10.1016/0896-6273(91)90168-Y; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HART AC, 1993, NATURE, V361, P732, DOI 10.1038/361732a0; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; NIETO MA, 1992, DEVELOPMENT, V116, P1137; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKINSON D, COMMUNICATION	31	627	673	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	1994	266	5186					816	819		10.1126/science.7973638	http://dx.doi.org/10.1126/science.7973638			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973638				2022-12-28	WOS:A1994PP75300044
J	TRAVIS, J				TRAVIS, J			NOVEL COURSE .1. DIGITAL NEUROSCIENCE	SCIENCE			English	Note																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					869	869		10.1126/science.7973646	http://dx.doi.org/10.1126/science.7973646			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973646				2022-12-28	WOS:A1994PP75300066
J	CHREN, MM; LANDEFELD, CS				CHREN, MM; LANDEFELD, CS			A COST-ANALYSIS OF TOPICAL DRUG REGIMENS FOR DERMATOPHYTE INFECTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERDIGITAL TINEA-PEDIS; TERBINAFINE; 1-WEEK; CREAM	Objective.-To examine the extra cost of using higher-priced drugs as initial therapy for dermatophyte infections, because the many available effective drugs vary considerably in cost. Design.-Cost analysis from the purchaser's perspective, comparing two prototypical regimens to treat tinea pedis: one in which all patients initially receive a fewer-priced drug and those with unresponsive infections receive a higher-priced drug at a follow-up office visit, and one in which all patients receive the higher-priced drug from the outset. The reference drug was miconazole, an imidazole available without a prescription, for which reported overall efficacy rates are 70% to 100%. Main Outcome Measures.-The threshold efficacy rate (the efficacy rate of miconazole below which it is always less expensive to use a specific higher-priced drug first) and the extra cost (of beginning therapy with a higher-priced drug). Results.-Assuming the Medicare-approved charge for a follow-up visit ($21.98), it is less expensive to begin therapy with a prescription drug only if the efficacy rate of miconazole is less than 55%; this threshold efficacy rate varied from 26% (for a $0 total cost of the follow-up visit) to 79% (for an $89 total cost of the follow-up visit). If the efficacy rate of miconazole is 70%, the extra cost per patient for all patients to receive the least expensive prescription antifungal drug instead of miconazole first was $15.23 and $8.64 if total visit costs were $0 and $21.98, miconazole remained the less expensive alternative as long as the total cost of the follow-up visit was less than $50.76. Conclusion.-For reported efficacy rates and standard costs of a follow-up office visit, using miconazole first and then treating only those patients with unresponsive infections with a higher-priced prescription drug is less expensive than treating ail patients with the higher-priced drug.	VET AFFAIRS MED CTR,PROGRAM HLTH CARE RES,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH; UNIV CLEVELAND HOSP,CLEVELAND,OH 44106; VET AFFAIRS MED CTR,DEPT MED,CLEVELAND,OH 44106	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	CHREN, MM (corresponding author), VET AFFAIRS MED CTR,DEPT DERMATOL,11-GW,10701 EAST BLVD,CLEVELAND,OH 44106, USA.							BERGSTRESSER PR, 1993, J AM ACAD DERMATOL, V28, P648, DOI 10.1016/S0190-9622(08)81787-2; BERMAN B, 1992, J AM ACAD DERMATOL, V26, P956, DOI 10.1016/0190-9622(92)70141-2; BLOOM BS, 1986, JAMA-J AM MED ASSOC, V256, P2523, DOI 10.1001/jama.256.18.2523; CHREN MM, 1994, J AM ACAD DERMATOL, V31, pS103, DOI 10.1016/S0190-9622(08)81278-9; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ELDAROUTI MA, 1990, INT J DERMATOL, V29, P521, DOI 10.1111/j.1365-4362.1990.tb04851.x; FULTON JE, 1975, ARCH DERMATOL, V111, P596, DOI 10.1001/archderm.111.5.596; HAY RJ, 1990, SEMIN DERMATOL, V9, P309; HAY RJ, 1992, CLIN EXP DERMATOL, V17, P2, DOI 10.1111/j.1365-2230.1992.tb00268.x; JONES HE, 1982, MED CLIN N AM, V66, P873, DOI 10.1016/S0025-7125(16)31399-2; MANDY SJ, 1974, JAMA-J AM MED ASSOC, V230, P72, DOI 10.1001/jama.230.1.72; ORTIZ LG, 1978, CLIN THER, V1, P444; SAWYER PR, 1975, DRUGS, V9, P406, DOI 10.2165/00003495-197509060-00002; Smith E B, 1976, Cutis, V17, P54; STERN RS, 1993, DERMATOLOGY GEN MED, P7; SVEJGAAR.E, 1973, ACTA DERM-VENEREOL, V53, P497; 1984, CAN MED ASSOC J, V130, P1428; 1993, MED LETT DRUGS THER, V35, P76; 1993, 1993 RED BOOK; 1984, CAN MED ASSOC J, V130, P1542	20	17	17	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	1994	272	24					1922	1925		10.1001/jama.272.24.1922	http://dx.doi.org/10.1001/jama.272.24.1922			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX927	7990244				2022-12-28	WOS:A1994PX92700037
J	BENDITT, DG; MIANULLI, M; LURIE, K; SAKAGUCHI, S; ADLER, S				BENDITT, DG; MIANULLI, M; LURIE, K; SAKAGUCHI, S; ADLER, S			MULTIPLE-SENSOR SYSTEMS FOR PHYSIOLOGICAL CARDIAC PACING	ANNALS OF INTERNAL MEDICINE			English	Article							RATE-RESPONSIVE PACEMAKER; SICK SINUS SYNDROME; RIGHT VENTRICULAR PRESSURE; VENOUS OXYGEN-SATURATION; DOUBLE-BLIND CROSSOVER; COMPLETE HEART-BLOCK; CHRONOTROPIC RESPONSE; DUAL-CHAMBER; EXERCISE PERFORMANCE; CLINICAL-EXPERIENCE	Purpose: To review the status of artificial sensors in cardiac pacemakers and the rationale for developing pacing systems that use multiple sensors. Data Sources: Journal articles published between 1982 and 1993 indexed in MEDLINE using the keywords pacemakers, sensors, and rate-adaptive, as well as abstracts and articles in the authors' personal files. Study Selection: Articles describing clinical experience with or clinical evaluation of cardiac pacing systems using multiple artificial sensors. Data Synthesis: Artificial sensors were created to adjust pacing rate reliably in response to changes in levels of physical exertion for patients with sinoatrial disease in whom exercise heart rate response is inadequate (for example, chronotropic incompetence in sinoatrial disease). To achieve this, various artificial sensors were developed and many reports confirm improved exertional tolerance. More recently, sensors have assumed a greater role in cardiac pacemakers. For example, sensors are used to permit automatic adjustment of certain programmable pacemaker settings, such as the atrioventricular interval. In the future, they may also be used to maximize pacemaker longevity by automatically optimizing energy output (voltage, pulse width). No single sensor is ideal for all potential applications, and investigators have advocated using two or more sensors. Several pacemakers that use multiple sensors with different but complementary operating characteristics are already commercially available outside the United States. Although preliminary findings are encouraging, additional clinical experience with these pacemakers is needed to determine their ultimate role in clinical practice. Conclusion: Simultaneous use of multiple complementary artificial sensors may permit development of cardiac pacemakers that operate more physiologically yet require less specialized medical follow-up.			BENDITT, DG (corresponding author), UNIV MINNESOTA, CTR CARIAC ARRHYTHMIA, DIV CARDIOVASC, BOX 341 UMHC, MINNEAPOLIS, MN 55455 USA.							ALPERT MA, 1987, AM HEART J, V113, P958, DOI 10.1016/0002-8703(87)90057-3; ALT E, 1987, CHEST, V92, P247, DOI 10.1378/chest.92.2.247; ALT E, 1988, PACE, V11, P1119, DOI 10.1111/j.1540-8159.1988.tb03963.x; ALT E, 1988, J ELECTROPHYSIOL, V2, P508; ANDERSON K, 1985, IMPLANTABLE SENSORS, P243; ANDERSON KM, 1986, PACE, V9, P954, DOI 10.1111/j.1540-8159.1986.tb06653.x; AUSUBEL K, 1985, CIRCULATION, V72, P1037, DOI 10.1161/01.CIR.72.5.1037; BEGEMANN MJ, 1993, RATE ADAPTIVE PACING, P359; BENDITT DG, 1989, AM J CARDIOL, V64, P27, DOI 10.1016/0002-9149(89)90647-4; BENDITT DG, 1987, ANN INTERN MED, V107, P714, DOI 10.7326/0003-4819-107-5-714; BENDITT DG, 1987, CIRCULATION, V75, P184, DOI 10.1161/01.CIR.75.1.184; BENDITT DG, 1988, CAN J CARDIOL, V4, P1; BENDITT DG, 1993, RATE ADAPTIVE PACING, P381; BENDITT DG, 1993, RATE ADAPTIVE PACING, P9; BENDITT DG, 1994, PACE, V17, P753; BENDITT DG, 1994, CARDIAC ELECTROPHYSI; BENNETT T, 1992, PACE, V15, P219, DOI 10.1111/j.1540-8159.1992.tb03066.x; BEYERSDORF F, 1986, ANN THORAC SURG, V42, P201, DOI 10.1016/S0003-4975(10)60519-X; BRANDT J, 1992, J AM COLL CARDIOL, V20, P633, DOI 10.1016/0735-1097(92)90018-I; BUCKINGHAM TA, 1988, J AM COLL CARDIOL, V11, P1269, DOI 10.1016/0735-1097(88)90291-4; BUETIKOFER J, 1987, 7TH P WORLD S CARD P, P53; CAMMILLI L, 1978, PACE, V1, P448, DOI 10.1111/j.1540-8159.1978.tb03506.x; CASABURI R, 1989, CHEST, V95, P6, DOI 10.1378/chest.95.1.6; DENDULK K, 1988, AM J CARDIOL, V61, P107; DONALDSON RM, 1983, BRIT MED J, V286, P667, DOI 10.1136/bmj.286.6366.667; FAERESTRAND S, 1987, PACE, V10, P1277; FAERESTRAND S, 1987, PACE, V10, P507, DOI 10.1111/j.1540-8159.1987.tb04514.x; FAERESTRAND S, 1993, RATE ADAPTIVE PACING, P335; FANANAPAZIR L, 1983, PACE, V6, P601, DOI 10.1111/j.1540-8159.1983.tb05301.x; FEARNOT NE, 1986, PACE, V9, P939, DOI 10.1111/j.1540-8159.1986.tb06651.x; FETTER J, 1988, AM J CARDIOL, V62, P901, DOI 10.1016/0002-9149(88)90890-9; HATANO K, 1989, PACE, V12, P16, DOI 10.1111/pace.1989.12.p1.16; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; HEUER H, 1986, HERZSCHRITTMACHER, V2, P64; HUMEN DP, 1985, PACE, V8, P52, DOI 10.1111/j.1540-8159.1985.tb05723.x; JUTZY RV, 1990, PACE, V13, P1838, DOI 10.1111/j.1540-8159.1990.tb06900.x; KARLOF I, 1975, ACTA MED SCAND, V197, P195; KATRITIS D, 1993, RATE ADAPTIVE PACING, P385; KAY GN, 1992, J AM COLL CARDIOL, V20, P1533, DOI 10.1016/0735-1097(92)90447-U; KAY GN, 1989, J AM COLL CARDIOL, V14, P1283, DOI 10.1016/0735-1097(89)90429-4; KOBAYASHI Y, 1993, RATE ADAPTIVE PACING, P405; KRASNER JL, 1966, J ASSOC ADV MED INST, V1, P14; KRISTENSSON BE, 1985, PACE, V8, P73, DOI 10.1111/j.1540-8159.1985.tb05726.x; KRISTENSSON BE, 1985, EUR HEART J, V6, P773, DOI 10.1093/oxfordjournals.eurheartj.a061940; LANDMAN MAJ, 1990, PACE, V13, P1615, DOI 10.1111/j.1540-8159.1990.tb06863.x; LAU CA, 1992, PACE, V15, P334, DOI 10.1111/j.1540-8159.1992.tb06503.x; LAU CP, 1988, PACE, V11, P744, DOI 10.1111/j.1540-8159.1988.tb06025.x; LAU CP, 1992, PACE, V15, P1177, DOI 10.1111/j.1540-8159.1992.tb03121.x; LAU CP, 1989, AM J CARDIOL, V63, P833, DOI 10.1016/0002-9149(89)90052-0; LAU CP, 1993, RATE ADAPTIVE PACING, P199; LAU CP, 1993, RATE ADAPTIVE CARDIA, P213; LAU CP, 1993, RATE ADAPTIVE CARDIA, P437; LEWALTER T, 1993, PACE, V16, P852; LINDEEDELSTAM C, 1992, PACE, V15, P1467, DOI 10.1111/j.1540-8159.1992.tb02920.x; LINDEMANS FW, 1986, PACE, V9, P978, DOI 10.1111/j.1540-8159.1986.tb06657.x; MACCARTER DJ, 1991, COMPUTERIZED CARDIOPULMONARY EXERCISE TESTING, P131; MCELROY PA, 1988, J AM COLL CARDIOL, V11, P94, DOI 10.1016/0735-1097(88)90172-6; MIANULLI M, 1993, PACE, V16, P873; MIANULLI M, 1993, PACE, V16, P926; MIANULLI MJ, 1993, RATE ADAPTIVE PACING, P43; NATHAN DA, 1963, AM J CARDIOL, V11, P362, DOI 10.1016/0002-9149(63)90130-9; NORDLANDER R, 1989, PACE, V12, P917, DOI 10.1111/j.1540-8159.1989.tb05028.x; OLDROYD KG, 1991, BRIT HEART J, V65, P188; PAUL V, 1989, PACE, V12, P1896, DOI 10.1111/j.1540-8159.1989.tb01882.x; RICKARDS AF, 1983, CLIN PROG PACING ELE, V1, P12; RICKARDS AF, 1992, EUR J CARDIAC PACING, V2, P23; ROSENQVIST M, 1986, AM HEART J, V111, P292, DOI 10.1016/0002-8703(86)90142-0; ROSSI P, 1984, PACE, V7, P1246, DOI 10.1111/j.1540-8159.1984.tb05691.x; RYDEN L, 1988, PACE, V11, P1051, DOI 10.1111/j.1540-8159.1988.tb03951.x; SANTINI M, 1990, AM J CARDIOL, V65, P729, DOI 10.1016/0002-9149(90)91379-K; SELLERS TD, 1987, PACE, V10, P467, DOI 10.1111/j.1540-8159.1987.tb04508.x; SENDEN PJ, 1990, PACE, V13, P1209; SIETSEMA KE, 1989, J APPL PHYSIOL, V67, P2535, DOI 10.1152/jappl.1989.67.6.2535; SINGER I, 1993, RATE ADAPTIVE PACING, P321; STANGL K, 1988, PACE, V11, P712, DOI 10.1111/j.1540-8159.1988.tb06021.x; STANGL K, 1988, PACE, V11, P1882, DOI 10.1111/j.1540-8159.1988.tb06324.x; STANGL K, 1990, PACE, V13, P2080, DOI 10.1111/j.1540-8159.1990.tb06946.x; SUGIURA T, 1991, J MED ENG TECHNOL, V15, P107, DOI 10.3109/03091909109016207; SUTTON R, 1980, PACE, V3, P207, DOI 10.1111/j.1540-8159.1980.tb04331.x; SUTTON R, 1990, PACE, V13, P1823, DOI 10.1111/j.1540-8159.1990.tb06897.x; VOGT P, 1988, PACE, V2, P1896; WHIPP BJ, 1972, J APPL PHYSIOL, V33, P351, DOI 10.1152/jappl.1972.33.3.351; Wilkoff BL, 1989, J ELECTROPHYSIOL, V3, P176, DOI DOI 10.1111/J.1540-8167.1989.TB01549.X; WIRTZFELD A, 1984, PACE, V7, P1257, DOI 10.1111/j.1540-8159.1984.tb05692.x; ZANINI R, 1990, PACE, V13, P2076, DOI 10.1111/j.1540-8159.1990.tb06945.x	85	12	12	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1994	121	12					960	968		10.7326/0003-4819-121-12-199412150-00010	http://dx.doi.org/10.7326/0003-4819-121-12-199412150-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW083	7978723				2022-12-28	WOS:A1994PW08300010
J	BATTISTUTTA, D; PALMER, J; WALTERS, M; WALKER, G; NANCARROW, D; HAYWARD, N				BATTISTUTTA, D; PALMER, J; WALTERS, M; WALKER, G; NANCARROW, D; HAYWARD, N			INCIDENCE OF FAMILIAL MELANOMA AND MLM2 GENE	LANCET			English	Note							INCREASING INCIDENCE; LINKAGE; LOCUS	The overall incidence of melanoma is increasing world wide. We investigated whether there has been an increase in familial melanoma by studying age at onset among different birth cohorts in 18 melanoma kindreds linked to a predisposition gene (MLM2) on chromosome 9. The cumulative incidence of melanoma was 21-fold higher (95% CI 5.2-84.6) among subjects born after 1959 than in those born before 1900. The expected age of onset of the group born after 1959 was 24 years earlier (21.0 vs 45.0 years). These data support the notion that phenotypic penetrance of the MLM2 gene is increasing, presumably as a result of the interaction of sunlight exposure and mutation at this locus.	QUEENSLAND INST MED RES,HERSTON,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute			hayward, nicholas k/C-1367-2015; hayward, nick/AAV-8802-2020	hayward, nicholas k/0000-0003-4760-1033; 				CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P489; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; GRUIS NA, 1993, MELANOMA RES, V3, P271; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; NAROD S, 1993, LANCET, V341, P1101, DOI 10.1016/0140-6736(93)92468-9; RING IT, 1989, T MENZIES F, V15, P157; WALKER GJ, 1994, ONCOGENE, V9, P819; WLKER GJ, 1993, MELANOMA RES, V4, P29	10	17	17	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1607	1608		10.1016/S0140-6736(94)90408-1	http://dx.doi.org/10.1016/S0140-6736(94)90408-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983995				2022-12-28	WOS:A1994PW05100011
J	LANGERMANN, S; PALASZYNSKI, S; SADZIENE, A; STOVER, CK; KOENIG, S				LANGERMANN, S; PALASZYNSKI, S; SADZIENE, A; STOVER, CK; KOENIG, S			SYSTEMIC AND MUCOSAL IMMUNITY INDUCED BY BCG VECTOR EXPRESSING OUTER-SURFACE PROTEIN-A OF BORRELIA-BURGDORFERI	NATURE			English	Article							ANTIBODY-SECRETING CELLS; ORAL IMMUNIZATION; CHOLERA-TOXIN; OSPA; MICE; ENUMERATION; VACCINE	THE bacillus Calmette-Guerin (BCG) is a live attenuated strain of Mycobacterium bovis which offers potential advantages as a vector for mucosal delivery of antigens(1-3). Recombinant BCG elicits protective humoral immune responses to a variety of antigens(4). Furthermore, BCG binds specifically to microfold cells(5) present in the epithelium overlying lymphoid follicles throughout the mucosal immune system(6-8). Here we show that a single intranasal vaccination with recombinant BCG expressing the outersurface protein A antigen from B. burgdorferi(9) results in a prolonged (more than one year) protective systemic IgG response and a highly sustained secretory IgA response which is disseminated throughout the mucosal immune system. Furthermore, intranasal immunization induces marked, organized lymphocyte accumulation in the proximal nasopharyngeal lymphoid tissue as well as at distal mucosal sites; the appearance and persistence of lymphoid aggregates correlates with the secretory immune responses. Thus intranasal immunization with recombinant BCG is a powerful method for inducing long-lasting secretory and systemic immune responses.	UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	LANGERMANN, S (corresponding author), MEDIMMUNE INC, GAITHERSBURG, MD 20878 USA.			Stover, Charles/0000-0002-7406-1696				ABRAHAM E, 1992, J IMMUNOL, V149, P3719; BERGSTROM S, 1989, MOL MICROBIOL, V3, P479, DOI 10.1111/j.1365-2958.1989.tb00194.x; CZERKINSKY C, 1987, P NATL ACAD SCI USA, V84, P2449, DOI 10.1073/pnas.84.8.2449; CZERKINSKY CC, 1983, J IMMUNOL METHODS, V65, P109, DOI 10.1016/0022-1759(83)90308-3; FIKRIG E, 1990, SCIENCE, V250, P553, DOI 10.1126/science.2237407; FUHRMAN JA, 1981, J EXP MED, V153, P534, DOI 10.1084/jem.153.3.534; FUJIMURA Y, 1986, Gastroenterologia Japonica, V21, P325; HANEBERG B, 1994, INFECT IMMUN, V62, P15, DOI 10.1128/IAI.62.1.15-23.1994; JACOBS WR, 1990, CURR TOP MICROBIOL, V155, P153; JACOBS WR, 1987, NATURE, V327, P532, DOI 10.1038/327532a0; KUPER CF, 1992, IMMUNOL TODAY, V13, P219; LANGERMANN S, 1993, CURR OPIN GASTROEN, V8, P983; MCDERMOTT MR, 1979, J IMMUNOL, V122, P1892; Neutra M R, 1992, Trends Cell Biol, V2, P134, DOI 10.1016/0962-8924(92)90099-9; OHAGAN DT, 1993, VACCINE, V11, P149, DOI 10.1016/0264-410X(93)90011-L; QULDING M, 1991, J CLIN INVEST, V88, P143; SADZIENE A, 1993, J INFECT DIS, V167, P165, DOI 10.1093/infdis/167.1.165; SCHWAN TG, 1988, J CLIN MICROBIOL, V26, P893, DOI 10.1128/JCM.26.5.893-895.1988; SEDGWICK JD, 1983, J IMMUNOL METHODS, V57, P301, DOI 10.1016/0022-1759(83)90091-1; SIMON MM, 1991, J INFECT DIS, V164, P123, DOI 10.1093/infdis/164.1.123; STOVER CK, 1993, J EXP MED, V178, P197, DOI 10.1084/jem.178.1.197; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; STOVER CK, 1994, RECOMBINANT VECTORS, P153; TRIER JS, 1991, GASTROENTEROL CLIN N, V20, P531; VAJDY M, 1992, IMMUNOLOGY, V75, P488; Young J T, 1981, Fundam Appl Toxicol, V1, P309, DOI 10.1016/S0272-0590(81)80037-1	26	143	153	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 8	1994	372	6506					552	555		10.1038/372552a0	http://dx.doi.org/10.1038/372552a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990928	Bronze			2022-12-28	WOS:A1994PW08200053
J	SPUDICH, JA				SPUDICH, JA			MOW MOLECULAR MOTORS WORK	NATURE			English	Article							MYOSIN HEAVY-CHAIN; ACTIN FILAMENT; MUSCULAR-CONTRACTION; MUSCLE-CONTRACTION; SLIDING DISTANCE; ATOMIC MODEL; STEP SIZE; INVITRO; MOVEMENT; ACTOMYOSIN	What is the molecular basis of cell movement and changes in cell shape? The integration of three approaches is revealing how the molecular motors that drive these processes move and produce force.	STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University	SPUDICH, JA (corresponding author), STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305, USA.							BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; Cooke R, 1990, CURR OPIN CELL BIOL, V2, P62, DOI 10.1016/S0955-0674(05)80032-8; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P659, DOI 10.1073/pnas.90.2.659; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343; HIBBERD MG, 1986, ANNU REV BIOPHYS BIO, V15, P119; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HOLMES KC, 1993, ADV EXP MED BIOL, V332, P15; HUXLEY AF, 1974, J PHYSIOL-LONDON, V243, P1; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; HUXLEY HUGH E., 1966, HARVEY LECT, V60, P85; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; KIEHART DP, 1989, EMBO J, V8, P913, DOI 10.1002/j.1460-2075.1989.tb03452.x; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; Korn ED, 1990, CURR OPIN CELL BIOL, V2, P57, DOI 10.1016/S0955-0674(05)80031-6; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MA YZ, 1994, BIOPHYS J, V66, P1542, DOI 10.1016/S0006-3495(94)80945-2; MABUCHI I, 1977, J CELL BIOL, V74, P251, DOI 10.1083/jcb.74.1.251; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; SADHU A, 1992, J BIOL CHEM, V267, P11352; SAITO K, 1994, BIOPHYS J, V66, P769, DOI 10.1016/S0006-3495(94)80853-7; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SHEETZ MP, 1983, NATURE, V303, P31, DOI 10.1038/303031a0; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SPUDICH JA, 1989, CELL REGUL, V1, P1; SPUDICH JA, 1985, NATURE, V315, P584, DOI 10.1038/315584a0; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1992, TRENDS BIOCHEM SCI, V17, P300, DOI 10.1016/0968-0004(92)90440-K; VALLEE RB, 1988, NATURE, V332, P561, DOI 10.1038/332561a0; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0	59	413	426	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					515	518		10.1038/372515a0	http://dx.doi.org/10.1038/372515a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990922				2022-12-28	WOS:A1994PW08200042
J	ZHANG, YY; PROENCA, R; MAFFEI, M; BARONE, M; LEOPOLD, L; FRIEDMAN, JM				ZHANG, YY; PROENCA, R; MAFFEI, M; BARONE, M; LEOPOLD, L; FRIEDMAN, JM			POSITIONAL CLONING OF THE MOUSE OBESE GENE AND ITS HUMAN HOMOLOG	NATURE			English	Article							ARTIFICIAL-CHROMOSOME LIBRARIES; POLYMERASE CHAIN-REACTION; DNA FRAGMENTS; MESSENGER-RNA; OB MUTATION; YEAST; IDENTIFICATION; MICE	The mechanisms that balance food intake and energy expenditure determine who will be obese and who will be lean. One of the molecules that regulates energy balance in the mouse is the obese (ob) gene. Mutation of ob results in profound obesity and type II diabetes as part of a syndrome that resembles morbid obesity in humans. The ob gene product may function as part of a signalling pathway from adipose tissue that acts to regulate the size of the body fat depot.	HOWARD HUGHES MED INST,NEW YORK,NY 10021; ROCKEFELLER UNIV,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University								ADOLPH EF, 1947, AM J PHYSIOL, V151, P110, DOI 10.1152/ajplegacy.1947.151.1.110; BAHARY N, 1990, P NATL ACAD SCI USA, V87, P8642, DOI 10.1073/pnas.87.21.8642; BAHARY N, 1993, MAMM GENOME, V4, P511, DOI 10.1007/BF00364786; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRAY GA, 1990, INT J OBESITY, V14, P909; BRAY GA, 1991, J NUTR, V121, P1146, DOI 10.1093/jn/121.8.1146; BROBECK JR, 1948, YALE J BIOL MED, V20, P545; BRUBECK JR, 1946, PHYSIOL REV, V25, P541; BURMEISTER M, 1989, TRENDS GENET, V5, P41, DOI 10.1016/0168-9525(89)90019-X; BURROS M, 1994, NY TIMES        0717; Cannon WB, 1912, AM J PHYSIOL, V29, P441, DOI 10.1152/ajplegacy.1912.29.5.441; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; COLEMAN DL, 1979, SCIENCE, V203, P663, DOI 10.1126/science.760211; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Dickie M. M., 1957, MOUSE NEWS LETT, V17, P52; DIETRICH W, 1992, GENETICS, V131, P423; FRIEDMAN JM, 1991, GENOMICS, V11, P1054, DOI 10.1016/0888-7543(91)90032-A; FRIEDMAN JM, 1984, J MOL BIOL, V179, P37, DOI 10.1016/0022-2836(84)90305-X; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GRUNDY SM, 1990, DM-DIS MON, V36, P645; HARTI DL, 1993, BIOTECHNIQUES, V15, P201; HEIJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; HERMANSON GG, 1991, NUCLEIC ACIDS RES, V19, P4943, DOI 10.1093/nar/19.18.4943; HERVEY GR, 1959, J PHYSIOL-LONDON, V145, P336, DOI 10.1113/jphysiol.1959.sp006145; HERVEY GR, 1969, NATURE, V222, P629, DOI 10.1038/222629a0; Hetherington AW, 1942, AM J PHYSIOL, V136, P609, DOI 10.1152/ajplegacy.1942.136.4.609; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; KENNEDY GC, 1953, PROC R SOC SER B-BIO, V140, P578, DOI 10.1098/rspb.1953.0009; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; MAYER J, 1955, ANN NY ACAD SCI, V63, P15, DOI 10.1111/j.1749-6632.1955.tb36543.x; NEEL JV, 1962, AM J HUM GENET, V14, P353; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Rubner M., 1894, Z BIOL, V30, P73; SABATINI D, 1989, METABOLIC BASIS INHE, P177; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STERNBERG NL, 1992, TRENDS GENET, V8, P11, DOI 10.1016/0168-9525(92)90018-Y; VENTER CJ, 1993, AUTOMATED DNA SEQUEN; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; YU YH, 1989, P NATL ACAD SCI USA, V86, P9931, DOI 10.1073/pnas.86.24.9931	49	10612	11489	33	1122	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					425	432		10.1038/372425a0	http://dx.doi.org/10.1038/372425a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984236				2022-12-28	WOS:A1994PV01200046
J	HENDERSON, CE; PHILLIPS, HS; POLLOCK, RA; DAVIES, AM; LEMEULLE, C; ARMANINI, M; SIMPSON, LC; MOFFET, B; VANDLEN, RA; KOLIATSOS, VE; ROSENTHAL, A				HENDERSON, CE; PHILLIPS, HS; POLLOCK, RA; DAVIES, AM; LEMEULLE, C; ARMANINI, M; SIMPSON, LC; MOFFET, B; VANDLEN, RA; KOLIATSOS, VE; ROSENTHAL, A			GDNF - A POTENT SURVIVAL FACTOR FOR MOTONEURONS PRESENT IN PERIPHERAL-NERVE AND MUSCLE	SCIENCE			English	Article							NEUROTROPHIC FACTOR; EMBRYONIC MOTONEURONS; MOTOR NEURONS; SCHWANN-CELLS; EXPRESSION; DEATH; RAT; INVITRO; INVIVO; CHICK	For survival, embryonic motoneurons in vertebrates depend on as yet undefined neurotrophic factors present in the limb bud. Members of the neurotrophin family are currently the best candidates for such neurotrophic factors, but inactivation of their receptor genes leads to only partial loss of motoneurons, which suggests that other factors are involved. Glial cell line-derived neurotrophic factor (GDNF), originally identified as a trophic factor specific for dopaminergic neurons, was found to be 75-fold more potent than the neurotrophins in supporting the survival of purified embryonic rat motoneurons in culture. GDNF messenger RNA was found in the immediate vicinity of motoneurons during the period of cell death in development. In vivo, GDNF rescues and prevents the atrophy of facial motoneurons that have been deprived of target-derived survival factors by axotomy. GDNF may therefore be a physiological trophic factor for spinal motoneurons. Its potency and specificity in vitro and in vivo also make it a good candidate for treatment of motoneuron disease.	GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080; IBDM,INSERM,U382,F-13288 MARSEILLE 9,FRANCE; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; SCH BIOL & MED SCI ST ANDREWS,ST ANDREWS,FIFE,SCOTLAND; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL NEUROL & NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,NEUROPATHOL LAB,BALTIMORE,MD 21205	Roche Holding; Genentech; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Roche Holding; Genentech; Roche Holding; Genentech; University of St Andrews; Johns Hopkins University; Johns Hopkins University			Davies, Alun M/A-4334-2010	Davies, Alun M/0000-0001-5841-8176; Henderson, Christopher/0000-0002-9936-3279	NINDS NIH HHS [NS 10580] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CAMU W, 1993, NEUROPROTOCOLS, V2, P191; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; ERNFORS P, 1988, NEURON, V1, P983, DOI 10.1016/0896-6273(88)90155-9; HALLER FR, 1971, AM J ANAT, V131, P1, DOI 10.1002/aja.1001310102; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HENDERSON CE, 1993, RESTOR NEUROL NEUROS, V5, P15, DOI 10.3233/RNN-1993-5105; JENSEN EBV, 1993, J MICROSC-OXFORD, V170, P35, DOI 10.1111/j.1365-2818.1993.tb03321.x; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; JONES GE, 1990, J CELL SCI, V97, P659; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; KOLIATSOS VE, 1994, J COMP NEUROL, V342, P35, DOI 10.1002/cne.903420105; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1989, TRENDS NEUROSCI, V12, P252, DOI 10.1016/0166-2236(89)90021-0; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; POULSEN KT, IN PRESS NEURON; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; STROMBERG I, 1993, EXP NEUROL, V124, P401, DOI 10.1006/exnr.1993.1214; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YANSURA DG, 1990, METHOD ENZYMOL, V185, P54	29	1119	1210	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1062	1064		10.1126/science.7973664	http://dx.doi.org/10.1126/science.7973664			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973664				2022-12-28	WOS:A1994PQ92400051
J	SPERRYN, PN				SPERRYN, PN			OVERUSE INJURY IN SPORT	BRITISH MEDICAL JOURNAL			English	Article									HILLINGDON HOSP,UXBRIDGE,MIDDX,ENGLAND		SPERRYN, PN (corresponding author), NEW VICTORIA HOSP,KINGSTON,SURREY,ENGLAND.								0	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1994	308	6941					1430	1432		10.1136/bmj.308.6941.1430	http://dx.doi.org/10.1136/bmj.308.6941.1430			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	7993419	Green Published			2022-12-28	WOS:A1994NP42000029
J	KLEYMAN, TR; ROBERTS, C; LING, BN				KLEYMAN, TR; ROBERTS, C; LING, BN			A MECHANISM FOR PENTAMIDINE-INDUCED HYPERKALEMIA - INHIBITION OF DISTAL NEPHRON SODIUM-TRANSPORT	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERKALEMIA; PENTAMIDINE; ACQUIRED IMMUNODEFICIENCY SYNDROME; ION TRANSPORT; POTASSIUM	PNEUMOCYSTIS-CARINII PNEUMONIA; CORTICAL COLLECTING TUBULE; POTASSIUM CHANNELS; PRIMARY CULTURES; THERAPY; AIDS	Objectives: To determine whether pentamidine directly affects the transport of renal ions and thus provides a mechanism for hyperkalemia, which develops in as many as 100% of patients with the acquired immunodeficiency syndrome (AIDS) who receive pentamidine for more than 6 days. Design: Transepithelial and single-channel electrical measurements were made on two models of distal-nephron ion transport: an amphibian distal-nephron cell line (A6) and primary cultures of rabbit cortical collecting tubules. Results: Luminal bath application of pentamidine to A6 monolayers inhibited the amiloride-sensitive, short-circuit current with a 50% inhibitory concentration of 700 mu M (five experiments). In the principal cell apical membranes of cortical collecting tubule primary cultures, amiloride-sensitive, 4-picosiemen Na+ channels in cell-attached patches were also identified. When the luminal membrane was directly exposed to 1.0 mu M of pentamidine in the patch pipette solution, channel activity decreased by 40% (11 experiments). Channel inhibition rapidly reversed with washout of intrapipette pentamidine (four experiments). In contrast, replacement of either the luminal bath outside the patch pipette (four experiments) or the serosal bath (five experiments) with pentamidine did not significantly affect Na+ channel activity in the patches. Conclusions: Luminal or ''urinary'' pentamidine inhibits distal nephron reabsorption of Na+ by blocking apical Na+ channels in a manner similar to ''potassium-sparing'' diuretics (for example, amiloride and triamterene). This results in a decrease in the electrochemical gradients that drive secretion of distal nephron K+. Because pentamidine is eliminated through urinary excretion, this renal tubular effect provides a mechanism for pentamidine-induced hyperkalemia.	EMORY UNIV, SCH MED, DIV RENAL, ATLANTA, GA 30322 USA; UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA; DEPT VET AFFAIRS MED CTR, PHILADELPHIA, PA 19104 USA; VET AFFAIRS MED CTR, ATLANTA, GA 30033 USA	Emory University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002111] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08-DK02111] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNS JS, 1991, J AM SOC NEPHROL, V1, P1061; BUFF DD, 1990, AM J MED, V88, P552, DOI 10.1016/0002-9343(90)90446-K; CHOI MJ, 1993, NEW ENGL J MED, V328, P703, DOI 10.1056/NEJM199303113281006; CONTE JE, 1987, J INFECT DIS, V156, P885, DOI 10.1093/infdis/156.6.885; DEVITA VT, 1969, NEW ENGL J MED, V280, P287, DOI 10.1056/NEJM196902062800602; EATON DC, 1988, ION CHANNELS, P251; EATON DC, 1994, IN PRESS KIDNEY INT; KLEYMAN TR, 1988, SEMIN NEPHROL, V8, P242; LACHAAL M, 1989, AM J MED, V87, P260, DOI 10.1016/S0002-9343(89)80147-0; LANG F, 1992, PHYSIOL REV, V72, P1, DOI 10.1152/physrev.1992.72.1.1; LING BN, 1991, AM J PHYSIOL, V261, pF933, DOI 10.1152/ajprenal.1991.261.6.F933; LING BN, 1991, KIDNEY INT, V40, P441, DOI 10.1038/ki.1991.231; MARINO PL, 1990, AM J MED, V89, P397, DOI 10.1016/0002-9343(90)90364-J; PELTZ S, 1989, AM J MED, V87, P698, DOI 10.1016/S0002-9343(89)80411-5; PONCE SP, 1985, MEDICINE, V64, P357, DOI 10.1097/00005792-198511000-00001; SANDS M, 1985, REV INFECT DIS, V7, P625; SCHLANGER LE, 1994, KIDNEY INT, V45, P1070, DOI 10.1038/ki.1994.143; Schlanger Lynn E., 1993, Journal of the American Society of Nephrology, V4, P878; SMALDONE GC, 1991, CHEST, V100, P1219, DOI 10.1378/chest.100.5.1219; WALZER PD, 1974, ANN INTERN MED, V80, P83, DOI 10.7326/0003-4819-80-1-83; WANG WH, 1992, ANNU REV PHYSIOL, V54, P81; WESTERN KA, 1970, ANN INTERN MED, V73, P695, DOI 10.7326/0003-4819-73-5-695	22	53	54	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					103	106		10.7326/0003-4819-122-2-199501150-00004	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7992983				2022-12-28	WOS:A1995QC05900004
J	FRANCOMANO, CA				FRANCOMANO, CA			THE GENETIC-BASIS OF DWARFISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; FIBROBLAST				FRANCOMANO, CA (corresponding author), NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892, USA.			Francomano, Clair/0000-0002-4032-7425				FRANCOMANO CA, 1994, HUM MOL GENET, V3, P787, DOI 10.1093/hmg/3.5.787; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; IWAMOTO M, 1991, J BIOL CHEM, V266, P461; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KOEBERL DD, 1990, AM J HUM GENET, V47, P202; LEMERRER M, 1994, NAT GENET, V6, P318; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; VELINOV M, 1994, NAT GENET, V6, P314, DOI 10.1038/ng0394-314	10	33	34	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					58	59		10.1056/NEJM199501053320113	http://dx.doi.org/10.1056/NEJM199501053320113			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990869				2022-12-28	WOS:A1995PZ49700013
J	FRIEDMAN, E				FRIEDMAN, E			COPING WITH CALAMITY - HOW WELL DOES HEALTH-CARE DISASTER PLANNING WORK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1990, HOSPITAL EARTHQUAKE; 1905, PRINCIPLES MED ETHIC; 1994, 1994 ACCREDITATION M, V2, P14	3	15	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1875	1879		10.1001/jama.272.23.1875	http://dx.doi.org/10.1001/jama.272.23.1875			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PW980	7990224				2022-12-28	WOS:A1994PW98000039
J	ROBINSON, CV; GROSS, M; EYLES, SJ; EWBANK, JJ; MAYHEW, M; HARTL, FU; DOBSON, CM; RADFORD, SE				ROBINSON, CV; GROSS, M; EYLES, SJ; EWBANK, JJ; MAYHEW, M; HARTL, FU; DOBSON, CM; RADFORD, SE			CONFORMATION OF GROEL-BOUND ALPHA-LACTALBUMIN PROBED BY MASS-SPECTROMETRY	NATURE			English	Article							MOLTEN GLOBULE STATE; GROUP HYDROGEN-EXCHANGE; EGG-WHITE LYSOZYME; STRUCTURAL CHARACTERIZATION; 2-DIMENSIONAL NMR; CHAPERONIN GROEL; 1.7-A RESOLUTION; CENTRAL CAVITY; HEN LYSOZYME; PROTEIN	The conformation of a three-disulphide derivative of bovine alpha-lactalbumin bound to the molecular chaperone GroEL has been investigated by monitoring directly its hydrogen exchange kinetics using electrospray ionization mass spectrometry. The bound protein is weakly protected from exchange to an extent closely similar to that of an uncomplexed molten globule state of the three-disulphide protein. Binding to GroEL in this system appears to involve relatively disordered partly folded states resembling intermediates formed in the very early stages of kinetic folding of many proteins in vitro.	UNIV OXFORD,OXFORD CTR MOLEC SCI,NEW CHEM LAB,OXFORD OX1 3QT,ENGLAND; UNIV OXFORD,OXFORD CTR MOLEC SCI,DYSON PERRINS LAB,OXFORD OX1 3QT,ENGLAND; EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	University of Oxford; University of Oxford; European Molecular Biology Laboratory (EMBL); Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Eyles, Stephen/F-4077-2010; Hartl, F. Ulrich/Y-8206-2019; Ewbank, Jonathan J/G-4948-2010	Ewbank, Jonathan J/0000-0002-1257-6862; robinson, carol/0000-0001-7829-5505; Eyles, Stephen/0000-0003-0451-2903; Radford, Sheena/0000-0002-3079-8039				ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; ACHARYA KR, 1991, J MOL BIOL, V221, P571; ALEXANDRESCU AT, 1993, BIOCHEMISTRY-US, V32, P1707, DOI 10.1021/bi00058a003; ARAMINI JM, 1992, BIOCHEMISTRY-US, V31, P6761, DOI 10.1021/bi00144a016; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCK M, 1994, J MOL BIOL, V237, P247, DOI 10.1006/jmbi.1994.1228; Bychkova V. E., 1993, CHEMTRACTS BIOCH MOL, V4, P133; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHOWDHURY SK, 1990, J AM CHEM SOC, V112, P9012, DOI 10.1021/ja00180a074; CHYAN CL, 1993, BIOCHEMISTRY-US, V32, P5681, DOI 10.1021/bi00072a025; CONNELLY GP, 1993, PROTEINS, V17, P87, DOI 10.1002/prot.340170111; CREIGHTON TE, 1992, BIOCHEMISTRY-US, V31, P12695; DOBSON CM, 1994, TRENDS BIOCHEM SCI, V19, P31, DOI 10.1016/0968-0004(94)90171-6; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.biophys.21.1.243; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3694, DOI 10.1021/bi00065a023; EYLES SJ, 1994, BIOCHEMISTRY-US, V333, P1534; FLYNN GC, 1993, P NATL ACAD SCI USA, V90, P10826, DOI 10.1073/pnas.90.22.10826; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; IKEGUCHI M, 1992, BIOCHEMISTRY-US, V31, P12695, DOI 10.1021/bi00165a021; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; JENG MF, 1991, J MOL BIOL, V221, P1045, DOI 10.1016/0022-2836(91)80191-V; KRONMAN MJ, 1989, CRIT REV BIOCHEM MOL, V24, P565, DOI 10.3109/10409238909080054; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LIGHTWAHL KJ, 1993, J AM CHEM SOC, V115, P5869, DOI 10.1021/ja00066a083; LISSIN NM, 1993, FEBS LETT, V324, P41, DOI 10.1016/0014-5793(93)81528-8; LOO JA, 1991, RAPID COMMUN MASS SP, V5, P101, DOI 10.1002/rcm.1290050303; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MIRANKER A, 1993, SCIENCE, V262, P896, DOI 10.1126/science.8235611; OKAZAKI A, 1994, NAT STRUCT BIOL, V1, P439, DOI 10.1038/nsb0794-439; PEDERSEN TG, 1993, J MOL BIOL, V230, P651, DOI 10.1006/jmbi.1993.1176; RADFORD SE, 1992, PROTEINS, V14, P237, DOI 10.1002/prot.340140210; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; RADFORD SE, 1991, BIOCHEM J, V273, P211, DOI 10.1042/bj2730211; RICHARME G, 1994, J BIOL CHEM, V269, P7095; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SHEWALE JG, 1984, J BIOL CHEM, V259, P4947; SMITH RD, 1990, ANAL CHEM, V62, P882, DOI 10.1021/ac00208a002; WANG M, 1989, J BIOL CHEM, V264, P21116; WOODWARD CK, 1994, CURR OPIN STRUC BIOL, V4, P112, DOI 10.1016/S0959-440X(94)90068-X; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0	51	202	202	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					646	651		10.1038/372646a0	http://dx.doi.org/10.1038/372646a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990955				2022-12-28	WOS:A1994PX30700077
J	TYCOWSKI, KT; SHU, MD; STEITZ, JA				TYCOWSKI, KT; SHU, MD; STEITZ, JA			REQUIREMENT FOR INTRON-ENCODED U22 SMALL NUCLEOLAR RNA IN 18S RIBOSOMAL-RNA MATURATION	SCIENCE			English	Article							EXTERNAL TRANSCRIBED SPACER; SMALL NUCLEAR-RNA; SACCHAROMYCES-CEREVISIAE; PRERIBOSOMAL RNA; PRE-RRNA; YEAST; U3; CLEAVAGE; DISRUPTION; PRECURSOR	The nucleoli of vertebrate cells contain a number of small RNAs that are generated by the processing of intron fragments of protein-coding gene transcripts. The host gene (UHG) for intron-encoded human U22 is unusual in that it specifies a polyadenylated but apparently noncoding RNA. Depletion of U22 from Xenopus oocytes by oligonucleotide-directed ribonuclease H targeting prevented the processing of 18S ribosomal RNA (rRNA) at both ends. The appearance of 18S rRNA was restored by injection of in vitro-synthesized U22 RNA. These results identify a cellular function for an intronencoded small RNA.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06536	Howard Hughes Medical Institute; Yale University					NIGMS NIH HHS [GM26154] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026154, R37GM026154] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; BELTRAME M, 1992, EMBO J, V11, P1531, DOI 10.1002/j.1460-2075.1992.tb05198.x; BOWMAN LH, 1983, MOL CELL BIOL, V3, P1501, DOI 10.1128/MCB.3.8.1501; CHU S, 1994, P NATL ACAD SCI USA, V91, P659, DOI 10.1073/pnas.91.2.659; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; FILIPOWICZ W, 1993, MOL BIOL REP, V18, P149, DOI 10.1007/BF00986770; FOURNIER MJ, 1993, TRENDS BIOCHEM SCI, V18, P131, DOI 10.1016/0968-0004(93)90020-N; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; Hadjiolov AA, 1985, NUCLEOLUS RIBOSOME B; HADJIOLOVA KV, 1993, EUR J BIOCHEM, V212, P211, DOI 10.1111/j.1432-1033.1993.tb17652.x; HADJIOLOVA KV, 1984, BIOCHIM BIOPHYS ACTA, V782, P195, DOI 10.1016/0167-4781(84)90024-1; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/j.1460-2075.1994.tb06530.x; HOGAN NC, 1994, J CELL BIOL, V125, P21, DOI 10.1083/jcb.125.1.21; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; JENSEN R, 1993, EMBO J, V12, P2549; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; MASER RL, 1989, P NATL ACAD SCI USA, V86, P6523, DOI 10.1073/pnas.86.17.6523; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; MOUGEY EB, 1993, MOL CELL BIOL, V13, P5990, DOI 10.1128/MCB.13.10.5990; PARKER KA, 1987, MOL CELL BIOL, V7, P2899, DOI 10.1128/MCB.7.8.2899; PECULIS BA, 1994, GENE DEV, V8, P2241, DOI 10.1101/gad.8.18.2241; PECULIS BA, 1993, CELL, V73, P1233, DOI 10.1016/0092-8674(93)90651-6; PFEIFER K, 1994, GENE DEV, V8, P1867, DOI 10.1101/gad.8.16.1867; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; PRIVES C, 1991, METHOD CELL BIOL, V36, P185; Sambrook J, 1989, MOL CLONING LABORATO; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; SCHMITT ME, 1993, MOL CELL BIOL, V13, P7935, DOI 10.1128/MCB.13.12.7935; SOLLNERWEBB B, 1993, CELL, V75, P403, DOI 10.1016/0092-8674(93)90374-Y; SOLLNERWEBB B, IN PRESS RIBOSOMAL R; STROKE IL, 1989, J MOL BIOL, V210, P497, DOI 10.1016/0022-2836(89)90126-5; TOLLERVEY D, 1985, EMBO J, V4, P3873, DOI 10.1002/j.1460-2075.1985.tb04160.x; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; TYCOWSKI KT, 1993, GENE DEV, V7, P1176, DOI 10.1101/gad.7.7a.1176; TYCOWSKI KT, UNPUB; WELLAUER PK, 1974, J MOL BIOL, V89, P379, DOI 10.1016/0022-2836(74)90526-9	41	132	134	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1558	1561		10.1126/science.7985025	http://dx.doi.org/10.1126/science.7985025			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985025				2022-12-28	WOS:A1994PV01500043
J	KISELEV, A; SUBRAMANIAM, S				KISELEV, A; SUBRAMANIAM, S			ACTIVATION AND REGENERATION OF RHODOPSIN IN THE INSECT VISUAL CYCLE	SCIENCE			English	Article							INVERTEBRATE PHOTORECEPTORS; ARRESTIN; PROTEIN; PIGMENT; MEMBRANES; PHOSPHORYLATION; TRANSDUCTION	Light absorption by rhodopsin generates metarhodopsin, which activates heterotrimeric guanine nucleotide-binding proteins (G proteins) in photoreceptor cells of vertebrates and invertebrates. In contrast to vertebrate metarhodopsins, most invertebrate metarhodopsins are thermally stable and regenerate rhodopsin by absorption of a second photon. In experiments with Rh1 Drosophila rhodopsin, the thermal stability of metarhodopsin was found not to be an intrinsic property of the visual pigment but a consequence of its interaction with arrestin (49 kilodaltons). The Stabilization of metarhodopsin resulted in a large decrease in the efficiency of G protein activation. Light absorption by thermally stable metarhodopsin initially regenerated an inactive rhodopsin-like intermediate, which was subsequently converted in the dark to active rhodopsin. The accumulation of inactive rhodopsin at higher light levels may represent a mechanism for gain regulation in the insect visual cycle.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University				Subramaniam, Sriram/0000-0003-4231-4115				BENTROP J, 1993, EUR J BIOCHEM, V216, P67, DOI 10.1111/j.1432-1033.1993.tb18117.x; BENTROP J, 1986, EUR J BIOCHEM, V161, P61, DOI 10.1111/j.1432-1033.1986.tb10124.x; BLUMENFELD A, 1985, P NATL ACAD SCI USA, V82, P7116, DOI 10.1073/pnas.82.20.7116; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; HAMDORF K, 1980, NATURE, V283, P859, DOI 10.1038/283859a0; HAMDORF K, 1977, BIOPHYS STRUCT MECH, V3, P163, DOI 10.1007/BF00535813; Hamdorf K., 1979, HDB SENSORY PHYSL, V7/6A, P145; HILLMAN P, 1983, PHYSIOL REV, V63, P668, DOI 10.1152/physrev.1983.63.2.668; HOFMANN KP, 1986, PHOTOBIOCH PHOTOBIOP, V13, P309; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; KISELEV AD, UNPUB; LEVINE E, 1987, J GEN PHYSIOL, V90, P575, DOI 10.1085/jgp.90.4.575; MATSUMOTO H, 1994, NEURON, V12, P997, DOI 10.1016/0896-6273(94)90309-3; OSTROY SE, 1978, J GEN PHYSIOL, V72, P717, DOI 10.1085/jgp.72.5.717; PAK WL, 1974, J GEN PHYSIOL, V63, P740, DOI 10.1085/jgp.63.6.740; PAK WL, 1991, PHOTOCHEM PHOTOBIOL, V53, P871, DOI 10.1111/j.1751-1097.1991.tb09901.x; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PAULSEN R, 1984, J COMP PHYSIOL, V155, P47, DOI 10.1007/BF00610930; RANGANATHAN R, 1991, TRENDS NEUROSCI, V14, P486, DOI 10.1016/0166-2236(91)90060-8; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; STRYER L, 1988, COLD SPRING HARB SYM, V53, P283, DOI 10.1101/SQB.1988.053.01.035; TANIMURA T, 1986, PHOTOCHEM PHOTOBIOL, V43, P225, DOI 10.1111/j.1751-1097.1986.tb09519.x; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174	26	46	47	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1369	1373		10.1126/science.7973725	http://dx.doi.org/10.1126/science.7973725			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973725				2022-12-28	WOS:A1994PT63200040
J	STEVENS, J				STEVENS, J			JAPAN PICKS A WINNER IN THE RICE GENOME PROJECT	SCIENCE			English	Editorial Material																			0	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1186	1187		10.1126/science.7973698	http://dx.doi.org/10.1126/science.7973698			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973698				2022-12-28	WOS:A1994PT13200037
J	WICKNER, WT				WICKNER, WT			HOW ATP DRIVES PROTEINS ACROSS MEMBRANES	SCIENCE			English	Editorial Material							SIGNAL SEQUENCE; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; TRANSLOCATION; YEAST; IMPORT; RECONSTITUTION; TRANSLATION; ELONGATION; RECEPTORS				WICKNER, WT (corresponding author), DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03755, USA.							AINGER KJ, 1986, EMBO J, V5, P951, DOI 10.1002/j.1460-2075.1986.tb04308.x; BLACHLYDYSON E, 1987, J CELL BIOL, V104, P1183, DOI 10.1083/jcb.104.5.1183; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FLOWER AM, 1994, J BACTERIOL, V176, P5607, DOI 10.1128/JB.176.18.5607-5614.1994; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HARMEY MA, 1976, GENETICS BIOGENESIS, P813; JOLY JC, 1994, P NATL ACAD SCI USA, V91, P4703, DOI 10.1073/pnas.91.11.4703; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KRONIDOU NG, IN PRESS P NATL ACAD; LILL R, 1990, CELL, V60, P259; MACCECCHINI ML, 1979, P NATL ACAD SCI USA, V76, P343, DOI 10.1073/pnas.76.1.343; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; RAPIEJKO PJ, 1994, MOL BIOL CELL, V5, P887, DOI 10.1091/mbc.5.8.887; RASSOW J, IN PRESS J CELL BIOL; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHNEIDER HC, IN PRESS NATURE; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; TOYN J, 1988, EMBO J, V7, P4347, DOI 10.1002/j.1460-2075.1988.tb03333.x; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0	31	50	50	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1197	1198		10.1126/science.7973701	http://dx.doi.org/10.1126/science.7973701			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973701				2022-12-28	WOS:A1994PT13200042
J	KREIL, G				KREIL, G			CONVERSION OF L-AMINO TO D-AMINO ACIDS - A POSTTRANSLATIONAL REACTION	SCIENCE			English	Editorial Material							OPIOID-PEPTIDES; ACHATINA-FULICA; SKIN; RESIDUE; NEUROPEPTIDE; DERMORPHIN; SEQUENCE				KREIL, G (corresponding author), AUSTRIAN ACAD SCI, INST MOLEC BIOL, BILLROTHSTR 11, A-5020 SALZBURG, AUSTRIA.							ERSPAMER V, 1992, INT J DEV NEUROSCI, V10, P3, DOI 10.1016/0736-5748(92)90003-I; GROSS E, 1971, J AM CHEM SOC, V93, P4634, DOI 10.1021/ja00747a073; HECK SD, 1994, SCIENCE, V266, P1065, DOI 10.1126/science.7973665; KALETTA C, 1991, EUR J BIOCHEM, V199, P411, DOI 10.1111/j.1432-1033.1991.tb16138.x; KAMATANI Y, 1990, FEBS LETT, V276, P95, DOI 10.1016/0014-5793(90)80516-L; KAMATANI Y, 1989, BIOCHEM BIOPH RES CO, V160, P1015, DOI 10.1016/S0006-291X(89)80103-2; KLEINKAUF H, 1969, P NATL ACAD SCI USA, V62, P226, DOI 10.1073/pnas.62.1.226; LAZARUS LH, 1993, PROG NEUROBIOL, V41, P473, DOI 10.1016/0301-0082(93)90027-P; LEE SG, 1977, P NATL ACAD SCI USA, V74, P2343, DOI 10.1073/pnas.74.6.2343; Lipmann F, 1941, J BIOL CHEM, V141, P163; MIGNOGNA G, 1993, EMBO J, V12, P4829, DOI 10.1002/j.1460-2075.1993.tb06172.x; MONTECUCCHI PC, 1981, INT J PEPT PROT RES, V17, P275; OHTA N, 1991, BIOCHEM BIOPH RES CO, V178, P486, DOI 10.1016/0006-291X(91)90133-R; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; SOYEZ D, 1994, J BIOL CHEM, V269, P18295; TANCREDI T, 1991, BIOPOLYMERS, V31, P751, DOI 10.1002/bip.360310620; TANNER ME, 1993, BIOCHEMISTRY-US, V32, P3998, DOI 10.1021/bi00066a021; YASUDA A, IN PRESS GEN COMP EN	18	63	63	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					996	997		10.1126/science.7973683	http://dx.doi.org/10.1126/science.7973683			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973683				2022-12-28	WOS:A1994PQ92400030
J	JOHNSTONE, RA				JOHNSTONE, RA			FEMALE PREFERENCE FOR SYMMETRICAL MALES AS A BY-PRODUCT OF SELECTION FOR MATE RECOGNITION	NATURE			English	Article							MALE SEXUAL ORNAMENTS; FLUCTUATING ASYMMETRY; EVOLUTION; PATTERNS; STRESS; BIASES	FLUCTUATING asymmetry (FA) refers to the random, stress-induced deviations from perfect symmetry that develop during the growth of bilaterally symmetrical traits(1,2). Individual differences in the level of FA may influence mate choice(3): in a number of species, females prefer to mate with males that have more symmetrical sexual ornaments(4-7). As the degree of FA has been shown to reflect the ability of individuals to cope with a wide variety of environmental stresses(2,8,9), it has been suggested that mating preferences for symmetry evolve for adaptive reasons, because the degree of FA provides honest information about male quality(10,11). Here I use simple, artificial neural networks to show that such preferences are likely to arise in the absence of any link between symmetry and quality, as a by-product of selection for mate recognition.			JOHNSTONE, RA (corresponding author), UNIV CAMBRIDGE,DEPT ZOOL,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.							ARAK A, 1993, PHILOS T R SOC B, V340, P207, DOI 10.1098/rstb.1993.0059; ENQUIST M, 1993, NATURE, V361, P446, DOI 10.1038/361446a0; HARVEY IF, 1993, ECOL ENTOMOL, V18, P198, DOI 10.1111/j.1365-2311.1993.tb01090.x; LEARY RF, 1989, TRENDS ECOL EVOL, V4, P214, DOI 10.1016/0169-5347(89)90077-3; LEIMAR O, 1986, AM NAT, V128, P469, DOI 10.1086/284581; MOLLER AP, 1993, BEHAV ECOL SOCIOBIOL, V32, P167; MOLLER AP, 1992, NATURE, V357, P238, DOI 10.1038/357238a0; MOLLER AP, 1990, ANIM BEHAV, V40, P1185, DOI 10.1016/S0003-3472(05)80187-3; MOLLER AP, 1993, BEHAV ECOL SOCIOBIOL, V32, P371, DOI 10.1007/BF00168820; PACKER C, 1993, NATURE, V362, P595, DOI 10.1038/362595a0; PALMER AR, 1986, ANNU REV ECOL SYST, V17, P391, DOI 10.1146/annurev.es.17.110186.002135; PARSONS PA, 1990, BIOL REV, V65, P131, DOI 10.1111/j.1469-185X.1990.tb01186.x; RADESATER T, 1993, ANIM BEHAV, V45, P626, DOI 10.1006/anbe.1993.1075; Ryan M.J., 1990, Oxford Surveys in Evolutionary Biology, V7, P157; RYAN MJ, 1993, PHILOS T ROY SOC B, V340, P187, DOI 10.1098/rstb.1993.0057; RYAN MJ, 1992, AM NAT, V139, pS4, DOI 10.1086/285303; STADDON JER, 1975, AM NAT, V109, P541, DOI 10.1086/283025; SWADDLE JP, 1994, NATURE, V367, P165, DOI 10.1038/367165a0; VANVALEN L, 1962, EVOLUTION, V16, P125; WATSON PJ, 1994, TRENDS ECOL EVOL, V9, P21, DOI 10.1016/0169-5347(94)90227-5; ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3	21	162	162	1	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					172	175		10.1038/372172a0	http://dx.doi.org/10.1038/372172a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969449				2022-12-28	WOS:A1994PQ68800054
J	PLEY, HW; FLAHERTY, KM; MCKAY, DB				PLEY, HW; FLAHERTY, KM; MCKAY, DB			3-DIMENSIONAL STRUCTURE OF A HAMMERHEAD RIBOZYME	NATURE			English	Article							SELF-CLEAVAGE REACTION; VIRUS SATELLITE RNA; EFFICIENT CLEAVAGE; MOLECULAR-DYNAMICS; PURINE AMINO; OLIGORIBONUCLEOTIDES; PHOSPHOROTHIOATE; GUANOSINES; MECHANISM; SEQUENCE	The hammerhead ribozyme is a small catalytic RNA motif made up of three base-paired stems and a core of highly conserved, non-complementary nucleotides essential for catalysis. The X-ray crystallographic structure of a hammerhead RNA-RNA ribozyme-inhibitor complex at 2.6 Angstrom resolution reveals that the base-paired stems are A-form helices and that the core has two structural domains. The first domain is formed by the sequence 5'-CUGA following stem I and is a sharp turn identical to the uridine turn of transfer RNA, whereas the second is a non-Watson-Crick three-base-pair duplex with a divalent-ion binding site. The phosphodiester backbone of the DNA inhibitor strand is splayed out at the phosphate 5' to the cleavage site. The structure indicates that the ribozyme may destabilize a substrate strand in order to facilitate twisting of the substrate to allow cleavage of the scissile bond.	STANFORD UNIV, SCH MED, DEPT BIOL STRUCT, BECKMAN LABS STRUCT BIOL, STANFORD, CA 94305 USA	Stanford University								BRANDHUBER BJ, 1987, J BIOL CHEM, V262, P12306; BRATTY J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P345, DOI 10.1016/0167-4781(93)90001-T; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUZAYAN JM, 1986, NUCLEIC ACIDS RES, V14, P9729, DOI 10.1093/nar/14.24.9729; BUZAYAN JM, 1986, NATURE, V323, P349, DOI 10.1038/323349a0; DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; DAHM SC, 1990, BIOCHIMIE, V72, P819, DOI 10.1016/0300-9084(90)90191-I; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; FU DJ, 1992, P NATL ACAD SCI USA, V89, P3985, DOI 10.1073/pnas.89.9.3985; FU DJ, 1993, BIOCHEMISTRY-US, V32, P10629, DOI 10.1021/bi00091a013; GRASBY JA, 1993, NUCLEIC ACIDS RES, V21, P4444, DOI 10.1093/nar/21.19.4444; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; PLEY HW, 1993, J BIOL CHEM, V268, P19656; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; ROSSMANN MG, 1976, ACTA CRYSTALLOGR A, V32, P774, DOI 10.1107/S0567739476001587; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; SANTALUCIA J, 1993, BIOCHEMISTRY-US, V32, P12612, DOI 10.1021/bi00210a009; SHELDON CC, 1989, NUCLEIC ACIDS RES, V17, P5679, DOI 10.1093/nar/17.14.5679; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; SLIM G, 1992, BIOCHEM BIOPH RES CO, V183, P605, DOI 10.1016/0006-291X(92)90525-P; STEIGEMANN W, 1974, THESIS TU MUNCHEN; TUSCHL T, 1993, P NATL ACAD SCI USA, V90, P6991, DOI 10.1073/pnas.90.15.6991; TUSCHL T, 1993, BIOCHEMISTRY-US, V32, P11658, DOI 10.1021/bi00094a023; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VANTOL H, 1990, NUCLEIC ACIDS RES, V18, P1971, DOI 10.1093/nar/18.8.1971; WILLIAMS DM, 1992, P NATL ACAD SCI USA, V89, P918, DOI 10.1073/pnas.89.3.918	36	939	983	4	71	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	1994	372	6501					68	74		10.1038/372068a0	http://dx.doi.org/10.1038/372068a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969422				2022-12-28	WOS:A1994PQ34800071
J	RIDDIHOUGH, G				RIDDIHOUGH, G			FIRST-LINE DEFENSE	NATURE			English	Article							BINDING	Structural insight into the trimeric organization of the human mannose-binding protein sheds light on the workings of the non-clonal, innate immune response in vertebrates.										HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	5	3	3	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					114	114		10.1038/372114a0	http://dx.doi.org/10.1038/372114a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969405				2022-12-28	WOS:A1994PQ34800086
J	SIGURDSSON, E; THORGEIRSSON, G; SIGVALDASON, H; SIGFUSSON, N				SIGURDSSON, E; THORGEIRSSON, G; SIGVALDASON, H; SIGFUSSON, N			UNRECOGNIZED MYOCARDIAL-INFARCTION - EPIDEMIOLOGY, CLINICAL CHARACTERISTICS, AND THE PROGNOSTIC ROLE OF ANGINA-PECTORIS - THE REYKJAVIK STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; ANGINA PECTORIS; CORONARY DISEASE; ELECTROCARDIOGRAPHY; RISK ASSESSMENT	CORONARY-ARTERY DISEASE; AUTONOMIC NEUROPATHY; WARNING SYSTEM; HEART-DISEASE; CHEST PAIN; FOLLOW-UP; SILENT; PREVALENCE; ISCHEMIA; MEN	Objective: To evaluate the incidence, prevalence, characteristics, and prognosis associated with clinically unrecognized myocardial infarction as diagnosed by electrocardiographic changes. Design: Prospective, population-based cohort study with 4- to 20-year follow-up. Setting: Icelandic Heart Association Preventive Clinic. Participants: 9141 men residing in the Reykjavik area who were born between 1907 and 1934. Measurements: Patients were assigned to categories of coronary heart disease at first visit on the basis of hospital records, Rose chest pain questionnaire, standardized 12-lead electrocardiogram, and history and physical examination. Incidence and prevalence of unrecognized myocardial infarction were determined, survival was measured, and causes of death were determined from death certificates and autopsy records. Results: Prevalence was strongly influenced by age. Nearly undetectable in the youngest age group, it increased to more than 5% in the group aged 75 to 79 years. Incidence was almost zero up to age 40, then increased steeply to more than 300 cases per year per 100 000 persons at age 60, and decreased with age after age 65. Ten- and 15-year survival probabilities were 51% and 45%, respectively, and were similar to those for patients with recognized myocardial infarction. One third of men with unrecognized and 58% of men with recognized myocardial infarction had a history of angina pectoris (P < 0.001). Angina pectoris had a greater effect on coronary heart disease mortality in the former group than in the latter. The risk ratio for unrecognized myocardial infarction was 4.6 without angina (95% CI, 2.4 to 8.6) and 16.9 with angina (CI, 9.4 to 30.3); the risk ratio for recognized myocardial infarction was 6.3 without angina (CI, 3.7 to 10.6) and 8.5 with angina (CI, 5.8 to 12.6). Conclusion: At least one third of all myocardial infarctions were unrecognized. Prognosis and risk factor profiles for patients with recognized and unrecognized myocardial infarction were similar. Although those with unrecognized myocardial infarction were less likely than those with recognized myocardial infarction to have a history of angina pectoris, angina in these cases was usually associated with ischemic electrocardiographic changes and a poor prognosis, suggesting severe coronary heart disease.	NATL UNIV HOSP REYKJAVIK, DEPT MED, IS-121 REYKJAVIK, ICELAND; GOTHENBURG UNIV, GOTHENBURG, SWEDEN; HLTH CTR MARIESTAD, MARIESTAD, SWEDEN; ICELAND HEART ASSOC, HEART PREVENT CLIN, IS-108 REYKJAVIK, ICELAND; NATL UNIV HOSP REYKJAVIK, DEPT MED LANDSPITALINN, IS-121 REYKJAVIK, ICELAND	Landspitali National University Hospital; University of Gothenburg; Icelandic Heart Association; Landspitali National University Hospital								AIRAKSINEN KEJ, 1992, DIABETES CARE, V15, P288, DOI 10.2337/diacare.15.2.288; [Anonymous], 1988, J CLIN EPIDEMIOL, V41, P105, DOI 10.1016/0895-4356(88)90084-4; Bertolet B D, 1989, Cardiovasc Clin, V20, P173; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; COHN PF, 1980, AM J CARDIOL, V45, P697, DOI 10.1016/S0002-9149(80)80024-5; COHN PF, 1988, AM J CARDIOL, V61, pB4; DROSTE C, 1983, J AM COLL CARDIOL, V1, P940, DOI 10.1016/S0735-1097(83)80214-9; DROSTE C, 1986, PAIN, V26, P199, DOI 10.1016/0304-3959(86)90075-8; HEDBLAD B, 1989, EUR HEART J, V10, P149, DOI 10.1093/oxfordjournals.eurheartj.a059455; Herrick JB, 1912, J AMER MED ASSOC, V59, P2015; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KANNEL WB, 1987, CIRCULATION, V75, P4; KANNEL WB, 1990, ADV CARDIOL, V37, P202; KOISTINEN MJ, 1992, ACTA DIABETOL, V28, P199, DOI 10.1007/BF00778998; MARGOLIS JR, 1973, AM J CARDIOL, V32, P1, DOI 10.1016/S0002-9149(73)80079-7; MEDALIE JH, 1976, ANN INTERN MED, V84, P526, DOI 10.7326/0003-4819-84-5-526; NADELMANN J, 1990, AM J CARDIOL, V66, P533, DOI 10.1016/0002-9149(90)90477-I; NIAKAN E, 1986, ARCH INTERN MED, V146, P2229, DOI 10.1001/archinte.146.11.2229; OSULLIVAN JJ, 1991, BRIT HEART J, V66, P313; PYORALA K, 1974, ANN CLIN RES, V6, P137; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; ROSE GA, 1968, CARDIOVASCULAR SURVE, P56; ROSEMAN MD, 1954, ANN INTERN MED, V41, P1, DOI 10.7326/0003-4819-41-1-1; ROSENMAN RH, 1970, J CHRON DIS, V23, P173, DOI 10.1016/0021-9681(70)90094-9; SIGURDSSON E, 1993, EUR HEART J, V14, P584, DOI 10.1093/eurheartj/14.5.584; URETSKY BF, 1977, AM J CARDIOL, V40, P498, DOI 10.1016/0002-9149(77)90062-5; YANO K, 1989, ARCH INTERN MED, V149, P1528, DOI 10.1001/archinte.149.7.1528; 1990, EGRET REFERENCE MANU	28	187	190	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					96	102		10.7326/0003-4819-122-2-199501150-00003	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7993002				2022-12-28	WOS:A1995QC05900003
J	WILLMS, JL				WILLMS, JL			THE INTERNISTS READING - PURPOSEFUL ECLECTICISM	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											WILLMS, JL (corresponding author), INST MED & HUMANITIES, POB 4587, MISSOULA, MT 59801 USA.							ARMSTRONG D, 1991, GREAT AM MED SHOW; BARNES P, 1976, RED NOSES; DOYLE AC, 1992, TALES HUMANISM VALUE; Gevitz N., 1988, OTHER HEALERS UNORTH, P124; MUKAND J, 1990, VITAL LINES CONTEMPO; Mulisch Harry, 1985, ASSAULT; Norman M., 1983, NIGHT MOTHER; Thornton L., 1991, IMAGINING ARGENTINA	8	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					158	158		10.7326/0003-4819-122-2-199501150-00028	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00028			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7992999				2022-12-28	WOS:A1995QC05900028
J	SCHLAEPFER, DD; HANKS, SK; HUNTER, T; VANDERGEER, P				SCHLAEPFER, DD; HANKS, SK; HUNTER, T; VANDERGEER, P			INTEGRIN-MEDIATED SIGNAL-TRANSDUCTION LINKED TO RAS PATHWAY BY GRB2 BINDING TO FOCAL ADHESION KINASE	NATURE			English	Article							PROTEIN-TYROSINE KINASE; CELL-ADHESION; SH3 DOMAIN; PHOSPHORYLATION; RECEPTOR	THE cytoplasmic focal adhesion protein-tyrosine kinase (FAK) localizes with surface integrin receptors at sites where cells attach to the extracellular matrix. Increased FAK tyrosine phosphorylation occurs upon integrin engagement with fibronectin. Here we show that adhesion of murine NIH3T3 fibroblasts to fibronectin promotes SH2-domain-mediated association of the GRB2 adaptor protein and the c-Src protein-tyrosine kinase (PTK) with FAK in vivo, and also results in activation of mitogen-activated protein kinase (MAPK). In v-Src-transformed NIH3T3, the association of v-Src, GRB2 and Sos with FAK is independent of cell adhesion to fibronectin. The GRB2 SH2 domain binds directly to tyrosine-phosphorylated FAK. Mutation of tyrosine residue 925 of FAK (YENV motif) to phenylalanine blocks GRB2 SH2-domain binding to PAK in vitro. Our results show that fibronectin binding to integrins on NIH3T3 fibroblasts promotes c-Src and FAK association and formation of an integrin-activated signalling complex. Phosphorylation of FAK at Tyr 925 upon fibronectin stimulation creates an SH2-binding site for GRB2 which may link integrin engagement to the activation of the Ras/MAPK signal transduction pathway.	VANDERBILT UNIV, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA	Vanderbilt University	SCHLAEPFER, DD (corresponding author), SALK INST, MOLEC BIOL & VIROL LAB, POB 85800, SAN DIEGO, CA 92186 USA.							BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB M, IN PRESS MOL CELL BI; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	22	1443	1471	1	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	1994	372	6508					786	791						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997267				2022-12-28	WOS:A1994PY21200055
J	VASSAR, R; CHAO, SK; SITCHERAN, R; NUNEZ, JM; VOSSHALL, LB; AXEL, R				VASSAR, R; CHAO, SK; SITCHERAN, R; NUNEZ, JM; VOSSHALL, LB; AXEL, R			TOPOGRAPHIC ORGANIZATION OF SENSORY PROJECTIONS TO THE OLFACTORY-BULB	CELL			English	Article							ODORANT RECEPTOR EXPRESSION; MITRAL TUFTED CELLS; MARKER PROTEIN; GENE-EXPRESSION; MESSENGER-RNA; RAT; FAMILY; EPITHELIUM; NEURONS; MOLECULES	The detection of odorant receptor mRNAs within the axon terminals of sensory neurons has permitted us to ask whether neurons expressing a given receptor project their axons to common glomeruli within the olfactory bulb. In situ hybridization with five different receptor probes demonstrates that axons from neurons expressing a given receptor converge on one, or at most, a few glomeruli within the olfactory bulb. Moreover, the position of specific glomeruli is bilaterally symmetric and is constant in different individuals within a species. These data support a model in which exposure to a given odorant may result in the stimulation of a spatially restricted set of glomeruli, such that the individual odorants would be associated with specific topographic patterns of activity within the olfactory bulb.	COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	VASSAR, R (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.			Sitcheran, Raquel/0000-0001-8916-9707; Axel, Richard/0000-0002-3141-4076; Vosshall, Leslie/0000-0002-6060-8099	NIGMS NIH HHS [T32 GM07367] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTIC L, 1986, BRAIN RES BULL, V16, P445, DOI 10.1016/0361-9230(86)90172-3; ASTIC L, 1987, BRAIN RES, V424, P144, DOI 10.1016/0006-8993(87)91204-2; BAIER H, 1994, J NEUROSCI, V14, P219; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BERKLEY KJ, 1985, DEV ORG PROCESSING S, P191; BRUNET JF, 1991, SCIENCE, V252, P856, DOI 10.1126/science.1840700; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; BUONVISO N, 1991, EUR J NEUROSCI, V3, P493, DOI 10.1111/j.1460-9568.1991.tb00836.x; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CONSTANTINEPATO.M, 1990, ANN REV NEUROSCI, V13, P129; DYKES RW, 1982, J NEUROPHYSIOL, V47, P389, DOI 10.1152/jn.1982.47.3.389; EHRLICH ME, 1990, MOL BRAIN RES, V7, P115, DOI 10.1016/0169-328X(90)90088-U; FARBMAN AI, 1980, DEV BIOL, V74, P205, DOI 10.1016/0012-1606(80)90062-7; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOODMAN CS, 1993, NEURON S, V10, P77; HABERLY LB, 1977, BRAIN RES, V129, P152, DOI 10.1016/0006-8993(77)90978-7; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; IMAMURA K, 1992, J NEUROPHYSIOL, V68, P1986, DOI 10.1152/jn.1992.68.6.1986; JIRIKOWSKI GF, 1990, P NATL ACAD SCI USA, V87, P7400, DOI 10.1073/pnas.87.19.7400; JOURDAN F, 1980, BRAIN RES, V188, P139, DOI 10.1016/0006-8993(80)90563-6; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P516; KATOH K, 1993, J NEUROPHYSIOL, V70, P2161, DOI 10.1152/jn.1993.70.5.2161; KAUER JS, 1987, BRAIN RES, V418, P255, DOI 10.1016/0006-8993(87)90093-X; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LANCET D, 1982, P NATL ACAD SCI-BIOL, V79, P670, DOI 10.1073/pnas.79.2.670; LANDRY C, 1992, J NEUROBIOL, V23, P89, DOI 10.1002/neu.480230109; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; LIVINGSTONE MS, 1987, J NEUROSCI, V7, P3416; LUSKIN MB, 1982, J COMP NEUROL, V209, P249, DOI 10.1002/cne.902090304; MARGOLIS FL, 1978, SOC NEUR ABSTR, V4, P88; MEISAMI E, 1989, DEV BRAIN RES, V46, P9, DOI 10.1016/0165-3806(89)90139-9; MEISAMI E, 1979, NEURAL GROWTH DIFFER; MELTON DA, 1984, NUCLEIC ACIDS RES, V13, P7035; MOHR E, 1991, EMBO J, V10, P2419, DOI 10.1002/j.1460-2075.1991.tb07781.x; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; NADI NS, 1981, BRAIN RES, V213, P365, DOI 10.1016/0006-8993(81)90241-9; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; OJIMA H, 1984, J COMP NEUROL, V230, P77, DOI 10.1002/cne.902300107; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; PERL ER, 1962, J NEUROPHYSIOL, V25, P337, DOI 10.1152/jn.1962.25.3.337; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; Ressler Kerry J., 1994, Current Opinion in Neurobiology, V4, P588, DOI 10.1016/0959-4388(94)90061-2; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; ROGERS KE, 1987, P NATL ACAD SCI USA, V84, P1704, DOI 10.1073/pnas.84.6.1704; ROYET JP, 1988, J COMP NEUROL, V270, P559, DOI 10.1002/cne.902700409; ROYET JP, 1987, BRAIN RES, V417, P1, DOI 10.1016/0006-8993(87)90173-9; SAUCIER D, 1986, BRAIN RES BULL, V16, P455, DOI 10.1016/0361-9230(86)90173-5; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHOENFELD TA, 1994, BRAIN RES BULL, V34, P183, DOI 10.1016/0361-9230(94)90059-0; SCHWOB JE, 1978, BRAIN RES, V151, P369, DOI 10.1016/0006-8993(78)90891-0; SCOTT JW, 1980, J COMP NEUROL, V194, P519, DOI 10.1002/cne.901940304; Shepherd G. M., 1991, OLFACTION MODEL SYST; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; VERHAAGEN J, 1990, J NEUROSCI RES, V26, P31, DOI 10.1002/jnr.490260105; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	64	981	996	0	34	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					981	991		10.1016/0092-8674(94)90029-9	http://dx.doi.org/10.1016/0092-8674(94)90029-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001145				2022-12-28	WOS:A1994PY08600008
J	ADOLPHS, R; TRANEL, D; DAMASIO, H; DAMASIO, A				ADOLPHS, R; TRANEL, D; DAMASIO, H; DAMASIO, A			IMPAIRED RECOGNITION OF EMOTION IN FACIAL EXPRESSIONS FOLLOWING BILATERAL DAMAGE TO THE HUMAN AMYGDALA	NATURE			English	Article							CIRCUMPLEX MODEL; IDENTITY; LESIONS; MONKEY	STUDIES in animals have shown that the amygdala receives highly processed visual input(1,2), contains neurons that respond selectively to faces(3), and that it participates in emotion(4,5) and social behaviour(6). Although studies in epileptic patients support its role in emotion(7), determination of the amygdala's function in humans has been hampered by the rarity of patients with selective amygdala lesions(8). Here, with the help of one such rare patient, we report findings that suggest the human amygdala may be indispensable to: (1) recognize fear in facial expressions; (2) recognize multiple emotions in a single facial expression; but (3) is not required to recognize personal identity from faces. These results suggest that damage restricted to the amygdala causes very specific recognition impairments, and thus constrains the broad notion that the amygdala is involved in emotion.	SALK INST BIOL STUDIES,LA JOLLA,CA 92186	Salk Institute	ADOLPHS, R (corresponding author), UNIV IOWA,COLL MED,DEPT NEUROL,DIV COGNIT NEUROSCI,IOWA CITY,IA 52242, USA.		Tudusciuc, Oana/C-1339-2011; Damasio, Antonio/AAD-1342-2019	Tranel, Daniel/0000-0002-1338-1389				AGGLETON J P, 1992, P485; AMARAL D G, 1992, P1; Amaral DG, 1992, AMYGDALA NEUROBIOLOG, P465; BLANCHARD DC, 1972, J COMP PHYSIOL PSYCH, V81, P281, DOI 10.1037/h0033521; DAMASIO AR, 1990, ANNU REV NEUROSCI, V13, P89, DOI 10.1146/annurev.ne.13.030190.000513; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; Damasio H, 1989, ANAL NEUROPSYCHOLOGY; Darwin C., 1965, EXPRESS EMOT MAN; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; Ekman P., 1976, PICTURES FACIAL AFFE; Ekman Paul, 1973, DARWIN FACIAL EXPRES; GUTTMAN L, 1968, PSYCHOMETRIKA, V33, P469, DOI 10.1007/BF02290164; HALGREN E, 1978, BRAIN, V101, P83, DOI 10.1093/brain/101.1.83; HASSELMO ME, 1989, BEHAV BRAIN RES, V32, P203, DOI 10.1016/S0166-4328(89)80054-3; HERZOG AG, 1976, BRAIN RES, V115, P57, DOI 10.1016/0006-8993(76)90822-2; HOFER PA, 1973, ACTA DERM-VENEREOL, V53, P5; HUMPHREYS GW, 1993, NEUROPSYCHOLOGIA, V31, P173, DOI 10.1016/0028-3932(93)90045-2; KLING A S, 1992, P353; KRUSKAL JB, 1964, PSYCHOMETRIKA, V29, P115, DOI 10.1007/BF02289694; LEDOUX JE, 1993, BEHAV BRAIN RES, V58, P69, DOI 10.1016/0166-4328(93)90091-4; NAHM FKD, 1993, NEUROPSYCHOLOGIA, V31, P727, DOI 10.1016/0028-3932(93)90125-J; ROLLS E T, 1992, P143; RUSSELL JA, 1989, J PERS SOC PSYCHOL, V57, P848, DOI 10.1037/0022-3514.57.5.848; RUSSELL JA, 1980, J PERS SOC PSYCHOL, V39, P1161, DOI 10.1037/h0077714; RUSSELL JA, 1991, PSYCHOL BULL, V110, P426, DOI 10.1037/0033-2909.110.3.426; RUSSELL JA, 1985, J PERS SOC PSYCHOL, V48, P1290, DOI 10.1037/0022-3514.48.5.1290; TRANEL D, 1988, NEUROLOGY, V38, P690, DOI 10.1212/WNL.38.5.690; TRANEL D, 1990, ARCH NEUROL-CHICAGO, V47, P349, DOI 10.1001/archneur.1990.00530030131029; WEISKRANTZ L, 1956, J COMP PHYSIOL PSYCH, V49, P381, DOI 10.1037/h0088009	29	1568	1597	4	217	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					669	672		10.1038/372669a0	http://dx.doi.org/10.1038/372669a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PX307	7990957				2022-12-28	WOS:A1994PX30700084
J	FROLOVA, L; LEGOFF, X; RASMUSSEN, HH; CHEPEREGIN, S; DRUGEON, G; KRESS, M; ARMAN, I; HAENNI, AL; CELIS, JE; PHILIPPE, M; JUSTESEN, J; KISSELEV, L				FROLOVA, L; LEGOFF, X; RASMUSSEN, HH; CHEPEREGIN, S; DRUGEON, G; KRESS, M; ARMAN, I; HAENNI, AL; CELIS, JE; PHILIPPE, M; JUSTESEN, J; KISSELEV, L			A HIGHLY CONSERVED EUKARYOTIC PROTEIN FAMILY POSSESSING PROPERTIES OF POLYPEPTIDE-CHAIN RELEASE FACTOR	NATURE			English	Article							TRANSFER RNA-SYNTHETASE; SACCHAROMYCES-CEREVISIAE; TRANSLATION FIDELITY; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; YEAST; TERMINATION; SUP45; HOMOLOGY; CLONING	THE termination of protein synthesis in ribosomes is governed by termination (stop) codons in messenger RNAs and by polypeptide chain release factors (RFs). Although the primary structure of prokaryotic RFs and yeast mitochrondrial RF is established(1-4), that of the only known eukaryotic RF (eRF)(5) remains obscure. Here we report the assignment of a family of tightly related proteins (designated eRF1) from lower and higher eukaryotes which are structurally and functionally similar to rabbit eRF. Two of these proteins, one from human(6) and the other from Xenopus laevis(7), have been expressed in yeast and Escherichia coli, respectively, purified and shown to be active in the in vitro RF assay. The other protein of this family, sup45 (sup1) of Saccharomyces cerevisiae, is involved in omnipotent suppression during translations(8-12). The amino-acid sequence of the eRF1 family is highly conserved. We conclude that the eRF1 proteins are directly implicated in the termination of translation in eukaryotes.	RUSSIAN ACAD SCI,VA ENGELHARDT MOLEC BIOL INST,MOSCOW 117984,RUSSIA; AARHUS UNIV,DEPT BIOL MOLEC,DK-800 AARHUS C,DENMARK; INST JACQUES MONOD,F-75251 PARIS 05,FRANCE; UNIV RENNES 1,CNRS,URA 256,DEPT BIOL & GENET DEV,F-35042 RENNES,FRANCE; AARHUS UNIV,INST MED BIOCHEM,DK-8000 AARHUS C,DENMARK; AARHUS UNIV,DANISH CTR HUMAN GENOME RES,DK-8000 AARHUS C,DENMARK; RUSSIAN ACAD SCI,INST MOLEC GENET,MOSCOW 123182,RUSSIA; CNRS,ERS0048,MOLEC ONCOL LAB,F-94802 VILLEJUIF,FRANCE	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Aarhus University; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; Aarhus University; Aarhus University; Russian Academy of Sciences; Centre National de la Recherche Scientifique (CNRS)			Cheperegin, Sergey/R-6594-2018	LE GOFF, Xavier/0000-0002-5297-2421				BEAUDET AL, 1971, P NATL ACAD SCI USA, V68, P619, DOI 10.1073/pnas.68.3.619; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BREINING P, 1986, NUCLEIC ACIDS RES, V14, P5187, DOI 10.1093/nar/14.13.5187; Caskey C T, 1974, Methods Enzymol, V30, P293; CRAIGEN WJ, 1990, MOL MICROBIOL, V4, P861, DOI 10.1111/j.1365-2958.1990.tb00658.x; FROLOVA LY, 1991, GENE, V109, P291, DOI 10.1016/0378-1119(91)90624-K; FROLOVA LY, 1993, EMBO J, V12, P4013; GARRET M, 1991, BIOCHEMISTRY-US, V30, P7809, DOI 10.1021/bi00245a021; GOLDSTEIN JL, 1970, P NATL ACAD SCI USA, V67, P99, DOI 10.1073/pnas.67.1.99; GRENETT HE, 1992, GENE, V110, P239, DOI 10.1016/0378-1119(92)90655-9; GRENTZMANN G, 1994, P NATL ACAD SCI USA, V91, P5848, DOI 10.1073/pnas.91.13.5848; HIMMELFARB HJ, 1985, MOL CELL BIOL, V5, P816, DOI 10.1128/MCB.5.4.816; INGE-VECHTOMOV S G, 1970, Genetika, V6, P103; KONECKI DS, 1977, J BIOL CHEM, V252, P4514; LEE CC, 1990, P NATL ACAD SCI USA, V87, P3508, DOI 10.1073/pnas.87.9.3508; MUKINI O, 1994, P NATL ACAD SCI USA, V91, P5798; PEL HJ, 1992, NUCLEIC ACIDS RES, V20, P4423, DOI 10.1093/nar/20.17.4423; PEL HJ, 1992, NUCLEIC ACIDS RES, V20, P6339, DOI 10.1093/nar/20.23.6339; RASMUSSEN HH, 1991, ELECTROPHORESIS, V12, P873, DOI 10.1002/elps.1150121107; STANSFIELD I, 1992, MOL MICROBIOL, V6, P3469, DOI 10.1111/j.1365-2958.1992.tb01782.x; Surguchovs AP, 1984, PHYSICOCHEMICAL BIOL, V4, P147; TASSAN JP, 1993, MOL CELL BIOL, V13, P2815, DOI 10.1128/MCB.13.5.2815; TATE WP, 1990, RIBOSOMES PROTEIN SY, P81; TUITE MF, 1993, BIOCHEM SOC T, V21, P857, DOI 10.1042/bst0210857	25	349	371	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					701	703		10.1038/372701a0	http://dx.doi.org/10.1038/372701a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990965				2022-12-28	WOS:A1994PX30700093
J	SHAKIL, AO; DIBISCEGLIE, AM				SHAKIL, AO; DIBISCEGLIE, AM			VASCULITIS AND CRYOGLOBULINEMIA RELATED TO HEPATITIS-C	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											SHAKIL, AO (corresponding author), NIH,BETHESDA,MD 20892, USA.		Shaikh, Obaid/AAL-5339-2021	Shaikh, Obaid/0000-0002-4955-9222					0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 15	1994	331	24					1624	1624						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW446	7969343				2022-12-28	WOS:A1994PW44600005
J	ERICKSON, SL; DESAUVAGE, FJ; KIKLY, K; CARVERMOORE, K; PITTSMEEK, S; GILLETT, N; SHEEHAN, KCF; SCHREIBER, RD; GOEDDEL, DV; MOORE, MW				ERICKSON, SL; DESAUVAGE, FJ; KIKLY, K; CARVERMOORE, K; PITTSMEEK, S; GILLETT, N; SHEEHAN, KCF; SCHREIBER, RD; GOEDDEL, DV; MOORE, MW			DECREASED SENSITIVITY TO TUMOR-NECROSIS-FACTOR BUT NORMAL T-CELL DEVELOPMENT IN TNF RECEPTOR-2-DEFICIENT MICE	NATURE			English	Article							FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; ENDOTOXIC-SHOCK; MONOCYTOGENES; RESISTANT; INFECTION; BINDING; DOMAIN; LINES	TUMOUR necrosis factor (TNF) elicits multiple biological effects through two distinct cell surface receptors, TNF-R1 (p55) and TNF-R2 (p75). Most TNF-mediated biological responses, such as cell death, gene induction, antiviral activity and cytokine production, have been attributed to TNF-R1 (refs 1-5). Gene targeting of this receptor confirms its role in the lethality attributable to low doses of lipopolysaccharide after sensitization with D-galactosamine(6,7); surprisingly, the toxicity of high doses of lipopolysaccharide was unaffected. The function of TNF-R2 is less well understood, although there are data supporting a role in T-cell development and the proliferation of cytotoxic T lymphocytes(8,9). To clarify the physiological role of TNF-R2, we have generated mice deficient in this receptor by gene targeting. The TNF-R2(-/-) mice show normal T-cell development and activity, but we find that they have increased resistance to TNF-induced death. Additionally, such mice injected subcutaneously with TNF show a dramatic decrease in tissue necrosis, indicating that this receptor plays a role in the necrotic effects of TNF.	GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT ENDOCRINE RES & PHARMACOL,S SAN FRANCISCO,CA 94080; WASHINGTON UNIV,SCH MED,CTR IMMUNOL,DEPT PATHOL,ST LOUIS,MO 63110	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Washington University (WUSTL)			Schreiber, Robert D/A-1276-2013; de Sauvage, Frederic/ABE-8400-2020; Schreiber, Robert/Q-7550-2019	Schreiber, Robert D/0000-0001-6311-0432; de Sauvage, Frederic/0000-0002-5275-2584; Schreiber, Robert/0000-0003-1590-2341				ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542	22	540	557	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					560	563		10.1038/372560a0	http://dx.doi.org/10.1038/372560a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990930				2022-12-28	WOS:A1994PW08200055
J	BOTTASSO, OA; INGLEDEW, N; KENI, M; MORINI, J; PIVIDORI, JF; ROOK, GAW; STANFORD, JL				BOTTASSO, OA; INGLEDEW, N; KENI, M; MORINI, J; PIVIDORI, JF; ROOK, GAW; STANFORD, JL			CELLULAR IMMUNE-RESPONSE TO COMMON MYCOBACTERIAL ANTIGENS IN SUBJECTS SEROPOSITIVE FOR TRYPANOSOMA-CRUZI	LANCET			English	Note							CHAGAS-DISEASE; TUBERCULOSIS; SUPPRESSION; LEPROSY	The immune response is impaired in the silent stage of Chagas' disease. We used quadruple skin-testing with new tuberculins in 37 adults who were symptom-free but seropositive for Trypanosoma cruzi and in 37 matched seronegative controls. Whereas 19% of controls responded to common mycobacterial antigens, none of the Chagas' seropositive group responded to them (p<0.006), demonstrating specificity in their unresponsiveness. The enhanced tuberculin reactivity after BCG vaccination in the control group was suppressed in seropositive subjects (p<0.002). Selective loss of response to common mycobacterial antigens may have implications for the autoimmune pathology of Chagas' disease, and for susceptibility to tuberculosis, leprosy, and HIV disease.	UCL, SCH MED, DEPT MED MICROBIOL, LONDON W1P 7LD, ENGLAND; UNIV NACL ROSARIO, FAC CIENCIAS MED, DIV INMUNOL, RA-2000 ROSARIO, SANTA FE, ARGENTINA; PROGRAMA PROV LUCHA CONTRA ENFERMADAD CHAGAS, RECONQUISTA, SANTA FE, ARGENTINA	University of London; University College London; UCL Medical School; National University of Rosario				Rook, Graham/0000-0002-8041-8110				BOTTASSO OA, 1982, MEDICINA-BUENOS AIRE, V42, P136; CUNNINGHAM DS, 1980, INFECT IMMUN, V30, P496; HERNANDEZPANDO R, 1994, IMMUNOLOGY, V82, P591; KHOO SH, 1993, 9 INT C AIDS BERL; LOCKWOOD DNJ, 1987, EUR J RESPIR DIS, V71, P348; MOSCA W, 1991, MEM I OSWALDO CRUZ, V86, P147, DOI 10.1590/S0074-02761991000200002; SHIELD MJ, 1977, J HYG-CAMBRIDGE, V78, P331, DOI 10.1017/S0022172400056230; STANFORD JL, 1974, TUBERCLE, V55, P143, DOI 10.1016/0041-3879(74)90008-7; VOLTARELLI JC, 1987, T ROY SOC TROP MED H, V81, P169, DOI 10.1016/0035-9203(87)90324-5; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P4267, DOI 10.1073/pnas.85.12.4267	10	14	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1540	1541		10.1016/S0140-6736(94)90351-4	http://dx.doi.org/10.1016/S0140-6736(94)90351-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983955				2022-12-28	WOS:A1994PV01700011
J	CROOK, T; MARSTON, NJ; SARA, EA; VOUSDEN, KH				CROOK, T; MARSTON, NJ; SARA, EA; VOUSDEN, KH			TRANSCRIPTIONAL ACTIVATION BY P53 CORRELATES WITH SUPPRESSION OF GROWTH BUT NOT TRANSFORMATION	CELL			English	Article							WILD-TYPE P53; KINASE-II PHOSPHORYLATION; DNA-BINDING; MUTANT P53; MONOCLONAL-ANTIBODIES; PROTEIN COMPLEXES; MDM-2 ONCOGENE; CELL-GROWTH; GENE; MUTATIONS	The tumor suppressor protein p53 shows growth and transformation suppression functions that are frequently lost by mutant proteins detected in cancers. Using a large series of p53 mutants, we have demonstrated an excellent correlation between transcriptional activation and growth suppression in p53-null human cells. Not all transcriptionally active mutants retain the ability to suppress transformation in primary rodent cells, however, and two tumor-derived point mutants displayed some evidence of both transforming and transactivating activity. Transformation by these mutants was not mediated by transdominant repression of endogenous p53 transactivating function, and cell lines expressing these p53 proteins showed elevated p53 transcriptional activity. Our results suggest that activation of transcriptional regulation by p53 will not necessarily result in tumor suppression.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research			Fraser, Elizabeth/M-7049-2015	Fraser, Elizabeth/0000-0001-8420-3208				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HARPER JW, 1993, CELL, V75, P805; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLSON DC, 1993, ONCOGENE, V8, P2353; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PEACOCK JW, 1990, ONCOGENE, V5, P1769; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SANG BC, 1994, ONCOGENE, V9, P853; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SLEBOS RJC, 1994, IN PRESS P NATL ACAD; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; TARUNINA M, 1993, ONCOGENE, V8, P3165; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHANG W, 1993, ONCOGENE, V8, P2555	88	241	243	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 2	1994	79	5					817	827		10.1016/0092-8674(94)90071-X	http://dx.doi.org/10.1016/0092-8674(94)90071-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001119				2022-12-28	WOS:A1994PW05400009
J	JIANG, XX; KHURSIGARA, G; RUBIN, RL				JIANG, XX; KHURSIGARA, G; RUBIN, RL			TRANSFORMATION OF LUPUS-INDUCING DRUGS TO CYTOTOXIC PRODUCTS BY ACTIVATED NEUTROPHILS	SCIENCE			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; HYDRALAZINE-INDUCED LUPUS; REACTIVE METABOLITES; PROCAINAMIDE; MYELOPEROXIDASE; HYDROXYLAMINE; RAT; PROPYLTHIOURACIL; CHLORPROMAZINE; ERYTHEMATOSUS	Drug-induced lupus is a serious side effect of certain medications, but the chemical features that confer this property and the underlying pathogenesis are puzzling. Prototypes of all six therapeutic classes of lupus-inducing drugs were highly cytotoxic only in the presence of activated neutrophils. Removal of extracellular hydrogen peroxide before, but not after, exposure of the drug to activated neutrophils prevented cytotoxicity. Neutrophil-dependent cytotoxicity required the enzymatic action of myeloperoxidase, resulting in the chemical transformation of the drug to a reactive product. The capacity of drugs to serve as myeloperoxidase substrates in vitro was associated with the ability to induce lupus in vivo.	SCRIPPS RES INST, WM KECK AUTOIMMUNE DIS CTR, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009574] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00833] Funding Source: Medline; NIA NIH HHS [R01 AG09574] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS LE, 1989, J LAB CLIN MED, V113, P482; ADAMS LE, 1993, LUPUS, V2, P89, DOI 10.1177/096120339300200205; ANDREAE WA, 1955, NATURE, V175, P859, DOI 10.1038/175859a0; AUCOIN DP, 1985, J PHARMACOL EXP THER, V234, P13; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BARR DP, 1993, ARCH BIOCHEM BIOPHYS, V303, P377, DOI 10.1006/abbi.1993.1298; BLOMGREN SE, 1973, SEMIN HEMATOL, V10, P345; BRETZ U, 1974, J CELL BIOL, V63, P251, DOI 10.1083/jcb.63.1.251; BUDINSKY RA, 1987, DRUG METAB DISPOS, V15, P37; CAMBRIDGE G, 1994, BRIT J RHEUMATOL, V33, P109; CLARK RA, 1983, ADV INFLAMMAT RES, V5, P107; DIXON M, 1979, ENZYMES, P345; EASTMOND DA, 1990, METHOD ENZYMOL, V186, P579; HARMON CE, 1982, CLIN RHEUM DIS, V8, P121; HEIN DW, 1989, AUTOIMMUNITY TOXICOL, P239; HOFSTRA AH, 1991, J RHEUMATOL, V18, P1673; HOFSTRA AH, 1992, DRUG METAB DISPOS, V20, P205; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; KELDER PP, 1991, CHEM-BIOL INTERACT, V79, P15, DOI 10.1016/0009-2797(91)90049-D; KUBICKAMURANYI M, 1993, TOXICOL APPL PHARM, V122, P88, DOI 10.1006/taap.1993.1175; LAHITA R, 1979, NEW ENGL J MED, V301, P1382, DOI 10.1056/NEJM197912203012506; NAKASHIMA I, 1994, J IMMUNOL, V152, P1064; NASSBERGER L, 1990, CLIN EXP IMMUNOL, V81, P380; NELSON SD, 1981, MOL PHARMACOL, V20, P195; RUBIN RL, 1989, J CLIN INVEST, V83, P1336, DOI 10.1172/JCI114020; RUBIN RL, 1987, J PHARMACOL EXP THER, V242, P833; RUBIN RL, UNPUB; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P399, DOI 10.1128/AAC.27.3.399; SMOLEN JE, 1979, ARTHRITIS ALLIED CON, P282; STREETER AJ, 1983, DRUG METAB DISPOS, V11, P184; UETRECHT JP, 1984, DRUG METAB DISPOS, V12, P77; VANZYL JM, 1989, BIOCHEM PHARMACOL, V38, P2363, DOI 10.1016/0006-2952(89)90477-2; VANZYL JM, 1990, BIOCHEM PHARMACOL, V40, P947, DOI 10.1016/0006-2952(90)90478-4; WALDHAUSER L, 1991, DRUG METAB DISPOS, V19, P354; Weinstein A, 1980, Prog Clin Immunol, V4, P1; WHEELER JF, 1991, DRUG METAB DISPOS, V19, P691; WOODHOUSE KW, 1990, BRIT MED BULL, V46, P22, DOI 10.1093/oxfordjournals.bmb.a072387; WOOSLEY RL, 1978, NEW ENGL J MED, V298, P1157, DOI 10.1056/NEJM197805252982101; Worthington C.C., 1988, WORTHINGTON MANUAL E, P254; YAMAMOTO K, 1991, BIOCHEM PHARMACOL, V41, P905; YUNG RL, 1994, RHEUM DIS CLIN N AM, V20, P61; 1994, US STATES PHARMACOPE, V1, P417	42	185	206	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	1994	266	5186					810	813		10.1126/science.7973636	http://dx.doi.org/10.1126/science.7973636			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973636				2022-12-28	WOS:A1994PP75300042
J	PHILLIPS, DM				PHILLIPS, DM			ENTEROCOCCUS-FAECALIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PHILLIPS, DM (corresponding author), POPULAT COUNCIL,1230 YORK AVE,NEW YORK,NY 10021, USA.								0	0	0	2	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					26	26		10.1056/NEJM199501053320105	http://dx.doi.org/10.1056/NEJM199501053320105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990862				2022-12-28	WOS:A1995PZ49700005
J	JOHNSON, RL; LAUFER, E; RIDDLE, RD; TABIN, C				JOHNSON, RL; LAUFER, E; RIDDLE, RD; TABIN, C			ECTOPIC EXPRESSION OF SONIC HEDGEHOG ALTERS DORSAL-VENTRAL PATTERNING OF SOMITES	CELL			English	Article							FLOOR PLATE; CHICK-EMBRYO; CELL PATTERN; NEURAL-TUBE; DIFFERENTIATION; NOTOCHORD; SIGNALS; GENE; MORPHOGENESIS; SPECIFICATION	Differentiation of somites into sclerotome, dermatome, and myotome is controlled by a complex set of inductive interactions. The ability of axial midline tissues, the notochord and floor plate, to induce sclerotome has been well documented and has led to models in which ventral somite identity is specified by signals derived from the notochord and floor plate. Herein, we provide evidence that Sonic hedgehog, a vertebrate homolog of the Drosophila segment polarity gene hedgehog, is a signal produced by the notochord and floor plate that directs ventral somite differentiation. Sonic hedgehog is expressed in ventral midline tissues at critical times during somite specification and has the ability, when ectopically expressed, to enhance the formation of sclerotome and antagonize the development of dermatome.			JOHNSON, RL (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA.			Laufer, Edward/0000-0002-4933-1017				AOYAMA H, 1988, DEVELOPMENT, V104, P15; BOBER E, 1994, DEVELOPMENT, V120, P603; BRANDSABERI B, 1993, ANAT EMBRYOL, V188, P239; BUFFINGER N, 1994, DEVELOPMENT, V120, P1443; CHRIST B, 1992, ANAT EMBRYOL, V186, P505; DANTO SI, 1984, J CELL BIOL, V98, P2179, DOI 10.1083/jcb.98.6.2179; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DIETRICH S, 1993, MECH DEVELOP, V44, P189, DOI 10.1016/0925-4773(93)90067-8; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FAN CM, 1994, CELL, V79; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; Gallera J., 1966, Revue Suisse de Zoologie, V73, P492; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; JACOB H J, 1974, Verhandlungen der Anatomischen Gesellschaft, V68, P581; JEFFS P, 1992, ANAT EMBRYOL, V185, P589; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KENNYMOBBS T, 1987, DEVELOPMENT, V100, P449; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOSEKI H, 1993, DEVELOPMENT, V119, P649; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; ORDAHL CP, 1993, MOL BASIS MORPHOGENE, P165; PACKARD DS, 1976, DEV BIOL, V53, P36, DOI 10.1016/0012-1606(76)90207-4; PLACZEK M, 1993, DEVELOPMENT, V117, P205; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; RONG PM, 1992, DEVELOPMENT, V115, P657; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; TAM PPL, 1994, ANAT EMBRYOL, V189, P275; THEILER K, 1988, ADV ANAT EMBRYOL CEL, V112, P1; WATTERSON RL, 1954, AM J ANAT, V95, P337, DOI 10.1002/aja.1000950302; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	46	380	406	0	12	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 30	1994	79	7					1165	1173		10.1016/0092-8674(94)90008-6	http://dx.doi.org/10.1016/0092-8674(94)90008-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001152				2022-12-28	WOS:A1994PZ86000008
J	DEVALIA, JL; RUSZNAK, C; HERDMAN, MJ; TRIGG, CJ; TARRAF, H; DAVIES, RJ				DEVALIA, JL; RUSZNAK, C; HERDMAN, MJ; TRIGG, CJ; TARRAF, H; DAVIES, RJ			EFFECT OF NITROGEN-DIOXIDE AND SULFUR-DIOXIDE ON AIRWAY RESPONSE OF MILD ASTHMATIC-PATIENTS TO ALLERGEN INHALATION	LANCET			English	Article							SULFUR-DIOXIDE; IN-VITRO; EXPOSURE; OZONE; ASSOCIATION; POLLUTION	Air pollution may enhance the airway response of asthmatic subjects to allergen inhalation. To test the hypothesis that sulphur dioxide and nitrogen dioxide alone or in combination could have a contributory role, we have studied the effect of 6 h exposure to air, 200 parts per billion (ppb) sulphur dioxide, 400 ppb nitrogen dioxide, and the two gases together on the airway response to inhaled allergen in ten volunteers with mild atonic asthma. The subjects were exposed to the gases in random order at weekly visits, then challenged with pre-determined concentrations of Dermatophagoides pteronyssinus allergen 10 min after each exposure. The forced expiratory volume in 1 s (FEV(1)), forced vital capacity (FVC), and cumulative breath units (CBU) of D pteronyssinus allergen required to produce a 20% fall in FEV(1) (PD(20)FEV(1)) were measured after each exposure. Compared with air, neither sulphur dioxide nor nitrogen dioxide nor the combination significantly altered FEV(1) or FVC. Although the decreases in PD(20)FEV(1) after exposure to each agent alone were not significant (41.2%, p=0.125 after nitrogen dioxide; 32.2%, p=0.506 after sulphur dioxide) the decrease after exposure to the combination was significant (60.5 [SE 8.1]%, p=0.015). Exposure to a combination of sulphur dioxide and nitrogen dioxide in concentrations that could be encountered in heavy traffic enhances the airway response to inhaled allergen, possibly as a result of previous airway inflammation.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT RESP MED & ALLERGY,LONDON EC1A 7BE,ENGLAND; CAIRO UNIV,SCH MED,CAIRO,EGYPT	University of London; Queen Mary University London; Egyptian Knowledge Bank (EKB); Cairo University			Herdman, Michael/AAI-7280-2020					ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363, DOI 10.1164/ajrccm/148.5.1363; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271, DOI 10.1165/ajrcmb/9.3.271; DEVALIA JL, 1993, EUR RESPIR J, V6, P1308; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72, DOI 10.1165/ajrcmb/4.1.72; HIGGINS ITT, 1990, AM REV RESPIR DIS, V141, P1136, DOI 10.1164/ajrccm/141.5_Pt_1.1136; JORRES R, 1990, EUR RESPIR J, V3, P132; KEHRL HR, 1987, AM REV RESPIR DIS, V135, P1124; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; KOENIG JQ, 1990, AM REV RESPIR DIS, V141, P377, DOI 10.1164/ajrccm/141.2.377; LINN WS, 1983, ENVIRON RES, V30, P340, DOI 10.1016/0013-9351(83)90219-0; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; ROSSI OVJ, 1993, THORAX, V48, P244, DOI 10.1136/thx.48.3.244; SAMET JM, 1989, AM REV RESPIR DIS, V139, P1073, DOI 10.1164/ajrccm/139.5.1073; SANDSTROM T, 1991, EUR RESPIR J, V3, P332; SCHWARTZ J, 1990, AM REV RESPIR DIS, V141, P62, DOI 10.1164/ajrccm/141.1.62; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; WALTERS S, 1994, THORAX, V49, P133, DOI 10.1136/thx.49.2.133; 1993, 3RD REPORT OXIDES NI; 1991, 1ST REPORT OZONE; 1992, 2ND REPORT SULPHUR D	22	182	182	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1668	1671		10.1016/S0140-6736(94)90458-8	http://dx.doi.org/10.1016/S0140-6736(94)90458-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996960				2022-12-28	WOS:A1994PX30200009
J	LAUFER, E; NELSON, CE; JOHNSON, RL; MORGAN, BA; TABIN, C				LAUFER, E; NELSON, CE; JOHNSON, RL; MORGAN, BA; TABIN, C			SONIC HEDGEHOG AND FGF-4 ACT THROUGH A SIGNALING CASCADE AND FEEDBACK LOOP TO INTEGRATE GROWTH AND PATTERNING OF THE DEVELOPING LIMB BUD	CELL			English	Article							APICAL ECTODERMAL RIDGE; POLARITY GENE HEDGEHOG; RETROVIRAL VECTORS; HOX-4 GENES; EXPRESSION; CELLS; ACTIVATION; HOMOLOG	Proper limb growth and patterning requires signals from the zone of polarizing activity in the posterior mesoderm and from the overlying apical ectodermal ridge (AER). Sonic hedgehog and Fgf-4, respectively, have recently been identified as candidates for these signals. We have dissected the roles of these secreted proteins in early limb development by ectopically regulating their activities in a number of surgical contexts. Our results indicate that Sonic hedgehog initiates expression of secondary signaling molecules, including Bmp-2 in the mesoderm and Fgf-4 in the ectoderm. The mesoderm requires ectodermally derived competence factors, which include Fgf-4, to activate target gene expression in response to Sonic hedgehog. The expression of Sonic hedgehog and Fgf-4 is coordinately regulated by a positive feedback loop operating between the posterior mesoderm and the overlying AER. Taken together, these data provide a basis for understanding the integration of growth and patterning in the developing limb.			LAUFER, E (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA.			Laufer, Edward/0000-0002-4933-1017				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON R, 1993, DEVELOPMENT, V117, P1421; Ausubel FM, 1988, MOL REPROD DEV; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CORNELL RA, 1994, DEVELOPMENT, V120, P453; DAVIS AP, 1994, DEVELOPMENT, V120, P2187; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DONO R, 1994, DEV BIOL, V163, P316, DOI 10.1006/dbio.1994.1151; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; FEKETE DM, 1993, MOL CELL BIOL, V13, P2604, DOI 10.1128/MCB.13.4.2604; FIETZ M, 1995, IN PRESS DEVELOPME S; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; GERARD M, 1993, EMBO J, V12, P3539, DOI 10.1002/j.1460-2075.1993.tb06028.x; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IZPISUABELMONTE JC, 1992, EMBO J, V11, P1451, DOI 10.1002/j.1460-2075.1992.tb05189.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KOYAMA E, 1993, PROG CLIN BIOL RES, V383, P51; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LABONNE C, 1994, DEVELOPMENT, V120, P463; LAUFER E, 1993, CURR BIOL, V3, P306, DOI 10.1016/0960-9822(93)90187-S; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MACCABE JA, 1979, J EMBRYOL EXP MORPH, V53, P67; MAVILIO F, 1988, DIFFERENTIATION, V37, P73, DOI 10.1111/j.1432-0436.1988.tb00798.x; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RILEY BB, 1993, DEVELOPMENT, V118, P95; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; TICKLE C, 1991, DEVELOPMENT, P113; TODT WL, 1987, DEVELOPMENT, V101, P501; VOGEL A, 1993, DEVELOPMENT, V119, P199; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0	48	708	730	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 16	1994	79	6					993	1003		10.1016/0092-8674(94)90030-2	http://dx.doi.org/10.1016/0092-8674(94)90030-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001146				2022-12-28	WOS:A1994PY08600009
J	POWERS, MA; FORBES, DJ				POWERS, MA; FORBES, DJ			CYTOSOLIC FACTORS IN NUCLEAR TRANSPORT - WHATS IMPORTIN	CELL			English	Review							PROTEIN IMPORT; PORE COMPLEX; 2 STEPS; BINDING; TRANSLOCATION; ENVELOPE; IDENTIFICATION				POWERS, MA (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033279] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM033279] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DASSO M, 1994, IN PRESS EMBO J; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; FABRE E, 1994, CURR OPIN CELL BIOL, V6, P335, DOI 10.1016/0955-0674(94)90023-X; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; NEWMEYER DD, 1990, J CELL BIOL, V110, P547, DOI 10.1083/jcb.110.3.547; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; SCHLENSTEDT G, 1995, IN PRESS P NATL ACAD; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; STERNEMARR R, 1992, J CELL BIOL, V116, P271, DOI 10.1083/jcb.116.2.271; STOCHAJ U, 1992, J CELL BIOL, V117, P473, DOI 10.1083/jcb.117.3.473; UYANO R, 1994, P NATL ACAD SCI USA, V91, P6880; Xue Zhixiong, 1994, Trends in Cell Biology, V4, P414, DOI 10.1016/0962-8924(94)90095-7; Yamasaki L, 1992, Trends Cell Biol, V2, P123, DOI 10.1016/0962-8924(92)90083-Y; YANG J, 1994, MOL CELL BIOL, V14, P5088, DOI 10.1128/MCB.14.8.5088; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	35	128	128	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 16	1994	79	6					931	934		10.1016/0092-8674(94)90024-8	http://dx.doi.org/10.1016/0092-8674(94)90024-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001141				2022-12-28	WOS:A1994PY08600003
J	ZANARIA, E; MUSCATELLI, F; BARDONI, B; STROM, TM; GUIOLI, S; GUO, WW; LALLI, E; MOSER, C; WALKER, AP; MCCABE, ERB; MEITINGER, T; MONACO, AP; SASSONECORSI, P; CAMERINO, G				ZANARIA, E; MUSCATELLI, F; BARDONI, B; STROM, TM; GUIOLI, S; GUO, WW; LALLI, E; MOSER, C; WALKER, AP; MCCABE, ERB; MEITINGER, T; MONACO, AP; SASSONECORSI, P; CAMERINO, G			AN UNUSUAL MEMBER OF THE NUCLEAR HORMONE-RECEPTOR SUPERFAMILY RESPONSIBLE FOR X-LINKED ADRENAL HYPOPLASIA CONGENITA	NATURE			English	Article							COUP TRANSCRIPTION FACTOR; DNA-BINDING DOMAINS; RETINOIC ACID; GENE SUPERFAMILY; GLYCEROL KINASE; GENOMIC ORGANIZATION; EXPRESSION; CLONING; PROTEIN; XP21	X-linked adrenal hypoplasia congenita is a developmental disorder of the human adrenal gland that results in profound hormonal deficiencies and is,lethal if untreated. We have isolated the gene responsible for the disease, DAX-1, which is deleted or mutated in X-linked adrenal hypoplasia patients. DAX-1 encodes a new member of the nuclear hormone receptor superfamily displaying a novel DNA-binding domain. The DAX-1 product acts as a dominant negative regulator of transcription mediated by the retinoic acid receptor.	UNIV PAVIA,I-27100 PAVIA,ITALY; JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND; LMU,KINDERPOLIKLIN,PADIAT GENET ABT,D-80336 MUNICH,GERMANY; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; ULP,CNRS,INSERM,INST GENET & BIOL MOLEC CELLULAIRE,IGBMC,F-67404 ILLKIRCH GRAFFENS,FRANCE; UNIV SASSARI,IST ISTOL & EMBRIOL,I-07100 SASSARI,ITALY	University of Pavia; Cancer Research UK; University of Oxford; University of Munich; Baylor College of Medicine; Baylor College of Medicine; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Sassari			Lalli, Enzo/F-7052-2013; Bardoni, Barbara/F-9918-2013; Monaco, Anthony P/A-4495-2010; Muscatelli, Françoise/P-4650-2016; Walker, Ann P/C-1628-2008; Moser, Claudio/B-4686-2010	Lalli, Enzo/0000-0002-0584-5681; Monaco, Anthony P/0000-0001-7480-3197; Muscatelli, Françoise/0000-0003-4001-6528; Moser, Claudio/0000-0002-9141-7850; Meitinger, Thomas/0000-0002-8838-8403; Bardoni, Barbara/0000-0001-6411-1517; Guioli, Silvana/0000-0002-4920-7745	Telethon [B.05] Funding Source: Medline	Telethon(Fondazione Telethon)		BALLABIO A, 1990, GENOMICS, V8, P263, DOI 10.1016/0888-7543(90)90281-X; BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; GOONEWARDENA P, 1989, CLIN GENET, V35, P5; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Kastner P., 1994, Vitamin A in health and disease., P189; Kelch RP, 1984, PEDIATR ADOLESC ENDO, V13, P156; KLETTER GB, 1991, TRENDS ENDOCRIN MET, V2, P123, DOI 10.1016/1043-2760(91)90001-4; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIU C, 1992, MOL ENDOCRIN, V7, P651; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Martin M.M., 1985, INT J ADOLESC MED HL, V1, P119; MATHARU PJ, 1992, BIOCHIM BIOPHYS ACTA, V1129, P331, DOI 10.1016/0167-4781(92)90512-X; MAVILIO F, 1986, NATURE, V324, P664, DOI 10.1038/324664a0; McKusick V.A., 1992, MENDELIAN INHERITANC; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; Sambrook J, 1989, MOL CLONING LABORATO; STEPHEN F, 1990, J MOL BIOL, V215, P403, DOI DOI 10.1006/JMBI.1990.9999; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANDERLEEDE BM, 1992, BIOCHEM BIOPH RES CO, V188, P695, DOI 10.1016/0006-291X(92)91112-4; WALKER AP, 1992, HUM MOL GENET, V1, P579, DOI 10.1093/hmg/1.8.579; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WORLEY KC, 1992, GENOMICS, V13, P957, DOI 10.1016/0888-7543(92)90007-F; WORLEY KC, 1993, GENOMICS, V16, P407, DOI 10.1006/geno.1993.1204	45	691	720	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					635	641		10.1038/372635a0	http://dx.doi.org/10.1038/372635a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990953				2022-12-28	WOS:A1994PX30700075
J	WYATT, JC				WYATT, JC			CLINICAL-DATA SYSTEMS .2. COMPONENTS AND TECHNIQUES	LANCET			English	Article							MEDICAL INFORMATICS; LANGUAGE; RECORDS				WYATT, JC (corresponding author), IMPERIAL CANC RES FUND,BIOMED INFORMAT UNIT,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.		Wyatt, Jeremy/F-8160-2010	Wyatt, Jeremy/0000-0001-7008-1473				BARNETT GO, 1993, ANN INTERN MED, V119, P1046, DOI 10.7326/0003-4819-119-10-199311150-00014; BARRIE JL, 1992, BRIT MED J, V304, P159, DOI 10.1136/bmj.304.6820.159; BLEICH HL, 1985, NEW ENGL J MED, V312, P756, DOI 10.1056/NEJM198503213121205; BLUM BI, 1986, CLIN INFORAMTION SYS; BRADSHAW KE, 1989, COMPUT BIOMED RES, V22, P575, DOI 10.1016/0010-4809(89)90077-3; BRAHAMS D, 1993, LANCET, V342, P1168, DOI 10.1016/0140-6736(93)92143-H; BUCKLAND R, 1993, BRIT MED J, V306, P287, DOI 10.1136/bmj.306.6873.287; CARTMILL RSV, 1992, LANCET, V339, P1520, DOI 10.1016/0140-6736(92)91275-D; COLLEN MF, 1986, WESTERN J MED, V145, P778; EMBERTON M, 1993, BRIT J HEALTHC COMP, V10, P32; GLOWNIAK JV, 1994, JAMA-J AM MED ASSOC, V271, P1934, DOI 10.1001/jama.271.24.1934; GOULD JD, 1984, HUM FACTORS, V26, P323, DOI 10.1177/001872088402600308; GREENES RA, 1990, JAMA-J AM MED ASSOC, V263, P1114; GULLIFORD MC, 1993, BRIT J CANCER, V67, P819, DOI 10.1038/bjc.1993.149; HOLBROOK J, 1990, ANN EMERG MED, V19, P139, DOI 10.1016/S0196-0644(05)81798-6; HOLLINGSWORTH TH, 1959, J R STAT SOC SER A-G, V122, P221, DOI 10.2307/2342604; JOHNSON J, 1989, COMPUTER         SEP, P11; JONES BL, 1986, CRIT REV PLANT SCI, V3, P295, DOI 10.1080/07352688609382214; KUHN K, 1992, METHOD INFORM MED, V31, P268; LAMS PM, 1986, RADIOLOGY, V158, P11, DOI 10.1148/radiology.158.1.3940365; LEANING MS, 1993, BRIT MED J, V307, P217, DOI 10.1136/bmj.307.6898.217; LINDBERG DAB, 1993, METHOD INFORM MED, V32, P281, DOI 10.1055/s-0038-1634945; LOCKE SE, 1992, JAMA-J AM MED ASSOC, V268, P1301, DOI 10.1001/jama.268.10.1301; LUCAS RW, 1976, BMJ-BRIT MED J, V2, P623, DOI 10.1136/bmj.2.6036.623; LURIE N, 1989, NEW ENGL J MED, V320, P1673, DOI 10.1056/NEJM198906223202507; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MURCHIE CJ, 1988, INT J CLIN MONIT COM, V5, P243, DOI 10.1007/BF02915914; Norman D. A., 1990, DESIGN EVERYDAY THIN; NORTON SL, 1981, COMPUT BIOMED RES, V14, P179, DOI 10.1016/0010-4809(81)90035-5; OLIVER RTD, 1993, FORUM CLIN COMPUTING; POWSNER SM, 1994, LANCET, V344, P386, DOI 10.1016/S0140-6736(94)91406-0; Rind D. M., 1994, Seventeenth Annual Symposium on Computer Applications in Medical Care. Patient-Centered Computing, P74; Rothwell D. J., 1994, Seventeenth Annual Symposium on Computer Applications in Medical Care. Patient-Centered Computing, P695; RUSSELL IJ, 1990, ACAD MED, V65, P333, DOI 10.1097/00001888-199005000-00015; SAFRAN C, 1989, ANN INTERN MED, V111, P751, DOI 10.7326/0003-4819-111-9-751; SCHREIBER F, 1938, J MICHIGAN MED SOC, V37, P909; SCHWARTZ RJ, 1985, M D COMPUT, V2, P19; SHERRER JR, 1990, MD COMPUTING, V7, P81; SHIFFMAN S, 1991, IEEE EXPERT      FEB, P41; SHORTLIFFE EH, 1991, MED DECIS MAKING, V11, pS2, DOI 10.1177/0272989X9101104s02; SHORTLIFFE EH, 1990, MED INFORMATICS; SITTIG DF, 1994, J AM MED INFORM ASSN, V1, P108, DOI 10.1136/jamia.1994.95236142; SMITH MF, 1994, BMJ-BRIT MED J, V308, P612, DOI 10.1136/bmj.308.6929.612; Wilton R., 1994, Seventeenth Annual Symposium on Computer Applications in Medical Care. Patient-Centered Computing, P279; 1986, PHYSICIANS CURRENT P; 1980, DHHS PHS801260 US HL; 1986, CLASSIFICATION SURGI	48	27	61	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1609	1614		10.1016/S0140-6736(94)90409-X	http://dx.doi.org/10.1016/S0140-6736(94)90409-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983996				2022-12-28	WOS:A1994PW05100012
J	DORSHKIND, K				DORSHKIND, K			TRANSCRIPTIONAL CONTROL POINTS DURING LYMPHOPOIESIS	CELL			English	Review							B-CELL DIFFERENTIATION; GENE-TRANSCRIPTION; DNA-BINDING; REARRANGEMENT; EXPRESSION; PROTEINS; MICE				DORSHKIND, K (corresponding author), UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521, USA.							BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CLEVERS HC, 1993, IMMUNOL TODAY, V14, P591, DOI 10.1016/0167-5699(93)90198-T; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; IKUTA K, 1992, ANNU REV IMMUNOL, V10, P759; KARASUYAMA H, 1994, CELL, V77, P133, DOI 10.1016/0092-8674(94)90241-0; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; ROLINK A, 1993, ADV IMMUNOL, V53, P123, DOI 10.1016/S0065-2776(08)60499-X; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; XIN XQ, 1993, J IMMUNOL, V151, P5398; ZHOU LJ, 1994, MOL CELL BIOL, V14, P3884, DOI 10.1128/MCB.14.6.3884; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	21	41	43	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 2	1994	79	5					751	753		10.1016/0092-8674(94)90065-5	http://dx.doi.org/10.1016/0092-8674(94)90065-5			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001114				2022-12-28	WOS:A1994PW05400003
J	GORLICH, D; PREHN, S; LASKEY, RA; HARTMANN, E				GORLICH, D; PREHN, S; LASKEY, RA; HARTMANN, E			ISOLATION OF A PROTEIN THAT IS ESSENTIAL FOR THE FIRST STEP OF NUCLEAR-PROTEIN IMPORT	CELL			English	Article							GTP-BINDING PROTEIN; 2 STEPS; SEQUENCE; PORE; TRANSLOCATION; IDENTIFICATION; LOCALIZATION; REPLICATION; ENVELOPE; SIGNALS	We have purified a cytosolic protein from Xenopus eggs that is essential for selective protein import into the cell nucleus. The purified protein, named importin, promotes signal-dependent binding of karyophilic proteins to the nuclear envelope. We have cloned, sequenced, and expressed a corresponding cDNA. Importin shows 44% sequence identity with SRP1p, a protein associated with the yeast nuclear pore complex. Complete, signal-dependent import into HeLa nuclei can be reconstituted by combining importin purified from Xenopus eggs or expressed in E. coli with Ran/TC4. Evidence for additional stimulatory factors is provided.	UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 3EJ, ENGLAND; HUMBOLDT UNIV BERLIN, INST BIOCHEM, D-10115 BERLIN, GERMANY; MAX DELBRUCK CTR MOLEC MED, D-13125 BERLIN, GERMANY	University of Cambridge; Humboldt University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	GORLICH, D (corresponding author), WELLCOME CRC INST, TENNIS COURT RD, CAMBRIDGE CB2 1QR, ENGLAND.		Görlich, Dirk/B-8296-2017; Hartmann, Enno/C-5687-2013	Görlich, Dirk/0000-0002-4343-5210; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; DUPREE P, 1992, GENE, V120, P325, DOI 10.1016/0378-1119(92)90118-9; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FABRE E, 1994, CURR OPIN CELL BIOL, V6, P335, DOI 10.1016/0955-0674(94)90023-X; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; LENO GH, 1991, METHOD CELL BIOL, V36, P561; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NEWMEYER DD, 1990, J CELL BIOL, V110, P547, DOI 10.1083/jcb.110.3.547; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; Yamasaki L, 1992, Trends Cell Biol, V2, P123, DOI 10.1016/0962-8924(92)90083-Y; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	33	627	635	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					767	778		10.1016/0092-8674(94)90067-1	http://dx.doi.org/10.1016/0092-8674(94)90067-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001116				2022-12-28	WOS:A1994PW05400005
J	SUN, XH				SUN, XH			CONSTITUTIVE EXPRESSION OF THE ID1 GENE IMPAIRS MOUSE B-CELL DEVELOPMENT	CELL			English	Article							NF-KAPPA-B; IMMUNOGLOBULIN LIGHT CHAIN; DNA-BINDING SUBUNIT; LOOP-HELIX PROTEINS; HEAVY-CHAIN; BONE-MARROW; TARGETED DISRUPTION; V(D)J RECOMBINATION; MEMBRANE EXON; TRANSCRIPTION	The Id proteins are inhibitors of the basic-helix-loop-helix (bHLH) transcription factors. In the B cell lineage, the Id1 and Id2 genes are expressed in pro-B cells and down-regulated during differentiation. To determine the role of bHLH proteins and the significance of downregulation of ld genes in B cell development, transgenic mice constitutively expressing the Id1 gene were generated. Their phenotype suggests that B cell development is impaired at an early stage. Primarily, these mice have few B220(+) IgM(+) mature B or B220(+) CD43(-) pre-B cells in the bone marrow, reduced frequencies of V(D)J and V(kappa)J(kappa) recombination of the immunoglobulin loci, and lower expression levels of the immunoglobulin, RAG-1, RAG-2, and lambda 5 genes.			SUN, XH (corresponding author), NYU,MED CTR,KAPLAN COMPREHENSIVE CANC CTR,DEPT CELL BIOL,NEW YORK,NY 10016, USA.							ALESSANDRINI A, 1991, MOL CELL BIOL, V11, P2096, DOI 10.1128/MCB.11.4.2096; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Blackwell T. K., 1988, Molecular Immunology., P1; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FELDHAUS AL, 1992, MOL CELL BIOL, V12, P1126, DOI 10.1128/MCB.12.3.1126; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; HARA E, 1994, J BIOL CHEM, V269, P2139; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P678, DOI 10.1093/nar/18.3.678; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; IGLESIAS A, 1991, EMBO J, V10, P2147, DOI 10.1002/j.1460-2075.1991.tb07749.x; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MISENER V, 1991, INT IMMUNOL, V3, P1129, DOI 10.1093/intimm/3.11.1129; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHLISSEL MS, 1994, J IMMUNOL, V153, P1645; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SHAPIRO AM, 1993, MOL CELL BIOL, V13, P5679, DOI 10.1128/MCB.13.9.5679; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; SU LK, 1990, MOL CELL BIOL, V10, P2619, DOI 10.1128/MCB.10.6.2619; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; XIN XQ, 1993, J IMMUNOL, V151, P5398; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	57	250	255	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 2	1994	79	5					893	900		10.1016/0092-8674(94)90078-7	http://dx.doi.org/10.1016/0092-8674(94)90078-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001126				2022-12-28	WOS:A1994PW05400016
J	KESSLER, F; BLOBEL, G; PATEL, HA; SCHNELL, DJ				KESSLER, F; BLOBEL, G; PATEL, HA; SCHNELL, DJ			IDENTIFICATION OF 2 GTP-BINDING PROTEINS IN THE CHLOROPLAST PROTEIN IMPORT MACHINERY	SCIENCE			English	Article							PRECURSOR PROTEINS; SEQUENCE-ANALYSIS; ENVELOPE; LOCALIZATION; MEMBRANES; REQUIRES; PATHWAY	Two of four proteins that associated with translocation intermediates during protein import across the outer chloroplast envelope membrane were identified as guanosine triphosphate (GTP)-binding proteins. Both proteins are integral membrane proteins of the outer chloroplast membrane, and both are partially exposed on the chloroplast surface where they were accessible to thermolysin digestion. Engagement of the outer membrane's import machinery by an import substrate was inhibited by slowly hydrolyzable or non-hydrolyzable GTP analogs. Thus, these GTP-binding proteins may function in protein import into chloroplasts.	RUTGERS STATE UNIV,DEPT BIOL SCI,NEWARK,NJ 07102; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,NEW YORK,NY 10021	Rutgers State University Newark; Rutgers State University New Brunswick; Howard Hughes Medical Institute; Rockefeller University			Kessler, Felix Henrique/AAO-1722-2020	Kessler, Felix/0000-0001-6409-5043				ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; MARSTON FAO, 1987, DNA CLONING PRACTICA, V3; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; Sambrook J, 1989, MOL CLONING LABORATO; SCHNELL D, UNPUB; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SCHNELL DJ, 1994, SCIENCE, V266, P100; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x	22	251	264	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1035	1039		10.1126/science.7973656	http://dx.doi.org/10.1126/science.7973656			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973656				2022-12-28	WOS:A1994PQ92400042
J	SCHUMACHER, MA; CHOI, KY; ZALKIN, H; BRENNAN, RG				SCHUMACHER, MA; CHOI, KY; ZALKIN, H; BRENNAN, RG			CRYSTAL-STRUCTURE OF LACI MEMBER, PURR, BOUND TO DNA - MINOR-GROOVE BINDING BY ALPHA-HELICES	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ESCHERICHIA-COLI; REPRESSOR PROTEIN; NUCLEOTIDE-SEQUENCE; REGULATORY PROTEINS; MOLECULAR-DYNAMICS; PURINE REPRESSOR; ACID INTERACTION; OPERATOR; GENE	The three-dimensional structure of a ternary complex of the purine repressor, PurR, bound to both its corepressor, hypoxanthine, and the 16-base pair purF operator site has been solved at 2.7 Angstrom resolution by x-ray crystallography. The bipartite Structure of PurR consists of an amino-terminal DNA-binding domain and a larger carboxyl-terminal corepressor binding and dimerization domain that is similar to that of the bacterial periplasmic binding proteins. The DNA-binding domain contains alpha helix-turn-helix motif that makes base-specific contacts in the major groove of the DNA. Base contacts are also made by residues of symmetry-related a helices, the ''hinge'' helices, which bind deeply in the minor groove, Critical to hinge helix-minor groove binding is the intercalation of the side chains of Leu(54) and its symmetry-related mate, Leu(54'), into the central CpG-base pair step. These residues thereby act as ''leucine levers'' to pry open the minor groove and kink the purF operator by 45 degrees.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA; PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Oregon Health & Science University; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Brennan, Richard/0000-0001-7647-485X	NIGMS NIH HHS [GM 24658, GM 49244] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024658, R37GM024658, R01GM049244] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; ALBERTI S, 1991, NEW BIOL, V3, P57; BARBIER CS, 1992, J BACTERIOL, V174, P2881, DOI 10.1128/JB.174.9.2881-2890.1992; BARKLEY MD, 1974, NATURE, V251, P247, DOI 10.1038/251247a0; BIN H, 1993, J BACTERIOL, V175, P3598, DOI 10.1128/jb.175.11.3598-3606.1993; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; Brennan RG, 1991, CURR OPIN STRUC BIOL, V1, P80, DOI 10.1016/0959-440X(91)90015-L; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHANG WI, 1994, BIOCHEMISTRY-US, V33, P3607, DOI 10.1021/bi00178a018; CHANG WI, 1993, J BIOL CHEM, V268, P17613; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; CHOI KY, 1994, J BIOL CHEM, V269, P24066; CHOI KY, 1994, J BACTERIOL, V176, P1767, DOI 10.1128/jb.176.6.1767-1772.1994; CHUPRINA VP, 1993, J MOL BIOL, V234, P446, DOI 10.1006/jmbi.1993.1598; CORTAY JC, 1994, J BIOL CHEM, V269, P14885; GORDON AJE, 1988, J MOL BIOL, V200, P239, DOI 10.1016/0022-2836(88)90237-9; GRALLA JD, 1992, TRANSCRIPTIONAL REGU, V2, P629; HAGERMAN PJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P125, DOI 10.1016/0167-4781(92)90066-9; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HE B, 1990, J BACTERIOL, V172, P4555, DOI 10.1128/jb.172.8.4555-4562.1990; HE B, 1994, J BACTERIOL, V176, P1009, DOI 10.1128/JB.176.4.1009-1013.1994; HE B, 1992, J BACTERIOL, V174, P130, DOI 10.1128/jb.174.1.130-136.1992; HE B, 1992, J BACTERIOL, V174, P7121, DOI 10.1128/jb.174.22.7121-7127.1992; HSIEH M, 1994, J BIOL CHEM, V269, P13825; JAENICKE R, 1990, FEBS LETT, V260, P233, DOI 10.1016/0014-5793(90)80111-U; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAPTEIN R, 1985, J MOL BIOL, V182, P179, DOI 10.1016/0022-2836(85)90036-1; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LAMERICHS RMJN, 1989, BIOCHEMISTRY-US, V28, P2985, DOI 10.1021/bi00433a037; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LEHMING N, 1988, P NATL ACAD SCI USA, V85, P7947, DOI 10.1073/pnas.85.21.7947; LU FH, UNPUB; MARKIEWICZ P, 1994, J MOL BIOL, V240, P421, DOI 10.1006/jmbi.1994.1458; MAUZY CA, 1992, PROTEIN SCI, V1, P843, DOI 10.1002/pro.5560010702; MENG LM, 1990, EUR J BIOCHEM, V187, P373, DOI 10.1111/j.1432-1033.1990.tb15314.x; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; MULLERHILL B, 1983, NATURE, V302, P163, DOI 10.1038/302163a0; NICHOLS JC, 1993, J BIOL CHEM, V268, P17602; OH BH, 1993, J BIOL CHEM, V268, P11348; OLAH GA, 1993, J BIOL CHEM, V268, P16241; ORNSTEIN RL, 1978, BIOPOLYMERS, V17, P2341, DOI 10.1002/bip.1978.360171005; PABO CO, 1990, SCIENCE, V247, P1210, DOI 10.1126/science.2315694; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; RAVISHANKER G, 1989, J BIOMOL STRUCT DYN, V6, P669, DOI 10.1080/07391102.1989.10507729; ROLFES RJ, 1988, J BIOL CHEM, V263, P19653; ROLFES RJ, 1990, J BACTERIOL, V172, P5758, DOI 10.1128/jb.172.10.5758-5766.1990; SADLER JR, 1983, P NATL ACAD SCI-BIOL, V80, P6785, DOI 10.1073/pnas.80.22.6785; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHUMACHER MA, 1994, J MOL BIOL, V242, P302, DOI 10.1006/jmbi.1994.1580; SCHUMACHER MA, 1993, J BIOL CHEM, V268, P12282; SCHUMACHER MA, UNPUB; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SIMONS A, 1984, P NATL ACAD SCI-BIOL, V81, P1624, DOI 10.1073/pnas.81.6.1624; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SPOTTS RO, 1991, J BIOL CHEM, V266, P22998; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TRAVERS AA, 1992, CURR OPIN STRUC BIOL, V2, P71; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VARTAK NB, 1991, RES MICROBIOL, V142, P951, DOI 10.1016/0923-2508(91)90005-U; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4; ZUIDERWEG ERP, 1983, P NATL ACAD SCI-BIOL, V80, P5837, DOI 10.1073/pnas.80.19.5837; ZWIEB C, 1989, GENE DEV, V3, P606, DOI 10.1101/gad.3.5.606	78	342	350	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	1994	266	5186					763	770		10.1126/science.7973627	http://dx.doi.org/10.1126/science.7973627			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973627				2022-12-28	WOS:A1994PP75300028
J	HALL, R; HAWKINS, PN; SCOTT, J; PEPYS, MB; POLAK, JM; DAVIES, KA				HALL, R; HAWKINS, PN; SCOTT, J; PEPYS, MB; POLAK, JM; DAVIES, KA			CARDIAC TRANSPLANTATION FOR AL AMYLOIDOSIS	BRITISH MEDICAL JOURNAL			English	Discussion							SYSTEMIC AMYLOIDOSIS; P COMPONENT; SURVIVAL; SCINTIGRAPHY; REGRESSION; TURNOVER				HALL, R (corresponding author), UNIV WALES COLL CARDIFF,CARDIFF,S GLAM,WALES.		Hawkins, Philip N/C-5573-2008					BENSON MD, 1986, ARTHRITIS RHEUM-US, V29, P683, DOI 10.1002/art.1780290515; CUETOGARCIA L, 1985, J AM COLL CARDIOL, V6, P737, DOI 10.1016/S0735-1097(85)80475-7; GERTZ MA, 1991, BLOOD, V77, P257; GERTZ MA, 1989, MAYO CLIN PROC, V64, P1505, DOI 10.1016/S0025-6196(12)65706-1; HAWKINS PN, 1993, ARTHRITIS RHEUM, V36, P842, DOI 10.1002/art.1780360616; HAWKINS PN, 1988, LANCET, V1, P1413; HAWKINS PN, 1993, Q J MED, V86, P365; HAWKINS PN, 1990, NEW ENGL J MED, V323, P508, DOI 10.1056/NEJM199008233230803; HOLMGREN G, 1993, LANCET, V341, P1113, DOI 10.1016/0140-6736(93)93127-M; HOSENPUD JD, 1991, CIRCULATION, V84, P338; KYLE RA, 1983, MAYO CLIN PROC, V58, P665	11	37	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1994	309	6962					1135	1137		10.1136/bmj.309.6962.1135	http://dx.doi.org/10.1136/bmj.309.6962.1135			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987109	Green Published			2022-12-28	WOS:A1994PP69100027
J	SIMOONS, ML				SIMOONS, ML			MYOCARDIAL-INFARCTION - ACE-INHIBITORS FOR ALL - FOR EVER	LANCET			English	Editorial Material							LEFT-VENTRICULAR DYSFUNCTION; CAPTOPRIL; THERAPY; ENALAPRIL; REPERFUSION; DILATATION; TRIAL				SIMOONS, ML (corresponding author), ERASMUS UNIV ROTTERDAM,THORAXCTR,3000 DR ROTTERDAM,NETHERLANDS.							[Anonymous], 1993, LANCET, V342, P821; BALL SG, 1994, LANCET, V343, P1632, DOI 10.1016/S0140-6736(94)93083-X; BONARJEE VVS, 1993, AM J CARDIOL, V72, P1004, DOI 10.1016/0002-9149(93)90853-5; DEGRAEFF PA, 1987, J CARDIOVASC PHARM, V9, pS37, DOI 10.1097/00005344-198700002-00009; Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico, 1994, LANCET, V343, P1115; HOCK CE, 1985, AM HEART J, V109, P222, DOI 10.1016/0002-8703(85)90587-3; KINGMA JH, IN PRESS EUR HEART J; KINGMA JH, 1989, CURRENT ADV ACE INHI, P291; NABEL EG, 1991, J AM COLL CARDIOL, V17, P467, DOI 10.1016/S0735-1097(10)80117-2; OLDROYD KG, 1991, AM J CARDIOL, V68, P713, DOI 10.1016/0002-9149(91)90641-W; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; PFEFFER MA, 1992, NEW ENGL J MED, V327, P369; SCHOEMAKER RG, 1991, J MOL CELL CARDIOL, V23, P187, DOI 10.1016/0022-2828(91)90105-U; SHARPE N, 1988, LANCET, V1, P255; SHARPE N, 1991, LANCET, V337, P872, DOI 10.1016/0140-6736(91)90202-Z; SIGURDSSON A, 1991, INT J CARDIOL, V33, P115, DOI 10.1016/0167-5273(91)90159-M; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; TOGNONI G, 1994, LANCET, V343, P1633; VANGILST WH, 1986, J CARDIOVASC PHARM, V8, P722; 1991, NEW ENGL J MED, V325, P293; 1987, NEW ENGL J MED, V316, P1429; 1991, AM J CARDIOL, V68, pD87	23	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					279	281		10.1016/S0140-6736(94)91333-1	http://dx.doi.org/10.1016/S0140-6736(94)91333-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7980780	Green Submitted			2022-12-28	WOS:A1994NZ23300002
J	VARGA, J; JIMENEZ, SA				VARGA, J; JIMENEZ, SA			MODULATION OF COLLAGEN GENE-EXPRESSION - ITS RELATION TO FIBROSIS IN SYSTEMIC-SCLEROSIS AND OTHER DISORDERS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							GROWTH-FACTOR-BETA; TGF-BETA; SKIN; ANTIBODY	Fibrosis is the pathologic hallmark of many common diseases. Much information has recently emerged about the cellular and biochemical events that result in its development and progression. It is now known that in affected tissues, chronic inflammation generally precedes fibrosis and that inflammatory cell-derived cytokines are crucial mediators of fibrogenesis. Several cytokines have been identified that influence wound healing and tissue repair processes in vivo and that modulate the production of collagen in vitro. Of these, transforming growth factor-beta is of the most interest because this pleiotropic cytokine is expressed at high levels during tissue remodeling and greatly affects the formation of connective tissue. Furthermore, it has been recently shown that transforming growth factor-beta can stimulate the transcription of collagen genes through the production or activation of specific DNA-binding trans-acting factors. A precise understanding of the molecular mechanisms responsible for the effects of this cytokine on collagen gene expression may allow the design of selective therapeutic interventions aimed at retarding or preventing the development of fibrosis.			VARGA, J (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, BLUEMLE LIFE SCI BLDG, 233 S 10TH ST, ROOM 509, PHILADELPHIA, PA 19107 USA.		Varga, John/AAK-6472-2021	Jimenez, Sergio/0000-0001-5213-1203	NIAMS NIH HHS [AR-42309, AR-19106] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042309] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BECK LS, 1993, J CLIN INVEST, V92, P2841, DOI 10.1172/JCI116904; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; FREUNDLICH B, 1992, ARTHRITIS RHEUM, V35, P1134, DOI 10.1002/art.1780351005; GABRIELLI A, 1993, CLIN IMMUNOL IMMUNOP, V68, P340, DOI 10.1006/clin.1993.1136; GIRI SN, 1993, THORAX, V48, P959, DOI 10.1136/thx.48.10.959; HIGLEY H, 1994, ARTHRITIS RHEUM, V37, P278, DOI 10.1002/art.1780370218; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; ISAKA Y, 1993, J CLIN INVEST, V92, P2597, DOI 10.1172/JCI116874; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KULOZIK M, 1990, J CLIN INVEST, V86, P917, DOI 10.1172/JCI114793; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NEHLS MC, 1993, J CLIN INVEST, V92, P2916, DOI 10.1172/JCI116914; PELTONEN J, 1990, J INVEST DERMATOL, V94, P365, DOI 10.1111/1523-1747.ep12874491; PELTONEN J, 1990, ARTHRITIS RHEUM-US, V33, P1829, DOI 10.1002/art.1780331211; QUAGLINO D, 1991, J INVEST DERMATOL, V97, P34; Rhodes Katherine, 1992, Gene Expression, V2, P59; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; RUDNICKA L, 1994, J CLIN INVEST, V93, P1709, DOI 10.1172/JCI117154; SHAH M, 1992, LANCET, V339, P213, DOI 10.1016/0140-6736(92)90009-R; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; SMITH E, 1994, RHEUMATOLOGY; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; WOLF YG, 1994, J CLIN INVEST, V93, P1172, DOI 10.1172/JCI117070	26	53	55	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1995	122	1					60	62		10.7326/0003-4819-122-1-199501010-00010	http://dx.doi.org/10.7326/0003-4819-122-1-199501010-00010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY502	7985897				2022-12-28	WOS:A1995PY50200010
J	FUCHS, CS; GIOVANNUCCI, EL; COLDITZ, GA; HUNTER, DJ; SPEIZER, FE; WILLETT, WC				FUCHS, CS; GIOVANNUCCI, EL; COLDITZ, GA; HUNTER, DJ; SPEIZER, FE; WILLETT, WC			A PROSPECTIVE-STUDY OF FAMILY HISTORY AND THE RISK OF COLORECTAL-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SELF-ADMINISTERED QUESTIONNAIRE; CORONARY HEART-DISEASE; ALCOHOL-CONSUMPTION; COLON; REPRODUCIBILITY; FREQUENCY; RECTUM; POLYPS	Background. A family history of colorectal cancer is recognized as a risk factor for the disease. However, as a result of the retrospective design of prior studies, the strength of this association is uncertain, particularly as it is influenced by characteristics of the person at risk and the affected family members. Methods. We conducted a prospective study of 32,085 men and 87,031 women who had not previously been examined by colonoscopy or sigmoidoscopy and who provided data on first-degree relatives with colorectal cancer, diet, and other risk factors for the disease. During the follow-up period, colorectal cancer was diagnosed in 148 men and 315 women. Results. The age-adjusted relative risk of colorectal cancer for men and women with affected first-degree relatives, as compared with those without a family history of the disease, was 1.72 (95 percent confidence interval, 1.34 to 2.19). The relative risk among study participants with two or more affected first-degree relatives was 2.75 (95 percent confidence interval, 1.34 to 5.63). For participants under the age of 45 years who had one or more affected first-degree relatives, the relative risk was 5.37 (95 percent confidence interval, 1.98 to 14.6), and the risk decreased with increasing age (P for trend, <0.001). Conclusions. A family history of colorectal cancer is associated with an increased risk of the disease, especially among younger people.	HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	FUCHS, CS (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DANA FARBER CANC INST,DIV MED ONCOL,44 BINNEY ST,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [P01CA055075, R01CA040935] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BONELLI L, 1988, INT J CANCER, V41, P513; CANNONALBRIGHT LA, 1989, CANCER, V64, P1971, DOI 10.1002/1097-0142(19891101)64:9<1971::AID-CNCR2820640935>3.0.CO;2-L; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; COLDITZ GA, 1987, INT J EPIDEMIOL, V16, P392, DOI 10.1093/ije/16.3.392; COX DR, 1972, J R STAT SOC B, V34, P187; DELEON MP, 1987, CANCER, V60, P2848, DOI 10.1002/1097-0142(19871201)60:11<2848::AID-CNCR2820601141>3.0.CO;2-F; DUNCAN JL, 1982, GUT, V23, P169, DOI 10.1136/gut.23.2.169; FISHER G, 1989, MED J AUSTRALIA, V150, P22, DOI 10.5694/j.1326-5377.1989.tb136314.x; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; KUNE GA, 1989, WORLD J SURG, V13, P124, DOI 10.1007/BF01671173; LEVIN B, 1992, CA-CANCER J CLIN, V42, P296, DOI 10.3322/canjclin.42.5.296; LOVETT E, 1976, BRIT J SURG, V63, P13, DOI 10.1002/bjs.1800630103; MACKLIN MT, 1960, J NATL CANCER I, V24, P551, DOI 10.1093/jnci/24.3.551; MAIRE P, 1984, GASTROEN CLIN BIOL, V8, P22; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Rothman K, 1986, MODERN EPIDEMIOLOGY; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SONDERGAARD JO, 1991, INT J CANCER, V47, P202, DOI 10.1002/ijc.2910470207; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STEPHENSON BM, 1991, BRIT J SURG, V78, P1162, DOI 10.1002/bjs.1800781005; STJOHN DJB, 1993, ANN INTERN MED, V118, P785, DOI 10.7326/0003-4819-118-10-199305150-00005; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; WOOLF CM, 1958, AM J HUM GENET, V10, P42	28	586	593	2	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 22	1994	331	25					1669	1674		10.1056/NEJM199412223312501	http://dx.doi.org/10.1056/NEJM199412223312501			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX382	7969357				2022-12-28	WOS:A1994PX38200001
J	PEREGO, M; HANSTEIN, C; WELSH, KM; DJAVAKHISHVILI, T; GLASER, P; HOCH, JA				PEREGO, M; HANSTEIN, C; WELSH, KM; DJAVAKHISHVILI, T; GLASER, P; HOCH, JA			MULTIPLE PROTEIN ASPARTATE PHOSPHATASES PROVIDE A MECHANISM FOR THE INTEGRATION OF DIVERSE SIGNALS IN THE CONTROL OF DEVELOPMENT IN BACILLUS-SUBTILIS	CELL			English	Article							BACILLUS-SUBTILIS; SPORULATION GENE; PHOSPHORYLATION; INITIATION; EXPRESSION; SYSTEM; TRANSCRIPTION; PHOSPHORELAY; CHROMOSOME; MUTATIONS	The initiation of sporulation in B. subtilis is regulated by the SpoOA transcription factor, which is activated by phosphorylation to central developmental switching from the vegetative to the sporulation state. The level of phosphorylation of SpoOA is regulated by the phosphorelay, a signal transduction system based on the protein-histidine kinase-response regulator two-component paradigm. To initiate sporulation, the cell must recognize and interpret a large variety of environmental, metabolic, and cell cycle signals that influence the phosphorylation level of SpoOA. We describe here a family of protein-aspartate phosphatases with activity on SpoOF similar to P, a response regulator component of the phosphorelay, that provide a mechanism for signal recognition and interpretation. These phosphatases function to drain the phosphorelay, lower SpoOA similar to P levels, and prevent sporulation, The integration of diverse environmental signals that affect the initiation of sporulation likely occurs through the competition between opposing activities of protein kinases and protein phosphatases.	UNIV PAVIA, DIPARTIMENTO GENET & MICROBIOL A BUZZATI TRAV, I-27100 PAVIA, ITALY; INST PASTEUR, DEPT REGULAT GENET EXPRESS, F-75724 PARIS, FRANCE; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	University of Pavia; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Scripps Research Institute	PEREGO, M (corresponding author), UNIV PARMA, DIPARTIMENTO FARMACEUT, VIA SCI, I-43100 PARMA, ITALY.		Glaser, Philippe/O-2641-2015	Glaser, Philippe/0000-0003-4156-2782	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019416, R01GM045727, R01GM019416] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45727, GM19416] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; DEDONDER RA, 1977, APPL ENVIRON MICROB, V33, P989, DOI 10.1128/AEM.33.4.989-993.1977; DUBNAU D, 1991, MOL MICROBIOL, V5, P11, DOI 10.1111/j.1365-2958.1991.tb01820.x; FERRARI E, 1988, J BACTERIOL, V170, P289, DOI 10.1128/JB.170.1.289-295.1988; GRIMSLEY JK, 1994, J BIOL CHEM, V269, P16977; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; HOCH JA, 1976, ADV GENET, V18, P69, DOI 10.1016/S0065-2660(08)60437-X; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MANDELSTAM J, 1974, J BACTERIOL, V120, P38, DOI 10.1128/JB.120.1.38-42.1974; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Miller J.H., 1972, EXPT MOL GENETICS; MUELLER JP, 1992, J BACTERIOL, V174, P4361, DOI 10.1128/JB.174.13.4361-4373.1992; MUELLER JP, 1992, J BACTERIOL, V174, P4374, DOI 10.1128/JB.174.13.4374-4383.1992; OHLSEN KL, 1994, P NATL ACAD SCI USA, V91, P1756, DOI 10.1073/pnas.91.5.1756; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEREGO M, 1988, MOL MICROBIOL, V2, P689, DOI 10.1111/j.1365-2958.1988.tb00079.x; PEREGO M, 1991, MOL MICROBIOL, V5, P173, DOI 10.1111/j.1365-2958.1991.tb01838.x; PEREGO M, 1991, J BACTERIOL, V173, P2514, DOI 10.1128/jb.173.8.2514-2520.1991; Perego Marta, 1993, P615; SANDMAN K, 1987, GENETICS, V117, P603; SPIEGELMAN G, 1990, J BACTERIOL, V172, P5011, DOI 10.1128/jb.172.9.5011-5019.1990; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STRAUCH MA, 1993, MOL MICROBIOL, V7, P337, DOI 10.1111/j.1365-2958.1993.tb01125.x; STRAUCH MA, 1993, MOL MICROBIOL, V7, P967, DOI 10.1111/j.1365-2958.1993.tb01188.x; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TRACH K, 1988, J BACTERIOL, V170, P4194, DOI 10.1128/jb.170.9.4194-4208.1988; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; YOUNGMAN P, 1984, MOL GEN GENET, V195, P424, DOI 10.1007/BF00341443	35	254	257	2	13	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					1047	1055		10.1016/0092-8674(94)90035-3	http://dx.doi.org/10.1016/0092-8674(94)90035-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001132				2022-12-28	WOS:A1994PY08600014
J	ABBOTT, A				ABBOTT, A			INSTITUTE LIVING ON ITS WITS	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					603	604						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990945				2022-12-28	WOS:A1994PX30700039
J	BAIN, G; MAANDAG, ECR; IZON, DJ; AMSEN, D; KRUISBEEK, AM; WEINTRAUB, BC; KROP, I; SCHLISSEL, MS; FEENEY, AJ; VANROON, M; VANDERVALK, M; TERIELE, HPJ; BERNS, A; MURRE, C				BAIN, G; MAANDAG, ECR; IZON, DJ; AMSEN, D; KRUISBEEK, AM; WEINTRAUB, BC; KROP, I; SCHLISSEL, MS; FEENEY, AJ; VANROON, M; VANDERVALK, M; TERIELE, HPJ; BERNS, A; MURRE, C			E2A PROTEINS ARE REQUIRED FOR PROPER B-CELL DEVELOPMENT AND INITIATION OF IMMUNOGLOBULIN GENE REARRANGEMENTS	CELL			English	Article							TRANSCRIPTION FACTOR BSAP; DNA-BINDING PROTEINS; HEAVY-CHAIN ENHANCER; FUNCTIONAL-ANALYSIS; LYMPHOCYTES-B; IGH ENHANCER; STEM-CELLS; EXPRESSION; PROMOTER; SEQUENCE	E12 and E47 are two helix-loop-helix transcription factors that arise by alternative splicing of the E2A gene. Both have been implicated in the regulation of immunoglobulin gene expression. We have now generated E2A (-/-) mice by gene targeting. E2A-null mutant mice fail to generate mature B cells. The arrest of B cell development occurs at an early stage, since no immunoglobulin DJ rearrangements can be detected in homozygous mutant mice. While immunoglobulin germline I-mu RAG-1, mb-1, CD19, and lambda 5 transcripts are dramatically reduced in fetal livers of E2A (-/-) mice, B29 and mu degrees transcripts are present, but at lower levels. In addition, we show that Pax-5 transcripts are significantly reduced in fetal livers of E2A (-/-) mice. These data suggest a crucial role for E2A products as central regulators in early B cell differentiation.	NETHERLANDS CANC INST, DEPT IMMUNOL, 1066 CX AMSTERDAM, NETHERLANDS; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA; NETHERLANDS CANC INST, DEPT MOLEC GENET, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute; Scripps Research Institute; Johns Hopkins University; Johns Hopkins University; Netherlands Cancer Institute	BAIN, G (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL 0116, LA JOLLA, CA 92130 USA.				NCI NIH HHS [CA54198-01] Funding Source: Medline; NHLBI NIH HHS [HL48702] Funding Source: Medline; NIAID NIH HHS [R01 AI34088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054198, R37CA054198] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ALESSANDRINI A, 1991, MOL CELL BIOL, V11, P2096, DOI 10.1128/MCB.11.4.2096; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FEENEY AJ, 1991, J IMMUNOL, V147, P4343; FEENEY AJ, 1992, J IMMUNOL, V149, P222; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; KUBO RT, 1989, J IMMUNOL, V142, P2736; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OKABE T, 1992, EUR J IMMUNOL, V22, P37, DOI 10.1002/eji.1830220107; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SERWE M, 1993, EMBO J, V12, P2321, DOI 10.1002/j.1460-2075.1993.tb05886.x; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; SU LK, 1990, MOL CELL BIOL, V10, P2619, DOI 10.1128/MCB.10.6.2619; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; TAKEDA J, 1990, MOL CELL BIOL, V10, P5027, DOI 10.1128/MCB.10.10.5027; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TSAO BP, 1988, NUCLEIC ACIDS RES, V16, P3239, DOI 10.1093/nar/16.8.3239; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132	53	636	643	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					885	892		10.1016/0092-8674(94)90077-9	http://dx.doi.org/10.1016/0092-8674(94)90077-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001125				2022-12-28	WOS:A1994PW05400015
J	ERIE, DA; YANG, GL; SCHULTZ, HC; BUSTAMANTE, C				ERIE, DA; YANG, GL; SCHULTZ, HC; BUSTAMANTE, C			DNA BENDING BY CRO PROTEIN IN SPECIFIC AND NONSPECIFIC COMPLEXES - IMPLICATIONS FOR PROTEIN SITE RECOGNITION AND SPECIFICITY	SCIENCE			English	Article							SCANNING FORCE MICROSCOPY; TATA-BOX COMPLEX; CRYSTAL-STRUCTURE; GEL-ELECTROPHORESIS; RNA-POLYMERASE; OPERATOR DNA; TRANSCRIPTION; ENDONUCLEASE; REPRESSOR; BINDING	Scanning force microscopy was used to resolve lambda Cro protein when bound as a single dimer or multiple dimers to its three operator (O-R) sites. The bend angles induced by binding of Cro to specific and nonspecific sites were determined and are 69 degrees +/- 11 degrees for specific and 62 degrees +/- 23 degrees for nonspecific complexes. Bending of the nonspecific sites is advantageous for a protein such as Cro that bends its specific site, because it increases the binding specificity of the protein and it can be used by the protein to sample contacts required for the recognition of its target sequence. It is proposed here that bending of nonspecific DNA may be a general property among DNA binding proteins that bend their specific sites.	UNIV OREGON,HOWARD HUGHES MED INST,EUGENE,OR 97403; UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403	Howard Hughes Medical Institute; University of Oregon; University of Oregon				Bustamante, Carlos/0000-0002-2970-0073	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029158, R37GM032543, R01GM032543, R37GM015792, R01GM015792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29158, GM-32543, GM-15792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; BUSTAMANTE C, 1992, BIOCHEMISTRY-US, V31, P22, DOI 10.1021/bi00116a005; BUSTAMANTE C, 1993, CURR OPIN STRUC BIOL, V3, P363, DOI 10.1016/S0959-440X(05)80107-1; BUSTAMANTE JF, 1994, SCIENCE, V265, P1599; CROTHERS DM, 1991, METHOD ENZYMOL, V208, P118; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FICKERT R, 1992, J MOL BIOL, V226, P59, DOI 10.1016/0022-2836(92)90124-3; GARCIA R, UNPUB; HATS JB, 1969, BIOPOLYMERS, V8, P531; HERMAN S, UNPUB; Hermann S., UNPUB; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; JOANICOT M, 1987, BIOPOLYMERS, V26, P315, DOI 10.1002/bip.360260211; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KELLER DJ, 1992, SURF SCI, V268, P333, DOI 10.1016/0039-6028(92)90973-A; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM JG, 1987, J MOL BIOL, V196, P149, DOI 10.1016/0022-2836(87)90517-1; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOUDELKA GB, 1991, NUCLEIC ACIDS RES, V19, P4115, DOI 10.1093/nar/19.15.4115; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; Landau L D., 1980, STATISTICAL PHYSIC 1, V5, P396; LANDAU LD, 1970, THEORY ELASTICITY, V7, P82; LECAM E, 1994, J MOL BIOL, V235, P1062, DOI 10.1006/jmbi.1994.1057; LESSER DR, 1993, P NATL ACAD SCI USA, V90, P7548, DOI 10.1073/pnas.90.16.7548; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LYUBCHENKO Y, 1991, P NATL ACAD SCI USA, V88, P5331, DOI 10.1073/pnas.88.12.5331; MATTHEW JB, 1985, J BIOL CHEM, V260, P5860; MEYERALMES FJ, 1994, J MOL BIOL, V236, P1, DOI 10.1006/jmbi.1994.1112; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PRENTKI P, 1987, EMBO J, V6, P2479, DOI 10.1002/j.1460-2075.1987.tb02529.x; PTASHNE M, 1992, GENETIC SWITCH GENE; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; SCHELLMAN JA, 1974, BIOPOLYMERS, V13, P217, DOI 10.1002/bip.1974.360130115; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STARR DE, UNPUB; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STOVER T, 1993, J BIOL CHEM, V268, P8645; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P439, DOI 10.1073/pnas.86.2.439; TAKEDA Y, 1992, P NATL ACAD SCI USA, V89, P8180, DOI 10.1073/pnas.89.17.8180; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; VANDERVLIET PC, 1993, BIOESSAYS, V15, P25, DOI 10.1002/bies.950150105; VESENKA J, 1992, ULTRAMICROSCOPY, V42, P1243, DOI 10.1016/0304-3991(92)90430-R; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; VONHIPPEL PH, 1994, SCIENCE, V263, P769, DOI 10.1126/science.8303292; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0; ZAUG AJ, 1985, BIOCHEMISTRY-US, V24, P6211, DOI 10.1021/bi00343a027; ZINKEL SS, 1990, BIOPOLYMERS, V29, P29, DOI 10.1002/bip.360290106	54	158	160	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1562	1566		10.1126/science.7985026	http://dx.doi.org/10.1126/science.7985026			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985026				2022-12-28	WOS:A1994PV01500044
J	HAQQ, CM; KING, CY; UKIYAMA, E; FALSAFI, S; HAQQ, TN; DONAHOE, PK; WEISS, MA				HAQQ, CM; KING, CY; UKIYAMA, E; FALSAFI, S; HAQQ, TN; DONAHOE, PK; WEISS, MA			MOLECULAR-BASIS OF MAMMALIAN SEXUAL DETERMINATION - ACTIVATION OF MULLERIAN-INHIBITING SUBSTANCE GENE-EXPRESSION BY SRY	SCIENCE			English	Article							HUMAN ANDROGEN RECEPTOR; DETERMINING REGION; HMG BOX; CRYSTAL-STRUCTURE; MINOR-GROOVE; DNA-SEQUENCES; DUCT SYNDROME; Y-CHROMOSOME; TATA ELEMENT; XY FEMALES	The pathway of male sexual development in mammals is initiated by SRY, a gene on the short arm of the Y chromosome. Its expression in the differentiating gonadal ridge directs testicular morphogenesis, characterized by elaboration of Mullerian inhibiting substance (MIS) and testosterone. SRY and MIS each belong to conserved gene families that function in the control of growth and differentiation. Structural and biochemical studies of the DNA binding domain of SRY (the HMG box) revealed a protein-DNA interaction consisting of partial side chain intercalation into a widened minor groove. Functional studies of SRY in a cell line from embryonic gonadal ridge demonstrated activation of a gene-regulatory pathway leading to expression of MIS. SRY molecules containing mutations associated with human sex reversal have altered structural interactions with DNA and failed to induce transcription of MIS.	MASSACHUSETTS GEN HOSP, PEDIAT SURG RES LABS, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT SURG, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital			King, Chih-Yen/ABG-2110-2021		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028138, R01HD030812] Funding Source: NIH RePORTER; NICHD NIH HHS [HD30812, P30HD28138] Funding Source: Medline; NIGMS NIH HHS [GM51558] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P16249; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; BOTFIELD MC, 1994, BIOCHEMISTRY-US, V33, P2349, DOI 10.1021/bi00175a001; BRASIER AR, 1987, CURRENT PROTOCOLS MO; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CATE RL, 1990, HDB EXPT PHARM, V95, pCH25; CEPKO C, 1987, CURRENT PROTOCOLS MO; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; CHAPELLE AD, 1972, AM J HUM GENET, V24, P71; COHEN DR, 1994, P NATL ACAD SCI USA, V91, P4372, DOI 10.1073/pnas.91.10.4372; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; GORENSTEIN DG, 1989, METHOD ENZYMOL, V177, P295; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUERRIER D, 1989, J CLIN ENDOCR METAB, V68, P46, DOI 10.1210/jcem-68-1-46; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAQQ C, 1990, J CELL BIOCHEM, V14, P301; HAQQ CM, 1993, P NATL ACAD SCI USA, V90, P1097, DOI 10.1073/pnas.90.3.1097; HAQQ CM, UNPUB; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HAVEL TF, 1991, J MOL BIOL, V217, P1, DOI 10.1016/0022-2836(91)90603-4; HAWKINS JR, 1992, HUM GENET, V88, P471, DOI 10.1007/BF00215684; HAWKINS JR, 1992, AM J HUM GENET, V51, P979; HINCK AP, 1993, PROTEIN ENG, V6, P221, DOI 10.1093/protein/6.2.221; HIROBE S, 1992, ENDOCRINOLOGY, V131, P854, DOI 10.1210/en.131.2.854; HOLLEY LH, 1989, P NATL ACAD SCI USA, V86, P152, DOI 10.1073/pnas.86.1.152; JACOBS PA, 1959, NATURE, V183, P302, DOI 10.1038/183302a0; JAGER RJ, 1992, HUM GENET, V90, P350; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; JONES DNM, 1994, STRUCTURE, V2, P609, DOI 10.1016/S0969-2126(00)00063-0; Jost, 1947, ARCH ANAT MICR MORPH, V36, P271; JOST A, 1972, ARCH ANAT MICROSC MO, V61, P415; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KNEBELMANN B, 1991, P NATL ACAD SCI USA, V88, P3767, DOI 10.1073/pnas.88.9.3767; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; LEE MM, 1993, ENDOCR REV, V14, P152, DOI 10.1210/er.14.2.152; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MCELREAVY K, 1992, P NATL ACAD SCI USA, V89, P11016, DOI 10.1073/pnas.89.22.11016; MCLAREN A, 1990, NATURE, V346, P216, DOI 10.1038/346216a0; MEYERSWALLEN V, COMMUNICATION; MILLER PS, 1987, ANTI-CANCER DRUG DES, V2, P117; MULLER J, 1992, J CLIN ENDOCR METAB, V75, P331, DOI 10.1210/jc.75.1.331; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PAGE DP, COMMUNICATION; PALMER MS, 1989, NATURE, V342, P937, DOI 10.1038/342937a0; PETERS R, UNPUB; PICARD JY, 1986, P NATL ACAD SCI USA, V83, P5464, DOI 10.1073/pnas.83.15.5464; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; TAKETO T, 1991, DEV BIOL, V146, P386, DOI 10.1016/0012-1606(91)90240-4; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; TOMMERUP N, 1993, NAT GENET, V4, P170, DOI 10.1038/ng0693-170; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; VILAIN E, 1993, DIFFERENTIATION, V52, P151, DOI 10.1111/j.1432-0436.1993.tb00625.x; WASHBURN LL, 1990, GENET RES, V56, P185, DOI 10.1017/S001667230003528X; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; WOOD WM, 1989, J BIOL CHEM, V264, P14840; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZWINGMAN T, 1993, P NATL ACAD SCI USA, V90, P814, DOI 10.1073/pnas.90.3.814	83	216	226	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 2	1994	266	5190					1494	1500		10.1126/science.7985018	http://dx.doi.org/10.1126/science.7985018			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985018				2022-12-28	WOS:A1994PV01500029
J	BLUMENFELD, JD; SEALEY, JE; SCHLUSSEL, Y; VAUGHAN, ED; SOS, TA; ATLAS, SA; MULLER, FB; ACEVEDO, R; ULICK, S; LARAGH, JH				BLUMENFELD, JD; SEALEY, JE; SCHLUSSEL, Y; VAUGHAN, ED; SOS, TA; ATLAS, SA; MULLER, FB; ACEVEDO, R; ULICK, S; LARAGH, JH			DIAGNOSIS AND TREATMENT OF PRIMARY HYPERALDOSTERONISM	ANNALS OF INTERNAL MEDICINE			English	Review							ATRIAL NATRIURETIC FACTOR; ALDOSTERONE-PRODUCING ADENOMA; CALCIUM-CHANNEL BLOCKADE; PLASMA-RENIN ACTIVITY; ESSENTIAL-HYPERTENSION; PEPTIDE; RADIOIMMUNOASSAY; RESPONSES	Objective: To characterize the clinical and laboratory features of primary aldosteronism and to evaluate which diagnostic tests can discriminate surgically curable forms of this syndrome. Design: Retrospective analysis of the following data from 82 patients with primary aldosteronism: blood pressure, serum electrolytes, urinary aldosterone anti electrolytes, computed tomographic scans, plasma renin and aldosterone before and during upright posture, atrial natriuretic peptide, and adrenal vein aldosterone and cortisol. Clinical outcomes assessed after treatment included blood pressure, serum electrolytes, anti plasma renin activity. Results: Drug therapy was discontinued before diagnostic tests were done in 56 of 82 patients (34 with adenomas and 22 with hyperplasia). Compared with patients with hyperplasia, those with adenomas had higher systolic (184 mm Hg and 161 mm Hg, respectively; P < 0.001) and diastolic blood pressures (112 mm Hg and 105 mm Hg; P = 0.03), lower serum potassium levels (3.0 mmol/L and 3.5 mmol/L; P < 0.001), and higher serum CO, (P = 0.001), atrial natriuretic peptide (P = 0.008), and urinary 18-methyl oxygenated cortisol metabolite levels (P = 0.02). In patients with adenomas, aldosterone secretion lateralized to one adrenal gland and did not increase during the postural stimulation test; preoperative urinary aldosterone levels were correlated with diastolic pressures (r = 0.58; P = 0.001). Hypertension was ''cured'' postoperatively in approximately 35% of patients with adenomas and those with hyperplasia (P > 0.2) but was ''improved'' more frequently in those with adenomas (P= 0.002). Cured patients from both groups were younger than those not cured (mean ages, 43 years anti 54 years, respectively; P = 0.002) and had lower preoperative mean plasma renin activity (0.17 ng/mL per hour and 0.50 ng/mL per hour; P < 0.001). All patient!; with adenomas in whom aldosterone secretion lateralized were either cured or improved. Conclusion: Of the 51 patients with primary aldosteronism who had adrenalectomy (43 patients with adenomas and 8 with hyperplasia), those most likely to be cured were younger and had lower plasma renin activity. In patients with adenomas who were cured or improved, aldosterone secretion was more likely to lateralize. Tests that distinguished adenomas from adrenal hyperplasia included the postural stimulation test, urinary excretion rates of 18-oxocortisol and 18-hydroxycortisol, and adrenal vein sampling.	VET AFFAIRS MED CTR, HYPERTENS RES LAB 151, BRONX, NY 10468 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	BLUMENFELD, JD (corresponding author), CORNELL UNIV, MED CTR,NEW YORK HOSP,CTR CARDIOVASC, 520 E 70TH ST, STARR 4, NEW YORK, NY 10021 USA.		Acevedo, Romina/HCI-4706-2022; Blumenfeld, Jon/ABC-1107-2021; Sealey, Jean/A-9562-2009		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000047] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00047] Funding Source: Medline; NHLBI NIH HHS [HL 18323] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEEVERS DG, 1976, Q J MED, V45, P401; BOLLI P, 1980, J CARDIOVASC PHARM, V2, pS399, DOI 10.1097/00005344-198002003-00013; BRAVO EL, 1983, AM J MED, V74, P641, DOI 10.1016/0002-9343(83)91022-7; BRAVO EL, 1988, HYPERTENSION, V11, P207; BRAVO EL, 1986, HYPERTENSION, V8, P191; BRAVO EL, 1985, HYPERTENSION, V7, P90, DOI 10.1161/01.HYP.7.1.90; BRUNNER HR, 1972, NEW ENGL J MED, V286, P441, DOI 10.1056/NEJM197203022860901; BUHLER FR, 1972, NEW ENGL J MED, V287, P1209, DOI 10.1056/NEJM197212142872401; BUHLER FR, 1974, HYPERTENSION MANUAL, P655; BURSZTYN M, 1988, AM J HYPERTENS, V1, pS88, DOI 10.1093/ajh/1.3.88S; CODY RJ, 1986, J CLIN INVEST, V78, P1362, DOI 10.1172/JCI112723; Conn JW., 1968, HARVEY LECT, V62, P257; FARMER RW, 1974, CLIN CHEM, V20, P411; FONTES RG, 1991, AM J HYPERTENS, V4, P786, DOI 10.1093/ajh/4.9.786; GANGULY A, 1973, J CLIN ENDOCR METAB, V36, P401, DOI 10.1210/jcem-36-2-401; Gordon R D, 1987, J Hypertens Suppl, V5, pS103; HAMLET SM, 1985, CLIN EXP PHARMACOL P, V12, P249, DOI 10.1111/j.1440-1681.1985.tb02641.x; HIRAMATSU K, 1981, ARCH INTERN MED, V141, P1589, DOI 10.1001/archinte.141.12.1589; IRONY I, 1990, AM J HYPERTENS, V3, P576, DOI 10.1093/ajh/3.7.576; IWAOKA T, 1990, ENDOCRINOL JAPON, V37, P151; LJUNGMAN S, 1990, AM J HYPERTENS, V3, P956, DOI 10.1093/ajh/3.12.956; MCLEOD MK, 1989, SURGERY, V106, P1161; MELBY JC, 1984, KIDNEY INT, V26, P769, DOI 10.1038/ki.1984.215; MELBY JC, 1967, NEW ENGL J MED, V277, P1050, DOI 10.1056/NEJM196711162772002; NADLER JL, 1985, J CLIN ENDOCR METAB, V60, P896, DOI 10.1210/jcem-60-5-896; NAKADA T, 1989, J UROLOGY, V142, P13, DOI 10.1016/S0022-5347(17)38650-0; PEDRINELLI R, 1988, HYPERTENSION, V12, P192, DOI 10.1161/01.HYP.12.2.192; RADIN DR, 1992, AM J ROENTGENOL, V158, P553, DOI 10.2214/ajr.158.3.1738993; SCOGGINS BA, 1972, ANN INTERN MED, V76, P891, DOI 10.7326/0003-4819-76-6-391; SEALEY JE, 1991, CLIN CHEM, V37, P1811; SEALEY JE, 1972, CIRC RES, V31, P367, DOI 10.1161/01.RES.31.3.367; STREETEN DHP, 1990, AM J HYPERTENS, V3, P360, DOI 10.1093/ajh/3.5.360; TORRES VE, 1990, NEW ENGL J MED, V322, P345, DOI 10.1056/NEJM199002083220601; TUNNY TJ, 1991, CLIN ENDOCRINOL, V34, P363, DOI 10.1111/j.1365-2265.1991.tb00306.x; TUNNY TJ, 1986, CLIN EXP PHARMACOL P, V13, P341, DOI 10.1111/j.1440-1681.1986.tb00360.x; ULICK S, 1993, J CLIN ENDOCR METAB, V76, P873, DOI 10.1210/jc.76.4.873; ULICK S, 1989, ADRENAL HYPERTENSION, P313; WEIBNERGER MH, 1984, ANN INTERN MED, V90, P386; YAMAJI T, 1986, J CLIN ENDOCR METAB, V63, P815, DOI 10.1210/jcem-63-4-815; 1990, NEW ENGL J MED, V323, P29	40	213	224	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					877	885		10.7326/0003-4819-121-11-199412010-00010	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7978702				2022-12-28	WOS:A1994PT62800010
J	CIESIELSKI, CA; MARIANOS, DW; SCHOCHETMAN, G; WITTE, JJ; JAFFE, HW				CIESIELSKI, CA; MARIANOS, DW; SCHOCHETMAN, G; WITTE, JJ; JAFFE, HW			THE 1990 FLORIDA DENTAL INVESTIGATION - THE PRESS AND THE SCIENCE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HIV TRANSMISSION	Since human immunodeficiency virus (HIV) transmission from a dentist to six of his patients was first reported in 1990 by the Florida Department of Health and Rehabilitative Services and the Centers for Disease Control and Prevention, controversy and speculation have surrounded the investigation of that case. This controversy has been fueled by the inability to determine exactly how the transmissions occurred. Many theories have appeared in the media and have led to confusion and uncertainty about the facts of this investigation. Recently, a magazine article and a newspaper article, as well as a segment on the television newsmagazine ''60 Minutes,'' presented information that was largely based on findings by investigators hired as part of private litigation and that cast doubt on the conclusion that the patients had been infected by the dentist. However, these reports omitted pertinent epidemiologic and laboratory evidence that shows that no other sources of HIV infection could be documented for the six dental patients. The scientific evidence indicates that the Florida dentist transmitted HIV to six of his patients.	FLORIDA DEPT HLTH & REHABIL SERV, TALLAHASSEE, FL 32399 USA; CTR DIS CONTROL & PREVENT, DIV ORAL HLTH, ATLANTA, GA 30333 USA	Florida Department of Health; Centers for Disease Control & Prevention - USA	CIESIELSKI, CA (corresponding author), CTR DIS CONTROL & PREVENT, DIV HIV AIDS E47, ATLANTA, GA 30333 USA.							BARR S, 1994, LEARS MAGAZINE   APR, P68; BARR S, 1994, NY TIMES        0416; BREO DL, 1993, JAMA-J AM MED ASSOC, V270, P2732, DOI 10.1001/jama.270.22.2732; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P337; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; DEBRY RW, 1993, NATURE, V361, P691, DOI 10.1038/361691a0; DORSCHNER J, 1991, MIAMI HERALD    1027, P7; DORSCHNER J, 1991, MIAMI HERALD    1027, P16; GOOCH B, 1993, J AM DENT ASSOC, V124, P38, DOI 10.14219/jada.archive.1993.0006; HIAASEN R, 1993, ATLANTA J CONST 0706, pC10; HILLIS DM, 1994, NATURE, V369, P24, DOI 10.1038/369024a0; JAFFE HW, 1994, ANN INTERN MED, V121, P855, DOI 10.7326/0003-4819-121-11-199412010-00005; LEWIS DL, 1994, JAMA-J AM MED ASSOC, V271, P983, DOI 10.1001/jama.271.13.983a; MYERS G, 1994, ANN INTERN MED, V121, P889, DOI 10.7326/0003-4819-121-11-199412010-00012; PEPPER DR, 1994, JAMA-J AM MED ASSOC, V271, P983, DOI 10.1001/jama.1994.03510370035024; SIEW CW, 1992, J AM DENT ASSOC, V123, P36, DOI 10.14219/jada.archive.1992.0149; 1992, CDCS INVESTIGATION H; 1991, AIDS ALERT, V6, P121; 1993, MMWR-MORBID MORTAL W, V42, P329	19	25	25	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					886	888		10.7326/0003-4819-121-11-199412010-00011	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7978703				2022-12-28	WOS:A1994PT62800011
J	PARSELL, DA; KOWAL, AS; SINGER, MA; LINDQUIST, S				PARSELL, DA; KOWAL, AS; SINGER, MA; LINDQUIST, S			PROTEIN DISAGGREGATION MEDIATED BY HEAT-SHOCK PROTEIN HSP104	NATURE			English	Article							RNA-POLYMERASE; YEAST-CELLS; DNAK; BINDING; HSP70; CHAPERONES; ORIGIN; REPA	THE heat-inducible members of the Hsp100 (or Clp) family of proteins share a common function in helping organisms to survive extreme stress, but the basic mechanism through which these proteins function is not understood(1-5) Hsp104 protects cells against a variety of stresses, under many physiological conditions(6,7) and its function has been evolutionarily conserved, at least from Saccharomyces cerevisiae to Arabidopsis thaliana(25). Homology with the Escherichia coli ClpA protein suggests that Hsp104 may provide stress tolerance by helping to rid the tell of heat-denatured proteins through proteolysis(1). But genetic analysis indicates that Hsp104 may function like Hsp70 as a molecular chaperones(8). Here we investigate the role of Hsp104 in vivo using a temperature-sensitive Vibrio harveyi luciferase-fusion protein as a test substrate(9). We find that Hsp104 does not protect luciferase from thermal denaturation, nor does it promote proteolysis of luciferase. Rather, Hsp104 functions in a manner not previously described for other heat-shock proteins: it mediates the resolubilization of heat-inactivated luciferase from insoluble aggregates.	UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PATHOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago								BYERS B, 1991, METHOD ENZYMOL, V194, P602; ESCHER A, 1989, P NATL ACAD SCI USA, V86, P6528, DOI 10.1073/pnas.86.17.6528; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; KRUGER E, 1994, J BACTERIOL, V176, P3360; KURTZ S, 1985, SEQUENCE SPECIFICITY, P611; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; SANCHEZ Y, 1993, J BACTERIOL, V175, P6484, DOI 10.1128/jb.175.20.6484-6491.1993; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SCHIRMER E, IN PRESS PL CELL; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHANER SL, 1982, BIOCHEMISTRY-US, V21, P5539, DOI 10.1021/bi00265a025; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; TRECO DA, 1989, CURRENT PROTOCOLS MO; VANTUINEN E, 1987, J HISTOCHEM CYTOCHEM, V35, P327, DOI 10.1177/35.3.3546482; WEBSTER DL, 1993, YEAST, V9, P1165, DOI 10.1002/yea.320091103; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WRIGHT R, 1989, METHOD CELL BIOL, V31, P473	25	727	743	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 1	1994	372	6505					475	478		10.1038/372475a0	http://dx.doi.org/10.1038/372475a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984243				2022-12-28	WOS:A1994PV01200060
J	PETERSEN, LA; BRENNAN, TA; ONEIL, AC; COOK, EF; LEE, TH				PETERSEN, LA; BRENNAN, TA; ONEIL, AC; COOK, EF; LEE, TH			DOES HOUSESTAFF DISCONTINUITY OF CARE INCREASE THE RISK FOR PREVENTABLE ADVERSE EVENTS	ANNALS OF INTERNAL MEDICINE			English	Article							HOSPITALIZED-PATIENTS; HEALTH-CARE; QUALITY; IMPACT; NEGLIGENCE; PROGRAMS; TRIAL	Objective: To study the relation between housestaff coverage schedules and the occurrence of preventable adverse events. Design: Case-control study. Setting: Urban teaching hospital. Patients: All 3146 patients admitted to the medical service during a 4-month period. Measurements: A previously tested confidential self-report system to identify adverse events, which were defined as unexpected complications of medical therapy that resulted in increased length of stay or disability at discharge. A panel of three board-certified internists confirmed events and evaluated preventability based on case summaries. Housestaff coverage was coded according to the day in the usual intern's schedule and to cross-coverage status. Cross-coverage was defined as care by a house officer who was not the patient's usual intern and not a member of the usual intern's patient care team. Coverage for an adverse event was assigned according to who was covering during the proximate cause of that event. Clinical data were collected for each patient and two matched controls. Results: Of the 124 adverse events reported and confirmed, 54 (44%) were judged potentially preventable. In the univariate analysis, patients with potentially preventable adverse events were more likely than their controls to be covered by a physician from another team at the time of the event (26% compared with 12% [odds ratio, 3.5; P = 0.01]). In the multivariate analysis, three factors were significant independent correlates of potentially preventable adverse events: cross-coverage (odds ratio, 6.1; 95% CI, 1.4 to 26.7), Acute Physiology and Chronic Health Evaluation II score (odds ratio per point, 1.2; CI, 1.1 to 1.4), and history of gastrointestinal bleeding (odds ratio, 4.7; CI, 1.2 to 19.0). Conclusion: Potentially preventable adverse events were strongly associated with coverage by a physician from another team, which may reflect management by housestaff unfamiliar with the patient. The results emphasize the need for careful attention to the outcome of work-hour reforms for housestaff.	BRIGHAM & WOMENS HOSP, CLIN EPIDEMIOL SECT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health								BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1990, ANN INTERN MED, V112, P221, DOI 10.7326/0003-4819-112-3-221; BRENNAN TA, 1989, MED CARE, V27, P1148, DOI 10.1097/00005650-198912000-00006; CAPLAN RA, 1991, JAMA-J AM MED ASSOC, V265, P1957, DOI 10.1001/jama.265.15.1957; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COHEN DI, 1986, NEW ENGL J MED, V314, P1553, DOI 10.1056/NEJM198606123142405; COLFORD JM, 1989, JAMA-J AM MED ASSOC, V261, P889, DOI 10.1001/jama.261.6.889; CONIGLIARO J, 1993, J GEN INTERN MED, V8, P502, DOI 10.1007/BF02600112; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; GREENLAND S, 1982, AM J EPIDEMIOL, V116, P547, DOI 10.1093/oxfordjournals.aje.a113439; HIATT HH, 1989, NEW ENGL J MED, V321, P480, DOI 10.1056/NEJM198908173210725; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KENNEDY JW, 1982, CATHETER CARDIO DIAG, V8, P5, DOI 10.1002/ccd.1810080103; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; LAINE C, 1993, JAMA-J AM MED ASSOC, V269, P374, DOI 10.1001/jama.269.3.374; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LOFGREN RP, 1990, J GEN INTERN MED, V5, P501, DOI 10.1007/BF02600880; MCCALL TB, 1989, JAMA-J AM MED ASSOC, V261, P909; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; Rothman K, 1986, MODERN EPIDEMIOLOGY; RUBENSTEIN LV, 1990, JAMA-J AM MED ASSOC, V264, P1974, DOI 10.1001/jama.264.15.1974; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; TEASDALE G, 1974, LANCET, V2, P81; TRONTELL MC, 1991, J GEN INTERN MED, V6, P445, DOI 10.1007/BF02598169; VINCENT CA, 1989, BMJ-BRIT MED J, V299, P1150, DOI 10.1136/bmj.299.6708.1150; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; 1987, NY STATE J MED, V87, P587; 1986, REPORT 4TH GRAND JUR, P50	30	504	503	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					866	872		10.7326/0003-4819-121-11-199412010-00008	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7978700				2022-12-28	WOS:A1994PT62800008
J	MOORE, J; ANDERSON, R				MOORE, J; ANDERSON, R			THE WHO AND WHY OF HIV VACCINE TRIALS	NATURE			English	Editorial Material									UNIV OXFORD,CTR EPIDEMIOL INFECT DIS,OXFORD OX1 3PS,ENGLAND	University of Oxford	MOORE, J (corresponding author), AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016, USA.							ALONSO PL, 1994, LANCET, V344, P1175, DOI 10.1016/S0140-6736(94)90505-3; 1994, NATURE, V371, P644	2	27	27	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					313	314		10.1038/372313a0	http://dx.doi.org/10.1038/372313a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969482	Bronze			2022-12-28	WOS:A1994PU28700025
J	SONDEK, J; LAMBRIGHT, DG; NOEL, JP; HAMM, HE; SIGLER, PB				SONDEK, J; LAMBRIGHT, DG; NOEL, JP; HAMM, HE; SIGLER, PB			GTPASE MECHANISM OF GPROTEINS FROM THE 1.7-ANGSTROM CRYSTAL-STRUCTURE OF TRANSDUCIN ALPHA-CENTER-DOT-GDP-CENTER-DOT-ALF4(-)	NATURE			English	Article							H-RAS P21; X-RAY; HYDROLYSIS; PROTEIN; MUTANTS; ACTIVATION; INHIBITION; MUTATIONS; ALUMINUM; FLUORIDE	ALUMINIUM fluoride (AlF4-) activates members of the heterotrimeric G-protein (G(alpha beta gamma)) family(1,2) by binding to inactive G(alpha).GDP near the site occupied by the gamma-phosphate in G(alpha).GTP (ref. 3). Here we describe the crystal structure of transducin alpha.GDP activated with aluminium fluoride (G(t alpha).GDP.AlF4-.H2O) at 1.7 Angstrom, a resolution sufficient to establish the coordination geometry of the bound aluminium fluoride as well as the extensive network of direct and water-mediated interactions that stabilize it. These observations are derived from three independent representations in the asymmetric unit, eliminating any chance of drawing conclusions based on stereochemistry imposed by crystal packing. Surprisingly, aluminium fluoride activates G(alpha).GDP by binding with a geometry resembling a pentavalent intermediate for GTP hydrolysis. The stabilizing interactions involve not only residues that interact with the gamma-phosphate in G(t alpha).GTP gamma S, but also conserved residues essential for GTPase activity. Thus the G(t alpha).GDP.AlF4-.H2O structure provides new insight into the mechanism of GTP hydrolysis.	YALE UNIV,BOYER CTR MOLEC MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,BOYER CTR MOLEC MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60680; UNIV SASSARI,IST FISIOL GEN & CHIM BIOL,I-07100 SASSARI,ITALY	Yale University; Howard Hughes Medical Institute; Yale University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Sassari			Hamm, Heidi E/G-2374-2014; Noel, Joseph P/A-9459-2009	Sondek, John/0000-0002-1127-8310				ANTONNY B, 1991, BIOCHEMISTRY-US, V30, P8287, DOI 10.1021/bi00098a002; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHUNG HH, 1993, SCIENCE, V259, P806, DOI 10.1126/science.8430333; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DUPUIS A, 1989, FEBS LETT, V255, P47, DOI 10.1016/0014-5793(89)81058-0; FOURQUET JL, 1986, REV CHIM MINER, V23, P183; FRECH M, 1994, BIOCHEMISTRY-US, V33, P3237, DOI 10.1021/bi00177a014; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GOODY RS, 1992, PHILOS T ROY SOC B, V336, P3, DOI 10.1098/rstb.1992.0037; GROTTEL M, 1992, J PHYS-CONDENS MAT, V4, P1837, DOI 10.1088/0953-8984/4/7/022; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARUTA S, 1993, J BIOL CHEM, V268, P7093; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; SCHEPARTZ A, 1987, J AM CHEM SOC, V109, P1814, DOI 10.1021/ja00240a036; SCHWEINS T, 1994, NAT STRUCT BIOL, V1, P476, DOI 10.1038/nsb0794-476; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; STRYER L, 1983, METHOD ENZYMOL, V96, P617; SUAREZ HG, 1991, ONCOGENE, V6, P677; SWAIN CG, 1952, J AM CHEM SOC, V74, P2538, DOI 10.1021/ja01130a024; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996	30	539	546	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					276	279		10.1038/372276a0	http://dx.doi.org/10.1038/372276a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969474				2022-12-28	WOS:A1994PR88900054
J	MADDOX, J				MADDOX, J			FRONTIERS OF IGNORANCE - IS THE BRAIN A COMPUTER	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					35	36						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969413				2022-12-28	WOS:A1994PQ34800048
J	WATKINS, SJ				WATKINS, SJ			FOR DEBATE - PUBLIC-HEALTH-2020	BRITISH MEDICAL JOURNAL			English	Article								The aim of public health is to improve the health of people in communities and in populations (protection from environmental hazards and provision for health needs). The challenge for public health doctors is to re-establish public health leadership of communities, address social and environmental causes of ill health, and link with primary care (a) to improve the health of neighbourhoods and (b) to combine perspectives in commissioning services. Current threats derive from organisational philosophies. For example, focusing on market development does not allow for population based functions and so neglects the main influences on health. The way forward is a network model of organisation in which small teams collaborate with each other to the common good. For example, successful commissioning authorities would have the public health leadership of the director of public health and the support of the chief executive, treasurer, and representatives of primary care, including a medical adviser from the family health services authority.			WATKINS, SJ (corresponding author), STOCKPORT HLTH AUTHOR,DIST OFF,STOCKPORT SK7 5AB,ENGLAND.							GABBAY J, 1994, BRIT MED J, V308, P1117, DOI 10.1136/bmj.308.6937.1117; Kanter R., 1989, GIANTS LEARN DANCE; 1993, PUBLIC HLTH FINANCE; 1993, NEW WORLDS NEW OPPOR	4	6	6	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1994	309	6962					1147	1149		10.1136/bmj.309.6962.1147	http://dx.doi.org/10.1136/bmj.309.6962.1147			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987113	Green Published			2022-12-28	WOS:A1994PP69100032
J	WOLF, HM; HAUBER, I; GULLE, H; THON, V; EGGENBAUER, H; FISCHER, MB; FIALA, S; EIBL, MM				WOLF, HM; HAUBER, I; GULLE, H; THON, V; EGGENBAUER, H; FISCHER, MB; FIALA, S; EIBL, MM			TWIN BOYS WITH MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II DEFICIENCY BUT INDUCIBLE IMMUNE-RESPONSES	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							HLA CLASS-II; SEVERE COMBINED IMMUNODEFICIENCY; MONOCLONAL-ANTIBODIES; GENE-EXPRESSION; CELL-LINES; ALPHA-CHAIN; ANTIGEN; PATIENT; MUTANT		UNIV VIENNA,INST IMMUNOL,A-1090 VIENNA,AUSTRIA; WILHELMINENSPITAL VIENNA,DEPT PEDIAT,VIENNA,AUSTRIA	University of Vienna; Wilhelminenspital			Fischer, Michael/AAU-5579-2020	Fischer, Michael/0000-0002-5876-0243				ADAMS TE, 1983, IMMUNOLOGY, V50, P613; BAXTERLOWE LA, 1989, J CLIN INVEST, V84, P613, DOI 10.1172/JCI114206; BENICHOU B, 1991, P NATL ACAD SCI USA, V88, P4285, DOI 10.1073/pnas.88.10.4285; COHEN BB, 1987, IMMUNOLOGY, V61, P255; DAS HK, 1983, P NATL ACAD SCI-BIOL, V80, P3543, DOI 10.1073/pnas.80.12.3543; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DEPREVAL C, 1985, NATURE, V318, P291, DOI 10.1038/318291a0; DEPREVAL C, 1988, NEW ENGL J MED, V318, P1295, DOI 10.1056/NEJM198805193182003; FISCHER MB, 1993, J ALLERGY CLIN IMMUN, V92, P340, DOI 10.1016/0091-6749(93)90178-I; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HUGO P, 1993, IMMUNOL REV, V135, P133, DOI 10.1111/j.1600-065X.1993.tb00647.x; HUME CR, 1989, HUM IMMUNOL, V26, P288, DOI 10.1016/0198-8859(89)90007-4; KLEIN C, 1993, J PEDIATR-US, V123, P921, DOI 10.1016/S0022-3476(05)80388-9; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; NIJENHUIS M, 1994, EUR J IMMUNOL, V24, P247, DOI 10.1002/eji.1830240139; Rosen FS, 1993, IMMUNODEFICIENCIES, P141; SEIDL C, 1992, J IMMUNOL, V148, P1576; SMITH CIE, 1988, CLIN EXP IMMUNOL, V74, P449; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; TODD RF, 1984, HUM IMMUNOL, V10, P23, DOI 10.1016/0198-8859(84)90083-1; WOLF HM, 1992, BRIT J HAEMATOL, V82, P374, DOI 10.1111/j.1365-2141.1992.tb06432.x; YANG Z, 1988, EMBO J, V7, P1965, DOI 10.1002/j.1460-2075.1988.tb03034.x	25	27	27	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 12	1995	332	2					86	90		10.1056/NEJM199501123320204	http://dx.doi.org/10.1056/NEJM199501123320204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA241	7990905				2022-12-28	WOS:A1995QA24100004
J	TONTONOZ, P; HU, ED; SPIEGELMAN, BM				TONTONOZ, P; HU, ED; SPIEGELMAN, BM			STIMULATION OF ADIPOGENESIS IN FIBROBLASTS BY PPAR-GAMMA-2, A LIPID-ACTIVATED TRANSCRIPTION FACTOR	CELL			English	Article							ENHANCER-BINDING-PROTEIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; HORMONE RECEPTOR SUPERFAMILY; PEROXISOME PROLIFERATOR; GENE-EXPRESSION; RETINOIC ACID; FATTY-ACIDS; ADIPOCYTE DIFFERENTIATION; 3T3-L1 PREADIPOCYTES; NUCLEAR RECEPTORS	Peroxisome proliferator-activated receptor gamma 2 (PPAR gamma 2) is an adipocyte-specific nuclear hormone receptor that has recently been identified as a key regulator of two fat cell enhancers. Transcriptional activation by PPAR gamma 2 is potentiated by a variety of lipids and lipid-like compounds, including naturally occurring polyunsaturated fatty acids. We demonstrate here that retroviral expression of PPAR gamma 2 stimulates adipose differentiation of cultured fibroblasts. PPAR activators promote the differentiation of PPAR gamma 2-expressing cells in a dose-dependent manner. C/EBP alpha, a second transcription factor induced during adipocyte differentiation, can cooperate with PPAR gamma 2 to stimulate the adipocyte program dramatically. Our results suggest that the physiologic role of PPAR gamma 2 is to regulate development of the adipose lineage in response to endogenous activators and that this factor may serve to link the process of adipocyte differentiation to systemic lipid metabolism.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	TONTONOZ, P (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031405, R37DK031405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31405] Funding Source: Medline; NIGMS NIH HHS [T32 GM07753, T32 GM007753] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; BENNETT PH, 1990, DIABETES MELLITUS TH, P357; BRANDES R, 1987, LIFE SCI, V40, P935, DOI 10.1016/0024-3205(87)90312-2; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; ENERBACK S, 1992, MOL CELL BIOL, V12, P4622, DOI 10.1128/MCB.12.10.4622; FINEBERG AP, 1984, ANAL BIOCHEM, V137, P266; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GHARBICHIHI J, 1993, BIOCHIM BIOPHYS ACTA, V1177, P8, DOI 10.1016/0167-4889(93)90150-N; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GRAVES RA, 1992, MOL CELL BIOL, V12, P1202, DOI 10.1128/MCB.12.3.1202; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KELLER H, 1993, TRENDS ENDOCRIN MET, V4, P291, DOI 10.1016/1043-2760(93)90048-J; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T, 1989, DECONTAMINATION DILU; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1995, IN PRESS NUCL ACIDS; TONTONOZ P, 1909, IN PRESS MOL CELL BI; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	49	3021	3149	6	189	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1147	1156		10.1016/0092-8674(94)90006-X	http://dx.doi.org/10.1016/0092-8674(94)90006-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001151				2022-12-28	WOS:A1994PZ86000006
J	COVINSKY, KE; GOLDMAN, L; COOK, EF; OYE, R; DESBIENS, N; REDING, D; FULKERSON, W; CONNORS, AF; LYNN, J; PHILLIPS, RS				COVINSKY, KE; GOLDMAN, L; COOK, EF; OYE, R; DESBIENS, N; REDING, D; FULKERSON, W; CONNORS, AF; LYNN, J; PHILLIPS, RS			THE IMPACT OF SERIOUS ILLNESS ON PATIENTS FAMILIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADULTS; SYSTEM; SERVICES	Objective.-To examine the impact of illness on the families of seriously ill adults and to determine the correlates of adverse economic impact. Design.-Data were collected during the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment (SUPPORT), a prospective cohort study of outcomes, preferences, and decision making in seriously ill hospitalized adults and their families. Setting.-Five tertiary care hospitals in the United States. Participants.-The 2661 seriously ill patients in nine diagnostic categories who survived their index hospitalization and were discharged home were eligible for this analysis, Surrogate and/or patient interviews about the impact of illness on the family were obtained for 2129 (80%) of these patients (mean age, 62 years; 43% women; 6-month survival, 75%). Outcome Measures.-Surrogates and patients were surveyed to determine the frequency of adverse caregiving and economic burdens, Multivariable analyses were performed to determine correlates of loss of family savings. Results.-One third (34%) of patients required considerable caregiving assistance from a family member. In 20% of cases, a family member had to quit work or make another major life change to provide care for the patient. Loss of most or all of the family savings was reported by 31% of families, whereas 29% reported loss of the major source of income. Patient factors independently associated with loss of the family's savings on multivariable analysis included poor functional status (odds ratio [OR], 1.40; 95% confidence interval [CI], 1.10 to 1.78 for patients needing assistance with three or more activities of daily living), lower family income (OR, 1.74; 95% CI, 1.37 to 2.21 for those with annual incomes below $25 000), and young age (OR, 2.85; 95% CI, 2.13 to 3.82 for those younger than 45 years compared with those 65 years or older). Conclusions.-Many families of seriously ill patients experience severe caregiving and financial burdens. Families of younger, poorer, and more functionally dependent patients are most likely to report loss of most or all of the family's savings.	BETH ISRAEL HOSP,DEPT MED,DIV GEN MED & PRIMARY CARE,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,DIV CLIN EPIDEMIOL,BOSTON,MA 02215; UNIV CALIF LOS ANGELES,MED CTR,SCH MED,LOS ANGELES,CA 90024; MARSHFIELD CLIN FDN MED RES & EDUC,MARSHFIELD,WI 54449; DUKE UNIV,MED CTR,DURHAM,NC; METROHLTH MED CTR,CASE WESTERN RESERVE UNIV,CLEVELAND,OH; DARTMOUTH HITCHCOCK MED CTR,HANOVER,NH; GEORGE WASHINGTON UNIV,CTR SUPPORT COORDINATION,WASHINGTON,DC	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Marshfield Clinic; Duke University; Case Western Reserve University; MetroHealth System; Dartmouth College; George Washington University				Connors, Alfred F./0000-0001-7123-3360				ALTMAN B, 1993, 930040 AG HLTH CAR P; ANDOLSEK KM, 1988, ARCH INTERN MED, V148, P2177, DOI 10.1001/archinte.148.10.2177; BODKIN CM, 1982, BRIT MED J, V284, P1542, DOI 10.1136/bmj.284.6328.1542; Hamel M., 1994, Journal of General Internal Medicine, V9, P43; HAYWARD RA, 1988, NEW ENGL J MED, V318, P1507, DOI 10.1056/NEJM198806093182305; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KATZ S, 1976, INT J HEALTH SERV, V6, P493, DOI 10.2190/UURL-2RYU-WRYD-EY3K; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; MUI AC, 1992, GERONTOLOGIST, V32, P205; MURPHY DJ, 1990, J CLIN EPIDEMIOL S, V43, pS1; PATRICK C, 1992, GEN HOSP PSYCHIAT, V14, P219, DOI 10.1016/0163-8343(92)90091-N; PRUNCHO RA, 1989, J AM GERIATR SOC, V37, P697; Rosner B., 2010, FUNDAMENTALS BIOSTAT; RUBENSTEIN LZ, 1984, J GERONTOL, V39, P686, DOI 10.1093/geronj/39.6.686; SIEGEL K, 1991, CANCER, V68, P1131, DOI 10.1002/1097-0142(19910901)68:5<1131::AID-CNCR2820680541>3.0.CO;2-N; STANLEY MJB, 1988, HEART LUNG, V17, P677; TAYLOR RJ, 1991, J GERONTOL, V46, pS210, DOI 10.1093/geronj/46.4.S210; ZWEIBEL NR, 1989, GERONTOLOGIST, V29, P615, DOI 10.1093/geront/29.5.615	20	372	379	1	36	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1839	1844		10.1001/jama.272.23.1839	http://dx.doi.org/10.1001/jama.272.23.1839			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PW980	7990218				2022-12-28	WOS:A1994PW98000032
J	LIU, J; LISSENS, W; SILBER, SJ; DEVROEY, P; LIEBAERS, I; VANSTEIRTEGHEM, A				LIU, J; LISSENS, W; SILBER, SJ; DEVROEY, P; LIEBAERS, I; VANSTEIRTEGHEM, A			BIRTH AFTER PREIMPLANTATION DIAGNOSIS OF THE CYSTIC-FIBROSIS DELTA-F508 MUTATION BY POLYMERASE CHAIN-REACTION IN HUMAN EMBRYOS RESULTING FROM INTRACYTOPLASMIC SPERM INJECTION WITH EPIDIDYMAL SPERM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							VAS-DEFERENS; CONGENITAL ABSENCE; HUMAN BLASTOMERES; REACTION ASSAY; EFFICIENCY; ALLELE; OOCYTE	Men with congenital bilateral absence of the vas deferens (CBAVD) have been regarded as presenting a mild form of cystic fibrosis (CF). In this article, we report a case of male-factor infertility, in which both partners are carriers of the Delta F508 mutation and the male partner has CBAVD. Microsurgical epididymal sperm aspiration (MESA) was performed to obtain spermatozoa; intracytoplasmic sperm injection (ICSI) was carried out on the oocytes since the motility of the spermatozoa was severely impaired; and embryo biopsy and a polymerase chain reaction (PCR) were carried out for preimplantation diagnosis of the CF Delta F508 mutation. Single-blastomere analysis was performed and indicated that two embryos were affected (homozygous Delta F508) and three embryos were carriers. After transfer of the latter three embryos, a singleton pregnancy was established. At amniocentesis, the Delta F508 carrier status of the fetus with a 46, XY karyotype was confirmed. A healthy boy was born and the presence of vasa deferentia, bilaterally, was confirmed. The CF sweat test was also normal. Successful fertilization can be obtained by combination of MESA and ICSI in patients with CBAVD. Preimplantation diagnosis of CF is indicated. Pregnancy and birth of normal children can ensue in such patients.	FREE UNIV BRUSSELS,UNIV HOSP,DEPT MED GENET,B-1090 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,UNIV HOSP,CTR REPROD MED,B-1090 BRUSSELS,BELGIUM; ST LUKES HOSP,DEPT UROL & MICROSURG,ST LOUIS,MO	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Saint Luke's Hospital - Missouri			Lissens, Willy/B-2892-2013	Lissens, Willy/0000-0003-3875-9955				ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; DUMUR V, 1990, LANCET, V336, P512, DOI 10.1016/0140-6736(90)92066-Q; GERVAIS R, 1993, NEW ENGL J MED, V328, P446, DOI 10.1056/NEJM199302113280619; LIU J, 1993, HUM REPROD, V8, P1481, DOI 10.1093/oxfordjournals.humrep.a138283; LIU J, 1992, LANCET, V339, P1190, DOI 10.1016/0140-6736(92)91133-S; LIU J, 1993, PRENATAL DIAG, V13, P873, DOI 10.1002/pd.1970130911; LIU J, 1993, FERTIL STERIL, V59, P815; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; PATRIZIO P, 1993, HUM REPROD, V8, P215, DOI 10.1093/oxfordjournals.humrep.a138025; SILBER S, 1987, LANCET, V2, P850; SILBER SJ, 1990, NEW ENGL J MED, V323, P1788, DOI 10.1056/NEJM199012273232602; SILBER SJ, 1991, NEW ENGL J MED, V325, P65; SMITZ J, 1992, HUM REPROD, V8, P1098; TEMPLE-SMITH P D, 1985, Journal of In Vitro Fertilization and Embryo Transfer, V2, P119, DOI 10.1007/BF01131497; TOURNAYE H, 1994, FERTIL STERIL, V61, P1045; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1055, DOI 10.1093/oxfordjournals.humrep.a138191; 1993, NEW ENGL J MED, V329, P1308	18	82	82	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1858	1860		10.1001/jama.272.23.1858	http://dx.doi.org/10.1001/jama.272.23.1858			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW980	7990220				2022-12-28	WOS:A1994PW98000035
J	MOHR, DN				MOHR, DN			ISOLATED VISUAL SYMPTOMS IN AN OLDER WOMAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											MOHR, DN (corresponding author), MAYO CLIN & MAYO GRAD SCH MED,ROCHESTER,MN, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1823	1823		10.1001/jama.272.23.1823	http://dx.doi.org/10.1001/jama.272.23.1823			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW980	7990215				2022-12-28	WOS:A1994PW98000027
J	ORRELL, RW; DEBELLEROCHE, JS				ORRELL, RW; DEBELLEROCHE, JS			SUPEROXIDE-DISMUTASE AND ALS	LANCET			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS		CHARING CROSS & WESTMINSTER MED SCH,DEPT BIOCHEM,LONDON W6 8RF,ENGLAND	Imperial College London	ORRELL, RW (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,ACAD UNIT NEUROSCI,LONDON,ENGLAND.		Orrell, Richard/L-2123-2013					BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; ELSHAFEY A, 1994, HUM MOL GENET, V3, P363, DOI 10.1093/hmg/3.2.363; ESTEBAN J, 1994, HUM MOL GENET, V3, P997, DOI 10.1093/hmg/3.6.997; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HENTATI A, 1994, NAT GENET, V7, P425, DOI 10.1038/ng0794-425; JENNER P, 1994, LANCET, V344, P796, DOI 10.1016/S0140-6736(94)92347-7; JONES CT, 1994, HUM MOL GENET, V3, P649, DOI 10.1093/hmg/3.4.649; KING AW, 1994, BIOCHEM SOC T, V22, pS149, DOI 10.1042/bst022149s; NAKANO R, 1994, BIOCHEM BIOPH RES CO, V200, P695, DOI 10.1006/bbrc.1994.1506; OGASAWARA M, 1993, NAT GENET, V5, P323, DOI 10.1038/ng1293-323; ROBBERECHT W, 1994, J NEUROCHEM, V62, P384; ROSEN DR, 1994, HUM MOL GENET, V3, P981, DOI 10.1093/hmg/3.6.981; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0	15	13	13	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1651	1652		10.1016/S0140-6736(94)90452-9	http://dx.doi.org/10.1016/S0140-6736(94)90452-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996955				2022-12-28	WOS:A1994PX30200003
J	LEWIN, B				LEWIN, B			ON NEURONAL SPECIFICITY AND THE MOLECULAR-BASIS OF PERCEPTION	CELL			English	Review							ODORANT RECEPTOR EXPRESSION; OLFACTORY EPITHELIUM; GENE-EXPRESSION; PATTERNS; ELEGANS											ASENJO AB, 1994, NEURON, V12, P1131, DOI 10.1016/0896-6273(94)90320-4; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CAMPOSORTEGA JA, 1994, ANNU REV GENET, V24, P387; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Descartes R., 1972, TREATISE MAN; DESCARTES R, 1963, OEUVRES PHILOSOPHIQU, V2; DESCARTES R, 1963, COMMUNICATION; DEVRIES SH, 1993, CELL, V72, P139, DOI 10.1016/S0092-8674(05)80033-9; DEVRIES SH, 1993, NEURON S, V10, P139; EISEN JS, 1994, ANNU REV NEUROSCI, V17, P1; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOODMAN CS, 1994, CELL, V78, P353, DOI 10.1016/0092-8674(94)90413-8; GOODMAN CS, 1993, NEURON S, V10, P77; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P19, DOI 10.1098/rspb.1981.0080; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P391, DOI 10.1113/jphysiol.1978.sp012546; MERBS SL, 1992, NATURE, V356, P433, DOI 10.1038/356433a0; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; NATHANS J, 1994, CELL, V78, P357, DOI 10.1016/0092-8674(94)90414-6; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; RESSLER KJ, 1994, IN PRESS CELL, V79; SENGUPTA P, 1994, CELL, V79, P971, DOI 10.1016/0092-8674(94)90028-0; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; WINDERICKX J, 1992, NATURE, V356, P431, DOI 10.1038/356431a0; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X	33	38	38	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					935	943		10.1016/0092-8674(94)90025-6	http://dx.doi.org/10.1016/0092-8674(94)90025-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001142				2022-12-28	WOS:A1994PY08600004
J	LIEBERMAN, EH; GERHARD, MD; UEHATA, A; WALSH, BW; SELWYN, AP; GANZ, P; YEUNG, AC; CREAGER, MA				LIEBERMAN, EH; GERHARD, MD; UEHATA, A; WALSH, BW; SELWYN, AP; GANZ, P; YEUNG, AC; CREAGER, MA			ESTROGEN IMPROVES ENDOTHELIUM-DEPENDENT, FLOW-MEDIATED VASODILATION IN POSTMENOPAUSAL WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						ESTROGEN REPLACEMENT THERAPY; MENOPAUSE; ENDOTHELIUM; VASODILATION; CORONARY DISEASE	ATHEROSCLEROTIC CORONARY-ARTERIES; SMOOTH-MUSCLE CELLS; NITRIC-OXIDE; RELAXING FACTOR; HEART-DISEASE; FOLLOW-UP; ESSENTIAL-HYPERTENSION; PLASMA-LIPOPROTEINS; RELAXANT FACTOR; ACETYLCHOLINE	Objective: To assess the effect of estrogen replacement therapy on endothelium-dependent vasodilation in postmenopausal women. Design: Double-blind, placebo-controlled, crossover trial. Setting: University medical center. Patients: 13 postmenopausal women aged 44 to 69 years (average age, 55 +/- 7 years). Intervention: Patients were randomly assigned to receive placebo, oral estradiol at a dose of 1 mg/d, and oral estradiol at a dose of 2 mg/d. Each treatment phase lasted 9 weeks. Measurements: High-resolution ultrasonography was used to measure vascular reactivity in a peripheral conduit vessel, the brachial artery. Endothelium-dependent vasodilation was determined by measuring the change in brachial artery diameter during increases in flow induced by reactive hyperemia. Endothelium-independent vasodilation was measured after sublingual nitroglycerin was administered. Results: Flow-mediated, endothelium-dependent vasodilation of the brachial artery was greater when patients received estradiol (13.5% and 11.6% for I-mg and 2-mg doses, respectively) than when patients received placebo (6.8%; P < 0.05 for each dose compared with placebo). In contrast, estrogen administration had no effect on endothelium-independent vasodilation as assessed by sublingual nitroglycerin. Conclusion: Short-term estrogen replacement therapy improves flow-mediated endothelium-dependent vasodilation in postmenopausal women. This improvement may be mediated by a direct effect of estrogen on vascular function or may be induced through modification of lipoprotein metabolism.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, BOSTON, MA 02115 USA; MT SINAI HOSP, MIAMI, FL USA; NATL DEF MED COLL, TOKOROZAWA, SAITAMA 359, JAPAN; STANFORD UNIV, MED CTR, DIV CARDIOVASC, STANFORD, CA 94305 USA; BRIGHAM & WOMENS HOSP, DEPT OBSTET GYNECOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; National Defense Medical College - Japan; Stanford University; Harvard University; Brigham & Women's Hospital				Ganz, Peter/0000-0002-0437-8882	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038780, K04HL002566] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02663, HL02566, HL38780] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; BUSSE R, 1987, N-S ARCH PHARMACOL, V336, P566; CELERMAJER DS, 1993, CIRCULATION, V88, P2149, DOI 10.1161/01.CIR.88.5.2149; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; CHANG WC, 1980, BIOCHIM BIOPHYS ACTA, V619, P107; COLBURN P, 1978, SCIENCE, V201, P817, DOI 10.1126/science.684408; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; COX DA, 1989, CIRCULATION, V80, P458, DOI 10.1161/01.CIR.80.3.458; CREAGER MA, 1990, J CLIN INVEST, V86, P228, DOI 10.1172/JCI114688; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GISCLARD V, 1988, J PHARMACOL EXP THER, V244, P19; GRIFFITH TM, 1984, NATURE, V308, P645, DOI 10.1038/308645a0; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; HONG MK, 1992, AM J CARDIOL, V69, P176, DOI 10.1016/0002-9149(92)91300-S; HORWITZ KB, 1982, J CLIN INVEST, V69, P750, DOI 10.1172/JCI110513; JIANG CW, 1992, AM J PHYSIOL, V263, pH271, DOI 10.1152/ajpheart.1992.263.1.H271; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; KEANEY JF, 1994, CIRCULATION, V89, P2251, DOI 10.1161/01.CIR.89.5.2251; KLEINMAN DG, 1988, APPLIED REGRESSION A; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUHN FE, 1991, AM J CARDIOL, V68, P1425, DOI 10.1016/0002-9149(91)90274-O; KUSHWAHA RS, 1991, ARTERIOSCLER THROMB, V11, P23, DOI 10.1161/01.ATV.11.1.23; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; LIAO JK, 1991, CIRC RES, V68, P1027, DOI 10.1161/01.RES.68.4.1027; LIEBERMAN EH, 1993, CIRCULATION, V88, P79; LINDER L, 1990, CIRCULATION, V81, P1762, DOI 10.1161/01.CIR.81.6.1762; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MACK TM, 1976, NEW ENGL J MED, V294, P1262, DOI 10.1056/NEJM197606032942304; MCDONALD TW, 1977, AM J OBSTET GYNECOL, V127, P572, DOI 10.1016/0002-9378(77)90351-9; MCGILL HC, 1981, CIRC RES, V48, P238, DOI 10.1161/01.RES.48.2.238; MILLER VM, 1990, AM J PHYSIOL, V258, pR1502, DOI 10.1152/ajpregu.1990.258.6.R1502; MILLER VM, 1988, PHLEBOLOGY, V3, P63; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; RAINBOW TC, 1980, BRAIN RES, V198, P239, DOI 10.1016/0006-8993(80)90362-5; REIS SE, 1994, CIRCULATION, V89, P52, DOI 10.1161/01.CIR.89.1.52; SIMON DI, 1993, ARTERIOSCLER THROMB, V13, P791, DOI 10.1161/01.ATV.13.6.791; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; SULLIVAN JM, 1988, ANN INTERN MED, V108, P358, DOI 10.7326/0003-4819-108-3-358; UEHATA A, 1993, CIRCULATION, V88, P618; UEHATA A, 1992, CIRCULATION, V86, P620; VANHOUTTE PM, 1985, CIRCULATION, V72, P728, DOI 10.1161/01.CIR.72.4.728; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WILLIAMS JK, 1992, J AM COLL CARDIOL, V20, P452, DOI 10.1016/0735-1097(92)90116-5; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680; YAGI K, 1986, BIOCHEM INT, V13, P1051; ZEIHER AM, 1991, CIRCULATION, V84, P1984, DOI 10.1161/01.CIR.84.5.1984; 1986, MMWR-MORBID MORTAL W, V35, P653	54	605	614	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1994	121	12					936	941		10.7326/0003-4819-121-12-199412150-00005	http://dx.doi.org/10.7326/0003-4819-121-12-199412150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW083	7978718				2022-12-28	WOS:A1994PW08300005
J	KARLSSON, L; PELERAUX, A; LINDSTEDT, R; LILJEDAHL, M; PETERSON, PA				KARLSSON, L; PELERAUX, A; LINDSTEDT, R; LILJEDAHL, M; PETERSON, PA			RECONSTITUTION OF AN OPERATIONAL MHC CLASS-II COMPARTMENT IN NONANTIGEN-PRESENTING CELLS	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; INVARIANT CHAIN; MICE LACKING; MOLECULES; PEPTIDE; ANTIGENS; TRANSPORT; BIOSYNTHESIS; ASSOCIATION; EXPRESSION	Professional antigen-presenting cells (APCs) have a distinct compartment in which class II molecules are proposed to acquire antigenic peptides. Genetic evidence suggests that human leukocyte antigen (HLA)-DM, an unusual class II molecule, participates in this process. Peptide acquisition was reconstituted in nonprofessional APCs by transfection of class II, invariant chain (Ii), and H-2M, the murine equivalent of DM. The H-2M heterodimer appeared in an endosomal compartment, not at the cell surface, and the localization was independent of Ii. The data presented show that H-2M, class II, and Ii are the minimally required components for efficient formation of stable class II-peptide complexes, and thus for a functional class II compartment.			KARLSSON, L (corresponding author), SCRIPPS RES INST, RW JOHNSON PHARMACEUT RES INST, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026610] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26610] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; CALAFAT J, 1994, J CELL BIOL, V126, P967, DOI 10.1083/jcb.126.4.967; CARRINGTON M, 1993, IMMUNOGENETICS, V38, P446; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; CHO SG, 1991, P NATL ACAD SCI USA, V88, P5197, DOI 10.1073/pnas.88.12.5197; DORNMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; KARLSSON L, 1991, NATURE, V351, P485, DOI 10.1038/351485a0; KARLSSON L, UNPUB; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; OWEN MJ, 1981, J BIOL CHEM, V256, P8987; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; RIBERDY JM, 1994, J CELL BIOL, V125, P1225, DOI 10.1083/jcb.125.6.1225; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; SADEGHNASSERI S, 1994, NATURE, V370, P647, DOI 10.1038/370647a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SALAMERO J, 1990, EMBO J, V9, P3489, DOI 10.1002/j.1460-2075.1990.tb07557.x; SANDERSON F, 1994, IMMUNOGENETICS, V39, P56; SIMONSEN A, 1993, INT IMMUNOL, V5, P903, DOI 10.1093/intimm/5.8.903; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; SYMINGTON FW, 1981, IMMUNOGENETICS, V14, P53, DOI 10.1007/BF00344299; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0	42	137	138	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1569	1573		10.1126/science.7985028	http://dx.doi.org/10.1126/science.7985028			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985028				2022-12-28	WOS:A1994PV01500046
J	SHAH, R; BENNETT, RJ; WEST, SC				SHAH, R; BENNETT, RJ; WEST, SC			GENETIC-RECOMBINATION IN ESCHERICHIA-COLI - RUVC PROTEIN CLEAVES HOLLIDAY JUNCTIONS AT RESOLUTION HOTSPOTS IN-VITRO	CELL			English	Article							T4 ENDONUCLEASE-VII; ESCHERICHIA-COLI; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; ENZYMATIC FORMATION; BRANCH MIGRATION; SUPERCOILED DNA; RECA PROTEIN; PHAGE-LAMBDA; INVITRO	The E. coli RuvC protein resolves Holliday junctions during genetic recombination and postreplication repair. Using recombination intermediates made by RecA protein, we have identified specific ''hotspots'' for RuvC resolution. Characterization of these sites reveals a common tetranucleotide sequence, with the consensus 5'-(A)/TTT down arrow(G)/(c)-3'. The correct orientation of the resolution site is required for cleavage. These observations suggest that the strand bias of this sequence will affect the outcome of recombinational crosses by directing resolution to either ''patch'' or ''splice'' recombinant products. Mutation of the consensus site in synthetic Holliday junctions abolishes or significantly reduces the efficiency of cleavage, although binding is unaffected, demonstrating that junction recognition and incision are biochemically separable events. We propose that efficient RuvC resolution requires the translocation of Holliday junctions to specific cleavage sites, thus providing a biochemical basis for the similar genetic defects observed in ruvA, ruvB, and ruvC mutants.			SHAH, R (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.			Bennett, Richard/0000-0001-7563-484X; West, Stephen/0000-0001-8848-9418				BARTH KA, 1988, GENETICS, V120, P329; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BENSON FE, 1994, J BIOL CHEM, V269, P5195; BERTRANDBURGGRAF E, 1994, MUTAT RES, V314, P287, DOI 10.1016/0921-8777(94)90072-8; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; DASGUPTA C, 1981, CELL, V25, P507, DOI 10.1016/0092-8674(81)90069-6; DICKIE P, 1987, J BIOL CHEM, V262, P14826; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DIXON DA, 1994, P NATL ACAD SCI USA, V91, P2980, DOI 10.1073/pnas.91.8.2980; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; HYDE H, 1994, J BIOL CHEM, V269, P5202; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; JENSCH F, 1986, EMBO J, V5, P181, DOI 10.1002/j.1460-2075.1986.tb04194.x; KEMPER B, 1990, STRUCTURE METHODS, V1, P215; KLEFF S, 1988, EMBO J, V7, P1527, DOI 10.1002/j.1460-2075.1988.tb02972.x; KOSAK HG, 1990, EUR J BIOCHEM, V194, P779, DOI 10.1111/j.1432-1033.1990.tb19469.x; KUZMINOV A, 1994, EMBO J, V13, P2764, DOI 10.1002/j.1460-2075.1994.tb06570.x; LILLEY DMJ, 1984, CELL, V36, P413, DOI 10.1016/0092-8674(84)90234-4; LLOYD RG, 1988, MOL GEN GENET, V212, P317, DOI 10.1007/BF00334702; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; MIZUUCHI K, 1982, CELL, V29, P357, DOI 10.1016/0092-8674(82)90152-0; Muller B, 1994, Methods Mol Biol, V30, P413; MULLER B, 1990, CELL, V60, P329, DOI 10.1016/0092-8674(90)90747-3; MULLER B, 1992, EMBO J, V11, P2685, DOI 10.1002/j.1460-2075.1992.tb05334.x; MURCHIE AIH, 1993, J MOL BIOL, V233, P77, DOI 10.1006/jmbi.1993.1486; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; PICKSLEY SM, 1990, J MOL BIOL, V212, P723, DOI 10.1016/0022-2836(90)90233-C; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; ROSENBERG SM, 1987, CELL, V48, P855, DOI 10.1016/0092-8674(87)90082-1; SAMBROOK E, 1989, MOL CLONING LABORATO; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; SHAH R, 1994, NUCLEIC ACIDS RES, V22, P2490, DOI 10.1093/nar/22.13.2490; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SIDDIQI I, 1991, GENETICS, V128, P7; SMITH JV, 1981, SCOT EDUC REV, V13, P25; SOLARO PC, 1993, J MOL BIOL, V230, P868, DOI 10.1006/jmbi.1993.1207; STAHL FW, 1979, ANNU REV GENET, V13, P7, DOI 10.1146/annurev.ge.13.120179.000255; SYMINGTON LS, 1985, P NATL ACAD SCI USA, V82, P7247, DOI 10.1073/pnas.82.21.7247; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1992, P NATL ACAD SCI USA, V89, P5226, DOI 10.1073/pnas.89.12.5226; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6082, DOI 10.1021/bi00141a018; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6; WEST SC, 1983, CELL, V32, P817, DOI 10.1016/0092-8674(83)90068-5; WEST SC, 1985, P NATL ACAD SCI USA, V82, P6445, DOI 10.1073/pnas.82.19.6445; WHITBY MC, 1993, CELL, V75, P341, DOI 10.1016/0092-8674(93)80075-P	56	134	136	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 2	1994	79	5					853	864		10.1016/0092-8674(94)90074-4	http://dx.doi.org/10.1016/0092-8674(94)90074-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001122				2022-12-28	WOS:A1994PW05400012
J	SPUDICH, JL				SPUDICH, JL			PROTEIN-PROTEIN INTERACTION CONVERTS A PROTON PUMP INTO A SENSORY RECEPTOR	CELL			English	Review							RHODOPSIN-I; TRANSDUCER PROTEIN; BACTERIORHODOPSIN; TRANSLOCATION; SPECTROSCOPY; MECHANISM				SPUDICH, JL (corresponding author), UNIV TEXAS,SCH MED,DEPT MICROBIOL & MOLEC GENET,HOUSTON,TX 77030, USA.							ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; BOGOMOLNI RA, 1994, P NATL ACAD SCI USA, V91, P10188, DOI 10.1073/pnas.91.21.10188; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; FERRANDOMAY E, 1993, EMBO J, V12, P2999, DOI 10.1002/j.1460-2075.1993.tb05968.x; FODOR SPA, 1989, J BIOL CHEM, V264, P18280; HOFMANN KP, 1994, IN PRESS BIOMEMBRANE, V2; KRAH M, 1994, EMBO J, V13, P2150, DOI 10.1002/j.1460-2075.1994.tb06491.x; KREBS MP, 1993, P NATL ACAD SCI USA, V90, P3486, DOI 10.1073/pnas.90.8.3486; KREBS MP, 1993, J BACTERIOL, V175, P1555, DOI 10.1128/JB.175.6.1555-1560.1993; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; Lipson E.D., 1991, Modern Cell Biology, V10, P1; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; OESTERHELT D, 1992, J BIOENERG BIOMEMBR, V24, P181, DOI 10.1007/BF00762676; OESTERHELT D, 1993, BIOCH ARCHAEA ARCHAE, P173; OLSON KD, 1993, BIOPHYS J, V65, P2578, DOI 10.1016/S0006-3495(93)81295-5; OPRIAN DD, 1992, J BIOENERG BIOMEMBR, V24, P211, DOI 10.1007/BF00762679; RATH P, 1994, BIOCHEMISTRY-US, V33, P5600, DOI 10.1021/bi00184a032; ROTHSCHILD KJ, 1992, J BIOENERG BIOMEMBR, V24, P147, DOI 10.1007/BF00762674; SPUDICH EN, 1993, J BIOL CHEM, V268, P16095; SPUDICH JL, 1993, J BACTERIOL, V175, P7755, DOI 10.1128/JB.175.24.7755-7761.1993; YAO VJ, 1992, P NATL ACAD SCI USA, V89, P11915, DOI 10.1073/pnas.89.24.11915; YAO VJ, 1994, J BACTERIOL, V176, P6931, DOI 10.1128/JB.176.22.6931-6935.1994	23	77	77	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 2	1994	79	5					747	750		10.1016/0092-8674(94)90064-7	http://dx.doi.org/10.1016/0092-8674(94)90064-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001113				2022-12-28	WOS:A1994PW05400002
J	KINOSHITA, J				KINOSHITA, J			AGRICULTURAL BIOTECH BLOOMS LATE	SCIENCE			English	Editorial Material																			0	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1184	1185		10.1126/science.7973697	http://dx.doi.org/10.1126/science.7973697			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973697				2022-12-28	WOS:A1994PT13200035
J	UNGERMANN, C; NEUPERT, W; CYR, DM				UNGERMANN, C; NEUPERT, W; CYR, DM			THE ROLE OF HSP70 IN CONFERRING UNIDIRECTIONALITY ON PROTEIN TRANSLOCATION INTO MITOCHONDRIA	SCIENCE			English	Article							YEAST MITOCHONDRIA; MEMBRANE TRANSLOCATION; INTERMEMBRANE SPACE; PRECURSOR PROTEIN; INNER MEMBRANE; IMPORT; CYTOCHROME-B2; RECOGNITION; PREPROTEINS; REQUIREMENT	The entry of segments of preproteins of defined lengths into the matrix space of mitochondria was studied. The mitochondrial chaperone Hsp70 (mtHsp70) interacted with proteins emerging from the protein import channel and stabilized translocation intermediates across the membranes in an adenosine triphosphate-dependent fashion. The chaperone bound to the presequence and mature parts of preproteins. In the absence of mtHsp70 binding, preproteins with less than 30 to 40 residues in the matrix diffused out of mitochondria. Thus, protein translocation was reversible up to a late stage. The import channels in both mitochondrial membranes constitute a passive pore that interacts weakly with polypeptide chains entering the matrix.	UNIV MUNICH,INST PHYSIOL CHEM,D-80336 MUNICH,GERMANY	University of Munich				Cyr, Douglas/0000-0002-4928-3414				BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; CYR DM, 1993, J BIOL CHEM, V268, P23751; DAUM G, 1982, J BIOL CHEM, V257, P3028; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HANNAVY K, 1993, CURR OPIN CELL BIOL, V5, P594; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HORST M, 1993, EMBO J, V12, P3035, DOI 10.1002/j.1460-2075.1993.tb05972.x; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; SANDERS SL, 1992, J BIOL CHEM, V267, P9881; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHNEIDER HC, IN PRESS NATURE; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; Theg Steven M., 1993, Trends in Cell Biology, V3, P186, DOI 10.1016/0962-8924(93)90212-J; VIEBROCK A, 1982, EMBO J, V1, P565, DOI 10.1002/j.1460-2075.1982.tb01209.x; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938	30	222	224	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1250	1253		10.1126/science.7973708	http://dx.doi.org/10.1126/science.7973708			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973708				2022-12-28	WOS:A1994PT13200056
J	MIYAZAKI, T; KAWAHARA, A; FUJII, H; NAKAGAWA, Y; MINAMI, Y; LIU, ZJ; OISHI, I; SILVENNOINEN, O; WITTHUHN, BA; IHLE, JN; TANIGUCHI, T				MIYAZAKI, T; KAWAHARA, A; FUJII, H; NAKAGAWA, Y; MINAMI, Y; LIU, ZJ; OISHI, I; SILVENNOINEN, O; WITTHUHN, BA; IHLE, JN; TANIGUCHI, T			FUNCTIONAL ACTIVATION OF JAK1 AND JAK3 BY SELECTIVE ASSOCIATION WITH IL-2 RECEPTOR SUBUNITS	SCIENCE			English	Article							INTERLEUKIN-2 RECEPTOR; SIGNAL-TRANSDUCTION; GAMMA-CHAIN; TYROSINE KINASE; CYTOPLASMIC REGION; LIGAND-BINDING; BETA-SUBUNIT; COMPONENT; FAMILY; SUPERFAMILY	The interleukin-2 receptor (IL-2) consists of three subunits: the IL-2R alpha, IL-2R beta, and IL-2R gamma chains, the last of which is also used in the receptors for IL-4, IL-7, and IL-9. Stimulation with IL-2 induces the tyrosine phosphorylation and activation of the Janus kinases Jak1 and Jak3. Jak1 and Jak3 were found to be selectively associated with the ''serine-rich'' region of IL-2R beta and the carboxyl-terminal region of IL-2R gamma, respectively. Both regions were necessary for IL-2 signaling. Furthermore, Jak3-negative fibroblasts expressing reconstituted IL-2R became responsive to IL-2 after the additional expression of Jak3 complementary DNA. Thus, activation of Jak1 and Jak3 may be a key event in IL-2 signaling.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital	MIYAZAKI, T (corresponding author), OSAKA UNIV, INST MOLEC & CELLULAR BIOL, 1-3 YAMADA OKA, SUITA, OSAKA 565, JAPAN.		witthuhn, bruce/GSE-3193-2022; Oishi, Isao/L-8639-2018; Miyazaki, Tadaaki/D-9368-2012; Fujii, Hodaka/A-2420-2008; Fujii, Hodaka/N-9792-2019	Oishi, Isao/0000-0003-3682-5349; Fujii, Hodaka/0000-0003-1296-4256; Fujii, Hodaka/0000-0003-1296-4256	NCI NIH HHS [P30 CA21765] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUNG MR, 1991, J IMMUNOL, V147, P1253; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAHARA A, 1994, MOL CELL BIOL, V14, P5433, DOI 10.1128/MCB.14.8.5433; KAWAHARA A, UNPUB; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; MINAMI Y, 1994, J IMMUNOL, V152, P5680; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; Minami Y., UNPUB; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WITTHUHN BA, UNPUB; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	36	521	533	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1045	1047		10.1126/science.7973659	http://dx.doi.org/10.1126/science.7973659			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973659				2022-12-28	WOS:A1994PQ92400045
J	MADDOX, J				MADDOX, J			FRONTIERS OF IGNORANCE - MOLECULES IN EMBRYOLOGY	NATURE			English	Editorial Material																			0	0	0	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					36	36						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969414				2022-12-28	WOS:A1994PQ34800049
J	FLAPAN, AD				FLAPAN, AD			MANAGEMENT OF PATIENTS AFTER THEIR FIRST MYOCARDIAL-INFARCTION	BMJ-BRITISH MEDICAL JOURNAL			English	Review							HEART-RATE-VARIABILITY; RISK STRATIFICATION; MORTALITY; THROMBOLYSIS; PROGNOSIS; TRIAL; PLACEBO; REHABILITATION; REINFARCTION; ASSOCIATION	In the past 20 years there has been a steady improve; ment in the short term prognosis of patients with myocardial infarction,(1) following the introduction of beta blockers, thrombolysis, and aspirin. Patients treated with thrombolytic drugs have a lower overall mortality after myocardial infarction but remain at risk of non-fatal reinfarction or death, and in one study almost half of all survivors of acute myocardial infarction died or suffered a further ischaemic event within three years.(2) It is therefore important to have a strategy to identify patients at high risk, to reduce the subsequent development of cardiac failure and mortality, and to have effective measures for secondary prevention to reduce the incidence of reinfarction as well as to promote rehabilitation.			FLAPAN, AD (corresponding author), ROYAL INFIRM, DEPT CARDIOL, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1981, JAMA, V246, P2073; [Anonymous], 1994, Lancet, V343, P499; ARNOLD AER, 1993, EUR HEART J, V14, P306, DOI 10.1093/eurheartj/14.3.306; BALL SG, 1993, LANCET, V342, P821; BETTERIDGE DJ, 1993, POSTGRAD MED J, V69, P359, DOI 10.1136/pgmj.69.811.359; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BOISSEL JP, 1982, NEW ENGL J MED, V307, P701; BREDDIN K, 1980, CIRCULATION, V62, P63; BURR ML, 1989, LANCET, V2, P757; CAIRNS JA, 1994, LANCET, V343, P497, DOI 10.1016/S0140-6736(94)91457-5; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; CHADDA K, 1986, CIRCULATION, V73, P503, DOI 10.1161/01.CIR.73.3.503; COOPER AJ, 1985, PRACTITIONER, V229, P575; CROSS SJ, 1993, BRIT HEART J, V70, P428; DALY LE, 1985, BMJ-BRIT MED J, V291, P935, DOI 10.1136/bmj.291.6500.935; DEBONO DP, 1991, BMJ-BRIT MED J, V302, P555; DEVREEDE JJM, 1991, J AM COLL CARDIOL, V18, P698, DOI 10.1016/0735-1097(91)90792-8; FARRELL TG, 1991, J AM COLL CARDIOL, V18, P687, DOI 10.1016/0735-1097(91)90791-7; FRIEDMAN M, 1986, AM HEART J, V112, P653, DOI 10.1016/0002-8703(86)90458-8; HANSEN JF, 1990, AM J CARDIOL, V66, P779; HELD PH, 1989, BMJ-BRIT MED J, V299, P1187, DOI 10.1136/bmj.299.6709.1187; HERLITZ J, 1984, AM J CARDIOL, V53, pD9; Impact Research Group, 1984, J AM COLL CARDIOL, V4, P1148; JENNINGS K, 1984, BRIT MED J, V288, P185, DOI 10.1136/bmj.288.6412.185; Kannel WB, 1975, EPIDEMIOLOGY CONTROL, P553; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; LAROVERE MT, 1988, CIRCULATION, V78, P816, DOI 10.1161/01.CIR.78.4.816; LEWIN B, 1992, LANCET, V339, P1036, DOI 10.1016/0140-6736(92)90547-G; LIM R, 1992, LANCET, V340, P161, DOI 10.1016/0140-6736(92)93226-D; MAGGIONI AP, 1993, CIRCULATION, V87, P312, DOI 10.1161/01.CIR.87.2.312; MARMOT MG, 1981, LANCET, V1, P580; MICKLEY H, 1994, BRIT HEART J, V71, P113; MORGAN CD, 1991, J AM COLL CARDIOL, V17, P1451, DOI 10.1016/0735-1097(91)90630-R; MOSS AJ, 1990, NEW ENGL J MED, V322, P743, DOI 10.1056/NEJM199003153221107; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; MOSS AJ, 1993, JAMA-J AM MED ASSOC, V269, P2379, DOI 10.1001/jama.269.18.2379; MUIR KW, 1992, BRIT MED J, V305, P808, DOI 10.1136/bmj.305.6857.808-a; MURRAY RG, 1993, BRIT HEART J, V70, P399; NORRIS RM, 1970, LANCET, V2, P485; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; OLSSON G, 1988, EUR HEART J, V9, P365, DOI 10.1093/oxfordjournals.eurheartj.a062512; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PICCALO G, 1992, AM J CARDIOL, V70, P31, DOI 10.1016/0002-9149(92)91385-H; ROUBIN GS, 1983, CIRCULATION, V67, P743, DOI 10.1161/01.CIR.67.4.743; SIMSON MB, 1981, CIRCULATION, V64, P235, DOI 10.1161/01.CIR.64.2.235; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; STEVENSON R, 1993, BRIT HEART J, V70, P415; STRUTHERS AD, 1993, BRIT HEART J, V70, P397; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701; WELD FM, 1981, CIRCULATION, V64, P306, DOI 10.1161/01.CIR.64.2.306; WILHELMSSON C, 1975, Lancet, V1, P415; WILLIAMS DO, 1992, CIRCULATION, V85, P533, DOI 10.1161/01.CIR.85.2.533	59	16	16	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 29	1994	309	6962					1129	1134		10.1136/bmj.309.6962.1129	http://dx.doi.org/10.1136/bmj.309.6962.1129			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987108	Green Published			2022-12-28	WOS:A1994PP69100026
J	PAPAVASSILIOU, AG				PAPAVASSILIOU, AG			TRANSCRIPTION FACTORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											PAPAVASSILIOU, AG (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAM,POSTFACH 102209,D-69012 HEIDELBERG,GERMANY.		Karamouzis, Michalis/AAD-2860-2020					LATCHMAN DS, 1991, EUKARYOTIC TRANSCRIP; ROSENTHAL N, 1994, NEW ENGL J MED, V331, P931, DOI 10.1056/NEJM199410063311408; Travers A., 1993, DNA PROTEIN INTERACT	3	79	84	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					45	47		10.1056/NEJM199501053320108	http://dx.doi.org/10.1056/NEJM199501053320108			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990864				2022-12-28	WOS:A1995PZ49700008
J	SANCHEZ, I; HUGHES, RT; MAYER, BJ; YEE, K; WOODGETT, JR; AVRUCH, J; KYRIAKIS, JM; ZON, LI				SANCHEZ, I; HUGHES, RT; MAYER, BJ; YEE, K; WOODGETT, JR; AVRUCH, J; KYRIAKIS, JM; ZON, LI			ROLE OF SAPK/ERK KINASE-1 IN THE STRESS-ACTIVATED PATHWAY REGULATING TRANSCRIPTION FACTOR C-JUN	NATURE			English	Article							MAP KINASE; PROTEIN-KINASE; PHOSPHORYLATION; EXPRESSION; TYROSINE; CLONING; FAMILY; MEK	THE stress-activated protein kinases (SAPKs), which are distantly related to the MAP kinases, are the dominant c-Jun amino-terminal protein kinases activated in response to a variety of cellular stresses, including treatment with tumour-necrosis factor-a and interleukin-beta (refs 1, 2). SAPK phosphorylation of c-Jun probably activates the c-Jun transactivation function(3). SAPKs are part of a signal transduction cascade related to, but distinct from, the MAPK pathway(1). We have now identified a novel protein kinase, called SAPK/ERK kinase-1 (SEK1), which is structurally related to the MAP kinase kinases (MEKs)(4). SEK1 is a potent activator of the SAPKs in vitro and in vivo. An inactive SEK1 mutant blocks SAPK activation by extracellular stimuli without interfering with the MAPK pathway. Although alternative mechanisms of SAPK activation may exist, as an immediate upstream activator of the SAPKs, SEK1 further defines a signalling cascade that couples cellular stress agonists to the c-Jun transcription factor.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; PRINCESS MARGARET HOSP, ONTARIO CANC INST, TORONTO M4X 1K9, ON, CANADA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	SANCHEZ, I (corresponding author), MASSACHUSETTS GEN HOSP E, MED SERV, DIABET RES LAB, 149 13TH ST, BOSTON, MA 02129 USA.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	28	961	982	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	1994	372	6508					794	798						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997269				2022-12-28	WOS:A1994PY21200057
J	WHITCOMB, DC; BLOCK, GD				WHITCOMB, DC; BLOCK, GD			ASSOCIATION OF ACETAMINOPHEN HEPATOTOXICITY WITH FASTING AND ETHANOL USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUCED HEPATIC NECROSIS; ENHANCED TOXICITY; N-ACETYLCYSTEINE; PROTECTIVE ROLE; FREE-RADICALS; HUMAN-LIVER; METABOLISM; PARACETAMOL; ALCOHOL; OVERDOSE	Objectives.-To evaluate the association of fasting and alcohol use with hepatotoxicity from acetaminophen ingested for therapeutic reasons. Design.-Retrospective case series. Setting.-Hospitals of the University of Pittsburgh (Pa) Medical Center. Patients.-A total of 126779 discharge summaries from January 1987 to July 1993 were reviewed using a comprehensive, whole-text-indexed medical database to identify all patients with acetaminophen ingestion and hepatotoxicity. These patients were categorized according to the intended acetaminophen use and dose of acetaminophen ingested. Main Outcomes Measured.-The independent variables of chronic alcohol use, recent alcohol use, and recent fasting were determined for all patients. Results.-Forty-nine patients with acetaminophen hepatotoxicity (aspartate aminotransferase > 1000 U/L) were identified. Twenty-one patients (43%) ingested acetaminophen for therapeutic purposes. All patients with hepatotoxicity took more than the recommended limit of 4 g/d. Recent fasting was more common than recent alcohol use among those who suffered hepatotoxicity after a dose of 4 to 10 g of acetaminophen per day (P=.02). Recent alcohol use was more common in the group who took more than 10 g/d than in those who took 4 to 10 g/d (P=.004). Conclusion.-Acetaminophen hepatotoxicity after a dose of 4 to 10 g/d was associated with fasting and less commonly with alcohol use. Patients who developed hepatoxicity after taking acetaminophen doses of greater than 10 g/d for therapeutic purposes were alcohol users. Acetaminophen hepatotoxicity after an overdose appears to be enhanced by fasting in addition to alcohol ingestion.	UNIV PITTSBURGH,DEPT MED,DIV GASTROENTEROL & HEPATOL,PITTSBURGH,PA; UNIV PITTSBURGH,DEPT PATHOL,PITTSBURGH,PA; UNIV PITTSBURGH,DEPT PHYSIOL & CELL BIOL,PITTSBURGH,PA; DEPT VET AFFAIRS MED CTR,PITTSBURGH,PA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ALTOMARE E, 1984, ALCOHOL CLIN EXP RES, V8, P405, DOI 10.1111/j.1530-0277.1984.tb05688.x; ALTOMARE E, 1984, BIOCHEM PHARMACOL, V33, P2207, DOI 10.1016/0006-2952(84)90655-5; BARKER JD, 1977, ANN INTERN MED, V87, P299, DOI 10.7326/0003-4819-87-3-299; BENSON GD, 1983, CLIN PHARMACOL THER, V33, P95, DOI 10.1038/clpt.1983.14; BRENT JA, 1993, J TOXICOL-CLIN TOXIC, V31, P139, DOI 10.3109/15563659309000383; BRENT JA, 1993, J TOXICOL-CLIN TOXIC, V31, P173, DOI 10.3109/15563659309000384; CLARK R, 1973, LANCET, V1, P66; CRITCHLEY JAJH, 1986, BRIT J CLIN PHARMACO, V22, P649, DOI 10.1111/j.1365-2125.1986.tb02953.x; DEMORAIS SMF, 1992, GASTROENTEROLOGY, V102, P577, DOI 10.1016/0016-5085(92)90106-9; DEMORAIS SMF, 1989, HEPATOLOGY, V10, P163, DOI 10.1002/hep.1840100207; EDWARDS D, 1986, ANN EMERG MED, V5, P1314; EMBY DJ, 1977, S AFR MED J, V51, P208; GOLDFINGER R, 1978, AM J GASTROENTEROL, V70, P385; GREGUS Z, 1988, DRUG METAB DISPOS, V16, P527; GREGUS Z, 1990, DRUG METAB DISPOS, V18, P10; HALL AH, 1986, JAMA-J AM MED ASSOC, V256, P1893, DOI 10.1001/jama.1986.03380140063015; HALL AH, 1986, ANN INTERN MED, V105, P624, DOI 10.7326/0003-4819-105-4-624_2; HALL AH, 1987, DIGEST DIS SCI, V32, P558, DOI 10.1007/BF01296042; HONG JY, 1987, BIOCHEM BIOPH RES CO, V142, P1077, DOI 10.1016/0006-291X(87)91525-7; JOHNSON MW, 1981, AM J GASTROENTEROL, V76, P530; JOLLOW DJ, 1974, PHARMACOLOGY, V12, P251, DOI 10.1159/000136547; JOLLOW DJ, 1973, J PHARMACOL EXP THER, V187, P195; KARTSONIS A, 1986, ANN INTERN MED, V105, P138, DOI 10.7326/0003-4819-105-1-138_2; KOOP DR, 1992, FASEB J, V6, P724, DOI 10.1096/fasebj.6.2.1537462; LEIST MH, 1985, J CLIN GASTROENTEROL, V7, P55, DOI 10.1097/00004836-198502000-00008; LICHT H, 1980, ANN INTERN MED, V92, P511, DOI 10.7326/0003-4819-92-4-511_1; LIEBER CS, 1991, J AM COLL NUTR, V10, P602; MADDREY WC, 1987, J CLIN GASTROENTEROL, V9, P180, DOI 10.1097/00004836-198704000-00014; MADHU C, 1989, J PHARMACOL EXP THER, V248, P1069; MCCLAIN CJ, 1980, JAMA-J AM MED ASSOC, V244, P251, DOI 10.1001/jama.244.3.251; MITCHELL JR, 1974, CLIN PHARMACOL THER, V16, P676; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P185; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; MROCHEK JE, 1974, CLIN CHEM, V20, P1086; PATEL M, 1992, PHARMACOGENETICS, V2, P28; PERROT N, 1989, EUR J CLIN INVEST, V19, P549, DOI 10.1111/j.1365-2362.1989.tb00273.x; PESSAYRE D, 1979, GASTROENTEROLOGY, V77, P264; PESSAYRE D, 1980, BIOCHEM PHARMACOL, V29, P2219, DOI 10.1016/0006-2952(80)90201-4; PETERSON RG, 1977, JAMA-J AM MED ASSOC, V237, P2406, DOI 10.1001/jama.237.22.2406; PRESCOTT LF, 1971, LANCET, V1, P519; PRESCOTT LF, 1983, AM J MED, V75, P113, DOI 10.1016/0002-9343(83)90241-3; PRESCOTT LF, 1977, LANCET, V2, P432; PRESCOTT LF, 1980, BR J CLIN PHARM, V10, P2915; PRICE VF, 1989, BIOCHEM PHARMACOL, V38, P289, DOI 10.1016/0006-2952(89)90039-7; PRICE VF, 1987, BIOCHEM PHARMACOL, V36, P427, DOI 10.1016/0006-2952(87)90346-7; PRICE VF, 1988, BIOCHEM PHARMACOL, V37, P1067, DOI 10.1016/0006-2952(88)90512-6; PRICE VF, 1984, XENOBIOTICA, V7, P533; READ RB, 1986, HUM TOXICOL, V5, P201, DOI 10.1177/096032718600500309; REINKE LA, 1979, RES COMMUN CHEM PATH, V23, P185; RUMACK BH, 1981, ARCH INTERN MED, V141, P380, DOI 10.1001/archinte.141.3.380; RUMACK BH, 1983, AM J MED, V75, P104, DOI 10.1016/0002-9343(83)90240-1; SEEFF LB, 1986, ANN INTERN MED, V104, P399, DOI 10.7326/0003-4819-104-3-399; SEEFF LB, 1986, ANN INTERN MED, V105, P624; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; TAKAHASHI T, 1993, HEPATOLOGY, V17, P236, DOI 10.1016/0270-9139(93)90083-Y; Thurman R. G, 1980, PHARMACOL REV, V31, P229; TREDGER JM, 1985, TOXICOLOGY, V36, P341, DOI 10.1016/0300-483X(85)90035-6; TREDGER JM, 1986, XENOBIOTICA, V16, P661, DOI 10.3109/00498258609043556; YANG CS, 1992, FASEB J, V6, P737, DOI 10.1096/fasebj.6.2.1537464; ZIMMERMAN HJ, 1986, ALCOHOL CLIN EXP RES, V10, P3, DOI 10.1111/j.1530-0277.1986.tb05605.x	60	322	334	0	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1845	1850		10.1001/jama.272.23.1845	http://dx.doi.org/10.1001/jama.272.23.1845			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW980	7990219				2022-12-28	WOS:A1994PW98000033
J	BONNEUX, L				BONNEUX, L			RWANDA - A CASE OF DEMOGRAPHIC ENTRAPMENT	LANCET			English	Editorial Material											BONNEUX, L (corresponding author), ERASMUS UNIV ROTTERDAM,DEPT PUBL HLTH,PB1738,3000 DR ROTTERDAM,NETHERLANDS.							[Anonymous], 1994, ECONOMIST; HOMERDIXON TF, 1993, SCI AM, P16; KING M, 1990, LANCET, V336, P664, DOI 10.1016/0140-6736(90)92156-C; KING M, 1993, LANCET, V341, P669, DOI 10.1016/0140-6736(93)90431-F; KING M, 1994, LANCET, V344, P528, DOI 10.1016/S0140-6736(94)91906-2; MCKEOWN T, 1976, ROLE MED; VERKUYL DAA, 1993, LANCET, V342, P473, DOI 10.1016/0140-6736(93)91597-F; VIS HL, 1994, LANCET, V344, P957, DOI 10.1016/S0140-6736(94)92312-4; 1993, WORLD HLTH STATISTIC	9	5	5	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1689	1690		10.1016/S0140-6736(94)90464-2	http://dx.doi.org/10.1016/S0140-6736(94)90464-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PX302	7996966				2022-12-28	WOS:A1994PX30200015
J	MILLER, HI				MILLER, HI			A NEED TO REINVENT BIOTECHNOLOGY REGULATION AT THE EPA	SCIENCE			English	Editorial Material									STANFORD UNIV,INST INT STUDIES,STANFORD,CA 94305	Stanford University	MILLER, HI (corresponding author), STANFORD UNIV,HOOVER INST,STANFORD,CA 94305, USA.							BIDINOTTO RJ, 1990, READERS DIGEST   OCT, P55; COOK RJ, 1992, COMMUNICATION   0917; FALK BW, 1994, SCIENCE, V263, P1395, DOI 10.1126/science.8179685; FISHER LJ, 1992, COMMUNICATION   0821; Fumento M., 1993, SCI SIEGE BALANCING, P19; GOODMAN RM, 1987, SCIENCE, V236, P48, DOI 10.1126/science.236.4797.48; HOYLE R, 1992, BIO-TECHNOL, V10, P742; HUTTNER SL, IN PRESS BIOTECHNOLO; MILLER HI, 1990, SCIENCE, V250, P490, DOI 10.1126/science.2237398; MILLER HI, IN PRESS BIOTECHNOLO; MOFFAT AS, 1994, SCIENCE, V265, P1804, DOI 10.1126/science.8091208; NAJ AK, 1989, WALL STREET J   0130; National Academy of Science Committee on the Introduction of Genetically Engineered Organisms into the Environment, 1987, INTRO RECOMBINANT DN; SEIDLER RJ, 1988, SPECIAL REPORT RELEA; STEWART RB, 1991, GENETIC REVOLUTION, P219; 1994, FINAL RULE TESTING M; 1992, EPA600991050 DOC; 1992, NATIONAL BIOTECHNOLO; 1989, FIELD TESTING GENETI; 1989, NY TIMES        0202, pA1; 1989, APPL MICROBIOL BIOT, V30, P541; 1994, FED REGISTER, V59, P45600; 1988, BIOSAFETY MICROBIOLO; 1992, FED REGISTER, V57, P6753	24	11	11	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1815	1818		10.1126/science.7997875	http://dx.doi.org/10.1126/science.7997875			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997875				2022-12-28	WOS:A1994PX38300024
J	VONARNIM, AG; DENG, XW				VONARNIM, AG; DENG, XW			LIGHT INACTIVATION OF ARABIDOPSIS PHOTOMORPHOGENIC REPRESSOR COP1 INVOLVES A CELL-SPECIFIC REGULATION OF ITS NUCLEOCYTOPLASMIC PARTITIONING	CELL			English	Article							NF-KAPPA-B; NUCLEAR-LOCALIZATION; GENE-EXPRESSION; PROTEIN-KINASE; BINDING-PROTEIN; PHYTOCHROME; THALIANA; ENCODES; TRANSDUCTION; DROSOPHILA	Arabidopsis COP1 acts as a repressor of photomorphogenesis in darkness, and light stimuli abrogate this suppressive action. COP1, when fused to beta-glucuronidase (GUS), is enriched in the nucleus in darkness, but not in the light, in hypocotyl cells of Arabidopsis seedlings and epidermal cells of onion bulbs. In Arabidopsis hypocotyl cells, the nuclear GUS-COP1 level changes in response to dark-light transitions and quantitatively correlates with the extent of repression of photomorphogenic development. In root cells, GUS-COP1 is constitutively nuclear, consistent with an established role of COP1 in suppressing root chloroplast development in both light and darkness. We conclude that COP1 acts inside the nucleus to suppress photomorphogenesis and that light inactivation of COP1 involves a cell type-specific control of its nucleocytoplasmic partitioning.	YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06520 USA	Yale University			Deng, Xing Wang/ABF-4107-2020	von Arnim, Albrecht/0000-0003-3472-3357	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047850] Funding Source: NIH RePORTER; NIGMS NIH HHS [1-R29-GM47850] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUTTER PS, 1994, BIOCHEM J, V300, P609, DOI 10.1042/bj3000609; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; ANG LH, 1994, PLANT CELL, V6, P613, DOI 10.1105/tpc.6.5.613; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; CASTLE LA, 1994, PLANT CELL, V6, P25, DOI 10.1105/tpc.6.1.25; CHORY J, 1993, TRENDS GENET, V9, P167, DOI 10.1016/0168-9525(93)90163-C; CITOVSKY V, 1994, P NATL ACAD SCI USA, V91, P3210, DOI 10.1073/pnas.91.8.3210; DENG XW, 1992, PLANT J, V2, P83, DOI 10.1111/j.1365-313X.1992.00083.x; DENG XW, 1994, CELL, V76, P423, DOI 10.1016/0092-8674(94)90107-4; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; DENG XW, 1991, GENE DEV, V5, P1172, DOI 10.1101/gad.5.7.1172; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; FURUYA M, 1993, ANNU REV PLANT PHYS, V44, P617, DOI 10.1146/annurev.pp.44.060193.003153; GOPLDFARB DS, 1994, CURR BIOL, V4, P57; HARTER K, 1994, PLANT CELL, V6, P545, DOI 10.1105/tpc.6.4.545; HARTER K, 1994, P NATL ACAD SCI USA, V91, P5038, DOI 10.1073/pnas.91.11.5038; ISOMURA T, 1992, NUCLEIC ACIDS RES, V20, P5305, DOI 10.1093/nar/20.20.5305; KAUFMAN LS, 1993, PLANT PHYSIOL, V102, P333, DOI 10.1104/pp.102.2.333; Kendrick RE, 1993, PHOTOMORPHOGENESIS P; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MCCURDY DW, 1986, J CELL BIOL, V103, P2541, DOI 10.1083/jcb.103.6.2541; MCNELLIS T, 1994, IN PRESS PLANT CEL; MCNELLIS TW, 1994, PLANT CELL, V6, P487, DOI 10.1105/tpc.6.4.487; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MISERA S, 1994, MOL GEN GENET, V244, P242, DOI 10.1007/BF00285451; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; Newmeyer DD, 1993, CURR OPIN CELL BIOL, V5, P395, DOI 10.1016/0955-0674(93)90003-9; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; REYMOND P, 1992, PLANT PHYSIOL, V100, P655, DOI 10.1104/pp.100.2.655; ROMERO LC, 1993, P NATL ACAD SCI USA, V90, P1465, DOI 10.1073/pnas.90.4.1465; ROMERO LC, 1991, FEBS LETT, V282, P342; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SHELDON LA, 1993, GENE DEV, V7, P1549, DOI 10.1101/gad.7.8.1549; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; VARAGONA MJ, 1992, PLANT CELL, V4, P1213, DOI 10.1105/tpc.4.10.1213; VIERSTRA RD, 1993, PLANT PHYSIOL, V103, P679, DOI 10.1104/pp.103.3.679; VONARNIM AG, 1993, J BIOL CHEM, V268, P19626; WARPEHA KMF, 1991, P NATL ACAD SCI USA, V88, P8925, DOI 10.1073/pnas.88.20.8925; WEI N, 1994, PLANT CELL, V6, P629, DOI 10.1105/tpc.6.5.629; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523	51	364	376	0	52	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 16	1994	79	6					1035	1045		10.1016/0092-8674(94)90034-5	http://dx.doi.org/10.1016/0092-8674(94)90034-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001131				2022-12-28	WOS:A1994PY08600013
J	HINKLE, G; WETTERER, JK; SCHULTZ, TR; SOGIN, ML				HINKLE, G; WETTERER, JK; SCHULTZ, TR; SOGIN, ML			PHYLOGENY OF THE ATTINE ANT FUNGI BASED ON ANALYSIS OF SMALL-SUBUNIT RIBOSOMAL-RNA GENE-SEQUENCES	SCIENCE			English	Article								Complete 16S-like ribosomal RNA coding regions were obtained from the fungal symbiont of five genera of attine (leaf-cutting) ants and two free-living fungi. Phylogenetic analyses with distance matrix, maximum likelihood, and parsimony methods revealed that the attine fungal symbionts are homobasidiomycetes in the order Agaricales. Comparison of the topology of the attine fungal symbiont phylogenetic tree with a tree based on attine ant morphology revealed a congruent branching pattern of the more derived attine ants and their fungal symbionts. The parallel branching pattern suggests a long-term coevolution of derived leaf-cutting attine ants and their fungal symbionts.	MARINE BIOL LAB, WOODS HOLE, MA 02543 USA; HARVARD UNIV, MUSEUM COMPARAT ZOOL, CAMBRIDGE, MA 02138 USA; CORNELL UNIV, DEPT ENTOMOL, ITHACA, NY 14853 USA	Marine Biological Laboratory - Woods Hole; Harvard University; Cornell University			Sogin, Mitchell/AAE-7186-2019		NIGMS NIH HHS [GM32964] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032964] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baroni Urbani C., 1980, STUTTGARTER BEITRA B, V54, P1; CHAPELA IH, 1994, SCIENCE, V266, P1691, DOI 10.1126/science.266.5191.1691; Cherrett J.M., 1989, P93; ELWOOD HJ, 1985, MOL BIOL EVOL, V2, P399; HERVEY A, 1977, BRITTONIA, V29, P226, DOI 10.2307/2805856; Holldobler B., 1990, pi; Kermarrec A., 1986, P231; KREISEL H, 1975, INDEX FUNGI 10, V4; Lee SB, 1990, PCR PROTOCOLS GUIDE, P282, DOI DOI 10.1016/B978-0-12-372180-8.50038-X; MARTIN MM, 1987, INVERTEBRATE MICROBI, P91; MEDLIN L, 1988, GENE, V71, P491, DOI 10.1016/0378-1119(88)90066-2; Mitter C., 1983, P65; OLSEN GJ, 1988, METHOD ENZYMOL, V164, P793; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; POWELL RJ, 1986, T BRIT MYCOL SOC, V87, P205, DOI 10.1016/S0007-1536(86)80022-5; SCHULTZ TR, IN PRESS SYSTEM ENTO; STRADLING DJ, 1986, EXPERIENTIA, V42, P962, DOI 10.1007/BF01941781; Swofford D., 1990, PAUP PHYLOGENETIC AN; Weber N.A., 1972, Memoirs Am phil Soc, V92, P1; Weber N.A., 1979, P77; WEBER NA, 1966, SCIENCE, V153, P587, DOI 10.1126/science.153.3736.587; Weber NA, 1958, P 10 INT C ENT, V2, P459; Weber NA., 1938, REV ENTOMOLOGIA, V9, P154; Wetterer James K., 1994, P309; Wilson E.O., 1986, P1; WILSON EO, 1985, SCIENCE, V229, P265, DOI 10.1126/science.229.4710.265	26	68	72	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	1994	266	5191					1695	1697		10.1126/science.7992052	http://dx.doi.org/10.1126/science.7992052			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992052				2022-12-28	WOS:A1994PW30800037
J	RAVOET, C; DEGREVE, J; VANDEWOUDE, K; KERGER, J; SCULIER, JP; LACOR, P; STRYCKMANS, P; PICCART, M				RAVOET, C; DEGREVE, J; VANDEWOUDE, K; KERGER, J; SCULIER, JP; LACOR, P; STRYCKMANS, P; PICCART, M			TUMOR STIMULATING EFFECTS OF RECOMBINANT HUMAN INTERLEUKIN-6	LANCET			English	Letter							CELL		FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,DEPT MED ONCOL & HEMATOL,B-1090 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel	RAVOET, C (corresponding author), FREE UNIV BRUSSELS,INST JULES BORDET,DEPT MED,B-1000 BRUSSELS,BELGIUM.		De Greve, Jacques/J-4939-2012	De Greve, Jacques/0000-0002-2389-0742				KOO AS, 1992, CANCER IMMUNOL IMMUN, V35, P97, DOI 10.1007/BF01741856; MULE JJ, 1990, J EXP MED, V171, P629, DOI 10.1084/jem.171.3.629; SERVE H, 1991, CANCER RES, V51, P3862; VANGAMEREN MM, 1994, BLOOD, V84, P1434; WEBER J, 1993, J CLIN ONCOL, V11, P499, DOI 10.1200/JCO.1993.11.3.499	5	27	27	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1576	1577		10.1016/S0140-6736(94)90387-5	http://dx.doi.org/10.1016/S0140-6736(94)90387-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983975				2022-12-28	WOS:A1994PV01700047
J	MULLER, U; CRISTINA, N; LI, ZW; WOLFER, DP; LIPP, HP; RULICKE, T; BRANDNER, S; AGUZZI, A; WEISSMANN, C				MULLER, U; CRISTINA, N; LI, ZW; WOLFER, DP; LIPP, HP; RULICKE, T; BRANDNER, S; AGUZZI, A; WEISSMANN, C			BEHAVIORAL AND ANATOMICAL DEFICITS IN MICE HOMOZYGOUS FOR A MODIFIED BETA-AMYLOID PRECURSOR PROTEIN GENE	CELL			English	Article							ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; STEM-CELLS; TARGETED DISRUPTION; TYPE-4 ALLELE; MESSENGER-RNA; MOUSE HOMOLOG; WATER-MAZE; RAT; PROTOONCOGENE	The beta-amyloid precursor protein (beta APP) gene of the mouse was disrupted by inserting into exon 2 a cassette containing a neomycin resistance gene and a putative transcription termination sequence. Contrary to expectation, brain and other tissues from mice homozygous for the insertion still contained beta APP-specific RNA, albeit at a level 5- to 10-fold lower than wild type and lacking the disrupted exon, which had been spliced out. The brain contained shortened beta APP-specific protein at a low level. Mutant mice were severely impaired in spatial learning and exploratory behavior and showed increased incidence of agenesis of the corpus callosum.	UNIV ZURICH, INST ANAT, CH-8057 ZURICH, SWITZERLAND; UNIV SPITAL ZURICH, INST NEUROPATHOL, BIOL ZENT LAB, CH-8091 ZURICH, SWITZERLAND	University of Zurich; University of Zurich; University Zurich Hospital	MULLER, U (corresponding author), UNIV ZURICH, INST MOLEK BIOL 1, CH-8093 ZURICH, SWITZERLAND.		Brandner, Sebastian/J-4562-2014	Brandner, Sebastian/0000-0002-9821-0342; Aguzzi, Adriano/0000-0002-0344-6708				ASHALL F, 1994, TRENDS BIOCHEM SCI, V19, P42, DOI 10.1016/0968-0004(94)90173-2; BERNASCONIGUASTALLA S, 1994, HIPPOCAMPUS, V4, P53, DOI 10.1002/hipo.450040107; BEYREUTHER K, 1991, ANN NY ACAD SCI, V640, P129; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CLARK RF, 1993, ARCH NEUROL-CHICAGO, V50, P1164, DOI 10.1001/archneur.1993.00540110044004; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; DOYLE E, 1990, NEUROSCI LETT, V115, P97, DOI 10.1016/0304-3940(90)90524-D; Gallyas F, 1979, Neurol Res, V1, P203; GANDY S, 1992, TRENDS PHARMACOL SCI, V13, P108, DOI 10.1016/0165-6147(92)90039-9; GENNARINI G, 1984, EUR J BIOCHEM, V142, P65, DOI 10.1111/j.1432-1033.1984.tb08251.x; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HARDY J, 1994, SCIENCE, V263, P454, DOI 10.1126/science.8290946; HEARD JM, 1987, MOL CELL BIOL, V7, P2425, DOI 10.1128/MCB.7.7.2425; HESS DT, 1983, J NEUROSCI METH, V8, P95, DOI 10.1016/0165-0270(83)90055-9; HILBICH C, 1993, J BIOL CHEM, V268, P26571; KANG J, 1990, BIOCHEM BIOPH RES CO, V166, P1192, DOI 10.1016/0006-291X(90)90992-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEITINGER B, 1994, BEHAV GENET, V24, P273, DOI 10.1007/BF01067194; Lipp H.-P., 1993, Society for Neuroscience Abstracts, V19, P799; Lipp H.-P., 1992, GENETICALLY DEFINED, P217; LUO LQ, 1992, NEURON, V9, P595, DOI 10.1016/0896-6273(92)90024-8; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MONTAG D, 1994, NEURON, V13, P229, DOI 10.1016/0896-6273(94)90472-3; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; NOGUCHI S, 1993, LANCET, V342, P737, DOI 10.1016/0140-6736(93)91728-5; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; REBECK GW, 1993, NEURON, V11, P575; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; Schopke R, 1991, Hippocampus, V1, P315, DOI 10.1002/hipo.450010322; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SMALL DH, 1994, J NEUROSCI, V14, P2117; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STGEORGEHYSLOP P, 1994, SCIENCE, V263, P537, DOI 10.1126/science.8290965; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WEHNER JM, 1990, BRAIN RES, V523, P181, DOI 10.1016/0006-8993(90)91485-Y; WOLFER DP, 1992, J NEUROSCI METH, V41, P65, DOI 10.1016/0165-0270(92)90124-V; YAMADA T, 1989, BIOCHEM BIOPH RES CO, V158, P906, DOI 10.1016/0006-291X(89)92808-8; YAMADA T, 1987, BIOCHEM BIOPH RES CO, V149, P665, DOI 10.1016/0006-291X(87)90419-0; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	55	271	282	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					755	765		10.1016/0092-8674(94)90066-3	http://dx.doi.org/10.1016/0092-8674(94)90066-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001115				2022-12-28	WOS:A1994PW05400004
J	FISHEL, R; EWEL, A; LEE, S; LESCOE, MK; GRIFFITH, J				FISHEL, R; EWEL, A; LEE, S; LESCOE, MK; GRIFFITH, J			BINDING OF MISMATCHED MICROSATELLITE DNA-SEQUENCES BY THE HUMAN MSH2 PROTEIN	SCIENCE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; ESCHERICHIA-COLI; SPONTANEOUS MUTATION; GENETIC INSTABILITY; REPAIR; CARCINOGENESIS; HETERODUPLEXES; TUMORIGENESIS; CARCINOMA; HOMOLOG	Alteration of the human mismatch repair gene hMSH2 has been linked to the microsatellite DNA instability found in hereditary nonpolyposis colon cancer and several sporadic cancers. This microsatellite DNA instability is thought to arise from defective repair of DNA replication errors that create insertion-deletion loop-type (IDL) mismatched nucleotides. Here, it is shown that purified hMSH2 protein efficiently and specifically binds DNA containing IDL mismatches of up to 14 nucleotides. These results support a direct role for hMSH2 in mutation avoidance and microsatellite stability in human cells.	UNIV N CAROLINA,LINEBERGER CANC RES CTR,DEPT MICROBIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	FISHEL, R (corresponding author), UNIV VERMONT,MARKEY CTR MOLEC GENET,SCH MED,DEPT MICROBIOL & MOLEC GENET,BURLINGTON,VT 05405, USA.				NCI NIH HHS [CA56542, R01 CA067007] Funding Source: Medline; NIGMS NIH HHS [GM31819, GM42342] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056542, R01CA067007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALANI E, UNPUB; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BISHOP DT, 1990, CANCER SURV, V9, P585; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BURKS RT, 1994, ONCOGENE, V9, P1163; CHI W, IN PRESS J BIOL CHEM; COX EC, 1976, ANNU REV GENET, V10, P135, DOI 10.1146/annurev.ge.10.120176.001031; DRAKE JW, 1976, ANNU REV BIOCHEM, V45, P11, DOI 10.1146/annurev.bi.45.070176.000303; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FISHEL R, UNPUB; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P10; GRIFFITH JP, UNPUB; HAN HJ, 1993, CANCER RES, V53, P5087; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEARN BA, 1989, J BACTERIOL, V171, P6473, DOI 10.1128/jb.171.12.6473-6481.1989; LEONG PM, 1986, J BACTERIOL, V168, P412, DOI 10.1128/jb.168.1.412-416.1986; LOEB LA, 1991, CANCER RES, V51, P3075; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; LYNCH HT, 1991, SEMIN ONCOL, V18, P337; MERLO A, 1994, CANCER RES, V54, P2098; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1989, J BIOL CHEM, V264, P6597; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; RENAN MJ, 1993, MOL CARCINOGEN, V7, P139; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; SCHOENBERG MP, 1994, BIOCHEM BIOPH RES CO, V198, P74, DOI 10.1006/bbrc.1994.1011; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHRIDHAR V, 1994, CANCER RES, V54, P2084; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, IN PRESS SCIENCE; WADA C, 1994, BLOOD, V83, P3449, DOI 10.1182/blood.V83.12.3449.bloodjournal83123449; WANG YH, 1992, J BIOL CHEM, V267, P4911; WETNUR JG, 1968, J MOL BIOL, V31, P349; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YEE CJ, 1994, CANCER RES, V54, P1641; YOUNG J, 1993, HUM MUTAT, V2, P351, DOI 10.1002/humu.1380020505	54	162	173	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1403	1405		10.1126/science.7973733	http://dx.doi.org/10.1126/science.7973733			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973733				2022-12-28	WOS:A1994PT63200049
J	CONQUET, F; BASHIR, ZI; DAVIES, CH; DANIEL, H; FERRAGUTI, F; BORDI, F; FRANZBACON, K; REGGIANI, A; MATARESE, V; CONDE, F; COLLINGRIDGE, GL; CREPEL, F				CONQUET, F; BASHIR, ZI; DAVIES, CH; DANIEL, H; FERRAGUTI, F; BORDI, F; FRANZBACON, K; REGGIANI, A; MATARESE, V; CONDE, F; COLLINGRIDGE, GL; CREPEL, F			MOTOR DEFICIT AND IMPAIRMENT OF SYNAPTIC PLASTICITY IN MICE LACKING MGLUR1	NATURE			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; CEREBELLAR PURKINJE-CELLS; LONG-TERM POTENTIATION; RAT-BRAIN; INVITRO; MOUSE; HIPPOCAMPUS; EXPRESSION; INDUCTION; ACTIVATION	Metabotropic glutamate receptor 1 (mGluR1) is a member of a large family of G-protein-coupled glutamate receptors, the physiological functions of which are largely unknown. Mice deficient in mGluR1 have severe motor coordination and spatial learning deficits. They have no gross anatomical or basic electrophysiological abnormalities in either the cerebellum or hippocampus, but they show impaired cerebellar long-term depression and hippocampal messy fibre long-term potentiation, mGluR1-deficient mice should therefore be valuable models for studying synaptic plasticity.	GLAXO SPA,GLAXO RES LABS,DEPT PHARMACOL,I-37100 VERONA,ITALY; UNIV PARIS 11,F-91405 ORSAY,FRANCE; CNRS,DEPT NEUROBIOL,F-91405 ORSAY,FRANCE; UNIV BIRMINGHAM,DEPT PHARMACOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	GlaxoSmithKline; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); University of Birmingham	CONQUET, F (corresponding author), GLAXO INST MOLEC BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND.		Collingridge, Graham L/C-4605-2015; Francesco, Ferraguti/AAD-3422-2020; collingridge, graham/AAI-8362-2020; Matarese, Valerie/ABE-1606-2020	Collingridge, Graham L/0000-0002-9572-5359; Francesco, Ferraguti/0000-0002-3843-5857; Matarese, Valerie/0000-0003-2687-194X; Bashir, Zafar/0000-0003-3650-2136				AGNATI LF, 1988, NEUROSCIENCE, V27, P785, DOI 10.1016/0306-4522(88)90183-2; BASHIR ZI, 1993, EUR J PHARMACOL, V239, P265, DOI 10.1016/0014-2999(93)91009-C; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BORTOLOTTO ZA, 1994, NATURE, V368, P740, DOI 10.1038/368740a0; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CREPEL F, 1991, J PHYSIOL-LONDON, V432, P123, DOI 10.1113/jphysiol.1991.sp018380; CREPEL F, 1986, J PHYSIOL-LONDON, V372, P1; DANIEL H, 1992, EXP BRAIN RES, V90, P327; Eccles J.C., 1967, CEREBELLUM NEURONAL, DOI [10.1016/0013-4694(69)90099-6, DOI 10.1016/0013-4694(69)90099-6]; FOTUHI M, 1993, J NEUROSCI, V13, P2001; HANSE E, 1992, EUR J NEUROSCI, V4, P1191, DOI 10.1111/j.1460-9568.1992.tb00144.x; HARTELL NA, 1994, NEUROREPORT, V5, P913, DOI 10.1097/00001756-199404000-00015; HAYASHI T, 1994, J NEUROSCI, V14, P3370; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; IRWIN S, 1959, ARCH INT PHARMACOD T, V188, P358; Ito M, 1990, Neuroreport, V1, P129; KABA H, 1994, SCIENCE, V265, P262, DOI 10.1126/science.8023145; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MANZONI OJ, 1994, EUR J NEUROSCI, V6, P1050, DOI 10.1111/j.1460-9568.1994.tb00599.x; MARTIN LJ, 1992, NEURON, V9, P259, DOI 10.1016/0896-6273(92)90165-A; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OCONNOR JJ, 1994, NATURE, V367, P557, DOI 10.1038/367557a0; PERKEL DJ, 1990, P ROY SOC B-BIOL SCI, V241, P116, DOI 10.1098/rspb.1990.0074; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; REIDEL G, 1993, NEUROPHARMACOLOGY, V32, P929; RICHTER-LEVIN G, 1994, NEUROPHARMACOLOGY, V33, P853, DOI 10.1016/0028-3908(94)90181-3; RIDEL G, 1994, NEUROSCI LETT, V167, P141; RYO Y, 1993, J NEUROSCI RES, V36, P19, DOI 10.1002/jnr.490360104; SANDBERG PR, 1985, NEUROBEHAV TOXICOL T, V7, P87; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; STAUB C, 1992, EUR J NEUROSCI, V4, P832, DOI 10.1111/j.1460-9568.1992.tb00193.x	39	640	647	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					237	243		10.1038/372237a0	http://dx.doi.org/10.1038/372237a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969468				2022-12-28	WOS:A1994PR88900041
J	BOUSSIOTIS, VA; BARBER, DL; NAKARAI, T; FREEMAN, GJ; GRIBBEN, JG; BERNSTEIN, GM; DANDREA, AD; RITZ, J; NADLER, LM				BOUSSIOTIS, VA; BARBER, DL; NAKARAI, T; FREEMAN, GJ; GRIBBEN, JG; BERNSTEIN, GM; DANDREA, AD; RITZ, J; NADLER, LM			PREVENTION OF T-CELL ANERGY BY SIGNALING THROUGH THE GAMMA(C) CHAIN OF THE IL-2 RECEPTOR	SCIENCE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; CTLA-4 COUNTER-RECEPTOR; HUMAN LYMPHOCYTES-T; CLONAL ANERGY; FUNCTIONAL COMPONENT; INTERLEUKIN-2; INDUCTION; ANTIGEN; MICE; PROLIFERATION	When stimulated through their antigen receptor without requisite costimulation, T cells enter a state of antigen-specific unresponsiveness, termed anergy. In this study, signaling through the common gamma chain of the interleukin-2 (IL-2), IL-4, and IL-7 receptors in the presence of antigen was found to be sufficient to prevent the induction of anergy. After culture with IL-2, IL-4, or IL-7, Jak3 kinase was tyrosine-phosphorylated, which correlated with the prevention of anergy. Therefore, a signal through the common gamma chain may regulate the decision of T cells to either clonally expand or enter a state of anergy.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	BOUSSIOTIS, VA (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,44 BINNEY ST,BOSTON,MA 02115, USA.		Freeman, Gordon/AAC-5380-2019; Ritz, Jerome/C-7929-2009	Freeman, Gordon/0000-0002-7210-5616; Ritz, Jerome/0000-0001-5526-4669; Barber, Dwayne/0000-0001-5528-8150	NCI NIH HHS [CA 40216] Funding Source: Medline; NIAID NIH HHS [AI 35225] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040216] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBER DL, 1994, MOL CELL BIOL, V14, P6506, DOI 10.1128/MCB.14.10.6506; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BHANDOOLA A, 1993, J IMMUNOL, V151, P2355; BOUSSIOTIS VA, 1993, J EXP MED, V178, P1753, DOI 10.1084/jem.178.5.1753; BOUSSIOTIS VA, UNPUB; BOUSSIOTIS VA, IN PRESS J EXP MED; DALLMAN MJ, 1991, J EXP MED, V173, P79, DOI 10.1084/jem.173.1.79; DISANTO JP, 1994, EUR J IMMUNOL, V24, P475, DOI 10.1002/eji.1830240232; ESSERY G, 1988, IMMUNOLOGY, V64, P413; FANSLOW WC, 1993, BLOOD, V81, P2998; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FOX DA, 1984, J IMMUNOL, V133, P1250; FREEMAN GJ, 1993, SCIENCE, V262, P907, DOI 10.1126/science.7694362; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FREEMAN GJ, 1993, J EXP MED, V178, P2185, DOI 10.1084/jem.178.6.2185; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GO C, 1992, J EXP MED, V175, P1327, DOI 10.1084/jem.175.5.1327; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HARPUR AG, 1992, ONCOGENE, V7, P1347; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JENKINS MK, 1988, J IMMUNOL, V140, P3324; JENKINS MK, 1987, P NATL ACAD SCI USA, V84, P5409, DOI 10.1073/pnas.84.15.5409; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAMIO M, 1990, INT IMMUNOL, V2, P521, DOI 10.1093/intimm/2.6.521; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LIN H, 1993, J EXP MED, V178, P1801, DOI 10.1084/jem.178.5.1801; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LOMBARDI G, 1994, J EXP MED, V264, P1587; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NAKARAI T, 1994, J EXP MED, V180, P241, DOI 10.1084/jem.180.1.241; NELSON JD, 1994, NATURE, V369, P333; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; WHITTHUHN BA, 1994, NATURE, V370, P153; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	51	318	325	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1039	1042		10.1126/science.7973657	http://dx.doi.org/10.1126/science.7973657			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973657				2022-12-28	WOS:A1994PQ92400043
J	RUSSELL, SM; JOHNSTON, JA; NOGUCHI, M; KAWAMURA, M; BACON, CM; FRIEDMANN, M; BERG, M; MCVICAR, DW; WITTHUHN, BA; SILVENNOINEN, O; GOLDMAN, AS; SCHMALSTIEG, FC; IHLE, JN; OSHEA, JJ; LEONARD, WJ				RUSSELL, SM; JOHNSTON, JA; NOGUCHI, M; KAWAMURA, M; BACON, CM; FRIEDMANN, M; BERG, M; MCVICAR, DW; WITTHUHN, BA; SILVENNOINEN, O; GOLDMAN, AS; SCHMALSTIEG, FC; IHLE, JN; OSHEA, JJ; LEONARD, WJ			INTERACTION OF IL-2R-BETA AND GAMMA(C) CHAINS WITH JAK1 AND JAK3 - IMPLICATIONS FOR XSCID AND XCID	SCIENCE			English	Article							HUMAN INTERLEUKIN-2 RECEPTOR; COMBINED IMMUNODEFICIENCY DISEASE; IL-2 RECEPTOR; TYROSINE PHOSPHORYLATION; FUNCTIONAL COMPONENT; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; LYMPHOCYTES-T; BETA; EXPRESSION	Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta (IL-2R beta) and common gamma (gamma(c)) chains. Mutations of gamma(c) can result in X-linked severe combined immunodeficiency (XSCID). IL-2, IL-4, IL-7 (whose receptors are known to contain gamma(c)) and IL-9 (whose receptor is shown here to contain gamma(c)) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3. Jak1 and Jak3 associated with IL-2R beta and gamma(c), respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma(c) associations. Truncations of gamma(c), and a gamma(c), point mutation causing moderate X-linked combined immunodeficiency (XCID), decreased gamma(c)-Jak3 association. Thus, gamma(c) mutations in at least some XSCID and XCID patients prevent normal Jak3 activation, suggesting that mutations of Jak3 may result in an XSCID-like phenotype.	NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, EXPTL IMMUNOL LAB, FREDERICK, MD 21702 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; UNIV TEXAS, MED BRANCH, DEPT PEDIAT, DIV IMMUNOL & ALLERGY, GALVESTON, TX 77555 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; St Jude Children's Research Hospital; University of Texas System; University of Texas Medical Branch Galveston	RUSSELL, SM (corresponding author), NHLBI, MOLEC IMMUNOL LAB, BLDG 10, BETHESDA, MD 20892 USA.		Russell, Sarah M/B-9341-2009; witthuhn, bruce/GSE-3193-2022; Leonard, Warren/AAA-1397-2022; McVicar, Daniel/G-1970-2015	Russell, Sarah M/0000-0001-5826-9641; Bacon, Chris/0000-0002-8268-2812; McVicar, Daniel/0000-0002-1112-5111	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASAO H, 1992, FEBS LETT, V304, P141, DOI 10.1016/0014-5793(92)80605-G; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BROOKS EG, 1990, J CLIN INVEST, V86, P1623, DOI 10.1172/JCI114884; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOLDMAN AS, 1992, EUR J IMMUNOL, V22, P1103, DOI 10.1002/eji.1830220435; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEONARD WJ, 1994, CURR OPIN IMMUNOL, V6, P631, DOI 10.1016/0952-7915(94)90152-X; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NAKARAI T, 1994, J EXP MED, V180, P241, DOI 10.1084/jem.180.1.241; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; RUSSELL SM, UNPUB; SALTZMAN EM, 1990, J BIOL CHEM, V265, P10138; SCHMALSTIEG FC, 1992, CLIN IMMUNOL IMMUNOP, V64, P71, DOI 10.1016/0090-1229(92)90061-R; SCHMALSTIEG FC, UNPUB; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAKESHITA T, 1990, INT IMMUNOL, V2, P477, DOI 10.1093/intimm/2.5.477; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; TSUDO M, 1989, P NATL ACAD SCI USA, V86, P1982, DOI 10.1073/pnas.86.6.1982; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	41	617	648	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1042	1045		10.1126/science.7973658	http://dx.doi.org/10.1126/science.7973658			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973658	Green Submitted			2022-12-28	WOS:A1994PQ92400044
J	CHEN, XS; SHELLER, JR; JOHNSON, EN; FUNK, CD				CHEN, XS; SHELLER, JR; JOHNSON, EN; FUNK, CD			ROLE OF LEUKOTRIENES REVEALED BY TARGETED DISRUPTION OF THE 5-LIPOXYGENASE GENE	NATURE			English	Article							PLATELET-ACTIVATING-FACTOR; MOUSE EAR EDEMA; MAST-CELLS; MICE; STIMULATION; PERITONITIS; MODULATION; MEDIATORS; PRODUCTS; INVITRO	LEUKOTRIENES constitute a class of potent biological mediators of inflammation and anaphylaxis (for reviews see refs 1 and 2). Their biosynthesis derives from 5-lipoxygenase-catalysed oxygenation of arachidonic acid in granulocytes, macrophages and mast cells. To examine the physiological importance of leukotrienes, we have disrupted the 5-lipoxygenase gene by homologous recombination in embryonic stem cells. 5-Lipoxygenase-deficient (5LX(-/-)) mice develop normally and are healthy. They show a selective opposition to certain inflammatory insults. Although there is no difference in their reaction to endotoxin shock, the 5LX(-/-) animals resist the lethal effects of shock induced by platelet-activating factor. Reaction to ear inflammation induced by phorbol ester is normal, whereas inflammation induced by arachidonic acid is markedly reduced. Contrasts mere also found in two models of leukocyte chemotaxis in vivo. The phenotype of 5LX(-/-) mice under injurious insult identifies the role for leukotrienes in the pathophysiology of select inflammatory states.	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University			Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233				BARBEE RW, 1994, CIRC RES, V74, P747, DOI 10.1161/01.RES.74.4.747; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BRAQUET P, 1987, PHARMACOL REV, V39, P97; CARLSON RP, 1985, AGENTS ACTIONS, V17, P197, DOI 10.1007/BF01966592; CLAESSON HE, 1985, BIOCHEM BIOPH RES CO, V131, P579, DOI 10.1016/0006-291X(85)91276-8; CRUMMEY A, 1987, AGENTS ACTIONS, V20, P69, DOI 10.1007/BF01965627; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FUNK CD, 1991, J BIOL CHEM, V266, P12508; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; INOUE H, 1988, PROSTAGLANDINS, V36, P731, DOI 10.1016/0090-6980(88)90016-0; LANARA E, 1982, BIOCHEM BIOPH RES CO, V109, P1148, DOI 10.1016/0006-291X(82)91897-6; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MARTIN TR, 1988, J APPL PHYSIOL, V64, P2318, DOI 10.1152/jappl.1988.64.6.2318; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; OGATA M, 1992, INFECT IMMUN, V60, P2432, DOI 10.1128/IAI.60.6.2432-2437.1992; PEMBER SO, 1983, BLOOD, V61, P1105; PIPER PJ, 1986, BRIT J PHARMACOL, V88, P595, DOI 10.1111/j.1476-5381.1986.tb10240.x; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; RAMOS BF, 1990, J IMMUNOL, V145, P1868; RAZIN E, 1982, P NATL ACAD SCI-BIOL, V79, P4665, DOI 10.1073/pnas.79.15.4665; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; STAHL GL, 1987, CIRC SHOCK, V23, P165; SUN XM, 1991, J IMMUNOL, V147, P509; VOELKEL NF, 1982, SCIENCE, V218, P286, DOI 10.1126/science.7123233; ZHANG Y, 1992, SCIENCE, V258, P1957, DOI 10.1126/science.1470922; ZHANG YY, 1992, P NATL ACAD SCI USA, V89, P485, DOI 10.1073/pnas.89.2.485; ZIBOH VA, 1986, CANCER RES, V46, P600	28	329	339	2	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					179	182		10.1038/372179a0	http://dx.doi.org/10.1038/372179a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969451				2022-12-28	WOS:A1994PQ68800056
J	KINLEN, LJ; JOHN, SM				KINLEN, LJ; JOHN, SM			WARTIME EVACUATION AND MORTALITY FROM CHILDHOOD LEUKEMIA IN ENGLAND AND WALES IN 1945-9	BRITISH MEDICAL JOURNAL			English	Article							LEUKEMIA; EXCESS	Objective-To discover whether the wartime government evacuation of children from London and other population centres to rural districts was associated with any increase in childhood leukaemia. Design-Observational study of mortality from leukaemia among the childhood population of England and Wales in relation to the unique population movements during the second world war. The 476 rural districts of England and Wales were ranked according to the ratio of government evacuees (two thirds of them children) to local children in September 1941. The districts were divided into three categories, each with similar numbers of children in 1947 but with different ratios of evacuees to local children (''low,'' ''intermediate,'' ''high''). Mortality from childhood leukaemia was examined in these three rural categories in 1945-9. Urban areas were also examined according to their exposure to evacuees. Setting-Local authority areas of England and Wales. Subjects-Children aged under 15. Results-47% excess of leukaemia at ages 0-14 years occurred in 1945-9 in the rural ''high'' category for evacuees relative to the ''low'' category, with a significant trend across the three categories. There were increases in both the 0-4 and 5-14 year age groups, but these were larger in the older age group. Rates 25% lower than average occurred in rural areas with few evacuees. Conclusion-These findings suggest that wartime evacuation increased the incidence of childhood leukaemia in rural areas and that other forms of population mixing may have contributed to the increases in past decades. Overall, they add to the appreciable evidence for an infective basis in childhood leukaemia.			KINLEN, LJ (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND.							BRADBEER G, 1993, LAND CHANGED ITS FAC; BROWN WMC, 1960, BRIT MED J, V2, P1539, DOI 10.1136/bmj.2.5212.1539; CALDER A, 1986, PEOPLES WAR BRITAIN; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1991, BRIT J CANCER, V64, P549, DOI 10.1038/bjc.1991.348; KINLEN LJ, 1993, BRIT MED J, V306, P743, DOI 10.1136/bmj.306.6880.743; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; KINLEN LJ, 1991, BRIT MED J, V303, P1357, DOI 10.1136/bmj.303.6814.1357; KNEALE GW, 1971, BRIT J PREV SOC MED, V25, P152; LANGFORD I, 1991, SOC SCI MED, V33, P435, DOI 10.1016/0277-9536(91)90325-7; ROOTES A, 1980, FRONT LINE COUNTY; Stocks P, 1941, J R STAT SOC, V104, P311, DOI 10.2307/2980120; Stocks P, 1942, J R STAT SOC, V105, P259, DOI 10.2307/2980435; TITMUSS RM, 1950, HIST 2ND WORLD WAR U; WOLFF SP, 1991, NATURE, V349, P23, DOI 10.1038/349023a0; 1951, STATISTICAL REV ENGL, V2; 1940, STATISTICS POPULATIO; 1949, ESTIMATES SEX AGE DI; 1947, STATISTICAL REV EN 1	19	42	42	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 5	1994	309	6963					1197	1202		10.1136/bmj.309.6963.1197	http://dx.doi.org/10.1136/bmj.309.6963.1197			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ662	7987150	Green Published			2022-12-28	WOS:A1994PQ66200019
J	MORELL, V				MORELL, V			JUNGCK,JOHN - GODFATHER OF VIRTUAL BIA AND GENETICS LABS	SCIENCE			English	Note																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					888	888		10.1126/science.7973647	http://dx.doi.org/10.1126/science.7973647			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973647				2022-12-28	WOS:A1994PP75300073
J	JARVIS, WR; BOLYARD, EA; BOZZI, CJ; BURWEN, DR; DOOLEY, SW; MARTIN, LS; MULLAN, RJ; SIMONE, PM				JARVIS, WR; BOLYARD, EA; BOZZI, CJ; BURWEN, DR; DOOLEY, SW; MARTIN, LS; MULLAN, RJ; SIMONE, PM			RESPIRATORS, RECOMMENDATIONS, AND REGULATIONS - THE CONTROVERSY SURROUNDING PROTECTION OF HEALTH-CARE WORKERS FROM TUBERCULOSIS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HIV-INFECTED PATIENTS; NOSOCOMIAL TRANSMISSION; OUTBREAK	Recent nosocomial outbreaks of tuberculosis have increased concern about the occupational acquisition of tuberculosis by health care workers. The Centers for Disease Control and Prevention (CDC), Department of Health and Human Services, and the Occupational Safety and Health Administration, Department of Labor, have issued recommendations and regulations in an effort to decrease health care workers' risk for exposure to patients with infectious tuberculosis. Within the CDC, the National Center for Infectious Diseases, the National Center for Prevention Services, and the National Institute for Occupational Safety and Health collaborated to produce the 1994 Guidelines for Preventing the Transmission of Tuberculosis in Health-Care Facilities. As stated in the Draft Guidelines, the major components of health care worker protection from Mycobacterium tuberculosis infection include administration or source controls, engineering controls, and respiratory protective devices. We review the evolution of the seemingly conflicting recommendations for respiratory protective devices made by these Centers of the CDC and explain how the recommendations in the current CDC Guidelines were reached.	CTR DIS CONTROL & PREVENT, DIV TB ELIMINAT, NCPS, ATLANTA, GA 30333 USA; CTR DIS CONTROL & PREVENT, NIOSH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	JARVIS, WR (corresponding author), CTR DIS CONTROL & PREVENT, HOSP INFECT PROGRAM, 1600 CLIFTON RD NE, MS E-69, ATLANTA, GA 30333 USA.							Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; JARVIS WR, 1993, RES MICROBIOL, V144, P117, DOI 10.1016/0923-2508(93)90025-W; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; LEIDEL NA, 1992, NIOSH RECOMMENDED GU; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; WENGER P, 1992, 1ST WORLD C TUB ROCK; 1982, CDC828371 US DEP HLT; 1993, MMWR-MORBID MORTAL W, V42, P696; 1987, DHHS NIOSH87116 PUBL; 1994, FED REG         0524, P26850; 1972, FED REGISTER, V37, P1910; 1993, DRAFT GUIDELINES PRE	18	43	44	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					142	146		10.7326/0003-4819-122-2-199501150-00011	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7992989				2022-12-28	WOS:A1995QC05900011
J	DURACK, DT				DURACK, DT			DRUG-THERAPY - PREVENTION OF INFECTIVE ENDOCARDITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							EXPERIMENTAL STREPTOCOCCAL ENDOCARDITIS; EXPERIMENTAL BACTERIAL-ENDOCARDITIS; POST-EXTRACTION BACTEREMIA; AMERICAN-HEART-ASSOCIATION; MITRAL-VALVE PROLAPSE; ANTIBIOTIC-PROPHYLAXIS; VIRIDANS STREPTOCOCCI; DENTAL PROCEDURES; AMOXICILLIN PROPHYLAXIS; VANCOMYCIN PROPHYLAXIS				DURACK, DT (corresponding author), HLTHCARE INT MED CTR,DEPT MED,BEARDMORE ST,CLYDEBANK G81 4DY,SCOTLAND.							[Anonymous], 1982, Lancet, V2, P1323; BALTCH AL, 1988, ARCH INTERN MED, V148, P1084, DOI 10.1001/archinte.148.5.1084; BARCO CT, 1991, J PERIODONTOL, V62, P510, DOI 10.1902/jop.1991.62.8.510; BASKIN G, 1989, AM J GASTROENTEROL, V84, P311; BAYLISS R, 1983, BRIT HEART J, V50, P513, DOI 10.1136/hrt.50.6.513; Bender I B, 1989, Compendium, V10, P475; BENDER I. B., 1958, JOUR AMER DENTAL ASSOC, V57, P54; BENDER IB, 1984, J AM DENT ASSOC, V109, P415, DOI 10.14219/jada.archive.1984.0432; BERNARD JP, 1981, J CLIN INVEST, V68, P1113, DOI 10.1172/JCI110337; BERNEY P, 1990, J INFECT DIS, V161, P281; Bernstein M, 1932, ANN INTERN MED, V5, P1138, DOI 10.7326/0003-4819-5-9-1138; BOR DH, 1984, AM J MED, V767, P711; BROOKS RG, 1988, AM J MED, V84, P617, DOI 10.1016/0002-9343(88)90145-3; BROOKS SL, 1980, J AM DENT ASSOC, V101, P41, DOI 10.14219/jada.archive.1980.0361; Burket LW, 1937, J DENT RES, V16, P521; BUTT J, 1978, AM J ROENTGENOL, V130, P715, DOI 10.2214/ajr.130.4.715; CAMARA DS, 1983, ARCH INTERN MED, V143, P1350, DOI 10.1001/archinte.143.7.1350; CLEMENS JD, 1984, J CHRON DIS, V37, P531, DOI 10.1016/0021-9681(84)90004-3; DAJANI A S, 1991, Circulation, V83, P1174; DAJANI AS, 1990, JAMA-J AM MED ASSOC, V264, P2919, DOI 10.1001/jama.264.22.2919; DELAYE J, 1985, EUR HEART J, V6, P826, DOI 10.1093/oxfordjournals.eurheartj.a061767; DENNING DW, 1984, BRIT MED J, V289, P1499, DOI 10.1136/bmj.289.6457.1499; Durack D T, 1972, Trans Assoc Am Physicians, V85, P222; DURACK DT, 1975, J PATHOL, V115, P81, DOI 10.1002/path.1711150204; DURACK DT, 1975, BRIT HEART J, V37, P478; DURACK DT, 1973, J CLIN INVEST, V52, P592, DOI 10.1172/JCI107220; DURACK DT, 1985, AM J MED, V78, P149, DOI 10.1016/0002-9343(85)90377-8; DURACK DT, 1972, BRIT J EXP PATHOL, V53, P50; DURACK DT, 1983, JAMA-J AM MED ASSOC, V250, P2318, DOI 10.1001/jama.250.17.2318; DURACK DT, 1972, BRIT J EXP PATHOL, V53, P44; DURACK DT, 1973, BRIT J EXP PATHOL, V54, P142; DURACK DT, 1977, J LAB CLIN MED, V90, P171; DURACK DT, 1990, HEART, P1230; DURACK DT, 1990, PRINCIPLES PRACTICE, P716; DURACK DT, 1977, AM HEART ASS MONOGRA, V52, P28; ENG RHK, 1986, ANTIMICROB AGENTS CH, V29, P699, DOI 10.1128/AAC.29.4.699; EVERETT ED, 1977, MEDICINE, V56, P61; Feldman L, 1938, ANN INTERN MED, V11, P2124, DOI 10.7326/0003-4819-11-12-2124; FRANCIOLI P, 1985, J INFECT DIS, V152, P83, DOI 10.1093/infdis/152.1.83; FRANCIOLI P, 1985, J ANTIMICROB CHEMOTH, V15, P297, DOI 10.1093/jac/15.suppl_A.297; FRANCIOLI PB, 1979, INFECT IMMUN, V24, P483, DOI 10.1128/IAI.24.2.483-491.1979; GARRISON PK, 1970, YALE J BIOL MED, V42, P394; GLAUSER MP, 1983, J INFECT DIS, V147, P568, DOI 10.1093/infdis/147.3.568; GLAUSER MP, 1987, J ANTIMICROB CHEMOTH, V20, P87, DOI 10.1093/jac/20.suppl_A.87; GLAUSER MP, 1982, J INFECT DIS, V146, P806, DOI 10.1093/infdis/146.6.806; Green J G, 1988, Gen Dent, V36, P131; GUNTHEROTH WG, 1984, AM J CARDIOL, V54, P797, DOI 10.1016/S0002-9149(84)80211-8; GUTSCHIK E, 1990, SCAND J DENT RES, V98, P144; HARVEY WP, 1961, AM J CARDIOL, V7, P793, DOI 10.1016/0002-9149(61)90397-6; HESS J, 1983, J ANTIMICROB CHEMOTH, V11, P555, DOI 10.1093/jac/11.6.555; HOFFMAN BI, 1978, ANN INTERN MED, V88, P658, DOI 10.7326/0003-4819-88-5-658; HOLBROOK WP, 1987, J ANTIMICROB CHEMOTH, V20, P439, DOI 10.1093/jac/20.3.439; Horder TJ, 1909, Q J MED, V2, P289; HORSTKOTTE D, 1987, EUR HEART J, V8, P379, DOI 10.1093/eurheartj/8.suppl_J.379; IMPERIALE TF, 1990, AM J MED, V88, P131, DOI 10.1016/0002-9343(90)90461-L; IVERT TSA, 1984, CIRCULATION, V69, P223, DOI 10.1161/01.CIR.69.2.223; JOKINEN MA, 1978, INT J ORAL MAXILLOF, V7, P450, DOI 10.1016/S0300-9785(78)80036-2; KAYE D, 1991, ANN INTERN MED, V114, P803, DOI 10.7326/0003-4819-114-9-803; KHAIRAT O, 1966, J CLIN PATHOL, V19, P561, DOI 10.1136/jcp.19.6.561; KUNZEL C, 1989, J HEALTH SOC BEHAV, V30, P330, DOI 10.2307/2136964; LAVIE CJ, 1989, JAMA-J AM MED ASSOC, V262, P3308, DOI 10.1001/jama.262.23.3308; MACFARLANE TW, 1984, BRIT DENT J, V156, P179, DOI 10.1038/sj.bdj.4805302; MALINVERNI R, 1987, CIRCULATION, V76, P376, DOI 10.1161/01.CIR.76.2.376; MALINVERNI R, 1988, CIRCULATION, V77, P182, DOI 10.1161/01.CIR.77.1.182; MALINVERNI R, 1987, J INFECT DIS, V156, P151, DOI 10.1093/infdis/156.1.151; MOREILLON P, 1986, J INFECT DIS, V154, P801, DOI 10.1093/infdis/154.5.801; Murrah V A, 1987, J Dent Educ, V51, P229; Okell CC, 1935, LANCET, V2, P869; ORMISTON JA, 1981, AUST NZ J MED, V11, P620, DOI 10.1111/j.1445-5994.1981.tb03536.x; PARRILLO JE, 1979, NEW ENGL J MED, V300, P296, DOI 10.1056/NEJM197902083000608; POGREL MA, 1975, BRIT DENT J, V139, P12, DOI 10.1038/sj.bdj.4803485; RICHARDSON JV, 1978, CIRCULATION, V58, P589, DOI 10.1161/01.CIR.58.4.589; ROBERTS GJ, 1992, INT J CARDIOL, V35, P311, DOI 10.1016/0167-5273(92)90228-U; Rushton MA, 1930, GUYS HOSP REP, V10, P39; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SADOWSKY D, 1988, CIRCULATION, V77, P1316, DOI 10.1161/01.CIR.77.6.1316; SADOWSKY D, 1984, J AM DENT ASSOC, V109, P425, DOI 10.14219/jada.archive.1984.0402; SCHIRGER A, 1960, J LAB CLIN MED, V53, P376; SCOPP IW, 1971, J AM DENT ASSOC, V83, P1294, DOI 10.14219/jada.archive.1971.0463; SEAWORTH BJ, 1986, AM J OBSTET GYNECOL, V154, P180, DOI 10.1016/0002-9378(86)90422-9; SHULMAN ST, 1984, CIRCULATION, V70, P1123; SIMMONS NA, 1993, J ANTIMICROB CHEMOTH, V31, P437, DOI 10.1093/jac/31.3.437; SLAVIN S, 1979, ARCH SURG-CHICAGO, V114, P937; SMITH RH, 1976, THORAX, V31, P373, DOI 10.1136/thx.31.4.373; SOUTHWICK FS, 1974, J CLIN PATHOL, V27, P261, DOI 10.1136/jcp.27.4.261; STARKEBAUM M, 1977, YALE J BIOL MED, V50, P49; STECKELBERG JM, 1993, INFECT DIS CLIN N AM, V7, P9; TANDBERG D, 1978, JAMA-J AM MED ASSOC, V239, P1789; TORNOS MP, 1992, ANN INTERN MED, V117, P567, DOI 10.7326/0003-4819-117-7-567; VANDERMEER JTM, 1992, LANCET, V339, P135, DOI 10.1016/0140-6736(92)90207-J; VANDERMEER JTM, 1992, ARCH INTERN MED, V152, P1869, DOI 10.1001/archinte.152.9.1869; VANDERMEER JTM, 1992, J ANTIMICROB CHEMOTH, V29, P187, DOI 10.1093/jac/29.2.187; VANDERMEER JTM, 1992, ARCH INTERN MED, V152, P1863, DOI 10.1001/archinte.152.9.1863; VANDERMEER JTM, 1991, EUR J CLIN MICROBIOL, V10, P728; VLAY SC, 1990, AM HEART J, V120, P1490, DOI 10.1016/0002-8703(90)90288-9; VOORN GP, 1994, ANTIMICROB AGENTS CH, V38, P487, DOI 10.1128/AAC.38.3.487; Weiss H, 1934, ARCH INTERN MED, V54, P710, DOI 10.1001/archinte.1934.00160170053005; WITZENBERGER T, 1982, J PERIODONTOL, V53, P172, DOI 10.1902/jop.1982.53.3.172; YIN TP, 1983, ENDOSCOPY, V15, P27, DOI 10.1055/s-2007-1018601; 1989, MED LETT DRUG THER, V31, P112	100	283	292	3	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					38	44		10.1056/NEJM199501053320107	http://dx.doi.org/10.1056/NEJM199501053320107			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990863				2022-12-28	WOS:A1995PZ49700007
J	ANDREW, E; ANIS, A; CHALMERS, T; CHO, M; CLARKE, M; FELSON, D; GOTZSCHE, P; GREENE, R; JADAD, A; JONAS, W; KLASSEN, T; KNIPSCHILD, P; LAUPACIS, A; MEINERT, CL; MOHER, D; NICHOL, G; OXMAN, A; PENMAN, MF; POCOCK, S; REISCH, J; SACKETT, D; SCHULZ, K; SNIDER, J; TUGWELL, P; TYSON, J; VARIN, F; WALOP, W; WALSH, S; WELLS, G				ANDREW, E; ANIS, A; CHALMERS, T; CHO, M; CLARKE, M; FELSON, D; GOTZSCHE, P; GREENE, R; JADAD, A; JONAS, W; KLASSEN, T; KNIPSCHILD, P; LAUPACIS, A; MEINERT, CL; MOHER, D; NICHOL, G; OXMAN, A; PENMAN, MF; POCOCK, S; REISCH, J; SACKETT, D; SCHULZ, K; SNIDER, J; TUGWELL, P; TYSON, J; VARIN, F; WALOP, W; WALSH, S; WELLS, G			A PROPOSAL FOR STRUCTURED REPORTING OF RANDOMIZED CONTROLLED TRIALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLE-BLIND TRIALS; CLINICAL-TRIALS; MEDICAL JOURNALS; BIAS; METHODOLOGY; GUIDELINES; ARTHRITIS; AUTHORS		OTTAWA CIVIC HOSP, LOEB MED RES INST, CLIN EPIDEMIOL UNIT, WRITING COMM, OTTAWA K1Y 4E9, ON, CANADA; NYCOMED IMAGING, OSLO, NORWAY; NEW ENGLAND MED CTR HLTH SERV RES & STUDY DESIGN, BOSTON, MA USA; UNIV CALIF SAN FRANCISCO, INST HLTH POLICY STUDIES, SAN FRANCISCO, CA 94143 USA; RADCLIFFE INFIRM, CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND; BOSTON UNIV, SCH MED, WRITING COMM, BOSTON, MA 02118 USA; NORD COCHRANE CTR, WRITING COMM, COPENHAGEN, DENMARK; AGCY HLTH CARE POLICY & RES, ROCKVILLE, MD USA; OXFORD REG PAIN RELIEF UNIT, OXFORD, ENGLAND; WALTER REED ARMY INST RES, WASHINGTON, DC USA; CHILDRENS HOSP EASTERN ONTARIO, DIV EMERGENCY MED, OTTAWA K1H 8L1, ON, CANADA; RYKSUNIV LIMBURG, VAKGOEP EPIDEMIOL, LIMBURG, NETHERLANDS; JOHNS HOPKINS UNIV, DEPT EPIDEMIOL, BALTIMORE, MD USA; BRIGHAM & WOMENS HOSP, CLIN EPIDEMIOL UNIT, BOSTON, MA 02115 USA; NATL INST PUBL HLTH, DEPT HLTH SERV, OSLO, NORWAY; OTTAWA GEN HOSP, MULTIPLE SCLEROSIS CLIN, OTTAWA K1H 8L6, ON, CANADA; UNIV LONDON, LONDON SCH HYG & TROP MED, MED STAT UNIT, WRITING COMM, LONDON, ENGLAND; UNIV TEXAS, HLTH SCI CTR, DEPT PEDIAT & MED COMP SCI, DALLAS, TX 75235 USA; UNIV OXFORD, NUFFIELD DEPT CLIN MED, WRITING COMM, OXFORD, ENGLAND; CTR DIS CONTROL & PREVENT, NATL CTR PREVENT SERV, DIV STD HIV PREVENT, ATLANTA, GA 30341 USA; UNIV OTTAWA, DEPT EPIDEMIOL & COMMUNITY MED, OTTAWA, ON, CANADA; UNIV OTTAWA, DEPT MED, WRITING COMM, OTTAWA, ON, CANADA; UNIV TEXAS, SW MED CTR, DEPT PEDIAT, DALLAS, TX USA; UNIV MONTREAL, FAC PHARM, MONTREAL H3C 3J7, PQ, CANADA; HLTH & WELF CANADA, DRUGS DIRECTORIE, DIV BIOMETR, OTTAWA, ON, CANADA; OTTAWA CIVIC HOSP, DEPT MED, OTTAWA K1Y 4E9, ON, CANADA	University of Ottawa; Ottawa Hospital Research Institute; University of California System; University of California San Francisco; Radcliffe Infirmary; University of Oxford; Boston University; Agency for Healthcare Research & Quality; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University of Ottawa; Children's Hospital of Eastern Ontario; Johns Hopkins University; Harvard University; Brigham & Women's Hospital; University of Ottawa; Ottawa Hospital Research Institute; University of London; London School of Hygiene & Tropical Medicine; University of Texas System; University of Texas Dallas; University of Oxford; Centers for Disease Control & Prevention - USA; University of Ottawa; University of Ottawa; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Universite de Montreal; University of Ottawa; Ottawa Hospital Research Institute			Nichol, Graham/Z-4996-2019; Tugwell, Peter/AFD-8076-2022; Oxman, Andrew/Y-3004-2019	Tugwell, Peter/0000-0001-5062-0556; Oxman, Andrew/0000-0002-5608-5061; Moher, David/0000-0003-2434-4206				ALTMAN DG, 1991, BRIT MED J, V302, P1481, DOI 10.1136/bmj.302.6791.1481; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; ALTMAN DG, 1991, STAT MED, V10, P1897, DOI 10.1002/sim.4780101206; ALTMAN DG, 1985, STATISTICIAN, V34, P125; AMERY A, 1969, ACTA MED SCAND, P1; BAAR J, 1989, J CLIN ONCOL, V7, P969, DOI 10.1200/JCO.1989.7.7.969; BAUER P, 1991, STAT MED, V10, P871, DOI 10.1002/sim.4780100609; BRAITMAN LE, 1991, ANN INTERN MED, V114, P515, DOI 10.7326/0003-4819-114-6-515; BULPITT CJ, 1988, LANCET, V2, P31; Canadian Cooperative Study Group, 1978, N Engl J Med, V299, P53; CANNER PL, 1980, NEW ENGL J MED, V303, P1038; CHALMERS I, 1993, ANN NY ACAD SCI, V703, P156, DOI 10.1111/j.1749-6632.1993.tb26345.x; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; Comans M L, 1990, Ned Tijdschr Geneeskd, V134, P2338; COOK DJ, 1992, CHEST, V102, pS305; DERSIMONIAN R, 1992, MED USES STATISTICS, P333; DONNER A, 1987, AM J EPIDEMIOL, V126, P972, DOI 10.1093/oxfordjournals.aje.a114735; DONNER A, 1990, INT J EPIDEMIOL, V19, P795, DOI 10.1093/ije/19.4.795; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; EVANS M, 1984, ARCH SURG-CHICAGO, V119, P109; FIELDS WS, 1970, J AMER MED ASSOC, V211, P1993, DOI 10.1001/jama.211.12.1993; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; Gardner M. J., 1989, STATISTICS CONFIDENC, P6; GARDNER MJ, 1986, BRIT MED J, V292, P810, DOI 10.1136/bmj.292.6523.810; GARDNER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1355, DOI 10.1001/jama.263.10.1355; GODFREY K, 1992, MED USES STAT, P233; GORE SM, 1992, LANCET, V340, P100, DOI 10.1016/0140-6736(92)90409-V; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; GOTZSCHE PC, 1990, DAN MED BULL, V37, P329; GRANT A, 1989, BRIT J OBSTET GYNAEC, V96, P397, DOI 10.1111/j.1471-0528.1989.tb02412.x; HAYNES RB, 1990, ANN INTERN MED, V113, P69, DOI 10.7326/0003-4819-113-1-69; HAYNES RB, 1987, ANN INTERN MED, V106, P598; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HILL AB, 1952, NEW ENGL J MED, V247, P113, DOI 10.1056/NEJM195207242470401; KARLOWSKI TR, 1975, JAMA-J AM MED ASSOC, V231, P1038, DOI 10.1001/jama.231.10.1038; LAST JM, 1988, DICT EPIDEMIOLOGY, P38; LAUPACIS A, 1989, J BONE JOINT SURG AM, V71A, P535; LAUPACIS A, 1991, ANN INTERN MED, V115, P818, DOI 10.7326/0003-4819-115-10-818; LAUPACIS A, 1992, ACP J CLUB       MAY, pA12; LEE YJ, 1991, STAT MED, V10, P1595, DOI 10.1002/sim.4780101011; MAHON WA, 1964, CAN MED ASSOC J, V90, P565; MAKUCH R, 1989, J CLIN EPIDEMIOL, V42, P503, DOI 10.1016/0895-4356(89)90146-7; McDowell I, 1987, MEASURING HLTH GUIDE; MCKINNEY WP, 1989, JAMA-J AM MED ASSOC, V261, P3430, DOI 10.1001/jama.261.23.3430; MOHER D, 1994, JAMA-J AM MED ASSOC, V272, P122, DOI 10.1001/jama.272.2.122; MOHER D, IN PRESS CONTROL CLI; MOSES LE, 1984, NEW ENGL J MED, V311, P442, DOI 10.1056/NEJM198408163110705; MOSTELLER F, 1980, CONTROL CLIN TRIALS, V1, P37, DOI 10.1016/S0197-2456(80)80006-7; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; POCOCK SJ, 1992, BMJ-BRIT MED J, V305, P235, DOI 10.1136/bmj.305.6847.235; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; Pocock SJ, 1983, CLIN TRIALS PRACTICA, P182; ROCHON PA, 1993, ARCH INTERN MED, V153, P243, DOI 10.1001/archinte.153.2.243; SACKETT DL, 1979, NEW ENGL J MED, V301, P1410, DOI 10.1056/NEJM197912273012602; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; SCHULZ KF, IN PRESS JAMA; SCHULZ KF, 1994, THESIS U LONDON LOND; SIMON R, 1985, CANCER TREAT REP, V69, P1; Steiner DL, 1989, HLTH MEASUREMENT SCA; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; ZELEN M, 1983, J CLIN ONCOL, V1, P164, DOI 10.1200/JCO.1983.1.2.164	65	215	217	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	1994	272	24					1926	1931		10.1001/jama.1994.03520240054041	http://dx.doi.org/10.1001/jama.1994.03520240054041			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX927	7990245				2022-12-28	WOS:A1994PX92700038
J	MELNICK, SL; SHERER, R; LOUIS, TA; HILLMAN, D; RODRIGUEZ, EM; LACKMAN, C; CAPPS, L; BROWN, LS; CARLYN, M; KORVICK, JA; DEYTON, L				MELNICK, SL; SHERER, R; LOUIS, TA; HILLMAN, D; RODRIGUEZ, EM; LACKMAN, C; CAPPS, L; BROWN, LS; CARLYN, M; KORVICK, JA; DEYTON, L			SURVIVAL AND DISEASE PROGRESSION ACCORDING TO GENDER OF PATIENTS WITH HIV-INFECTION - THE TERRY-BEIRN-COMMUNITY-PROGRAMS FOR CLINICAL RESEARCH ON AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; UNITED-STATES; NATURAL-HISTORY; WOMEN; EXPERIENCE; EPIDEMIC; MEN; TUBERCULOSIS; ZIDOVUDINE	Objective.-To compare disease progression and mortality between women and men infected with human immunodeficiency virus (HIV). Design.-Multicenter cohort. Setting.-Seventeen community-based centers participating in the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Patients.-A total of 768 women and 3779 men enrolled in one or more of 11 protocols between September 7, 1990, and September 30, 1993. Main Outcome Measures.-Survival and opportunistic events. Results.-The median CD4(+) cell count at enrollment into the cohort was 0.240 x10(9)/L (240/mu L) for women and 0.137 x10(9)/L for men (P<.001). Compared with men, women were younger (36 vs 38 years), more likely to be African American or Hispanic (78% vs 44%), and more likely to have reported a history of injection drug use (49% vs 27%). Women had been followed up fora median of 14.5 months and men for 15.5 months. The adjusted relative risk (RR) for death among women compared with men was 1.33 (95% confidence interval [CI], 1.06 to 1.67; P=.01) and for disease progression (including death) was 0.97 (95% CI, 0.82 to 1.15; P=.72). Women were at increased risk for bacterial pneumonia (RR, f.38; 95% CI, 1.05 to 1.92) and at reduced risk for the development of Kaposi's sarcoma (RR, 0.16; 95% CI, 0.04 to 0.65) and oral hairy leukoplakia (RR, 0.54; 95% CI, 0.31 to 0.94). The increased risk of death and bacterial pneumonia for women compared with men was primarily evident among those with a history of injection drug use (RR, 1.68 for death, 95% CI, 1.20 to 2.35, P=.003; RR, 1.53 for bacterial pneumonia, 95% CI, 1.03 to 2.29, P=.04). Among patients without a history of disease progression at entry, death was the first event reported for more women than men (27.5% vs 12.2%). Conclusions.-Compared with men, HIV-infected women in the CPCRA were at increased risk of death but not disease progression. Risks of most incident opportunistic diseases were similar for women and men; however, women were at an increased risk of bacterial pneumonia. These findings may reflect differential access to health care and standard treatments or different socioeconomic status and social support for women compared with men.	UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH PUBL HLTH, DIV BIOSTAT, MINNEAPOLIS, MN 55455 USA; COOK CTY HOSP, COOK CTY HIV PRIMARY CARE CTR, CHICAGO, IL 60612 USA; BRONX PERINATAL CONSORTIUM, BRONX, NY USA; COLUMBIA UNIV, HARLEM HOSP CTR, DIV INFECT DIS, NEW YORK, NY USA; ADDICT RES & TREATMENT CORP, BROOKLYN, NY USA; COLUMBIA UNIV, HARLEM HOSP MED CTR, COLL PHYS & SURG, NEW YORK, NY USA; PROSPECT ASSOCIATES, ROCKVILLE, MD USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; John H Stroger Junior Hospital Cook County; Columbia University; Columbia University; American Institutes for Research	MELNICK, SL (corresponding author), NIAID, DIV AIDS,EPIDEMIOL BRANCH,6003 EXECUT BLVD, ROOM 2C09, MSC 7620, BETHESDA, MD 20892 USA.							[Anonymous], 1992, MMWR Recomm Rep, V41, P1; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; BURKE DS, 1990, JAMA-J AM MED ASSOC, V263, P2074, DOI 10.1001/jama.263.15.2074; CARLYN M, 1992, 6TH INT C AIDS SAN F; CARPENTER CCJ, 1991, MEDICINE, V70, P307, DOI 10.1097/00005792-199109000-00003; CARPENTER CCJ, 1989, AM J MED, V86, P771, DOI 10.1016/0002-9343(89)90471-3; CARR A, 1991, CHANGES HLTH CARE SO; CHANG HGH, 1993, AM J EPIDEMIOL, V138, P341, DOI 10.1093/oxfordjournals.aje.a116864; CHU SY, 1990, JAMA-J AM MED ASSOC, V264, P225, DOI 10.1001/jama.264.2.225; COX DR, 1972, J R STAT SOC B, V34, P187; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; DUGUERNY J, 1993, AIDS, V7, P1027, DOI 10.1097/00002030-199308000-00001; ELLERBROCK TV, 1991, JAMA-J AM MED ASSOC, V265, P2971, DOI 10.1001/jama.265.22.2971; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; FINEBERG SA, 1990, MODERN PATHOL, V3, P575; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; GREENBERG AE, 1992, AIDS, V6, P849, DOI 10.1097/00002030-199208000-00014; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOSS MP, 1991, ARCH INTERN MED, V151, P342, DOI 10.1001/archinte.151.2.342; LEMP GF, 1992, J INFECT DIS, V166, P74, DOI 10.1093/infdis/166.1.74; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MILLER HG, 1990, AIDS 2 DECADE, P48; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOR V, 1992, MED CARE, V30, P17, DOI 10.1097/00005650-199201000-00002; MUNOZ A, 1992, J ACQ IMMUN DEF SYND, V5, P694; PHILLIPS AN, 1994, AIDS, V8, P831, DOI 10.1097/00002030-199406000-00017; PRICE R, 1992, 8TH INT C AIDS AMST; QUINN TC, 1992, J INFECT DIS, V165, P541, DOI 10.1093/infdis/165.3.541; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SANDE MA, 1993, JAMA-J AM MED ASSOC, V270, P2583, DOI 10.1001/jama.270.21.2583; SCHECHTER MT, 1994, J CLIN EPIDEMIOL, V47, P59, DOI 10.1016/0895-4356(94)90034-5; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SHAW Nancy, 1986, WHAT DO AIDS PHYSICI, P142; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1; ZIERLER S, 1991, AM J PUBLIC HEALTH, V81, P572, DOI 10.2105/AJPH.81.5.572; 1993, HIV AIDS SURVEILLANC; 1990, MMWR-MORBID MORTAL W, V39, P845; 1987, MMWR MORB MORTAL S1S, V36, P3; 1992, HIV AM PROFILE CHALL; 1991, AM LIVING AIDS 2ND A; 1986, MMWR-MORBID MORTAL W, V35, P334; 1991, TWIN EPIDEMICS SUBST	46	153	155	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	1994	272	24					1915	1921		10.1001/jama.272.24.1915	http://dx.doi.org/10.1001/jama.272.24.1915			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX927	7990243				2022-12-28	WOS:A1994PX92700036
J	CHANG, Y; CESARMAN, E; PESSIN, MS; LEE, F; CULPEPPER, J; KNOWLES, DM; MOORE, PS				CHANG, Y; CESARMAN, E; PESSIN, MS; LEE, F; CULPEPPER, J; KNOWLES, DM; MOORE, PS			IDENTIFICATION OF HERPESVIRUS-LIKE DNA-SEQUENCES IN AIDS-ASSOCIATED KAPOSIS-SARCOMA	SCIENCE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; EPSTEIN-BARR-VIRUS; HOMOSEXUAL MEN; CYTOMEGALO-VIRUS; BISEXUAL MEN; COHORT; INFECTION; COFACTORS; DISEASE; GENOME	Representational difference analysis was used lo isolate unique sequences present in more than 90 percent of Kaposi's sarcoma (KS) tissues obtained from patients with acquired immunodeficiency syndrome (AIDS). These sequences were not present in tissue DNA from non-AIDS patients, but were present in 15 percent of non-KS tissue DNA samples from AIDS patients. The sequences are homologous to, but distinct from, capsid and tegument protein genes of the Gammaherpesvirinae, herpesvirus saimiri and Epstein-Barr virus. These KS-associated herpesvirus-like (KSHV) sequences appear to define a new human herpesvirus.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT BIOL MOLEC,PALO ALTO,CA 94304; NEW YORK CITY DEPT HLTH,DIS INTERVENT COMMISS,NEW YORK,NY 10013; COLUMBIA UNIV,SCH PUBL HLTH,DIV EPIDEMIOL,NEW YORK,NY 10013	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; New York City Department of Health & Mental Hygiene; Columbia University	CHANG, Y (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,630 W 168TH ST,NEW YORK,NY 10032, USA.		Moore, Patrick S./F-3960-2011; Moore, Patrick/GVR-8294-2022; Chang, Yuan/F-4146-2011	Moore, Patrick S./0000-0002-8132-858X; Chang, Yuan/0000-0003-1125-4041; Pessin, Melissa/0000-0003-3990-6494				ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARCHIBALD CP, 1992, EPIDEMIOLOGY, V3, P203, DOI 10.1097/00001648-199205000-00004; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BENDSOE N, 1990, EUR J CANCER, V26, P699, DOI 10.1016/0277-5379(90)90120-I; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1992, LANCET, V339, P632, DOI 10.1016/0140-6736(92)90793-3; BERAL V, 1991, BRIT MED J, V302, P624, DOI 10.1136/bmj.302.6777.624; BIGGAR RJ, 1994, AM J EPIDEMIOL, V139, P362, DOI 10.1093/oxfordjournals.aje.a117008; BOVENZI P, 1993, LANCET, V341, P1288, DOI 10.1016/0140-6736(93)91198-U; DREW WL, 1982, LANCET, V2, P125; Giraldo G, 1983, Antibiot Chemother (1971), V32, P1; HAVERKOS HW, 1985, SEX TRANSM DIS, V12, P203, DOI 10.1097/00007435-198510000-00007; HOLMBERG SD, 1990, CANCER DETECT PREV, V14, P331; JAHAN N, 1989, AIDS RES HUM RETROV, V5, P225, DOI 10.1089/aid.1989.5.225; JOHNSTON GS, 1990, CANCER DETECT PREV, V14, P337; KATZ MH, 1994, J INFECT DIS, V170, P198, DOI 10.1093/infdis/170.1.198; KINGSLEY L, UNPUB; LIFSON AR, 1990, AM J EPIDEMIOL, V131, P221, DOI 10.1093/oxfordjournals.aje.a115492; LIN JC, 1993, BLOOD, V81, P3372; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LO SC, 1992, INT J SYST BACTERIOL, V42, P357, DOI 10.1099/00207713-42-3-357; PELLICI PG, 1985, J EXP MED, V162, P1015; PETERMAN TA, 1991, CANCER SURV, V10, P23; SAFAI B, 1980, CANCER, V45, P1472, DOI 10.1002/1097-0142(19800315)45:6<1472::AID-CNCR2820450629>3.0.CO;2-A; SCHECHTER MT, 1991, AM J EPIDEMIOL, V134, P485, DOI 10.1093/oxfordjournals.aje.a116120; SIDDIQUI A, 1983, P NATL ACAD SCI-BIOL, V80, P4861, DOI 10.1073/pnas.80.15.4861; VANDENBERG F, 1989, J CLIN PATHOL, V42, P128, DOI 10.1136/jcp.42.2.128; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WANG RYH, 1993, CLIN INFECT DIS, V17, P724, DOI 10.1093/clinids/17.4.724	30	4582	4793	5	201	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1865	1869		10.1126/science.7997879	http://dx.doi.org/10.1126/science.7997879			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997879	Green Submitted			2022-12-28	WOS:A1994PX38300036
J	NESTLER, EJ				NESTLER, EJ			HARD TARGET - UNDERSTANDING DOPAMINERGIC NEUROTRANSMISSION	CELL			English	Review							RECEPTOR SYNERGISM; BASAL GANGLIA; BRAIN; RAT; D1				NESTLER, EJ (corresponding author), YALE UNIV,SCH MED,MOLEC PSYCHIAT LAB,NEW HAVEN,CT 06508, USA.							BERRETTA S, 1992, J NEUROPHYSIOL, V6, P767; BERTORELLO AM, 1990, NATURE, V347, P386, DOI 10.1038/347386a0; CAINE SB, 1993, SCIENCE, V260, P1814, DOI 10.1126/science.8099761; CIVELLI O, 1993, ANN REV PHARM TOXICO, V32, P281; DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175; GERFEN CR, 1992, ANNU REV NEUROSCI, V15, P285, DOI 10.1146/annurev.neuro.15.1.285; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; NEVE RL, 1993, TRENDS NEUROSCI, V16, P251, DOI 10.1016/0166-2236(93)90174-K; PIOMELLI D, 1991, NATURE, V353, P164, DOI 10.1038/353164a0; SELF DW, 1992, BRAIN RES, V582, P349, DOI 10.1016/0006-8993(92)90155-3; SIBLEY DR, 1993, INT REV NEURBIOL, V25, P391; SLEF DW, 1995, ANN REV NEUROSCI, V18, P463; SURMEIER DJ, 1993, TRENDS NEUROSCI, V16, P299, DOI 10.1016/0166-2236(93)90103-S; WEISS B, 1993, NEUROSCIENCE, V56, P607; WHITE FJ, 1993, D1 D2 DOPAMINE RECEP, P79; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; Xu M., 1994, CELL, V79; ZHANG M, 1993, NEUROSCI LETT, V161, P223, DOI 10.1016/0304-3940(93)90299-Z	20	64	66	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					923	926		10.1016/0092-8674(94)90022-1	http://dx.doi.org/10.1016/0092-8674(94)90022-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001139				2022-12-28	WOS:A1994PY08600001
J	ROSSMACDONALD, P; ROEDER, GS				ROSSMACDONALD, P; ROEDER, GS			MUTATION OF A MEIOSIS-SPECIFIC MUTS HOMOLOG DECREASES CROSSING-OVER BUT NOT MISMATCH CORRECTION	CELL			English	Article							MEIOTIC CHROMOSOME SYNAPSIS; SACCHAROMYCES-CEREVISIAE; SYNAPTONEMAL COMPLEX; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; GENE CONVERSION; SHUTTLE VECTORS; YEAST; RECOMBINATION; REPAIR	MSH4 is a novel meiosis-specific gene required for wild-type levels of spore viability in S. cerevisiae. The predicted product of the MSH4 gene is homologous to the MutS family of proteins; however, msh4-null mutants have no apparent defect in mismatch repair. msh4 mutant strains display wild-type levels of gene conversion and postmelotic segregation, but they show a reduction in crossing over and a resultant increase in nondisjunction of homologous chromosomes at meiosis I. Immunofluorescence experiments demonstrate that the Msh4 protein is localized to discrete sites on pachytene chromosomes. We propose that Msh4 interacts with a recombination intermediate to influence its resolution.			ROSSMACDONALD, P (corresponding author), YALE UNIV,DEPT BIOL,POB 6666,NEW HAVEN,CT 06520, USA.				NIGMS NIH HHS [GM28904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028904] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1994, GENETICS, V137, P19; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BELL LR, 1982, COLD SPRING HARB SYM, V47, P829, DOI 10.1101/SQB.1983.047.01.095; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BUCKINGHAM LE, 1990, P NATL ACAD SCI USA, V87, P9406, DOI 10.1073/pnas.87.23.9406; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; BYERS B, 1975, P NATL ACAD SCI USA, V72, P5056, DOI 10.1073/pnas.72.12.5056; Carpenter ATC, 1988, GENETIC RECOMBINATIO, P529, DOI [10.1038/ng1287, DOI 10.1038/NG1287]; COLLINS I, 1994, CELL, V76, P65, DOI 10.1016/0092-8674(94)90173-2; ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; ENGEBRECHT JA, 1989, GENETICS, V121, P237; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FOGEL S, 1981, MOL BIOL YEAST SACCH, P289; GORBALENYA AE, 1990, J MOL BIOL, V213, P583, DOI 10.1016/S0022-2836(05)80243-8; HABER JE, 1992, TRENDS GENET, V8, P446, DOI 10.1016/0168-9525(92)90329-3; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; JONES GH, 1984, CONTROLLING EVENTS M, P293; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LOIDL J, 1991, CHROMOSOMA, V100, P221, DOI 10.1007/BF00344155; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MORTIMER RK, 1991, MOL CELLULAR BIOL YE, P737; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; NILSSONTILLGREN T, 1981, CARLSBERG RES COMMUN, V46, P65, DOI 10.1007/BF02906199; OHLENDORF DH, 1983, J MOL EVOL, V19, P109, DOI 10.1007/BF02300748; ORRWEAVER TL, 1985, MICROBIOL REV, V49, P33, DOI 10.1128/MMBR.49.1.33-58.1985; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REENAN RAG, 1992, GENETICS, V132, P963; REENAN RAG, 1992, GENETICS, V132, P975; ROCKMILL B, 1990, GENETICS, V126, P563; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; SEIFERT HS, 1986, P NATL ACAD SCI USA, V83, P735, DOI 10.1073/pnas.83.3.735; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLARO PC, 1993, J MOL BIOL, V230, P868, DOI 10.1006/jmbi.1993.1207; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VOELKELMEIMAN K, 1990, GENETICS, V124, P561; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WHITBY MC, 1993, CELL, V75, P341, DOI 10.1016/0092-8674(93)80075-P; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238	49	312	327	0	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					1069	1080		10.1016/0092-8674(94)90037-X	http://dx.doi.org/10.1016/0092-8674(94)90037-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001134				2022-12-28	WOS:A1994PY08600016
J	DICKEY, W				DICKEY, W			EPILEPSY, CEREBRAL CALCIFICATIONS, AND CELIAC-DISEASE	LANCET			English	Editorial Material							CELIAC-DISEASE				DICKEY, W (corresponding author), ANTRIM HOSP,ANTRIM,NORTH IRELAND.							AMBROSETTO G, 1992, EPILEPSIA, V33, P476, DOI 10.1111/j.1528-1157.1992.tb01695.x; BARDELLA MT, 1994, ARCH DIS CHILD, V70, P211, DOI 10.1136/adc.70.3.211; CHAPMAN RWG, 1978, BRIT MED J, V2, P250, DOI 10.1136/bmj.2.6132.250; COOKE WT, 1966, BRAIN, V89, P683, DOI 10.1093/brain/89.4.683; ERRANZ E, 1994, GUT, V35, P476; FERREIRA M, 1992, GUT, V33, P1633, DOI 10.1136/gut.33.12.1633; Garwicz S, 1976, Pediatr Radiol, V5, P5, DOI 10.1007/BF00988654; GOBBI G, 1992, LANCET, V340, P439; MAGAUDDA A, 1993, J NEUROL NEUROSUR PS, V56, P885, DOI 10.1136/jnnp.56.8.885; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; PIATTELLA L, 1993, CHILD NERV SYST, V9, P172; SAMMARITANO M, 1988, Neurology, V38, P239; TIACCI C, 1993, EPILEPSIA, V34, P528, DOI 10.1111/j.1528-1157.1993.tb02592.x; TORTORELLA G, 1993, NEUROPEDIATRICS, V24, P341, DOI 10.1055/s-2008-1071569	14	17	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1585	1586		10.1016/S0140-6736(94)90400-6	http://dx.doi.org/10.1016/S0140-6736(94)90400-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983988				2022-12-28	WOS:A1994PW05100003
J	SALAM, I; KATELARIS, P; LEIGHSMITH, S; FARTHING, MJG				SALAM, I; KATELARIS, P; LEIGHSMITH, S; FARTHING, MJG			RANDOMIZED TRIAL OF SINGLE-DOSE CIPROFLOXACIN FOR TRAVELERS DIARRHEA	LANCET			English	Article							TRAVELERS DIARRHEA; THERAPY; LOPERAMIDE; PLACEBO; SULFAMETHOXAZOLE; TRIMETHOPRIM; INVITRO	Diarrhoea is the most common illness affecting travellers to developing countries. Our study was compare the efficacy of a single 500 ciprofloxacin with placebo for treatment of acute diarrhoea in travellers. British troops who were within their first 8 weeks of deployment in Belize and who presented within 24 h of the onset of diarrhoea, were randomised to receive either ciprofloxacin 500 mg or placebo. Every subject recorded the number and consistency of stools and presence of any other associated symptoms for 72 h or until recovery. Of 88 subjects enrolled, 83 were evaluable, of whom 45 received ciprofloxacin and 38 placebo. Groups did not differ with regard to duration or severity of diarrhoea at randomisation. Mean (SE) duration of diarrhoea, as assessed by time to the last liquid and last unformed stool, was reduced from 50.4 (4.5) h and 53.5 (4.4) h, respectively, in the placebo group to 20.9 (3.4) h and 24.8 (3.8) h in those receiving ciprofloxacin (p<0.0001). Mean number of liquid stools was reduced from 11.4 (1.2) in the placebo group to 5.0 (0.7) in the ciprofloxacin-treated group (p<0.0001). The cumulative percentages of subjects with no unformed stool after 24 h, 48 h, and 72 h were, respectively, 64%, 82%, and 93% in the ciprofloxacin group and 11%, 42%, and 79% in the placebo group (p<0.0001, p<0.001, and not significant, respectively). A single 500 mg dose of ciprofloxacin was an effective empirical treatment for reducing the duration and severity of diarrhoea in travellers. The regimen should maximise compliance and reduce the cost and duration of therapy.	ST BARTHOLOMEWS HOSP,DEPT GASTROENTEROL,LONDON EC1 7BF,ENGLAND; QUEEN ELIZABETH MIL HOSP,DEPT MED & GASTROENTEROL,LONDON SE18 4QH,ENGLAND; COMMANDO ROYAL MARINES 45,ARBROATH,SCOTLAND	University of London; Queen Mary University London								ARDUINO RC, 1993, BAILLIERE CLIN GASTR, V7, P365, DOI 10.1016/0950-3528(93)90046-U; BLACK RE, 1990, REV INFECT DIS, V12, P573; BLACK RE, 1986, REV INFECT DIS S, V8, P131; DUPONT HL, 1993, NEW ENGL J MED, V328, P1821, DOI 10.1056/NEJM199306243282507; ERICSSON CD, 1990, JAMA-J AM MED ASSOC, V263, P257, DOI 10.1001/jama.263.2.257; ERICSSON CD, 1987, ANN INTERN MED, V106, P216, DOI 10.7326/0003-4819-106-2-216; FARTHING MJG, 1994, GUT, V35, P1, DOI 10.1136/gut.35.1.1; FARTHING MJG, 1992, BRIT J HOSP MED, V48, P82; GOODMAN LJ, 1990, ARCH INTERN MED, V150, P541, DOI 10.1001/archinte.150.3.541; GOODMAN LJ, 1984, ANTIMICROB AGENTS CH, V25, P504, DOI 10.1128/AAC.25.4.504; GORBACH SL, 1982, NEW ENGL J MED, V307, P881, DOI 10.1056/NEJM198209303071409; HYAMS KC, 1991, NEW ENGL J MED, V325, P1423, DOI 10.1056/NEJM199111143252006; PETRUCCELLI BP, 1992, J INFECT DIS, V165, P557, DOI 10.1093/infdis/165.3.557; PICHLER HET, 1987, AM J MED, V82, P329; STEFFEN R, 1993, J ANTIMICROB CHEMOTH, V31, P767, DOI 10.1093/jac/31.5.767; STEFFEN R, 1988, J INFECT DIS, V157, P1008, DOI 10.1093/infdis/157.5.1008; STEFFEN R, 1987, BAILLIERE CLIN GASTR, V1, P361, DOI 10.1016/0950-3528(87)90009-1; TAYLOR DN, 1991, ANN INTERN MED, V114, P731, DOI 10.7326/0003-4819-114-9-731; WOLFSON JS, 1985, ANTIMICROB AGENTS CH, V28, P581, DOI 10.1128/AAC.28.4.581	19	83	84	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1537	1539		10.1016/S0140-6736(94)90350-6	http://dx.doi.org/10.1016/S0140-6736(94)90350-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983954				2022-12-28	WOS:A1994PV01700010
J	URBANEK, P; WANG, ZQ; FETKA, I; WAGNER, EF; BUSSLINGER, M				URBANEK, P; WANG, ZQ; FETKA, I; WAGNER, EF; BUSSLINGER, M			COMPLETE BLOCK OF EARLY B-CELL DIFFERENTIATION AND ALTERED PATTERNING OF THE POSTERIOR MIDBRAIN IN MICE LACKING PAX5/BSAP	CELL			English	Article							TRANSCRIPTION FACTOR BSAP; HOMEOBOX-CONTAINING GENE; PROTO-ONCOGENE INT-1; DNA-BINDING PROTEIN; IMMUNOGLOBULIN HEAVY; PAIRED BOX; CHAIN GENE; WAARDENBURG SYNDROME; TARGETED DISRUPTION; HINDBRAIN BOUNDARY	The Pax5 gene, coding for the transcription factor BSAP, was mutated in the mouse germline by targeted disruption. Homozygous mutant mice were born alive, became growth retarded, and usually died within three weeks. About 5% of mutants survived to adulthood and were fertile, but severely runted. Morphogenesis of the posterior midbrain was affected as early as embryonic day 16.5, leading to a reduction of the inferior colliculus near the midline and to altered foliation of the anterior cerebellum. Moreover, all mutants failed to produce small pre-B, B, and plasma cells owing to a complete arrest of B cell development at an early precursor stage. These data define a key role for Pax5 in early a lymphopoiesis and midbrain patterning.	RES INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Busslinger, Meinrad J./J-1249-2016	Busslinger, Meinrad J./0000-0002-9111-9351; Wagner, Erwin F/0000-0001-7872-0196				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ASANO M, 1992, MECH DEVELOP, V39, P29, DOI 10.1016/0925-4773(92)90023-D; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BOBER E, 1994, DEVELOPMENT, V120, P603; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BUCKWALTER MS, 1993, GENOMICS, V17, P279, DOI 10.1006/geno.1993.1322; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DUCHEN LW, 1964, BRAIN, V87, P367, DOI 10.1093/brain/87.2.367; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; GOULDING M, 1993, GENOMICS, V17, P355, DOI 10.1006/geno.1993.1332; GOULDING M, 1994, DEVELOPMENT, V120, P957; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HAGMAN J, 1994, CURR OPIN IMMUNOL, V6, P222, DOI 10.1016/0952-7915(94)90095-7; HALLONET MER, 1990, DEVELOPMENT, V108, P19; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; INOUYE M, 1980, J COMP NEUROL, V190, P357, DOI 10.1002/cne.901900209; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KANTOR AB, 1993, ANNU REV IMMUNOL, V11, P501, DOI 10.1146/annurev.immunol.11.1.501; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; KRAUSS S, 1992, NATURE, V360, P87, DOI 10.1038/360087a0; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; LIAO F, 1992, J IMMUNOL, V148, P2909; MARTINEZ S, 1989, EUR J NEUROSCI, V1, P549, DOI 10.1111/j.1460-9568.1989.tb00362.x; MASTERTON RB, 1992, TRENDS NEUROSCI, V15, P280, DOI 10.1016/0166-2236(92)90077-L; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MILLEN KJ, 1994, DEVELOPMENT, V120, P695; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; OKABE T, 1992, EUR J IMMUNOL, V22, P37, DOI 10.1002/eji.1830220107; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROTHMAN P, 1991, MOL CELL BIOL, V11, P5551, DOI 10.1128/MCB.11.11.5551; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; STOYKOVA A, 1994, J NEUROSCI, V14, P1395, DOI 10.1523/JNEUROSCI.14-03-01395.1994; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; WAKATSUKI Y, 1994, J EXP MED, V179, P1099, DOI 10.1084/jem.179.4.1099; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WATERS SH, 1989, MOL CELL BIOL, V9, P5594, DOI 10.1128/MCB.9.12.5594; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WURST W, 1994, DEVELOPMENT, V120, P2065; XU LZ, 1992, INT IMMUNOL, V4, P875, DOI 10.1093/intimm/4.8.875; YOON C. H., 1957, JOUR HEREDITY, V48, P176; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	66	660	666	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					901	912		10.1016/0092-8674(94)90079-5	http://dx.doi.org/10.1016/0092-8674(94)90079-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001127				2022-12-28	WOS:A1994PW05400017
J	DOWNES, CS; CLARKE, DJ; MULLINGER, M; GIMENEZABIAN, JF; CREIGHTON, AM; JOHNSON, RT				DOWNES, CS; CLARKE, DJ; MULLINGER, M; GIMENEZABIAN, JF; CREIGHTON, AM; JOHNSON, RT			A TOPOISOMERASE II-DEPENDENT G2 CYCLE CHECKPOINT IN MAMMALIAN-CELLS	NATURE			English	Article							PREMATURE CHROMOSOME CONDENSATION; ULTRAVIOLET-IRRADIATION; MITOTIC CHROMOSOMES; STRAND BREAKS; EGG EXTRACTS; DNA; REPLICATION; SEPARATION; INHIBITION; CAFFEINE	THE enzyme DNA topoisomerase II, which removes the catenations formed between the DNA molecules of sister chromatids during replication(1) and is a structural component of chromosome cores(2), is needed for chromosome condensation in yeast(3) and in Xenopus extracts(4-6). Inhibitors of topoisomerase II arrest mammalian cells before mitosis in the G2 phase of the cell cycle(7), but also produce DNA damage, which causes arrest through established checkpoint controls(8). It is open to question whether cells need topoisomerase II to leave G2, or control late-cycle progression in response to its activity. Bisdioxopiperazines are topoisomerase II inhibitors that act without producing direct DNA damage(9); the most potent, ICRF-193, blocks mammalian entry into but not exit from mitosis. Here we show that checkpoint-evading agents such as caffeine override this block to produce abortively condensed chromosomes, indicating that topoisomerase II is needed for complete condensation. We find that exit from G2 is regulated by a catenation-sensitive checkpoint mechanism which is distinct from the G2-damage checkpoint.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT REPROD PHYSIOL,MED CHEM LAB,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London	DOWNES, CS (corresponding author), UNIV CAMBRIDGE,DEPT ZOOL,CRC,MAMMALIAN CELL DNA REPAIR RES GRP,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.		Abián, Juan F Giménez/E-6372-2015	Abián, Juan F Giménez/0000-0002-9220-286X; Clarke, Duncan/0000-0002-7795-3294				ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; AHNSTROM G, 1974, INT J RADIAT BIOL, V26, P493, DOI 10.1080/09553007414551511; CLARKE DJ, 1993, J CELL SCI, V105, P563; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; CREIGHTON AM, 1969, NATURE, V222, P384, DOI 10.1038/222384a0; CREIGHTON AM, 1979, ADV MED ONCOL RES ED, V5, P83; Downes CS, 1991, P NATL ACAD SCI USA, V88, P2616; GORBSKY GJ, 1994, CANCER RES, V54, P1042; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; ISHIDA R, 1991, CANCER RES, V51, P4909; ISHIMI Y, 1992, MOL CELL BIOL, V12, P4007, DOI 10.1128/MCB.12.9.4007; Johnson Robert David, 1994, CELL CYCLE PRACTICAL, P1; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; KALWINSKY DK, 1983, CANCER RES, V43, P1592; LOCK RB, 1990, CANCER RES, V50, P3761; MA XJ, 1993, J BIOL CHEM, V268, P6182; MORGAN TL, 1991, EXP CELL RES, V197, P125, DOI 10.1016/0014-4827(91)90489-H; MUSK SRR, 1990, BIOCHIM BIOPHYS ACTA, V1052, P53, DOI 10.1016/0167-4889(90)90057-K; MUSK SRR, 1988, J CELL SCI, V90, P591; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; RUFAS JS, 1987, GENOME, V29, P706, DOI 10.1139/g87-121; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SHARPE HBA, 1970, NATURE, V226, P524, DOI 10.1038/226524a0; SQUIRES S, 1982, MUTAT RES, V95, P389, DOI 10.1016/0027-5107(82)90273-1; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; TOLMACH LJ, 1980, RADIAT RES, V82, P374, DOI 10.2307/3575387; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	30	281	287	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					467	470		10.1038/372467a0	http://dx.doi.org/10.1038/372467a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984241				2022-12-28	WOS:A1994PV01200058
J	HOOPER, JE				HOOPER, JE			DISTINCT PATHWAYS FOR AUTOCRINE AND PARACRINE WINGLESS SIGNALING IN DROSOPHILA EMBRYOS	NATURE			English	Article							CELL-CELL COMMUNICATION; HEDGEHOG GENE; PATCHED GENE; PROTEIN; TRANSCRIPTION; SECRETION; PRODUCT; EXPRESSION; EPIDERMIS; MUTATIONS	Two secreted proteins, Wingless(1,2) and Hedgehog(3,4), instruct cell fates within the segmented epidermis of Drosophila embryos (reviewed in ref. 5). Wingless (Wg) is expressed by the most posterior cells in each parasegment; Hedgehog (Hh) is expressed in the most anterior cells of the next parasegment. Immediately after gastrulation, the two cell types are mutually dependent(6,7). Local Wg signalling stabilizes Hh expression(8-10) and local Hh signalling stabilizes Wg expression(11,12). Direct Wg autoregulation (autocrine signalling) is masked by its paracrine role in maintaining hh, which in turn maintains wg. I have used zeste-white3 (zw3)(13) and patched (ptc)(11,14) mutant backgrounds to uncouple genetically this positive-feedback loop and to study autocrine Wg signalling. I report here that direct Wg autoregulation differs from Wg signalling to adjacent cells in the importance of fused (fu), smoothened (smo) and cubitus interruptus (ci) relative to zw3 and armadillo (arm). I also find that Wg autoregulation during this early hh-dependent phase differs from later Wg autoregulation(15) by lack of gooseberry (gsb) participation.			HOOPER, JE (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT CELLULAR & STRUCT BIOL, DENVER, CO 80262 USA.							ARIAS AM, 1988, DEVELOPMENT, V103, P157; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; CAMPOSORTEGA JA, 1985, EMBRYONIC DEV DROSOP, P1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; FORBES AJ, 1993, DEVELOPMENT, P115; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LI XL, 1993, EMBO J, V12, P1427, DOI 10.1002/j.1460-2075.1993.tb05786.x; MOHLER J, 1992, DEVELOPMENT, V115, P957; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, J CELL SCI, V105, P993; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WIESCHAUS E, 1986, ROUX ARCH DEV BIOL, V195, P63, DOI 10.1007/BF00444042	31	118	122	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 1	1994	372	6505					461	464		10.1038/372461a0	http://dx.doi.org/10.1038/372461a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984239				2022-12-28	WOS:A1994PV01200056
J	OUBRIDGE, C; ITO, N; EVANS, PR; TEO, CH; NAGAI, K				OUBRIDGE, C; ITO, N; EVANS, PR; TEO, CH; NAGAI, K			CRYSTAL-STRUCTURE AT 1.92 ANGSTROM RESOLUTION OF THE RNA-BINDING DOMAIN OF THE U1A SPLICEOSOMAL PROTEIN COMPLEXED WITH AN RNA HAIRPIN	NATURE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; X-RAY-DIFFRACTION; HNRNP-C-PROTEINS; A-PROTEIN; PREMESSENGER RNA; SYNTHETASE; SNRNA; RECOGNITION; POLYADENYLATION; CRYSTALLOGRAPHY	The crystal structure of the RNA-binding domain of the small nuclear ribonucleoprotein U1A bound to a 21-nucleotide RNA hairpin has been determined at 1.92 Angstrom resolution. The ten-nucleotide RNA loop binds to the surface of the beta-sheet as an open structure, and the AUUGCAC sequence of the loop interacts extensively with the conserved RNP1 and RNP2 motifs and the C-terminal extension of the RNP domain. These interactions include stacking of RNA bases with aromatic side chains of proteins and many direct and water-mediated hydrogen bonds. The structure reveals the stereochemical basis for sequence-specific RNA recognition by the RNP domain.			OUBRIDGE, C (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.			Oubridge, Chris/0000-0001-8492-8305				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACH M, 1990, NUCLEIC ACIDS RES, V18, P449, DOI 10.1093/nar/18.3.449; BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; COSIER J, 1986, J APPL CRYSTALLOGR, V19, P105, DOI 10.1107/S0021889886089835; GALT MJ, 1991, OLIGONUCLEOTIDE SYNT, P25; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GORLACH M, 1994, J BIOL CHEM, V269, P23074; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; HABETS WJ, 1987, P NATL ACAD SCI USA, V84, P2421, DOI 10.1073/pnas.84.8.2421; HALL KB, 1994, BIOCHEMISTRY-US, V33, P10076, DOI 10.1021/bi00199a035; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOWE PWA, 1994, EMBO J, V13, P3873, DOI 10.1002/j.1460-2075.1994.tb06698.x; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KROL A, 1990, NUCLEIC ACIDS RES, V18, P3803, DOI 10.1093/nar/18.13.3803; LESLIE AGW, 1992, JOINT CCP4 AND ESF E; LINDAHL M, 1994, EMBO J, V13, P1249, DOI 10.1002/j.1460-2075.1994.tb06376.x; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NAGAI K, 1991, ISOMORPHOUS REPLACEM, P141; NAGAI K, 1994, RNA PROTEIN INTERACT, P150; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SHELDRICK GM, 1991, ISOMORPHOUS REPLACEM, P23; SILLEKENS PTG, 1987, EMBO J, V6, P3841, DOI 10.1002/j.1460-2075.1987.tb02721.x; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; VANGELDER CWG, 1993, EMBO J, V12, P5191, DOI 10.1002/j.1460-2075.1993.tb06214.x; WITTEKIND M, 1992, BIOCHEMISTRY-US, V31, P6254, DOI 10.1021/bi00142a013	50	800	816	3	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					432	438		10.1038/372432a0	http://dx.doi.org/10.1038/372432a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984237				2022-12-28	WOS:A1994PV01200047
J	SURRIDGE, C				SURRIDGE, C			FOREWARNED IS 4-ARMED	NATURE			English	Editorial Material							BINDING; P53							Surridge, Christopher/0000-0003-4264-5176				CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581	5	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					482	482		10.1038/372482a0	http://dx.doi.org/10.1038/372482a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984245	Bronze			2022-12-28	WOS:A1994PV01200062
J	WANG, ZQ; FUNG, MR; BARLOW, DP; WAGNER, EF				WANG, ZQ; FUNG, MR; BARLOW, DP; WAGNER, EF			REGULATION OF EMBRYONIC GROWTH AND LYSOSOMAL TARGETING BY THE IMPRINTED IGF2/MPR GENE	NATURE			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; FACTOR-II; TME LOCUS; MOUSE; CELLS; ACTIVATION; DISRUPTION; PROTEINS; BINDING; DEFECTS	THE receptor for insulin-like growth factor type 2, also known as the cation-independent mannose-6-phosphate receptor (Igf2/Mpr), is a multifunctional receptor thought to play a role in lysosomal targeting, cell growth and signal transduction(1-8). Igf2/Mpr has been mapped to the mouse Tme(9) locus and shown to be an imprinted gene(10), which further suggests a role in embryonic growth regulation. To define the functions of Igf2/Mpr, we have generated mice lacking this gene. We report here that maternal inheritance of an Igf2/Mpr null allele (-/+) as well as homozygosity for the inactive allele (-/-) is generally lethal at birth and mutants are about 30% larger, indicating that maternal expression of Igf2/Mpr is essential for late embryonic development and growth regulation. The phenotype is probably caused by an excess of Igf2 because the introduction of an Igf2 null allele rescued the Igf2/Mpr mutant mice. Mutant mice also have organ and skeletal abnormalities and missort mannose-6-phosphate-tagged proteins. A few (-/+) mice reactivated their paternal Igf2/Mpr allele in some tissues and survived to adults. But no (-/-) mice survived, indicating a role for the reactivated paternal allele in postnatal survival.			WANG, ZQ (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Wagner, Erwin F/0000-0001-7872-0196				BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHLARA TM, 1990, CELL, V64, P849; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FILSON A, 1993, DEVELOPMENT, V116, P731; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; FRANKEL HA, 1977, PEDIATR RES, V11, P811, DOI 10.1203/00006450-197707000-00007; HERZOG V, 1987, EMBO J, V6, P555, DOI 10.1002/j.1460-2075.1987.tb04790.x; JOHNSON DR, 1974, GENETICS, V76, P795; Kaufman M.H., 1992, ATLAS MOUSE DEV; KORNFELD S, 1992, REV BIOCH, V61, P307; KOSTER A, 1993, EMBO J, V12, P5219, DOI 10.1002/j.1460-2075.1993.tb06217.x; KYLE JW, 1988, J BIOL CHEM, V263, P16230; LATHAM KE, 1994, GENE DEV, V8, P290, DOI 10.1101/gad.8.3.290; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; LUDWIG T, 1993, EMBO J, V12, P5225, DOI 10.1002/j.1460-2075.1993.tb06218.x; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOULLIER P, 1993, TRANSPLANTATION, V56, P427, DOI 10.1097/00007890-199308000-00034; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NOLAN CM, 1989, METABOLIC BASIS INHE, P1589; OKA Y, 1985, J BIOL CHEM, V260, P9435; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; VOGLER C, 1990, AM J PATHOL, V136, P2207; von Figura K, 1991, Curr Opin Cell Biol, V3, P642, DOI 10.1016/0955-0674(91)90035-W; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0	30	397	416	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					464	467		10.1038/372464a0	http://dx.doi.org/10.1038/372464a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984240				2022-12-28	WOS:A1994PV01200057
J	KOFF, WC				KOFF, WC			THE NEXT STEPS TOWARD A GLOBAL AIDS VACCINE	SCIENCE			English	Editorial Material							ENVELOPE; ANTIBODIES; INDUCTION; IMMUNITY; ISSUES				KOFF, WC (corresponding author), UNITED BIOMED,VACCINE RES & DEV,25 DAVIDS DR,HAUPPAUGE,NY 11790, USA.							CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; COHEN J, 1994, SCIENCE, V264, P1839, DOI 10.1126/science.8009201; COONEY EL, 1993, P NATL ACAD SCI USA, V90, P1882, DOI 10.1073/pnas.90.5.1882; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; DIXON DO, 1993, J ACQ IMMUN DEF SYND, V6, P485; ESPARZA J, 1993, CURR OPIN INFECT DIS, V6, P218, DOI 10.1097/00001432-199304000-00014; ESPARZA J, 1993, AIDS RES HUM RETR S1, V9, pS1133; FAST PE, 1993, AIDS, V7, pS147, DOI 10.1097/00002030-199301001-00020; GOLDING H, 1989, J CLIN INVEST, V83, P1430, DOI 10.1172/JCI114034; HAYNES BF, 1993, SCIENCE, V260, P1279, DOI 10.1126/science.8493572; KARZON DT, 1992, VACCINE, V10, P1039, DOI 10.1016/0264-410X(92)90114-Y; KOFF WC, 1988, SCIENCE, V241, P426, DOI 10.1126/science.3293212; LASKY LA, 1986, SCIENCE, V233, P209, DOI 10.1126/science.3014647; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; Mariner W K, 1987, Law Med Health Care, V15, P17; MARINER WK, 1992, HEALTH AFFAIR, V11, P255, DOI 10.1377/hlthaff.11.1.255; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MASCOLA JR, 1993, AIDS RES HUM RETROV, V9, P1175, DOI 10.1089/aid.1993.9.1175; MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0; MYERS G, 1993, HUMAN RETROVIRUSES A; PETRICCIANI JC, 1993, VACCINE, V11, P873, DOI 10.1016/0264-410X(93)90364-4; PHILLIPS DM, 1994, AIDS, V8, P719, DOI 10.1097/00002030-199406000-00001; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; SCHWARTZ DH, 1993, LANCET, V342, P69, DOI 10.1016/0140-6736(93)91283-R; STEIN RE, 1992, VACCINE RES DEV, V1, P223; VERMUND SH, 1994, CURR OPIN INFECT DIS, V7, P82, DOI 10.1097/00001432-199402000-00014; VERMUND SH, 1993, EFFICACY HIV VACCINE, P187; WEININGER BG, IN PRESS AIDS; 1994, HIV VACCINES ACCELER; 1993, HUMAN IMMUNODEFICIEN; 1985, VACCINE SUPPLY INNOV; 1991, VACCINE, V9, P703	32	16	17	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1335	1337		10.1126/science.7973724	http://dx.doi.org/10.1126/science.7973724			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973724				2022-12-28	WOS:A1994PT63200030
J	CHIRUVOLU, S; WARRINER, HE; NARANJO, E; IDZIAK, SHJ; RADLER, JO; PLANO, RJ; ZASADZINSKI, JA; SAFINYA, CR				CHIRUVOLU, S; WARRINER, HE; NARANJO, E; IDZIAK, SHJ; RADLER, JO; PLANO, RJ; ZASADZINSKI, JA; SAFINYA, CR			A PHASE OF LIPOSOMES WITH ENTANGLED TUBULAR VESICLES	SCIENCE			English	Article							THERMAL FLUCTUATIONS; MEMBRANES; LECITHIN; TRANSITION; ADHESION; SYSTEM; L3	An equilibrium phase belonging to the family of bilayer liposomes in ternary mixtures of dimyristoylphosphatidylcholine (DMPC), water, and geraniol (a biological alcohol derived from oil-soluble vitamins that acts as a cosurfactant) has been identified. Electron and optical microscopy reveal the phase, labeled L(tv), to be composed of highly entangled tubular vesicles. In situ x-ray diffraction confirms that the tubule walls are multilamellar with the lipids in the chain-melted state. Macroscopic observations show that the L(tv) phase coexists with the well-known L(4) phase of spherical vesicles and a bulk L(alpha) phase. However, the defining characteristic oi the L(tv) phase is the Weissenberg rod climbing effect under shear, which results from its polymer-like entangled microstructure.	UNIV CALIF SANTA BARBARA, DEPT CHEM ENGN,MAT RES LAB, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, DEPT MAT,MAT RES LAB, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, DEPT PHYS, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, BIOCHEM & MOLEC BIOL PROGRAM, SANTA BARBARA, CA 93106 USA; EXXON RES & ENGN CO, ANNANDALE, NJ 08801 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Exxon Mobil Corporation			Rädler, Joachim/AAD-8747-2019	Rädler, Joachim/0000-0002-5846-1489	NIGMS NIH HHS [GM47334] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047334] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1992, INTERMOLECULAR SURFA; Bangham A.D., 1973, METHODS MEMBR BIOL, V1, P1; BELLARE JR, 1988, J ELECTRON MICR TECH, V10, P87, DOI 10.1002/jemt.1060100111; Ben-Shaul A., 1994, MICELLES MEMBRANES M; Bird RB, 1977, DYNAMICS POLYM LIQUI, V1; CANTU L, 1990, EUROPHYS LETT, V13, P561, DOI 10.1209/0295-5075/13/6/015; CATES ME, 1990, J PHYS-CONDENS MAT, V2, P6869, DOI 10.1088/0953-8984/2/33/001; COULON C, 1991, PHYS REV LETT, V66, P1709, DOI 10.1103/PhysRevLett.66.1709; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P7132, DOI 10.1073/pnas.83.19.7132; HARBICH W, 1990, J PHYS-PARIS, V51, P1027, DOI 10.1051/jphys:0199000510100102700; HARBICH W, 1984, CHEM PHYS LIPIDS, V36, P39, DOI 10.1016/0009-3084(84)90089-6; HELFRICH W, 1985, CHEM SCRIPTA, V25, P32; HELFRICH W, 1986, J PHYS-PARIS, V47, P321, DOI 10.1051/jphys:01986004702032100; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; HERVE P, 1993, J PHYS II, V3, P1255, DOI 10.1051/jp2:1993196; HOFFMANN H, 1992, LANGMUIR, V8, P2629, DOI 10.1021/la00047a011; JANIAK MJ, 1979, J BIOL CHEM, V254, P6068; KALER EW, 1989, SCIENCE, V245, P1371, DOI 10.1126/science.2781283; KLOSGEN B, 1993, EUR BIOPHYS J, V22, P340; LASIC DD, 1993, LIPOSOMES PHYSICS AP; MCINTOSH TJ, 1989, BIOPHYS J, V55, P897, DOI 10.1016/S0006-3495(89)82888-7; Papahadjopoulos D., 1978, ANN NY ACAD SCI, V308, P1, DOI [10.1111/j.1749-6632.1978.tb22009.x, DOI 10.1111/J.1749-6632.1978.TB22009.X]; PORTE G, 1988, EUROPHYS LETT, V7, P713, DOI 10.1209/0295-5075/7/8/008; PORTE G, 1989, J PHYS-PARIS, V50, P1335, DOI 10.1051/jphys:0198900500110133500; ROUX D, 1988, J PHYS-PARIS, V49, P307, DOI 10.1051/jphys:01988004902030700; SAFINYA CR, 1986, PHYS REV LETT, V57, P2718, DOI 10.1103/PhysRevLett.57.2718; SAFINYA CR, 1989, PHYS REV LETT, V62, P1134, DOI 10.1103/PhysRevLett.62.1134; Safran S. A., 1994, STAT THERMODYNAMICS; SCHNEIDER MB, 1984, J PHYS-PARIS, V45, P1457, DOI 10.1051/jphys:019840045090145700; SCHNEIDER MB, 1984, BIOPHYS J, V45, P891, DOI 10.1016/S0006-3495(84)84235-6; SERVUSS RM, 1989, J PHYS-PARIS, V50, P809, DOI 10.1051/jphys:01989005007080900; SERVUSS RM, 1987, PHYSICS COMPLEX SUPR; SPECTOR M, UNPUB; STREY R, 1990, J CHEM SOC FARADAY T, V86, P2253, DOI 10.1039/ft9908602253; TARDIEU A, 1973, J MOL BIOL, V75, P711, DOI 10.1016/0022-2836(73)90303-3; WEISSENBERG K, 1947, NATURE, V159, P310, DOI 10.1038/159310a0	36	89	91	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	1994	266	5188					1222	1225		10.1126/science.7973704	http://dx.doi.org/10.1126/science.7973704			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973704	Green Submitted			2022-12-28	WOS:A1994PT13200049
J	COLLINS, R; BAIGENT, C; SANDERCOCK, P; PETO, R				COLLINS, R; BAIGENT, C; SANDERCOCK, P; PETO, R			ANTIPLATELET THERAPY FOR THROMBOPROPHYLAXIS - THE NEED FOR CAREFUL CONSIDERATION OF THE EVIDENCE FROM RANDOMIZED TRIALS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VENOUS THROMBOSIS; SYSTEMATIC OVERVIEWS; PULMONARY-EMBOLISM; SURGERY; HEPARIN; THROMBOEMBOLISM; PREVENTION; ASPIRIN		WESTERN GEN HOSP, DEPT CLIN NEUROSCI, APT CLIN SECTRETARIAT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND	University of Edinburgh	COLLINS, R (corresponding author), RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED,ICRF,BHF,MRC, CLIN TRIAL SERV UNIT, APT STAT SECRETARIAT, OXFORD OX2 6HE, ENGLAND.		sandercock, peter/GQI-3167-2022	sandercock, peter/0000-0001-8484-0135				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1994, BMJ, V308, P235; [Anonymous], 1994, BMJ, V308, P159; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; CHRISMAN OD, 1976, J BONE JOINT SURG AM, V58, P918, DOI 10.2106/00004623-197658070-00003; COHEN AT, 1994, BRIT MED J, V309, P1213, DOI 10.1136/bmj.309.6963.1213; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; COLLINS R, 1987, STAT MED, V6, P245, DOI 10.1002/sim.4780060308; DALEN JE, 1986, CHEST, V89, pS370, DOI 10.1378/chest.89.5_Supplement.370S; HUBER O, 1992, ARCH SURG-CHICAGO, V127, P310; HUME M, 1978, ORTHOP CLIN N AM, V9, P761; KAKKAR V V, 1975, Lancet, V2, P45; KAKKAR VV, 1993, LANCET, V341, P259, DOI 10.1016/0140-6736(93)92614-Y; KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248; LAVERICK MD, 1991, BRIT MED J, V303, P549, DOI 10.1136/bmj.303.6802.549; LOWE GDO, 1992, BMJ-BRIT MED J, V305, P567; MACMAHON S, 1994, J BONE JOINT SURG BR, V76B, P521, DOI 10.1302/0301-620X.76B4.8027132; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; RODGERS A, 1994, AUST NZ J SURG, V64, P167, DOI 10.1111/j.1445-2197.1994.tb02170.x; SCHONDORF TH, 1976, HAEMOSTASIS, V5, P250; SCURR JH, 1988, BRIT MED J, V297, P28, DOI 10.1136/bmj.297.6640.28; SOREFF J, 1975, ACTA ORTHOP SCAND, V46, P246, DOI 10.3109/17453677508989215; 1990, TREATMENT EARLY BRAI, V1; 1992, PREVENTION VENOUS TH	24	63	63	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	1994	309	6963					1215	1217		10.1136/bmj.309.6963.1215	http://dx.doi.org/10.1136/bmj.309.6963.1215			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ662	7987156	Green Published			2022-12-28	WOS:A1994PQ66200027
J	FESKENS, EJM; HAVEKES, LM; KALMIJN, S; DEKNIJFF, P; LAUNER, LJ; KROMHOUT, D				FESKENS, EJM; HAVEKES, LM; KALMIJN, S; DEKNIJFF, P; LAUNER, LJ; KROMHOUT, D			APOLIPOPROTEIN E4 ALLELE AND COGNITIVE DECLINE IN ELDERLY MEN	BRITISH MEDICAL JOURNAL			English	Article							FAMILIAL ALZHEIMER-DISEASE; CORONARY HEART-DISEASE; E POLYMORPHISM; TYPE-4 ALLELE; CHROMOSOME-19; STATE; GENE; APOE; RISK	Objectives-To determine whether polymorphism of apolipoprotein E-notably, the e4 allele- predicts cognitive deterioration in the general population. Design-Population based cohort investigated in 1990 and in 1993. Setting-Zutphen, the Netherlands. Subjects-Representative cohort of 538 Dutch men aged 70-89 at baseline. Main outcome measures-Cognitive function assessed by mini mental state examination, change in cognitive function and incidence of impaired cognitive function at three years. Results-The baseline prevalence of impaired cognitive function (mini mental state examination score less than or equal to 25) was higher among carriers of the e4 allele compared wth men without the allele (41.0% (55) v 31.1% (122) P=0.03), and this result was still valid after adjustment for age, occupation, smoking, alcohol use, and cardiovascular diseases. The decline in cognitive function at three years was largest in men homozygous for e4 (-2.4 points), intermediate in those heterozygous for e4 (-0.7 points), and lowest in men without e4 (-0.1 points), and it was independent of other risk factors (P=0.02). The risk of developing impaired cognitive function during follow up was significantly increased in allele carriers compared with non-carriers (27.6% (16/58) v 15.5% (32/207)). The adjusted odds ratio was 2.87 (95% confidence interval 1.29 to 6.42). Twenty two per cent of the risk of developing impaired cognitive function in this population may be attributable to the e4 allele. Conclusions-The apolipoprotein e4 allele predisposes to cognitive decline in a general population of elderly men.	TNO,INST PREVENT HLTH RES PG TNO,GAUBIUS LAB,LEIDEN,NETHERLANDS; ROTTERDAM MED SCH,DEPT EPIDEMIOL & BIOSTAT,ROTTERDAM,NETHERLANDS	Netherlands Organization Applied Science Research	FESKENS, EJM (corresponding author), NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT CHRONIC DIS & ENVIRONM EPIDEMIOL,POB 1,3720 BA BILTHOVEN,NETHERLANDS.		Feskens, Edith/ABI-1446-2020; Kromhout, Daan/A-8566-2014; Feskens, Edith JM/A-3757-2012; de Knijff, Peter/Y-2519-2018	Feskens, Edith/0000-0001-5819-2488; de Knijff, Peter/0000-0002-0899-771X				BLOEMBERG BPM, 1989, AM J EPIDEMIOL, V130, P1047, DOI 10.1093/oxfordjournals.aje.a115405; COLSHER PL, 1991, EPIDEMIOL REV, V13, P1; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DALLONGEVILLE J, 1992, J LIPID RES, V33, P447; DAS HK, 1985, J BIOL CHEM, V260, P6240; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; FILTENBAUM GG, 1988, PSYCHOL MED, V18, P1023; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HAVEKES LM, 1987, J LIPID RES, V28, P445; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; KEYS A, 1967, ACTA MED SCAND, V460, P1; LAUNER LJ, 1992, NEUROEPIDEMIOLOGY, V11, pS12; LAUNER LJ, 1993, J GERONTOL, V48, P271; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NOGUCHI S, 1993, LANCET, V342, P737, DOI 10.1016/0140-6736(93)91728-5; OLAISEN B, 1982, HUM GENET, V62, P233, DOI 10.1007/BF00333526; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PIORIER J, 1993, LANCET, V342, P697; REBECK GW, 1993, NEURON, V11, P575; Rose G, 1968, CARDIOVASCULAR SURVE; Roth M, 1988, CAMDEX CAMBRIDGE EXA; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; SHERRILL BC, 1980, J BIOL CHEM, V255, P1804; SIEDEL J, 1981, J CLIN CHEM CLIN BIO, V19, P838; SIU AL, 1991, ANN INTERN MED, V134, P1303; SMIT M, 1988, HUM GENET, V80, P287, DOI 10.1007/BF01790099; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; VANBOCKXMEER FM, 1992, LANCET, V340, P879, DOI 10.1016/0140-6736(92)93288-X; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; 1990, STAT USERS GUIDE; 1993, LANCET, V342, P737; 1978, TECHNICAL REPORT SER, V628	34	151	153	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 5	1994	309	6963					1202	1206		10.1136/bmj.309.6963.1202	http://dx.doi.org/10.1136/bmj.309.6963.1202			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ662	7987151	Green Published			2022-12-28	WOS:A1994PQ66200020
J	BLAND, JM; ALTMAN, DG				BLAND, JM; ALTMAN, DG			MATCHING .9.	BRITISH MEDICAL JOURNAL			English	Note									IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	BLAND, JM (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.								0	92	93	2	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1994	309	6962					1128	1128		10.1136/bmj.309.6962.1128	http://dx.doi.org/10.1136/bmj.309.6962.1128			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987107	Bronze, Green Published			2022-12-28	WOS:A1994PP69100025
J	AUSTOKER, J				AUSTOKER, J			CANCER PREVENTION IN PRIMARY-CARE - SCREENING FOR CERVICAL-CANCER .7.	BRITISH MEDICAL JOURNAL			English	Article							SMEAR TEST; CONTROLLED TRIAL; PROGRAM; MORTALITY; TRENDS; CALL	Cervical screening has been shown to be effective in several countries, although not by means of randomised controlled trials. A screening programme has been in operation in the United Kingdom since 1964, but it has, in the past, been beset with problems of organisation, accountability, and commitment. The introduction in 1988 of a systematic call and recall system and the setting up of an NHS cervical screening programme national coordinating network has brought a greater sense of coherence. Coverage of the target population in England between 1989-90 and 1992-3 increased from 61% to 83%, and there is a strong indication that cervical screening is now beginning to reach those most at risk-namely, older women from lower social classes. Primary care is central to the overall success of the cervical screening programme. General practitioners are in a unique position to invite women for a smear test, to take smears, to ensure that abnormal smear test results are followed up, and to check on reasons for non-attendance. Numerous studies have looked at the involvement of general practice in cervical screening, identifying many ways in which the programme can be improved. Many practices are now running well organised and effective programmes.			AUSTOKER, J (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,PRIMARY CARE EDUC GRP,OXFORD OX2 6PE,ENGLAND.							[Anonymous], 1994, J CLIN PATHOL, V47, P481; AUSTOKER J, 1994, CRC13 CANC RES CAMP; AUSTOKER J, 1992, CERVICAL SCREENING; BEARDOW R, 1989, BMJ-BRIT MED J, V299, P98, DOI 10.1136/bmj.299.6691.98; DUNCAN I, 1992, GUIDELINES CLIN PRAC; ELLMAN R, 1990, J ROY SOC MED, V83, P94, DOI 10.1177/014107689008300213; FLANNELLY G, 1994, BRIT MED J, V308, P1399, DOI 10.1136/bmj.308.6941.1399; HAKAMA M, 1988, CANCER SURV, V7, P403; HAVELOCK C, 1988, J ROY COLL GEN PRACT, V38, P207; HAVELOCK GM, 1990, CYTOPATHOLOGY, V1, P59; Holland WW, 1990, SCREENING HLTH CARE; LAARA E, 1987, LANCET, V1, P1247; MCPHERSON A, 1992, WOMENS PROBLEMS GENE, P227; MEADOWS P, 1987, J ROY COLL GEN PRACT, V37, P500; NATHOO V, 1988, BRIT MED J, V296, P1041, DOI 10.1136/bmj.296.6628.1041; NICHOLS S, 1987, J ROY COLL GEN PRACT, V37, P540; PIERCE M, 1989, BMJ-BRIT MED J, V299, P160, DOI 10.1136/bmj.299.6692.160; PIKE C, 1992, GUIDELINES FAIL SAFE; SASIENI P, 1991, LANCET, V338, P818, DOI 10.1016/0140-6736(91)90701-P; SHAFI MI, 1992, BRIT MED J, V305, P1040, DOI 10.1136/bmj.305.6861.1040; SHROFF KJ, 1988, BRIT MED J, V297, P1317, DOI 10.1136/bmj.297.6659.1317; SIGURDSSON K, 1993, INT J CANCER, V54, P563, DOI 10.1002/ijc.2910540408; SOUTTER WP, 1994, BMJ-BRIT MED J, V308, P1421, DOI 10.1136/bmj.308.6941.1421; WILKINSON C, 1990, BRIT MED J, V300, P440, DOI 10.1136/bmj.300.6722.440; WILKINSON C, 1992, BRIT J GEN PRACT, V42, P336; WILSON A, 1987, BRIT MED J, V295, P181, DOI 10.1136/bmj.295.6591.181-a; 1993, OFFICE POPULATIO DH2, V19; 1994, OFFICE POPULATIO MB1, V21; 1994, KC53 DEP HLTH FORM; 1989, TAKING CERVICAL SMEA; 1993, KC61 DEP HLTH FORM; 1991, CERVICAL SCREENING I; 1994, CRC12 CANC RES CAMP; [No title captured]	34	92	94	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					241	248		10.1136/bmj.309.6949.241	http://dx.doi.org/10.1136/bmj.309.6949.241			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ180	7980803	Green Published			2022-12-28	WOS:A1994NZ18000019
J	KONDE, M; INGENBLEEK, Y; DAFFE, M; SYLLA, B; BARRY, O; DIALLO, S				KONDE, M; INGENBLEEK, Y; DAFFE, M; SYLLA, B; BARRY, O; DIALLO, S			GOITROUS ENDEMIC IN GUINEA	LANCET			English	Article							NUTRITIONAL-STATUS; DARFUR REGION; GOITER; MILLET; SUDAN; EPIDEMIOLOGY; ETIOLOGY	We identified a major goitrous area in the Republic of Guinea, characterised by an overall goitre prevalence of 70% in adults. Thyroid swelling was sometimes present at birth and affected 55% of schoolchildren. A difference between sexes appeared at puberty. Endemic cretinism, mainly in its myxoedematous form, was found in about 2% of goitrous patients. In this region, iodine deficiency is the primary causative factor (median urinary concentrations of 16 mu g/L, and in 69% of inhabitants below the critical threshold of 20 mu g/L). The diet contained substantial amounts of thiocyanate anions (median 6 mg/L in urine and in 27%, more than 10 mg/L) likely to further depress iodine bioavailability. Other dietary compounds, notably flavonoids were suspected to contribute. Overall nutritional and general health appeared satisfactory. The affected population is borderline euthyroid with a trend towards hypothyroidism in protracted disease. This area of Guinea may be regarded as the epicentre of the west African endemic acid as one of the most severely goitrous regions ever described, requiring urgent public health measures.	UNIV STRASBOURG 1,DEPT FOOD SCI,F-67400 ILLKIRCH GRAFFENS,FRANCE; DIRECT PUBL HLTH,CONAKRY,GUINEA	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ALDRIDGE WN, 1945, ANALYST, V70, P474; BEDIAKO BM, 1985, STUDIES PREVALENCE E, P1; BENMILOUD M, 1983, CASSAVA TOXICITY THY, P49; BENNETT S, 1991, World Health Statistics Quarterly, V44, P98; BOURDOUX P, 1986, PAHO SCI PUBL, V502, P115; COURTOIS P, 1982, NUTR FACTORS INVOLVE, P65; DEVISSCHER M, 1980, THYROID GLAND, P377; Dunn JT, 1990, ICCIDDUNICEFWHO3 TEC, P1; ELTOM M, 1985, ACTA ENDOCRINOL-COP, V108, P356, DOI 10.1530/acta.0.1080356; ELTOM M, 1984, ACTA MED SCAND, V215, P467; GAITAN B, 1986, PAHO WHO SCI PUBL, V502, P28; GAITAN E, 1989, J CLIN ENDOCR METAB, V68, P707, DOI 10.1210/jcem-68-4-707; HERSHMAN JM, 1986, PAHO WHO SCI PUBL, V502, P96; INGENBLEEK Y, 1980, LANCET, V1, P388; INGENBLEEK Y, 1975, METABOLISM, V24, P633, DOI 10.1016/0026-0495(75)90143-2; INGENBLEEK Y, 1985, INT J VITAM NUTR RES, V55, P91; INGENBLEEK Y, 1994, ANNU REV NUTR, V14, P495, DOI 10.1146/annurev.nu.14.070194.002431; INGENBLEEK Y, 1979, METABOLISM, V28, P9, DOI 10.1016/0026-0495(79)90162-8; Ingenbleek Y., 1980, THYROID GLAND, P499; KELLY FC, 1960, WHO MONOGR SER, V44, P117; KLOPFENSTEIN CF, 1983, NUTR REP INT, V27, P1039; KOUTRAS DA, 1980, ENDEMIC GOITER ENDEM, P255; LATAPIE JL, 1981, ANN ENDOCRINOL-PARIS, V42, P517; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; OLIVEIRA AL, 1991, B WORLD HEALTH ORGAN, V63, P347; OSMAN AK, 1981, ECOL FOOD NUTR, V11, P121, DOI 10.1080/03670244.1981.9990666; PEREZ C, 1960, WHO MONOGRAPHS SERIE, V44, P369; ROUX F, 1983, MED NUTR, V19, P339; Sandell E. B., 1937, MICROCHIM ACTA, V1, P9, DOI [10.1007/BF01476194, DOI 10.1007/BF01476194]; Snedecor G. W., 1967, STATISTICAL METHODS, P91; STANBURY JB, 1980, IODINE NUTRITION HLT, P1; WILSON DC, 1954, T ROY SOC TROP MED H, V48, P481, DOI 10.1016/0035-9203(54)90083-8; WOLLMAN SH, 1962, AM J PHYSIOL, V203, P517, DOI 10.1152/ajplegacy.1962.203.3.517	33	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1675	1678		10.1016/S0140-6736(94)90461-8	http://dx.doi.org/10.1016/S0140-6736(94)90461-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996963				2022-12-28	WOS:A1994PX30200012
J	ROY, R; ADAMCZEWSKI, JP; SEROZ, T; VERMEULEN, W; TASSAN, JP; SCHAEFFER, L; NIGG, EA; HOEIJMAKERS, JHJ; EGLY, JM				ROY, R; ADAMCZEWSKI, JP; SEROZ, T; VERMEULEN, W; TASSAN, JP; SCHAEFFER, L; NIGG, EA; HOEIJMAKERS, JHJ; EGLY, JM			THE MO15 CELL-CYCLE KINASE IS ASSOCIATED WITH THE TFIIH TRANSCRIPTION DNA-REPAIR FACTOR	CELL			English	Article							RNA POLYMERASE-II; CARBOXYL-TERMINAL-DOMAIN; CATALYTIC SUBUNIT; PROTEIN-KINASE; FACTOR-DELTA; RAT-LIVER; PURIFICATION; COMPONENT; HELICASE; ATPASE	A protein kinase activity that phosphorylates the G-terminal domain (CTD) of RNA polymerase II and is associated with the basal transcription-repair factor TFIIH (also called BTF2) resides with MO15, a cyclin-dependent protein kinase that was first found to be involved in cell cycle regulation. Using in vivo and in vitro repair assays, we show that MO15 is important for nucleotide excision repair, most likely through its association with TFIIH, thus providing an unexpected link among three important cellular mechanisms.	INST GENET & BIOL MOLEC & CELLULAIRE, CNRS, INSERM, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; ERASMUS UNIV ROTTERDAM, CTR MED GENET, DEPT CELL BIOL & GENET, 3000 DR ROTTERDAM, NETHERLANDS; SWISS INST EXPTL CANC RES, CH-1066 EPALINGES, SWITZERLAND	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Erasmus University Rotterdam; Swiss Institute Experimental Cancer Research			Hoeijmakers, Jan/AAX-6972-2021; Vermeulen, Wim/W-8708-2019	Vermeulen, Wim/0000-0003-3616-734X; schaeffer, laurent/0000-0001-6600-503X; nigg, erich/0000-0003-4835-5719				BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; CHALUT C, 1994, BIOESSAYS, V16, P651, DOI 10.1002/bies.950160910; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DAHMUS ME, 1994, TRANSCRIPTION MECHAN, P243; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GERARD M, 1991, J BIOL CHEM, V266, P20940; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MA LB, 1994, MOL CELL BIOL, V14, P4126, DOI 10.1128/MCB.14.6.4126; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; ROY R, 1994, J BIOL CHEM, V269, P9826; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SVEJSTRUP JQ, 1994, IN PRESS NATURE; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; VERMEULEN W, 1994, AM J HUM GENET, V54, P191; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; WU LT, 1994, ONCOGENE, V9, P2089	33	407	412	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 16	1994	79	6					1093	1101		10.1016/0092-8674(94)90039-6	http://dx.doi.org/10.1016/0092-8674(94)90039-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001135	Green Published			2022-12-28	WOS:A1994PY08600018
J	HARRISON, SL; MACLENNAN, R; SPEARE, R; WRONSKI, I				HARRISON, SL; MACLENNAN, R; SPEARE, R; WRONSKI, I			SUN EXPOSURE AND MELANOCYTIC NEVI IN YOUNG AUSTRALIAN CHILDREN	LANCET			English	Article							CUTANEOUS MALIGNANT-MELANOMA; BENIGN PIGMENTED NEVI; DYSPLASTIC NEVI; VANCOUVER MOLE; NEVOCYTIC NEVI; RISK-FACTORS; COMMON; PREVALENCE; SCHOOLCHILDREN; QUEENSLAND	Queensland, Australia, has the highest rates of melanoma in the world and Queensland children have the greatest numbers of melanocytic naevi, the strongest risk factor for melanoma. Although both melanoma and naevi are broadly related to sun exposure in childhood, the relation to individual exposure early in life is difficult to study retrospectively in adults. We surveyed 506 children aged 1-6 years who had been born in Townsville, North Queensland, Sun exposure was assessed by questionnaire and melanocytic naevi were counted using a standard international protocol. Very high counts (upper quarter) of melanocytic naevi were Significantly associated with sun exposure of more than 4 hours per day (adjusted relative risk ratio 3.29; 95% CI 1.12-9.69), and with a history of sunburn (1.89; 1.11-3.21). Melanocytic naevus counts increased with age, light skin reflectance, and freckling. With exposure to intense ultraviolet light in Townsville, children develop melanocytic naevi early in life and in large numbers. We found that both acute and chronic exposure to sun are associated with their development.	QUEENSLAND INST MED RES,EPIDEMIOL UNIT,BRISBANE,QLD 4006,AUSTRALIA	QIMR Berghofer Medical Research Institute	HARRISON, SL (corresponding author), JAMES COOK UNIV N QUEENSLAND,DEPT PUBL HLTH & TROP MED,ANTON BREINI CTR,TOWNSVILLE,QLD 4811,AUSTRALIA.		Harrison, Simone Lee/U-3429-2018; Harrison, Simone Lee/CAF-2591-2022	Harrison, Simone Lee/0000-0001-5309-0773; Harrison, Simone Lee/0000-0001-5309-0773; Speare, Rick/0000-0002-9993-1213				ARMSTRONG BK, 1986, J NATL CANCER I, V77, P329; AUGUSTSSON A, 1991, ACTA DERM-VENEREOL, V71, P512; AUGUSTSSON A, 1991, ACTA DERM-VENEREOL, V71, P518; COOKE KR, 1985, INT J CANCER, V36, P175, DOI 10.1002/ijc.2910360208; ELWOOD JM, 1986, BRIT J CANCER, V53, P65, DOI 10.1038/bjc.1986.10; ENGLISH DR, 1994, AM J EPIDEMIOL, V139, P1; ENGLISH DR, 1990, IARC90002 INT AG RES; GALLAGHER RP, 1990, ARCH DERMATOL, V126, P466, DOI 10.1001/archderm.126.4.466; GALLAGHER RP, 1990, ARCH DERMATOL, V126, P770, DOI 10.1001/archderm.126.6.770; GREEN A, 1989, J AM ACAD DERMATOL, V20, P1054, DOI 10.1016/S0190-9622(89)70131-6; GREEN A, 1985, INT J CANCER, V35, P297, DOI 10.1002/ijc.2910350303; GROB JJ, 1990, CANCER, V66, P387, DOI 10.1002/1097-0142(19900715)66:2<387::AID-CNCR2820660232>3.0.CO;2-J; HALPERN AC, 1991, ARCH DERMATOL, V127, P995, DOI 10.1001/archderm.127.7.995; HOLLY EA, 1987, J AM ACAD DERMATOL, V17, P460; HOLMAN CDJ, 1984, JNCI-J NATL CANCER I, V72, P257; HORNBY F, 1986, TOWNSVILLE REGION SO; KELLY JW, 1994, J AM ACAD DERMATOL, V30, P40, DOI 10.1016/S0190-9622(94)70005-2; Kopf A W, 1978, J Dermatol Surg Oncol, V4, P153; KOPF AW, 1986, ARCH DERMATOL, V122, P1003, DOI 10.1001/archderm.122.9.1003; Lund CC., SURG GYNECOL OBSTET, V79, P352; MACKIE RM, 1985, BRIT J DERMATOL, V113, P167, DOI 10.1111/j.1365-2133.1985.tb02060.x; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; MOSTELLER RD, 1987, NEW ENGL J MED, V317, P1098, DOI 10.1056/nejm198710223171717; NICHOLLS EM, 1973, CANCER, V32, P191, DOI 10.1002/1097-0142(197307)32:1<191::AID-CNCR2820320129>3.0.CO;2-W; OSTERLIND A, 1988, INT J CANCER, V42, P200, DOI 10.1002/ijc.2910420210; POPE DJ, 1992, ARCH DERMATOL, V128, P1201, DOI 10.1001/archderm.128.9.1201; RAMPEN FHJ, 1988, J AM ACAD DERMATOL, V18, P679, DOI 10.1016/S0190-9622(88)70090-0; SIGG C, 1989, DERMATOLOGICA, V179, P123, DOI 10.1159/000248337; SORAHAN T, 1990, J AM ACAD DERMATOL, V22, P747, DOI 10.1016/0190-9622(90)70102-N; SWERDLOW AJ, 1986, BRIT MED J, V292, P1555, DOI 10.1136/bmj.292.6535.1555	30	163	164	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1529	1532		10.1016/S0140-6736(94)90348-4	http://dx.doi.org/10.1016/S0140-6736(94)90348-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983952				2022-12-28	WOS:A1994PV01700008
J	ESPINOZA, FH; OGAS, J; HERSKOWITZ, I; MORGAN, DO				ESPINOZA, FH; OGAS, J; HERSKOWITZ, I; MORGAN, DO			CELL-CYCLE CONTROL BY A COMPLEX OF THE CYCLIN HCS26 (PCL1) AND THE KINASE PHO85	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; PHOSPHATASE; SYSTEM; GENE; G1; TRANSCRIPTION; REGULATORS; PHASE; CDC28	The events of the eukaryotic cell cycle are governed by cyclin-dependent kinases (cdk's), whose activation requires association with cyclin regulatory subunits expressed at specific cell cycle stages. In the budding yeast Saccharomyces cerevisiae, the cell cycle is thought to be controlled by a single cdk, CDC28. Passage through the G(1) phase of the cell cycle is regulated by complexes of CDC28 and G(1) cyclins (CLN1, CLN2, and CLN3). A putative G(1) cyclin, HCS26, has recently been identified. In a/alpha diploid cells lacking CLN1 and CLN2, HCS26 is required for passage through G(1). HCS26 does not associate with CDC28, but instead associates with PHO85, a closely related protein kinase. Thus, budding yeast, like higher eukaryotes, use multiple cdk's in the regulation of cell cycle progression.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco				Morgan, David/0000-0001-8753-4416; Ogas, Joe/0000-0002-1332-7729; Espinoza, Francisco/0000-0002-1855-1914	NATIONAL CANCER INSTITUTE [R01CA052481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018738, R01AI018738] Funding Source: NIH RePORTER; NCI NIH HHS [CA52481] Funding Source: Medline; NIAID NIH HHS [AI18738] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; ESPINOZA FH, UNPUB; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; MURPHTY SM, 1993, MOL CELL BIOL, V19, P5290; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; OGAS J, UNPUB; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOHE A, 1988, MOL GEN GENET, V214, P162, DOI 10.1007/BF00340196; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; UEDA Y, 1975, J BACTERIOL, V122, P911, DOI 10.1128/JB.122.3.911-922.1975; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299	22	133	139	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1388	1391		10.1126/science.7973730	http://dx.doi.org/10.1126/science.7973730			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973730				2022-12-28	WOS:A1994PT63200045
J	BOISMENU, R; HAVRAN, WL				BOISMENU, R; HAVRAN, WL			MODULATION OF EPITHELIAL-CELL GROWTH BY INTRAEPITHELIAL GAMMA-DELTA T-CELLS	SCIENCE			English	Article							DENDRITIC EPIDERMAL-CELLS; ANTIGEN RECEPTORS; MURINE EPIDERMIS; EXPRESSION; LYMPHOCYTES; KGF	The role played in immune surveillance by gamma delta T cells residing in various epithelia has not been clear. It is shown here that activated gamma delta T cells obtained from skin and intestine express the epithelial cell mitogen keratinocyte growth factor (KGF). In contrast, intraepithelial alpha beta T cells, as well as all lymphoid alpha beta and gamma delta T cell populations tested, did not produce KGF or promote the growth of cultured epithelial cells. These results suggest that intraepithelial gamma delta T cells function in surveillance and in repair of damaged epithelial tissues.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032751, R29AI032751, R21AI032751] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32751] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON JP, 1991, ANNU REV IMMUNOL, V9, P679, DOI 10.1146/annurev.iy.09.040191.003335; ARSANOW D, 1989, NATURE, V341, P60; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BERGSTRESSER PR, 1984, J INVEST DERMATOL, V83, P83, DOI 10.1111/1523-1747.ep12262587; BERGSTRESSER PR, 1983, J INVEST DERMATOL, V81, P286, DOI 10.1111/1523-1747.ep12518332; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BOISMENU R, UNPUB; BOTTARO DP, 1993, J BIOL CHEM, V268, P9180; FALCO JP, 1988, ONCOGENE, V2, P573; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; HAVRAN WL, 1991, SCIENCE, V252, P1430, DOI 10.1126/science.1828619; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HAVRAN WL, UNPUB; KUZIEL WA, 1987, NATURE, V328, P263, DOI 10.1038/328263a0; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; PANOS RJ, 1993, J CLIN INVEST, V92, P969, DOI 10.1172/JCI116673; PAYER E, 1992, SPRINGER SEMIN IMMUN, V13, P315; RON D, 1993, J BIOL CHEM, V268, P2984; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; STINGL G, 1987, P NATL ACAD SCI USA, V84, P2430, DOI 10.1073/pnas.84.8.2430; ULICH TR, 1994, AM J PATHOL, V144, P862; ULICH TR, 1994, J CLIN INVEST, V93, P1298, DOI 10.1172/JCI117086; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8	26	548	559	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1253	1255		10.1126/science.7973709	http://dx.doi.org/10.1126/science.7973709			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973709				2022-12-28	WOS:A1994PT13200057
J	ROTHMAN, JE				ROTHMAN, JE			MECHANISM OF INTRACELLULAR PROTEIN-TRANSPORT	NATURE			English	Review							ADP-RIBOSYLATION FACTOR; GTP-BINDING-PROTEIN; INTEGRAL MEMBRANE-PROTEIN; SYNAPTOSOMAL-ASSOCIATED PROTEIN; CLATHRIN-COATED VESICLES; SENSITIVE FUSION PROTEIN; YEAST SECRETORY PATHWAY; CELL-FREE SYSTEM; ACYL-COENZYME-A; VESICULAR TRANSPORT	Recent advances have uncovered the general protein apparatus used by all eukaryotes for intracellular transport, including secretion and endocytosis, and for triggered exocytosis of hormones and neurotransmitters. Membranes are shaped into vesicles by cytoplasmic coats which then dissociate upon GTP hydrolysis. Both vesicles and their acceptor membranes carry targeting. proteins which interact specifically to initiate docking. A general apparatus then assembles at the docking site and fuses the vesicle with its target.			ROTHMAN, JE (corresponding author), MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USA.							AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; ALMERS W, 1991, ANN NY ACAD SCI, V635, P318, DOI 10.1111/j.1749-6632.1991.tb36502.x; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BERGERON JJ, 1973, J CELL BIOL, V59, P73, DOI 10.1083/jcb.59.1.73; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRAELL WA, 1984, CELL, V39, P511, DOI 10.1016/0092-8674(84)90458-6; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUNN B, 1993, NATURE, V362, P563, DOI 10.1038/362563a0; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; DUNPHY WG, 1981, P NATL ACAD SCI-BIOL, V78, P7453, DOI 10.1073/pnas.78.12.7453; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; FRIES E, 1980, P NATL ACAD SCI-BIOL, V77, P3870, DOI 10.1073/pnas.77.7.3870; GEPPERT M, IN PRESS CELL; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HESS DT, 1992, J NEUROSCI, V12, P4634; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; HUTTNER WB, 1993, NATURE, V365, P104, DOI 10.1038/365104a0; INOUE A, 1992, J BIOL CHEM, V267, P10613; JAMIESON JD, 1967, J CELL BIOL, V34, P597, DOI 10.1083/jcb.34.2.597; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LADINSKY MS, 1994, J CELL BIOL, V127, P29, DOI 10.1083/jcb.127.1.29; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MONCK JR, 1992, J CELL BIOL, V119, P1395, DOI 10.1083/jcb.119.6.1395; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PALADE GE, 1959, SUBCELLULAR PARTICLE, P64; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PAQUET MR, 1986, J BIOL CHEM, V261, P4367; PEARSE BMF, 1976, P NATL ACAD SCI USA, V73, P1255, DOI 10.1073/pnas.73.4.1255; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTH TF, 1964, J CELL BIOL, V20, P313, DOI 10.1083/jcb.20.2.313; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1984, J CELL BIOL, V99, P260, DOI 10.1083/jcb.99.1.260; ROTHMAN JE, 1984, TRENDS BIOCHEM SCI, V9, P176, DOI 10.1016/0968-0004(84)90132-4; ROTHMAN JE, 1992, METH ENZYM, V219; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	126	2055	2102	7	368	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 3	1994	372	6501					55	63		10.1038/372055a0	http://dx.doi.org/10.1038/372055a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969419				2022-12-28	WOS:A1994PQ34800069
J	MORGAN, R; KING, D; PRAJAPATI, C; ROWE, J				MORGAN, R; KING, D; PRAJAPATI, C; ROWE, J			VIEWS OF ELDERLY PATIENTS AND THEIR RELATIVES ON CARDIOPULMONARY-RESUSCITATION	BRITISH MEDICAL JOURNAL			English	Article							ATTITUDES; DECISIONS		BROADGREEN HOSP,DEPT MED,LIVERPOOL L14 3LB,MERSEYSIDE,ENGLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; University of Liverpool								DAVIES KN, 1993, J ROY COLL PHYS LOND, V27, P127; DOYAL L, 1993, BRIT MED J, V306, P1593, DOI 10.1136/bmj.306.6892.1593; SCHADE SG, 1989, J MED ETHICS, V15, P186, DOI 10.1136/jme.15.4.186; STEWART K, 1990, BRIT MED J, V300, P785, DOI 10.1136/bmj.300.6727.785; STOLMAN CJ, 1990, ARCH INTERN MED, V150, P653, DOI 10.1001/archinte.150.3.653	5	70	70	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1677	1678		10.1136/bmj.308.6945.1677a	http://dx.doi.org/10.1136/bmj.308.6945.1677a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	7993423	Green Published			2022-12-28	WOS:A1994NU48300022
J	HRUBAN, RH; VANDERRIET, P; EROZAN, YS; SIDRANSKY, D				HRUBAN, RH; VANDERRIET, P; EROZAN, YS; SIDRANSKY, D			MOLECULAR-BIOLOGY AND THE EARLY DETECTION OF CARCINOMA OF THE BLADDER - THE CASE OF HUMPHREY,HUBERT,H	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							P53 GENE-MUTATIONS; URINARY CYTOLOGY; ALLELIC LOSS; CANCER; IDENTIFICATION; CHROMOSOME-17P; ASSOCIATION		JOHNS HOPKINS MED INST, DEPT OTOLARYNGOL HEAD & NECK SURG, BALTIMORE, MD 21205 USA; JOHNS HOPKINS MED INST, DEPT PATHOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine								BAKER SJ, 1990, CANCER RES, V50, P7717; BERMAN E, 1979, HUBERT TRIUM TRAGEDY; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BRODY JE, 1976, NY TIMES        1008, pI11; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1993, ONCOGENE, V8, P1083; CLARK M, 1976, NEWSWEEK        1018, P87; COHN V, 1978, WASHINGTON POST 0326, pC1; ELBOLKAINY MN, 1980, J UROLOGY, V124, P20, DOI 10.1016/S0022-5347(17)55271-4; FARROW GM, 1976, CANCER RES, V36, P2495; FUJIMOTO K, 1992, CANCER RES, V52, P1393; HABUCHI T, 1992, J UROLOGY, V148, P1595, DOI 10.1016/S0022-5347(17)36977-X; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOPKINS SC, 1983, J UROLOGY, V130, P61, DOI 10.1016/S0022-5347(17)50953-2; MAO L, 1994, CANCER RES, V54, P1634; MURPHY WM, 1984, CANCER, V53, P1555, DOI 10.1002/1097-0142(19840401)53:7<1555::AID-CNCR2820530723>3.0.CO;2-G; OKA K, 1991, MOL CARCINOGEN, V4, P10, DOI 10.1002/mc.2940040104; OLUMI AF, 1990, CANCER RES, V50, P7081; PAPANICOLAOU GN, 1945, SCIENCE, V101, P519, DOI 10.1126/science.101.2629.519; RUPPERT JM, 1993, CANCER RES, V53, P5093; SARKIS AS, 1993, INT J ONCOL, V3, P355; SARKIS AS, 1993, J NATL CANCER I, V85, P53, DOI 10.1093/jnci/85.1.53; SARNACKI CT, 1971, J UROLOGY, V106, P761, DOI 10.1016/S0022-5347(17)61391-0; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; Solberg C., 1984, H HUMPHREY BIOGRAPHY; SORENSON GD, 1994, CANCER EPIDEM BIOMAR, V3, P67; SPRUCK CH, 1994, CANCER RES, V54, P784; SPRUCK CH, 1993, CANCER RES, V53, P2427; SPRUCK CH, 1993, CANCER RES, V53, P1162; TADA M, 1993, CANCER RES, V53, P2472; TSAI YC, 1990, CANCER RES, V50, P44; 1976, TIME            1018, P100; 1976, NY TIMES        1016, P6	36	68	68	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 5	1994	330	18					1276	1278		10.1056/NEJM199405053301805	http://dx.doi.org/10.1056/NEJM199405053301805			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ512	7993407	Bronze			2022-12-28	WOS:A1994NJ51200005
J	DINUBILE, MJ; HOKAMA, Y				DINUBILE, MJ; HOKAMA, Y			THE CIGUATERA POISONING SYNDROME FROM FARM-RAISED SALMON	ANNALS OF INTERNAL MEDICINE			English	Note							CIGUATOXIN		UNIV HAWAII, JOHN A BURNS SCH MED, DEPT PATHOL, HONOLULU, HI 96822 USA	University of Hawaii System	DINUBILE, MJ (corresponding author), UNIV MED & DENT NEW JERSEY, COOPER HOSP,MED CTR,DIV INFECT DIS, EDUC & RES BLDG, 401 HADDON AVE, CAMDEN, NJ 08103 USA.							DEFUSCO DJ, 1993, AM J MED, V95, P240, DOI 10.1016/0002-9343(93)90268-T; HOKAMA Y, 1990, J CLIN LAB ANAL, V4, P213, DOI 10.1002/jcla.1860040313; KIMURA LH, 1982, TOXICON, V20, P907, DOI 10.1016/0041-0101(82)90078-2; KODAMA AM, 1989, TOXICON, V27, P1051, DOI 10.1016/0041-0101(89)90156-6; LAWRENCE DN, 1980, JAMA-J AM MED ASSOC, V244, P254, DOI 10.1001/jama.244.3.254; MIYAHARA JT, 1979, RES COMMUN CHEM PATH, V25, P177; MORRIS PD, 1990, SOUTH MED J, V83, P379, DOI 10.1097/00007611-199004000-00005; SCHEUER PJ, 1967, SCIENCE, V155, P1267, DOI 10.1126/science.155.3767.1267; Underman A E, 1993, Curr Clin Top Infect Dis, V13, P203; 1986, MMWR-MORBID MORTAL W, V35, P263	10	16	16	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					113	114		10.7326/0003-4819-122-2-199501150-00006	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7992985				2022-12-28	WOS:A1995QC05900006
J	WILKINSON, HA; FITZGERALD, K; GREENWALD, I				WILKINSON, HA; FITZGERALD, K; GREENWALD, I			RECIPROCAL CHANGES IN EXPRESSION OF THE RECEPTOR LIN-12 AND ITS LIGAND LAG-2 PRIOR TO COMMITMENT IN A C-ELEGANS CELL FATE DECISION	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DROSOPHILA-NOTCH; GENE; HOMOLOG; SEQUENCES; AUTONOMY; ENCODES; MOTCH; SET	During development of the C. elegans hermaphrodite gonad, two cells interact with each other, so that one chooses to become the anchor cell (AC) and the other becomes a ventral uterine precursor cell (VU). This interaction is mediated by the receptor LIN-12 and its apparent ligand LAG-2. We show that initially lin-12 and lag-2 are expressed in both cells, but prior to commitment, the expression patterns change in a reciprocal manner, so that lin-12 expression becomes restricted to the presumptive VU and lag-2 expression becomes restricted to the presumptive AC. In addition, lin-12 activity promotes expression of lin-12 and represses expression of lag-2. Furthermore, we show that positive autoregulation of lin-12 transcription in the presumptive VU is mediated by a cis-acting 5' regulatory sequence and is necessary to specify the VU fate. Our results suggest that transcriptional control is a component of the feedback mechanism involved in specifying the AC and VU fates.	COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	WILKINSON, HA (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.				NIGMS NIH HHS [GM37602] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037602] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNER S, 1974, GENETICS, V77, P71; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DELAMO FF, 1992, DEVELOPMENT, V115, P737; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; EMMONS SW, 1979, P NATL ACAD SCI USA, V76, P1333, DOI 10.1073/pnas.76.3.1333; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FIRE A, 1993, GENET ANAL TECH APPL, V9, P151; FITZGERALD K, 1993, DEVELOPMENT, V119, P1019; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GREENWALD J, 1994, CURR OPIN GENET DEV, V4, P556; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HIRSH D, 1976, DEV BIOL, V49, P200, DOI 10.1016/0012-1606(76)90267-0; HODGKIN J, 1989, GENETICS, V123, P301; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KIMBLE J, 1979, DEV BIOL, V81, P208; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; REAUME AG, 1992, DEV BIOL, V154, P377, DOI 10.1016/0012-1606(92)90076-S; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SEYDOUX G, 1990, CELL, V61, P939, DOI 10.1016/0092-8674(90)90060-R; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SUNDARAM M, 1993, GENETICS, V135, P755; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; TAX FE, 1994, THESIS U WASHINGTON; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; Wigglesworth VB, 1940, J EXP BIOL, V17, P180; WILKINSON HA, 1994, THESIS PRINCETON U P; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	44	212	216	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1187	1198		10.1016/0092-8674(94)90010-8	http://dx.doi.org/10.1016/0092-8674(94)90010-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001154				2022-12-28	WOS:A1994PZ86000010
J	STARFIELD, B; POWE, NR; WEINER, JR; STUART, M; STEINWACHS, D; SCHOLLE, SH; GERSTENBERGER, A				STARFIELD, B; POWE, NR; WEINER, JR; STUART, M; STEINWACHS, D; SCHOLLE, SH; GERSTENBERGER, A			COSTS VS QUALITY IN DIFFERENT TYPES OF PRIMARY-CARE SETTINGS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MARYLAND; MIX	Objective.-To determine the relationship between efficiency in use of resources and quality of care provided by physicians serving as the usual source of care for patients in a state Medicaid program. Design.-Retrospective quality-of-care review of 2024 outpatient medical records of 135 providers sampled from system-wide Medicaid claims data in Maryland. Subjects.-Providers in three types of practice settings (hospital outpatient clinic, community health center, and physician's office) were stratified into three case mix-adjusted resource use groups (high, medium, and low). A sample of patients with the diagnoses of diabetes, hypertension, asthma, well-child care, or otitis media were identified from Medicaid claims forms from visits during 1988. Case mix was controlled by the application of the ambulatory care groups, a method that characterizes populations according to their burden of morbidity. Main Outcome Measures.-Nurses from the local peer review organization audited medical records using explicit criteria for quality of care in several categories: evidence of impaired access, evidence of compromised technical quality, evidence of inappropriate care, outcome of care, and several generic indicators of quality, Well-adult care was assessed for patients with the adult diagnoses. Results.-Although there were some systematic differences by type of facility in some aspects of quality of care (more access problems for patients in hospital clinics and more technical quality problems for patients in office-based practice), there were no consistent differences in quality of care overall for patients in different types of settings and no consistent relationships between cost-efficiency and quality of care, However, patients in medium-cost community hearth centers had the best or second best scores for most of the 21 comparisons of type of quality assessed. Conclusions. Quality of care provided for common conditions in primary care is not associated with costs generated by providers. Policies directed toward the choice of low-cost vs high-cost providers will not necessarily lead to a deterioration in the quality of care. States can both improve quality and lower costs by consistent monitoring of programs over time. The finding of generally higher quality of care for patients in medium-cost community health centers deserves further study.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; MARYLAND DEPT HLTH & MENTAL HYG,BALTIMORE,MD 21202; AMER COLL PHYSICIANS,PHILADELPHIA,PA 19106	Johns Hopkins University; Maryland Department of Health & Mental Hygiene; American College of Physicians	STARFIELD, B (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,DIV HLTH POLICY,BALTIMORE,MD 21205, USA.				AHRQ HHS [R01 HS06170775] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BRESLAU N, 1975, J MED EDUC, V50, P965; EISENBERG J, 1986, DOCTORS DECISIONS CO; IEZZONI LI, 1992, AHCPR920056 US DEP H; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; PALMER RH, 1984, MED CARE, V22, P632, DOI 10.1097/00005650-198407000-00005; SAFRAN DG, 1994, JAMA-J AM MED ASSOC, V271, P1579, DOI 10.1001/jama.271.20.1579; STARFIELD B, 1991, HEALTH SERV RES, V26, P53; Starfield B., 1992, PRIMARY CARE CONCEPT; STUART ME, 1993, MED CARE, V31, P1119, DOI 10.1097/00005650-199312000-00005; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P3298, DOI 10.1001/jama.262.23.3298	12	159	160	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	1994	272	24					1903	1908		10.1001/jama.272.24.1903	http://dx.doi.org/10.1001/jama.272.24.1903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PX927	7990241				2022-12-28	WOS:A1994PX92700034
J	CARPENTER, L; BARTLEY, M				CARPENTER, L; BARTLEY, M			FAT, FEMALE, AND POOR	LANCET			English	Editorial Material							ADULTHOOD; OBESITY		UNIV OXFORD NUFFIELD COLL,OXFORD,ENGLAND	University of Oxford	CARPENTER, L (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,OXFORD,ENGLAND.							Blaxter M., 1990, HLTH LIFESTYLES; BRADDON FFM, 1986, BMJ-BRIT MED J, V293, P299, DOI 10.1136/bmj.293.6542.299; Dex S., 1987, WOMENS OCCUPATIONAL; Erikson Robert, 1992, CONSTANT FLUX; GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406; JOSHI H, 1988, LONGITUDINAL DATA AN; LEON D, 1994, LANCET; POWER C, 1988, INT J OBESITY, V12, P445; SARGENT JD, 1994, ARCH PEDIAT ADOL MED, V148, P681, DOI 10.1001/archpedi.1994.02170070019003; SITTHIAMORN C, 1994, LANCET; STUNKARD AJ, 1993, NEW ENGL J MED, V329, P1036, DOI 10.1056/NEJM199309303291411; 1991, HLTH NATION	12	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1715	1716		10.1016/S0140-6736(94)92880-0	http://dx.doi.org/10.1016/S0140-6736(94)92880-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7996996				2022-12-28	WOS:A1994PY28100003
J	ESPINEL, CH				ESPINEL, CH			CARAVAGGIO IL-AMORE-DORMIENTE - A SLEEPING CUPID WITH JUVENILE RHEUMATOID-ARTHRITIS	LANCET			English	Article									GEORGETOWN UNIV,SCH MED,ARLINGTON,VA 22205	Georgetown University	ESPINEL, CH (corresponding author), BLOOD PRESSURE CTR,1715 N GEORGE MASON DR,SUITE 401,ARLINGTON,VA 22205, USA.							ANSELL BM, 1969, TXB RHEUMATIC DISEAS; Bertolotti A., 1881, ARTISTI LOMBARDI ROM, V11, P50; BONSANTI G, 1984, CARAVAGGIO, P49; BREWER EJ, 1977, ARTHRITIS RHEUM, V10, P195; Cassidy JT, 1990, TXB PEDIATRIC RHEUMA, P113; CHIARINI M, 1992, PITTI PALACE GUIDE C; CULLEN B, 1986, IRISH MED J, V79, P72; FRIEDLAENDER W, 1985, FMR, V9, P66; GREGORI M, 1991, GALLERIA PALATINA, P310; Sgarbi V, 1985, FRANCO MARIA RICCI F, V9, P46; Still G F, 1897, Med Chir Trans, V80, P47	11	14	14	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1750	1752		10.1016/S0140-6736(94)92891-6	http://dx.doi.org/10.1016/S0140-6736(94)92891-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7997006	hybrid			2022-12-28	WOS:A1994PY28100014
J	SCHAFER, AI				SCHAFER, AI			HYPERCOAGULABLE STATES - MOLECULAR-GENETICS TO CLINICAL-PRACTICE	LANCET			English	Review							PROTEIN-C DEFICIENCY; ANTITHROMBIN-III; VENOUS THROMBOSIS; PLASMINOGEN-ACTIVATOR; RECURRENT THROMBOSIS; PRETHROMBOTIC STATE; THROMBOPHILIA; ASSOCIATION; MECHANISMS; PREVALENCE	Several physiological antithrombotic proteins-including antithrombin, protein C, protein S, tissue factor pathway inhibitor, and components of the fibrinolytic system-act as inhibitors at strategic sites in the coagulation cascade to maintain normal blood fluidity under normal circumstances. The molecular basis of specific inherited hypercoagulable states has been recently elucidated. With the description of resistance to activated protein C, which is the commonest coagulation defect associated with thrombophilia, a specific primary hypercoagulable slate can be identified in over 50% of patients with thrombophilia. Although the prevalence in the normal population of some ''prothrombotic'' mutations is remarkably high, most affected individuals do not have clinical thrombotic complications, so it is likely that clinically apparent hypercoagulable states result. from multigene interactions, and that clinical episodes of thrombosis are precipitated by acquired prothrombotic insults in patients with an inherited predisposition to thrombosis.	VET AFFAIRS MED CTR,HOUSTON,TX 77030	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	SCHAFER, AI (corresponding author), BAYLOR COLL MED,DEPT MED,2002 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; ALVING BM, 1993, HOSP PRACT, V28, P109, DOI 10.1080/21548331.1993.11442755; AOKI N, 1978, J CLIN INVEST, V61, P1186, DOI 10.1172/JCI109034; BAUER KA, 1987, BLOOD, V70, P343; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DEMERS C, 1992, ANN INTERN MED, V116, P754, DOI 10.7326/0003-4819-116-9-754; DREYFUS M, 1991, NEW ENGL J MED, V325, P1565, DOI 10.1056/NEJM199111283252207; ENGESSER L, 1987, BRIT J HAEMATOL, V67, P355, DOI 10.1111/j.1365-2141.1987.tb02357.x; GIROLAMI A, 1994, LANCET, V343, P1288, DOI 10.1016/S0140-6736(94)92177-6; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; GRIFFIN JH, 1993, BLOOD, V82, P1989; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; KITCHENS CS, 1985, SEMIN THROMB HEMOST, V11, P293, DOI 10.1055/s-2007-1004383; KOOPMAN J, 1993, J CLIN INVEST, V91, P1637, DOI 10.1172/JCI116371; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; LEGNANI C, 1994, LANCET, V343, P541, DOI 10.1016/S0140-6736(94)91494-X; LOTTENBERG R, 1985, AM J HEMATOL, V19, P181, DOI 10.1002/ajh.2830190211; LUZZATTO G, 1990, SEMIN ONCOL, V17, P147; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MEADE TW, 1990, BRIT J HAEMATOL, V74, P77, DOI 10.1111/j.1365-2141.1990.tb02541.x; MENACHE D, 1990, BLOOD, V75, P33; MILETICH J, 1987, NEW ENGL J MED, V317, P991, DOI 10.1056/NEJM198710153171604; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; NACHMAN RL, 1993, ANN INTERN MED, V119, P819, DOI 10.7326/0003-4819-119-8-199310150-00008; NILSSON IM, 1985, BRIT MED J, V290, P1453, DOI 10.1136/bmj.290.6480.1453; SCHAFER AI, 1985, ANN INTERN MED, V102, P814, DOI 10.7326/0003-4819-102-6-814; SCHAFER AI, 1987, ANNU REV MED, V38, P211, DOI 10.1146/annurev.med.38.1.211; SCHAFER AI, 1993, ANNU REV MED, V44, P155, DOI 10.1146/annurev.med.44.1.155; SIE P, 1985, LANCET, V2, P414; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; TAIT RC, 1990, BRIT J HAEMATOL, V75, P141, DOI 10.1111/j.1365-2141.1990.tb02635.x; TRAN TH, 1985, LANCET, V2, P413	36	85	97	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1739	1742		10.1016/S0140-6736(94)92888-6	http://dx.doi.org/10.1016/S0140-6736(94)92888-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7997003				2022-12-28	WOS:A1994PY28100011
J	MULLER, O; QUINONES, M; CHAM, K; AIKINS, M; GREENWOOD, B				MULLER, O; QUINONES, M; CHAM, K; AIKINS, M; GREENWOOD, B			DETECTING PERMETHRIN ON TREATED BED NETS	LANCET			English	Letter							CHILDREN				MULLER, O (corresponding author), MRC LABS,POB 273,BANJUL,GAMBIA.							ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; FALBE J, 1989, ROMPO CHEM LEXIKON, V1, P368; GRAVES PM, 1987, B WORLD HEALTH ORGAN, V65, P869; Rozendaal J. A., 1989, Tropical Diseases Bulletin, V86, pR1; 1993, B WORLD HEALTH ORGAN, V71, P281	5	14	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1699	1700		10.1016/S0140-6736(94)90481-2	http://dx.doi.org/10.1016/S0140-6736(94)90481-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996972				2022-12-28	WOS:A1994PX30200030
J	HARTWELL, LH; KASTAN, MB				HARTWELL, LH; KASTAN, MB			CELL-CYCLE CONTROL AND CANCER	SCIENCE			English	Review							WILD-TYPE P53; FLOW CYTOMETRIC ANALYSIS; ATAXIA-TELANGIECTASIA GENE; ACUTE MYELOID-LEUKEMIA; SACCHAROMYCES-CEREVISIAE; DNA-DAMAGE; MYELOGENOUS LEUKEMIA; FUSION TRANSCRIPT; C-MYC; NEOPLASTIC TRANSFORMATION	Multiple genetic changes occur during the evolution of normal cells into cancer cells. This evolution is facilitated in cancer cells by loss of fidelity in the processes that replicate, repair, and segregate the genome. Recent advances in our understanding of the cell cycle reveal how fidelity is normally achieved by the coordinated activity of cyclin-dependent kinases, checkpoint controls, and repair pathways and how this fidelity can be abrogated by specific genetic changes. These insights suggest molecular mechanisms for cellular transformation and may help to identify potential targets for improved cancer therapies.	JOHNS HOPKINS UNIV HOSP,DEPT ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine	HARTWELL, LH (corresponding author), UNIV WASHINGTON,DEPT GENET,SK-50,SEATTLE,WA 98195, USA.				NATIONAL CANCER INSTITUTE [R01CA061949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005777, R37ES005777] Funding Source: NIH RePORTER; NCI NIH HHS [CA 61949] Funding Source: Medline; NIEHS NIH HHS [ES 05777] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AFSHARI CA, 1993, ENVIRON HEALTH PERSP, V101, P9, DOI 10.2307/3431837; AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; ASKEW DS, 1991, ONCOGENE, V6, P1915; AVIVI L, 1989, HUM GENET, V83, P165, DOI 10.1007/BF00286711; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BENN PA, 1976, AM J HUM GENET, V28, P465; BENNETT CB, 1993, P NATL ACAD SCI USA, V90, P5613, DOI 10.1073/pnas.90.12.5613; BENNETT WP, 1993, CANCER RES, V53, P4817; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYLE JO, 1993, CANCER RES, V53, P4477; Brash Don, COMMUNICATION; BUSSE PM, 1977, RADIAT RES, V71, P666, DOI 10.2307/3574634; CARDER P, 1993, ONCOGENE, V8, P1397; CASSON AG, 1991, CANCER RES, V51, P4495; CERUTTI PA, 1991, SCIENCE, V3, P1; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; CUTLER RG, 1989, J GERONTOL, V44, P25, DOI 10.1093/geronj/44.6.25; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DIX D, 1989, J GERONTOL, V44, P139; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DREWS RE, 1992, MOL CELL BIOL, V12, P198, DOI 10.1128/MCB.12.1.198; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; ERICKSON P, 1992, BLOOD, V80, P1825; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FIELD JK, 1993, ARCH OTOLARYNGOL, V119, P1118; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FORD MD, 1984, MUTAT RES, V125, P115, DOI 10.1016/0027-5107(84)90038-1; FUKASAWA K, UNPUB; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; GREIDER CW, 1990, BIOESSAYS, V12, P363, DOI 10.1002/bies.950120803; HARPER JW, 1993, CELL, V75, P805; HART RW, 1976, MECH AGEING DEV, V5, P67, DOI 10.1016/0047-6374(76)90009-9; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; HOLLIDAY R, 1985, CANCER SURV, V4, P557; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HUFFAKER TC, 1988, J CELL BIOL, V106, P1997, DOI 10.1083/jcb.106.6.1997; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; IMRAY FP, 1983, MUTAT RES, V112, P369; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KALTIONIEMI A, 1992, SCIENCE, V258, P818; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KHANNA KK, 1993, ONCOGENE, V8, P3307; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KNIGHT RD, 1993, INT J CANCER, V54, P589, DOI 10.1002/ijc.2910540412; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; KORNBLUTH S, 1992, MOL CELL BIOL, V12, P3216, DOI 10.1128/MCB.12.7.3216; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LEACH FS, 1993, CANCER RES, V53, P2231; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVINE DS, 1991, P NATL ACAD SCI USA, V88, P6427, DOI 10.1073/pnas.88.15.6427; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li W. W., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P418; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOEB LA, 1989, CANCER RES, V49, P5489; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LOWE SW, UNPUB; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Murray A, 1993, CELL CYCLE INTRO; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NAGASAWA H, 1985, MUTAT RES, V148, P71, DOI 10.1016/0027-5107(85)90209-X; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NOBORI T, 1994, SCIENCE, V368, P753; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; NOWELL PC, 1986, CANCER RES, V46, P2203; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; O'Connor P M, 1992, Semin Cancer Biol, V3, P409; OCONNOR P, COMMUNICATION; OGDEN GR, 1993, J CLIN PATHOL, V46, P169, DOI 10.1136/jcp.46.2.169; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTANI H, 1993, J BIOL CHEM, V268, P22733; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PARSHAD R, 1985, P NATL ACAD SCI USA, V82, P5400, DOI 10.1073/pnas.82.16.5400; PETERSON RDA, 1992, LEUKEMIA, V6, P8; PETO R, 1975, BRIT J CANCER, V32, P411, DOI 10.1038/bjc.1975.242; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRICE BD, 1994, CANCER RES, V54, P896; QUINLAN RA, 1980, J CELL SCI, V46, P341; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAY FA, 1992, MUTAT RES, V284, P265, DOI 10.1016/0027-5107(92)90011-P; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; REID BJ, 1993, GASTROENTEROLOGY, V105, P119, DOI 10.1016/0016-5085(93)90017-7; RIEDER CL, 1989, ANEUPLOIDY MECHANISM; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SANFORD KK, 1990, J NATL CANCER I, V82, P1050, DOI 10.1093/jnci/82.12.1050; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SEQAWA K, 1993, ONCOGENE, V8, P543; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHELDRICK KS, 1993, BIOESSAYS, V15, P775, DOI 10.1002/bies.950151202; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHUEFER P, 1993, CANCER REWS, V53, P4946; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SINGH B, 1992, MOL CARCINOGEN, V6, P182, DOI 10.1002/mc.2940060303; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SPENCER F, 1992, P NATL ACAD SCI USA, V89, P8908, DOI 10.1073/pnas.89.19.8908; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TAYLOR AMR, 1989, INT J RADIAT BIOL, V56, P677, DOI 10.1080/09553008914551901; Trosko J E, 1975, Adv Cancer Res, V21, P391, DOI 10.1016/S0065-230X(08)60976-8; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WAGATA T, 1993, CANCER RES, V53, P846; WANG LD, 1993, CANCER RES, V53, P1783; WARNER HR, 1989, J GERONTOL, V44, P45, DOI 10.1093/geronj/44.6.45; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; WEINERT TA, 1993, GENETICS, V134, P63; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WINEY M, 1993, TRENDS GENET, V9, P300, DOI 10.1016/0168-9525(93)90247-F; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WOLMAN S. R., 1964, CYTOGENETICS [BASEL], V3, P45, DOI 10.1159/000129797; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZAHN Q, 1994, CANCER RES, V54, P2755; ZIMMERMAN JA, 1989, J GERONTOL, V44, P19, DOI 10.1093/geronj/44.6.19; ZURHAUSEN H, 1989, ADV VIRAL ONCOL, P1	175	2252	2406	3	329	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1821	1828		10.1126/science.7997877	http://dx.doi.org/10.1126/science.7997877			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997877				2022-12-28	WOS:A1994PX38300026
J	PETTIT, DL; PERLMAN, S; MALINOW, R				PETTIT, DL; PERLMAN, S; MALINOW, R			POTENTIATED TRANSMISSION AND PREVENTION OF FURTHER LTP BY INCREASED CAMKII ACTIVITY IN POSTSYNAPTIC HIPPOCAMPAL SLICE NEURONS	SCIENCE			English	Article							LONG-TERM POTENTIATION; DEPENDENT PROTEIN-KINASE; DENSITY PROTEIN; FASCIA DENTATA; SYNAPTIC ENHANCEMENT; SYNTHETIC MACHINERY; NMDA RECEPTORS; CA1 NEURONS; CALMODULIN; ACTIVATION	Calcium-calmodulin-dependent protein kinase II (CaMKII) is a necessary component of the cellular machinery underlying learning and memory. Here, a constitutively active form of this enzyme, CaMKII(1-290), was introduced into neurons of hippocampal slices with a recombinant vaccinia virus to test the hypothesis that increased postsynaptic activity of this enzyme is sufficient to produce long-term synaptic potentiation (LTP), a prominent cellular model of learning and memory. Postsynaptic expression of CaMKII(1-290) increased CaMKII activity, enhanced synaptic transmission, and prevented more potentiation by an LTP-inducing protocol. These results, together with previous studies, suggest that postsynaptic CaMKII activity is necessary and sufficient to generate LTP.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; UNIV IOWA,NEUROSCI PROGRAM,DEPT PEDIAT,IOWA CITY,IA 52242; UNIV IOWA,NEUROSCI PROGRAM,DEPT MICROBIOL,IOWA CITY,IA 52242	Cold Spring Harbor Laboratory; University of Iowa; University of Iowa								AKERS RF, 1985, BRAIN RES, V334, P147, DOI 10.1016/0006-8993(85)90576-1; ALFORD S, 1993, J PHYSIOL-LONDON, V469, P693, DOI 10.1113/jphysiol.1993.sp019838; ASZTELY F, 1992, SYNAPSE, V11, P342, DOI 10.1002/syn.890110409; BAILINGER C, 1990, J CELL BIOL, V111, P1763; BLISS TVP, 1983, J PHYSIOL-LONDON, V334, P475, DOI 10.1113/jphysiol.1983.sp014507; CHARRIAUTMARLANGUE C, 1991, P NATL ACAD SCI USA, V88, P10232, DOI 10.1073/pnas.88.22.10232; COHEN ME, 1990, P NATL ACAD SCI USA, V87, P8990, DOI 10.1073/pnas.87.22.8990; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; Dingledine R., 1984, BRAIN SLICES; FUKANAGA K, 1993, J BIOL CHEM, V268, P7863; GOLDENRING JR, 1984, J NEUROCHEM, V42, P1077, DOI 10.1111/j.1471-4159.1984.tb12713.x; GUSTAFSSON B, 1988, NEUROSCI LETT, V85, P77, DOI 10.1016/0304-3940(88)90432-6; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARRIS EW, 1984, BRAIN RES, V323, P132, DOI 10.1016/0006-8993(84)90275-0; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MACKETT M, 1985, DNA CLONING PRACTICA; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALENKA RC, 1986, NATURE, V319, P774; MALENKA RC, 1986, NATURE, V321, P695; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1994, P NATL ACAD SCI USA, V91, P8170, DOI 10.1073/pnas.91.17.8170; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MCNAUGHTON BL, 1981, J NEUROPHYSIOL, V46, P952, DOI 10.1152/jn.1981.46.5.952; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MCNAUGHTON BL, 1982, J PHYSIOL-LONDON, V324, P249, DOI 10.1113/jphysiol.1982.sp014110; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MULLER D, 1988, P NATL ACAD SCI USA, V85, P6997, DOI 10.1073/pnas.85.18.6997; MULLER W, 1992, J NEUROPHYSIOL, V68, P2264, DOI 10.1152/jn.1992.68.6.2264; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PERKEL DJ, 1993, NEURON, V11, P817, DOI 10.1016/0896-6273(93)90111-4; PETTIT DL, 1983, COLD SPRING HARB SYM, V48, P745; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; REGEHR WG, 1990, NATURE, V345, P807, DOI 10.1038/345807a0; REYMANN KG, 1986, BRAIN RES BULL, V17, P291, DOI 10.1016/0361-9230(86)90234-0; REYMANN KG, 1988, BRAIN RES, V440, P305, DOI 10.1016/0006-8993(88)91000-1; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STEWARD O, 1988, J NEUROSCI, V8, P176; STEWARD O, 1986, J NEUROSCI, V6, P3079; STEWARD O, 1991, J COMP NEUROL, V314, P545, DOI 10.1002/cne.903140311; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WEISSKOPF MG, 1993, NATURE, V362, P423, DOI 10.1038/362423a0; YAMAGATA Y, 1991, J BIOL CHEM, V266, P15391	53	257	259	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1881	1885		10.1126/science.7997883	http://dx.doi.org/10.1126/science.7997883			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997883				2022-12-28	WOS:A1994PX38300040
J	GRAHAM, A; FRANCISWEST, P; BRICKELL, P; LUMSDEN, A				GRAHAM, A; FRANCISWEST, P; BRICKELL, P; LUMSDEN, A			THE SIGNALING MOLECULE BMP4 MEDIATES APOPTOSIS IN THE RHOMBENCEPHALIC NEURAL CREST	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; VENTRALIZING FACTOR; HINDBRAIN; CELLS	THE pattern of skeletal structures and muscles in the branchial region of the head is profoundly influenced by the neural crest whose cells arise at discrete segmental levels of the chick hindbrain: specifically, rhombomeres (r)1 + 2, r4 and r6, whereas r3 and r5 are crest-depleted(2). We have demonstrated that an interaction between even-numbered rhombomeres and r3/r5 effects this depletion of neural crest, resulting in the sculpting of discrete migratory streams of neural crest(3). This mechanism acts through increased expression of msx2 and the induction of apoptosis in dorsal cells of r3 and r5 (ref. 3) (Fig. 1A). Here we demonstrate that the signalling molecule Bmp4 is expressed in r3 and r5 and is dependent on the neighbouring rhombomeres. Addition of recombinant BMP4 protein to explant cultures of r3 or r5, which produce neural crest when isolated from their neighbouring rhombomeres, upregulates msx2 and reinstates apoptosis in the neural crest population.	UCL, SCH MED, DEPT MOLEC PATHOL, MED MOLEC BIOL UNIT, LONDON W1P 6DB, ENGLAND	University of London; University College London; UCL Medical School	GRAHAM, A (corresponding author), UNITED MED & DENT SCH, GUYS HOSP, DIV ANAT & CELL BIOL, MRC, LONDON SE1 9RT, ENGLAND.		graham, anthony/B-1864-2008; Lumsden, Andrew/C-5146-2009	graham, anthony/0000-0003-2011-7188; 				ACHESON A, 1993, SOC NEUR ABSTR, V19; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; DALE L, 1992, DEVELOPMENT, V115, P573; DELANNET M, 1992, DEVELOPMENT, V116, P275; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; GRAHAM A, 1993, DEVELOPMENT, V119, P233; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; JONES CM, 1992, DEVELOPMENT, V115, P639; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; VANIO S, 1993, CELL, V75, P45	12	441	448	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					684	686		10.1038/372684a0	http://dx.doi.org/10.1038/372684a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990961				2022-12-28	WOS:A1994PX30700088
J	REILLY, D; TAYLOR, MA; BEATTIE, NGM; CAMPBELL, JH; MCSHARRY, C; AITCHISON, TC; CARTER, R; STEVENSON, RD				REILLY, D; TAYLOR, MA; BEATTIE, NGM; CAMPBELL, JH; MCSHARRY, C; AITCHISON, TC; CARTER, R; STEVENSON, RD			IS EVIDENCE FOR HOMEOPATHT REPRODUCIBLE	LANCET			English	Article							HORMESIS; THERAPY	We tested, under independent conditions, the reproducibility of evidence from two previous trials that homoeopathy differs from placebo. The test model was again homoeopathic immunotherapy. 28 patients with allergic asthma, most of them sensitive to house-dust mite, were randomly allocated to receive either oral homoeopathic imm;notherapy to their principal allergen or identical placebo. The test treatments were given as a complement to their unaltered conventional care. A daily visual analogue scale of overall symptom intensity was the outcome measure. A difference in visual analogue score in favour of homoeopathic immunotherapy appeared within one week of starting treatment and persisted for up to 8 weeks (p=0.003). There were similar trends in respiratory function and bronchial reactivity tests. A meta-analysis of all three trials strengthened the evidence that homoeopathy does more than placebo (p=0.0004). Is the reproducibility of evidence in favour of homoeopathy proof of its activity or proof of the clinical trial's capacity to produce false-positive results?	GLASGOW ROYAL INFIRM, DEPT MED RES, GLASGOW G31 2ER, LANARK, SCOTLAND; UNIV GLASGOW, WESTERN INFIRM, DEPT IMMUNOL, GLASGOW, LANARK, SCOTLAND; UNIV GLASGOW, DEPT STAT, GLASGOW, LANARK, SCOTLAND	University of Glasgow; University of Glasgow; University of Glasgow	REILLY, D (corresponding author), UNIV GLASGOW, DEPT MED, GLASGOW, LANARK, SCOTLAND.			McSharry, Charles/0000-0003-4758-9038				ADAMS L, 1985, CLIN SCI, V69, P7, DOI 10.1042/cs0690007; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; CARTER R, 1986, BREATH, V29, P8; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DERNANGEAT JL, 1992, J MED NUCL BIOPHY, V16, P135; DHAND R, 1988, RESPIRATION, V54, P255, DOI 10.1159/000195533; DSOUZA MF, 1983, CLIN ALLERGY, V13, P329, DOI 10.1111/j.1365-2222.1983.tb02608.x; ENDLER PC, 1994, ULTRA HIGH DILUTION; GIBSON RG, 1980, BR HOMOEOPATHIC J, V69, P151; GLEIK J, 1988, CHAOS; GRACELY RH, 1985, LANCET, V1, P43; HARDY J, 1984, COMMUNICATIONS, V11, P75; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KNIPSCHILD P, 1991, J CLIN EPIDEMIOL, V44, P461, DOI 10.1016/0895-4356(91)90208-Q; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MACKLIS RM, 1991, J NUCL MED, V32, P350; Meyers D A, 1990, Agents Actions Suppl, V30, P87; MORRISOWEN RM, 1981, BR HOMOEOPATHIC J, V70, P70; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P129, DOI 10.1016/0091-6749(87)90120-5; Pocock SJ., 2013, CLIN TRIALS PRACTICA; REIL GH, 1985, Z KARDIOL, V74, P65; REILLY DT, 1986, LANCET, V2, P881; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; STARK RD, 1982, BRIT J DIS CHEST, V76, P269, DOI 10.1016/S0007-0971(82)80031-4; STARK RD, 1980, J CLIN RESP PHYSL, V16, P244; STEBBING ARD, 1982, SCI TOTAL ENVIRON, V22, P213, DOI 10.1016/0048-9697(82)90066-3; THOMPSON RA, 1989, LANCET, V1, P259; VELLEMAN PF, 1980, J AM STAT ASSOC, V75, P609, DOI 10.2307/2287657; VITHOULKAS G, 1985, HOMOEOPATHY, P72; 1855, HOMOEOPATHY, V13, P674; 1983, BR J HOSP MED, V30, P377; 1988, NATURE, V30, P787	32	167	171	0	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 10	1994	344	8937					1601	1606		10.1016/S0140-6736(94)90407-3	http://dx.doi.org/10.1016/S0140-6736(94)90407-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983994				2022-12-28	WOS:A1994PW05100010
J	FUJITA, A; OKA, C; ARIKAWA, Y; KATAGAI, T; TONOUCHI, A; KUHARA, S; MISUMI, Y				FUJITA, A; OKA, C; ARIKAWA, Y; KATAGAI, T; TONOUCHI, A; KUHARA, S; MISUMI, Y			A YEAST GENE NECESSARY FOR BUD-SITE SELECTION ENCODES A PROTEIN SIMILAR TO INSULIN-DEGRADING ENZYMES	NATURE			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; EXPRESSION; SEQUENCE; CLONING; DISRUPTION	CELLS Of the yeast Saccharomyces cerevisiae choose bud sites in a non-random spatial pattern that depends on mating type: axial for haploid cells and bipolar for ala diploid cells(1,2). We identified a mutant yeast, axl1, in which the budding pattern is altered from axial to bipolar. Expression of the AXL1 gene is repressed in a/alpha diploid cells. With the ectopic expression of AXL1, a/alpha cells exhibited an axial budding pattern, thus AXL1 is a key morphological determinant that distinguishes the budding pattern of haploid cells from that of ala diploid cells(2). AXL1 encodes a protein similar in sequence to the human and Drosophila insulin-degrading enzymes(3,4) and to the Escherichia coli ptr gene product(5). The axial budding pattern might result from degradation of a target protein by the putative Axl1 protease.	IND RES INST CHIBA PREFECTURE, WAKABA KU, CHIBA 264, JAPAN; NAGANO STATE LAB FOOD TECHNOL, NAGANO 380, JAPAN; KYUSHU UNIV, GRAD SCH GENET RESOURCES TECHNOL, HIGASHI KU, FUKUOKA 812, JAPAN; FUKUOKA UNIV, SCH MED, DEPT BIOCHEM, JONAN KU, FUKUOKA 81401, JAPAN	Kyushu University; Fukuoka University	FUJITA, A (corresponding author), AGCY IND SCI & TECHNOL, NATL INST BIOSCI & HUMAN TECHNOL, 1-1 HIGASHI, TSUKUBA, IBARAKI 305, JAPAN.							AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; BUTLER G, 1991, MOL CELL BIOL, V11, P476, DOI 10.1128/MCB.11.1.476; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHENG YSE, 1979, J BIOL CHEM, V254, P4698; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P7695, DOI 10.1093/nar/14.19.7695; FLESCHER EG, 1993, J CELL BIOL, V122, P373, DOI 10.1083/jcb.122.2.373; FUJITA A, 1990, GENE, V89, P93, DOI 10.1016/0378-1119(90)90210-I; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; KIRSCHNER RJ, 1983, J BIOL CHEM, V258, P967; KUO WL, 1990, MOL ENDOCRINOL, V4, P1580, DOI 10.1210/mend-4-10-1580; MILLER AM, 1985, NATURE, V314, P598, DOI 10.1038/314598a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RINE J, 1987, GENETICS, V116, P9; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; STILLMAN DJ, 1992, GENE DEV, V6, P93; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035	21	117	119	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 8	1994	372	6506					567	570		10.1038/372567a0	http://dx.doi.org/10.1038/372567a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990931				2022-12-28	WOS:A1994PW08200057
J	ANDERSEN, HR; THUESEN, L; BAGGER, JP; VESTERLUND, T; THOMSEN, PEB				ANDERSEN, HR; THUESEN, L; BAGGER, JP; VESTERLUND, T; THOMSEN, PEB			PROSPECTIVE RANDOMIZED TRIAL OF ATRIAL VERSUS VENTRICULAR PACING IN SICK-SINUS SYNDROME	LANCET			English	Article							NODE DISEASE; ATRIOVENTRICULAR-BLOCK; STIMULATION MODE; DUAL-CHAMBER; FOLLOW-UP; NATURAL-HISTORY; FIBRILLATION; RISK; IMPLANTATION; DYSFUNCTION	In patients with sick-sinus syndrome, single-chamber atrial pacing has been reported, in retrospective studies, to be associated with lower frequencies of atrial fibrillation, thromboembolism, heart failure, and mortality than ventricular pacing; although single-chamber ventricular pacing is most commonly used. We did a prospective randomised trial in 225 consecutive patients (142 women, 83 men; mean age 76 years) with the sick-sinus syndrome, randomised to atrial (n=110) or ventricular (n=115) pacing and followed for up to 5 years (mean 40 [SD 18] months). During follow-up, the frequency of atrial fibrillation was higher in the ventricular group, except at the first follow-up at 3 months. Thromboembolic events (stroke or peripheral arterial embolus) occurred in 20 patients in the ventricular group and in 6 patients in the atrial group (p=0.0083). 25 patients died in the ventricular group compared with 21 in the atrial group (p=0.74). Heart failure estimated by the New York Heart Association classification and by the daily doses of diuretics did not differ between the two groups. Atrioventricular block occurred in 2 patients in the atrial group. Patients with sick-sinus syndrome should be treated with atrial pacing rather than ventricular pacing because atrial pacing is associated with lower frequencies of atrial fibrillation, thromboembolic complications, and a low risk of atrioventricular block.	CARDIOVASC RES CTR,AARHUS,DENMARK		ANDERSEN, HR (corresponding author), AARHUS UNIV HOSP,SKEJBY SYGEHUS,DEPT CARDIOL,DK-8200 AARHUS N,DENMARK.							ASKENAZI J, 1984, AM J CARDIOL, V53, P99, DOI 10.1016/0002-9149(84)90691-X; BEDOTTO JB, 1990, J AM COLL CARDIOL, V15, P658, DOI 10.1016/0735-1097(90)90642-3; BERNSTEIN AD, 1992, AM J CARDIOL, V69, P331, DOI 10.1016/0002-9149(92)90229-R; BERNSTEIN SB, 1988, AM J CARDIOL, V61, P113, DOI 10.1016/0002-9149(88)91315-X; BRANDT J, 1992, J AM COLL CARDIOL, V20, P633, DOI 10.1016/0735-1097(92)90018-I; BREIVIK K, 1979, ACTA MED SCAND, V206, P153; CABIN HS, 1990, AM J CARDIOL, V65, P1112, DOI 10.1016/0002-9149(90)90323-S; CAIRNS JA, 1991, CIRCULATION, V84, P469, DOI 10.1161/01.CIR.84.2.469; CAMM AJ, 1990, PACE, V13, P695, DOI 10.1111/j.1540-8159.1990.tb02091.x; ELSHOT SRE, 1993, INT J CARDIOL, V38, P303, DOI 10.1016/0167-5273(93)90249-G; HAYWOOD GA, 1990, PACE, V13, P2054, DOI 10.1111/j.1540-8159.1990.tb06941.x; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; KERR CR, 1989, PACE, V12, P1049, DOI 10.1111/j.1540-8159.1989.tb01925.x; KUBICA J, 1990, PACE, V13, P1737, DOI 10.1111/j.1540-8159.1990.tb06882.x; LAMAS GA, 1992, PACE, V15, P1109, DOI 10.1111/j.1540-8159.1992.tb03112.x; LEE MA, 1994, J AM COLL CARDIOL, V24, P225, DOI 10.1016/0735-1097(94)90567-3; MARKEWITZ A, 1986, PACE, V9, P1115, DOI 10.1111/j.1540-8159.1986.tb06679.x; PETERSEN P, 1989, LANCET, V1, P175; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; ROSENQVIST M, 1991, AM J CARDIOL, V67, P148, DOI 10.1016/0002-9149(91)90437-P; SANFILIPPO AJ, 1990, CIRCULATION, V82, P792, DOI 10.1161/01.CIR.82.3.792; SANTINI M, 1990, AM J CARDIOL, V65, P729, DOI 10.1016/0002-9149(90)91379-K; SASAKI Y, 1988, PACE, V11, P1575, DOI 10.1111/j.1540-8159.1988.tb06277.x; SIMON AB, 1979, PACE, V2, P305, DOI 10.1111/j.1540-8159.1979.tb03650.x; STANGL K, 1990, PACE, V13, P2080, DOI 10.1111/j.1540-8159.1990.tb06946.x; STONE JM, 1982, AM HEART J, V104, P1319, DOI 10.1016/0002-8703(82)90162-4; ZANINI R, 1989, PACE, V12, P1065, DOI 10.1111/j.1540-8159.1989.tb01927.x; ZANINI R, 1990, PACE, V13, P2076, DOI 10.1111/j.1540-8159.1990.tb06945.x; ZEHENDER M, 1992, CIRCULATION, V85, P596, DOI 10.1161/01.CIR.85.2.596; 1992, ANN INTERN MED, V116, P6; 1991, CIRCULATION, V84, P527; 1992, ANN INTERN MED, V116, P1	32	348	358	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1523	1528		10.1016/S0140-6736(94)90347-6	http://dx.doi.org/10.1016/S0140-6736(94)90347-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983951				2022-12-28	WOS:A1994PV01700007
J	BROWN, EM; DELOUVOIS, J; BAYSTON, R; HEDGES, AJ; JOHNSTON, RA; LEES, P				BROWN, EM; DELOUVOIS, J; BAYSTON, R; HEDGES, AJ; JOHNSTON, RA; LEES, P			ANTIMICROBIAL PROPHYLAXIS IN NEUROSURGERY AND AFTER HEAD-INJURY	LANCET			English	Review							BASILAR SKULL FRACTURE; ANTIBIOTIC-PROPHYLAXIS; MENINGITIS; IMPREGNATION; INFECTION; SURGERY; SHUNTS; RISK		PUBL HLTH LAB SERV HEADQUARTERS, LONDON NW9 5DF, ENGLAND; FRENCHAY HOSP, BRISTOL BS16 1LE, AVON, ENGLAND; CITY HOSP, NOTTINGHAM NG5 1PB, ENGLAND; UNIV BRISTOL, BRISTOL, AVON, ENGLAND; SO GEN HOSP, GLASGOW G51 4TF, LANARK, SCOTLAND; SOUTHAMPTON GEN HOSP, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND	University of Nottingham; University of Bristol; University of Glasgow; University of Southampton			Bayston, Roger/AAD-5427-2019; Bayston, Roger/E-7699-2019	Bayston, Roger/0000-0002-8312-3844; 				BAYSTON R, 1981, J CLIN PATHOL, V34, P1057, DOI 10.1136/jcp.34.9.1057; BAYSTON R, 1989, J NEUROL NEUROSUR PS, V52, P605, DOI 10.1136/jnnp.52.5.605; Bayston R, 1990, Z Kinderchir, V45 Suppl 1, P5; BROWN EM, 1993, J ANTIMICROB CHEMOTH, V31, P49, DOI 10.1093/jac/31.suppl_B.49; BRYAN CS, 1979, J NEUROSURG, V51, P240, DOI 10.3171/jns.1979.51.2.0240; BULLOCK R, 1990, BRIT MED J, V300, P1576, DOI 10.1136/bmj.300.6739.1576; ELJAMEL M S, 1990, British Journal of Neurosurgery, V4, P381, DOI 10.3109/02688699008992759; ELJAMEL MS, 1993, BRIT J NEUROSURG, V7, P501, DOI 10.3109/02688699308995072; FRAZEE RC, 1988, POSTGRAD MED, V83, P267, DOI 10.1080/00325481.1988.11700238; HAINES SJ, 1994, NEUROSURGERY, V34, P87; HAINES SJ, 1980, NEUROSURGERY, V6, P355, DOI 10.1227/00006123-198004000-00001; HAND WL, 1970, ANN INTERN MED, V73, P862, DOI 10.7326/0003-4819-73-5-862; HIRSCHMANN JV, 1985, BACTERIAL MENINGITIS, P95; IGNELZI RJ, 1975, J NEUROSURG, V43, P721, DOI 10.3171/jns.1975.43.6.0721; LANGLEY JM, 1993, CLIN INFECT DIS, V17, P98, DOI 10.1093/clinids/17.1.98; LEECH PJ, 1973, LANCET, V1, P1013; MENDELOW AD, 1990, HOSP UPDATE, V16, P195; ODIO C, 1984, AM J DIS CHILD, V138, P17, DOI 10.1001/archpedi.1984.02140390009004; RATHORE MH, 1991, PEDIATR INFECT DIS J, V10, P87, DOI 10.1097/00006454-199102000-00001; RIEDER MJ, 1987, CAN MED ASSOC J, V136, P935; SIEGMANIGRA Y, 1993, CLIN INFECT DIS, V17, P843, DOI 10.1093/clinids/17.5.843; TENNEY JH, 1985, J NEUROSURG, V62, P243, DOI 10.3171/jns.1985.62.2.0243; WALTERS BC, 1985, Z KINDERCHIR, V40, P15; Zrebeet H A, 1986, Del Med J, V58, P741	24	69	69	4	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 3	1994	344	8936					1547	1551						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983958				2022-12-28	WOS:A1994PV01700014
J	RICE, DP				RICE, DP			COST-OF-ILLNESS STUDIES - FACT OR FICTION	LANCET			English	Editorial Material							LIFE				RICE, DP (corresponding author), UNIV CALIF SAN FRANCISCO,INST HLTH & AGING,SAN FRANCISCO,CA 94143, USA.							FARNHAM PG, 1994, PUBLIC HEALTH REP, V109, P311; HODGSON TA, 1982, MILBANK FUND Q, V60, P429, DOI 10.2307/3349801; MISHAN EJ, 1971, J POLIT ECON, V79, P687, DOI 10.1086/259784; Rice D.P., 1966, HLTH EC SERIES, V6; RICE DP, 1990, ADM901694 US ALC DRU; Rice DP, 1989, COST INJURY US REPOR; ROBINSON JC, 1986, MILBANK Q, V64, P133, DOI 10.2307/3350008; Schelling Thomas C., 1968, PROBLEMS PUBLIC EXPE, P127; SCITOVSKY AA, 1987, PUBLIC HEALTH REP, V102, P5	9	140	141	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1519	1520		10.1016/S0140-6736(94)90342-5	http://dx.doi.org/10.1016/S0140-6736(94)90342-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PV017	7983947				2022-12-28	WOS:A1994PV01700002
J	FACKLER, ML; HUTH, EJ; PITKIN, RM; RENNIE, D; BEGG, C; GREENLAND, S; OLKIN, I; STROUP, DF; DEEN, DF; LAU, J; DERISH, P; EASTWOOD, S; LANG, T; NICHOLS, K				FACKLER, ML; HUTH, EJ; PITKIN, RM; RENNIE, D; BEGG, C; GREENLAND, S; OLKIN, I; STROUP, DF; DEEN, DF; LAU, J; DERISH, P; EASTWOOD, S; LANG, T; NICHOLS, K			CALL FOR COMMENTS ON A PROPOSAL TO IMPROVE REPORTING OF CLINICAL-TRIALS IN THE BIOMEDICAL LITERATURE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							MEDICAL JOURNALS; GUIDELINES		WOUND BALLIST REVIEW, HAWTHORNE, FL USA; ON LINE JOURNAL CLIN TRIALS, PHILADELPHIA, PA USA; OBSTET & GYNECOL, LOS ANGELES, CA USA; JOURNAL AMER MED ASSOC, SAN FRANCISCO, CA USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; CALIF STATE UNIV LOS ANGELES, LOS ANGELES, CA 90032 USA; STANFORD UNIV, STANFORD, CA 94305 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA 30341 USA; UNIV CALIF SAN FRANCISCO, BRAIN TUMOR RES CTR, SAN FRANCISCO, CA 94143 USA; TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA; CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA; ALZA CORP, PALO ALTO, CA USA	American Medical Association; Memorial Sloan Kettering Cancer Center; California State University System; California State University Los Angeles; Stanford University; Centers for Disease Control & Prevention - USA; University of California System; University of California San Francisco; Tufts Medical Center; Cleveland Clinic Foundation; Johnson & Johnson; Johnson & Johnson USA			Lang, Tom/AAN-9087-2020	Lang, Tom/0000-0002-7482-7727				ALTMAN DG, 1983, BRIT MED J, V286, P1489, DOI 10.1136/bmj.286.6376.1489; ALTMAN DG, 1991, J R STAT SOC A STAT, V154, P223, DOI 10.2307/2983040; BAILAR JC, 1988, ANN INTERN MED, V108, P266, DOI 10.7326/0003-4819-108-2-266; Bailar JC, 1992, MED USES STAT, V2nd; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; Dawson-Saunders B, 1994, BASIC CLIN BIOSTATIS, P344; FINNEY DJ, 1992, P ROY SOC B-BIOL SCI, V249, P1; FINNEY DJ, 1992, PHIL T R SOC LOND B, V337, P381; Glantz SA, 1992, PRIMER BIOSTATISTICS, P440; International Committee of Medical Journal Editors, 1993, JAMA-J AM MED ASSOC, V269, P2282, DOI DOI 10.1001/JAMA.1993.03500170112052; MURRAY GD, 1988, BRIT J SURG, V75, P664, DOI 10.1002/bjs.1800750714; OLKIN I, 1992, SCIENCES         JUL, P30	12	61	66	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					894	895		10.7326/0003-4819-121-11-199412010-00015	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00015			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7978706				2022-12-28	WOS:A1994PT62800015
J	GOULDING, EH; TIBBS, GR; SIEGELBAUM, SA				GOULDING, EH; TIBBS, GR; SIEGELBAUM, SA			MOLECULAR MECHANISM OF CYCLIC-NUCLEOTIDE-GATED CHANNEL ACTIVATION	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; SUBUNIT STOICHIOMETRY; BINDING-SPECIFICITY; POTASSIUM CHANNELS; RECEPTOR CHIMERAS; INACTIVATION; MEMBRANE; DOMAIN; GMP	STUDIES on the activation of ligand- and voltage-gated ion channels have identified regions involved in both ligand binding(1) and voltage sensing(2), but relatively little is known about how such domains are coupled to channel opening. Here we investigate the structural basis for the activation of cyclic-nucleotide-gated channels, which are directly opened by cytoplasmic cyclic nucleotides(3,4) but are structurally homologous to voltage-gated channels(5-7). By constructing chimaeras between cyclic-nucleotide-gated channels cloned from bovine retinal photoreceptors(8) and catfish olfactory neurons(7), we identify two distinct domains that are important for ligand binding and channel gating. A putative alpha-helix in the carboxy-terminal binding domain determines the selectivity of the channel for activation by cGMP relative to cAMP. A domain in the amino-terminal region determines the ease with which channels open and thus influences agonist efficacy. We propose that channel opening is coupled to an allosteric conformational change in the binding site which enhances agonist binding. Thus, cyclic nucleotides activate the channel by binding tightly to the open state and stabilizing it.	COLUMBIA UNIV,HOWARD HUGHES MED INST,DEPT PHARMACOL,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	GOULDING, EH (corresponding author), COLUMBIA UNIV,HOWARD HUGHES MED INST,CTR NEUROBIOL & BEHAV,DEPT PHYSIOL,722 W 168TH ST,NEW YORK,NY 10032, USA.							AVIS JM, 1993, BIOCHEMISTRY-US, V32, P5321, DOI 10.1021/bi00071a006; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; CASTILLO JD, 1957, P ROY SOC          B, V146, P369; CATTERALL WA, 1989, SCIENCE, V243, P236, DOI 10.1126/science.2536189; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; GOULDING EH, 1993, NATURE, V364, P61, DOI 10.1038/364061a0; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; GUY HR, 1991, SCIENCE, V254, P730, DOI 10.1126/science.1658932; JACKSON MB, 1992, BIOPHYS J, V63, P1443, DOI 10.1016/S0006-3495(92)81706-X; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KRAMER RH, 1994, NEURON, V12, P655, DOI 10.1016/0896-6273(94)90220-8; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAKAMURA T, 1987, NATURE, V325, P342; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SHEN NV, 1993, NEURON, V11, P67; SKOOG DA, 1982, FUNDAMENTALS ANAL CH, P75; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	30	177	178	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					369	374		10.1038/372369a0	http://dx.doi.org/10.1038/372369a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969497				2022-12-28	WOS:A1994PU28700058
J	NOWAK, R				NOWAK, R			NOVEL PROGRAM .1. ADVANCED RESEARCH IN BIOTECHNOLOGY	SCIENCE			English	Note																			0	0	0	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					863	863		10.1126/science.7973645	http://dx.doi.org/10.1126/science.7973645			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973645				2022-12-28	WOS:A1994PP75300062
J	NEHLS, M; PFEIFER, D; SCHORPP, M; HEDRICH, H; BOEHM, T				NEHLS, M; PFEIFER, D; SCHORPP, M; HEDRICH, H; BOEHM, T			NEW MEMBER OF THE WINGED-HELIX PROTEIN FAMILY DISRUPTED IN MOUSE AND RAT NUDE MUTATIONS	NATURE			English	Article							GENE FORK-HEAD; TRANSCRIPTION FACTORS; EMBRYO; THYMUS; DOMAIN; MICE	MUTATIONS at the nude locus of mice and rats disrupt normal hair growth and thymus development(1,2), causing nude mice and rats to be immune-deficient. The mouse nude locus has been localized on chromosome 11 (refs 3, 4) within a region of <1 megabase(5). Here we show that one of the genes from this critical region, designated whn, encodes a new member of the winged-helix domain family of transcription factors(6.7), and that it is disrupted on mouse au and rat rnuN alleles. Mutant transcripts do not encode the characteristic DNA-binding domain, strongly suggesting that the whn gene is the nude gene. Mutations in winged-helix domain genes cause homeotic transformations in Drosophila(8) and distort cell-fate decisions during vulval development in Caenorhabditis elegans(9). The whn gene is thus the first member of this class of genes to be implicated in a specific developmental defect in vertebrates.	HANNOVER MED SCH,ZENT TIERVERSUCHSANLAGE,D-30625 HANNOVER,GERMANY; UNIV FREIBURG,DEPT MED 1,MOLEC MED GRP,D-79106 FREIBURG,GERMANY	Hannover Medical School; University of Freiburg								BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CASH JM, 1993, MAMM GENOME, V4, P37, DOI 10.1007/BF00364661; CORDIER AC, 1980, AM J ANAT, V157, P227, DOI 10.1002/aja.1001570303; HEDRICH HJ, 1990, GENETIC MONITORING I; KOPFMAIER P, 1990, ACTA ANAT, V139, P178; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LI C, 1992, GENOMICS, V13, P658, DOI 10.1016/0888-7543(92)90138-I; LISITSYN AN, 1994, NAT GENET, V6, P57; Lyon M., 1989, GENETIC VARIANTS STR; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEHLS M, 1994, ONCOGENE, V9, P2169; NEHLS M, 1994, EUR J IMMUNOL, V24, P1721, DOI 10.1002/eji.1830240742; PALACIOS R, 1991, EUR J IMMUNOL, V21, P109, DOI 10.1002/eji.1830210117; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKAHASHI Y, 1992, J EXP MED, V175, P873, DOI 10.1084/jem.175.3.873; VANVLIET E, 1985, EUR J IMMUNOL, V15, P675, DOI 10.1002/eji.1830150707; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5	21	537	547	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					103	107		10.1038/372103a0	http://dx.doi.org/10.1038/372103a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969402				2022-12-28	WOS:A1994PQ34800083
J	LOCALIO, AR; HAMORY, BH; SHARP, TJ; WEAVER, SL; TENHAVE, TR; LANDIS, JR				LOCALIO, AR; HAMORY, BH; SHARP, TJ; WEAVER, SL; TENHAVE, TR; LANDIS, JR			COMPARING HOSPITAL MORTALITY IN ADULT PATIENTS WITH PNEUMONIA - A CASE-STUDY OF STATISTICAL-METHODS IN A MANAGED CARE PROGRAM	ANNALS OF INTERNAL MEDICINE			English	Article							MYOCARDIAL-INFARCTION; SEVERITY; SURGERY; RATES; RISK; MEDISGROUPS; INFORMATION; ILLNESS; QUALITY; TRIALS	Objective: To compare and contrast a managed care program's analysis of differences in hospital mortality with results obtained by accepted statistical methods. Design: A re-analysis of computerized discharge data using the same method used by a managed care program, and using conventional methods of categorical data analysis. One thousand computer simulations of a method for comparing hospitals by severity-adjusted mortality were done to determine the probabiiity of falsely identifying hospitals as high-mortality outliers. Setting: 22 acute care hospitals in central Pennsylvania. Patients: All adult patients with pneumonia (n = 4587; diagnosis-related groups 089-090) less than 65 years of age who were discharged from the 22 hospitals in 1989, 1990, and 1991, excluding patients with the acquired immunodeficiency syndrome and transplant recipients. Measurements: In-hospital mortality adjusted for age and severity of illness using MedisGroups admission severity group score. Results: The hospital that had the highest mortality for adult pneumonia according to the managed care program's analysis did not, according to an appropriate analysis, differ significantly from other area hospitals (likelihood ratio test, P = 0.23). Random variation in this sample of patients with a low average mortality rate (3.5%) showed a 60% chance that 1 or more of the 22 hospitals would be falsely identified as a ''high-mortality outlier'' when simplistic statistical methods were used. Conclusion: Organizations seeking to compare the quality of hospitals and physicians through outcome data need to recognize that simplistic methods applicable to large samples fail when applied to the outcomes of typical patients, such as those admitted for pneumonia. Although these comparisons are much in demand, careful attention must be paid to their statistical methods to ensure validity and fairness.			LOCALIO, AR (corresponding author), PENN STATE UNIV, COLL MED, CTR BIOSTAT & EPIDEMIOL, POB 850, HERSHEY, PA 17033 USA.		Landis, J. Richard/A-9330-2010	Ten Have, Thomas/0000-0003-0026-3073; Landis, J Richard/0000-0001-8099-0988				AGRESTI A, 1990, CATEGORICAL DATA ANA, P230; AITKIN M, 1989, STATISTICAL MODELLIN, P213; ALEMI F, 1990, MED CARE, V28, P762, DOI 10.1097/00005650-199009000-00006; ALTMAN LK, 1992, NY TIMES        0114, P63; ANDERS G, 1993, WALL STREET J   0913, V122, pB4; ANDERS G, 1993, WALL STREET J   0913, V122, pB1; ARMITAGE P, 1971, STATISTICAL METHODS, P76; ARMITAGE P, 1971, STATISTICAL METHODS, P111; BLUMBERG MS, 1991, JAMA-J AM MED ASSOC, V265, P2965; BURNS R, 1993, AM J PUBLIC HEALTH, V83, P966, DOI 10.2105/AJPH.83.7.966; COTTON VR, 1993, PULMONARY CRITICAL C, P1; DIEHR P, 1990, AM J PUBLIC HEALTH, V80, P1343, DOI 10.2105/AJPH.80.11.1343; DIEHR P, 1992, MED CARE, V30, P484, DOI 10.1097/00005650-199206000-00003; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; GREENLAND S, 1991, EPIDEMIOLOGY, V2, P387, DOI 10.1097/00001648-199109000-00015; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HANNAN EL, 1992, MED CARE, V30, P892, DOI 10.1097/00005650-199210000-00002; HARTZ AJ, 1992, AM J PUBLIC HEALTH, V82, P1631, DOI 10.2105/AJPH.82.12.1631; Hoaglin D.C., 1983, UNDERSTANDING ROBUST; HORN SD, 1991, MED CARE, V29, P305, DOI 10.1097/00005650-199104000-00001; IEZZONI L, 1991, HLTH CARE QUALITY MA, P177; IEZZONI LI, 1992, MED CARE, V30, P347, DOI 10.1097/00005650-199204000-00005; IEZZONI LI, 1988, JAMA-J AM MED ASSOC, V260, P3159, DOI 10.1001/jama.260.21.3159; IEZZONI LI, 1991, JAMA-J AM MED ASSOC, V265, P3006, DOI 10.1001/jama.265.22.3006; IEZZONI LI, 1991, INQUIRY-J HEALTH CAR, V28, P117; INGLEFINGER JA, 1983, BIOSTATISTICS CLIN M, P168; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; KAHN HA, 1989, STATISTICAL METHODS, P144; Kahneman D., 1982, JUDGMENT UNCERTAINTY, P32; KRAKAUER H, 1991, STAT MED, V10, P521, DOI 10.1002/sim.4780100405; LUFT HS, 1986, JAMA-J AM MED ASSOC, V255, P2780, DOI 10.1001/jama.255.20.2780; MAXWELL SE, 1989, DESIGNING EXPT ANAL, P171; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MEIER B, 1994, NY TIMES        0331, V143, pA1; MEIER B, 1994, NY TIMES        0331, V143, pB8; MOSES LE, 1985, NEW ENGL J MED, V312, P890, DOI 10.1056/NEJM198504043121405; MOSTELLER F, 1977, DATA ANAL REGRESSION, P221; PAULY MV, 1992, BROOK L REV, V58, P35; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; ROSENTHAL E, 1993, NY TIMES        1227, V143, pB5; SMITH DW, 1991, MED CARE, V29, P1108, DOI 10.1097/00005650-199111000-00004; THOMAS DC, 1985, AM J EPIDEMIOL, V122, P1080, DOI 10.1093/oxfordjournals.aje.a114189; TOPOL EJ, 1994, ANN INTERN MED, V120, P65, DOI 10.7326/0003-4819-120-1-199401010-00011; WOOLSEY C, 1992, BUSINESS INSURA 0914, P11; WOOLSEY C, 1992, BUSINESS INSURA 0914, P3; [No title captured]; 1992, CONSUMER GUIDE CORON; 1993, MED UTILIZATION REV, V21, P1; 1992, MEDICARE HOSPITAL IN, pR3; [No title captured]	53	46	46	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					125	132		10.7326/0003-4819-122-2-199501150-00009	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QC059	7992987				2022-12-28	WOS:A1995QC05900009
J	MARIN, ML; VEITH, FJ				MARIN, ML; VEITH, FJ			TRANSFEMORAL REPAIR OF ABDOMINAL AORTIC-ANEURYSM	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											MARIN, ML (corresponding author), MONTEFIORE MED CTR,111 E 210TH ST,BRONX,NY 10467, USA.								0	12	13	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	1994	331	26					1751	1751						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ266	7984196				2022-12-28	WOS:A1994PZ26600005
J	SAUNDERS, NJ				SAUNDERS, NJ			WHY MONITOR PEAK VANCOMYCIN CONCENTRATIONS	LANCET			English	Article							RENAL-FUNCTION; THERAPY	Peak and trough serum concentrations are routinely measured to monitor vancomycin therapy. Optimal therapy depends upon maintaining a concentration above that necessary for antibacterial activity and is therefore determined by the trough concentration. I determined the post dose increases in serum drug concentrations in routine clinical practice in adult patients without renal failure. Mean increases of 16.6 mg/L (SD 6.1) (peak samples collected 1 h post infusion) were measured from 165 paired samples. The results suggest that as long as trough concentrations do not exceed 15 mg/L, peak levels will not exceed normally accepted safe concentrations, and therefore do not need to be measured.			SAUNDERS, NJ (corresponding author), HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT INFECT DIS & BACTERIOL, DU CANE RD, LONDON W12 0NN, ENGLAND.		mouton, johan w/C-5915-2014; Saunders, Nigel J/W-6745-2019	mouton, johan w/0000-0001-6736-4149; Saunders, Nigel/0000-0002-0160-4573				ACKERMAN BH, 1992, ANTIMICROB AGENTS CH, V36, P1766, DOI 10.1128/AAC.36.8.1766; CANTU TG, 1994, CLIN INFECT DIS, V18, P533; EDWARDS DJ, 1987, CLIN PHARMACY, V6, P652; ENG RHK, 1989, CHEMOTHERAPY, V35, P320, DOI 10.1159/000238688; FARBER BF, 1983, ANTIMICROB AGENTS CH, V23, P138, DOI 10.1128/AAC.23.1.138; FREEMAN CD, 1993, ANN PHARMACOTHER, V27, P594; GERACI JE, 1956, P STAFF M MAYO CLIN, V31, P564; GERACI JE, 1958, P STAFF M MAYO CLIN, V33, P172; HOOK EW, 1978, AM J MED, V65, P411, DOI 10.1016/0002-9343(78)90766-0; KIRBY WMM, 1960, NEW ENGL J MED, V262, P49, DOI 10.1056/NEJM196001142620201; MOELLERING RC, 1994, CLIN INFECT DIS, V18, P544, DOI 10.1093/clinids/18.4.544; PEETERMANS WE, 1990, ANTIMICROB AGENTS CH, V34, P1869, DOI 10.1128/AAC.34.10.1869; RODVOLD KA, 1987, CLIN PHARMACY, V6, P655; SORRELL TC, 1982, ANN INTERN MED, V97, P344, DOI 10.7326/0003-4819-97-3-344; TRABER PG, 1981, ANN INTERN MED, V95, P458, DOI 10.7326/0003-4819-95-4-458; VACANI PF, 1993, J CLIN PATHOL, V46, P890, DOI 10.1136/jcp.46.10.890; WAISBREN BA, 1960, ARCH INTERN MED, V106, P179, DOI 10.1001/archinte.1960.03820020019005	17	70	74	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 24	1994	344	8939-4					1748	1750		10.1016/S0140-6736(94)92890-8	http://dx.doi.org/10.1016/S0140-6736(94)92890-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7997005				2022-12-28	WOS:A1994PY28100013
J	STAEHLINGHAMPTON, K; HOFFMANN, FM; BAYLIES, MK; RUSHTON, E; BATE, M				STAEHLINGHAMPTON, K; HOFFMANN, FM; BAYLIES, MK; RUSHTON, E; BATE, M			DPP INDUCES MESODERMAL GENE-EXPRESSION IN DROSOPHILA	NATURE			English	Article							DORSAL VENTRAL AXIS; GERM LAYERS; CELL FATES; ACTIVIN-A; BOX GENES; PATTERN; EMBRYO; INDUCTION; HOMOLOG; MORPHOGENESIS	INDUCTIVE interactions between germ layers are an essential feature of the development of many organisms. In several species these interactions are mediated by members of the transforming growth factor-beta (TGF beta) family(1,2). In amphibians, different concentrations of activin can induce different types of mesoderm in the animal cap assay(3-5). In Drosophila, a member of the TGF beta family, decapentaplegic (dpp)(6,7), acts as an inductive signal. Midway through embryogenesis, dpp is expressed in the visceral mesoderm, and enhances the expression of the homeotic gene labial in the underlying midgut endoderm(8,9). Earlier in development, however, dpp expression is limited to the dorsal ectoderm(10). At this stage in development, thickveins, a dpp receptor(11-13), is expressed in the mesoderm(12,13), and this suggests that ectodermal dpp might not only be required for development of dorsal ectoderm(14,15), but could also act inductively to mediate pattern formation in the underlying mesoderm. Here we show, by expressing dpp ectopically in the ectoderm and mesoderm and by examining dpp null mutant embryos, that dpp regulates expression of mesodermal genes.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND	University of Cambridge	STAEHLINGHAMPTON, K (corresponding author), UNIV WISCONSIN,MCARDLE LAB CANC RES,1400 UNIV AVE,MADISON,WI 53706, USA.			Hoffmann, F. Michael/0000-0002-2770-9656	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BATE M, 1993, CR ACAD SCI III-VIE, V316, P1055; BEER J, 1987, ROUX ARCH DEV BIOL, V196, P222, DOI 10.1007/BF00376346; BODMER R, 1990, DEVELOPMENT, V110, P661; BODMER R, 1993, DEVELOPMENT, V118, P719; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CASTELLIGAIR J, 1994, DEVELOPMENT, V120, P1983; GOMEZ MR, 1993, EMBO J, V12, P1121; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; MICHELSON AM, 1994, DEVELOPMENT, V120, P755; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; RAY RP, 1991, DEVELOPMENT, V113, P35; Seidel F, 1940, NATURWISSENSCHAFTEN, V28, P433, DOI 10.1007/BF01557878; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STAEHLINGHAMPTON K, 1994, DEV BIOL, V164, P502, DOI 10.1006/dbio.1994.1219; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; WHARTON KA, 1993, DEVELOPMENT, V117, P807	29	174	176	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					783	786						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997266				2022-12-28	WOS:A1994PY21200054
J	WAGNER, T; WIRTH, J; MEYER, J; ZABEL, B; HELD, M; ZIMMER, J; PASANTES, J; BRICARELLI, FD; KEUTEL, J; HUSTERT, E; WOLF, U; TOMMERUP, N; SCHEMPP, W; SCHERER, G				WAGNER, T; WIRTH, J; MEYER, J; ZABEL, B; HELD, M; ZIMMER, J; PASANTES, J; BRICARELLI, FD; KEUTEL, J; HUSTERT, E; WOLF, U; TOMMERUP, N; SCHEMPP, W; SCHERER, G			AUTOSOMAL SEX REVERSAL AND CAMPOMELIC DYSPLASIA ARE CAUSED BY MUTATIONS IN AND AROUND THE SRY-RELATED GENE SOX9	CELL			English	Article							TESTIS-DETERMINING REGION; TRANSCRIPTIONAL ACTIVATOR; XY FEMALES; HMG BOX; DELETION; PROTEIN; HYBRIDIZATION; DIFFERENTIATION; EXPRESSION; SEQUENCES	A human autosomal XY sex reversal locus, SRA1, associated with the skeletal malformation syndrome campomelic dysplasia (CMPD1), has been placed at distal 17q, The SOX9 gene, a positional candidate from the chromosomal location and expression pattern reported for mouse Sox9, was isolated and characterized, SOX9 encodes a putative transcription factor structurally related to the testis-determining factor SRY and is expressed in many adult tissues, and in fetal testis and skeletal tissue, Inactivating mutations on one SOX9 allele identified in nontranslocation CMPD1-SRA1 cases point to haploinsufficiency far SOX9 as the cause for both campomelic dysplasia and autosomal XY sex reversal. The 17q breakpoints in three CMPD1 translocation cases map 50 kb or more from SOX9.	UNIV MAINZ,DEPT PEDIAT,D-55101 MAINZ,GERMANY; UNIV VIGO,DEPT BIOLOXIA FUNDAMENTAL,XENET LAB,E-36200 VIGO,SPAIN; ENTE OSPEDALIERO OSPED GALLIERA,I-16128 GENOA,ITALY; KINDERKLIN,D-28277 BREMEN,GERMANY; GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT,INST SAUGETIERGENET,D-85764 OBERSCHLEISSHEIM,GERMANY; JOHN F KENNEDY INST,DANISH CTR HUMAN GENOME RES,DK-2600 GLOSTRUP,DENMARK; ULLEVAL UNIV HOSP,DEPT MED GENET,N-0407 OSLO,NORWAY	Johannes Gutenberg University of Mainz; Universidade de Vigo; Ente Ospedaliero Ospedali Galliera; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Aarhus University; University of Oslo	WAGNER, T (corresponding author), UNIV FREIBURG,INST HUMAN GENET,HUGSTETTER STR 55,D-79106 FREIBURG,GERMANY.		Tommerup, Niels/T-8776-2017; Wirth, Judith/J-4992-2019; Wirth, Jutta/H-1302-2011	Tommerup, Niels/0000-0003-2304-0112; Wirth, Jutta/0000-0001-6530-3991; Pasantes, Juan J/0000-0001-6515-3946				BALLABIO A, 1993, NAT GENET, V3, P277, DOI 10.1038/ng0493-277; BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; BENNETT CP, 1993, J MED GENET, V30, P518, DOI 10.1136/jmg.30.6.518; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; BRICARELLI FD, 1981, HUM GENET, V57, P15; CAPEL B, 1993, NAT GENET, V5, P301, DOI 10.1038/ng1193-301; CLEPET C, 1993, HUM MOL GENET, V2, P2007, DOI 10.1093/hmg/2.12.2007; COHEN DR, 1994, P NATL ACAD SCI USA, V91, P4372, DOI 10.1073/pnas.91.10.4372; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; EBENSPERGER C, 1991, ANN GENET-PARIS, V34, P233; Eiken Hans Geir, 1992, Human Mutation, V1, P388, DOI 10.1002/humu.1380010507; FISHER E, 1994, NAT GENET, V7, P5, DOI 10.1038/ng0594-5; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; HOUSTON CS, 1983, AM J MED GENET, V15, P3, DOI 10.1002/ajmg.1320150103; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAWCZAK M, 1992, HUM GENET, V90, P41; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LYNCH SA, 1993, J MED GENET, V30, P683, DOI 10.1136/jmg.30.8.683; MARAIA R, 1991, CLIN GENET, V39, P401; MCCONLOGUE L, 1988, NUCLEIC ACIDS RES, V16, P9869, DOI 10.1093/nar/16.20.9869; MCELREAVY K, 1992, P NATL ACAD SCI USA, V89, P11016, DOI 10.1073/pnas.89.22.11016; MCKUSICK VA, 1992, CATALOGS AUTOSOMAL D, P1262; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MUNDLOS S, 1991, MATRIX, V11, P339, DOI 10.1016/S0934-8832(11)80205-2; RIED T, 1992, GENE CHROMOSOME CANC, V4, P69, DOI 10.1002/gcc.2870040109; SCHAFER R, 1988, ELECTROPHORESIS, V9, P369, DOI 10.1002/elps.1150090804; SCHILHAM MW, 1993, NUCLEIC ACIDS RES, V21, P20098; SIMPSON JL, 1981, HUM GENET, V58, P91; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STEVANOVIC M, 1993, HUM MOL GENET, V2, P2013, DOI 10.1093/hmg/2.12.2013; THURMON TF, 1973, J PEDIATR-US, V83, P841, DOI 10.1016/S0022-3476(73)80384-1; TOMMERUP N, 1993, NAT GENET, V4, P170, DOI 10.1038/ng0693-170; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; WILKIE AOM, 1993, AM J MED GENET, V46, P597, DOI 10.1002/ajmg.1320460527; WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744; YOUNG ID, 1992, J MED GENET, V29, P251, DOI 10.1136/jmg.29.4.251	43	1205	1246	2	51	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					1111	1120		10.1016/0092-8674(94)90041-8	http://dx.doi.org/10.1016/0092-8674(94)90041-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001137				2022-12-28	WOS:A1994PY08600020
J	REDEKER, V; LEVILLIERS, N; SCHMITTER, JM; LECAER, JP; ROSSIER, J; ADOUTTE, A; BRE, MH				REDEKER, V; LEVILLIERS, N; SCHMITTER, JM; LECAER, JP; ROSSIER, J; ADOUTTE, A; BRE, MH			POLYGLYCYLATION OF TUBULIN - A POSTTRANSLATIONAL MODIFICATION IN AXONEMAL MICROTUBULES	SCIENCE			English	Article							ALPHA-TUBULIN; BETA-TUBULIN; TERMINAL DOMAIN; CELLS; PARAMECIUM; BRAIN; DETYROSINATION; NUCLEATION; SUBTILISIN; PROTEINS	A posttranslational modification was detected in the carboxyl-terminal region of axonemal tubulin from Paramecium. Tubulin carboxyl-terminal peptides were isolated and analyzed by Edman degradation sequencing, mass spectrometry, and amino acid analysis. All of the peptides, derived from both alpha and beta tubulin subunits, were modified by polyglycylation, containing up to 34 glycyl units covalently bound to the gamma carboxyl group of glutamyl residues. This modification, present in one of the most stable microtubular systems, may influence microtubule stability or axoneme function, or both.	INST ALFRED FESSARD,CNRS,UNITE PROPRE RECH 2212,F-91198 GIF SUR YVETTE,FRANCE; UNIV PARIS 11,BIOL CELLULAIRE LAB 4,CNRS,URA 1134,F-91405 ORSAY,FRANCE; ECOLE POLYTECH,BIOCHIM LAB,CNRS,URA 240,F-91128 PALAISEAU,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)			Redeker, Virginie/L-8929-2018	Redeker, Virginie/0000-0003-2694-8388				ADOUTTE A, 1991, BIOL CELL, V71, P227, DOI 10.1016/0248-4900(91)90069-Y; ADOUTTE A, 1980, J CELL BIOL, V84, P717, DOI 10.1083/jcb.84.3.717; ADOUTTE A, 1985, J MOL EVOL, V22, P220, DOI 10.1007/BF02099751; ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; BRE MH, 1987, J CELL BIOL, V105, P1283, DOI 10.1083/jcb.105.3.1283; BRE MH, 1994, CELL MOTIL CYTOSKEL, V27, P327; BULINSKI JC, 1988, J CELL BIOL, V106, P1213, DOI 10.1083/jcb.106.4.1213; CALLEN AM, IN PRESS BIOL CELL; CANAS B, 1993, ANAL BIOCHEM, V211, P179, DOI 10.1006/abio.1993.1253; Dentler W.L., 1990, P31; DUPUIS P, 1992, EMBO J, V11, P3713, DOI 10.1002/j.1460-2075.1992.tb05456.x; DUPUIS P, 1992, THESIS U PARIS 11; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; FACKENTHAL JD, 1993, DEV BIOL, V158, P213, DOI 10.1006/dbio.1993.1180; Fleury A., UNPUB; GEUENS G, 1989, J CELL BIOL, V108, P939, DOI 10.1083/jcb.108.3.939; GEUSS U, 1990, Journal of Protein Chemistry, V9, P299; GREER K, 1989, CELL MOVEMENT, V2, P47; HAGIWARA H, 1994, J BIOL CHEM, V269, P3581; Johnson Karl A., 1993, Trends in Cell Biology, V3, P156, DOI 10.1016/0962-8924(93)90136-O; KHAWAJA S, 1988, J CELL BIOL, V106, P2167; LEDIZET M, 1987, P NATL ACAD SCI USA, V84, P5720, DOI 10.1073/pnas.84.16.5720; LEVILLIERS N, UNPUB; MARY J, 1994, FEBS LETT, V353, P89, DOI 10.1016/0014-5793(94)01018-8; MATSUBARA H, 1970, METHOD ENZYMOL, V19, P642; MEJILLANO MR, 1991, J BIOL CHEM, V266, P657; MELKI R, 1991, BIOCHEMISTRY-US, V30, P11536, DOI 10.1021/bi00113a008; PATURLELAFANECHERE L, 1991, BIOCHEMISTRY-US, V30, P10523, DOI 10.1021/bi00107a022; PIPERNO G, 1977, P NATL ACAD SCI USA, V74, P1600, DOI 10.1073/pnas.74.4.1600; RAYBIN D, 1977, J CELL BIOL, V73, P492, DOI 10.1083/jcb.73.2.492; REDEKER V, 1991, J BIOL CHEM, V266, P23461; REDEKER V, 1992, FEBS LETT, V313, P185, DOI 10.1016/0014-5793(92)81441-N; RUDIGER M, 1993, EUR J BIOCHEM, V218, P107, DOI 10.1111/j.1432-1033.1993.tb18357.x; RUDIGER M, 1992, FEBS LETT, V308, P101, DOI 10.1016/0014-5793(92)81061-P; SACKETT DL, 1989, BIOCHEMISTRY-US, V28, P2662, DOI 10.1021/bi00432a045; SCHULZE E, 1987, J CELL BIOL, V105, P1020; SERRANO L, 1984, P NATL ACAD SCI-BIOL, V81, P5989, DOI 10.1073/pnas.81.19.5989; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; WEHLAND J, 1987, J CELL SCI, V88, P185	39	220	229	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1688	1691		10.1126/science.7992051	http://dx.doi.org/10.1126/science.7992051			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992051				2022-12-28	WOS:A1994PW30800035
J	BENEDETTI, J; COREY, L; ASHLEY, R				BENEDETTI, J; COREY, L; ASHLEY, R			RECURRENCE RATES IN GENITAL HERPES AFTER SYMPTOMATIC FIRST-EPISODE INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						CARDIAC PACING, ARTIFICIAL; PACEMAKER, ARTIFICIAL; SENSORS, ARTIFICIAL; HEART RATE; ARRHYTHMIA	SIMPLEX VIRUS-INFECTION; CANADIAN MULTICENTER TRIAL; ORAL ACYCLOVIR; DOUBLE-BLIND; INTRAVENOUS ACYCLOVIR; TYPE-2 INFECTION; TRANSMISSION; SUPPRESSION; ANTIBODIES; THERAPY	Objective: To evaluate the frequency of reactivation of genital herpes infection and to identify predictors for recurrence. Design: Prospective, observational cohort study. Setting: Research clinic. Patients: 457 consecutive patients who did not have acute-phase serum antibodies to herpes simplex virus type 2 (HSV-2) but who did have herpes simplex vines (HSV) isolated from genital lesions. Results: Eighty-nine percent of patients with HSV-2 had at least one recurrence during follow-up (median, 391 days); the median monthly recurrence rate was 0.34. Thirty-eight percent had at least 6 recurrences during the first year and 20% had more than 10 recurrences. The median monthly recurrence rate was 0.43 for men and 0.33 for women (difference, 0.10 [95% CI, 0.03 to 0.19]; P < 0.01). Twenty-six percent of women and 8% of men had no or 1 recurrence in year 1 of follow-up, whereas 14% of women and 26% of men had more than 10 recurrences. Patients who had severe primary HSV-2 infection (duration, greater than or equal to 35 days) had recurrences nearly twice as often (0.66 compared with 0.36 recurrences per month [95% CI, 0.18 to 0.57]) and had a shorter time to first recurrence when compared with those who had shorter first episodes. Conclusions: Almost all persons with initially symptomatic HSV-2 infection have symptomatic recurrences. More than 35% of such patients have frequent recurrences. Recurrence rates are especially high in persons with an extended first episode of infection, regardless of whether they receive antiviral chemotherapy with acyclovir. Men with genital HSV-2 infection have about 20% more recurrences than do women, a factor that may contribute to the higher rate of HSV-2 transmission from men to women than from women to men and to the continuing epidemic of genital herpes in the United States.	UNIV WASHINGTON, DIV VIROL, SEATTLE, WA 98144 USA	University of Washington; University of Washington Seattle			Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030619, P01AI030731] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-30731, AI-30619] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY R, 1991, ANN INTERN MED, V115, P520, DOI 10.7326/0003-4819-115-7-520; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; ASHLEY RL, 1993, SEX TRANSM DIS, V20, P230, DOI 10.1097/00007435-199307000-00009; BERNSTEIN DI, 1984, AM J MED, V77, P1055, DOI 10.1016/0002-9343(84)90188-8; BOUCHER FD, 1990, PEDIATR INFECT DIS J, V9, P499, DOI 10.1097/00006454-199007000-00009; Breiman L., 1984, CLASSIFICATION REGRE; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; BRYSON YJ, 1983, NEW ENGL J MED, V308, P916, DOI 10.1056/NEJM198304213081602; BURKE RL, 1991, VIROLOGY, V181, P793; CHRISTENSON B, 1992, J INFECTION, V25, P147, DOI 10.1016/0163-4453(92)93943-K; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; COREY L, 1978, NEW ENGL J MED, V299, P986, DOI 10.1056/NEJM197811022991805; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; COREY L, 1983, ANN INTERN MED, V98, P973, DOI 10.7326/0003-4819-98-6-973; COREY L, 1983, ANN INTERN MED, V98, P914, DOI 10.7326/0003-4819-98-6-914; COREY L, 1982, NEW ENGL J MED, V306, P1313, DOI 10.1056/NEJM198206033062201; COX DR, 1972, J R STAT SOC B, V34, P187; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1551, DOI 10.1056/NEJM198406143102402; FRENKEL LM, 1993, ANN INTERN MED, V118, P414, DOI 10.7326/0003-4819-118-6-199303150-00003; JOHNSON R, 1993, US GENITAL HERPES TR; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; LAFFERTY WE, 1984, ANTIMICROB AGENTS CH, V26, P887, DOI 10.1128/AAC.26.6.887; LAFFERTY WE, 1987, NEW ENGL J MED, V316, P1444, DOI 10.1056/NEJM198706043162304; LEBLANC M, 1992, BIOMETRICS, V48, P411, DOI 10.2307/2532300; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1984, JAMA-J AM MED ASSOC, V252, P1147, DOI 10.1001/jama.252.9.1147; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MINDEL A, 1987, LANCET, V1, P1171; MINDEL A, 1982, LANCET, V1, P697; NAHMIAS AJ, 1990, SCAND J INFECT DIS, P19; NILSEN AE, 1982, LANCET, V2, P571; SACKS SL, 1991, J INFECT DIS, V164, P665, DOI 10.1093/infdis/164.4.665; SACKS SL, 1987, J INFECT DIS, V155, P178, DOI 10.1093/infdis/155.2.178; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401	35	306	313	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					847	854		10.7326/0003-4819-121-11-199412010-00004	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7978697				2022-12-28	WOS:A1994PT62800004
J	MAROTTOLI, RA; COONEY, LM; WAGNER, DR; DOUCETTE, J; TINETTI, ME				MAROTTOLI, RA; COONEY, LM; WAGNER, DR; DOUCETTE, J; TINETTI, ME			PREDICTORS OF AUTOMOBILE CRASHES AND MOVING VIOLATIONS AMONG ELDERLY DRIVERS	ANNALS OF INTERNAL MEDICINE			English	Article						AGE FACTORS; ACCIDENTS, TRAFFIC; COPYING PROCESSES; WALKING; FOOT ABNORMALITIES, ACQUIRED	DRIVING PERFORMANCE; NORTHEASTERN OHIO; ALZHEIMER-TYPE; OLDER DRIVERS; AGE; ACCIDENTS; DEMENTIA; MOBILITY; TRAUMA; RISK	Objective: To identify the factors associated with automobile crashes, moving violations, and being stopped by police in a cohort of elderly drivers. Design: Prospective cohort study. Setting: Urban community. Participants: All 283 persons who drove between 1990 and 1991, selected from a representative cohort of community-living persons aged 72 years and older in New Haven, Connecticut. Measurements: Data on independent variables in five domains (demographic, health, psychosocial, activity, and physical performance) were collected in structured interviews before events occurred. The outcome measure was the self-report of involvement in automobile crashes, moving violations, or being stopped by police in a 1-year period. Results: Of the 283 drivers, 13% reported a crash, a moving violation, or being stopped by police in 1 year. The baseline factors associated with the occurrence of adverse events in multivariable analysis (with adjustment for driving frequency and housing type) were the following: poor design copying on the Mini-Mental State Examination (relative risk, 2.7; 95% CI, 1.5 to 5.0), fewer blocks walked (relative risk, 2.3; CI, 1.3 to 4.0), and more foot abnormalities (relative risk, 1.9; CI, 1.1 to 3.3). These risk factors were combined for assessment of their ability to predict the occurrence of adverse driving events. If no factors were present, 6% of drivers had events; if 1 factor was present, 12% had events; if 2 factors were present, 26% had events; and if 3 factors were present, 47% had events. Conclusions: In this urban population, several simple clinical measures correlated with the risk for adverse driving events.	VET AFFAIRS MED CTR, NEW HAVEN, CT USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	MAROTTOLI, RA (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, POB 208025, 333 CEDAR ST, NEW HAVEN, CT 06520 USA.				NIA NIH HHS [AG 07449] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007449] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARANCIK JI, 1986, AM J EPIDEMIOL, V123, P846, DOI 10.1093/oxfordjournals.aje.a114314; BERKMAN LF, 1986, AM J EPIDEMIOL, V124, P372, DOI 10.1093/oxfordjournals.aje.a114408; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; BURG A, 1971, HUM FACTORS, V13, P79, DOI 10.1177/001872087101300110; CERRELLI E, 1989, DOT HS807402 NAT HIG; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; CRANCER A, 1968, J AMER MED ASSOC, V205, P272, DOI 10.1001/jama.1968.03140310030006; Crancer A Jr, 1970, Northwest Med, V69, P409; DAVISON PA, 1985, OPHTHAL PHYSL OPT, V5, P195, DOI 10.1111/j.1475-1313.1985.tb00656.x; DIPIETRO L, 1993, MED SCI SPORT EXER, V25, P628; DOEGE TC, 1986, MED CONDITIONS AFFEC; EVANS L, 1988, J TRAUMA, V28, P368, DOI 10.1097/00005373-198803000-00013; EVANS L, 1988, J GERONTOL, V43, pS186, DOI 10.1093/geronj/43.6.S186; FIFE D, 1984, AM J PUBLIC HEALTH, V74, P473, DOI 10.2105/AJPH.74.5.473; FILLENBAUM GG, 1981, J GERONTOL, V36, P428, DOI 10.1093/geronj/36.4.428; Fleiss JL, 1981, STAT METHODS RATES P; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRIEDLAND RP, 1988, ANN NEUROL, V24, P782, DOI 10.1002/ana.410240613; HANSOTIA P, 1991, NEW ENGL J MED, V324, P22, DOI 10.1056/NEJM199101033240105; Henkind P, 1983, COMPENDIUM OPHTHALMO; HOPPENFELD S, 1976, PHYSICAL EXAMINATION; HUNT L, 1993, J AM GERIATR SOC, V41, P747, DOI 10.1111/j.1532-5415.1993.tb07465.x; JOHNSON CA, 1983, ARCH OPHTHALMOL-CHIC, V101, P371; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; KELTNER JL, 1987, OPHTHALMOLOGY, V94, P1180; KLEIN R, 1991, HUM FACTORS, V33, P521, DOI 10.1177/001872089103300504; LEGHSMITH J, 1986, J ROY SOC MED, V79, P200, DOI 10.1177/014107688607900404; LIDDELL FDK, 1982, J EPIDEMIOL COMMUN H, V36, P140, DOI 10.1136/jech.36.2.140; LUCASBLAUSTEIN MJ, 1988, J AM GERIATR SOC, V36, P1087, DOI 10.1111/j.1532-5415.1988.tb04394.x; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; MCCOY GF, 1989, J TRAUMA, V29, P494, DOI 10.1097/00005373-198904000-00013; MCFARLAND RA, 1964, J GERONTOL, V19, P190, DOI 10.1093/geronj/19.2.190; MCGUIRE FL, 1973, J APPL PSYCHOL, V57, P300, DOI 10.1037/h0034728; McLay P, 1989, Int Disabil Stud, V11, P50; OWSLEY C, 1991, PSYCHOL AGING, V6, P403, DOI 10.1037/0882-7974.6.3.403; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RAFFLE AB, 1976, MED ASPECTS FITNESS; RETCHIN SM, 1988, J AM GERIATR SOC, V36, P813, DOI 10.1111/j.1532-5415.1988.tb04265.x; SHINAR D, 1991, HUM FACTORS, V33, P507, DOI 10.1177/001872089103300503; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; TINETTI ME, 1988, JAMA-J AM MED ASSOC, V259, P1190, DOI 10.1001/jama.259.8.1190; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x; WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174, DOI 10.1093/oxfordjournals.aje.a114212; WALLER JA, 1965, NEW ENGL J MED, V273, P1413, DOI 10.1056/NEJM196512232732605; WALLER JA, 1967, J CHRON DIS, V20, P615, DOI 10.1016/0021-9681(67)90038-0; WILLIAMS AF, 1989, AM J PUBLIC HEALTH, V79, P326, DOI 10.2105/AJPH.79.3.326; Wilson T, 1983, Int Rehabil Med, V5, P170; 1991, PHYSICIANS GUIDE DRI	48	178	178	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					842	846		10.7326/0003-4819-121-11-199412010-00003	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7978696				2022-12-28	WOS:A1994PT62800003
J	PLATT, OS; BRAMBILLA, DJ; ROSSE, WF; MILNER, PF; CASTRO, O; STEINBERG, MH; KLUG, PP				PLATT, OS; BRAMBILLA, DJ; ROSSE, WF; MILNER, PF; CASTRO, O; STEINBERG, MH; KLUG, PP			MORTALITY IN SICKLE-CELL DISEASE - LIFE EXPECTANCY AND RISK-FACTORS FOR EARLY DEATH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-GLOBIN GENE; FAT-EMBOLISM; PAIN CRISIS; CHILDREN; THALASSEMIA; ANEMIA	Background. Information on life expectancy and risk factors for early death among patients with sickle cell disease (sickle cell anemia, sickle cell-hemoglobin C disease, and the sickle cell-P-thalassemias) is needed to counsel patients, target therapy, and design clinical trials. Methods. We followed 3764 patients who ranged from birth to 66 years of age at enrollment to determine the life expectancy and calculate the median age at death. In addition, we investigated the circumstances of death for all 209 adult patients who died during the study, and used proportional-hazards regression analysis to identify risk factors for early death among 964 adults with sickle cell anemia who were followed for at least two years. Results. Among children and adults with sickle cell anemia (homozygous for sickle hemoglobin), the median age at death was 42 years for males and 48 years for females. Among those with sickle cell-hemoglobin C disease, the median age at death was 60 years for males and 68 years for females. Among adults with sickle cell disease, 18 percent of the deaths occurred in patients with overt organ failure, predominantly renal. Thirty-three percent were clinically free of organ failure but died during an acute sickle crisis (78 percent had pain, the chest syndrome, or both; 22 percent had stroke). Modeling revealed that in patients with sickle cell anemia, the acute chest syndrome, renal failure, seizures, a base-line white-cell count above 15,000 cells per cubic millimeter, and a low level of fetal hemoglobin were associated with an increased risk of early death. Conclusions. Fifty percent of patients with sickle cell anemia survived beyond the fifth decade. A large proportion of those who died had no overt chronic organ failure but died during an acute episode of pain, chest syndrome, or stroke. Early mortality was highest among patients whose disease was symptomatic. A high level of fetal hemoglobin predicted improved survival and is probably a reliable childhood forecaster of adult life expectancy.	CHILDRENS HOSP,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; NEW ENGLAND RES INST,WATERTOWN,MA; DUKE UNIV,SCH MED,DEPT MED,DURHAM,NC 27706; MED COLL GEORGIA,DEPT MED,AUGUSTA,GA 30912; HOWARD UNIV,CTR SICKLE CELL DIS,DEPT MED,WASHINGTON,DC; DEPT VET AFFAIRS MED CTR,HEMATOL ONCOL SECT,JACKSON,MS; UNIV MISSISSIPPI,SCH MED,DEPT MED,JACKSON,MS; TEXAS TECH UNIV,HLTH SCI CTR,DIV HEMATOL,AMARILLO,TX	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; HealthCore, Inc; Duke University; University System of Georgia; Augusta University; Howard University; University of Mississippi; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo				Brambilla, Donald/0000-0002-7276-4689; Steinberg, Martin/0000-0001-8800-8020				CHARACHE S, 1967, ANN INTERN MED, V67, P1195, DOI 10.7326/0003-4819-67-6-1195; CNAAN A, 1989, STAT MED, V8, P1255, DOI 10.1002/sim.4780081009; COLE TB, 1986, AM J DIS CHILD, V140, P1255, DOI 10.1001/archpedi.1986.02140260057025; DACIE J, 1960, HAEMOLYTIC ANAEMIA 1; DELABRY LO, 1990, J CLIN EPIDEMIOL, V43, P153, DOI 10.1016/0895-4356(90)90178-R; Diggs LMAH., 1973, SICKLE CELL DIS DIAG; DIXON WJ, 1992, BMDP STATISTICAL SOF, V2; DOZY AM, 1979, NATURE, V280, P605, DOI 10.1038/280605a0; EMBURY SH, 1980, J CLIN INVEST, V66, P1319, DOI 10.1172/JCI109984; GASTON M, 1982, AM J PEDIAT HEMATOL, V4, P197; HAUPT HM, 1982, CHEST, V81, P332, DOI 10.1378/chest.81.3.332; HUTCHINSON RM, 1973, J CLIN PATHOL, V26, P620, DOI 10.1136/jcp.26.8.620; LEIKIN SL, 1989, PEDIATRICS, V84, P500; ODENHEIMER DJ, 1984, AM J MED GENET, V18, P461, DOI 10.1002/ajmg.1320180316; PARFREY NA, 1985, AM J CLIN PATHOL, V84, P209, DOI 10.1093/ajcp/84.2.209; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; POWARS D, 1990, SEMIN HEMATOL, V27, P360; SHAPIRO MP, 1984, ARCH INTERN MED, V144, P181, DOI 10.1001/archinte.144.1.181; STEINBERG MH, 1984, BLOOD, V63, P1353; THOMAS AN, 1982, BRIT MED J, V285, P633, DOI 10.1136/bmj.285.6342.633; 1988, DHHS PHS881101 PUBL	21	2191	2252	4	201	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 9	1994	330	23					1639	1644		10.1056/NEJM199406093302303	http://dx.doi.org/10.1056/NEJM199406093302303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP220	7993409				2022-12-28	WOS:A1994NP22000003
J	SOX, HC				SOX, HC			PREVENTIVE HEALTH-SERVICES IN ADULTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BREAST-CANCER DETECTION; FECAL OCCULT BLOOD; PROSTATE-SPECIFIC ANTIGEN; COLORECTAL-CANCER; DEATH RATES; MORTALITY; WOMEN; CARCINOMA; PROJECT; DISEASE				SOX, HC (corresponding author), DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT MED, LEBANON, NH 03756 USA.							AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], COMMON SCREENING TES; [Anonymous], 1989, GUIDE CLIN PREVENTIV; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; BRAWER MK, 1990, UROL CLIN N AM, V17, P759; BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CATALONA WJ, 1991, NEW ENGL J MED, V325, P1324; DIETRICH AJ, 1992, BRIT MED J, V304, P687, DOI 10.1136/bmj.304.6828.687; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; GOLDBLOOM R, 1991, CAN MED ASSOC J, V144, P425; GOLDBLOOM R, 1988, CAN MED ASSOC J, V138, P618; GOLDBLOOM R, 1992, CAN MED ASSOC J, V147, P867; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; GRAVERSEN PH, 1990, UROLOGY, V36, P493, DOI 10.1016/0090-4295(90)80184-O; HAYWARD RS, 1991, ANN INTERN MED, V115, P332; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; HULLEY SB, 1993, JAMA-J AM MED ASSOC, V269, P1416, DOI 10.1001/jama.269.11.1416; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; LOGAN AG, 1993, CAN MED ASSOC J, V148, P521; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MANDEL JS, 1993, NEW ENGL J MED, V329, P672; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MILLER AB, 1993, CAN MED ASSOC J, V148, P718; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; OMALLEY MS, 1990, PREVENTING DISEASE R, P251; RANSOHOFF DF, 1993, JAMA-J AM MED ASSOC, V269, P1278, DOI 10.1001/jama.269.10.1278; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SELBY JV, 1993, ANN INTERN MED, V118, P1, DOI 10.7326/0003-4819-118-1-199301010-00001; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SMITH GD, 1993, BRIT MED J, V306, P1648; IN PRESS AM J PREV H; 1991, CAN MED ASSOC J, V145, P1091; 1991, CAN MED ASSOC J, V145, P413	42	85	85	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	1994	330	22					1589	1595		10.1056/NEJM199406023302208	http://dx.doi.org/10.1056/NEJM199406023302208			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN215	7993408				2022-12-28	WOS:A1994NN21500008
J	ADAMS, WJ; MORRIS, DL				ADAMS, WJ; MORRIS, DL			SHORT-COURSE CIMETIDINE AND SURVIVAL WITH COLORECTAL-CANCER	LANCET			English	Letter											ADAMS, WJ (corresponding author), UNIV NEW S WALES,ST GEORGE HOSP,DEPT SURG,KOGARTH,NSW 2217,AUSTRALIA.							ADAMS WJ, 1994, AUST NZ J SURG, V64, P847, DOI 10.1111/j.1445-2197.1994.tb04562.x; ADAMS WJ, 1994, GUT, V35, P1632, DOI 10.1136/gut.35.11.1632; JASS JR, 1987, LANCET, V1, P1303; KUMAR A, 1990, DICP ANN PHARMAC, V24, P289, DOI 10.1177/106002809002400316; TONNESEN H, 1988, LANCET, V2, P990	5	78	82	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1768	1769		10.1016/S0140-6736(94)92907-6	http://dx.doi.org/10.1016/S0140-6736(94)92907-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7997018				2022-12-28	WOS:A1994PY28100036
J	KIM, JS; URBAN, RG; STROMINGER, JL; WILEY, DC				KIM, JS; URBAN, RG; STROMINGER, JL; WILEY, DC			TOXIC SHOCK SYNDROME TOXIN-1 COMPLEXED WITH A CLASS-II MAJOR HISTOCOMPATIBILITY MOLECULE HLA-DR1	SCIENCE			English	Article							STAPHYLOCOCCAL ENTEROTOXIN-B; HIGH-AFFINITY BINDING; RECEPTOR BETA-CHAIN; HLA-DR; T-CELLS; MACROMOLECULAR CRYSTALLOGRAPHY; PROTEIN STRUCTURES; SUPERANTIGEN; ANTIGEN; IDENTIFICATION	The three-dimensional structure of a Staphylococcus aureus superantigen, toxic shock syndrome toxin-1 (TSST-1), complexed with a human class II major histocompatibility molecule (DR1), was determined by x-ray crystallography. The TSST-1 binding site on DR1 overlaps that of the superantigen S. aureus enterotoxin B (SEB), but the two binding modes differ. Whereas SEB binds primarily off one edge of the peptide binding site of DR1, TSST-1 extends over almost one-half of the binding site and contacts both the flanking alpha helices of the histocompatibility antigen and the bound peptide. This difference suggests that the T cell receptor (TCR) would bind to TSST-1:DR1 very differently than to DR1:peptide or SEB:DR1. It also suggests that TSST-1 binding may be dependent on the peptide, though less so than TCR binding, providing a possible explanation for the inability of TSST-1 to competitively block SEB binding to all DR1 molecules on cells (even though the binding sites of TSST-1 and SEB on DR1 overlap almost completely) and suggesting the possibility that T cell activation by superantigen could be directed by peptide antigen.	CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; CHILDRENS HOSP, MOLEC MED LAB, BOSTON, MA 02115 USA; HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University								ACHARYA KR, 1994, NATURE, V367, P94, DOI 10.1038/367094a0; BETHGE PH, 1984, J APPL CRYSTALLOGR, V17, P215, DOI 10.1107/S0021889884011365; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLANCO L, 1990, INFECT IMMUN, V58, P3020, DOI 10.1128/IAI.58.9.3020-3028.1990; BONVENTRE PF, 1993, INFECT IMMUN, V61, P793, DOI 10.1128/IAI.61.3.793-799.1993; BRAUNSTEIN NS, 1992, J EXP MED, V175, P1301, DOI 10.1084/jem.175.5.1301; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CHINTAGUMPALA MM, 1991, J IMMUNOL, V147, P3876; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CHOI YW, 1990, NATURE, V346, P471, DOI 10.1038/346471a0; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; EDWIN C, 1991, J INFECT DIS, V163, P524, DOI 10.1093/infdis/163.3.524; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; FLEISCHER B, 1991, EUR J IMMUNOL, V21, P1331, DOI 10.1002/eji.1830210537; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GORGA JC, 1987, J BIOL CHEM, V262, P16087; HUDSON KR, COMMUNICATION; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KARP DR, 1990, NATURE, V346, P474, DOI 10.1038/346474a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MURRAY DL, 1993, 93RD GEN M AM SOC MI, V64; PANINABORDIGNON P, 1992, J EXP MED, V176, P1779, DOI 10.1084/jem.176.6.1779; PRASAD GS, 1993, BIOCHEMISTRY-US, V32, P13762, DOI 10.1021/bi00213a001; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1991, J EXP MED, V173, P1183, DOI 10.1084/jem.173.5.1183; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHOLL PR, 1989, J IMMUNOL, V143, P2583; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; SOOS JM, 1993, BIOCHEM BIOPH RES CO, V191, P1211, DOI 10.1006/bbrc.1993.1346; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; THIBODEAU J, 1994, SCIENCE, V266, P1874, DOI 10.1126/science.7997881; THIBODEAU J, 1994, J EXP MED, V179, P1029, DOI 10.1084/jem.179.3.1029; WANG BC, 1985, METHOD ENZYMOL, V115, P90	44	249	258	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 16	1994	266	5192					1870	1874		10.1126/science.7997880	http://dx.doi.org/10.1126/science.7997880			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997880				2022-12-28	WOS:A1994PX38300037
J	CHAISSON, RE; BENSON, CA; DUBE, MP; HEIFETS, LB; KORVICK, JA; ELKIN, S; SMITH, T; CRAFT, JC; SATTLER, FR; STOOL, EW; MACGREGOR, RR; BUEHNER, T; WU, AW; BARNES, GL; BECKER, R; URBANSKI, P; RICHARDSON, W; HAFNER, R; DIXON, D; FEIGAL, DW; DELLERSON, M; GUPTA, S; HENRY, D; SCHLAGER, S				CHAISSON, RE; BENSON, CA; DUBE, MP; HEIFETS, LB; KORVICK, JA; ELKIN, S; SMITH, T; CRAFT, JC; SATTLER, FR; STOOL, EW; MACGREGOR, RR; BUEHNER, T; WU, AW; BARNES, GL; BECKER, R; URBANSKI, P; RICHARDSON, W; HAFNER, R; DIXON, D; FEIGAL, DW; DELLERSON, M; GUPTA, S; HENRY, D; SCHLAGER, S			CLARITHROMYCIN THERAPY FOR BACTEREMIC MYCOBACTERIUM-AVIUM COMPLEX DISEASE - A RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING STUDY IN PATIENTS WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Article						MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM INTRACELLULARE INFECTION; CLARITHROMYCIN; ACQUIRED IMMUNODEFICIENCY SYNDROME; DOSE RESPONSE RELATIONSHIP, DRUG	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY-SYNDROME; INTRACELLULARE BACTEREMIA; NATURAL-HISTORY; INFECTION; CLOFAZIMINE; ETHAMBUTOL; VIRUS; CIPROFLOXACIN; AZITHROMYCIN	Objective: To determine the antimicrobial activity and tolerability of clarithromycin for treating bacteremic Mycobacterium avium complex disease in patients with the acquired immunodeficiency syndrome (AIDS). Design: A randomized, double-blind, dose-ranging study. Setting: Outpatient clinics. Patients: 154 patients with human immunodeficiency virus (HIV) infection and blood cultures positive for M. avium complex who had symptomatic disease. Interventions: Random assignment to clarithromycin at dosages of 500 mg, 1000 mg, or 2000 mg twice daily for 12 weeks. Main Outcome Measure: Median number of colony-forming units of M. avium complex per milliliter of blood. Results: Clarithromycin decreased mycobacterial CFUs from 2.7 to 2.8 log 10/mL of blood at baseline to less than 0 log 10/mL during follow-up (P < 0.0001). After 2 weeks, patients receiving 500 mg twice daily were less likely to be culture negative than were patients receiving 1000 or 2000 mg twice daily (11% compared with 33% or 29%; P = 0.08). At 6 weeks, the median number of CFUs of M. avium complex/mL of blood was 0 or 1 for all three groups. Clarithromycin-resistant isolates of M. avium complex developed in 46% of patients at a median of 16 weeks. Median survival was longer in patients assigned to 500 mg twice daily (median, 249 days) than in patients assigned to 1000 mg or 2000 mg. Death in the first 12 weeks was lowest in the 500-mg group (P = 0.007). Conclusions: Clarithromycin therapy acutely decreased M. avium complex bacteremia in patients with HIV infection by more than 99%. Clarithromycin, 500 mg twice daily, was well tolerated and associated with better survival. Emergence of clarithromycin-resistant organisms was an important problem.	RUSH MED COLL, RUSH PRESBYTERIAN ST LUKES MED CTR, INFECT DIS SECT, CHICAGO, IL 60612 USA; UNIV SO CALIF, LOS ANGELES CTY MED CTR, LOS ANGELES, CA 90033 USA; NATL JEWISH CTR IMMUNOL & RESP MED, DENVER, CO 80206 USA; ABBOTT LABS, ABBOTT PK, IL 60064 USA; NIAID, BETHESDA, MD 20892 USA; BIOPHARM INC, PHILADELPHIA, PA USA; AMI PK PLAZA HOSP, HOUSTON, TX USA; UNIV PENN, PHILADELPHIA, PA 19104 USA; SAN DIEGO COMMUNITY RES GRP, SAN DIEGO, CA USA; UNIV CALIF SAN DIEGO, SAN DIEGO, CA 92103 USA	Rush University; University of Southern California; National Jewish Health; Abbott Laboratories; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Pennsylvania; University of California System; University of California San Diego	CHAISSON, RE (corresponding author), JOHNS HOPKINS UNIV, SCH MED, AIDS SERV, 600 N WOLFE ST, CARNEGIE 292, BALTIMORE, MD 21287 USA.		Wu, Albert/AAJ-4780-2021		NCRR NIH HHS [5M01RR00722] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGINS BD, 1989, J INFECT DIS, V159, P784, DOI 10.1093/infdis/159.4.784; [Anonymous], 1948, Br Med J, V2, P769; BENSON CA, 1991, ARCH INTERN MED, V151, P582, DOI 10.1001/archinte.151.3.582; CHAISSON RE, 1992, AM REV RESPIR DIS, V146, P285, DOI 10.1164/ajrccm/146.2.285; CHIU J, 1990, ANN INTERN MED, V113, P358, DOI 10.7326/0003-4819-113-5-358; DAUTZENBERG B, 1993, ARCH INTERN MED, V153, P368, DOI 10.1001/archinte.153.3.368; DAUTZENBERG B, 1991, AM REV RESPIR DIS, V144, P564, DOI 10.1164/ajrccm/144.3_Pt_1.564; FERNANDES PB, 1989, ANTIMICROB AGENTS CH, V33, P1531, DOI 10.1128/AAC.33.9.1531; HAVLIR D, 1993, J CLIN MICROBIOL, V31, P1794, DOI 10.1128/JCM.31.7.1794-1798.1993; HAWKINS CC, 1986, ANN INTERN MED, V105, P184, DOI 10.7326/0003-4819-105-2-184; HEIFETS L, 1993, ANTIMICROB AGENTS CH, V37, P2364, DOI 10.1128/AAC.37.11.2364; HEIFETS LB, 1992, AM REV RESPIR DIS, V145, P856, DOI 10.1164/ajrccm/145.4_Pt_1.856; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; HORSBURGH CR, 1991, AM REV RESPIR DIS, V144, P557, DOI 10.1164/ajrccm/144.3_Pt_1.557; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; HOY J, 1990, J INFECT DIS, V161, P801, DOI 10.1093/infdis/161.4.801; JACOBSON MA, 1991, J INFECT DIS, V164, P994, DOI 10.1093/infdis/164.5.994; JI BH, 1992, ANTIMICROB AGENTS CH, V36, P2839, DOI 10.1128/AAC.36.12.2839; KEMPER C, 1992, 8 INT C AIDS 3 STD W; KEMPER CA, 1992, ANN INTERN MED, V116, P466, DOI 10.7326/0003-4819-116-6-466; MASUR H, 1987, J INFECT DIS, V155, P127, DOI 10.1093/infdis/155.1.127; MASUR H, 1993, NEW ENGL J MED, V329, P898, DOI 10.1056/NEJM199309163291228; NIGHTINGALE SD, 1992, J INFECT DIS, V165, P1082, DOI 10.1093/infdis/165.6.1082; NIGHTINGALE SD, 1993, ANTIMICROB AGENTS CH, V37, P1869, DOI 10.1128/AAC.37.9.1869; PETTY B, 1992, 32ND ICAAC AN; TSUKAMURA M, 1988, AM REV RESPIR DIS, V137, P144, DOI 10.1164/ajrccm/137.1.144; YOUNG LS, 1991, LANCET, V338, P1107, DOI 10.1016/0140-6736(91)91965-W; 1952, BRIT MED J, V2, P735	28	255	260	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1994	121	12					905	911		10.7326/0003-4819-121-12-199412150-00001	http://dx.doi.org/10.7326/0003-4819-121-12-199412150-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW083	7978715				2022-12-28	WOS:A1994PW08300001
J	FUKUDA, K; STRAUS, SE; HICKIE, I; SHARPE, MC; DOBBINS, JG; KOMAROFF, A; SCHLUEDERBERG, A; JONES, JF; LLOYD, AR; WESSELY, S; GANTZ, NM; HOLMES, GP; BUCHWALD, D; ABBEY, S; REST, J; LEVY, JA; JOLSON, H; PETERSON, DL; VERCOULEN, JHMM; TIRELLI, U; EVENGARD, B; NATELSON, BH; STEELE, L; REYES, M; REEVES, WC				FUKUDA, K; STRAUS, SE; HICKIE, I; SHARPE, MC; DOBBINS, JG; KOMAROFF, A; SCHLUEDERBERG, A; JONES, JF; LLOYD, AR; WESSELY, S; GANTZ, NM; HOLMES, GP; BUCHWALD, D; ABBEY, S; REST, J; LEVY, JA; JOLSON, H; PETERSON, DL; VERCOULEN, JHMM; TIRELLI, U; EVENGARD, B; NATELSON, BH; STEELE, L; REYES, M; REEVES, WC			THE CHRONIC FATIGUE SYNDROME - A COMPREHENSIVE APPROACH TO ITS DEFINITION AND STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							DIAGNOSTIC INTERVIEW; MENTAL-HEALTH; FOLLOW-UP; EPIDEMIOLOGY; PREVALENCE; POPULATION; INSTRUMENT; DISORDERS; HISTORY; SCALE	The complexities of the chronic fatigue syndrome and the methodologic problems associated with its study indicate the need for a comprehensive, systematic, and integrated approach to the evaluation, classification, and study of persons with this condition and other fatiguing illnesses. We propose a conceptual framework and a set of guidelines that provide such an approach. Our guidelines include recommendations for the clinical evaluation of fatigued persons, a revised case definition of the chronic fatigue syndrome, and a strategy for subgrouping fatigued persons in formal investigations.	NIH, CLIN INVEST LAB, BETHESDA, MD 20892 USA; PRINCE HENRY HOSP, SYDNEY, NSW, AUSTRALIA; UNIV NEW S WALES, SYDNEY, NSW, AUSTRALIA; UNIV OXFORD, WARNEFORD HOSP, DEPT PSYCHIAT, OXFORD OX3 7JX, ENGLAND; BRIGHAM & WOMENS HOSP, DIV GEN MED, BOSTON, MA 02115 USA; HARVARD UNIV, BOSTON, MA 02115 USA; UNIV COLORADO, DENVER, CO 80202 USA; UNIV LONDON KINGS COLL, SCH MED & DENT, LONDON WC2R 2LS, ENGLAND; POLYCLIN MED CTR, HARRISBURG, PA USA; PENN STATE COLL MED, HARRISBURG, PA USA; TEXAS A&M UNIV, HLTH SCI CTR, TEMPLE, TX 76508 USA; SCOTT & WHITE MEM HOSP & CLIN, TEMPLE, TX 76508 USA; UNIV WASHINGTON, MED CTR, SEATTLE, WA 98195 USA; UNIV TORONTO, TORONTO, ON, CANADA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; US FDA, ROCKVILLE, MD 20857 USA; LAKE TAHOE MED CTR, INCLINE VILLAGE, NV USA; UNIV NIJMEGEN HOSP, 6500 HB NIJMEGEN, NETHERLANDS; CTR REG RIFERMINENTO ONCOL, AVIANO, ITALY; HUDDINGE UNIV HOSP, KAROLINSKA INST, STOCKHOLM, SWEDEN; UNIV MED & DENT NEW JERSEY, NEW JERSEY MED SCH, NEWARK, NJ 07103 USA; ALTA BATES COMMUNITY HOSP, BERKELEY, CA USA	National Institutes of Health (NIH) - USA; University of New South Wales Sydney; University of Oxford; Harvard University; Brigham & Women's Hospital; Harvard University; University of Colorado System; University of Colorado Denver; University of London; King's College London; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Scott & White Medical Center; University of Washington; University of Washington Seattle; University of Toronto; University of California System; University of California San Francisco; US Food & Drug Administration (FDA); Radboud University Nijmegen; IRCCS Aviano (CRO); IRCCS CROB; Karolinska Institutet; Rutgers State University New Brunswick; Rutgers State University Medical Center	FUKUDA, K (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, MAILSTOP A15, ATLANTA, GA 30333 USA.		Lloyd, Andrew/E-7334-2017; Wessely, Simon C/A-8713-2008; Lloyd, Andrew/AAF-6071-2022; Vercoulen, J.H.M.M./L-4706-2015; Hickie, Ian B/K-8975-2015; Lloyd, Andrew/AFJ-8960-2022	Lloyd, Andrew/0000-0001-6277-8887; Hickie, Ian B/0000-0001-8832-9895; Lloyd, Andrew/0000-0001-6277-8887; Fukuda, Keiji/0000-0002-9598-9565; sharpe, michael/0000-0002-6474-9980; Wessely, Simon Charles/0000-0002-6743-9929				BAROFSKY I, 1991, REV INFECT DIS, V13, pS94; BATES DW, 1993, ARCH INTERN MED, V153, P2759, DOI 10.1001/archinte.153.24.2759; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BRAY GA, 1992, AM J CLIN NUTR, V55, P488, DOI 10.1093/ajcn/55.2.488s; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; GUNN WJ, 1993, CIBA F SYMP, V173, P83; HICKIE I, IN PRESS PSYCHOL MED; HOLMES GP, 1988, ANN INTERN MED, V109, P512; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; HOLMES GP, 1989, INFECTIOUS MONONUCLE, P172; KATON W, 1992, ARCH INTERN MED, V152, P1604, DOI 10.1001/archinte.152.8.1604; KLONOFF DC, 1992, CLIN INFECT DIS, V15, P812, DOI 10.1093/clind/15.5.812; Kroenke K, 1989, Compr Ther, V15, P3; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; KRUESI MJP, 1989, J CLIN PSYCHIAT, V50, P53; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; KUCZMARSKI R J, 1992, American Journal of Clinical Nutrition, V55, p495S, DOI 10.1093/ajcn/55.2.495s; LANE TJ, 1990, AM J MED SCI, V299, P313, DOI 10.1097/00000441-199005000-00005; LEWIS G, 1992, J EPIDEMIOL COMMUN H, V46, P92, DOI 10.1136/jech.46.2.92; LLOYD AR, 1990, MED J AUSTRALIA, V153, P522, DOI 10.5694/j.1326-5377.1990.tb126191.x; LLOYD AR, 1988, LANCET, V1, P1286; MANU P, 1991, SOUTHERN MED J, V84, P451, DOI 10.1097/00007611-199104000-00010; MANU P, 1989, PSYCHOSOMATICS, V30, P388, DOI 10.1016/S0033-3182(89)72244-1; MANU P, 1988, ARCH INTERN MED, V148, P2213, DOI 10.1001/archinte.148.10.2213; MATTHEWS DA, 1988, ANN INTERN MED, V109, P511, DOI 10.7326/0003-4819-109-6-511; MAWLE AC, 1993, INFECT AGENT DIS, V2, P333; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; PETERSON PK, 1991, MINN MED, V74, P21; Piper B, 1989, KEY ASPECTS COMFORT, P199; PRICE RK, 1992, PUBLIC HEALTH REP, V107, P514; ROBINS LN, 1988, ARCH GEN PSYCHIAT, V45, P1069; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; SCHLUEDERBERG A, 1992, ANN INTERN MED, V117, P325, DOI 10.7326/0003-4819-117-4-325; SCHWARTZ JE, 1993, J PSYCHOSOM RES, V37, P753, DOI 10.1016/0022-3999(93)90104-N; SHAFRAN SD, 1991, AM J MED, V90, P730; SHARPE M, 1992, BRIT MED J, V305, P147, DOI 10.1136/bmj.305.6846.147; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; STRAUS SE, 1992, ARCH INTERN MED, V152, P1569, DOI 10.1001/archinte.152.8.1569; SWARTZ MN, 1988, NEW ENGL J MED, V319, P1726, DOI 10.1056/NEJM198812293192608; VERCOULEN JHMM, 1994, J PSYCHOSOM RES, V38, P383, DOI 10.1016/0022-3999(94)90099-X; WALKER EA, 1993, J GEN INTERN MED, V8, P436, DOI 10.1007/BF02599621; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; WILSON A, 1994, AM J MED, V96, P544, DOI 10.1016/0002-9343(94)90095-7; WILSON A, 1994, BRIT MED J, V308, P756, DOI 10.1136/bmj.308.6931.756	46	3546	3702	7	254	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1994	121	12					953	959		10.7326/0003-4819-121-12-199412150-00009	http://dx.doi.org/10.7326/0003-4819-121-12-199412150-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW083	7978722				2022-12-28	WOS:A1994PW08300009
J	VARTIVARIAN, SE; PAPADAKIS, KA; PALACIOS, JA; MANNING, JT; ANAISSIE, EJ				VARTIVARIAN, SE; PAPADAKIS, KA; PALACIOS, JA; MANNING, JT; ANAISSIE, EJ			MUCOCUTANEOUS AND SOFT-TISSUE INFECTIONS CAUSED BY XANTHOMONAS-MALTOPHILIA - A NEW SPECTRUM	ANNALS OF INTERNAL MEDICINE			English	Article							GRAM-NEGATIVE BACILLI; PSEUDOMONAS-MALTOPHILIA	Objective: To describe the mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia in patients with cancer. Design: A retrospective 15-month clinical study. Setting: Academic, referral-based cancer center. Patients: Of 237 patients with X. maltophilia isolated from all sites during the 15-month study period, 114 patients were judged to have true X. maltophilia infections. Only patients with mucocutaneous and soft tissue infections were included in the study. Results: 17 (15%) of the 114 patients with X. maltophilia infection had mucocutaneous and soft tissue infections: Six patients had metastatic cellulitis, 5 had primary cellulitis usually associated with catheter use, and 6 had infected mucocutaneous ulcers. The metastatic cellulitis consisted of previously undescribed multiple, hard, tender nodules with surrounding and distant cellulitis (5 patients) or ecthyma gangrenosum (1 patient). Four of these patients died of the infection. Metastatic cellulitis and mucocutaneous infections occurred in hospitalized, neutropenic patients who received broad-spectrum antibiotics (beta-lactams, quinolones), often with in vitro activity against the infecting organisms. Response usually correlated with recovery from myelosuppression and administration of trimethoprim-sulfamethoxazole with or without ticarcillin-clavulanate. Catheter removal contributed to response in the treatment of primary cellulitis. Conclusions: Mucocutaneous and soft tissue infections caused by X. maltophilia are not uncommon, and X. maltophilia can cause metastatic nodular skin lesions that mimic disseminated fungal infections. It also causes serious morbidity and high mortality in patients with metastatic skin nodules and can cause superinfections in patients receiving broad-spectrum beta-lactam or quinolone antibiotics to which the organisms are susceptible when the infections develop. Catheter removal contributes to a favorable outcome in patients with catheter-associated cellulitis without bacteremia. Xanthomonas maltophilia infection should be added to the differential diagnosis of mucocutaneous or soft tissue infection in patients with cancer. Trimethoprim-sulfamethoxazole with or without ticarcillin-clavulanate is the current treatment of choice for culture-proven infections, but early empiric therapy may improve outcome.			VARTIVARIAN, SE (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, 1515 HOLCOMBE BLVD, BOX 47, HOUSTON, TX 77030 USA.							AGGER WA, 1986, REV INFECT DIS, V8, P927; BAGEL J, 1986, AM J MED, V80, P528, DOI 10.1016/0002-9343(86)90736-9; BALTIMORE RS, 1990, PEDIATR INFECT DIS J, V9, P143, DOI 10.1097/00006454-199002000-00017; BOTTONE EJ, 1986, J CLIN MICROBIOL, V24, P995, DOI 10.1128/JCM.24.6.995-997.1986; CALANDRA GB, 1992, CLIN INFECT DIS, V15, pS148, DOI 10.1093/clind/15.Supplement_1.S148; DYTE PH, 1977, MED J AUSTRALIA, V1, P444, DOI 10.5694/j.1326-5377.1977.tb130797.x; ELTING LS, 1990, MEDICINE, V69, P296, DOI 10.1097/00005792-199009000-00003; Fleming M G, 1987, Pediatr Dermatol, V4, P18, DOI 10.1111/j.1525-1470.1987.tb00746.x; GARDNER P, 1970, AM J MED, V48, P735, DOI 10.1016/S0002-9343(70)80009-2; GILARDI GL, 1972, ANN INTERN MED, V77, P211, DOI 10.7326/0003-4819-77-2-211; GILARDI GL, 1969, AM J CLIN PATHOL, V51, P58; HARLOWE HD, 1972, LARYNGOSCOPE, V82, P882, DOI 10.1288/00005537-197205000-00015; HOLMES B, 1979, J CLIN PATHOL, V32, P66, DOI 10.1136/jcp.32.1.66; Kealey G P, 1986, J Burn Care Rehabil, V7, P409, DOI 10.1097/00004630-198609000-00006; KERR KG, 1991, REV INFECT DIS, V13, P762; KHARDORI N, 1990, REV INFECT DIS, V12, P997; MARKLEY K, 1957, ANN SURG, V145, P175, DOI 10.1097/00000658-195702000-00005; MARSHALL WF, 1989, MAYO CLIN PROC, V64, P1097, DOI 10.1016/S0025-6196(12)64979-9; MORRISON AJ, 1986, J CLIN MICROBIOL, V24, P52, DOI 10.1128/JCM.24.1.52-55.1986; MUDER RR, 1987, ARCH INTERN MED, V147, P1672, DOI 10.1001/archinte.147.9.1672; NAGAI T, 1984, J CLIN MICROBIOL, V20, P1003, DOI 10.1128/JCM.20.5.1003-1005.1984; PEDERSEN MM, 1970, AM J CLIN PATHOL, V54, P178; PHAM BN, 1992, ARCH DERMATOL, V128, P702, DOI 10.1001/archderm.128.5.702b; PICOU KA, 1979, ARCH DERMATOL, V115, P459, DOI 10.1001/archderm.115.4.459; REED RK, 1976, J PEDIATR-US, V88, P977, DOI 10.1016/S0022-3476(76)81054-2; ROBERTS R, 1982, JAMA-J AM MED ASSOC, V248, P2156, DOI 10.1001/jama.248.17.2156; SANGEORZAN JA, 1990, ARCH DERMATOL, V126, P832, DOI 10.1001/archderm.126.6.832; SCHLOSSBERG D, 1980, ARCH DERMATOL, V116, P446, DOI 10.1001/archderm.116.4.446; SOUTHERN PM, 1974, TEX REP BIOL MED, V32, P880; VARTIVARIAN S, 1994, ANTIMICROB AGENTS CH, V38, P624, DOI 10.1128/AAC.38.3.624; WISHART MM, 1976, MED J AUSTRALIA, V2, P710, DOI 10.5694/j.1326-5377.1976.tb128238.x; ZURAVLEFF JJ, 1982, REV INFECT DIS, V4, P1236	32	83	87	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1994	121	12					969	973		10.7326/0003-4819-121-12-199412150-00011	http://dx.doi.org/10.7326/0003-4819-121-12-199412150-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW083	7978724				2022-12-28	WOS:A1994PW08300011
J	LOPATIN, AN; MAKHINA, EN; NICHOLS, CG				LOPATIN, AN; MAKHINA, EN; NICHOLS, CG			POTASSIUM CHANNEL BLOCK BY CYTOPLASMIC POLYAMINES AS THE MECHANISM OF INTRINSIC RECTIFICATION	NATURE			English	Article							GUINEA-PIG HEART; INWARD RECTIFICATION; VENTRICULAR CELLS; MAGNESIUM BLOCK; EXPRESSION; MEMBRANE; MYOCYTES; CLONING; MG-2+	INWARDLY rectifying potassium channels conduct ions more readily in the inward than the outward direction, an essential property for normal electrical activity(1,2). Although voltage-dependent block by internal magnesium ions may underlie inward rectification in some channels(3-5), an intrinsic voltage-dependent closure of the channel plays a contributory, or even exclusive, role in others(4,6-9). Here me report that, rather than being intrinsic to the channel protein, so-called intrinsic rectification of strong inward rectifiers requires soluble factors that are not Mg2+ and can be released from Xenopus oocytes and other cells. Biochemical and biophysical characterization identifies these factors as polyamines (spermine, spermidine, putrescine and cadaverine). The results suggest that intrinsic rectification results from voltage-dependent block of the channel pore by polyamines, not from a voltage sensor intrinsic to the channel protein(10).	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Nichols, Colin/D-6336-2012					ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; Bachrach U., 1973, FUNCTION NATURALLY O; CALDARERA CM, 1974, J MOL CELL CARDIOL, V6, P95, DOI 10.1016/0022-2828(74)90013-3; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GERBAUT L, 1991, CLIN CHEM, V37, P2117; HATHAWAY GM, 1984, ARCH BIOCHEM BIOPHYS, V233, P133, DOI 10.1016/0003-9861(84)90609-X; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HORIE M, 1987, J PHYSIOL-LONDON, V387, P251, DOI 10.1113/jphysiol.1987.sp016572; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KURACHI Y, 1985, J PHYSIOL-LONDON, V366, P365, DOI 10.1113/jphysiol.1985.sp015803; LASCHET J, 1992, EPILEPSY RES, V12, P151, DOI 10.1016/0920-1211(92)90035-R; LEECH CA, 1981, J PHYSIOL-LONDON, V319, P295, DOI 10.1113/jphysiol.1981.sp013909; LOPATIN AN, 1994, J GEN PHYSIOL, V103, P203, DOI 10.1085/jgp.103.2.203; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MAKHIMA EN, J BIOL CHEM, V269, P20469; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; MIYAMOTO S, 1993, ARCH BIOCHEM BIOPHYS, V300, P63, DOI 10.1006/abbi.1993.1009; NICHOLS CG, 1994, J PHYSIOL-LONDON, V476, P399, DOI 10.1113/jphysiol.1994.sp020141; OLIVA C, 1990, J GEN PHYSIOL, V96, P299, DOI 10.1085/jgp.96.2.299; OSHOURNE HB, 1989, BIOCHEM BIOPH RES CO, V158, P520; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; SACAAN AI, 1990, MOL PHARMACOL, V38, P705; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; TANAKA Y, 1982, J BIOCHEM-TOKYO, V91, P2029, DOI 10.1093/oxfordjournals.jbchem.a133896; TRAUTWEIN W, 1958, PFLUG ARCH GES PHYS, V266, P324, DOI 10.1007/BF00416781; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0	30	719	731	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					366	369		10.1038/372366a0	http://dx.doi.org/10.1038/372366a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969496				2022-12-28	WOS:A1994PU28700057
J	NIE, SM; CHIU, DT; ZARE, RN				NIE, SM; CHIU, DT; ZARE, RN			PROBING INDIVIDUAL MOLECULES WITH CONFOCAL FLUORESCENCE MICROSCOPY	SCIENCE			English	Article							SINGLE DNA-MOLECULES; CORRELATION SPECTROSCOPY; EXPERIMENTAL REALIZATION; GEL-ELECTROPHORESIS; OPTICAL MICROSCOPY; LIGHT-MICROSCOPY; PHYCOERYTHRIN; VISUALIZATION; MANIPULATION; DYES	Confocal fluorescence microscopy coupled with a diffraction-limited laser beam and a high-efficiency detection system has been used to study the diffusive movement and emission process of individual fluorescent molecules in the liquid phase at room temperature. The high detection sensitivity achieved at fast data acquisition speeds (greater than 1 kilohertz) allows real-time observation of single-molecule fluorescence without statistical analysis. The results show fluorescence-cycle saturation at the single-molecule level and multiple recrossings of a single molecule into and out of the probe volume as well as the triplet state.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305	Stanford University			Zare, Richard N./A-8410-2009; Nie, Shuming/E-4843-2011	Zare, Richard/0000-0001-5266-4253				AMBROSE WP, 1994, SCIENCE, V265, P364, DOI 10.1126/science.265.5170.364; ASIMOV MM, 1990, J LUMIN, V46, P243, DOI 10.1016/0022-2313(90)90020-C; AUZANNEAU I, 1993, CR ACAD SCI III-VIE, V316, P459; BETZIG E, 1992, SCIENCE, V257, P189, DOI 10.1126/science.257.5067.189; BETZIG E, 1991, SCIENCE, V251, P1468, DOI 10.1126/science.251.5000.1468; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; BUSTAMANTE C, 1991, ANNU REV BIOPHYS BIO, V20, P415, DOI 10.1146/annurev.bb.20.060191.002215; Dempster D. N., 1974, Journal of Photochemistry, V2, P343, DOI 10.1016/0047-2670(73)80032-2; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; FELLER W, 1971, INTRO PROBABILITY TH, V1; GUTTLER F, 1994, CHEM PHYS LETT, V217, P393, DOI 10.1016/0009-2614(94)87003-9; ISHIKAWA M, 1994, JPN J APPL PHYS 1, V33, P1571, DOI 10.1143/JJAP.33.1571; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; KOPPEL DE, 1974, PHYS REV A, V10, P1938, DOI 10.1103/PhysRevA.10.1938; MAGDE D, 1974, BIOPOLYMERS, V13, P29, DOI 10.1002/bip.1974.360130103; MAGDE D, 1974, BIOPOLYMERS, V13, P1; MOERNER WE, 1994, SCIENCE, V265, P46, DOI 10.1126/science.265.5168.46; MORIKAWA K, 1981, J BIOCHEM-TOKYO, V89, P693, DOI 10.1093/oxfordjournals.jbchem.a133247; NG KC, 1992, ANAL CHEM, V69, P2914; NGUYEN DC, 1987, ANAL CHEM, V59, P2158, DOI 10.1021/ac00144a032; ORRIT M, 1993, J PHYS CHEM-US, V97, P10256, DOI 10.1021/j100142a003; PECK K, 1989, P NATL ACAD SCI USA, V86, P4087, DOI 10.1073/pnas.86.11.4087; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; QIAN H, 1991, APPL OPTICS, V30, P1185, DOI 10.1364/AO.30.001185; RAMPINO NJ, 1991, ANAL BIOCHEM, V194, P278, DOI 10.1016/0003-2697(91)90230-Q; RIGLER R, 1993, EUR BIOPHYS J BIOPHY, V22, P169, DOI 10.1007/BF00185777; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; SCHNEIDER MB, 1981, APPL OPTICS, V20, P1382, DOI 10.1364/AO.20.001382; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; SMITH SB, 1989, SCIENCE, V243, P203, DOI 10.1126/science.2911733; SOPER SA, 1993, PHOTOCHEM PHOTOBIOL, V57, P972, DOI 10.1111/j.1751-1097.1993.tb02957.x; TRAUTMAN JK, 1994, NATURE, V369, P40, DOI 10.1038/369040a0; WASHIZU M, 1990, IEEE T IND APPL, V26, P1165, DOI 10.1109/28.62403; WHITTEN WB, 1991, ANAL CHEM, V63, P1027, DOI 10.1021/ac00010a019; XIE XS, 1994, SCIENCE, V265, P361, DOI 10.1126/science.265.5170.361	36	518	584	3	194	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1018	1021		10.1126/science.7973650	http://dx.doi.org/10.1126/science.7973650			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973650				2022-12-28	WOS:A1994PQ92400036
J	BUNDRED, NJ; MORGAN, DAL; DIXON, JM				BUNDRED, NJ; MORGAN, DAL; DIXON, JM			ABC OF BREAST DISEASES - MANAGEMENT OF REGIONAL NODES IN BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article									CHRISTIE HOSP,MANCHESTER,LANCS,ENGLAND; CITY HOSP NOTTINGHAM,NOTTINGHAM,ENGLAND; ROYAL INFIRM,EDINBURGH,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	Christie NHS Foundation Trust; Christie Hospital; Nottingham University Hospital NHS Trust; Nottingham City Hospital; Royal Infirmary of Edinburgh; University of Edinburgh	BUNDRED, NJ (corresponding author), UNIV S MANCHESTER HOSP,MANCHESTER M20 8LR,LANCS,ENGLAND.			Morgan, David/0000-0002-2291-1740					0	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 5	1994	309	6963					1222	1225		10.1136/bmj.309.6963.1222	http://dx.doi.org/10.1136/bmj.309.6963.1222			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ662	7987158	Green Published			2022-12-28	WOS:A1994PQ66200029
J	COHEN, AT; SKINNER, JA; KAKKAR, VV				COHEN, AT; SKINNER, JA; KAKKAR, VV			ANTIPLATELET TREATMENT FOR THROMBOPROPHYLAXIS - A STEP FORWARD OR BACKWARDS	BRITISH MEDICAL JOURNAL			English	Article							LOW-DOSE HEPARIN; LOW-MOLECULAR-WEIGHT; VENOUS THROMBOEMBOLISM; ACETYLSALICYLIC-ACID; POSTOPERATIVE THROMBOEMBOLISM; STANDARD HEPARIN; DOUBLE-BLIND; PREVENTION; SURGERY; THROMBOSIS	A recent meta-analysis from the Antiplatelet Trialists' Collaboration recommended that antilatelet treatment either alone or, for greater effect, in addition to other proved forms of thromboprophylaxis should be considered for patients at high risk of thromboembolism. This paper argues that the current evidence does not justify the adoption of aspirin or other antiplatelet treatment for venous thromboprophylaxis, especially when more effective alternatives exist. Furthermore, several issues relating to this latest meta-analysis need to be debated.	THROMBOSIS RES INST,LONDON SW3 6LR,ENGLAND	Thrombosis Research Institute				Skinner, John/0000-0002-1901-9057				[Anonymous], 1994, BMJ, V308, P235; CHRISMAN OD, 1976, J BONE JOINT SURG AM, V58, P918, DOI 10.2106/00004623-197658070-00003; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; DESIMONIAN R, 1986, CONTROLLED CLIN TRIA, V7, P177; FLEISS JL, 1991, J CLIN EPIDEMIOL, V44, P127, DOI 10.1016/0895-4356(91)90261-7; FLICOTEAUX H, 1977, PATHOL BIOL, V25, P55; GENTON E, 1975, NEW ENGL J MED, V293, P1174, DOI 10.1056/NEJM197512042932305; HUME M, 1978, ORTHOP CLIN N AM, V9, P761; HUME M, 1977, AM J SURG, V133, P420, DOI 10.1016/0002-9610(77)90125-8; Huque MF, 1988, PROC BIOPHARM SECT A, V2, P28; KAKKAR VV, 1993, LANCET, V341, P259, DOI 10.1016/0140-6736(93)92614-Y; LOEW D, 1977, THROMB RES, V11, P81, DOI 10.1016/0049-3848(77)90070-6; MCKENNA R, 1980, BRIT MED J, V280, P514, DOI 10.1136/bmj.280.6213.514; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; SCHONDORF TH, 1976, HAEMOSTASIS, V5, P250; SOREFF J, 1975, ACTA ORTHOP SCAND, V46, P246, DOI 10.3109/17453677508989215; THOMPSON SG, 1991, LANCET, V338, P1127, DOI 10.1016/0140-6736(91)91975-Z; VINAZZER H, 1980, THROMB RES, V17, P177, DOI 10.1016/0049-3848(80)90304-7; ZEKERT F, 1980, MUNCHEN MED WOCHEN, V122, P1495	20	43	46	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 5	1994	309	6963					1213	1215		10.1136/bmj.309.6963.1213	http://dx.doi.org/10.1136/bmj.309.6963.1213			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ662	7987155	Green Published			2022-12-28	WOS:A1994PQ66200026
J	LORI, F; MALYKH, A; CARA, A; SUN, D; WEINSTEIN, JN; LISZIEWICZ, J; GALLO, RC				LORI, F; MALYKH, A; CARA, A; SUN, D; WEINSTEIN, JN; LISZIEWICZ, J; GALLO, RC			HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE-1 REPLICATION	SCIENCE			English	Article							DRUG-COMBINATIONS; HTLV-III; INFECTION; PROTEASE; AIDS; ACTIVATION; MECHANISM; THERAPY; INVITRO; TISSUE	Hydroxyurea, a drug widely used in therapy of several human diseases, inhibits deoxynucleotide synthesis-and, consequently, DNA synthesis-by blocking the cellular enzyme ribonucleotide reductase. Hydroxyurea inhibits human immunodeficiency virus-type 1 (HIV-1) DNA synthesis in activated peripheral blood lymphocytes by decreasing the amount of intracellular deoxynucleotides, thus suggesting that this drug has an antiviral effect. Hydroxyurea has now been shown to block HIV-1 replication in acutely infected primary human lymphocytes (quiescent and activated) and macrophages, as well as in brood cells infected in vivo obtained from individuals with acquired immunodeficiency syndrome (AIDS). The antiviral effect was achieved at nontoxic doses of hydroxyurea, lower than those currently used in human therapy. Combination of hydroxyurea with the nucleoside analog didanosine (2',3'-dideoxyinosine, or ddl) generated a synergistic inhibitory effect without increasing toxicity. In some instances, inhibition of HIV-1 by hydroxyurea was irreversible, even several weeks after suspension of drug treatment. The indirect inhibition of HIV-1 by hydroxyurea is not expected to generate high rates of escape mutants. Hydroxyurea therefore appears to be a possible candidate for AIDS therapy.	NCI,MOLEC PHARMACOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	LORI, F (corresponding author), NCI,TUMOR CELL BIOL LAB,BLDG 37,BETHESDA,MD 20892, USA.		Cara, Andrea/M-4865-2015; Cara, Andrea/AAA-4238-2021	Cara, Andrea/0000-0003-4967-1895; Cara, Andrea/0000-0003-4967-1895; Weinstein, John/0000-0001-9401-6908; Lisziewicz, Julianna/0000-0002-3349-4495				ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; BELT RJ, 1980, CANCER, V46, P455, DOI 10.1002/1097-0142(19800801)46:3<455::AID-CNCR2820460306>3.0.CO;2-N; BIANCHI V, 1986, J BIOL CHEM, V261, P6037; BUNOW B, 1990, ANN NY ACAD SCI, V616, P490; CHARACHE S, 1991, HEMATOL ONCOL CLIN N, V5, P571, DOI 10.1016/S0889-8588(18)30432-5; DONEHOWER RC, 1992, SEMIN ONCOL, V19, P11; GAO WY, 1993, P NATL ACAD SCI USA, V90, P8925, DOI 10.1073/pnas.90.19.8925; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GOULAOUIC H, 1994, VIROLOGY, V200, P87, DOI 10.1006/viro.1994.1166; JACK JA, 1990, CELL, V61, P213; KAGEYAMA S, 1992, ANTIMICROB AGENTS CH, V36, P926, DOI 10.1128/AAC.36.5.926; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LORI F, 1992, J VIROL, V66, P5067, DOI 10.1128/JVI.66.8.5067-5074.1992; LORI F, UNPUB; MALLEY SD, 1994, LANCET, V343, P1292, DOI 10.1016/S0140-6736(94)92182-2; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MEYERHANS A, 1994, J VIROL, V68, P535, DOI 10.1128/JVI.68.1.535-540.1994; MORGAN JS, 1986, BIOCHEM BIOPH RES CO, V134, P1254, DOI 10.1016/0006-291X(86)90385-2; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; OTTO MJ, 1993, P NATL ACAD SCI USA, V90, P7543, DOI 10.1073/pnas.90.16.7543; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; SELIGMANN M, 1994, LANCET, V343, P871; SLABAUGH MB, 1991, J VIROL, V65, P2290, DOI 10.1128/JVI.65.5.2290-2298.1991; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; WEINSTEIN JN, 1990, ANN NY ACAD SCI, V616, P367; YARBRO JW, 1992, SEMIN ONCOL, V19, P1; YARCHOAN R, 1993, TRENDS PHARMACOL SCI, V14, P196, DOI 10.1016/0165-6147(93)90208-2	29	319	340	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					801	805		10.1126/science.7973634	http://dx.doi.org/10.1126/science.7973634			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973634				2022-12-28	WOS:A1994PP75300039
J	RODERICK, PJ; JONES, I; RALEIGH, VS; MCGEOWN, M; MALLICK, N				RODERICK, PJ; JONES, I; RALEIGH, VS; MCGEOWN, M; MALLICK, N			POPULATION NEED FOR RENAL REPLACEMENT THERAPY IN THAMES REGIONS - ETHNIC DIMENSION	BRITISH MEDICAL JOURNAL			English	Article							DISEASE; PREVALENCE; FAILURE; INSULIN; CENSUS; ASIANS	Objectives-To determine the use of renal replacement therapy by ethnic origin and to ascertain the variation in provision of such therapy and to relate this to the distribution of ethnic minority populations. Design-Analysis of retrospective and cross sectional data from 19 renal units. Setting-All four Thames regional health authorities. Subjects-Patients resident in the Thames regions who were accepted as new patients for renal replacement therapy during 1991 and 1992 and the patients who were already undergoing such treatment between December 1992 and April 1993. Main outcome measures-Rates of acceptance for and prevalence of renal replacement therapy among white, black, and Asian people. Results-The average annual acceptance rates per million in 1991-2 were 61 for white people, 175 for black people, and 178 for Asians, and the prevalences per million were 351, 918, and 957 respectively. The relative risks increased with age. A threefold increase in the acceptance rate occurred in people aged under 55 in both the black and Asian populations, suggesting that the higher rates are probably not due to factors related to access alone. Treatment rates varied considerably among districts, reflecting both the distribution of ethnic minority populations and access to services. Conclusion-Black and Asian people receive and have a greater need for renal replacement therapy, and the need will increase as these populations age. These findings have important implications for the provision of renal services in districts with a high proportion of ethnic minorities and for the management of diabetes mellitus and hypertension, two important causes of end stage renal failure in these populations.	NW THAMES REG HLTH AUTHOR,LONDON,ENGLAND; UNIV LONDON QUEEN MARY & WESTFIELD COLL,LONDON,ENGLAND; UNIV SURREY,INST PUBL HLTH,GUILDFORD,SURREY,ENGLAND; QUEENS UNIV BELFAST,BELFAST,ANTRIM,NORTH IRELAND; MANCHESTER ROYAL INFIRM,MANCHESTER,LANCS,ENGLAND	University of London; Queen Mary University London; University of Surrey; Queens University Belfast; University of Manchester				Jones, Ian/0000-0002-1682-9134				BALARAJAN R, 1978, OPCS SERIES DS, V9, P103; BEECH R, 1994, HLTH CARE NEEDS ASSE; BURDEN AC, 1992, DIABETIC MED, V9, P641, DOI 10.1111/j.1464-5491.1992.tb01860.x; COWIE CC, 1990, DIABETES, V321, P1074; CRUICKSHANK JK, 1991, LANCET, V338, P842, DOI 10.1016/0140-6736(91)91501-K; Eggers P W, 1984, Health Care Financ Rev, V5, P69; FEEST TG, 1990, BRIT MED J, V301, P897, DOI 10.1136/bmj.301.6757.897; GARDNER MJ, 1989, STATISTICS CONFIDENC; GLOVER GR, 1993, BRIT MED J, V307, P506, DOI 10.1136/bmj.307.6902.506-a; HIATT RA, 1982, AM J PUBLIC HEALTH, V72, P829, DOI 10.2105/AJPH.72.8.829; HOPKINS A, 1993, ACCESSIBILITY HLTH C; MATHER HM, 1985, BRIT MED J, V291, P1081, DOI 10.1136/bmj.291.6502.1081; MCCLELLAN W, 1988, AM J KIDNEY DIS, V12, P285, DOI 10.1016/S0272-6386(88)80221-X; MCGEOWN MG, 1990, BRIT MED J, V301, P900, DOI 10.1136/bmj.301.6757.900; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; PAZIANAS M, 1991, NEPHROL DIAL TRANSPL, V6, P931, DOI 10.1093/ndt/6.12.931; ROSTAND SG, 1982, NEW ENGL J MED, V306, P1276, DOI 10.1056/NEJM198205273062106; SAMANTA A, 1986, BRIT MED J, V293, P366, DOI 10.1136/bmj.293.6543.366-a; SHULMAN NB, 1991, CIRCULATION, V83, P1477, DOI 10.1161/01.CIR.83.4.1477; THOMPSON EJ, 1993, BRIT MED J, V307, P803, DOI 10.1136/bmj.307.6907.803-b; 1991, PROVISION SERVICES A; [No title captured]; 1993, REPORT INDEPENDENT R; 1992, NEPHROL DIAL TRANSPL, V7, P10; 1994, 1991 CENSUS USER GUI	25	76	76	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1994	309	6962					1111	1114		10.1136/bmj.309.6962.1111	http://dx.doi.org/10.1136/bmj.309.6962.1111			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987102	Green Published			2022-12-28	WOS:A1994PP69100018
J	KASISKE, BL; MA, JZ; KALIL, RSN; LOUIS, TA				KASISKE, BL; MA, JZ; KALIL, RSN; LOUIS, TA			EFFECTS OF ANTIHYPERTENSIVE THERAPY ON SERUM-LIPIDS	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY HEART-DISEASE; BLOOD-PRESSURE; HYPERTENSIVE PATIENTS; PLASMA-LIPIDS; LIPOPROTEINS; AGENTS; DIURETICS; INSULIN; TRIALS; DRUGS	Purpose: To compare and contrast the effects of antihypertensive agents on serum lipids and blood pressure in different patient populations. Data Sources: A MEDLINE search and bibliographies from recent comprehensive reviews were used to identify trials that provided sufficient data to calculate the change in one or more serum lipid values measured before and after antihypertensive therapy. Study Selection: 474 controlled and uncontrolled clinical trials investigated the effects of 85 antihypertensive agents on lipids and blood pressure in more than 65 000 patients. Data Extraction: Data on triglyceride and total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol levels; blood pressure; patient characteristics; and study design. Data Synthesis: Differences in the effects of agents, adjusted for differences in patient populations and study design, were examined using multiple linear regression analysis that was weighted by study quality and inverse variance. Diuretics caused relative increases in cholesterol levels (regression coefficient = 0.13 mmol/L; 95% CI, 0.09 to 0.18 mmol/L) that were greater with higher doses (additional effect of high dose, 0.12 mmol/L; CI, 0.04 to 0.20 mmol/L) and were worse in blacks than in nonblacks (additional effect in blacks, 0.13 mmol/L; CI, 0.01 to 0.26 mmol/L). beta-blockers caused increases in triglyceride levels (0.35 mmol/L; CI, 0.31 to 0.39 mmol/L) that were substantially smaller for agents with intrinsic sympathomimetic activity (amelioration of beta-blocker increase, -0.21 mmol/L; CI, -0.27 to -0.16 mmol/L). When combined with cardioselectivity, beta-blockers with intrinsic sympathomimetic activity favorably affected lipids and reduced both total (-0.14 mmol/L; CI, -0.24 to -0.04 mmol/L) and LDL cholesterol revels (-0.17 mmol/L; CI, -0.28 to -0.07 mmol/L). alpha-Blockers beneficially affected total cholesterol (-0.23 mmol/L; CI, -0.28 to -0.18 mmol/L), LDL cholesterol (-0.20 mmol/L; CI, -0.25 to -0.15 mmol/L), triglycerides (-0.07 mmol/L; CI, -0.11 to -0.03 mmol/L), and, in younger persons, HDL cholesterol (0.02 mmol/L; 0.01 to 0.04 mmol/L). Converting enzyme inhibitors reduced triglycerides (-0.07 mmol/L; CI, -0.12 to -0.02 mmol/L), and, in patients with diabetes, total cholesterol (-0.22 mmol/L; CI, -0.34 to -0.10 mmol/L). Vasodilators reduced total (-0.22 mmol/l; CI, -0.30 to -0.10 mmol/L) and LDL cholesterol (-0.22 mmol/L; CI, -0.29 to -0.11 mmol/L) and increased HDL cholesterol (0.06 mmol/L; CI, 0.02 to 0.09 mmol/L). Conclusion: With the exception of calcium antagonists, nearly all antihypertensive agents affect serum lipids. These effects differ among patient populations.	UNIV MINNESOTA, COLL MED, SCH PUBL HLTH, DIV BIOSTAT, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	KASISKE, BL (corresponding author), HENNEPIN CTY MED CTR, DEPT MED, 701 PK AVE, MINNEAPOLIS, MN 55415 USA.							AMES RP, 1986, DRUGS, V32, P260, DOI 10.2165/00003495-198632030-00003; AMES RP, 1988, AM J HYPERTENS, V1, P421, DOI 10.1093/ajh/1.4.421; BERNE C, 1991, J INTERN MED, V229, P119; BLACK HR, 1991, AM HEART J, V121, P707, DOI 10.1016/0002-8703(91)90451-M; CALLAHAN CM, 1991, ANN INTERN MED, V114, P216, DOI 10.7326/0003-4819-114-3-216; CAPPUCCIO FP, 1989, J HYPERTENS, V7, P941, DOI 10.1097/00004872-198912000-00003; CHAIT A, 1989, AM J MED, V86, P5, DOI 10.1016/0002-9343(89)90120-4; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; DEVINE EC, 1983, NURS RES, V32, P267; FERRANNINI E, 1991, AM HEART J, V121, P1274, DOI 10.1016/0002-8703(91)90433-I; FERRARI P, 1989, S AFR MED J S, V76, P13; GILES TD, 1992, HYPERTENSION, V19, pI124, DOI 10.1161/01.HYP.19.1_Suppl.I124; GRIMM RH, 1991, AM HEART J, V122, P910, DOI 10.1016/0002-8703(91)90811-U; HAWKINS DW, 1989, PHARMACOTHERAPY PATH, P97; HORAN MJ, 1991, AM J MED SCI, V301, P402, DOI 10.1097/00000441-199106000-00010; HUNNINGHAKE DB, 1991, AM HEART J, V121, P696, DOI 10.1016/0002-8703(91)90449-R; KANNEL WB, 1989, AM HEART J, V118, P1012, DOI 10.1016/0002-8703(89)90237-8; KASISKE BL, 1993, ANN INTERN MED, V118, P129, DOI 10.7326/0003-4819-118-2-199301150-00009; KRONE W, 1988, AM HEART J, V116, P1729, DOI 10.1016/0002-8703(88)90222-0; LARDINOIS CK, 1988, ARCH INTERN MED, V148, P1280, DOI 10.1001/archinte.148.6.1280; LARDINOIS CK, 1992, CURR OPIN LIPIDOL, V3, P274; LEVY D, 1990, AM HEART J, V119, P712, DOI 10.1016/S0002-8703(05)80050-X; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MOSER M, 1990, J HYPERTENS, V8, pS9, DOI 10.1097/00004872-199006002-00003; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; NORUSIS MJ, 1988, STATISTICAL PACKAGE; PAOLISSO G, 1992, J HUM HYPERTENS, V6, P175; RAFTERY EB, 1990, INT J CARDIOL, V28, P143, DOI 10.1016/0167-5273(90)90054-9; Raudenbush S. W., 1994, HDB RES SYNTHESIS, P301, DOI DOI 10.1111/ACPS.12078; REAVEN GM, 1987, LANCET, V2, P435; ROBERTS WC, 1989, AM HEART J, V117, P709, DOI 10.1016/0002-8703(89)90757-6; ROHLFING JJ, 1986, WESTERN J MED, V145, P210; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; Stokes 3rd J, 1989, HYPERTENSION S1, V13, pI13; WEIDMANN P, 1988, DRUGS, V35, P118, DOI 10.2165/00003495-198800356-00017; WORTMAN PM, 1983, EVALUATION STUDIES R, P536	38	177	180	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					133	141		10.7326/0003-4819-122-2-199501150-00010	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7992988				2022-12-28	WOS:A1995QC05900010
J	OWENS, DM; NELSON, DK; TALLEY, NJ				OWENS, DM; NELSON, DK; TALLEY, NJ			THE IRRITABLE-BOWEL-SYNDROME - LONG-TERM PROGNOSIS AND THE PHYSICIAN-PATIENT INTERACTION	ANNALS OF INTERNAL MEDICINE			English	Article						COLONIC DISEASES, FUNCTIONAL; PHYSICIAN-PATIENT RELATIONS; DIARRHEA; ABDOMINAL PAIN	ALTERNATIVE MEDICINE; EPIDEMIOLOGY; ENCOUNTERS; DISCOURSE; CRITIQUE	Objective: To evaluate the long-term course and prognosis associated with the irritable bowel syndrome (IBS) and to determine the influence of an effective physician-patient relationship on subsequent health care use. Design: Prospective review of medical records. Setting: Tertiary referral center. Patients: 112 consecutive Olmsted County, Minnesota, residents who were first diagnosed with IBS at the Mayo Clinic during the period 1961-1963. Results: The median follow-up was 29 years (range, 1 to 32 years) and patients made a median of 2 return visits for IBS-related symptoms (range, 0 to 12 visits). In addition to abdominal pain, diarrhea (reported by 50% of patients) was the predominant bowel symptom at diagnosis. Organic gastrointestinal disease occurred in 10 patients a median of 15 years after diagnosis of IBS. Survival in patients with IBS did not differ from expected survival (27 deaths; median survival > 30 years after initial diagnosis). A positive physician-patient interaction, defined a priori using objective criteria in the written record, was associated with fewer return visits for IBS. Of the eight variables examined, notations in the medical record about psychosocial history, precipitating factors, and discussion of diagnosis and treatment with patients were associated with fewer return visits for IBS-related symptoms. Conclusions: When diagnosed according to current criteria, IBS is associated with a good prognosis and the diagnosis is unlikely to be changed to that of an organic disease during follow-up. A positive physician-patient interaction may be related to reduced use of ambulatory health services by patients with IBS.	MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA	Mayo Clinic			Talley, Nicholas J/D-5399-2013	Talley, Nicholas J/0000-0003-2537-3092	NIA NIH HHS [R01 AG099440] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLPORT GW, 1942, B SOCIAL SCI RES COU, V49, pR12; BARFOOT M, 1990, PSYCHOL MED, V20, P263, DOI 10.1017/S0033291700017591; BERTAKIS KD, 1991, J FAM PRACTICE, V32, P175; CAMILLERI M, 1992, ANN INTERN MED, V116, P1001, DOI 10.7326/0003-4819-116-12-1001; CHAUDHARY NA, 1962, Q J MED, V31, P307; Drossman D., 1990, GASTR INT, V3, P159; DROSSMAN DA, 1992, ANN INTERN MED, V116, P1009, DOI 10.7326/0003-4819-116-12-1009; FREEMON B, 1971, PEDIATR RES, V5, P298; HALL JA, 1988, MED CARE, V26, P657, DOI 10.1097/00005650-198807000-00002; HARVEY RF, 1987, LANCET, V1, P963; HOLMES KM, 1982, BRIT MED J, V285, P1533, DOI 10.1136/bmj.285.6354.1533; Houston WR, 1938, ANN INTERN MED, V11, P1416, DOI 10.7326/0003-4819-11-8-1416; INUI TS, 1982, MED CARE, V20, P535, DOI 10.1097/00005650-198206000-00001; JONES R, 1992, BRIT MED J, V304, P87, DOI 10.1136/bmj.304.6819.87; KLEIN KB, 1988, GASTROENTEROLOGY, V95, P232, DOI 10.1016/0016-5085(88)90319-8; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; LUPTON D, 1992, AUST J PUBLIC HEALTH, V16, P145; PAGANO MP, 1992, COMMUNICATING EFFECT; PHILLIPS SF, 1992, MOTILITY DISORDERS G, P299; PUTNAM SM, 1985, MED CARE, V23, P74, DOI 10.1097/00005650-198501000-00008; Roter D.L., 1992, DOCTORS TALKING PATI; Ryle JA, 1928, LANCET, V2, P1115; SMART HL, 1986, GUT, V27, P826, DOI 10.1136/gut.27.7.826; SVENDSEN JH, 1985, SCAND J GASTROENTERO, V20, P415, DOI 10.3109/00365528509089673; TALLEY NJ, 1991, GASTROENTEROLOGY, V101, P927, DOI 10.1016/0016-5085(91)90717-Y; Thompson WG., 1989, GASTROENTEROL INT, V2, P92; VERHOEF MJ, 1990, CAN MED ASSOC J, V142, P121; WAITZKIN H, 1990, MED CARE, V28, P473, DOI 10.1097/00005650-199006000-00001; WALLER SL, 1969, LANCET, V2, P753	29	248	252	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					107	+		10.7326/0003-4819-122-2-199501150-00005	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7992984				2022-12-28	WOS:A1995QC05900005
J	RAWLINGS, JS; RAWLINGS, VB; READ, JA				RAWLINGS, JS; RAWLINGS, VB; READ, JA			PREVALENCE OF LOW-BIRTH-WEIGHT AND PRETERM DELIVERY IN RELATION TO THE INTERVAL BETWEEN PREGNANCIES AMONG WHITE AND BLACK-WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERPREGNANCY INTERVAL; MATERNAL DEPLETION; RACIAL-DIFFERENCES; INFANT-MORTALITY; GESTATIONAL-AGE; RISK-FACTORS; HEALTH; CHILD; LABOR	Background. The higher mortality rate among black infants than among white infants in the United States results largely from the greater frequency of low birth weight and prematurity among black infants. Higher rates of low birth weight and preterm delivery have been associated with shorter intervals between pregnancies. Methods. We studied a racially mixed population of women in military families, who had access to free, high quality health care. A total of 1922 white and black women had two consecutive, singleton pregnancies during the study period. We determined the outcome of the second of each pair of pregnancies and the length of time between the pregnancies. Results. Short interpregnancy intervals (calculated from delivery to the next conception) were more frequent among black than among white women. A total of 7.7 percent of the 298 black women and 3.2 percent of the 1628 white women delivered premature, low-birth-weight infants (P < 0.001). Among the black women, an interpregnancy interval of less than nine months was associated with a significantly greater prevalence of preterm delivery and low birth weight in the neonates (11.6 percent, vs. 4.4 percent for longer interpregnancy intervals; P = 0.020). Among the white women, only intervals of less than three months between pregnancies were associated with a greater prevalence of prematurity and low birth weight in the infants (11.8 percent vs. 2.8 percent; P < 0.001). Of the black women, 46.3 percent had interpregnancy intervals of less than nine months; 4.2 percent of the white women had interpregnancy intervals of less than three months. Conclusions. A short interval between pregnancies is a risk factor for low birth weight and preterm delivery, and such intervals are more common among black than among white women. The relative frequency of intervals of less than nine months between pregnancies may be an important factor in the wide disparity in pregnancy outcomes between white and black women in the United States.	MADIGAN ARMY MED CTR,DEPT OBSTET & GYNECOL,TACOMA,WA 98431	Madigan Army Medical Center	RAWLINGS, JS (corresponding author), MADIGAN ARMY MED CTR,DEPT PEDIAT,TACOMA,WA 98431, USA.							ADAMS MM, 1993, OBSTET GYNECOL, V81, P65; ARMITAGE P, 1973, STATISTICAL METHODS; BAKKETEIG LS, 1979, AM J OBSTET GYNECOL, V135, P1086, DOI 10.1016/0002-9378(79)90742-7; BALLARD JL, 1991, J PEDIATR-US, V119, P417, DOI 10.1016/S0022-3476(05)82056-6; BRODY DJ, 1987, AM J PERINAT, V4, P50, DOI 10.1055/s-2007-999736; CAAN B, 1987, AM J CLIN NUTR, V45, P29, DOI 10.1093/ajcn/45.1.29; Eastman NJ, 1944, AM J OBSTET GYNECOL, V47, P445, DOI 10.1016/S0002-9378(15)32197-9; EISNER V, 1979, AM J PUBLIC HEALTH, V69, P887, DOI 10.2105/AJPH.69.9.887; ERICKSON JD, 1978, J EPIDEMIOL COMMUN H, V32, P124, DOI 10.1136/jech.32.2.124; FEDRICK J, 1973, BMJ-BRIT MED J, V4, P753, DOI 10.1136/bmj.4.5895.753; FERRAZ EM, 1988, AM J EPIDEMIOL, V128, P1111; FORTNEY JA, 1984, PUBLIC HEALTH, V98, P73, DOI 10.1016/S0033-3506(84)80099-2; FOSTER HW, 1993, J NATL MED ASSOC, V85, P516; HATHOUT H, 1982, INT J GYNECOL OBSTET, V20, P145, DOI 10.1016/0020-7292(82)90028-5; HEBERT CC, 1986, EUR J OBSTET GYN R B, V22, P125, DOI 10.1016/0028-2243(86)90056-0; HUTTLY SRA, 1992, PEDIATRICS, V89, P1049; KLEBANOFF MA, 1988, AM J PUBLIC HEALTH, V78, P667, DOI 10.2105/AJPH.78.6.667; KLEINMAN JC, 1987, NEW ENGL J MED, V317, P749, DOI 10.1056/NEJM198709173171207; LANG JM, 1990, AM J EPIDEMIOL, V132, P304, DOI 10.1093/oxfordjournals.aje.a115659; LIEBERMAN E, 1987, NEW ENGL J MED, V317, P743, DOI 10.1056/NEJM198709173171206; LIEBERMAN E, 1989, OBSTET GYNECOL, V74, P1; MAVALANKAR DV, 1991, AM J EPIDEMIOL, V133, P958, DOI 10.1093/oxfordjournals.aje.a115976; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MILLER JE, 1991, FAM PLANN PERSPECT, V23, P62, DOI 10.2307/2135451; MILLER JE, 1989, J BIOSOC SCI, V21, P235, DOI 10.1017/S0021932000017922; RAWLINGS JS, 1992, AM J DIS CHILD, V146, P313, DOI 10.1001/archpedi.1992.02160150053020; SANTELLI JS, 1990, J ADOLESCENT HEALTH, V11, P240, DOI 10.1016/0197-0070(90)90356-7; SCHOENDORF KC, 1992, NEW ENGL J MED, V326, P1522, DOI 10.1056/NEJM199206043262303; SPIERS PS, 1976, AM J EPIDEMIOL, V104, P15, DOI 10.1093/oxfordjournals.aje.a112269; SPURLOCK CW, 1987, PEDIATRICS, V80, P262; WEGMAN ME, 1992, PEDIATRICS, V90, P835; WINIKOFF B, 1983, STUD FAMILY PLANN, V14, P231, DOI 10.2307/1965748; WINKVIST A, 1992, AM J PUBLIC HEALTH, V82, P691, DOI 10.2105/AJPH.82.5.691; WISE PH, 1985, NEW ENGL J MED, V313, P360, DOI 10.1056/NEJM198508083130605; ZIMMER BG, 1979, SOC BIOL, V26, P161, DOI 10.1080/19485565.1979.9988374; [No title captured]	36	146	149	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 12	1995	332	2					69	74		10.1056/NEJM199501123320201	http://dx.doi.org/10.1056/NEJM199501123320201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QA241	7990903				2022-12-28	WOS:A1995QA24100001
J	HIROSE, K; IINO, M				HIROSE, K; IINO, M			HETEROGENEITY OF CHANNEL DENSITY IN INOSITOL-1,4,5-SENSITIVE TRISPHOSPHATE-SENSITIVE CA2+ STORES	NATURE			English	Article							VASCULAR SMOOTH-MUSCLE; CALCIUM RELEASE; FLUORESCENT INDICATOR; INTRACELLULAR STORES; 1,4,5-TRISPHOSPHATE; CELLS; MECHANISM; MOBILIZATION; DEPENDENCE	INOSITOL-1,4,5-trisphosphate (InsP(3))-induced Ca2+ release is a key mechanism for intracellular Ca2+ mobilization(1). The rate of Ca2+ release declines progressively with time until a higher concentration of InsP(3) is added, which is referred to as the incremental detection mechanism(2). Two hypotheses have been postulated to explain these complex kinetics: (1) Ca2+ stores consist of multiple compartments (quanta) with different sensitivities to InsP(3) (refs 3-7), and (2) the rate of Ca2+ release is modulated by the Ca2+ concentration in the lumen of Ca2+ stores(8-12). We studied this phenomenon by real-time measurement of the luminal Ca2+ concentration of Ca2+ stores using a Ca2+-sensitive fluorescent dye, but our results were not explained by either of these hypotheses. Here we report that the complex kinetics of Ca2+ release results from the heterogeneous density of equally InsP(3)-sensitive channels on the Ca2+ stores. This heterogeneity creates Ca2+ stores with apparently different sensitivities to InsP(3), which may have different functions in Ca2+ mobilization.			HIROSE, K (corresponding author), UNIV TOKYO, FAC MED, DEPT PHARMACOL, BUNKYO KU, TOKYO 113, JAPAN.			Hirose, Kenzo/0000-0002-8944-6513				AHNERTHILGER G, 1988, TRENDS PHARMACOL SCI, V9, P195, DOI 10.1016/0165-6147(88)90081-8; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; HIROSE K, 1993, BIOCHEM BIOPH RES CO, V194, P726, DOI 10.1006/bbrc.1993.1882; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; INO M, 1989, J GEN PHYSIOL, V94, P363, DOI 10.1085/jgp.94.2.363; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KOBAYASHI S, 1988, BIOCHEM BIOPH RES CO, V153, P625, DOI 10.1016/S0006-291X(88)81141-0; LOOMISHUSSELBEE JW, 1993, BIOCHEM J, V289, P861, DOI 10.1042/bj2890861; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MUALLEM S, 1989, J BIOL CHEM, V264, P205; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PARYS JB, 1993, J BIOL CHEM, V268, P25206; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; SHORT AD, 1993, J BIOL CHEM, V268, P25887; Somlyo AV, 1980, HDB PHYSL          2, P33; SWILLENS S, 1992, MOL PHARMACOL, V41, P110; UYAMA Y, 1992, BRIT J PHARMACOL, V106, P208, DOI 10.1111/j.1476-5381.1992.tb14316.x	29	114	116	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	1994	372	6508					791	794						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997268				2022-12-28	WOS:A1994PY21200056
J	NELSON, HD; NEVITT, MC; SCOTT, JC; STONE, KL; CUMMINGS, SR				NELSON, HD; NEVITT, MC; SCOTT, JC; STONE, KL; CUMMINGS, SR			SMOKING, ALCOHOL, AND NEUROMUSCULAR AND PHYSICAL FUNCTION OF OLDER WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; CIGARETTE-SMOKING; MAINTAINING MOBILITY; POSTMENOPAUSAL WOMEN; ARTERIAL-DISEASE; ALAMEDA COUNTY; HEART-DISEASE; BREAST-CANCER; LATE-LIFE; CONSUMPTION	Objective.-To determine the associations of current and lifetime smoking and alcohol use with physical function in an older population. Design.-Survey. Setting.-Four clinic centers in the United States. Participants.-A total of 9704 community-dwelling, ambulatory white women 65 years or older recruited from four areas of the United States. Main Outcome Measures.-Twelve performance tests of muscle strength, agility and coordination, gait and balance, and self-reported functional status. Results.-Compared with women who never smoked, current smokers had significantly poorer function on all of the performance measures except grip strength after adjusting for age, history of stroke, body mass index, clinic site, physical activity, and alcohol use (P<.05). This decrease in function was 50% to 100% as great as that associated with a 5-year increase in age, and most measures worsened with increasing numbers of pack-years. Compared with current moderate drinkers, nondrinkers had significantly poorer function on all of the performance measures except tandem walk (P<.05). Evaluation of a dose effect with alcohol was limited by the small number of heavy drinkers in the study. Conclusions.-In this population, women who currently smoke are weaker and have poorer balance and poorer performance on measures of integrated physical function than nonsmokers. Smoking is associated with a decline in physical function. Current moderate drinkers have better physical function compared with nondrinkers, but associations of function with heavy drinkers could not be assessed.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV MARYLAND,DEPT EPIDEMIOL & PREVENT MED,BALTIMORE,MD	University of California System; University of California San Francisco; University System of Maryland; University of Maryland Baltimore	NELSON, HD (corresponding author), OREGON HLTH SCI UNIV,DIV GEN INTERNAL MED,3181 SW SAM JACKSON PK RD,L475,PORTLAND,OR 97201, USA.			Ensrud, Kristine/0000-0002-9069-3036; Cauley, Jane A/0000-0003-0752-4408				ADAMS RD, 1977, PRINCIPLES NEUROLOGY, P812; ALANKO T, 1984, RES ADV ALCOHOL DRUG, V8, P209; ARMOR D, 1982, ENCY HDB ALCOHOLISM; BAER L, 1985, AM J MED, V78, P564, DOI 10.1016/0002-9343(85)90396-1; BALFOUR DJK, 1982, PHARMACOL THERAPEUT, V16, P269, DOI 10.1016/0163-7258(82)90058-4; BELCH JJF, 1984, THROMB HAEMOSTASIS, V51, P6; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; BOHANNON RW, 1986, PHYS THER, V66, P206, DOI 10.1093/ptj/66.2.206; BRANCH LG, 1982, AM J PUBLIC HEALTH, V72, P1373, DOI 10.2105/AJPH.72.12.1373; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; BUSBY WJ, 1988, J AM GERIATR SOC, V36, P301, DOI 10.1111/j.1532-5415.1988.tb02355.x; CASSIDENTI DL, 1990, AM J OBSTET GYNECOL, V163, P1953, DOI 10.1016/0002-9378(90)90780-B; CAULEY JA, 1987, J CHRON DIS, V40, P115, DOI 10.1016/0021-9681(87)90062-2; CERHAN JR, 1993, AM J EPIDEMIOL, V137, P870, DOI 10.1093/oxfordjournals.aje.a116748; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; CRIQUI MH, 1989, AM J EPIDEMIOL, V129, P1110, DOI 10.1093/oxfordjournals.aje.a115233; FITTI JE, 1987, VITAL HEALTH STAT, V21, P1; FORTMANN SP, 1986, AM J EPIDEMIOL, V124, P706, DOI 10.1093/oxfordjournals.aje.a114445; FOWKES FGR, 1989, BRIT MED J, V298, P405, DOI 10.1136/bmj.298.6671.405; FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205; GARG R, 1993, ARCH INTERN MED, V153, P1211, DOI 10.1001/archinte.153.10.1211; GAVALER JS, 1985, J STUD ALCOHOL, V46, P495, DOI 10.15288/jsa.1985.46.495; GURALNIK JM, 1989, AM J PUBLIC HEALTH, V79, P703, DOI 10.2105/AJPH.79.6.703; GURALNIK JM, 1993, AM J EPIDEMIOL, V137, P845, DOI 10.1093/oxfordjournals.aje.a116746; HARRIS T, 1989, AM J PUBLIC HEALTH, V79, P698, DOI 10.2105/AJPH.79.6.698; HATCHER EM, 1977, ALCOHOL CLIN EXP RES, V1, P371; HOFSTETTER A, 1986, NEW ENGL J MED, V314, P79, DOI 10.1056/NEJM198601093140204; KANNEL WB, 1985, J AM GERIATR SOC, V33, P13, DOI 10.1111/j.1532-5415.1985.tb02853.x; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; KAWACHI I, 1993, JAMA-J AM MED ASSOC, V269, P232, DOI 10.1001/jama.269.2.232; KIRCH DG, 1988, CELL MOL NEUROBIOL, V8, P285, DOI 10.1007/BF00711170; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KRISKA AM, 1988, AM J EPIDEMIOL, V127, P1053, DOI 10.1093/oxfordjournals.aje.a114881; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; LACROIX AZ, 1993, AM J EPIDEMIOL, V137, P858, DOI 10.1093/oxfordjournals.aje.a116747; LAPORTE RE, 1983, J GERONTOL, V38, P394, DOI 10.1093/geronj/38.4.394; Leveille S. G., 1992, J WOMENS HEALTH, V1, P53; Lohman TG, 1988, ANTHROPOMETRIC STAND, P177, DOI DOI 10.1002/AJHB.1310040323; MCBRIDE PE, 1992, MED CLIN N AM, V76, P333, DOI 10.1016/S0025-7125(16)30356-X; MOR V, 1989, J CLIN EPIDEMIOL, V42, P895, DOI 10.1016/0895-4356(89)90103-0; NEVITT JC, 1990, 2ND 50 YEARS PROMOTI, P263; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; NOWAK J, 1987, CIRCULATION, V76, P6, DOI 10.1161/01.CIR.76.1.6; OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PINSKY JL, 1987, J CHRON DIS, V40, pS159, DOI 10.1016/S0021-9681(87)80045-0; SCHATZKIN A, 1987, NEW ENGL J MED, V316, P1169, DOI 10.1056/NEJM198705073161901; SCHERR PA, 1992, J AM GERIATR SOC, V40, P651, DOI 10.1111/j.1532-5415.1992.tb01954.x; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; TARTER RE, 1975, DIS NERV SYST, V36, P185; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701; VOGT MT, 1993, AM J EPIDEMIOL, V137, P559, DOI 10.1093/oxfordjournals.aje.a116709; WAGENKNECHT LE, 1992, AM J PUBLIC HEALTH, V82, P33, DOI 10.2105/AJPH.82.1.33; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; 1980, HLTH CONSEQUENCES SM	57	145	149	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1825	1831		10.1001/jama.272.23.1825	http://dx.doi.org/10.1001/jama.272.23.1825			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PW980	7990216				2022-12-28	WOS:A1994PW98000030
J	DIAMOND, J				DIAMOND, J			HIV TESTING IN PRISON - WHATS THE CONTROVERSY	LANCET			English	Editorial Material							INMATES				DIAMOND, J (corresponding author), MERRITHEW MEM HOSP,MARTINEZ,CA 94553, USA.							ALBERT P, 1992, AIDS PRACTICE MANUAL, P14; ANDRUS JK, 1989, AM J PUBLIC HEALTH, V79, P840, DOI 10.2105/AJPH.79.7.840; BEHRENDT C, 1994, AM J EPIDEMIOL, V139, P918, DOI 10.1093/oxfordjournals.aje.a117098; CASTRO K, 1991, 7 INT C AIDS FLOR; GREENBERG R, 1994, 10 INT C AIDS YOK; HAMMETT T, 1994, 1992 UPDATE HIV AIDS; HARDING TW, 1992, WHO GLOBAL PROGRAMME, P15; HORSBURGH CR, 1990, AM J PUBLIC HEALTH, V80, P209, DOI 10.2105/AJPH.80.2.209; HOXIE NJ, 1990, AM J PUBLIC HEALTH, V80, P1129, DOI 10.2105/AJPH.80.9.1129; MAUER M, 1994, AM BARS INT USE INCA; 1994, MIDYEAR PRISONER STA; 1994, HIV AIDS SURVEILLANC, V6, P15; 1990, MMWR-MORBID MORTAL W, V39, P273; 1993, WHO GUIDELINES HIV I	14	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1650	1651		10.1016/S0140-6736(94)90451-0	http://dx.doi.org/10.1016/S0140-6736(94)90451-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PX302	7996954				2022-12-28	WOS:A1994PX30200002
J	LUNDBERG, JON; HELLSTROM, PM; LUNDBERG, JM; ALVING, K				LUNDBERG, JON; HELLSTROM, PM; LUNDBERG, JM; ALVING, K			GREATLY INCREASED LUMINAL NITRIC-OXIDE IN ULCERATIVE-COLITIS	LANCET			English	Note								A role for nitric oxide (NO) in ulcerative colitis has been suggested because mucosal NO synthase activity, measured by indirect assays, is increased in this disorder. We directly measured luminal NO in the colons of twelve controls and six patients with active ulcerative colitis. During colonoscopy, gas was aspirated from different parts of the colon and immediately analysed by a chemiluminescence technique. NO concentrations were more than 100 times higher in the patients than in the controls. Luminal NO is rapidly and easily measurable and may be used to monitor inflammatory bowel disease.	KAROLINSKA HOSP,DEPT MED,S-10401 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital	LUNDBERG, JON (corresponding author), KAROLINSKA INST,DEPT PHARMACOL,S-17177 STOCKHOLM,SWEDEN.		Alving, Kjell/M-4579-2014	Alving, Kjell/0000-0003-0784-0443; Hellstrom, Per/0000-0001-8428-0772; Lundberg, Jon/0000-0002-0174-5210				ALVING K, 1993, EUR RESPIR J, V6, P1368; BOUGHTONSMITH NK, 1993, LANCET, V342, P338, DOI 10.1016/0140-6736(93)91476-3; HARTLEY MG, 1992, J MED MICROBIOL, V36, P96, DOI 10.1099/00222615-36-2-96; JI XB, 1989, BIOCHEM ARCH, V5, P61; LUNDBERG JON, 1994, GUT, V35, P1543, DOI 10.1136/gut.35.11.1543; LUNDBERG JON, 1994, EUR RESPIR J, V7, P1501, DOI 10.1183/09031936.94.07081501; MIDDLETON SJ, 1993, LANCET, V341, P465, DOI 10.1016/0140-6736(93)90211-X; MONCADA S, 1991, PHARMACOL REV, V43, P109; TEPPERMAN BL, 1993, AM J PHYSIOL, V265, pG214, DOI 10.1152/ajpgi.1993.265.2.G214; WHITTLE BJR, 1994, NITRIC OXIDE GASTROI, P267	10	224	236	1	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1673	1674		10.1016/S0140-6736(94)90460-X	http://dx.doi.org/10.1016/S0140-6736(94)90460-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996962				2022-12-28	WOS:A1994PX30200011
J	BENEZRA, R				BENEZRA, R			AN INTERMOLECULAR DISULFIDE BOND STABILIZES E2A HOMODIMERS AND IS REQUIRED FOR DNA-BINDING AT PHYSIOLOGICAL TEMPERATURES	CELL			English	Article							LOOP-HELIX PROTEINS; NF-KAPPA-B; TRANSCRIPTIONAL-ACTIVATION; MYOD; INVIVO; GENE; DAUGHTERLESS; REGULATOR; MUTATIONS; SUBUNITS	It is demonstrated in this report that purified E2A helix-loop-helix (HLH) proteins spontaneously form homodimers that are linked by an intermolecular disulfide bond. These homodimers bind DNA at physiological temperatures but fail to associate with either Id or MyoD. When the disulfide bond is reduced by an activity present in muscle cell lysates or disrupted by site-directed mutagenesis, the monomeric form of the protein is strongly favored at 37 degrees C. These E2A monomers cannot bind DNA but heterodimerize efficiently with Id and MyoD. It is also shown that an intermolecular disulfide bond cross-links E2A homodimers in B cells but not in muscle cells in which only heterodimers have been detected. These results suggest a novel mechanism for regulating the dimerization status and DNA binding properties of E2A HLH transcription factors.			BENEZRA, R (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DAVIS RL, 1990, CELL, V60, P773; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GOLDENBERG DP, 1993, BIOCHEMISTRY-US, V32, P2835, DOI 10.1021/bi00062a015; HARA E, 1994, J BIOL CHEM, V269, P2139; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MAK KL, 1992, MOL CELL BIOL, V12, P4334, DOI 10.1128/MCB.12.10.4334; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SHIRAKATA M, 1993, GENE DEV, V7, P2456, DOI 10.1101/gad.7.12a.2456; SHUE GL, 1994, J BIOL CHEM, V269, P2707; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; THAYER MJ, 1993, P NATL ACAD SCI USA, V90, P6483, DOI 10.1073/pnas.90.14.6483; TOLEDANO N, 1994, CELL, V78, P897; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; XANTHOUDAKIS S, 1992, EMBO J, V121, P3323	39	90	90	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					1057	1067		10.1016/0092-8674(94)90036-1	http://dx.doi.org/10.1016/0092-8674(94)90036-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001133				2022-12-28	WOS:A1994PY08600015
J	XU, M; HU, XT; COOPER, DC; MORATALLA, R; GRAYBIEL, AM; WHITE, FJ; TONEGAWA, S				XU, M; HU, XT; COOPER, DC; MORATALLA, R; GRAYBIEL, AM; WHITE, FJ; TONEGAWA, S			ELIMINATION OF COCAINE-INDUCED HYPERACTIVITY AND DOPAMINE-MEDIATED NEUROPHYSIOLOGICAL EFFECTS IN DOPAMINE D1 RECEPTOR MUTANT MICE	CELL			English	Article							RAT NUCLEUS-ACCUMBENS; DISCRIMINATIVE STIMULUS PROPERTIES; LOCOMOTOR HYPERACTIVITY; STIMULATION ENABLES; ADENYLATE-CYCLASE; VENTRAL STRIATUM; XENOPUS OOCYTES; BASAL GANGLIA; D2 RECEPTORS; BRAIN	The brain mesoaccumbens dopamine system is intricately Involved in the psychomotor stimulant activities of cocaine. However, the extent to which different dopamine receptors mediate these effects has not yet been firmly established. The present study used dopamine D1 receptor mutant mice produced by gene targeting to investigate the role of this receptor in the effects induced by cocaine. In contrast with wild-type mice, which showed a dose-dependent increase in locomotion, D1 mutant mice exhibited a dose-dependent decrease. Electrophysiological studies of dopamine-sensitive nucleus accumbens neurons demonstrated a marked reduction in the inhibitory effects of cocaine on the generation of action potentials. In addition, the inhibitory effects of dopamine as well as D1 and D2 agonists were almost completely abolished, whereas those of serotonin were unaffected. DS-like dopamine receptor binding was also normal. These results demonstrate the essential role of the D1 receptor in the locomotor stimulant effects of cocaine and in dopamine-mediated neurophysiological effects within the nucleus accumbens.	MIT, CTR LEARNING & MEM, DEPT BIOL, CAMBRIDGE, MA 02139 USA; FINCH UNIV HLTH SCI, CHICAGO MED SCH, DEPT NEUROSCI, NEUROPSYCHOPHARMACOL LAB, N CHICAGO, IL 60064 USA; MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Chicago Medical School; Massachusetts Institute of Technology (MIT)	XU, M (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.		Moratalla, Rosario V/H-9280-2015	Moratalla, Rosario V/0000-0002-7623-8010; Graybiel, Ann/0000-0002-4326-7720	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004093, R01DA008037, R37DA004093] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 08037, DA 00207, DA 04093] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ARNT J, 1987, EUR J PHARMACOL, V133, P137, DOI 10.1016/0014-2999(87)90144-0; ARNT J, 1992, EUR J PHARMACOL, V213, P259, DOI 10.1016/0014-2999(92)90690-6; BARRETT RL, 1989, PSYCHOPHARMACOLOGY, V99, P13, DOI 10.1007/BF00634445; Bergman J., 1990, Behav Pharmacol, V1, P355; BERTORELLO AM, 1990, NATURE, V347, P386, DOI 10.1038/347386a0; BHAT RV, 1993, J PHARMACOL EXP THER, V267, P496; BISCHOFF S, 1986, EUR J PHARMACOL, V129, P367, DOI 10.1016/0014-2999(86)90449-8; BRADBERRY CW, 1993, J NEUROCHEM, V60, P1429, DOI 10.1111/j.1471-4159.1993.tb03305.x; BRIGGS CA, 1991, BRIT J PHARMACOL, V104, P1038, DOI 10.1111/j.1476-5381.1991.tb12546.x; BRITTON DR, 1991, PHARMACOL BIOCHEM BE, V39, P911, DOI 10.1016/0091-3057(91)90052-4; CABIB S, 1991, PSYCHOPHARMACOLOGY, V105, P335, DOI 10.1007/BF02244427; CAINE SB, 1994, J PHARMACOL EXP THER, V270, P209; CALLAHAN PM, 1994, PSYCHOPHARMACOLOGY, V115, P110, DOI 10.1007/BF02244759; CALLAHAN PM, 1991, PSYCHOPHARMACOLOGY, V103, P50, DOI 10.1007/BF02244073; CAMPS M, 1989, NEUROSCIENCE, V28, P275, DOI 10.1016/0306-4522(89)90179-6; CHURCH WH, 1987, EUR J PHARMACOL, V139, P345, DOI 10.1016/0014-2999(87)90592-9; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; CLARK D, 1987, SYNAPSE, V1, P347, DOI 10.1002/syn.890010408; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; GALEY D, 1977, BRAIN RES, V124, P83, DOI 10.1016/0006-8993(77)90865-4; GERFEN CR, 1992, ANNU REV NEUROSCI, V15, P285, DOI 10.1146/annurev.neuro.15.1.285; GEYER MA, 1976, BRAIN RES, V106, P257, DOI 10.1016/0006-8993(76)91024-6; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; GREEN AR, 1976, NATURE, V260, P487; HU XT, 1990, J NEUROSCI, V10, P2318; HU XT, 1994, SYNAPSE, V17, P43, DOI 10.1002/syn.890170106; HUBNER CB, 1991, PSYCHOPHARMACOLOGY, V105, P151, DOI 10.1007/BF02244301; JACOBS BL, 1976, LIFE SCI, V19, P777, DOI 10.1016/0024-3205(76)90303-9; JOHANSEN PA, 1991, J NEURAL TRANSM-GEN, V86, P97, DOI 10.1007/BF01250571; JOYCE EM, 1983, NEUROPHARMACOLOGY, V22, P1141, DOI 10.1016/0028-3908(83)90051-5; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; KOOB GF, 1987, NEUROSCI LETT, V79, P315, DOI 10.1016/0304-3940(87)90451-4; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; LINDVALL O, 1983, CHEM NEUROANATOMY, P229; LOH EA, 1990, PSYCHOPHARMACOLOGY, V101, P262, DOI 10.1007/BF02244137; MAHAN LC, 1990, P NATL ACAD SCI USA, V87, P2196, DOI 10.1073/pnas.87.6.2196; MALDONADO R, 1993, PHARMACOL BIOCHEM BE, V45, P239, DOI 10.1016/0091-3057(93)90112-7; Marsden C. D., 1992, SEMIN NEUROSCI, V4, P171; MCQUADE RD, 1988, LIFE SCI, V43, P1861, DOI 10.1016/S0024-3205(88)80003-1; MOGENSON GJ, 1980, PROG NEUROBIOL, V14, P69, DOI 10.1016/0301-0082(80)90018-0; MOGENSON GJ, 1987, PROG PSYCHOB PHYSIOL, V12, P117; MURRAY AM, 1989, EUR J PHARMACOL, V160, P377, DOI 10.1016/0014-2999(89)90093-9; PAUL ML, 1992, J NEUROSCI, V12, P3729, DOI 10.1523/jneurosci.12-10-03729.1992; PHILLIPS AG, 1983, PROG NEURO-PSYCHOPH, V7, P585, DOI 10.1016/0278-5846(83)90029-5; PRADHAN SN, 1978, COMMUN PSYCHOPHARMAC, V2, P481; PYCOCK CJ, 1980, NATURE, V286, P74, DOI 10.1038/286074a0; RAPPAPORT MS, 1993, BRAIN RES, V616, P242, DOI 10.1016/0006-8993(93)90215-9; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROBBINS TW, 1989, NEUROSCI BIOBEHAV R, V13, P155, DOI 10.1016/S0149-7634(89)80025-9; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; SEGAL DS, 1987, PSYCHOPHARMACOL BULL, V23, P417; SIMON H, 1988, BRAIN RES, V447, P335, DOI 10.1016/0006-8993(88)91136-5; Spano P F, 1978, Adv Biochem Psychopharmacol, V19, P155; SPEALMAN RD, 1991, J PHARMACOL EXP THER, V258, P945; STOOF JC, 1984, LIFE SCI, V35, P2281, DOI 10.1016/0024-3205(84)90519-8; SURMEIER DJ, 1992, P NATL ACAD SCI USA, V89, P10178, DOI 10.1073/pnas.89.21.10178; SURMEIER DJ, 1993, TRENDS NEUROSCI, V16, P299, DOI 10.1016/0166-2236(93)90103-S; SVENSSON K, 1994, J NEURAL TRANSM-GEN, V95, P71, DOI 10.1007/BF01283032; TASSIN JP, 1978, BRAIN RES, V141, P267, DOI 10.1016/0006-8993(78)90197-X; TAYLOR D, 1979, RES COMMUN PSYCH PSY, V4, P447; TELLA SR, 1994, PHARMACOL BIOCHEM BE, V48, P151, DOI 10.1016/0091-3057(94)90511-8; UNDIE AS, 1990, J PHARMACOL EXP THER, V253, P987; VEZINA P, 1991, EUR J NEUROSCI, V3, P1001, DOI 10.1111/j.1460-9568.1991.tb00036.x; WACHTEL SR, 1992, PSYCHOPHARMACOLOGY, V109, P41, DOI 10.1007/BF02245478; WACHTEL SR, 1989, SYNAPSE, V4, P327, DOI 10.1002/syn.890040409; WADDINGTON JL, 1993, D1 D2 DOPAMINE RECEP, P51; WALAAS I, 1981, NEUROSCIENCE, V6, P399, DOI 10.1016/0306-4522(81)90132-9; WALTERS JR, 1987, SCIENCE, V236, P719; WATERS N, 1993, J NEURAL TRANSM-GEN, V94, P11, DOI 10.1007/BF01244979; White F.J., 1990, Behav Pharmacol, V1, P303; WHITE FJ, 1986, J NEUROSCI, V6, P274; WHITE FJ, 1988, PHARMACOL BIOCHEM BE, V30, P189, DOI 10.1016/0091-3057(88)90442-X; WHITE FJ, 1987, EUR J PHARMACOL, V135, P101, DOI 10.1016/0014-2999(87)90764-3; WHITE FJ, 1993, J PHARMACOL EXP THER, V266, P1075; WHITE FJ, 1994, IN PRESS NEUROBIOLOG; WHITE FJ, 1993, D1 D2 DOPAMINE RECEP, P79; WHITE FJ, 1992, COCAINE PHARM PHYSL, P261; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; WOOD DM, 1989, PHARMACOL BIOCHEM BE, V33, P453, DOI 10.1016/0091-3057(89)90529-7; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; ZAHM DS, 1992, NEUROSCIENCE, V50, P751, DOI 10.1016/0306-4522(92)90202-D	83	292	297	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 16	1994	79	6					945	955		10.1016/0092-8674(94)90026-4	http://dx.doi.org/10.1016/0092-8674(94)90026-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001143				2022-12-28	WOS:A1994PY08600005
J	ABBOTT, A				ABBOTT, A			BOOTSTRAPPING A NEW INSTITUTE	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					607	607						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990947				2022-12-28	WOS:A1994PX30700043
J	LEVY, HL; WAISBREN, SE; LOBBREGT, D; ALLRED, E; SCHULER, A; TREFZ, FK; SCHWEITZER, SM; SARDHARWALLA, IB; WALTER, JH; BARWELL, BE; BERLIN, CM; LEVITON, A				LEVY, HL; WAISBREN, SE; LOBBREGT, D; ALLRED, E; SCHULER, A; TREFZ, FK; SCHWEITZER, SM; SARDHARWALLA, IB; WALTER, JH; BARWELL, BE; BERLIN, CM; LEVITON, A			MATERNAL MILD HYPERPHENYLALANINEMIA - AN INTERNATIONAL SURVEY OF OFFSPRING OUTCOME	LANCET			English	Article							HEAD CIRCUMFERENCE; PHENYLKETONURIA; INTELLIGENCE; PREGNANCIES; FETUS; BIRTH	Maternal phenylketonuria (PKU) has adverse effects on the offspring including microcephaly, mental retardation, congenital heart disease, and intrauterine growth retardation. Maternal non-PKU mild hyperphenyalaninaemia (MHP) is believed to be benign, but whether there may be long-term consequences to offspring is unclear. In an international survey we have obtained information about 86 MHP mothers with MHP (blood phenylalanine 167-715 mu mol/L), their 219 untreated pregnancies, and 173 offspring. Spontaneous fetal loss (13% of pregnancies), congenital heart disease (2.3% of offspring), and severe non-cardiac anomalies (2.9% of offspring) occurred at frequencies within expected limits for the general population. For weight and length at birth the median percentile was the 50th but that for birth head circumference was the 25th. Median z-scores for birth length and head circumference were significantly lower for offspring of mothers with phenylalanine concentrations above 400 mu mol/L than for those whose mothers had lower values (p=0.05 and p=0.005, respectively). The median intelligence quotient (IQ) of the offspring (3-27 years) was 100 for those whose mothers had higher phenylalanine concentrations and 108 for those of the lower phenylalaninaemia group. However, offspring IQ correlated slightly more closely with maternal IQ (r=0.53, p<0.01) than with maternal phenylalanine concentration (r=0.45, p=0.02). Maternal MHP does not seem to have serious consequences for the fetus. A maternal phenylalanine concentration of less than 400 mu mol/L does not warrant intervention. Nevertheless, maternal blood phenylalanine above this value is associated with slightly lower birth measurements and offspring IQ than lower maternal blood phenylalanine concentrations.	HARVARD UNIV,SCH MED,BOSTON,MA; PKU LAB,BUDAPEST,HUNGARY; UNIV HEIDELBERG,HEIDELBERG,GERMANY; CHILDRENS HOSP,HANNOVER,GERMANY; ROYAL MANCHESTER CHILDRENS HOSP,MANCHESTER,LANCS,ENGLAND; SHEFFIELD CHILDRENS HOSP,REG NEONATAL SCREENING LAB,SHEFFIELD,S YORKSHIRE,ENGLAND; PENN STATE UNIV,MILTON S HERSHEY MED CTR,HERSHEY,PA 17033	Harvard University; Harvard Medical School; Ruprecht Karls University Heidelberg; Royal Manchester Children's Hospital; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	LEVY, HL (corresponding author), CHILDRENS HOSP,IC SMITH ROOM 106,BOSTON,MA 02115, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD023149] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-2-3149] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CARTIER L, 1982, AM J PUBLIC HEALTH, V72, P1386, DOI 10.2105/AJPH.72.12.1386; COSTELLO PM, 1994, EUR J PEDIATR, V153, P260; DORMAN C, 1991, DEV MED CHILD NEUROL, V33, P267; DROGARI E, 1987, LANCET, V2, P927; GARDINER RM, 1990, J INHERIT METAB DIS, V13, P627, DOI 10.1007/BF01799517; GUTTLER F, 1980, ACTA PAEDIATR SC   S, V280, P7; HEINONEN OP, 1977, BIRTH DEFECTS DRUGS, P65; KOCH R, 1993, AM J DIS CHILD, V147, P1224, DOI 10.1001/archpedi.1993.02160350098015; LENKE RR, 1980, NEW ENGL J MED, V303, P1202, DOI 10.1056/NEJM198011203032104; LEVITON A, 1993, J CHILD NEUROL, V8, P64, DOI 10.1177/088307389300800109; LEVY HL, 1987, ENZYME, V38, P312, DOI 10.1159/000469221; LEVY HL, 1992, AM J MED GENET, V44, P439, DOI 10.1002/ajmg.1320440411; LEVY HL, 1983, NEW ENGL J MED, V309, P1269, DOI 10.1056/NEJM198311243092101; LEVY HL, 1984, J PEDIATR-US, V104, P245, DOI 10.1016/S0022-3476(84)81003-3; LYNN R, 1987, NATURE, V328, P797, DOI 10.1038/328797a0; Matarazzo J. D., 1972, WECHSLERS MEASUREMEN; MITCHELL SC, 1971, CIRCULATION, V43, P323, DOI 10.1161/01.CIR.43.3.323; NIKLASSON A, 1991, ACTA PAEDIATR SCAND, V80, P756, DOI 10.1111/j.1651-2227.1991.tb11945.x; NISWANDER KR, 1972, DHEW NIH73379 PUBL; PLATT LD, 1992, AM J OBSTET GYNECOL, V166, P1150, DOI 10.1016/S0002-9378(11)90601-2; ROCHE AF, 1987, PEDIATRICS, V79, P706; SCHOONHEYT WE, 1994, CLIN CHIM ACTA, V225, P165, DOI 10.1016/0009-8981(94)90044-2; SMITH I, 1990, ARCH DIS CHILD, V65, P472, DOI 10.1136/adc.65.5.472; VENTURA SJ, 1992, MONTHLY VITAL ST 6 S, V41; WAISBREN SE, 1990, J PEDIATR-US, V116, P926, DOI 10.1016/S0022-3476(05)80654-7; WAISBREN SE, 1988, AM J PUBLIC HEALTH, V78, P789, DOI 10.2105/AJPH.78.7.789; [No title captured]; 1994, J PEDIATR, V124, P383	28	35	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1589	1594		10.1016/S0140-6736(94)90404-9	http://dx.doi.org/10.1016/S0140-6736(94)90404-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983992				2022-12-28	WOS:A1994PW05100007
J	KEYSTONE, JS				KEYSTONE, JS			SINGLE-DOSE ANTIBIOTIC-TREATMENT FOR TRAVELERS DIARRHEA	LANCET			English	Editorial Material							TRAVELERS DIARRHEA; CIPROFLOXACIN; SHIGELLOSIS; PREVENTION; THERAPY				KEYSTONE, JS (corresponding author), UNIV TORONTO,TORONTO HOSP,DEPT MED,TROP DIS UNIT,TORONTO,ON,CANADA.							BENNISH ML, 1992, ANN INTERN MED, V117, P727, DOI 10.7326/0003-4819-117-9-727; DUPONT HL, 1985, ANN INTERN MED, V102, P260, DOI 10.7326/0003-4819-102-2-260; DUPONT HL, 1993, NEW ENGL J MED, V328, P1821, DOI 10.1056/NEJM199306243282507; DUPONT HL, 1993, DRUGS, V6, P910; FARTHING MJG, 1992, GASTROENTEROLOGY INT, V5, P162; GORBACH SL, 1982, NEW ENGL J MED, V307, P881, DOI 10.1056/NEJM198209303071409; GOTUZZO E, 1989, ANTIMICROB AGENTS CH, V33, P1101, DOI 10.1128/AAC.33.7.1101; MURPHY GS, 1985, ANN INTERN MED, V102, P582; PETRUCCELLI BP, 1992, J INFECT DIS, V165, P557, DOI 10.1093/infdis/165.3.557; SALAM I, 1994, LANCET, V344, P1537, DOI 10.1016/S0140-6736(94)90350-6; STEFFEN R, 1986, REV INFECT DIS, V8, pS122; STEFFEN R, 1987, J INFECT DIS, V156, P84, DOI 10.1093/infdis/156.1.84; Taylor, 1994, J Travel Med, V1, P119, DOI 10.1111/j.1708-8305.1994.tb00576.x; TELLIER R, 1992, INFECT DIS CLIN N AM, V6, P333	14	8	8	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1520	1521		10.1016/S0140-6736(94)90343-3	http://dx.doi.org/10.1016/S0140-6736(94)90343-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983948				2022-12-28	WOS:A1994PV01700003
J	OBRIEN, E				OBRIEN, E			THE LAND MINE CRISIS - A GROWING EPIDEMIC OF MUTILATION	LANCET			English	Editorial Material											OBRIEN, E (corresponding author), ROYAL COLL SURGEONS IRELAND,SCH MED,DUBLIN,IRELAND.							Cahill K. M., 1995, CLEARING FIELDS SOLU; MCGRATH R, 1993, LANCET, V342, P628, DOI 10.1016/0140-6736(93)91751-7	2	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1522	1522		10.1016/S0140-6736(94)90345-X	http://dx.doi.org/10.1016/S0140-6736(94)90345-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983950				2022-12-28	WOS:A1994PV01700005
J	HAHNE, K; HAUCKE, V; RAMAGE, L; SCHATZ, G				HAHNE, K; HAUCKE, V; RAMAGE, L; SCHATZ, G			INCOMPLETE ARREST IN THE OUTER-MEMBRANE SORTS NADH-CYTOCHROME-B(5) REDUCTASE TO 2 DIFFERENT SUBMITOCHONDRIAL COMPARTMENTS	CELL			English	Article							MITOCHONDRIAL PROTEIN IMPORT; AMINO-TERMINAL REGION; RAT-LIVER MICROSOMES; YEAST MITOCHONDRIA; INTERMEMBRANE SPACE; SACCHAROMYCES-CEREVISIAE; INNER MEMBRANE; NADH-CYTOCHROME-B5 REDUCTASE; ENDOPLASMIC-RETICULUM; GEL-ELECTROPHORESIS	The S. cerevisiae gene MCR1 encodes two mitochondrial isoforms of NADH-cytochrome b(5) reductase. The primary translation product has an amino-terminal matrix-targeting signal, followed by a stretch of 21 uncharged amino acids. This precursor protein is inserted into the outer membrane, but only about one-third of the molecules become firmly anchored to the outer face of that membrane. The remaining molecules pass through the outer membrane into the inner membrane, are cleaved by inner membrane protease 1, and are released into the intermembrane space. Incomplete translocation arrest in the outer membrane is a novel mechanism by which the product of a single gene is sorted into different compartments of the same organelle.	UNIV BASEL, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND	University of Basel				Haucke, Volker/0000-0003-3119-6993	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037803] Funding Source: NIH RePORTER; NIGMS NIH HHS [2 RO1 GM37803] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BIBUS CR, 1988, J BIOL CHEM, V263, P13097; BOGUTA M, 1994, MOL CELL BIOL, V14, P2298, DOI 10.1128/MCB.14.4.2298; BORGESE N, 1990, BIOCHEM J, V266, P341, DOI 10.1042/bj2660341; BORGESE N, 1986, BIOCHEM J, V239, P393, DOI 10.1042/bj2390393; BRANDT A, 1991, METHOD CELL BIOL, V34, P369; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CHEVALLIER MR, 1980, GENE, V11, P11, DOI 10.1016/0378-1119(80)90082-7; CSUKAI M, 1994, EUR J BIOCHEM, V219, P441, DOI 10.1111/j.1432-1033.1994.tb19957.x; DAUM G, 1982, J BIOL CHEM, V257, P3028; DESANTIS A, 1984, ARCH BIOCHEM BIOPHYS, V232, P354; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GIETL C, 1992, BIOCHIM BIOPHYS ACTA, V1100, P217, DOI 10.1016/0167-4838(92)90476-T; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HASE T, 1986, FEBS LETT, V197, P199, DOI 10.1016/0014-5793(86)80326-X; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HEIM R, 1992, EUR J BIOCHEM, V205, P333, DOI 10.1111/j.1432-1033.1992.tb16784.x; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; HINES V, 1993, J BIOL CHEM, V268, P449; HORST M, 1993, EMBO J, V12, P3035, DOI 10.1002/j.1460-2075.1993.tb05972.x; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; JENSEN RE, 1992, MOL CELL BIOL, V12, P4677, DOI 10.1128/MCB.12.10.4677; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P187, DOI 10.1093/oxfordjournals.jbchem.a131434; Maniatis T., 1982, MOL CLONING; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NAKAI M, 1993, J BIOL CHEM, V268, P24262; NAKAI M, 1989, J BIOCHEM-TOKYO, V106, P181, DOI 10.1093/oxfordjournals.jbchem.a122811; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; NISHINO H, 1986, J BIOCHEM, V100, P1523, DOI 10.1093/oxfordjournals.jbchem.a121859; OSHINO N, 1971, J BIOCHEM, V69, P155, DOI 10.1093/oxfordjournals.jbchem.a129444; OZOLS J, 1985, J BIOL CHEM, V260, P1953; PASSON PG, 1972, BIOCHIM BIOPHYS ACTA, V275, P62, DOI 10.1016/0005-2728(72)90024-2; PERIMAN D, 1984, MOL CELL BIOL, V4, P1682; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PIETRINI G, 1992, J CELL BIOL, V117, P975, DOI 10.1083/jcb.117.5.975; PRATJE E, 1986, EMBO J, V5, P1313, DOI 10.1002/j.1460-2075.1986.tb04361.x; PROSSER IM, 1990, PLANT MOL BIOL, V15, P187, DOI 10.1007/BF00017743; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; REDDY VVR, 1977, J BIOL CHEM, V252, P2797; RIEZMAN H, 1983, EMBO J, V2, P1105, DOI 10.1002/j.1460-2075.1983.tb01553.x; ROISE D, 1988, J BIOL CHEM, V263, P4509; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ G, 1993, PROTEIN SCI, V2, P141; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SCOTT EM, 1959, BIOCHIM BIOPHYS ACTA, V34, P584, DOI 10.1016/0006-3002(59)90324-5; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPIESS M, 1989, J BIOL CHEM, V264, P19117; TOMATSU S, 1989, GENE, V80, P353; WESSELS HP, 1990, J CELL BIOL, V111, P2923, DOI 10.1083/jcb.111.6.2923; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YUBISUI T, 1987, P NATL ACAD SCI USA, V84, P3609, DOI 10.1073/pnas.84.11.3609; YUBISUI T, 1986, J BIOCH, V99, P401	70	106	107	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					829	839		10.1016/0092-8674(94)90072-8	http://dx.doi.org/10.1016/0092-8674(94)90072-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001120				2022-12-28	WOS:A1994PW05400010
J	SCHIESTL, RH; KHOGALI, F; CARLS, N				SCHIESTL, RH; KHOGALI, F; CARLS, N			REVERSION OF THE MOUSE PINK-EYED UNSTABLE MUTATION INDUCED BY LOW-DOSES OF X-RAYS	SCIENCE			English	Article							DOUBLE-STRAND BREAKS; INTRACHROMOSOMAL RECOMBINATION; IONIZING-RADIATION; CHROMOSOME-ABNORMALITIES; MOLECULAR-GENETICS; SPOT-TEST; CANCER; CELLS; CARCINOGENS; FREQUENCY	Deletions and other genome rearrangements can be caused by radiation and are associated with carcinogenesis and inheritable diseases. The pink-eyed unstable (p(un)) mutation in the mouse is caused by a gene duplication and reverts to wild type by deletion of one copy. Reversion events in the mouse embryo were detected as black spots on the fur of the animals or microscopically as partially black hair in a background of colorless hair. The frequency of partially black hair was increased by x-rays at very low doses. A linear dose-response relation was found between 1 and 100 centigray.			SCHIESTL, RH (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT MOLEC & CELLULAR TOXICOL, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006593] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06593] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLOCHER D, 1982, INT J RADIAT BIOL, V42, P317, DOI 10.1080/09553008214551231; BRENNAN RJ, 1994, MUTAT RES, V308, P159, DOI 10.1016/0027-5107(94)90151-1; BRILLIANT MH, 1991, SCIENCE, V252, P566, DOI 10.1126/science.1673574; CAIRNS J, 1981, NATURE, V289, P353, DOI 10.1038/289353a0; CARLS N, 1994, MUTAT RES, V320, P293, DOI 10.1016/0165-1218(94)90082-5; CHANG WP, 1991, INT J RADIAT BIOL, V60, P483, DOI 10.1080/09553009114552331; CHANG WSP, 1992, MUTAT RES, V270, P191, DOI 10.1016/0027-5107(92)90130-T; FAHRIG R, 1975, MOL GEN GENET, V138, P309, DOI 10.1007/BF00264800; GONDO Y, 1993, P NATL ACAD SCI USA, V90, P297, DOI 10.1073/pnas.90.1.297; GROSOVSKY AJ, 1985, P NATL ACAD SCI USA, V82, P2092, DOI 10.1073/pnas.82.7.2092; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HANSEN MF, 1988, CELL, V53, P172, DOI 10.1016/0092-8674(88)90376-5; HIROBE T, 1984, ANAT REC, V208, P589, DOI 10.1002/ar.1092080414; LITTLE JB, 1993, HEMATOL ONCOL CLIN N, V7, P337, DOI 10.1016/S0889-8588(18)30244-2; MAYER TC, 1973, DEV BIOL, V34, P39, DOI 10.1016/0012-1606(73)90337-0; MELVOLD RW, 1971, MUTAT RES, V12, P171, DOI 10.1016/0027-5107(71)90138-2; MITELMAN F, 1990, CANCER DETECT PREV, V14, P527; MODAN B, 1992, EUR J CANCER, V28A, P1010, DOI 10.1016/0959-8049(92)90442-5; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; RUSSELL LB, 1981, MUTAT RES, V86, P355, DOI 10.1016/0165-1110(81)90011-7; RUSSELL LB, 1954, J CELL COMPAR PHYSL, V43, pA103, DOI 10.1002/jcp.1030430407; RUSSELL WL, 1962, P NATL ACAD SCI USA, V48, P1724, DOI 10.1073/pnas.48.10.1724; SANDBERG AA, 1991, MUTAT RES, V247, P231, DOI 10.1016/0027-5107(91)90019-K; SCHIESTL RH, 1988, GENETICS, V119, P237; SCHIESTL RH, 1989, NATURE, V337, P285, DOI 10.1038/337285a0; SCHIESTL RH, 1989, CARCINOGENESIS, V10, P1445, DOI 10.1093/carcin/10.8.1445; SCHLAGER G, 1967, GENETICS, V57, P319; SEARLE AG, 1982, MUTAT RES, V92, P205, DOI 10.1016/0027-5107(82)90224-X; STEPHENSON DA, 1988, MUTAT RES, V197, P101, DOI 10.1016/0027-5107(88)90145-5; STYLES JA, 1985, MUTAT RES, V154, P183, DOI 10.1016/0165-1110(85)90017-X; THACKER J, 1986, MUTAT RES, V160, P267, DOI 10.1016/0027-5107(86)90137-5; UPTON AC, 1992, ANNU REV PUBL HEALTH, V13, P127, DOI 10.1146/annurev.pu.13.050192.001015; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WARD JF, 1990, INT J RADIAT BIOL, V57, P1141, DOI 10.1080/09553009014551251; WARD JF, 1987, INT C ANTICARCINOGEN, P321; WINTERSBERGER U, 1982, NATURWISSENSCHAFTEN, V69, P107, DOI 10.1007/BF00376714; ZHANG LH, 1992, CARCINOGENESIS, V13, P609, DOI 10.1093/carcin/13.4.609	38	77	78	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 2	1994	266	5190					1573	1576		10.1126/science.7985029	http://dx.doi.org/10.1126/science.7985029			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985029				2022-12-28	WOS:A1994PV01500047
J	STEINER, NC; CLARKE, L				STEINER, NC; CLARKE, L			A NOVEL EPIGENETIC EFFECT CAN ALTER CENTROMERE FUNCTION IN FISSION YEAST	CELL			English	Article							POSITION-EFFECT VARIEGATION; SCHIZOSACCHAROMYCES-POMBE; TRANSCRIPTIONAL STATES; CHROMATIN STRUCTURE; CHROMOSOME; DNA; SEQUENCE; REGIONS; INHERITANCE; CEREVISIAE	A novel epigenetic mechanism that can affect minichromosome centromere function in vivo has been identified in S. pombe. This epigenetic system can result in the conversion of a nonfunctional centromere to a functional one without changes in the content, structural arrangement, or chemical modification state of the minichromosomal DNA. The conversion from a centromere-inactive to an active state, which is evident with minichromosomes carrying abbreviated centromeric DNA constructions, occurs with a relatively high frequency during mitotic cell divisions and readily provides an in vivo essay for proper centromere formation. The centromere-targeted epigenetic system supports a model for centromere function that involves specific de novo folding of centromeric components into a higher order chromatin structure.	UNIV CALIF SANTA BARBARA, DEPT BIOL SCI, SANTA BARBARA, CA 93106 USA	University of California System; University of California Santa Barbara					NIGMS NIH HHS [GM-33783] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033783] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; BAUM M, 1994, MOL BIOL CELL, V5, P747, DOI 10.1091/mbc.5.7.747; BLOOM K, 1993, CELL, V73, P621, DOI 10.1016/0092-8674(93)90242-I; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CLARKE L, 1986, P NATL ACAD SCI USA, V83, P8253, DOI 10.1073/pnas.83.21.8253; CLARKE L, 1985, ANNU REV GENET, V19, P29, DOI 10.1146/annurev.ge.19.120185.000333; CLARKE L, 1990, TRENDS GENET, V6, P150, DOI 10.1016/0168-9525(90)90149-Z; CLARKE L, 1990, MOL CELL BIOL, V10, P1863, DOI 10.1128/MCB.10.5.1863; CLARKE L, 1993, COLD SPRING HARB SYM, V58, P687, DOI 10.1101/SQB.1993.058.01.076; EARNSHAW WC, 1985, CHROMOSOMA, V92, P290, DOI 10.1007/BF00329812; FISHEL B, 1988, MOL CELL BIOL, V8, P754, DOI 10.1128/MCB.8.2.754; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRIGLIATTI T, 1991, METHOD CELL BIOL, V35, P587; HAHNENBERGER KM, 1991, MOL CELL BIOL, V11, P2206, DOI 10.1128/MCB.11.4.2206; HAHNENBERGER KM, 1989, P NATL ACAD SCI USA, V86, P577, DOI 10.1073/pnas.86.2.577; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HSU TC, 1975, CYTOGENET CELL GENET, V15, P41, DOI 10.1159/000130497; KENDAL WS, 1988, CANCER RES, V48, P1060; Kohli J, 1989, MOL BIOL FISSION YEA, P75; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; Luria SE, 1943, GENETICS, V28, P491; LYON MF, 1992, ANNU REV GENET, V26, P17, DOI 10.1146/annurev.ge.26.120192.000313; Maniatis T., 1982, MOL CLONING; MANN C, 1983, P NATL ACAD SCI-BIOL, V80, P228, DOI 10.1073/pnas.80.1.228; MONK M, 1990, TRENDS GENET, V6, P110, DOI 10.1016/0168-9525(90)90124-O; MURAKAMI S, 1991, CHROMOSOMA, V101, P214, DOI 10.1007/BF00365153; NAKASEKO Y, 1986, EMBO J, V5, P1011, DOI 10.1002/j.1460-2075.1986.tb04316.x; NAKASEKO Y, 1987, NUCLEIC ACIDS RES, V15, P4705, DOI 10.1093/nar/15.12.4705; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; POLIZZI C, 1991, J CELL BIOL, V112, P191, DOI 10.1083/jcb.112.2.191; Sandell L L, 1992, Trends Cell Biol, V2, P10, DOI 10.1016/0962-8924(92)90138-D; SHAFFER CD, 1993, TRENDS GENET, V9, P35, DOI 10.1016/0168-9525(93)90171-D; SOLTER D, 1988, ANNU REV GENET, V22, P127; STEINER NC, 1993, MOL CELL BIOL, V13, P4578, DOI 10.1128/MCB.13.8.4578; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; WILLARD HF, 1990, TRENDS GENET, V6, P410, DOI 10.1016/0168-9525(90)90302-M	38	132	135	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					865	874		10.1016/0092-8674(94)90075-2	http://dx.doi.org/10.1016/0092-8674(94)90075-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001123				2022-12-28	WOS:A1994PW05400013
J	WALKER, S; HAYES, S; OHARE, P				WALKER, S; HAYES, S; OHARE, P			SITE-SPECIFIC CONFORMATIONAL ALTERATION OF THE OCT-1 POU DOMAIN-DNA COMPLEX AS THE BASIS FOR DIFFERENTIAL RECOGNITION BY VMW65 (VP16)	CELL			English	Article							IMMEDIATE-EARLY GENE; TYPE-1 TRANSACTIVATOR VMW65; OCTAMER-BINDING-PROTEIN; TRANSCRIPTION COMPLEX; REGULATORY PROTEIN; CELLULAR FACTOR; HOMEO DOMAIN; SEQUENCES; INTERACTS; SUBDOMAINS	We show that the presence of a regulatory cis-acting element that flanks the core octamer site and dictates selectivity in the response to Vmw65 (VP16), while dispensable for POU binding per se, induces a conformational alteration in the nature of the POU domain in the DNA complex. A single substitution in the flanking signal distorts the POU complex and without affecting overall POU binding prevents Vmw65 interaction. Alternatively, substitution of a residue in the homeodomain predicted to contact the GARAT region prevents its recognition even on a wild-type motif, causing a reversion to the DNA binding pattern seen on a cellular motif and at the same time inefficient recognition by Vmw65. The results indicate that Vmw65 recognizes a particular POU domain conformation induced by the presence of the flanking GARAT region.			WALKER, S (corresponding author), MARIE CURIE RES INST,CHART,OXTED RH8 OTL,SURREY,ENGLAND.							APRHYS CMJ, 1989, J VIROL, V63, P2798, DOI 10.1128/JVI.63.6.2798-2812.1989; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GREAVES RF, 1990, J VIROL, V64, P2716, DOI 10.1128/JVI.64.6.2716-2724.1990; HAYES S, 1993, J VIROL, V67, P852, DOI 10.1128/JVI.67.2.852-862.1993; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; KATAN M, 1990, NUCLEIC ACIDS RES, V18, P6871, DOI 10.1093/nar/18.23.6871; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KRISTIE TM, 1987, P NATL ACAD SCI USA, V84, P71, DOI 10.1073/pnas.84.1.71; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; MACKEM S, 1982, J VIROL, V44, P939, DOI 10.1128/JVI.44.3.939-949.1982; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OHARE P, 1993, ALPHA HERPESVIRUSES, P145; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; PRESTON CM, 1984, J VIROL, V50, P708, DOI 10.1128/JVI.50.3.708-716.1984; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; TULLIUS TD, 1989, ANNU REV BIOPHYS BIO, V18, P213, DOI 10.1146/annurev.bb.18.060189.001241; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974	33	76	77	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 2	1994	79	5					841	852		10.1016/0092-8674(94)90073-6	http://dx.doi.org/10.1016/0092-8674(94)90073-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001121				2022-12-28	WOS:A1994PW05400011
J	DINUBILE, MJ				DINUBILE, MJ			SHORT-COURSE ANTIBIOTIC-THERAPY FOR RIGHT-SIDED ENDOCARDITIS CAUSED BY STAPHYLOCOCCUS-AUREUS IN INJECTION-DRUG USERS	ANNALS OF INTERNAL MEDICINE			English	Article							COMBINATION THERAPY; RESISTANT; GENTAMICIN; VANCOMYCIN; ADDICTS; SYNERGISM; VARIANTS	Right-sided endocarditis caused by Staphylococcus aureus is a frequent complication of injection drug use. Fortunately, the prognosis for this infection when treated with the standard regimen of 4 to 6 weeks od parenteral antistaphylococcal antibiotics is favorable. Nevertheless, in many cases, once drug users feel better, they leave the hospital against medical advice before completing the full course of antibiotic therapy. This problem has stimulated interest in shortening the duration of antibiotic treatment by adding an aminoglycoside antibiotic to a penicillinase-resistant penicillin. Data from in vitro synergy studies and animal models of endocarditis suggest that S. aureus can be eradicated more quickly by combination therapy than by monotherapy. Reports of three prospective, nonrandomized clinical trials have been published that support the use of a a-week course of a penicillinase-resistant penicillin and an aminoglycoside antibiotic to treat uncomplicated, exclusively right-sided endocarditis caused by methicillin-susceptibte S. aureus in injection drug users.			DINUBILE, MJ (corresponding author), UNIV MED & DENT NEW JERSEY, COOPER HOSP UNIV MED CTR, ROBERT WOOD JOHNSON MED SCH, DIV INFECT DIS, CAMDEN, NJ 08103 USA.							ALDRIDGE KE, 1992, DIAGN MICR INFEC DIS, V15, P517, DOI 10.1016/0732-8893(92)90101-X; BAYER AS, 1990, CHEST, V98, P200, DOI 10.1378/chest.98.1.200; BRUMFITT W, 1989, NEW ENGL J MED, V320, P1188, DOI 10.1056/NEJM198905043201806; BRYANT RE, 1977, JAMA-J AM MED ASSOC, V237, P569, DOI 10.1001/jama.237.6.569; CHAMBERS HF, 1988, ANN INTERN MED, V109, P619, DOI 10.7326/0003-4819-109-8-619; CHRISTIE RV, 1948, BRIT MED J, V1, P1, DOI 10.1136/bmj.1.4539.1; COKER AO, 1989, E AFR MED J, V66, P141; DWORKIN RJ, 1989, LANCET, V2, P1071; Espinosa F J, 1993, Enferm Infecc Microbiol Clin, V11, P235; GERACI JE, 1953, CIRCULATION, V8, P494, DOI 10.1161/01.CIR.8.4.494; HAMBURGER M, 1952, JAMA-J AM MED ASSOC, V149, P542, DOI 10.1001/jama.1952.02930230016005; HECHT SR, 1992, ANN INTERN MED, V117, P560, DOI 10.7326/0003-4819-117-7-560; HODELCHRISTIAN SL, 1990, ANTIMICROB AGENTS CH, V34, P1278, DOI 10.1128/AAC.34.6.1278; KARCHMER AW, 1979, JAMA-J AM MED ASSOC, V241, P1801, DOI 10.1001/jama.241.17.1801; KERNODLE DS, 1989, J INFECT DIS, V159, P103, DOI 10.1093/infdis/159.1.103; KORZENIOWSKI O, 1982, ANN INTERN MED, V97, P496, DOI 10.7326/0003-4819-97-4-496; LAPUMA J, 1988, ARCH INTERN MED, V148, P1809, DOI 10.1001/archinte.148.8.1809; LEVINE DP, 1991, ANN INTERN MED, V115, P674, DOI 10.7326/0003-4819-115-9-674; LEVINE DP, 1986, REV INFECT DIS, V8, P374; MALACOFF RF, 1979, JAMA-J AM MED ASSOC, V241, P1807, DOI 10.1001/jama.241.17.1807; MANOLIS AS, 1988, ARCH INTERN MED, V148, P2461, DOI 10.1001/archinte.148.11.2461; MEDERSKISAMORAJ BD, 1983, J INFECT DIS, V147, P751, DOI 10.1093/infdis/147.4.751; PARKER RH, 1980, ANN INTERN MED, V93, P832, DOI 10.7326/0003-4819-93-6-832; RADBERG G, 1992, J ANTIMICROB CHEMOTH, V30, P489, DOI 10.1093/jac/30.4.489; ROBBINS MJ, 1986, AM HEART J, V111, P128, DOI 10.1016/0002-8703(86)90564-8; SANDE MA, 1976, J LAB CLIN MED, V88, P118; SMALL PM, 1990, ANTIMICROB AGENTS CH, V34, P1227, DOI 10.1128/AAC.34.6.1227; SPIEGEL CA, 1988, J CLIN MICROBIOL, V26, P2270, DOI 10.1128/JCM.26.11.2270-2274.1988; TORRESTORTOSA M, 1994, EUR J CLIN MICROBIOL, V13, P533; Uete Tetsuo, 1992, Japanese Journal of Antibiotics, V45, P943; WATANAKUNAKORN C, 1974, ANTIMICROB AGENTS CH, V6, P802, DOI 10.1128/AAC.6.6.802; WILSON WR, 1984, ANN INTERN MED, V100, P816, DOI 10.7326/0003-4819-100-6-816; WILSON WR, 1978, CIRCULATION, V57, P1158, DOI 10.1161/01.CIR.57.6.1158; WOLFE JC, 1974, ANN INTERN MED, V81, P178, DOI 10.7326/0003-4819-81-2-178	34	66	70	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					873	876		10.7326/0003-4819-121-11-199412010-00009	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7978701				2022-12-28	WOS:A1994PT62800009
J	BURMEISTER, WP; HUBER, AH; BJORKMAN, PJ				BURMEISTER, WP; HUBER, AH; BJORKMAN, PJ			CRYSTAL-STRUCTURE OF THE COMPLEX OF RAT NEONATAL FC RECEPTOR WITH FC	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; IMMUNOGLOBULIN-G; NEWBORN RAT; INTESTINE; BINDING; CRYSTALLIZATION; EXPRESSION; REFINEMENT; TRANSPORT; FRAGMENT	THE neonatal Fc receptor (FcRn) transports maternal immunoglobulin G (IgG) to the bloodstream of the newborn. FcRn is structurally similar to class I major histocompatibility complex (MHC) molecules(1,2), despite differences in the ligands they bind (the Fc portion of IgG and antigenic peptides, respectively). A low-resolution crystal structure of the complex between FcRn and Fc localizes the binding site for Fc to the side of FcRn, distinct from the tops of the alpha 1 and alpha 2 domains which serve as the peptide and T-cell receptor binding sites in class I molecules. FcRn binds to Fc at the interface between the Fc C(H)2 and C(H)3 domains, which contains several histidine residues that could account for the sharply pH-dependent FcRn/IgG interaction(3). A dimer of FcRn heterodimers observed in the co-crystals and in the crystals of FcRn alone(2) could be involved in binding Fc, correlating with the 2:1 binding stoichiometry between FcRn and IgG (ref. 4) and suggesting an unusual orientation of FcRn on the membrane.	CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125; CALTECH,DIV BIOL 15629,PASADENA,CA 91125	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology				Burmeister, Wim/0000-0003-0876-6118				AHOUSE JJ, 1993, J IMMUNOL, V151, P6076; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; GUDDAT LW, 1993, P NATL ACAD SCI USA, V90, P4271, DOI 10.1073/pnas.90.9.4271; HARRIS LJ, 1992, NATURE, V360, P369, DOI 10.1038/360369a0; HOBBS SM, 1987, J BIOL CHEM, V262, P8041; HUBER AH, 1993, J MOL BIOL, V230, P1077, DOI 10.1006/jmbi.1993.1220; HUBER AH, 1994, THESIS CALTECH; JAKOI ER, 1985, J IMMUNOL, V135, P3360; JONES TA, 1993, CRYSTALLOGRAPHIC COM; Kabat EA, 1991, SEQUENCES PROTEINS I; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; RAGHAVAN M, 1994, IMMUNITY, V1, P303, DOI 10.1016/1074-7613(94)90082-5; RODEWALD R, 1976, J CELL BIOL, V71, P666, DOI 10.1083/jcb.71.2.666; RODEWALD R, 1973, J CELL BIOL, V58, P189, DOI 10.1083/jcb.58.1.189; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SIMISTER NE, 1989, COLD SPRING HARB SYM, V54, P571, DOI 10.1101/SQB.1989.054.01.068; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; WALLACE KH, 1980, BIOCHEM J, V188, P9, DOI 10.1042/bj1880009; ZHENG Y, 1991, BIOCHEMISTRY-US, V30, P9125, DOI 10.1021/bi00102a002; 1979, SERC UK COLLABORATIV	28	386	548	2	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					379	383		10.1038/372379a0	http://dx.doi.org/10.1038/372379a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969498				2022-12-28	WOS:A1994PU28700060
J	MALINOW, R				MALINOW, R			LTP - DESPERATELY SEEKING RESOLUTION	SCIENCE			English	Editorial Material							LONG-TERM POTENTIATION; GLUTAMATE RELEASE; NMDA RECEPTORS; HIPPOCAMPUS; PROBABILITY; PLASTICITY; SYNAPSE				MALINOW, R (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.							BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLINE HT, 1991, TRENDS NEUROSCI, V14, P104, DOI 10.1016/0166-2236(91)90071-2; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1994, P NATL ACAD SCI USA, V91, P8170, DOI 10.1073/pnas.91.17.8170; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483; MORRIS RGM, 1990, PHILOS T ROY SOC B, V329, P187, DOI 10.1098/rstb.1990.0164; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; MURPHY TH, 1994, NATURE, V263, P529; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0	21	53	55	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1195	1196		10.1126/science.7973700	http://dx.doi.org/10.1126/science.7973700			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973700				2022-12-28	WOS:A1994PT13200041
J	WINFREE, AT				WINFREE, AT			ELECTRICAL TURBULENCE IN 3-DIMENSIONAL HEART-MUSCLE	SCIENCE			English	Article							SUDDEN CARDIAC DEATH; VENTRICULAR-FIBRILLATION; EXCITABLE MEDIA; SPIRAL BREAKUP; TACHYCARDIA; DOGS; MYOCARDIUM; MECHANISM; REENTRY; WAVES	Rotors or vortex action potentials with a diameter of about 1 centimeter and a rotation period of about 0.1 second occur in normal myocardium just before transition to fibrillation, a disorderly pattern of action potential propagation. Numerical models and corresponding mathematical analysis have recently suggested candidate mechanisms, all two-dimensional, for this transition from periodic electrical activity to something resembling turbulence. However, comparably recent experiments unanimously show that rotors, and the spiral waves they radiate, remain stably periodic in two-dimensional myocardium. This seeming paradox suggests a transition mediated through disorderly dynamics of the electrical vortex in three dimensions, as a ''vortex filament.''			WINFREE, AT (corresponding author), UNIV ARIZONA, DEPT ECOL & EVOLUT BIOL, TUCSON, AZ 85721 USA.							ALFERNESS C, 1994, PACE, V17, P876, DOI 10.1111/j.1540-8159.1994.tb01428.x; ALLESSIE MA, 1989, EUR HEART J, V10, P2, DOI 10.1093/eurheartj/10.suppl_E.2; [Anonymous], 1989, NEW ENGL J MED, V321, P406; BAER M, 1994, J CHEM PHYS, V100, P1; BAUDINETTE RV, 1978, J COMP PHYSIOL, V127, P337, DOI 10.1007/BF00738418; BAYLY PV, 1993, J CARDIOVASC ELECTR, V4, P533, DOI 10.1111/j.1540-8167.1993.tb01242.x; BEELER GW, 1977, J PHYSIOL-LONDON, V268, P177, DOI 10.1113/jphysiol.1977.sp011853; CARLISLE EJF, 1990, EUR HEART J, V11, P173, DOI 10.1093/oxfordjournals.eurheartj.a059674; CHEN PS, 1988, CIRC RES, V62, P1191, DOI 10.1161/01.RES.62.6.1191; COURTEMANCHE M, 1993, PHYS REV LETT, V70, P2182, DOI 10.1103/PhysRevLett.70.2182; Courtemanche M, 1991, INT J BIFURCAT CHAOS, V1, P431, DOI 10.1142/S0218127491000336; DAMLE RS, 1992, CIRCULATION, V86, P1547, DOI 10.1161/01.CIR.86.5.1547; DAVIDENKO JM, 1992, NATURE, V355, P349, DOI 10.1038/355349a0; DILLON SM, 1988, CIRC RES, V63, P182, DOI 10.1161/01.RES.63.1.182; EISENBERG MS, 1986, SCI AM, V254, P37, DOI 10.1038/scientificamerican0586-37; FISHLER MG, 1991, PACE, V14, P1694, DOI 10.1111/j.1540-8159.1991.tb02750.x; FRAZIER DW, 1989, J CLIN INVEST, V83, P1039, DOI 10.1172/JCI113945; GOTOH M, 1993, PACE, V16, P897; HILL BC, 1990, J CARDIOVASC PHARM, V16, P871, DOI 10.1097/00005344-199012000-00003; HOLT JP, 1968, AM J PHYSIOL, V215, P704, DOI 10.1152/ajplegacy.1968.215.3.704; ITO H, 1991, PHYS REV LETT, V66, P671, DOI 10.1103/PhysRevLett.66.671; JALIFE J, 1991, J CARDIOVASC ELECTR, V2, pS133; JANSE MJ, 1989, PHYSIOL REV, V69, P1049, DOI 10.1152/physrev.1989.69.4.1049; KARMA A, 1994, PHYSICA D, V73, P113, DOI 10.1016/0167-2789(94)90228-3; KAVANAGH KM, 1992, CIRCULATION, V85, P680, DOI 10.1161/01.CIR.85.2.680; LOWN B, 1979, AM J CARDIOL, V43, P313, DOI 10.1016/S0002-9149(79)80021-1; LUO CH, 1994, NATURE, V74, P1071; MEDVINSKY AB, 1984, SELF ORG AUTOWAVES S; MOE GK, 1964, AM HEART J, V67, P200, DOI 10.1016/0002-8703(64)90371-0; PANFILOV A, 1993, PHYS LETT A, V176, P295, DOI 10.1016/0375-9601(93)90921-L; Panfilov AV, 1991, INT J BIFURCAT CHAOS, V1, P219, DOI 10.1142/S0218127491000142; PANFILOV AV, 1993, J CARDIOVASC ELECTR, V4, P412, DOI 10.1111/j.1540-8167.1993.tb01280.x; PERTSOV AM, 1993, CIRC RES, V72, P631, DOI 10.1161/01.RES.72.3.631; POOL R, 1990, SCIENCE, V247, P1294, DOI 10.1126/science.2315697; ROSENSHTRAUKH LV, 1989, CIRC RES, V64, P213, DOI 10.1161/01.RES.64.2.213; SCHALIJ MJ, 1992, AM J PHYSIOL, V263, pH1466, DOI 10.1152/ajpheart.1992.263.5.H1466; SHIBATA N, 1988, AM J PHYSIOL, V255, pH891, DOI 10.1152/ajpheart.1988.255.4.H891; STANDISH A, 1994, SCIENCE, V263, P232, DOI 10.1126/science.8284675; STEINBOCK O, 1993, PHYS REV E, V47, P1506, DOI 10.1103/PhysRevE.47.1506; Streeter D.D., 1979, HDB PHYSL, VVolume 1, P61; SUGIMOTO T, 1967, CIRC RES, V21, P601, DOI 10.1161/01.RES.21.5.601; SWAIN HH, 1970, U MICH MED CENT J, V36, P122; WINFREE AT, 1991, THEORY OF HEART, P477; WINFREE AT, 1973, SCIENCE, V181, P937, DOI 10.1126/science.181.4103.937; WINFREE AT, 1989, J THEOR BIOL, V138, P353, DOI 10.1016/S0022-5193(89)80200-0; WINFREE AT, 1990, ANN NY ACAD SCI, V591, P190; WINFREE AT, 1994, NATURE, V371, P233, DOI 10.1038/371233a0; WINFREE AT, 1983, SCI AM, V248, P144, DOI 10.1038/scientificamerican0583-144; WINFREE AT, 1973, ADV BIOL MED PHYS, V16, P115; WINFREE AT, 1994, WHOLE HERT MODELING; WINFREE AT, 1994, CARDIAC ELECTROPHYSI, P379; WINFREE AT, 1987, WHEN TIME BREAKS DOW, P205; WINFREE AT, 1990, CARDIAC ELECTROPHYSI, P224; WINFREE AT, 1993, CARDIAC MAPPING, P655; WITKOWSKI FX, 1990, ANN NY ACAD SCI, V591, P219; ZIPES DP, 1975, AM J CARDIOL, V36, P37, DOI 10.1016/0002-9149(75)90865-6; ZOU XQ, 1993, PHYS REV E, V47, pR800, DOI 10.1103/PhysRevE.47.R800	57	368	378	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1003	1006		10.1126/science.7973648	http://dx.doi.org/10.1126/science.7973648			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973648				2022-12-28	WOS:A1994PQ92400032
J	BEZOUSKA, K; YUEN, CT; OBRIEN, J; CHILDS, RA; CHAI, WG; LAWSON, AM; DRBAL, K; FISEROVA, A; POSPISIL, M; FEIZI, T				BEZOUSKA, K; YUEN, CT; OBRIEN, J; CHILDS, RA; CHAI, WG; LAWSON, AM; DRBAL, K; FISEROVA, A; POSPISIL, M; FEIZI, T			RETRACTED: OLIGOSACCHARIDE LIGANDS FOR NKR-P1 PROTEIN ACTIVATE NK CELLS AND CYTOTOXICITY (Retracted article. See vol. 500, pg. 492, 2013)	NATURE			English	Article; Retracted Publication							NATURAL-KILLER-CELLS; MEDIATED CYTO-TOXICITY; GANGLIOSIDES; GLYCOLIPIDS; RECOGNITION; MOLECULE; MANNOSE; GLYCOPROTEINS; SPECIFICITY; ANTIBODIES	A diversity of high-affinity oligosaccharide ligands are Identified for NKR-P1, a membrane protein on natural killer (NH) cells which contains an extracellular Ca2+-dependent lectin domain. Interactions of such oligosaccharides on the target cell surface with NKR-P1 on the killer cell surface are crucial both for target cell recognition and for delivery of stimulatory or inhibitory signals linked to the NH cytolytic machinery. NK-resistant tumour cells are rendered susceptible by preincubation with liposomes expressing NKR-P1 ligands, suggesting that purging of tumour or virally infected cells in vivo may be a therapeutic possibility.	NORTHWICK PK HOSP & CLIN RES CTR, GLYCOSCI LAB, GLYCOBIOL GRP, HARROW HA1 3UJ, MIDDX, ENGLAND; NORTHWICK PK HOSP & CLIN RES CTR, GLYCOSCI LAB, MASS SPECTROMETRY GRP, HARROW HA1 3UJ, MIDDX, ENGLAND; CHARLES UNIV, FAC SCI, DEPT BIOCHEM, CR-12840 PRAGUE 2, CZECH REPUBLIC; ACAD SCI CZECH REPUBL, INST MICROBIOL, DEPT IMMUNOL & GNOTOBIOL, CR-14220 PRAGUE 4, CZECH REPUBLIC	Imperial College London; Imperial College London; Charles University Prague; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences				Feizi, Ten/0000-0001-6495-0329				ANDO I, 1987, INT J CANCER, V40, P12, DOI 10.1002/ijc.2910400104; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BEZOUSKA K, 1994, J BIOL CHEM, V269, P16945; BRUNNER KT, 1968, IMMUNOLOGY, V14, P181; CHAMBERS WH, 1986, J IMMUNOL, V137, P1469; CHAMBERS WH, 1989, J EXP MED, V169, P1373, DOI 10.1084/jem.169.4.1373; CHAMBERS WH, 1993, GLYCOBIOLOGY, V3, P9, DOI 10.1093/glycob/3.1.9; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CHUSED TM, 1987, CYTOMETRY, V8, P396, DOI 10.1002/cyto.990080409; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; EBEL F, 1992, BIOCHEMISTRY-US, V31, P12190, DOI 10.1021/bi00163a031; FEIZI T, 1987, BIOCHEM J, V245, P1; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FEIZI T, 1994, METHOD ENZYMOL, V230, P484; FEIZI T, 1979, J EXP MED, V149, P975, DOI 10.1084/jem.149.4.975; FEIZI T, 1989, CIBA F S, V145, P62; Feizi Ten, 1993, Current Opinion in Structural Biology, V3, P701, DOI 10.1016/0959-440X(93)90053-N; FORBES JT, 1981, P NATL ACAD SCI-BIOL, V78, P5797, DOI 10.1073/pnas.78.9.5797; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; GOOI HC, 1985, J BIOL CHEM, V260, P3218; GRAYSON G, 1992, CELL IMMUNOL, V139, P18, DOI 10.1016/0008-8749(92)90096-8; HAKOMORI S, 1985, CANCER RES, V45, P2405; HAUBECK HD, 1985, J IMMUNOL, V134, P65; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN M, 1992, J BIOL CHEM, V267, P13661; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LOVELESS RW, 1992, EMBO J, V11, P813, DOI 10.1002/j.1460-2075.1992.tb05118.x; MCCOY J P JR, 1991, Glycobiology, V1, P321, DOI 10.1093/glycob/1.4.321; MCEVER RP, 1991, J CELL BIOCHEM, V45, P156, DOI 10.1002/jcb.240450206; OHMORI K, 1989, BLOOD, V74, P255; ROBINSON PJ, 1979, IMMUNOLOGICAL METHOD, V3, P125; Ryan James C., 1992, Natural Immunity, V11, P279; RYAN JC, 1992, J IMMUNOL, V149, P1631; RYAN JC, 1991, J IMMUNOL, V147, P3244; SCHWARZMANN G, 1987, METHOD ENZYMOL, V138, P319; SCUDDER P, 1986, EUR J BIOCHEM, V157, P365, DOI 10.1111/j.1432-1033.1986.tb09678.x; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; VUJANOVIC NL, 1988, J EXP MED, V167, P15, DOI 10.1084/jem.167.1.15; WARD JM, 1983, AM J PATHOL, V111, P1; YAMAMOTO H, 1985, CELL IMMUNOL, V96, P409, DOI 10.1016/0008-8749(85)90371-5; YOGEESWARAN G, 1981, INT J CANCER, V28, P517, DOI 10.1002/ijc.2910280419; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145; YOKOYAMA WM, 1993, CURR OPIN IMMUNOL, V5, P67, DOI 10.1016/0952-7915(93)90083-5; YOUNG WW, 1980, J IMMUNOL, V124, P199; YOUNG WW, 1981, J IMMUNOL, V126, P1; YUEN CT, 1994, J BIOL CHEM, V269, P1595	50	268	272	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	1994	372	6502					150	157		10.1038/372150a0	http://dx.doi.org/10.1038/372150a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969447				2022-12-28	WOS:A1994PQ68800047
J	MADDOX, J				MADDOX, J			FRONTIERS OF IGNORANCE - THE AGE OF AUSTRALOPITHECINES	NATURE			English	Editorial Material																		CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0	2	0	0	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					31	32						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969409				2022-12-28	WOS:A1994PQ34800042
J	MADDOX, J				MADDOX, J			FRONTIERS OF IGNORANCE - MIGRATION OUT OF AFRICA	NATURE			English	Editorial Material																			0	1	1	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					32	32						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969410				2022-12-28	WOS:A1994PQ34800044
J	GRIEB, P; RYBA, M; STELMASIAK, Z; NOWICKI, J; SOLSKI, J; JAKUBOWSKA, B				GRIEB, P; RYBA, M; STELMASIAK, Z; NOWICKI, J; SOLSKI, J; JAKUBOWSKA, B			CLADRIBINE TREATMENT OF MULTIPLE-SCLEROSIS	LANCET			English	Letter									SCI & CLIN CTR DEMYELINATING DIS,LUBLIN,POLAND; ACAD MED LUBLIN,DEPT CLIN ANALYT,LUBLIN,POLAND	Medical University of Lublin	GRIEB, P (corresponding author), POLISH ACAD SCI,MED RES CTR,DEPT NEUROPHYSIOL,PL-00784 WARSAW,POLAND.		Grieb, Pawel/AAT-8173-2021; Solarska, Beata Jakubowska-/F-6723-2015	Solski, Janusz/0000-0003-2884-1509				GORSKI A, 1993, IMMUNOPHARMACOLOGY, V26, P197, DOI 10.1016/0162-3109(93)90035-O; GORSKI A, 1993, TRANSPLANTATION, V56, P1253; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LIKOSKY WH, 1991, J NEUROL NEUROSUR PS, V54, P1055, DOI 10.1136/jnnp.54.12.1055; STELMASIAK Z, 1994, J NEUROL, V241, pS90	5	13	13	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					538	538						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7980785				2022-12-28	WOS:A1994PC53500036
J	RICHARDS, T				RICHARDS, T			THE OVERSEAS DOCTORS TRAINING SCHEME - FAILING EXPECTATIONS	BRITISH MEDICAL JOURNAL			English	Article								The Overseas Doctors Training Scheme needs appraisal. Set up 10 years ago to improve the quality of postgraduate training that overseas (non-European) doctors receive in Britain, the scheme has been popular, but it is questionable how far it has achieved its aims. If Britain is to continue to employ large numbers of overseas doctors in training grades, both through the scheme and through independent arrangements, the apparent mismatch between their expectations and the reality of what Britain offers must be tackled.										ARAYA R, 1989, BRIT MED J, V299, P980, DOI 10.1136/bmj.299.6705.980; CHANDIRAMANI VA, 1993, BRIT MED J, V306, P1546, DOI 10.1136/bmj.306.6891.1546-a; ESMAIL A, 1993, BRIT MED J, V306, P691, DOI 10.1136/bmj.306.6879.691; GIBNEY E, 1990, BR J HOSP MED, V4, P254; HALE R, 1990, BR J HOSP MED, V43, P182; LISTER J, 1986, NEW ENGL J MED, V315, P1038, DOI 10.1056/NEJM198610163151630; LOWRY S, 1994, BRIT MED J, V308, P1624, DOI 10.1136/bmj.308.6944.1624; MIAN TA, 1994, BRIT MED J, V308, P208, DOI 10.1136/bmj.308.6922.208b; ROWLEY DI, 1990, BRIT J HOSP MED, V43, P182; SINGH S, 1994, BRIT MED J, V308, P1169, DOI 10.1136/bmj.308.6937.1169; TODD GRG, 1993, BRIT MED J, V306, P1546, DOI 10.1136/bmj.306.6891.1546-c; VARMAN SS, 1993, BRIT MED J, V306, P1546, DOI 10.1136/bmj.306.6891.1546-b; WILLIAMS DI, 1982, BR POSTGRAD MED FED; 1993, BRIT MED J, V306, P865; 1993, BRIT MED J, V307, P1567; 1984, BRIT MED J, V288, P1175	16	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1627	1631		10.1136/bmj.308.6944.1627	http://dx.doi.org/10.1136/bmj.308.6944.1627			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	7993422	Green Published			2022-12-28	WOS:A1994NT52800028
J	MENZIES, D; FANNING, A; YUAN, L; FITZGERALD, M				MENZIES, D; FANNING, A; YUAN, L; FITZGERALD, M			CURRENT CONCEPTS - TUBERCULOSIS AMONG HEALTH-CARE WORKERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HIV-INFECTED PATIENTS; HOSPITAL EMPLOYEES; NOSOCOMIAL TRANSMISSION; PULMONARY TUBERCULOSIS; DECISION-ANALYSIS; HOUSE STAFF; SKIN-TEST; RISK; PERSONNEL		MCGILL UNIV,DEPT MED,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT EPIDEMIOL,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT BIOSTAT,MONTREAL,PQ,CANADA; ALBERTA HLTH,TB SERV,EDMONTON,AB,CANADA; UNIV TORONTO,DEPT PREVENT MED & BIOSTAT,TORONTO,ON,CANADA; VANCOUVER GEN HOSP,VANCOUVER,BC,CANADA; UNIV BRITISH COLUMBIA,VANCOUVER,BC,CANADA	McGill University; McGill University; McGill University; Alberta Health Services (AHS); University of Toronto; University of British Columbia; University of British Columbia								ADAL KA, 1994, NEW ENGL J MED, V331, P169, DOI 10.1056/NEJM199407213310306; AITKEN ML, 1987, AM REV RESPIR DIS, V136, P805, DOI 10.1164/ajrccm/136.4.805; ASHLEY MJ, 1971, AM REV RESPIR DIS, V104, P851; ATUK NO, 1971, J AMER MED ASSOC, V218, P1795; BARRETTCONNOR E, 1979, JAMA-J AM MED ASSOC, V241, P33, DOI 10.1001/jama.241.1.33; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BERMAN J, 1981, AM J PUBLIC HEALTH, V71, P1217, DOI 10.2105/AJPH.71.11.1217; BLOOM BR, 1992, NATURE, V358, P538, DOI 10.1038/358538b0; BURRILL D, 1985, CAN MED ASSOC J, V132, P137; Calder R A, 1991, Bull Int Union Tuberc Lung Dis, V66, P103; CAPEWELL S, 1988, TUBERCLE, V69, P113, DOI 10.1016/0041-3879(88)90073-6; CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559; CHAN JC, 1985, SOUTHERN MED J, V78, P1061, DOI 10.1097/00007611-198509000-00009; CHEN CC, 1992, AM J INFECT CONTROL, V20, P177, DOI 10.1016/S0196-6553(05)80143-9; CLAGUE JE, 1991, TUBERCLE, V72, P265, DOI 10.1016/0041-3879(91)90052-T; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; COLLINS CH, 1982, TUBERCLE, V63, P151, DOI 10.1016/S0041-3879(82)80025-1; CONDOS R, 1993, AM REV RESPIR DIS, V147, pA124; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; CRAVEN RB, 1975, ANN INTERN MED, V82, P628, DOI 10.7326/0003-4819-82-5-628; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; EHRENKRA.NJ, 1972, ANN INTERN MED, V77, P377, DOI 10.7326/0003-4819-77-3-377; FEREBEE SH, 1969, ADV TUBERC RES, V17, P28; FITZGERALD JM, 1990, AM REV RESPIR DIS, V142, P848, DOI 10.1164/ajrccm/142.4.848; FRAMPTON MW, 1992, ANN INTERN MED, V117, P312, DOI 10.7326/0003-4819-117-4-312; FRASER VJ, 1993, INFECT CONT HOSP EP, V14, P623; GEISELER PJ, 1986, AM REV RESPIR DIS, V133, P773; GREENBERG PD, 1991, AM REV RESPIR DIS, V143, P490, DOI 10.1164/ajrccm/143.3.490; GRIST NR, 1981, J CLIN PATHOL, V34, P655, DOI 10.1136/jcp.34.6.655; GRIST NR, 1991, J CLIN PATHOL, V44, P667, DOI 10.1136/jcp.44.8.667; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; HARRINGTON JM, 1976, BRIT MED J, V1, P759, DOI 10.1136/bmj.1.6012.759; HUTTON MD, 1990, J INFECT DIS, V161, P286, DOI 10.1093/infdis/161.2.286; ISEMAN MD, 1992, ANN INTERN MED, V117, P251, DOI 10.7326/0003-4819-117-3-251; KENT J, 1993, 9TH P INT C AIDS 4TH, P330; KWAN SYL, 1990, CHINESE MED J-PEKING, V103, P909; LOUDON RG, 1969, AM REV RESPIR DIS, V99, P109; LOUGHREY C, 1992, American Review of Respiratory Disease, V145, pA103; LUNDGREN R, 1987, TUBERCLE, V68, P147, DOI 10.1016/0041-3879(87)90032-8; LUNN JA, 1989, J SOC OCCUP MED, V39, P30; MACGREGOR RR, 1975, AM J MED, V58, P221, DOI 10.1016/0002-9343(75)90573-2; MACHER JM, 1993, INFECT CONT HOSP EP, V14, P723; MALASKY C, 1990, AM REV RESPIR DIS, V142, P505, DOI 10.1164/ajrccm/142.3.505; MENZIES R, 1994, ANN INTERN MED, V120, P190, DOI 10.7326/0003-4819-120-3-199402010-00003; NARDELL EA, 1993, INFECT CONT HOSP EP, V14, P681; NARDELL EA, IN PRESS AM J INFECT; NETTLEMAN MD, 1994, ANN INTERN MED, V121, P37, DOI 10.7326/0003-4819-121-1-199407010-00007; OTTEN J, 1992, WORLD C TUBERCULOSIS, P51; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; PIERCE JR, 1992, CHEST, V101, P581, DOI 10.1378/chest.101.2.581; PRICE LE, 1987, INFECT CONT HOSP EP, V8, P97, DOI 10.1017/S0195941700067254; RAAD I, 1989, INFECT CONT HOSP EP, V10, P465, DOI 10.1086/645922; RAMIREZ JA, 1992, INFECT CONT HOSP EP, V13, P579, DOI 10.2307/30148459; REDWOOD E, 1993, AM REV RESPIR DIS, V147, pA119; REID DD, 1957, BMJ-BRIT MED J, V2, P10, DOI 10.1136/bmj.2.5035.10; RILEY RL, 1976, AM REV RESPIR DIS, V113, P413; RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286; RILEY RL, 1962, AM REV RESPIR DIS, V85, P511; ROSE DN, 1986, JAMA-J AM MED ASSOC, V256, P2709, DOI 10.1001/jama.256.19.2709; ROUILLON A, 1976, TUBERCLE, V57, P275, DOI 10.1016/S0041-3879(76)80006-2; RUBEN FL, 1977, AM REV RESPIR DIS, V115, P23; SAIDER DE, 1982, AM REV RESPIR DIS, V125, P108; SEPKOWITZ KA, 1994, ANN INTERN MED, V120, P71, DOI 10.7326/0003-4819-120-1-199401010-00012; SHARP V, 1993, 9TH P INT C AIDS 4TH, P329; STROUD L, 1993, 33RD INT C ANT AG CH, P608; STYBLO K, 1978, B INT UNION TUBERC S, V51, P101; SUGITA M, 1990, ACTA PATHOL JAPON, V40, P116; THOMPSON NJ, 1979, AM REV RESPIR DIS, V119, P587; VALWAY S, 1993, 33 INT C ANT AG CHEM, P231; VOGELER DM, 1978, AM REV RESPIR DIS, V117, P227; Wells WF, 1934, AM J HYG, V20, P611, DOI 10.1093/oxfordjournals.aje.a118097; WELLS WF, 1955, AIRBORNE CONTAGION A; 1994, TECHNOL RESPIR THER, V14, P1; 1992, AM REV RESPIR DIS, V146, P1623; 1993, FED REGISTER, V58, P52810; 1993, MMWR-MORBID MORTAL W, V42, P363; 1982, B WORLD HEALTH ORGAN, V60, P555; 1991, MMWR-MORBID MORTAL W, V40, P585; 1992, NIOSH RECOMMENDED GU, P1; 1993, HOSP INFECT CONTROL, V20, P17	82	271	280	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 12	1995	332	2					92	98		10.1056/NEJM199501123320206	http://dx.doi.org/10.1056/NEJM199501123320206			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA241	7990907				2022-12-28	WOS:A1995QA24100006
J	LEE, ES; LOCKER, J; NALESNIK, M; REYES, J; JAFFE, R; ALASHARI, M; NOUR, B; TZAKIS, A; DICKMAN, PS				LEE, ES; LOCKER, J; NALESNIK, M; REYES, J; JAFFE, R; ALASHARI, M; NOUR, B; TZAKIS, A; DICKMAN, PS			THE ASSOCIATION OF EPSTEIN-BARR-VIRUS WITH SMOOTH-MUSCLE TUMORS OCCURRING AFTER ORGAN-TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; LYMPHOPROLIFERATIVE DISORDERS; EXPRESSION; CHILDREN; AIDS; LEIOMYOSARCOMA; LYMPHOCYTES; CHROMOSOME; INFECTION; ALLOGRAFT	Background. Epstein-Barr virus (EBV) has been associated with nasopharyngeal carcinoma, some lymphomas, and lymphoproliferative disease after organ transplantation. Many lymphoproliferative tumors that occur after transplantation are clonal, a property that classifies them as neoplastic. Clonality can be determined by analysis of the extrachromosomal circular DNA episomes produced by EBV infection. Methods. We describe three young children in whom smooth-muscle tumors developed 18 months to 5 1/2 years after liver transplantation with immunosuppression, We examined the tumors by microscopy and with immunohistochemical studies and molecular genetic analyses of the EBV DNA. Results. The tumors were composed of spindle cells with smooth-muscle features and resembled those described in patients with the acquired immunodeficiency syndrome, Immunohistochemical analysis was negative for EBV latent membrane protein and EBV receptor (CD21), but positive for EBV nuclear antigen 2. In situ hybridization revealed nuclear EBV sequences, and molecular genetic analysis showed the EBV genome to be clonal in all three patients. Conclusions. Smooth-muscle tumors that developed after organ transplantation contained clonal EBV, suggesting that the virus has a role in the development of these neoplastic lesions.	CHILDRENS HOSP PITTSBURGH, DEPT PATHOL, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, MED CTR, DEPT PATHOL, PITTSBURGH, PA USA; CHILDRENS HOSP PITTSBURGH, DIV TRANSPLANT SURG, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Nour, Bakr/0000-0003-1684-1907	NATIONAL CANCER INSTITUTE [P01CA047445] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47445-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRANDWEIN M, 1990, VIRCHOWS ARCH A, V416, P281, DOI 10.1007/BF01605288; BROOKS JJ, 1989, DIAGNOSTIC SURGICAL, P166; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BUSH JL, 1989, LAB MED, V20, P318, DOI 10.1093/labmed/20.5.318; CHADWICK EG, 1990, JAMA-J AM MED ASSOC, V263, P3182, DOI 10.1001/jama.263.23.3182; COHEN JI, 1991, MEDICINE, V70, P137, DOI 10.1097/00005792-199103000-00005; DOYLE H, 1991, CLIN TRANSPLANT, V5, P60; GULLEY ML, 1992, CANCER, V70, P185, DOI 10.1002/1097-0142(19920701)70:1<185::AID-CNCR2820700129>3.0.CO;2-J; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; KLINGER HP, 1972, CYTOGENETICS, V11, P424, DOI 10.1159/000130208; LOCKER J, 1989, AM J PATHOL, V135, P977; MCLOUGHLIN LC, 1991, CANCER, V67, P2618, DOI 10.1002/1097-0142(19910515)67:10<2618::AID-CNCR2820671036>3.0.CO;2-5; MIDDLETON T, 1991, ADV VIRUS RES, V40, P19; MUELLER BU, 1992, PEDIATRICS, V90, P460; NALESNIK MA, 1988, AM J PATHOL, V133, P173; PENN I, 1989, Critical Reviews in Oncogenesis, V1, P27; PURTILO DT, 1992, LAB INVEST, V67, P5; RADIN DR, 1992, AM J ROENTGENOL, V159, P545, DOI 10.2214/ajr.159.3.1503021; RANDHAWA PS, 1991, AM J PATHOL, V138, P1027; ROSS JS, 1992, HUM PATHOL, V23, P69, DOI 10.1016/0046-8177(92)90014-T; SAUVAGEAU G, 1990, J GEN VIROL, V71, P379, DOI 10.1099/0022-1317-71-2-379; SCHAEFER BC, 1991, P NATL ACAD SCI USA, V88, P6550, DOI 10.1073/pnas.88.15.6550; UMLAS J, 1991, AM J SURG PATHOL, V15, P1181, DOI 10.1097/00000478-199112000-00009; VANHOEVEN KH, 1993, AM J SURG PATHOL, V17, P1176, DOI 10.1097/00000478-199311000-00011; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; YOUSEM SA, 1991, CHEST, V99, P275, DOI 10.1378/chest.99.2.275	26	354	370	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					19	25		10.1056/NEJM199501053320104	http://dx.doi.org/10.1056/NEJM199501053320104			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990861	Bronze			2022-12-28	WOS:A1995PZ49700004
J	RICHMOND, JB; FEIN, R				RICHMOND, JB; FEIN, R			THE HEALTH-CARE MESS - A BIT OF HISTORY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											RICHMOND, JB (corresponding author), HARVARD UNIV,SCH MED,DEPT SOCIAL MED,641 HUNTINGTON AVE,BOSTON,MA 02115, USA.							GINZBERG E, 1984, NEW ENGL J MED, V310, P1162, DOI 10.1056/NEJM198405033101806; MCKINLAY JB, 1988, INT J HEALTH SERV, V18, P191, DOI 10.2190/YEVW-6C44-YCYE-CGEU; Relman A S, 1983, Health Aff (Millwood), V2, P5, DOI 10.1377/hlthaff.2.2.5	3	15	15	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 4	1995	273	1					69	71		10.1001/jama.273.1.69	http://dx.doi.org/10.1001/jama.273.1.69			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PZ042	7996654				2022-12-28	WOS:A1995PZ04200031
J	SCOTT, MP				SCOTT, MP			INTIMATIONS OF A CREATURE	CELL			English	Review							HOMEOBOX-CONTAINING GENE; TRANSCRIPTION FACTORS; NUCLEAR-PROTEIN; CELL FATES; DROSOPHILA; ENCODES; HEART; ULTRABITHORAX; ANTENNAPEDIA; EXPRESSION		STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University	SCOTT, MP (corresponding author), STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305, USA.							AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BATESON W, 1984, MATERIALS STUDY VARI; BODMER R, 1993, DEVELOPMENT, V118, P719; BODMER R, 1995, IN PRESS TRENDS CARD; BURKE AC, 1995, IN PRESS DEVELOPMENT; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; GAUNT SJ, 1994, INT J DEV BIOL, V38, P549; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; KELSH R, 1993, DEVELOPMENT, V117, P293; KENYON C, 1994, CELL, V78, P175, DOI 10.1016/0092-8674(94)90288-7; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LINTS TJ, 1993, DEVELOPMENT, V119, P419; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MANAK JR, 1994, IN PRESS DEVELOPME S; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; WARREN R, 1994, IN PRESS NATURE, V372; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WHITE RAH, 1985, NATURE, V318, P567, DOI 10.1038/318567a0	30	54	55	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1121	1124		10.1016/0092-8674(94)90001-9	http://dx.doi.org/10.1016/0092-8674(94)90001-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001147				2022-12-28	WOS:A1994PZ86000001
J	KASS, EM; SZANIAWSKI, WK; LEVY, H; LEACH, J; SRINIVASAN, K; RIVES, C				KASS, EM; SZANIAWSKI, WK; LEVY, H; LEACH, J; SRINIVASAN, K; RIVES, C			RICKETTSIALPOX IN A NEW-YORK-CITY-HOSPITAL, 1980 TO 1989	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOUNTAIN SPOTTED-FEVER	Background. Rickettsialpox is caused by Rickettsia akari, which is transmitted from rodents to humans by bloodsucking mites. The initial skin lesion forms an eschar and is followed by the development of fever, malaise, myalgia, and 5 to 40 maculopapules and papulovesicles. The disease, which responds to tetracycline, can be mistaken for chickenpox. The diagnosis has been based on an increase in serum antibody titers against R. akari over a period of three to eight weeks. We discuss a more rapid technique that uses direct immunofluorescence to identify R. akari in paraffin-embedded tissue, and we describe the histopathological findings of lesional skin. Methods. We studied 13 patients (age, 11 months to 58 years) who were seen at Lincoln Hospital in New York City from 1980 to 1989 and were suspected of having rickettsialpox. In nine patients serum samples were obtained during the acute and convalescent phases of the illness for indirect fluorescent-antibody testing. Punch-biopsy specimens of skin lesions were examined by microscopy and by direct fluorescent-antibody testing with an anti-R. rickettsii globulin conjugated with fluorescein isothiocyanate. Results. The diagnosis was confirmed in all 13 patients by indirect or direct fluorescent-antibody techniques, Direct fluorescent-antibody testing of eschars from seven patients was positive in five patients, but negative in two patients who had serologically confirmed rickettsialpox. In contrast, direct fluorescent-antibody testing of papulovesicles from nine patients was positive in only one patient. Histopathological analysis of the eschars revealed extensive necrosis and inflammation. In biopsy specimens of papulovesicles, dermal edema, subepidermal vesicles, and vascular changes were present. Conclusions. The combination of direct fluorescent-antibody testing of an eschar from the presumed site of inoculation and histopathological examination of papulovesicles for distinctive features represents an improved method of diagnosing rickettsialpox.	DERMATOPATHOL ASSOCIATES NEW YORK,NEW ROCHELLE,NY 10805; NEW YORK MED COLL,DEPT DERMATOL,NEW YORK,NY; NEW YORK MED COLL,DEPT PATHOL,NEW YORK,NY; LINCOLN HOSP CTR,NEW YORK,NY; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341	New York Medical College; New York Medical College; Centers for Disease Control & Prevention - USA								BRETTMAN LR, 1981, MEDICINE, V60, P363, DOI 10.1097/00005792-198109000-00004; DOLGOPOL VB, 1948, AM J PATHOL, V24, P119; GREENBERG M, 1947, B NEW YORK ACAD MED, V23, P338; GREENBERG M, 1947, JAMA-J AM MED ASSOC, V133, P901, DOI 10.1001/jama.1947.02880130001001; HEBERT GA, 1980, J CLIN MICROBIOL, V11, P503; HUEBNER RJ, 1946, PUBLIC HEALTH REP, V61, P1605, DOI 10.2307/4585895; HUEBNER RJ, 1947, PUBLIC HEALTH REP, V62, P777, DOI 10.2307/4586142; HUEBNER RJ, 1946, PUBLIC HEALTH REP, V61, P1677, DOI 10.2307/4585913; JACKSON EB, 1957, AM J HYG, V66, P301, DOI 10.1093/oxfordjournals.aje.a119903; JACOBSON JM, 1989, INT J DERMATOL, V28, P271, DOI 10.1111/j.1365-4362.1989.tb04821.x; KRINSKY WL, 1983, REV INFECT DIS, V5, P1118; LACKMAN DB, 1963, CLIN PEDIATR, V2, P296, DOI 10.1177/000992286300200602; MCCALMONT C, 1989, DERMATOL CLIN, V7, P591, DOI 10.1016/S0733-8635(18)30588-6; NICHOLS E, 1953, ANN INTERN MED, V39, P92, DOI 10.7326/0003-4819-39-1-92; PATERSON PY, 1966, B NEW YORK ACAD MED, V42, P579; PHILIP RN, 1976, J CLIN MICROBIOL, V3, P51; ROSE HM, 1949, ANN INTERN MED, V31, P871, DOI 10.7326/0003-4819-31-5-871; SHANKMAN B, 1946, NEW YORK STATE J MED, V46, P2156; SUSSMAN L N, 1946, NY Med, V2, P27; WALKER DH, 1978, J INFECT DIS, V137, P206, DOI 10.1093/infdis/137.2.206; 1982, LANCET, V1, P148	21	56	56	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 15	1994	331	24					1612	1617		10.1056/NEJM199412153312403	http://dx.doi.org/10.1056/NEJM199412153312403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW446	7969341	Bronze			2022-12-28	WOS:A1994PW44600003
J	HARRIES, AD; CULLINAN, T				HARRIES, AD; CULLINAN, T			HERBIS ET ORBIS - THE DANGERS OF TRADITIONAL EYE MEDICINES	LANCET			English	Editorial Material									COLL MED,DEPT COMMUNITY HLTH,BLANTYRE,MALAWI	University of Malawi	HARRIES, AD (corresponding author), COLL MED,DEPT MED,BLANTYRE,MALAWI.							CHIRAMBO MC, 1976, BRIT J OPHTHALMOL, V60, P665, DOI 10.1136/bjo.60.9.665; COURTRIGHT P, 1994, BRIT J OPHTHALMOL, V74, P810; MCMOLI TE, 1984, BRIT J OPHTHALMOL, V68, P401, DOI 10.1136/bjo.68.6.401; YORSTON D, 1994, J TROP MED HYG, V97, P211	4	7	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1588	1588		10.1016/S0140-6736(94)90403-0	http://dx.doi.org/10.1016/S0140-6736(94)90403-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983991				2022-12-28	WOS:A1994PW05100006
J	MISHRA, M; BISWAS, UK; JHA, AM; KHAN, AB				MISHRA, M; BISWAS, UK; JHA, AM; KHAN, AB			AMPHOTERICIN VERSUS SODIUM STIBOGLUCONATE IN FIRST-LINE TREATMENT OF INDIAN KALA-AZAR	LANCET			English	Article							LEISHMANIASIS	Patients do not always respond to treatment of visceral leishmaniasis with pentavalent antimony, and the drug has toxic effects. Amphotericin B might first-line treatment for alternative compared the efficacy of amphotericin and sodium stibogluconate in a prospective randomised trial in 80 uncomplicated and parasitologically confirmed cases of Indian kala-azar. None of the patients had received an antileishmanial agent before. Sodium stibogluconate was given at 20 mg/kg in two divided doses daily for 40 days, and amphotericin in fourteen doses of 0.5 mg/kg infused in 5% dextrose on alternate days. All 40 patients randomised to amphotericin were cured; of the 40 patients assigned to sodium stibogluconate, 28 (70%) showed initial cure and 25 (62.5%) showed definitive cure (p<0.001). With amphotericin, there was quicker abatement of fever and more complete spleen regression with no serious adverse effects. Amphotericin is effective in the first-line treatment of Indian kala-azar and superior to antimony therapy.			MISHRA, M (corresponding author), DARBHANGA MED COLL & HOSP,DARBHANGA 846003,BIHAR,INDIA.							BERMAN JD, 1988, REV INFECT DIS, V10, P560; CHUNGE CN, 1984, E AFR MED J, V61, P120; CROFT SL, 1991, J ANTIMICROB CHEMOTH, V28, P111, DOI 10.1093/jac/28.suppl_B.111; MISHRA M, 1991, LANCET, V337, P926, DOI 10.1016/0140-6736(91)90268-T; MISHRA M, 1992, LANCET, V340, P1256, DOI 10.1016/0140-6736(92)92952-C; NEVA FA, 1992, CECIL TXB MED, P1982; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PRATA ALUIZIO, 1963, TRANS ROY SOC TROP MED AND HYG, V57, P266, DOI 10.1016/0035-9203(63)90183-4; WOLF JE, 1990, INFECT IMMUN, V58, P1296, DOI 10.1128/IAI.58.5.1296-1300.1990; 1990, WHO TECH REP SER, V793, P50	10	81	83	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1599	1600		10.1016/S0140-6736(94)90406-5	http://dx.doi.org/10.1016/S0140-6736(94)90406-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983993				2022-12-28	WOS:A1994PW05100009
J	DELLAPORTA, SL; CALDERONURREA, A				DELLAPORTA, SL; CALDERONURREA, A			THE SEX DETERMINATION PROCESS IN MAIZE	SCIENCE			English	Article							ZEA-MAYS L; FLOWER DEVELOPMENT; PLANTS; DIFFERENTIATION; GENE; EAR	Maize partitions the sexes into different flowers on the plant, a condition called monoecy, which facilitates outcrossing. Sex determination in maize is a complex process involving an interplay between genetic determinants, the environment, and hormones. Unisexuality of flowers is achieved by the process of selective arrest and abortion of the inappropriate organ primordia within a bisexual floral meristem. Floral organ abortion is associated with the degeneration of cells within an immature primordia. Masculinizing genes are required for gynoecial abortion, feminizing genes arrest stamen development, and both types also control secondary sexual traits involving morphological characteristics of floral tissues. Gibberellins, steroid-like plant hormones, appear to play a pivotal role in the stamen abortion process and the feminization of floral tissues.			DELLAPORTA, SL (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038148] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38148] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOMMINENI VR, 1990, SEX PLANT REPROD, V3, P109, DOI 10.1007/BF00198854; BOMMINENI VR, 1990, PLANT SCI, V68, P239, DOI 10.1016/0168-9452(90)90230-L; BONNETT O. T., 1948, ANN MISSOURI BOT GARD, V35, P269, DOI 10.2307/2394693; Bonnett OT, 1940, J AGRIC RES, V60, P0025; BRACALE M, 1991, PLANT SCI, V80, P67, DOI 10.1016/0168-9452(91)90273-B; CHENG PC, 1983, AM J BOT, V70, P450, DOI 10.2307/2443252; CHENG PY, COMMUNICATION; COEN ES, 1991, ANNU REV PLANT PHYS, V42, P241, DOI 10.1146/annurev.pp.42.060191.001325; DAWE RK, 1990, DEV BIOL, V142, P233, DOI 10.1016/0012-1606(90)90167-H; DELLAPORTA SL, 1993, PLANT CELL, V5, P1241, DOI 10.1105/tpc.5.10.1241; DELONG A, 1993, CELL, V74, P757, DOI 10.1016/0092-8674(93)90522-R; DURAND B, 1991, PLANT SCI, V80, P49, DOI 10.1016/0168-9452(91)90272-A; Emerson RA, 1920, J HERED, V11, P65, DOI 10.1093/oxfordjournals.jhered.a101971; GRANT S, 1994, PLANT J, V6, P471, DOI 10.1046/j.1365-313X.1994.6040471.x; GRANT S, 1994, DEV GENET, V15, P214, DOI 10.1002/dvg.1020150304; HANSEN DJ, 1976, CROP SCI, V16, P371, DOI 10.2135/cropsci1976.0011183X001600030013x; HELENTJARIS T, 1988, GENETICS, V118, P353; IRISH EE, 1994, DEV GENET, V15, P155, DOI 10.1002/dvg.1020150206; IRISH EE, 1989, PLANT CELL, V1, P737, DOI 10.1105/tpc.1.8.737; Jones DF, 1925, J HERED, V16, P339, DOI 10.1093/oxfordjournals.jhered.a102629; JONES DF, 1932, 6TH P INT C GEN, V2, P104; KRISHNAMOORTHY HN, 1976, Z PFLANZENPHYSIOL, V79, P91, DOI 10.1016/S0044-328X(76)80082-7; MARIANI C, 1990, NATURE, V347, P737, DOI 10.1038/347737a0; MARIANI C, 1992, NATURE, V357, P384, DOI 10.1038/357384a0; MOHANRAM HY, 1964, PHYTOMORPHOLOGY, V14, P414; NICKERSON NORTON H., 1955, ANN MISSOURI BOT GARDEN, V42, P195, DOI 10.2307/2394655; NICKERSON NORTON H., 1959, ANN MISSOURI BOT GARD, V46, P19, DOI 10.2307/2394566; PHINNEY BO, 1984, SEB SEMINAR SERIES, V3, P17; PHINNEY BO, 1961, PLANT GROWTH REGUL, P489; POETHIG RS, 1982, MAIZE BIOL RES, P9; ROOD SB, 1980, PLANT PHYSIOL, V66, P793, DOI 10.1104/pp.66.5.793; SHERRY RA, 1993, AM J BOT, V80, P283, DOI 10.2307/2445351; TALO A, COMMUNICATION; VEIT B, 1991, DEVELOPMENT S, V1, P105; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WESTERGAARD M, 1958, ADV GENET, V9, P217, DOI 10.1016/S0065-2660(08)60163-7; Yampolsky C., 1922, BIBLIOTHECA GENETICA, V3, P1; YE D, 1991, PLANT SCI, V80, P93, DOI 10.1016/0168-9452(91)90275-D	38	127	143	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1501	1505		10.1126/science.7985019	http://dx.doi.org/10.1126/science.7985019			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985019				2022-12-28	WOS:A1994PV01500030
J	WAGNER, RW				WAGNER, RW			GENE INHIBITION USING ANTISENSE OLIGODEOXYNUCLEOTIDES	NATURE			English	Article							NF-KAPPA-B; IN-VIVO; OLIGONUCLEOTIDES; EXPRESSION; INVIVO; LEUKEMIA; VIRUS; SELECTION; MOLECULES; INVITRO	Antisense oligodeoxynucleotides (ODNs) have great promise as agents for the specific manipulation of gene expression. Until recently, nonspecific effects of ODNs often confounded the interpretation of antisense studies. Improvements in ODN chemistry and cellular delivery techniques now allow for more potent and specific gene inhibition. This review critically evaluates recent progress in the development of antisense ODNs.			WAGNER, RW (corresponding author), GILEAD SCI,353 LAKESIDE DR,FOSTER CITY,CA 94404, USA.							ABE J, 1994, BIOCHEM BIOPH RES CO, V198, P116; AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; ALPER J, 1993, BIO-TECHNOL, V11, P1225; AMARATUNGA A, 1993, J BIOL CHEM, V268, P17427; AZAD RF, 1993, ANTIMICROB AGENTS CH, V37, P1945, DOI 10.1128/AAC.37.9.1945; Bayever E, 1993, Antisense Res Dev, V3, P383; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BENNETT CF, 1994, J IMMUNOL, V152, P3530; BENNETT MR, 1994, J CLIN INVEST, V93, P820, DOI 10.1172/JCI117036; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHIASSON BJ, 1992, EUR J PHARM-MOLEC PH, V227, P451, DOI 10.1016/0922-4106(92)90167-T; COLIGE A, 1993, BIOCHEMISTRY-US, V32, P7, DOI 10.1021/bi00052a002; DEAN NM, 1994, J BIOL CHEM, V269, P16416; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; EPSTEIN SE, 1993, CIRCULATION, V88, P1351, DOI 10.1161/01.CIR.88.3.1351; FENSTER SD, 1994, BIOCHEMISTRY-US, V33, P8391, DOI 10.1021/bi00194a002; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; GAO WY, 1992, MOL PHARMACOL, V41, P223; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HIJIYA N, 1994, P NATL ACAD SCI USA, V911, P4499; KAMANO H, 1992, BIOCHEM INT, V26, P537; KIRKLAND MA, 1993, LANCET, V342, P614, DOI 10.1016/0140-6736(93)91438-R; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KITAJIMA I, 1992, J BIOL CHEM, V267, P25881; MAISTER P, 1994, BIOWORLD TODAY, V5, P3; MCCARTHY MM, 1994, BRAIN RES, V636, P55; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; MONIA BP, 1993, J BIOL CHEM, V268, P14514; MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; OFFENSPERGER WB, 1993, EMBO J, V12, P1257, DOI 10.1002/j.1460-2075.1993.tb05767.x; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; PEREZ JR, 1994, P NATL ACAD SCI USA, V91, P5957, DOI 10.1073/pnas.91.13.5957; PERLAKY L, 1993, ANTI-CANCER DRUG DES, V8, P3; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; RATHBONE MP, 1992, IN VITRO CELL DEV-AN, V28A, P529; SHAW JP, 1991, NUCLEIC ACIDS RES, V19, P747, DOI 10.1093/nar/19.4.747; SHI Y, 1994, CIRCULATION, V90, P944, DOI 10.1161/01.CIR.90.2.944; SIMONS M, 1994, J CLIN INVEST, V93, P2351, DOI 10.1172/JCI117240; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SKORSKI T, 1994, P NATL ACAD SCI USA, V91, P4504, DOI 10.1073/pnas.91.10.4504; SKUTELLA T, 1994, NEUROSCI LETT, V167, P55, DOI 10.1016/0304-3940(94)91026-X; STANDIFER KM, 1994, NEURON, V12, P805, DOI 10.1016/0896-6273(94)90333-6; STEIN CA, 1992, LEUKEMIA, V6, P967; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; Whitesell L, 1991, Antisense Res Dev, V1, P343; WOOLF TM, 1992, P NATL ACAD SCI USA, V89, P7305, DOI 10.1073/pnas.89.16.7305; YAKUBOV L, 1993, J BIOL CHEM, V268, P18818; YAO GQ, 1993, ANTIMICROB AGENTS CH, V37, P1420, DOI 10.1128/AAC.37.7.1420; ZHOU LW, 1994, J PHARMACOL EXP THER, V268, P1015	53	803	1039	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					333	335		10.1038/372333a0	http://dx.doi.org/10.1038/372333a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969490				2022-12-28	WOS:A1994PU28700046
J	KINOSHITA, J; MERVIS, J				KINOSHITA, J; MERVIS, J			SEND IN THE CLONES	SCIENCE			English	Editorial Material																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1187	1187		10.1126/science.7973699	http://dx.doi.org/10.1126/science.7973699			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973699				2022-12-28	WOS:A1994PT13200038
J	ADLEMAN, LM				ADLEMAN, LM			MOLECULAR COMPUTATION OF SOLUTIONS TO COMBINATORIAL PROBLEMS	SCIENCE			English	Article								The tools of molecular biology were used to solve an instance of the directed Hamiltonian path problem. A small graph was encoded in molecules of DNA, and the ''operations'' of the computation were performed with standard protocols and enzymes. This experiment demonstrates the feasibility of carrying out computations at the molecular level.	UNIV SO CALIF,INST MOLEC & MED TECHNOL,LOS ANGELES,CA 90089	University of Southern California	ADLEMAN, LM (corresponding author), UNIV SO CALIF,DEPT COMP SCI,941 W 37TH PL,LOS ANGELES,CA 90089, USA.							BRADLEY D, 1993, SCIENCE, V259, P890, DOI 10.1126/science.259.5097.890; CRANDALL BC, 1992, NANOTECHNOLOGY; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; Feynman R.P, 1961, MINATURIZATION, P282, DOI DOI 10.1201/9781315217178; Garey M.R., 1979, COMPUTERS INTRACTABI; Karp R. M., 1972, P COMPL COMP COMP, P85; Merkle R. C., 1993, Nanotechnology, V4, P21, DOI 10.1088/0957-4484/4/1/002; Rogers Jr H., 1987, THEORY RECURSIVE FUN; Sambrook J., 1989, MOL CLONING; SCHNEIDER TD, 1991, J THEOR BIOL, V148, P125, DOI 10.1016/S0022-5193(05)80467-9; Watson J. D., 1987, MOL BIOL GENE	11	2664	2992	20	422	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1021	1024		10.1126/science.7973651	http://dx.doi.org/10.1126/science.7973651			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973651				2022-12-28	WOS:A1994PQ92400037
J	CHANDRAKUMAR, M; EVANS, J				CHANDRAKUMAR, M; EVANS, J			DOES THE TYPE OF SEWAGE DRAINAGE AFFECT HEALTH	BRITISH MEDICAL JOURNAL			English	Article											CHANDRAKUMAR, M (corresponding author), E KENT HLTH AUTHOR,DEPT PUBL HLTH MED,DOVER CT16 1JT,KENT,ENGLAND.							BALARAJAN R, 1991, BRIT MED J, V303, P144; DEAN AD, 1990, EPI INFO VERISON 5 D; PIKE EB, 1990, 2518MCP DEP ENV WAT; RAJARATNAM G, 1992, J PUBLIC HEALTH MED, V14, P72; 1992, SPSS WINDOWS	5	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 5	1994	309	6963					1208	1208		10.1136/bmj.309.6963.1208	http://dx.doi.org/10.1136/bmj.309.6963.1208			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PQ662	7987153	Green Published			2022-12-28	WOS:A1994PQ66200023
J	TUSCHL, T; GOHLKE, C; JOVIN, TM; WESTHOF, E; ECKSTEIN, F				TUSCHL, T; GOHLKE, C; JOVIN, TM; WESTHOF, E; ECKSTEIN, F			3-DIMENSIONAL MODEL FOR THE HAMMERHEAD RIBOZYME BASED ON FLUORESCENCE MEASUREMENTS	SCIENCE			English	Article							RESONANCE ENERGY-TRANSFER; 4-WAY DNA JUNCTION; RNA; CLEAVAGE; PREDICTIONS; PARAMETERS	For the understanding of the catalytic function of the RNA hammerhead ribozyme, a three-dimensional model is essential but neither a crystal nor a solution structure has been available. Fluorescence resonance energy transfer (FRET) was used to study the structure of the ribozyme in solution in order to establish the relative spatial orientation of the three constituent Watson-Crick base-paired helical segments. Synthetic constructs were labeled with the fluorescence donor (5-carboxyfluorescein) and acceptor (5-carboxytetramethylrhodamine) located at the ends of the strands constituting the ribozyme molecule. The acceptor helix in helix pairs I and III and in II and III was varied in length from 5 to 11 and 5 to 9 base pairs, respectively, and the FRET efficiencies were determined and correlated with a reference set of labeled RNA duplexes. The FRET efficiencies were predicted on the basis of vector algebra analysis, as a function of the relative helical orientations in the ribozyme constructs, and compared with experimental values. The data were consistent with a Y-shaped arrangement of the ribozyme with helices I and II in close proximity and helix III pointing away. These orientational constraints were used for molecular modeling of a three-dimensional structure of the complete ribozyme.	MAX PLANCK INST EXPTL MED, D-37075 GOTTINGEN, GERMANY; INST MOLEK BIOTECHNOL EV, MOLEK BIOL ABT, D-07745 JENA, GERMANY; MAX PLANCK INST BIOPHYS CHEM, D-37077 GOTTINGEN, GERMANY; CNRS, INST BIOL MOLEC & CELLULAIRE, F-67084 STRASBOURG, FRANCE	Max Planck Society; Max Planck Society; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ALTMAN S, 1993, P NATL ACAD SCI USA, V90, P10898, DOI 10.1073/pnas.90.23.10898; ARNOTT S, 1972, BIOCHEM BIOPH RES CO, V48, P1392, DOI 10.1016/0006-291X(72)90867-4; AURUP H, 1994, NUCLEIC ACIDS RES, V22, P20, DOI 10.1093/nar/22.1.20; BRATTY J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P345, DOI 10.1016/0167-4781(93)90001-T; BRUENING G, 1989, METHOD ENZYMOL, V180, P546; CARDULLO RA, 1988, P NATL ACAD SCI USA, V85, P8790, DOI 10.1073/pnas.85.23.8790; CLEGG RM, 1993, P NATL ACAD SCI USA, V90, P2994, DOI 10.1073/pnas.90.7.2994; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; CLEGG RM, 1992, BIOCHEMISTRY-US, V31, P4846, DOI 10.1021/bi00135a016; Crooke S, 1993, ANTISENSE RES APPLIC, P83; DENMAN RB, 1993, BIOTECHNIQUES, V15, P1090; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; Forster, 1951, FLUORESZENZ ORGANISC; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FU DJ, 1993, BIOCHEMISTRY-US, V32, P10629, DOI 10.1021/bi00091a013; GAST FU, 1994, BIOCHEMISTRY-US, V33, P1788, DOI 10.1021/bi00173a023; GOHIKE C, IN PRESS P NATL ACAD; Goldstein H., 1980, CLASSICAL MECH, V2nd ed; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; HEUS HA, 1991, J MOL BIOL, V217, P113, DOI 10.1016/0022-2836(91)90615-D; HODGSON RAJ, 1994, NUCLEIC ACIDS RES, V22, P1620, DOI 10.1093/nar/22.9.1620; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JEFFRIES AC, 1989, NUCLEIC ACIDS RES, V17, P1371, DOI 10.1093/nar/17.4.1371; KEESE P, 1987, VIROIDS VIROID LIKE, P1; KIM R, 1994, ACTA CRYSTALLOGR D, V50, P290, DOI 10.1107/S0907444993013071; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LONG DM, 1993, FASEB J, V7, P25, DOI 10.1096/fasebj.7.1.8422971; MARSCHALL P, IN PRESS CELL MOL NE; MASSIRE C, 1994, J MOL GRAPHICS, V12, P201, DOI 10.1016/0263-7855(94)80088-X; MEI HY, 1989, P NATL ACAD SCI USA, V86, P9727, DOI 10.1073/pnas.86.24.9727; MERGNY JL, 1994, NUCLEIC ACIDS RES, V22, P920, DOI 10.1093/nar/22.6.920; MORRISON LE, 1993, BIOCHEMISTRY-US, V32, P3095, DOI 10.1021/bi00063a022; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; OZAKI H, 1992, NUCLEIC ACIDS RES, V20, P5205, DOI 10.1093/nar/20.19.5205; PLEY HW, 1993, J BIOL CHEM, V268, P19656; ROSSI JJ, 1992, AIDS RES HUM RETROV, V8, P183, DOI 10.1089/aid.1992.8.183; SIXOU S, IN PRESS DNA INTERAC; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; THEISEN P, 1992, TETRAHEDRON LETT, V33, P5033, DOI 10.1016/S0040-4039(00)61181-4; TUSCHL T, 1993, P NATL ACAD SCI USA, V90, P6991, DOI 10.1073/pnas.90.15.6991; TUSCHL T, 1993, BIOCHEMISTRY-US, V32, P11658, DOI 10.1021/bi00094a023; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8	43	212	218	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	1994	266	5186					785	789		10.1126/science.7973630	http://dx.doi.org/10.1126/science.7973630			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973630				2022-12-28	WOS:A1994PP75300034
J	OKANO, T; YOSHIZAWA, T; FUKADA, Y				OKANO, T; YOSHIZAWA, T; FUKADA, Y			PINOPSIN IS A CHICKEN PINEAL PHOTORECEPTIVE MOLECULE	NATURE			English	Article							N-ACETYLTRANSFERASE ACTIVITY; CONE VISUAL PIGMENTS; GLAND; RHODOPSIN; INVITRO; IDENTIFICATION; CULTURE; RETINA; CLOCK; LIGHT	IN avian pinealocytes, an environmental light signal resets the phase of the endogenous circadian pacemaker that controls the rhythmic production of melatonin(1-6). Investigation of the pineal phototransduction pathway should therefore reveal the molecular mechanism of the biological clock. The presence of rhodopsin-like photoreceptive pigment(4,5,7-9), transducin-like immunoreaction(10), and cyclic GMP-dependent cation-channel activity(11) in the avian pinealocytes suggests that there is a similarity between retinal rod cells and pinealocytes in the phototransduction pathway. We have now cloned chicken pineal cDNA encoding the photoreceptive molecule, which is 43-48% identical in amino-acid sequence to vertebrate retinal opsins. Pineal opsin, produced by transfection of complementary DNA into cultured cells, was reconstituted with 11-cis-retinal, resulting in formation of a blue-sensitive pigment (lambda(max) approximate to 470 nm). In the fight of this functional evidence and because the gene is specifically expressed only in the pineal gland, we conclude that it is a pineal photosensor and name it pinopsin.	OSAKA SANGYO UNIV, FAC ENGN, DEPT INFORMAT SYST ENGN, DAITO, OSAKA 574, JAPAN; UNIV TOKYO, COLL ARTS & SCI, DEPT PURE & APPL SCI, BUNKYO KU, TOKYO 153, JAPAN	University of Tokyo			吉孝, 深田/G-5090-2014	Okano, Toshiyuki/0000-0001-6740-6265				ARAKI M, 1992, DEV BRAIN RES, V65, P85, DOI 10.1016/0165-3806(92)90011-K; BINKLEY SA, 1978, SCIENCE, V202, P1198, DOI 10.1126/science.214852; DEGUCHI T, 1981, NATURE, V290, P706, DOI 10.1038/290706a0; DEGUCHI T, 1979, SCIENCE, V203, P1245, DOI 10.1126/science.424750; DRYER SE, 1991, NATURE, V353, P756, DOI 10.1038/353756a0; FOSTER RG, 1989, J COMP PHYSIOL A, V165, P553, DOI 10.1007/BF00611241; KASAL CA, 1979, SCIENCE, V203, P656, DOI 10.1126/science.569904; KOJIMA D, 1992, P NATL ACAD SCI USA, V89, P6841, DOI 10.1073/pnas.89.15.6841; KUWATA O, 1990, FEBS LETT, V272, P128, DOI 10.1016/0014-5793(90)80465-U; MASUDA H, 1994, TISSUE CELL, V26, P101, DOI 10.1016/0040-8166(94)90086-8; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; OKANO T, 1989, BIOCHEMISTRY-US, V28, P8848, DOI 10.1021/bi00448a025; OKANO T, 1992, P NATL ACAD SCI USA, V89, P5932, DOI 10.1073/pnas.89.13.5932; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J, 1989, MOL CLONING LABORATO; SUN JH, 1991, NEUROSCI LETT, V133, P97, DOI 10.1016/0304-3940(91)90066-3; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAKAO M, 1988, VISION RES, V28, P471, DOI 10.1016/0042-6989(88)90169-1; VANVEEN T, 1986, P NATL ACAD SCI USA, V83, P912; WALLINGFORD JC, 1988, EXP EYE RES, V46, P909, DOI 10.1016/S0014-4835(88)80042-3; ZATZ M, 1988, BRAIN RES, V453, P63, DOI 10.1016/0006-8993(88)90143-6	21	268	275	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	1994	372	6501					94	97		10.1038/372094a0	http://dx.doi.org/10.1038/372094a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969427				2022-12-28	WOS:A1994PQ34800080
